<SEC-DOCUMENT>0000875045-19-000017.txt : 20190424
<SEC-HEADER>0000875045-19-000017.hdr.sgml : 20190424
<ACCEPTANCE-DATETIME>20190424164637
ACCESSION NUMBER:		0000875045-19-000017
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		121
CONFORMED PERIOD OF REPORT:	20190331
FILED AS OF DATE:		20190424
DATE AS OF CHANGE:		20190424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		19764364

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-2019331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3FC26C40D3C35C5FB9EE2EB318A753D8"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;10-Q</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number 0-19311</font></div><div style="line-height:120%;padding-top:9px;text-align:center;"><img src="biogenlogostandardrgbr.jpg" alt="biogenlogostandardrgbr.jpg" style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;height:30px;width:92px;"></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:4%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">33-0112644</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">225 Binney Street, Cambridge, MA 02142</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(617)&#160;679-2000</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:42%;"></td><td style="width:19%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Large&#160;accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated filer</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Emerging growth company</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;No&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;19, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">193,893,397</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="sFE7F126231085FA098ED44F3EE2ADDDE"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">FORM&#160;10-Q &#8212; Quarterly Report</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Quarterly Period Ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:81%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;I&#160;&#8212; </font><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#sE0AD8662740E5132B12C7909EA226059"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">FINANCIAL INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements (unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s63B09A9AF8A358C9826E09A335F53C8F"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Income&#160;&#8212; For the Three Months Ended March 31, 2019 and 2018</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s63B09A9AF8A358C9826E09A335F53C8F">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD4CDE7CC29B35C43A56E79F86B1EBE0B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three Months Ended March 31, 2019 and 2018</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sD4CDE7CC29B35C43A56E79F86B1EBE0B">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sAA22BE7CB9D25BF8B877E1058B39A219"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets&#160;&#8212; As of March 31, 2019 and December&#160;31, 2018</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sAA22BE7CB9D25BF8B877E1058B39A219">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s9CEB70D4567651E3A2A6D3E94535615C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows&#160;&#8212; For the Three Months Ended March 31, 2019 and 2018</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s9CEB70D4567651E3A2A6D3E94535615C">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sef3f7bbbb4274f9bbe61bd70448d89d5"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Equity &#8212; For the Three Months Ended March 31, 2019 and 2018</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sef3f7bbbb4274f9bbe61bd70448d89d5">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s912311AC365F568C801CFF158B682053"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s912311AC365F568C801CFF158B682053">11</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s1A42F48BA7C25AD3BD2A4450A7523421"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s1A42F48BA7C25AD3BD2A4450A7523421">43</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sEDA795895BDB56BDB464A7868BCCF36F"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sEDA795895BDB56BDB464A7868BCCF36F">64</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s8A85DB9EC0535E218DE359455022D954"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s8A85DB9EC0535E218DE359455022D954">67</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;II&#160;&#8212; </font><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#sE0ABE5CBAFA75E53AE93684EA55C7399"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">OTHER INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s920101B03B1E5105968F63C16FE9B2AF"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s920101B03B1E5105968F63C16FE9B2AF">68</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s795C9CEE08075F55A0EACE9F715B8617"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s795C9CEE08075F55A0EACE9F715B8617">68</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s1937C625670856D0825B189E5053207E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s1937C625670856D0825B189E5053207E">83</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s235EAF4F4756541F839656F0D7FE4ED8"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Exhibits</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s235EAF4F4756541F839656F0D7FE4ED8">83</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE534E1800196571A96DD740791D0FD5B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Signatures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE534E1800196571A96DD740791D0FD5B">85</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="sBC5D2568628F5885B40DBF284383139B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; "would" and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expenses; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete, including increased competition from generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our plans and investments in our core and emerging growth areas, as well as implementation of our 2017 corporate strategy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intention to commit resources relating to research and development programs and business development opportunities, as well as the potential benefits and results of, and the anticipated timing to complete, certain business development transactions, including acquisitions and divestitures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filings and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse safety events involving our marketed products or generic or biosimilar versions of our marketed products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, including anticipated investments and divestitures, and activities in new or existing manufacturing facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.) intent to voluntarily depart from the European Union (E.U.);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws, regulatory requirements, judicial decisions and accounting standards; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated costs and tax treatment of the spin-off of our hemophilia business.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in this report to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</font></div></td></tr></table><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and ZINBRYTA&#174;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">are registered trademarks of Biogen. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FLIXABI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FUMADERM</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and IMRALDI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are trademarks of Biogen. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ENBREL&#174;, FAMPYRA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, GAZYVA&#174;, HUMIRA&#174;, OCREVUS&#174;, REMICADE&#174;, SkySTAR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and other trademarks referenced in this report are the property of their respective owners. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sE0AD8662740E5132B12C7909EA226059"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I FINANCIAL INFORMATION</font></div><div><a name="sD4B4C1F3DF675E1895B489291C47C6CF"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s63B09A9AF8A358C9826E09A335F53C8F"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,680.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,523.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">517.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">443.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">292.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,489.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,131.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">602.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">446.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">563.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">496.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">567.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">501.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on assets and liabilities held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">115.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">103.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss (gain) on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,987.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,596.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,502.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,534.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">357.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(41.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,860.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,493.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">422.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">322.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,408.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,171.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,408.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,172.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">196.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">197.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sD4CDE7CC29B35C43A56E79F86B1EBE0B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,408.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,172.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(29.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,429.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,185.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,429.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,184.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="sAA22BE7CB9D25BF8B877E1058B39A219"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, <br>2018</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,243.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,224.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,665.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,313.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,088.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,958.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">527.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">526.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">770.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">929.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">682.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">965.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">687.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,942.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,640.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,372.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,375.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,013.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,601.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">447.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,056.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,120.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,639.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,706.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax asset</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,074.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,153.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,898.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,690.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26,445.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25,288.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">238.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">378.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">97.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,435.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,861.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,148.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,295.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,943.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,741.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,636.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">436.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,353.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,389.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12,623.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,257.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(219.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(240.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17,026.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16,257.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13,829.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13,039.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13,822.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13,031.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26,445.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25,288.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="s9CEB70D4567651E3A2A6D3E94535615C"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,408.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,171.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and impairments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">121.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">168.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on assets and liabilities held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">115.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">228.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized (gain) loss on strategic investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(375.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(136.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(134.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">129.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(138.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(121.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax assets and liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">170.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">257.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other changes in operating assets and liabilities, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(171.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,459.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,457.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales and maturities of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,489.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,068.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(825.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,919.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration paid related to Fumapharm AG acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(300.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(600.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(127.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(194.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">238.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,346.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of treasury stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(655.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(250.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments related to issuance of stock for share-based compensation arrangements, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(679.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(268.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,019.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,535.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,224.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,573.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,243.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,108.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="sef3f7bbbb4274f9bbe61bd70448d89d5"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:10%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">221.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(240.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">16,257.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(23.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(2,977.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">13,039.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(8.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">13,031.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">1,408.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">1,408.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">1,408.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">20.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">20.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">20.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Capital contribution by noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(2.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(655.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(655.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(655.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(2.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(65.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(590.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">655.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">16.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">16.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">16.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(48.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(48.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(48.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Compensation related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">49.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">49.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">49.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">219.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(219.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">17,026.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(23.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">13,829.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(7.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">13,822.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:10%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">97.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(318.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15,810.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,977.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,612.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,598.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,172.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,172.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,171.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(250.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(250.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(250.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(122.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(127.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">250.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Adoption of new accounting guidance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">478.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">479.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">479.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">234.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(303.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17,334.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,053.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,037.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><a name="s912311AC365F568C801CFF158B682053"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="sC0B480616D9D5CF4819ABFAE5A4A8E10"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also commercialize biosimilars of advanced biologics.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K).</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including Parkinson's disease, ALS, progressive supranuclear palsy, AD, stroke, epilepsy, cognitive impairment associated with schizophrenia and pain.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the European Union (E.U.).</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2018 Form&#160;10-K. Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Assets and Liabilities Held For Sale</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held-for-sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvement for Lessors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and ASU No. 2019-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Codification Improvements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$463.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and a corresponding operating lease liability of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$526.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the adoption of the new leasing standards, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will become effective for us on January 1, 2020, and requires adoption using a modified retrospective approach, with certain exceptions. Based on the composition of our investment portfolio, current market conditions and historical credit loss activity, the adoption of this standard is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FASB issued ASU No. 2018-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative and Hedging</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><a name="sDF9DBBD0D88C50C29DC6D88251AAA168"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Acquisition of Nightstar Therapeutics plc</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into an agreement to acquire Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. NST's lead asset is NSR-REP1 for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder, which leads to blindness and has no approved treatments. NST&#8217;s second clinical program is NSR-RPGR for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no approved treatments.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the proposed acquisition, we would pay NST shareholders </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.50</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cash for each issued and outstanding NST share, which represents an expected total transaction value of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$800.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on a fully diluted basis, after expected transaction expenses and anticipated cash acquired at closing. We plan to fund the proposed acquisition of NST through available cash and to account for it as an acquisition of a business. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is intended that the proposed acquisition will be implemented by means of a U.K. Court-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006. The proposed acquisition remains subject to customary closing conditions, including the approval by NST shareholders and the issuance of an order by the U.K. Court. We expect to complete the proposed acquisition by mid-year 2019. </font></div><div><a name="s15efdc30ef404c7baeb0f96c2e9f43ab"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Divestitures</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$890.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cash, subject to certain working capital adjustments and other contractual terms. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the proposed transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with such guarantees. We may adjust this estimate based upon changes in business conditions, which may result in the recognition of additional losses. We are also obligated to indemnify FUJIFILM for liabilities that may exist relating to certain business activities incurred prior to the closing of the proposed transaction.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we have not included these contingent payments in our estimate of the fair value of the operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the proposed transaction, we also expect to enter into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM would use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determined that the operations to be disposed of in the proposed transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2019 the assets and liabilities related to our Hiller&#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale. The following table presents information related to the carrying value of the major classes of assets and liabilities that were reclassified as held for sale in our condensed consolidated balance sheets:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">27.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">629.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">69.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance on disposal group on assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(115.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets held for sale</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">682.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities held for sale</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">97.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019 we recorded a loss of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$174.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our condensed consolidated statements of income. This estimated loss includes a pre-tax loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$115.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflecting our current estimated fair value of the assets and liabilities held for sale, adjusting for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and our estimate of the fair value of an adverse commitment of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the proposed transaction. Our total estimated loss is based on current exchange rates and business conditions, and any changes to these factors through the closing date of the transaction will result in adjustments to the carrying values of the related assets and liabilities as well as a corresponding adjustment to the loss amount recognized on the sale.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of assets and liabilities expected to be sold to FUJIFILM is a Level 3 measurement and is based on the expected consideration from the sale, including the valuation of the adverse commitment, as discussed above.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proposed transaction remains subject to customary closing conditions, including filings and clearances under the Danish Competition Act. We expect to complete the proposed transaction in the second half of 2019. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&#248;d facility to FUJIFILM at carrying value.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><a name="s84C98E8242F9535897E0FD211FD7DB3C"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">717.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">281.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">998.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">728.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">258.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">986.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">327.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">173.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">500.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">178.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">550.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">245.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">460.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">462.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,290.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">693.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,983.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,350.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">675.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,025.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">223.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">295.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">518.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">188.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">175.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">363.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">124.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">124.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">174.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">174.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,513.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,166.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,680.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,538.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">985.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,523.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">888.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,051.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">141.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">680.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">826.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(25.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(24.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(60.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(233.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(294.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(92.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(378.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(474.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">932.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,083.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">175.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">176.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">907.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">874.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,083.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,051.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:78%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">390.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">349.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">126.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">517.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">443.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">264.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">140.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">292.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the three months ended March 31, 2019 and 2018, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$206.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these condensed consolidated financial statements. For additional information on our collaboration arrangement with AbbVie Inc. (AbbVie), please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K. For additional information on our contract manufacturing agreements with Bioverativ, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><a name="s6CEC503CC3BD5ED3A7FA2AB5D9430628"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">199.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">606.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">108.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">133.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">770.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">770.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">929.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">770.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the three months ended March 31, 2019, we sold hemophilia related inventory to Bioverativ with a cost basis totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$173.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;pursuant to the terms of the manufacture and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$890.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cash, subject to certain working capital adjustments and other contractual terms. As a result, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of work in process inventory was reclassified to assets held for sale in our condensed consolidated balance sheets as of March 31, 2019. Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred. In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&#248;d facility to FUJIFILM at carrying value.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><a name="s852A20D550525AEBA3B3F79B8344FB29"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:21%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(542.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(542.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,744.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">261.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,734.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">480.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">480.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">476.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">476.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,638.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,389.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,249.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,638.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,330.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,308.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,731.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,675.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,056.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,727.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,607.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,120.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization and impairment of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$103.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period. The decrease in amortization and impairment of acquired intangible asset was primarily due to a net overall decrease in our expected rate of amortization for acquired intangible assets. This was primarily due to lower amortization subsequent to the impairment in the fourth quarter of 2018 of the U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and higher expected lifetime revenues of TYSABRI. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and 2018, we had no impairment charges.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$256.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. Acquired and in-licensed rights and patents also includes our rest of world license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. The net book value of the TYSABRI asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,980.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and the net book value of the TECFIDERA asset as of March 31, 2019, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$63.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our TECFIDERA license rights, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the third quarter of 2018. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">200.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">290.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">230.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">190.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,706.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reclassification of goodwill to assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(69.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,639.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The reclassification of goodwill to assets held for sale relates to an allocation based upon the relative fair value of the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the three months ended March 31, 2019, goodwill was reviewed for impairment due to the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, and based upon this review, no impairments were recognized. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;accumulated impairment losses related to goodwill.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other includes changes related to foreign currency exchange rate fluctuations. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><a name="s2A009B64198F54778C08DBA87CEF74A4"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2019 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,881.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,881.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,835.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,835.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">921.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">921.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">281.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">281.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">904.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">884.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">104.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">104.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,958.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,938.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">445.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">705.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">705.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,459.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,459.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">969.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">969.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">615.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">563.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,102.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,050.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">434.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;impairments of our assets measured and carried at fair value during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our agreement with Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">model, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,500.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,486.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,489.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,480.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,022.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">995.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">995.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,795.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,738.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,745.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,737.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,838.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,722.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,802.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,722.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,155.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,943.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,037.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd., Stromedix Inc. and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">409.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$265.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the expected timing of the achievement of certain remaining development milestones, a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to an increase in the interest rate used to revalue our contingent consideration liabilities during the period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><a name="s265844FADD8B5CDFA91992CAEBB63685"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">446.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">192.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,074.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">279.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">168.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">194.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,881.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">705.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2019 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">981.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">981.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">852.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">854.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">683.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">683.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">237.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">237.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">280.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">280.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,035.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,038.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">489.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">904.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,608.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,607.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">854.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">851.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">706.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">705.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">264.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">263.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,694.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,689.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">496.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">615.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated<br>Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,665.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,665.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,314.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,313.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,234.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,237.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,235.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,232.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">135.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">134.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,035.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,038.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,694.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,689.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,489.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,068.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,049.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was reflected as a component of other current assets in our condensed consolidated balance sheet, with the remaining balance included in investments and other assets. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is included in investments and other assets in our condensed consolidated balance sheet. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in equity securities include approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of Ionis' common stock, acquired in June 2018 at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$625.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is remeasured each reporting period and carried at fair value. This investment is classified as a Level 2 marketable security due to certain holding period restrictions. The remainder of our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1. The effect of the holding period restrictions on our Ionis stock valuation are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis' common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in our strategic investment portfolio primarily reflects an increase in the fair value in our investment in Ionis' common stock as well as an increase in the value of a non-marketable equity security.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our June 2018 investment in Ionis' common stock, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><a name="sADCF7973B1545E76902AFA85B30838AF"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,722.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,701.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">170.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">99.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">79.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">72.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,144.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,239.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$44.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$44.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes attributable to changes in interest rates. The carrying value of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes as of March 31 2019 and December&#160;31, 2018, includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">seven months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of March 31, 2019 and December&#160;31, 2018, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency forward contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$895.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$735.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to these contracts were recognized as a component of other income (expense), net for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">101.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s6F8030393ABF53D4A6B5A981CB5EDCBA"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,841.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,797.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, depreciation expense totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$52.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$65.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.7 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;outstanding related to the construction of this facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. As a result, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$629.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of property, plant and equipment, which is primarily comprised of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$312.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for buildings and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$286.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for machinery and equipment, was reclassified to assets held for sale in our condensed consolidated balance sheets as of March 31, 2019. Additionally, we ceased recording depreciation on these assets as depreciation is not recorded during the period in which a long-lived asset or disposal group is classified as held for sale, even if the asset or disposal group continues to generate revenue during the period. For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div><a name="safe52a97e4464494ac4a68b9aa42e2d9"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease real estate, including laboratory and office space, and certain equipment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our leases have remaining lease terms ranging from less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;year to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;years. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one year</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;year to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;years. Our subleases do not include an option to renew as they are coterminous with our operating leases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All of our leases qualify as operating leases. The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:41%;"></td><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">447.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">72.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">436.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of lease costs in our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:41%;"></td><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sublease income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net lease cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The minimum lease payments, net of income from subleases, for the next five years and thereafter is expected to be as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">69.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">81.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">76.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">69.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">66.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">577.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Present value of operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">87.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">80.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">601.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(26.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(25.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(58.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(182.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">156.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">418.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:83%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term in years</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.88</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets obtained in exchange for lease obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. As a result, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of operating lease assets and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of operating lease liabilities were reclassified to assets held for sale in our condensed consolidated balance sheets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div><a name="s625B92B281BE5EAB91B79B95784355D7"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;Equity</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2019 Share Repurchase Program). Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. We did not repurchase any shares of our common stock under our 2019 Share Repurchase Program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2018 Share Repurchase Program). Our 2018 Share Repurchase Program does not have an expiration date. All share repurchases under our 2018 Share Repurchase Program will be retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$655.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From April 1, 2019 through April 24, 2019, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$491.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2018 Share Repurchase Program. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remained available under our 2018 Share Repurchase Program as of April 24, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(31.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(243.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(240.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(16.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(30.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(261.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(219.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(104.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(318.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(104.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(316.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(24.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(29.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(133.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(130.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(303.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:37%;"></td><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div><a name="sB3B4FF086D8451D780E50BE977E00B70"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13.&#160;&#160;&#160;&#160;Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,408.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,172.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">196.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">197.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><a name="s0E88ED481E3A5182A9EB946329E12100"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14. &#160;&#160;&#160;&#160;Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">27.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><a name="s7687745644985AE6B6C459090D6D11EE"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark assets held for sale</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Global Intangible Low-Taxed Income (GILTI)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Changes in Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the three months ended March&#160;31, 2019, compared to the same period in 2018, the increase in our effective tax rate was primarily due to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;tax expense related to the proposed divestiture of our subsidiary that owns our Hiller&#248;d, Denmark manufacturing operations.&#160;Although we are recognizing a loss on the proposed divestiture of such subsidiary, the proposed divestiture requires us to write off certain deferred tax assets upon the classification of our Hiller&#248;d, Denmark manufacturing operations as held for sale and results in a taxable gain in certain jurisdictions.&#160;The effect of this increase to our 2019 effective tax rate was partially offset by a higher effective tax rate in 2018 resulting from the sale of inventory, the tax effect of which had been included within prepaid taxes at December 31, 2017, at a higher effective tax rate. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">International Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to the Danish Tax Authority (SKAT) for assessments received for 2009, 2011 and 2013 regarding withholding taxes on certain payments made by our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. We continue to dispute the assessments for all of these periods and believe that the tax positions taken related to these payments are valid. Any amount refunded by SKAT associated with this withholding tax receivable will be paid to our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. This withholding tax receivable from SKAT will be included within the assets that will be transferred to FUJIFILM as part of the proposed transaction. Under the share purchase agreement, FUJIFILM is required to remit any future proceeds refunded by SKAT to us. We have assessed the collectability of the receivable from FUJIFILM and regard it as a contingent gain, which does not meet the probable threshold for recognition under ASC 450, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">therefore we have recorded a pre-tax charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to write the asset down to zero as a component of the loss on assets and liabilities held for sale in the first quarter of 2019. For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Federal and State Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. As a result, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our deferred tax liability was reclassified to liabilities held for sale in our condensed consolidated balance sheets as of March 31, 2019. For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div><a name="sA08BA247D125587BA8EEB4A560CACF83"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(47.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(50.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">376.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">357.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(41.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, gain (loss) on investments, net, as reflected in the table above, substantially relate to marketable equity securities held at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The increase in gain (loss) on investments, net, compared to the prior year period, was primarily due to an increase in the fair value in our investment in Ionis' common stock as well as an increase in the value of a non-marketable equity security.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements. For additional information on our investment in Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">907.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">874.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">216.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">261.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">195.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">224.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">160.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">320.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">444.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">99.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">125.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">708.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">609.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,435.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,861.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,353.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,389.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and included accrued income taxes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$796.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$791.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div><a name="sFD8E691869705C4EB4970780B7E8FD36"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our BAN2401 and Elenbecestat Collaboration, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration were immaterial. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expense incurred and, beginning January 1, 2019, is reimbursing us for&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expense incurred. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, following the results of a futility analysis conducted by an independent data monitoring committee, we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia. As a result of this decision, in the first quarter of 2019, we accrued approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the termination of various clinical trials and research and development contracts net of the expected </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales and marketing expense incurred were shared in proportion to the same region-based profit split that would have been utilized to co-promote aducanumab had it been commercialized. For additional information on the Aducanumab Collaboration Agreement, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">162.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">89.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense our condensed consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestone payments as well as potential royalties on net commercial sales. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Skyhawk, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was recorded as research and development expense in our condensed consolidated statements of income and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$115 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;attributed to inventory, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$615 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;attributed to developed technology and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$170 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;attributed to in-process research and development. A deferred tax liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$225 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;years and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;years, respectively, one quarter in arrears. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflecting our share of losses for the fourth quarter of 2018 totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and amortization of basis differences of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">729.9 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$642.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of BENEPALI, FLIXABI and IMRALDI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the European Commission granted a marketing authorization in the E.U. for IMRALDI. In April 2018 we and Samsung Bioepis entered into an agreement with AbbVie for the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales in our condensed consolidated statements of income. We began to recognize revenues on sales of IMRALDI to third parties in the E.U. in the fourth quarter of 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect Samsung Bioepis' </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration profits, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in revenues in relation to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis and our other significant collaboration arrangements, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><a name="sC5DB5BA5C3AE5158A9DB9F513C832524"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD, including aducanumab. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, following the results of a futility analysis conducted by an independent data monitoring committee, we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimbursed Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$112.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our investments in Neurimmune and other variable interest entities, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><a name="sCC356CD2C9025CE4A45F3486F5CAFC5E"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19.&#160;&#160;&#160;&#160;Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH&#160;(Fresenius Kabi)&#160;commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen commercializes in Europe, infringes the French counterpart of European Patent No. 3 148 510&#160;(the &#8216;510 Patent), which was issued in June 2018 and expires in May 2035. In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of the Danish Utility Models. In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the Dusseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. A hearing has been scheduled for May 2019 in the proceeding in Denmark.  No hearing has been scheduled in the other proceedings. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom counterpart of the &#8216;510 Patent. Fresenius Kabi has filed a counterclaim asserting infringement of the United Kingdom counterpart of the &#8216;510 Patent and seeking damages and an injunction to restrain infringement if the patent is found valid and infringed. A trial has been set for July 2019. In December 2018 Biogen B.V. and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the &#8216;510 Patent. A trial has been set for October 2019. An estimate of the possible loss or range of loss in the above matters cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Gedeon Richter PLC asserted to Biogen and Samsung Bioepis UK Limited that IMRALDI infringes European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035. We dispute the assertion. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss was denied in part. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we and certain other drug manufacturers and pharmacy benefit managers were served with a qui tam action filed by John Borzilleri on behalf of the U.S. and certain states in the U.S. District Court for the District of Rhode Island. The case was filed under seal in January 2014 and unsealed in April 2018 after the U.S. declined to intervene. The case alleges agreements with pharmacy benefit managers in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys' fees and costs. We, the other defendants and the U.S. have moved to dismiss the case and the motions are pending. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. In March 2018 the court dismissed the complaint with prejudice. The plaintiff's appeal is pending. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, 2018 and 2019 we initiated patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patent infringement proceedings pursuant to the Hatch-Waxman Act are pending against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Banner Life Sciences LLC, Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shipla Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware and against Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial date has not been set in the Delaware actions against Banner Life Sciences LLC or Zydus Pharmaceuticals (USA) Inc. A December 2019 trial date has been set for the other Delaware actions, and a trial date has been set for February 2020 in the West Virginia action against Mylan Pharmaceuticals Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan Pharmaceuticals Inc. filed a petition with the U.S. Patent Trial and Appeal Board seeking </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. On February 6, 2019, the U.S. Patent Trial and Appeal Board instituted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;review of the '514 Patent.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the European Patent Office (EPO) revoked our European patent number 2 137 537 (the '537 Patent), which includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for March 2020.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and the appeal is pending. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Boards of Appeal and the Enlarged Board of Appeal, if applicable, to make a final determination.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish &#8216;263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU &#8216;127 Patent) (&#8220;Administration of agents to treat inflammation&#8221;).  The Polish &#8216;263 Patent concerns administration of natalizumab (TYSABRI) to treat MS. The Polish &#8216;263 Patent expires in February 2023. A hearing has been scheduled for May 2019. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of The Hague (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which also concerns administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. The Dutch and German counterparts were ruled invalid and we have appealed. No date for a hearing on the merits has been set in the Italian action.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. In October 2018 EMD Serono and Pfizer filed an appeal from the judgment in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we learned that the Prosecution Office of Milan was investigating our interactions with certain healthcare providers in Italy.&#160;In January 2019 the Prosecution Office dismissed the proceeding. We consider the matter closed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;including interest and penalties.&#160;We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending.&#160;We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><a name="s1A42F48BA7C25AD3BD2A4450A7523421"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K).</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. Additionally, a significant portion of our revenues are concentrated on sales of our products in increasingly competitive markets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including Parkinson's disease, ALS, progressive supranuclear palsy, AD, stroke, epilepsy, cognitive impairment associated with schizophrenia (CIAS) and pain.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the E.U. For additional </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved MS products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing MS products. Our products may also face increased competitive pressures from the introduction of generic versions, prodrugs of existing therapies, biosimilars of existing products, other products approved under abbreviated regulatory pathways and other technologies. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures as well as the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the competition and pricing risks that could negatively impact our product sales, please read Item 3.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Quantitative and Qualitative Disclosures About Market Risk </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Brexit</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the U.K. electorate voted in a referendum to voluntarily depart from the E.U., known as Brexit. In March 2017 the U.K. government formally notified the European Council of its intention to leave the E.U. and began to negotiate the terms of the future relationship between the U.K. and the E.U. upon exit, which is expected to occur in October 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The potential impact on our results of operations and liquidity resulting from Brexit remains unclear. The actual effects of Brexit will depend upon many factors and significant uncertainty remains with respect to the ultimate resolution of the Brexit negotiations. The final outcome of these negotiations may impact certain of our research, commercial and general business operations in the U.K. and the E.U., including the approval and supply of our products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compliance with any resulting regulatory mandates may prove challenging and the macroeconomic impact on our sales and consolidated results of operations from these developments remains unknown. We do not, however, expect Brexit to have a material impact on our consolidated results of operations as approximately 2% of our total product revenues for each of the three months ended March 31, 2019 and 2018, were derived from U.K. sales.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have implemented measures to meet E.U. legal requirements and continue to modify our business operations to prepare for the U.K.'s separation from the E.U. However, we cannot predict the direction Brexit-related developments will take nor the impact of those developments on our European operations and the economies of the markets where we operate. Therefore, we will continue to monitor developments in this area and assess any potential impact on our business and results of operations.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><a name="s8A55814721C65A5998BC252CE6B2CD02"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</font></div><div style="line-height:120%;text-align:justify;"><img src="financialhighlights.jpg" alt="financialhighlights.jpg" style="height:426px;width:317px;"></div><div><a name="s9EE7C73AB0DD5608AB13D5DD370C3812"></a></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.15</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 29.1% over </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.54</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our net income and diluted earnings per share attributable to Biogen Inc. for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the three months ended March 31, 2018, reflects the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$3,489.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 11.5% over </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$3,131.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,680.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 6.2% over </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,523.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to a 42.5% increase in revenues from SPINRAZA and a 36.8% increase in revenues from our biosimilar products. These increases were partially offset by a 2.1% net decrease in our MS product revenues, primarily resulting from a decrease in our Interferon product revenues, as well as the unfavorable impact of foreign currency exchange, net of gains recognized in relation to the settlement of certain cash flow hedge instruments under </font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:48px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our foreign currency hedging program, of $23.3 million.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$517.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 16.7% over </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$443.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to a 11.5% increase in net sales of RITUXAN in the U.S. and a 45.5% increase in royalty revenues on sales of OCREVUS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$292.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 77.9% over </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$164.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to the sale of hemophilia related inventory to Bioverativ Inc. (Bioverativ) totaling $206.8 million. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,987.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">24.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,596.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">35.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in cost of sales, a $115.5 million loss recorded on assets and liabilities held for sale, a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">13.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in research and development and a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">13.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in selling, general and administrative expenses. These increases were partially offset by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">34.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in amortization and impairment of acquired intangible assets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. was unfavorably impacted by an increase in our effective tax rate to 22.7% for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from 21.6% for the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Condition, Liquidity and Capital Resources:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,459.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net cash flows from operations for the first quarter of 2019, which were primarily driven by earnings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities totaled approximately </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$5.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$4.9 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of March&#160;31, 2019 and December 31, 2018, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We repurchased and retired approximately 2.4 million shares of our common stock at a cost of approximately $655.8 million during the first quarter of 2019 under a program authorized by our Board of Directors in August 2018 to repurchase up to $3.5 billion of our common stock (2018 Share Repurchase Program).</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions, Divestitures, Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. In connection with this agreement, we made an upfront payment of $74.0 million to Skyhawk.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Skyhawk, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Proposed Acquisition of Nightstar Therapeutics plc</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into an agreement to acquire Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. NST's lead asset is NSR-REP1 for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder, which leads to blindness and has no approved treatments. NST&#8217;s second clinical program is NSR-RPGR for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no approved treatments.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the proposed acquisition, we would pay NST shareholders </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.50</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cash for each issued and outstanding NST share, which represents an expected total transaction value of approximately $800.0 million on a fully diluted basis, after expected transaction expenses and anticipated cash acquired at closing. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is intended that the proposed acquisition will be implemented by means of a U.K. Court-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006. The proposed acquisition remains subject to customary closing conditions, including the approval by NST shareholders and the issuance of an order by the U.K. Court. We expect to complete the proposed acquisition by mid-year 2019.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed acquisition of NST, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(FUJIFILM) under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$890.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cash, subject to certain working capital adjustments and other contractual terms. The proposed transaction remains subject to customary closing conditions, including filings and clearances under the Danish Competition Act. We expect to complete the proposed transaction in the second half of 2019. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Key Developments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB098 (diroximel fumarate)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2019 we and Alkermes plc announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of RMS. The NDA has been assigned a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019. If approved, we intend to market diroximel fumarate under the brand name VUMERITY, which has been conditionally accepted by the FDA and will be confirmed upon approval.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab (AB mAb)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, following the results of a futility analysis conducted by an independent data monitoring committee, we and Eisai Co., Ltd. (Eisai) announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Eisai, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2019 Share Repurchase Program</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2019 Share Repurchase Program). Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. We did not repurchase any shares of our common stock under our 2019 Share Repurchase Program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><a name="sFD1F413F0A7B5467AD26AC85AB24E397"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:5px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,513.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,538.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,166.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">985.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,680.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">76.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,523.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">517.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">443.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">292.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,489.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,131.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</font></div><div style="line-height:120%;padding-top:5px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">998.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">986.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">500.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">550.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">460.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">462.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,983.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">74.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,025.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">518.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">363.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">124.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">174.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,680.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,523.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><a name="s5ED060E6A7E157EA9003E339EBD3CF2E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;"><img src="tecfidera.jpg" alt="tecfidera.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 1.5% decrease in U.S. TECFIDERA revenues was primarily due to a decrease in unit sales volume of 6% and higher discounts and allowances, partially offset by price increases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 9.0% increase in rest of world TECFIDERA revenues was primarily due to an increase in unit sales volumes of 15%, primarily related to our European and Latin American markets, partially offset by pricing reductions in certain European countries. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate an increase in TECFIDERA demand on a global basis in 2019, compared to 2018, notwithstanding increasing competition from additional treatments for MS. We expect volume growth in our international markets to exceed volume declines in the U.S. We also expect price reductions in certain European countries.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</font></div><div style="line-height:120%;text-align:left;"><img src="interferon.jpg" alt="interferon.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 11.9% decrease in U.S. Interferon revenues was primarily due to a decrease in Interferon unit sales volumes of 13%, which was primarily attributable to patients transitioning to other MS therapies, partially offset by price increases. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 3.0% decrease in rest of world Interferon revenues was primarily due to pricing reductions in certain European countries.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that Interferon revenues will continue to decline in both the U.S. and international markets in 2019, compared to 2018, as a result of increasing competition from our other MS products as well as other treatments for MS, including biosimilars, and pricing reductions in certain European markets.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;"><img src="tysabri.jpg" alt="tysabri.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 1.9% decrease in U.S. TYSABRI revenues was primarily due to a decrease in unit sales volumes of 7%, partially offset by price increases and lower discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 1.4% increase in rest of world TYSABRI revenues was primarily due to an increase in unit sales volumes of 6%.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate TYSABRI demand to be stable on a global basis in 2019, compared to 2018, with expected volume declines in the U.S. due to increasing competition from additional treatments for MS, including OCREVUS, to be offset by volume growth in our international markets.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;text-align:left;"><img src="spinraza.jpg" alt="spinraza.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 18.8% increase in U.S. SPINRAZA revenues was primarily due to an increase in unit sales volumes of 17%.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 67.8% increase in rest of world SPINRAZA revenues was primarily due to an increase in unit sales volumes of 93%, partially offset by the unfavorable impact of foreign currency exchange of $13.1 million. Rest of world SPINRAZA revenues for the first quarter of 2019 were also favorably impacted by approximately $14.0 million as we reached a price reimbursement agreement in France, which resulted in the recognition of additional revenues in relation to sales for the period August 2017, the date upon which we began to sell SPINRAZA in France, and December 2018 as we had a change in the estimated amount of revenues for which we determined that a significant reversal was not probable. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that the rate at which SPINRAZA revenues will grow will moderate in 2019, compared to 2018, primarily due to a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including a potential gene therapy product for the treatment of SMA Type 1, which could come to market in the U.S. in 2019. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Ionis Pharmaceuticals, Inc. (Ionis), please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BENEPALI, FLIXABI and IMRALDI</font></div><div style="line-height:120%;"><img src="biosimilars.jpg" alt="biosimilars.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 36.8% increase in biosimilar revenues was primarily due to the launch of IMRALDI in the fourth quarter of 2018, partially offset by the unfavorable impact of foreign currency exchange of $9.6 million.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2019 we expect strong revenue growth for our biosimilar business, primarily driven by the continued launch of IMRALDI.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="sCCBB1683BD025CEC981B786A1D3B7741"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</font></div><div style="line-height:120%;"><img src="anticd20revenues.jpg" alt="anticd20revenues.jpg" style="height:346px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,226.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,096.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">172.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">153.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,053.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">942.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">390.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">349.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues, net was primarily due to increased net sales of RITUXAN in the U.S. of 11.5%. This increase in net sales of RITUXAN in the U.S. reflects selling price increases and an increase in unit sales volume of 7%, partially offset by higher discounts and allowances.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in U.S. product revenues, net compared to the same period in 2018, also reflects an increase in GAZYVA unit sales volume of 12%.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in collaboration costs and expenses was primarily due to higher cost of goods sold on RITUXAN.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are aware of anti-CD20 molecules, including biosimilar products, in development that if successfully developed and approved, may compete with RITUXAN. In 2018 the FDA approved a rituximab biosimilar in the U.S. A biosimilar of RITUXAN could come to market in the U.S. in 2019, which may adversely affect the pre-tax profits of our collaboration arrangements with Genentech, which would, in turn, adversely affect our co-promotion profits in the U.S. in future years.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs consist of royalty revenues on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in other revenues from anti-CD20 therapeutic programs was primarily due to sales growth of OCREVUS. Royalty revenues recognized on sales of OCREVUS for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled $111.6 million and $76.7 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div></div></div><div><a name="s383A6E94E51E50E99DF401B275FA25B2"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">268.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">91.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">151.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">292.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships include revenues from our technical development services and manufacturing agreements with Samsung Bioepis and royalty revenues on biosimilar products from Samsung Bioepis. Revenues from collaborative and other relationships also include our 50% share of the co-promotion losses of ZINBRYTA in the U.S. with AbbVie Inc. (AbbVie).</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the closing of the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, FUJIFILM will assume responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis and we will no longer recognize revenue amounts earned under our manufacturing and technical services agreements with Samsung Bioepis. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborative and other relationships, including revenues recognized under our technical development services and manufacturing agreements with Samsung Bioepis, and our collaboration arrangement with AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our 2018 10-K.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Royalty and Corporate Revenues</font></div><div style="line-height:120%;"><img src="otherrevenue.jpg" alt="otherrevenue.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenues primarily from amounts earned under contract manufacturing agreements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in other royalty and corporate revenues was due to higher contract manufacturing revenues, primarily resulting from $206.8 million in revenues recognized under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, compared to $47.0 million recognized in the first quarter of 2018. These increases were partially offset by the reduction in royalty revenues due to the expiration of certain of our patents. The increase in Bioverativ revenues over the prior year comparative period was due to sales of most of the remaining hemophilia inventory on hand.</font></div><div><a name="sE471CE1A9F7A5D3987607D9E3C0FBD16"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:left;"><img src="reservesfordisandallow.jpg" alt="reservesfordisandallow.jpg" style="height:372px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reserves for discounts and allowances as a percentage of gross product revenues was 23.0%, as compared to 24.3% in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives.</font></div><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in discounts was primarily due to changes in wholesaler invoicing in certain European markets. </font></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment assistance, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </font></div><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to higher governmental rebates and allowances in the rest of world, due in part to an increase in SPINRAZA sales volumes worldwide, partially offset by decreased Medicaid rebates in the U.S.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenues are recognized, resulting in a reduction to product sales. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return reserves were relatively consistent.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenue reserves, please read Note 4, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><a name="s287FD9D39F595CDE859204DD02F28A10"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">602.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">446.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">563.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">496.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">567.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">501.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on assets and liabilities held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">115.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">103.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss (gain) on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(305.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(75.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,987.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,596.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sD8BBEC704BCE5D00A8EB577A6108D6E4"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="costofsales.jpg" alt="costofsales.jpg" style="height:293px;width:317px;"></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily due to higher contract manufacturing shipments, primarily resulting from the sale of hemophilia related inventory to Bioverativ with a cost basis totaling $173.5 million pursuant to the terms of the manufacture and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, and increased sales of our biosimilar products. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily due to increased royalties payable to Ionis on higher sales of SPINRAZA, partially offset by a decrease in royalties payable on sales of TYSABRI resulting from the expiration of certain third party royalties.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><a name="sDC8B00C8B47A5466947A556E50E262BB"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;"><img src="rdandpercentofrevenue.jpg" alt="rdandpercentofrevenue.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;"><img src="researchanddev.jpg" alt="researchanddev.jpg" style="height:622px;width:317px;"></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in research and development expense was primarily due to an increase in milestone and upfront expenses and an increase in costs incurred in connection with our early and late stage programs. These increases were partially offset by a decrease in costs incurred with our marketed products and other research and development costs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Milestone and Upfront Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in milestone and upfront expenses was primarily due to the recognition of a $38.5 million charge to research and development expense upon entering into our collaboration and research development services agreement with Skyhawk.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Early Stage Programs</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in spending related to our early stage programs was primarily due to the development of BIIB054 (&#945;-synuclein mAb) in Parkinson's disease, the development of BAN2401(A&#946; mAb) in AD pursuant to our collaboration arrangement with Eisai and the development of BIIB104 (AMPA) in CIAS, partially offset by a decrease in costs associated with the development of BIIB074 (vixotrigine) in trigeminal neuralgia and the development of BIIB093 (glibenclamide IV) in large hemispheric infarction (LHI), which was advanced to a late stage program in the third quarter of 2018. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Late Stage Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in spending related to our late stage programs was primarily due to costs incurred resulting from the discontinuation of our Phase 3 aducanumab trials, net of an expected Eisai reimbursement, and the development of BIIB093 in LHI. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, following the results of a futility analysis conducted by an independent data monitoring committee, we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia. As a result of this decision, in the first quarter of 2019, we accrued approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 Eisai initiated a global Phase 3 trial for the development of BAN2401 in early AD. Under our collaboration arrangement, Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Eisai, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketed Products</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in spending related to our marketed products was primarily due to a decrease in spend on ZINBRYTA subsequent to the voluntary worldwide withdrawal of ZINBRYTA for RMS, which we and AbbVie announced in March 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;"><img src="sganda.jpg" alt="sganda.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in selling, general and administrative expenses was primarily due to an increase in corporate giving, an increase in commercialization costs as we continued to expand into new international markets and an increase in pre-commercialization costs related to our AD programs. These increases were partially offset by a decrease in operational spend on ZINBRYTA subsequent to the voluntary worldwide withdrawal of ZINBRYTA for RMS, which we and AbbVie announced in March 2018. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><a name="sc9ed0c5bc9fd42ff870f9027b1e9c4cd"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss on Assets and Liabilities Held For Sale</font></div><div style="line-height:120%;"><img src="lossonheldforsale.jpg" alt="lossonheldforsale.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$890.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cash, subject to certain working capital adjustments and other contractual terms. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the proposed transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with such guarantees. We may adjust this estimate based upon changes in business conditions, which may result in the recognition of additional losses. We are also obligated to indemnify FUJIFILM for liabilities that may exist relating to certain business activities incurred prior to the closing of the proposed transaction.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we have not included these contingent payments in our estimate of the fair value of the operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the proposed transaction, we also expect to enter into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM would use the Hiller&#248;d facility to produce commercial </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">products for us, such as TYSABRI, as well as other third-party products. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determined that the operations to be disposed of in the proposed transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2019 the assets and liabilities related to our Hiller&#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale and were reclassified to assets and liabilities held for sale in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019 we recorded a loss of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$174.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our condensed consolidated statements of income. This estimated loss includes a pre-tax loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$115.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflecting our current estimated fair value of the assets and liabilities held for sale, adjusting for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and our estimate of the fair value of an adverse commitment of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the proposed transaction. Our total estimated loss is based on current exchange rates and business conditions, and any changes to these factors through the closing date of the transaction will result in adjustments to the carrying values of the related assets and liabilities as well as a corresponding adjustment to the loss amount recognized on the sale.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of assets and liabilities expected to be sold to FUJIFILM is a Level 3 measurement and is based on the expected consideration from the sale, including the valuation of the adverse purchase commitment, as discussed above.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proposed transaction remains subject to customary closing conditions, including filings and clearances under the Danish Competition Act. We expect to complete the proposed transaction in the second half of 2019. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We expect to complete the proposed transaction in the second half of 2019. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&#248;d facility to FUJIFILM at carrying value.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div><div><a name="s5ECD9452F261588088FD764CE6DF9CBF"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization and Impairment of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="amortofacquireintanassets.jpg" alt="amortofacquireintanassets.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the third quarter of 2018. The results of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA analyses were impacted by changes in the estimated timing and impact of other alternative MS formulations, including OCREVUS. The outcome of this most recent analysis resulted in a net overall decrease in our expected rate of amortization for acquired intangible assets, which was primarily </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">related to higher expected lifetime revenues of TYSABRI. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, decreased primarily due to a net overall decrease in our expected rate of amortization for acquired intangible assets. This was primarily due to lower amortization subsequent to the impairment in the fourth quarter of 2018 of the U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and higher expected lifetime revenues of TYSABRI. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and 2018, we had no impairment charges.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">In Process Research &amp; Development (IPR&amp;D) related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenues and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies and changes in program economics and related impact of foreign currency exchange rates, and evaluating industry data regarding the productivity of clinical research and the </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">development process. Changes in our estimates of these items may result in a significant change to our valuation of our IPR&amp;D assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the amortization and impairment of our acquired intangible assets, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div><a name="s08031CD2E95355A7A18222B0A8B883B5"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit (Loss) Sharing</font></div><div style="line-height:120%;"><img src="collabprofitshare.jpg" alt="collabprofitshare.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing includes our partner's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis and our partner's 50% share of the co-promotion profits or losses in the E.U. and Canada related to our collaboration agreement with AbbVie on the commercialization of ZINBRYTA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net profit-sharing expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect Samsung Bioepis' </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration profits, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period. The increase in profit-sharing expense was primarily due to increased collaboration profits resulting from increased biosimilar sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report. For additional information on our collaboration arrangement with AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our 2018 Form 10-K.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s98DC8C919FD95607B53FFC9F2C5C465C"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss (Gain) on Fair Value Remeasurement of Contingent Consideration</font></div><div style="line-height:120%;"><img src="fvonremeasurementofcc.jpg" alt="fvonremeasurementofcc.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a loss (gain) on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The change in the fair value remeasurement of contingent consideration for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to changes in the expected timing of the achievement of certain remaining development milestones, a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><a name="s5ABE041DD8115CDCB09D0D9F23477986"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;"><img src="oie.jpg" alt="oie.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the changes in other income (expense), net primarily reflects an increase in the fair value in our investment in Ionis' common stock, as well as an increase in the value of a non-marketable equity security. </font></div><div><a name="s27D0E9C35E37510785EE03CFD9F79372"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</font></div><div style="line-height:120%;"><img src="incometaxprovision.jpg" alt="incometaxprovision.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the three months ended March&#160;31, 2019, compared to the same period in 2018, the increase in </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our effective tax rate was primarily due to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;tax expense related to the proposed divestiture of our subsidiary that owns our Hiller&#248;d, Denmark manufacturing operations.&#160;Although we are recognizing a loss on the proposed divestiture of such subsidiary, the proposed divestiture requires us to write off certain deferred tax assets upon the classification of our Hiller&#248;d, Denmark manufacturing operations as held for sale and results in a taxable gain in certain jurisdictions.&#160;The effect of this increase to our 2019 effective tax rate was partially offset by a higher effective tax rate in 2018 resulting from the sale of inventory, the tax effect of which had been included within prepaid taxes at December 31, 2017, at a higher effective tax rate. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our uncertain tax positions and income tax rate reconciliation for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 15, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div><a name="sC1FF5F36B73B588C8002B80538359DBA"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity in Loss of Investee, Net of Tax</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><img src="equityinlossofinvestee.jpg" alt="equityinlossofinvestee.jpg" style="height:213px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of March 31, 2019, our ownership percentage remained at approximately 49.9%.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflecting our share of losses for the fourth quarter of 2018 totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and amortization of basis differences of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is recorded one quarter in arrears.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><a name="s2CD3165E056E5CECB3581AFF36453ED3"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,243.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,224.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,665.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,313.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(28.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,372.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,375.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,281.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,913.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,943.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,943.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,942.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,640.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3,148.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,295.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,793.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,345.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sDC54B23A499B5993AC06CAA19030534D"></a></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities, net of</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.0 million upfront payment </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">made to Skyhawk upon entering into a collaboration and research and development services agreement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$45.0 million upfront payment made to C4 Therapeutics (C4T) upon entering into a collaborative research and license agreement; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$655.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the final contingent payment made to former shareholders of Fumapharm AG and holders of their rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$127.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment.</font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$194.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned from our operations. We expect to continue funding our current and planned operating requirements principally through our cash flows from operations, as well as our existing cash resources. We believe that our existing funds, when combined </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read Item 3. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our 2019 Share Repurchase Program, which is a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock. Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. We did not repurchase any shares of our common stock under our 2019 Share Repurchase Program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized our 2018 Share Repurchase Program, which is a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock. Our 2018 Share Repurchase Program does not have an expiration date. All share repurchases under our 2018 Share Repurchase Program will be retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$655.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From April 1, 2019 through April 24, 2019, we repurchased and retired approximately 2.1 million shares of our common stock at a cost of approximately $491.6 million under our 2018 Share Repurchase Program. Approximately $1.0 billion remained available under our 2018 Share Repurchase Program as of April 24, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had cash, cash equivalents and marketable securities totaling approximately $5.3 billion compared to approximately $4.9 billion as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The net increase in cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to cash flows from operations, partially offset by cash used for share repurchases, contingent payments made to former shareholders of Fumapharm AG and holders of their rights, net purchases of property, plant and equipment and upfront payments made to Skyhawk and C4T.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets in our condensed consolidated balance sheet as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and December 31, 2018, includes the carrying value of our investment in Samsung Bioepis of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$642.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. As Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment. Investments and other assets, as of March 31, 2019 and December 31, 2018, also includes an asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$884.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$563.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, reflecting the fair value of our investment in Ionis' common stock, which is subject to certain holding period restrictions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Skyhawk and Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Ionis and C4T, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These Senior Notes were issued at a discount and are amortized as additional interest expense over the period from issuance through maturity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015, we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair and carrying values of our outstanding borrowings as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital is defined as current assets less current liabilities. The change in working capital at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects an increase in total current assets of approximately $1,301.7 million and a decrease in total current liabilities of approximately $146.5 million.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net increase in total current assets was primarily driven by the reclassification of assets associated with the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, an increase in net cash, cash equivalents and marketable securities, as described above, an increase in net amounts due in connection with our collaboration arrangement with Samsung Bioepis and an increase in accounts receivable, net related to our ongoing operations. These increases were partially offset by a decrease in inventory resulting from the sale of hemophilia related inventory to Bioverativ.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net decrease in current liabilities was primarily due to a reduction in accrued expenses and other, partially offset by an increase in income taxes payable and a reclassification of deferred tax liabilities to liabilities held for sale in relation to our proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations. The net decrease in accrued expenses and other was primarily related to a decrease in the accrual of contingent payments related to FUMADERM and TECFIDERA and a decrease in the accrual for employee compensation and benefits.</font></div></div></div><div><a name="s4970666F982255428086BF6DD4D7CD2C"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,459.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,457.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">238.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,346.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(82.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(679.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(268.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">152.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sABB805AB4A8E509FAAD75137832680BA"></a></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">non-cash operating items such as depreciation and amortization, impairment charges,unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with </font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">transactions and when they are recognized in results of operations;&#160;and</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net cash flows provided by operating activities increased primarily due to higher net income offset by changes in assets and liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows provided by investing activities was primarily due to a decrease in net proceeds related to marketable securities, partially offset by a decrease in contingent payments made to former shareholders of Fumapharm AG and holders of their rights.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in financing activities was primarily due to an increase in cash used for share repurchases. </font></div><div><a name="s92E4EE5B13A75BAC82C43AD8AF1DFB8B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been no material changes in our contractual obligations since </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation plc, full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales that exceed $2.0 billion. Royalty payments to Elan and other third parties are </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">recognized as cost of sales in our condensed consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11% and 15%, which are recognized as cost of sales in our condensed consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd. (Convergence), Stromedix, Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN) in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately $1.0 billion in remaining milestones related to these acquisitions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately $6.9 billion, including approximately $0.9 billion in development milestones, approximately $1.8 billion in regulatory milestones and approximately $4.2 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval or commercial milestones.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately $187.0 million of milestone payments during the remainder of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately $58.0 million in our condensed consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately $480.0 million in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately $119.3 million of liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of both </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of $697.0 million under a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). Of the amounts accrued as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to a $150.0 million overpayment of taxes made in 2018. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</font></div><div><a name="sFF39AEC69DB855DB84ADFB32B157C6B2"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards please read Note&#160;1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Accounting Policies - New Accounting Pronouncements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div><a name="sAEDFF79BC3C6525980A9E85DF0D754E4"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Assets and Liabilities Held For Sale</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held-for-sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of our critical accounting estimates, please read Part&#160;II, Item&#160;7. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our 2018 Form&#160;10-K. Except as discussed above, there have been no material changes to these critical accounting estimates since our 2018 Form&#160;10-K.</font></div><div><a name="sEDA795895BDB56BDB464A7868BCCF36F"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks that may affect our results of operations, cash flows and fair values </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counterparty.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. We have operations or maintain distribution relationships in the U.S., Europe, Canada, Asia and Central and South America. In addition, we recognize our share of pre-tax co-promotion profits on RITUXAN in Canada. As a result, our condensed consolidated financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Danish krone, Japanese yen and South Korean won.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenues will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expenses, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenues and expenses will increase when reported in U.S. dollars.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100%, which indicated that Argentina's economy is highly inflationary. This categorization did not have </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a material impact on our results of operations or financial position as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and is not expected to have a material impact on our results of operations or financial position in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of foreign currency exchange rate changes on revenues and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $296.0 million and $290.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Hedge Program</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. dollar and the South Korean won as a result of exercising our option to increase our ownership percentage in Samsung Bioepis to approximately 49.9%. We entered into foreign currency forward contracts to manage the foreign currency risk with our forward contracts used to hedge changes in the spot rate over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">seven months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement would result in a hypothetical decrease in fair value of approximately $63.0 million and $64.0 million, respectively. The estimated fair value was determined by measuring the impact of the hypothetical spot rate movement on outstanding forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $18.0 million and $19.0 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8&#160;million. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in certain international markets in which we operate have implemented measures, and may in the future implement new or additional </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the way our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our financial position or results of operations. There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, to impose restrictions on the coverage of certain drugs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition in many markets from generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways.&#160;Generic versions of drugs, biosimilars and other products approved under abbreviated regulatory pathways are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the price that we receive for branded products and the volume of branded products that we sell, which will negatively impact our revenues.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to long collection periods for our accounts receivable and greater collection risk in certain countries. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s8A85DB9EC0535E218DE359455022D954"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</font></div><div style="line-height:120%;padding-top:10px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We implemented internal controls to ensure management properly assessed the impact of the new lease accounting standards on our condensed consolidated financial statements to facilitate adoption of the new leasing standards effective January 1, 2019. There were no significant changes to our internal control over financial reporting due to the adoption of the new standards.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><a name="sE0ABE5CBAFA75E53AE93684EA55C7399"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Part&#160;II&#160;&#8212; OTHER INFORMATION</font></div><div><a name="s920101B03B1E5105968F63C16FE9B2AF"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal proceedings as of March 31, 2019, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our unaudited condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</font></div><div><a name="s795C9CEE08075F55A0EACE9F715B8617"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. Additionally, a significant portion of our revenues are concentrated on sales of our products in increasingly competitive markets. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenues and results of operations or could cause a decline in our stock price: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition or changes in, or implementation of, reimbursement policies and practices of payors and other third parties; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA has been approved by, among others, the FDA, the European Commission and the Japanese Ministry of Health, Labor and Welfare, and is in the early stages of commercial launch in certain markets. In addition to risks associated with new product launches and the other factors described in these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ability to successfully commercialize SPINRAZA may be adversely affected due to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within certain SMA markets, which may impact our ability to develop additional relationships with the associated medical and scientific community;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the lack of readiness of healthcare providers to treat patients with SMA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effectiveness of our commercial strategy for marketing SPINRAZA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to maintain a positive reputation among patients, healthcare providers and others in the SMA community, which may be impacted by pricing and reimbursement decisions relating to SPINRAZA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential gene therapy or oral products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenues and results of operations or could cause a decline or volatility in our stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors' reimbursement policies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products varies significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may not only limit the revenues from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.&#160;In addition, competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products or treatments brought to market by our competitors could cause revenues for our products to decrease due to potential price reductions and lower sales volumes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, increasingly seek ways to reduce their costs. Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients. Such measures include more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients&#8217; use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Payors also increasingly seek price discounts or rebates in connection with the placement of our products on their formularies or those they manage and control costs by imposing restrictions on access to or usage of our products, such as by requiring prior authorization or step therapy. Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Ultimately, additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection that will be afforded to our products and processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. Under the Drug Price </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, a manufacturer may file an Abbreviated New Drug Application, seeking approval of a generic copy of an approved innovator product, or a NDA under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, which may be for a new or improved version of the original innovator product. The manufacturers are allowed to rely on the safety and efficacy data of the innovator&#8217;s product, may not need to conduct clinical trials, can market a competing version of a product after the expiration or loss of patent exclusivity or the expiration or loss of regulatory exclusivity and often charge significantly lower prices. Upon the expiration or loss of patent protection or the expiration or loss of regulatory exclusivity for a product, especially a small molecule product, the major portion of revenues for that product may be dramatically reduced in a very short period of time. If we cannot prevent others from exploiting our inventions, we will not derive the expected benefit from them. Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third parties, which could result in financial, legal, business or reputational harm to us.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenues for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon the successful development of additional indications for our existing products as well as the successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung BioLogics or licenses or acquisitions from third parties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of uncertainty and risk. Only a small number of research and development programs result in the commercialization of a product. Furthermore, the development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining regulatory approval from the FDA and other regulatory agencies that have limited experience with the development of such therapies. In addition, clinical trial data are subject to differing interpretations and, even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, may limit the scope of the approval or may deny approval altogether. Consequently, it may be difficult to predict the time and cost of product development of novel approaches for the treatment of diseases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing and research and development and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition in many markets from generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways.&#160;Generic versions of drugs, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the price that we receive for branded products and the volume of branded products that we sell, which will negatively impact our revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, including TECFIDERA, our business may be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of biosimilars, follow-on products, generic versions of branded MS products, prodrugs or products approved under other abbreviated regulatory pathways, which would be significantly less costly than our products to bring to market and would be offered for sale at lower prices, and could result in a significant percentage of the sales of our products being lost to such biosimilars, follow-on products, generic versions of branded MS products, prodrugs or products approved under other abbreviated regulatory pathways;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the off-label use by physicians of therapies indicated for other conditions to treat MS patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract and maintain new and current patients to our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products or generic or biosimilars of our MS products, or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products or generic or biosimilars of our MS products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives, external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations, or the disposition of certain of our assets or operations. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement. Furthermore, if we decide to dispose of certain of our assets or operations, we are not certain that we will be able to identify a suitable counterparty or if we will be able to reach agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may fail to initiate or complete transactions for many reasons and we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data. Our computer systems continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">development of a product or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products, or generic or biosimilar versions of our marketed products, may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in liabilities, loss of revenues, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges or other adverse impacts on our results of operations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy or liver injury in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative and other third-party relationships for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships subjects us to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborators or third parties devote to our programs, products or product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise under an agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators or other third parties, and the underlying agreement with our collaborators or other third parties may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators or third parties fail to perform; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborators or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third-party relationships and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of products under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborators or other third parties to comply with applicable laws and regulatory requirements in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any improper conduct or actions on the part of our collaborators or other third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, and could adversely impact our ability to conduct business, our operating results and our reputation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, or revenues from products could decline and/or we may not realize the anticipated benefits of the collaboration arrangements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenues and may continue to adversely affect our revenues and results of operations in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. If we, or our vendors or donation recipients, are deemed to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the European Medicines Agency's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Further, certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we partner with or acquire in emerging markets.&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our sales and operations are subject to the risks of doing business internationally, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including generics, biosimilars and prodrugs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates that may adversely impact our revenues, net income and value of certain of our investments; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">diverse data privacy and protection requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effects of the implementation of the U.K.'s decision to voluntarily depart from the E.U., known as Brexit;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of tariffs or embargoes and other trade restrictions, including the recent tariffs imposed by the U.S. and China and the possibility of additional tariffs or other trade restrictions relating to trade between the two countries.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the Foreign Corrupt Practices Act (FCPA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have experienced changes in management and other key personnel in critical functions across our organization in recent years. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. Further, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change emphasis on our existing business programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. We cannot ensure you that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe we currently have sufficient large-scale manufacturing capacity to meet our near-term manufacturing requirements. However, due to the long lead times necessary for the expansion of manufacturing capacity, in 2015 we made the decision to expand our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required. In addition, we have made and expect to make significant investments in connection with the building of this manufacturing facility with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity would have a negative effect on our financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:54px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with current Good Manufacturing Practices (cGMP).</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilars, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If Samsung Bioepis or such other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Ability to Provide Adequate Supply.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties, we may be unable to meet higher than anticipated demand; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success   and/or the success of Samsung Bioepis in this business area.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilar products, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, as Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions and other business development activities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws, including the Tax Cuts and Jobs Act of 2017 (2017 Tax Act). </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from 35% to 21%, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as global intangible low-taxed income and includes base erosion prevention measures on non-U.S. earnings. These changes became effective in 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimates concerning the impact of the 2017 Tax Act on our accounting and on our business remain subject to developing interpretations of the provisions of the 2017 Tax Act. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial condition. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate an owned or leased property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time our Board of Directors authorizes share repurchase programs, including, most recently, our 2018 Share Repurchase Program and our 2019 Share Repurchase Program. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our agreements applicable to the repurchase </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">of shares. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption in the past, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may be exposed to claims and liabilities as a result of the spin-off of our hemophilia business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, in connection with the spin-off of our hemophilia business, we distributed all of the then outstanding shares of Bioverativ common stock to Biogen shareholders pursuant to a separation agreement. In March 2018 Bioverativ was acquired by Sanofi and is now an indirect wholly-owned subsidiary of Sanofi.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The spin-off of our hemophilia business was intended to qualify for tax-free treatment to Biogen and its shareholders under the Internal Revenue Code. Completion of the spin-off was conditioned upon, among other things, our receipt of a favorable opinion from our tax advisors with respect to the tax-free nature of the transaction. The opinion is not binding on the U.S. Internal Revenue Service (IRS) or the courts, and there can be no assurance that the IRS or the courts will not challenge the qualification of the spin-off as a tax-free transaction or that any such challenge would not prevail. If the spin-off is determined to be taxable, the full financial benefits expected to result from the separation may not be achieved and/or Biogen and its shareholders could incur significant tax liabilities, which could adversely affect our business, financial condition or results of operations and the value of our stock could be adversely impacted.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bioverativ agreed to indemnify us for certain potential liabilities that may arise, but we cannot guarantee that Bioverativ will be able to satisfy its indemnification obligations. Third parties could also seek to hold us responsible for any of these liabilities or obligations, and the indemnity rights we have under the separation agreement may not be sufficient to fully cover all of these liabilities and obligations. Even if we are successful in obtaining indemnification, we may have to bear costs temporarily. In addition, our indemnity obligations to Bioverativ may be significant. These risks could negatively affect our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><a name="s1937C625670856D0825B189E5053207E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity under our 2018 Share Repurchase Program during the first quarter of 2019:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced Programs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($ in millions)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January 2019</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">484,590</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">304.14</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">484,590</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February 2019</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">225,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">321.78</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">225,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,927.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March 2019</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,733,664</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">251.49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,733,664</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,491.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,443,254</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">268.41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our 2019 Share Repurchase Program, which is a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock. Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. We did not repurchase any shares of our common stock under our 2019 Share Repurchase Program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized our 2018 Share Repurchase Program, which is a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock. Our 2018 Share Repurchase Program does not have an expiration date. All share repurchases under our 2018 Share Repurchase Program will be retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$655.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From April 1, 2019 through April 24, 2019, we repurchased and retired approximately 2.1 million shares of our common stock at a cost of approximately $491.6 million under our 2018 Share Repurchase Program. During this time, we paid an average price per share of $235.99. As of April 24, 2019, we have repurchased and retired approximately 8.8 million shares of our common stock at a cost of approximately $2.5 billion under our 2018 Share Repurchase Program. Approximately $1.0 billion remained available under our 2018 Share Repurchase Program as of April 24, 2019.</font></div><div><a name="s235EAF4F4756541F839656F0D7FE4ED8"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><a name="s6FDD82A0189E52D982C4F3B34CA83955"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT&#160;INDEX&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exhibit</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description of Exhibit</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019331xex101.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2019 Form of Performance-Based Management Incentive Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019331xex311.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019331xex312.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019331xex321.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2019, formatted in XBRL (Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flows, and (v)&#160;Notes to Condensed Consolidated Financial Statements.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+&#160;&#160;&#160;&#160;Filed herewith </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">++&#160;&#160;&#160;&#160;Furnished herewith</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><a name="sE534E1800196571A96DD740791D0FD5B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sFE7F126231085FA098ED44F3EE2ADDDE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;padding-left:492px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:27.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIOGEN INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(principal financial officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;24, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>biib-2019331xex101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s18aa2d5f98b345ceb1f6642d6cd751bf"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Exhibit 10.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PERFORMANCE-BASED MANAGEMENT INCENTIVE PLAN</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1. Purpose</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Performance-Based Management Incentive Plan (this &#8220;Plan&#8221;) is established by Biogen Inc. (the &#8220;Company&#8221;) to attract and retain persons of outstanding abilities and to stimulate efforts to bring about strong operating performance and reward the individuals who contribute to this performance. This Plan supersedes and replaces any performance-based management incentive plan previously adopted by the Company or its predecessors and applies to awards granted on or after January 1, 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2. Basic Concepts</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Award programs under this Plan shall be developed under the following basic concepts:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:12pt;">There shall be an identification of performance periods, which may be a minimum of six (6)&#160;and a maximum of sixty (60)&#160;consecutive months in length. Because multiple awards may be granted to a Participant under this Plan, performance periods need not be sequential and may overlap or occur simultaneously.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:12pt;">With respect to each performance period, there shall be a determination of (i)&#160;eligible Participants, (ii)&#160;the amount of each participant&#8217;s target incentive awards, (iii)&#160; the applicable performance goals, based on the Performance Criteria listed in Section&#160;4.B below and/or such other Company and/or individual performance goals as may be approved by the Compensation and Management Development Committee of the Board of Directors of the Company (the &#8220;Committee&#8221;), and (iv)&#160;the extent to which performance relative to each such performance goal shall determine the amount of the award payable to a Participant.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3. Eligibility</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:12pt;">&#160;Participation in this Plan shall be limited to executive officers of the Company and its subsidiaries and affiliates.  Each employee participating in this Plan is referred to as a &#8220;Participant.&#8221;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:12pt;">Unless otherwise authorized by the Committee, Participants shall be excluded from participation in any other cash bonus or incentive program of the Company or any of its subsidiaries and affiliates; provided, however, that Participants shall not be excluded from participation in any equity incentive plan adopted by the Company (whether or not such awards are settled in stock or in cash).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4. Determination of Awards</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:12pt;">Except as provided otherwise in this Section&#160;4, awards under this Plan shall be paid on account of the attainment of one or more performance goals which: (i)&#160;are established by the Committee; (ii)&#160;are based on one or more of the criteria listed below in Section 4.B and/or such other Company and/or individual performance goals as may be approved by the Committee, and (iii)&#160;state the method for computing the amount of compensation payable to a Participant if the performance goal or goals are attained.  Unless otherwise determined by the Committee, Performance Criteria or other performance goals shall be adopted with respect to each performance period by the Committee (A) for performance periods of one year or more, no later than ninety (90) days after the commencement of the performance period; and (B) for periods of less than one year, before twenty-five percent (25%) of the performance period has elapsed. The Committee may waive </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">the achievement of one or more of the applicable performance goals in the case of the death or disability of the Participant or under such other circumstances as the Committee determines are appropriate. The Committee may provide that if certain specified goals are not met, no awards will be made for the performance period to which such goals relate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:12pt;">Performance goals shall be based on specified Company or individual criteria, which may include objectively determinable measures of performance relating to any of, or to any combination of, the following (measured either absolutely or comparatively (including, without limitation, by reference to an index or indices or the performance of one or more companies) and determined either on a consolidated basis or, as the context permits, on a divisional, functional, subsidiary, line of business, project or geographical basis or in combinations thereof and subject to such adjustments, if any, as the Committee specifies (&#8220;Performance Criteria&#8221;)): sales; revenues; assets; expenses; earnings before or after deduction for all or any portion of interest, taxes, depreciation, or amortization or other items, whether or not on a continuing operations or an aggregate or per share basis; return on equity, investment, capital or assets; one or more operating ratios; borrowing levels, leverage ratios or credit rating; market share; capital expenditures; cash flow; stock price; stockholder return; sales of particular products or services; customer acquisition, expansion or retention; acquisitions and divestitures (in whole or in part); joint ventures and strategic alliances; spin-offs,&#160;split-ups&#160;and the like; reorganizations; recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings; or achievement of clinical trial or research objectives. A Performance Criterion and any targets with respect thereto determined by the Committee need not be based upon an increase, a positive or improved result or avoidance of loss and may be based on GAAP,&#160;non-GAAP&#160;or other metrics as contemplated hereby.  The Committee may provide that one or more of the Performance Criteria applicable to an award will be adjusted to reflect events (for example, but without limitation, acquisitions or dispositions) occurring during the performance period that affect the applicable Performance Criterion or Criteria.  Performance goals may also consist of such other individual performance criteria and/or subjective Company performance criteria as determined by the Committee.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">C.</font><font style="font-family:inherit;font-size:12pt;">Except as provided in Section 8.B below, no incentive awards shall be paid to Participants under this Plan unless and until the Committee determines that the applicable Performance Criteria or other performance goals have been attained, and such determination will be final and conclusive.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">D.</font><font style="font-family:inherit;font-size:12pt;">A Participant may receive an incentive award under this Plan that is less than, equal to or greater than his or her target incentive award. The Committee may in its sole discretion adjust an incentive award otherwise payable to a Participant, including on the basis of Company and/or specific individual goals, which may be based on nonobjective factors related to the performance of the Company and/or the Participant, as the case may be.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5. Basis of Participation in Award Programs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:12pt;">Awards may, but are not required to, be denominated in (i.e., valued by reference to) the Common Stock of the Company or units of Common Stock of the Company; provided, however, that any awards denominated in cash will be paid in cash as provided in Section&#160;8.A below. Awards denominated in cash may be expressed as a percentage of the annual base pay of the Participant or as a specified dollar amount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:12pt;">In addition to any other terms and conditions set forth in this Plan, all or part of the grant, vesting and/or payment of an award may be made subject to future service and such other restrictions and conditions as may be established by the Committee, and as may be set forth in any award agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6. Administration</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:12pt;">The overall administration of this Plan shall be under the direction of the Committee.  The Committee has discretionary authority, subject only to the express provisions of this Plan, to interpret this Plan; determine eligibility for and grant awards; determine, modify or waive the terms and conditions of any award; prescribe forms, rules and procedures; and otherwise do all things necessary or desirable to carry out the purposes of this Plan. Determinations of the Committee made under this Plan will be conclusive and will bind all persons. The Committee may delegate: (i)&#160;to one or more of its members such of its duties, powers and responsibilities as it may determine and (ii)&#160;to such employees or other persons as it determines such ministerial tasks as it deems appropriate.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:12pt;">Responsibility for the ministerial administration of this Plan (for example, payment of awards approved by the Committee) shall be under the direction of the Company&#8217;s Head of Human Resources.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7. Determination of Incentive Awards; Limitations on Awards</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:12pt;">The maximum amount payable under this Plan to any Participant during any calendar year may not exceed $6,000,000 for the Chief Executive Officer and $3,000,000 for any other Participant.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:12pt;">The final determination of the extent to which the Performance Criteria and/or other performance goals were achieved for an award will be made by the Committee promptly following the availability of all necessary performance results.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">C.</font><font style="font-family:inherit;font-size:12pt;">For the avoidance of doubt, in no event will any payment of an award exceed 225% of the Participant&#8217;s target incentive award.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8. Payments; Effect of Termination of Employment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:12pt;">All payments of awards hereunder shall be made in cash within the sooner of 90&#160;days following the end of the applicable performance period or March 15 of the year following the calendar year in which the award was earned.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:12pt;">If a Participant&#8217;s employment terminates during a performance period due to death or disability, a determination of the amount payable to the Participant or his or her estate will be made as soon as practicable thereafter. Unless otherwise determined by the Committee, the amount to be paid under these circumstances shall be determined by multiplying the Participant&#8217;s target incentive award by a fraction, the numerator of which is the number of days completed during the performance period before termination of employment, and the denominator of which is the original length of the performance period. Payment of awards under this Section&#160;8.B will be made within the sooner of 90&#160;days of the termination of employment or March 15 of the year following the calendar year in which employment terminated. If a Participant&#8217;s employment terminates during a performance period for any reason other than death or disability, unless the Committee determines otherwise, payment will not be made in respect of any award.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9. General Conditions</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:12pt;">While it is the intent of the Company to continue this Plan indefinitely, the Company reserves the right to amend, modify or terminate this Plan, any incentive program under this Plan or any Participant&#8217;s participation in this Plan at any time or on such conditions as the Committee shall deem appropriate; provided, however, that to the extent that stockholder approval is required pursuant to law or by reason of the rules of the applicable exchange on which shares of the Company&#8217;s common stock is publicly traded, no such amendment or modification shall be effective until such time as such stockholder approval is obtained.  Except </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">as provided in 8.B above, no Participant shall have any right to any incentive award under this Plan until such award and the amount thereof has been finally approved by the Committee and communicated to such Participant after the end of the performance period for which the award is being made and the Participant remains employed with the Company through such date.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:12pt;">This Plan is not a contract between the Company and any Participant. Neither the establishment of this Plan, nor any action taken hereunder, shall be construed as giving any Participant any right to be retained in the employ of the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">C.</font><font style="font-family:inherit;font-size:12pt;">The Committee may cancel, rescind, withhold or otherwise limit or restrict any unpaid award (or require the repayment of an award) at any time if the Participant is not in compliance with all applicable provisions of this Plan and award agreement, if any, or if the Participant engages in any &#8220;Detrimental Activity&#8221; or as otherwise provided under any applicable clawback or recoupment policy of the Company, as in effect from time to time.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:72px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">1)</font><font style="font-family:inherit;font-size:12pt;">In particular, but not in limitation of the foregoing, in the event that a Participant engages or has engaged in Detrimental Activity, any amounts payable to the Participant in the year in which termination of employment occurs under this Plan may be forfeited and the entire amount of any payments made during such year of termination of employment shall be repaid to the Company.  Each Participant, by accepting or being deemed to have accepted an award under this Plan, agrees to cooperate fully with the Committee to effectuate any forfeiture required under this Plan. The Participant (and neither the Committee nor the Company) will be solely responsible for any adverse tax or other consequences to a Participant that may arise in connection with this Section 9.C.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:72px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">2)</font><font style="font-family:inherit;font-size:12pt;">For purposes of this Plan, &#8220;Detrimental Activity&#8221; shall include any action or failure to act that, in the sole determination of the Committee: (i)(a) constitutes financial malfeasance that is materially injurious to the Company, (b)&#160;violates the Company&#8217;s Code of Conduct, (c)&#160;results in the Company&#8217;s restatement of its earnings, financial results or financial statements or (d)&#160;results in a violation or breach of law or contract that is materially injurious to the Company or (ii)&#160;violates any non-competition, non-disclosure or non-solicitation agreement with the Company, or in the event that the Participant has not entered into any such agreement with the Company, the Participant engages in any &#8220;Competitive Activity.&#8221;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:72px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:24px;">3)</font><font style="font-family:inherit;font-size:12pt;">For purposes of this Plan, &#8220;Competitive Activity&#8221; shall include:  (i)&#160; the rendering of services for any organization or engaging directly or indirectly in any business which is or becomes competitive with the Company, or which organization or business, or the rendering of services to such organization or business, is or becomes otherwise prejudicial to or in conflict with the interests of the Company; (ii)&#160;the disclosure to anyone outside the Company, or the use in other than the Company&#8217;s business, without prior written authorization from the Company, of any confidential information or material relating to the business of the Company, acquired by the Participant either during or after employment with the Company or (iii)&#160;any attempt directly or indirectly to induce any employee of the Company to be employed or perform services elsewhere or any attempt directly or indirectly to solicit the trade or business of any current or prospective customer, supplier or partner of the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">D.</font><font style="font-family:inherit;font-size:12pt;">A Participant&#8217;s right and interest under this Plan may not be assigned or transferred, and any attempted assignment or transfer shall be null and void and shall extinguish, in the Company&#8217;s sole discretion, the Company&#8217;s obligation under this Plan to pay incentive awards with respect to the Participant.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">E.</font><font style="font-family:inherit;font-size:12pt;">This Plan shall be unfunded. The Company shall not be required to establish any special or separate fund, or to make any other segregation of assets, to assure payment of awards.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">F.</font><font style="font-family:inherit;font-size:12pt;">The Company shall have the right to deduct from incentive awards paid any taxes or other amounts required by law to be withheld.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">G.</font><font style="font-family:inherit;font-size:12pt;">Awards under this Plan are intended either to be exempt from the rules of Section&#160;409A of the Code or to satisfy those rules, and shall be construed accordingly. Notwithstanding anything to the contrary in this Plan, neither the Company, nor any affiliate, nor the Committee, nor any person acting on behalf of the Company, any affiliate, or the Committee, shall be liable to any Participant or to the estate or beneficiary of any Participant or to any other holder of an award by reason of any acceleration of income, or any additional tax, asserted by reason of the failure of an award to satisfy the requirements of Section&#160;409A of the Code or by reason of Section&#160;4999 of the Code.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">H.</font><font style="font-family:inherit;font-size:12pt;">The validity, construction, interpretation and effect of this Plan shall exclusively be governed by and determined in accordance with the laws of the State of Delaware, without giving effect to its conflict of laws provisions.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(Approved 02.12.2019)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>biib-2019331xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s56BBA9F53B105BDF969F03C4C1D7EF90"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Michel Vounatsos, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;font-size:10pt;text-indent:-48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April&#160;24, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>biib-2019331xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA929D98C2BEB5988A20352938F848F51"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Jeffrey D. Capello, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April&#160;24, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer and Chief Accounting Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>biib-2019331xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7BC0BFFF7A115DCDB27DD091378F9956"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2019 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: April&#160;24, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: April&#160;24, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer and Chief Accounting Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>biib-20190331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:8815FDFA6E9F52BC9150324A6A6187B5,x:093b8d629b43457f91d08994d4b4db48-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:biib="http://www.biogenidec.com/20190331" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="biib-20190331.xsd" xlink:type="simple" />
	<xbrli:context id="FD2019Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:WorkinprocessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:OperatingleaseassetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1remainingrepurchaseamount_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Sharerepurchases_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-04-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="KRW">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit>
	<biib:AdditionalMilestonePayment contextRef="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" decimals="-8" id="Fact-3774EECC71FED28827B4CAB8BC642B53" unitRef="usd">2000000000</biib:AdditionalMilestonePayment>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2019Q1YTD" decimals="-5" id="Fact-A92548907BDF5297BCB708493D7611CE" unitRef="usd">24500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-DF1BD2F4FE2C56EC97CD1344C226AD94" unitRef="usd">25100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-42B00D84E5DC5409863E21D256AF504D" unitRef="usd">-300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-89BB8A7437CF51BE84309C3A1AE18B53" unitRef="usd">-300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2018Q4" decimals="-5" id="Fact-B46F6D1446D1579EADBDD4E77BDAC221" unitRef="usd">143500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2019Q1" decimals="-5" id="Fact-538DDE4578A0558C8D42CEBBF5C82DE4" unitRef="usd">135000000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2018Q4" decimals="-5" id="Fact-0B7B631463AD5AECB6B153FC8DBF31C2" unitRef="usd">143200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2019Q1" decimals="-5" id="Fact-7231D04459165AFF9492FB1199CD2FD3" unitRef="usd">134900000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2019Q1YTD" id="Fact-3BF5BBE6DA7B593082638153660772E3">P12M</biib:AverageMaturityOfMarketableSecurities>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2019Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-916104B7B1EE5256ACD57D5028C205B0" unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Collaborationexpensesaccrual contextRef="FI2018Q4" decimals="-5" id="Fact-9327E23E17D25BE59935F1A9EAAC6626" unitRef="usd">261600000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationexpensesaccrual contextRef="FI2019Q1" decimals="-5" id="Fact-23E9724E6D845589BE2A033DFCF0B4E6" unitRef="usd">216600000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationprofitlosssharing contextRef="FD2018Q1YTD" decimals="-5" id="Fact-08AD4310B4D45F1392FA230BD61A0474" unitRef="usd">42500000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2018Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-48EE60F53DB055448C3B2C92E708EFF1" unitRef="usd">43800000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2019Q1YTD" decimals="-5" id="Fact-4CF2906FE0D152F681001711330879D8" unitRef="usd">58100000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2019Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-6C7A4BEF0E4650229E543A34EB82FA80" unitRef="usd">58100000</biib:Collaborationprofitlosssharing>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2019Q1YTD" decimals="-5" id="Fact-4883BB9781F85EA9982E68C9242024BB" unitRef="usd">826200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-73AE420A9E0851C9A9A08D9034EFD571" unitRef="usd">680300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-49061C4BF9B35822B82ABB17F41B8090" unitRef="usd">141200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-B0D0C320913F5CA8A3D81735817B188B" unitRef="usd">4700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease contextRef="FD2018Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" decimals="-5" id="Fact-D0D64872307D4C6F1E45362E2DA66B1A" unitRef="usd">0</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
	<biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease contextRef="FD2019Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" decimals="-5" id="Fact-ECA5AA2744063FADB104362D972AFC2E" unitRef="usd">4400000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
	<biib:DisposalGroupOperatingLeaseAssets contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-5BE1D5DE596E6EEF379635DECF82FDE7" unitRef="usd">2500000</biib:DisposalGroupOperatingLeaseAssets>
	<biib:DisposalGroupOperatingleaseliabilities contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-2DC466939D2B98FB604235E5E0372811" unitRef="usd">1700000</biib:DisposalGroupOperatingleaseliabilities>
	<biib:DisposalGroupOperatingleaseliabilities contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-B5F2BE58CB496C4897FA368BEE608026" unitRef="usd">2500000</biib:DisposalGroupOperatingleaseliabilities>
	<biib:DuefromantiCD20therapeuticprograms contextRef="FI2018Q4" decimals="-5" id="Fact-BB963D006B095AB09D9BD0037B18B23C" unitRef="usd">526900000</biib:DuefromantiCD20therapeuticprograms>
	<biib:DuefromantiCD20therapeuticprograms contextRef="FI2019Q1" decimals="-5" id="Fact-20A3E621A4995BA5A5ADDE0F318B7B51" unitRef="usd">527100000</biib:DuefromantiCD20therapeuticprograms>
	<biib:EffectiveTaxRateReconciliationGILTItax contextRef="FD2018Q1YTD" decimals="3" id="Fact-C9C1901FC4C05E01B997F0F3038BE183" unitRef="number">0.013</biib:EffectiveTaxRateReconciliationGILTItax>
	<biib:EffectiveTaxRateReconciliationGILTItax contextRef="FD2019Q1YTD" decimals="3" id="Fact-09410AE7B6F450CCB8A0C1D00FC0B64F" unitRef="number">0.019</biib:EffectiveTaxRateReconciliationGILTItax>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2018Q1YTD_srt_MajorCustomersAxis_biib_DistributorOneMember" decimals="3" id="Fact-FE7C5CF755BEE42DBBD3C4EFEA7F9A12" unitRef="number">0.340</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2018Q1YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" decimals="3" id="Fact-3AEE0C119EE63BEA758CC4EFAAAE9A6A" unitRef="number">0.159</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_biib_DistributorOneMember" decimals="INF" id="Fact-1ABCAD13ECDB5EE92904C4EFD05CC944" unitRef="number">0.313</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" decimals="INF" id="Fact-FCA743B04B0DF17B8671C4EF77EA8D55" unitRef="number">0.142</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction contextRef="FI2018Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-FC87AA5E6CCF56EF90211362436EA74B" unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
	<biib:Equitymethodinvestmentbasisdifferenceamortizationperiod contextRef="FD2019Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember" id="Fact-D686375CAF0E6335B18636C4AC472BA2">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
	<biib:Equitymethodinvestmentbasisdifferenceamortizationperiod contextRef="FD2019Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember" id="Fact-27F76ACF25D7FC6932AF36C2420D969E">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
	<biib:Expenseincurredbythecollaboration contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-29154B3CD7EF5FF7AF6C829CF1554851" unitRef="usd">63600000</biib:Expenseincurredbythecollaboration>
	<biib:Expenseincurredbythecollaboration contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-9333626A86A4515DB7E5984F845FD90E" unitRef="usd">7100000</biib:Expenseincurredbythecollaboration>
	<biib:Expenseincurredbythecollaboration contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-A77353BE60565808AE4C84C6A6873186" unitRef="usd">52200000</biib:Expenseincurredbythecollaboration>
	<biib:Expenseincurredbythecollaboration contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-F3658E529189554494CC5FD9B84A1A35" unitRef="usd">162500000</biib:Expenseincurredbythecollaboration>
	<biib:Expenseincurredbythecollaboration contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-7450173CB12B5F928EC97F4B56170064" unitRef="usd">20900000</biib:Expenseincurredbythecollaboration>
	<biib:Expenseincurredbythecollaboration contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-A9D902A36EB95B3EA72A3713FF7D2D26" unitRef="usd">68000000</biib:Expenseincurredbythecollaboration>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-46F2BA60D25C5C3CB8F26BDBD166F7B1" unitRef="usd">63600000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-04B4CA5B87255D20B25BDC72434032F7" unitRef="usd">3900000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-ACC8723D96E052E1904F4DD42DD3A2BE" unitRef="usd">26100000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-07AB011958945FFE816D27C7D5246FE9" unitRef="usd">89400000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-9F1E4638311F58F48BA050CE79927D03" unitRef="usd">11600000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-1FA37A1C9ACA5A04ACF1B4012F795F68" unitRef="usd">34000000</biib:Expensereflectedwithinstatementsofincome>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2019Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact-580553218122507F970D1005E1F9A317">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2019Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" id="Fact-871AD10DE3645ED5BA4A030B1AB1028B">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:InterestInSubsidiary contextRef="FD2019Q1YTD" decimals="INF" id="Fact-D4D51565E32958298D019DC4E7C409E6" unitRef="number">1.00</biib:InterestInSubsidiary>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-A63DE001FBBE5AB193B69183912C7539" unitRef="usd">936500000</biib:Inventorynetcurrentandnoncurrent>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2019Q1" decimals="-5" id="Fact-C7D33BB528AB56F7B03D8252B545102D" unitRef="usd">770200000</biib:Inventorynetcurrentandnoncurrent>
	<biib:InventorysoldtoBioverativcost contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember" decimals="-5" id="Fact-6CD9AB6A210115E9D460360689EDE62D" unitRef="usd">173500000</biib:InventorysoldtoBioverativcost>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2018Q4" decimals="-5" id="Fact-76A6ACF37E1B52CBAD54932229DE0914" unitRef="usd">28700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2019Q1" decimals="-5" id="Fact-13FCD479D17451968D60A1DCA8B5AF6B" unitRef="usd">112200000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:Investmentincommonstocksharespurchased contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-F8717D1BF019E28D7908C59BE360FC0D" unitRef="shares">11500000</biib:Investmentincommonstocksharespurchased>
	<biib:NetMinimumLeasePayments contextRef="FI2018Q4" decimals="-5" id="Fact-8CDBABAF080D742FE989367865516A7C" unitRef="usd">418800000</biib:NetMinimumLeasePayments>
	<biib:NetMinimumLeasePaymentsThereafter contextRef="FI2018Q4" decimals="-5" id="Fact-4D62950B4444D10941FF367864094145" unitRef="usd">156900000</biib:NetMinimumLeasePaymentsThereafter>
	<biib:NetMinimumLeasePaymentsWithInFiveYear contextRef="FI2018Q4" decimals="-5" id="Fact-F193D22A831A1A67B632367862FBEDE3" unitRef="usd">46700000</biib:NetMinimumLeasePaymentsWithInFiveYear>
	<biib:NetMinimumLeasePaymentsWithInFourYear contextRef="FI2018Q4" decimals="-5" id="Fact-EB1D6A72CD0DCDBE493A367861C252CA" unitRef="usd">47700000</biib:NetMinimumLeasePaymentsWithInFourYear>
	<biib:NetMinimumLeasePaymentsWithInOneYear contextRef="FI2018Q4" decimals="-5" id="Fact-0ABFD84FDAA68BDB3B7136785E64933A" unitRef="usd">60200000</biib:NetMinimumLeasePaymentsWithInOneYear>
	<biib:NetMinimumLeasePaymentsWithInThreeYear contextRef="FI2018Q4" decimals="-5" id="Fact-41F9A391DA22E35B4907367860A85379" unitRef="usd">52200000</biib:NetMinimumLeasePaymentsWithInThreeYear>
	<biib:NetMinimumLeasePaymentsWithInTwoYear contextRef="FI2018Q4" decimals="-5" id="Fact-09B0358D0B8AE6764DC136785F81A2C2" unitRef="usd">55100000</biib:NetMinimumLeasePaymentsWithInTwoYear>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2019Q1YTD" decimals="-5" id="Fact-881B2DAB8DD8679DFD4A35CB0DB5962C" unitRef="usd">100000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-91BE8CBB7911630F72D235CB0A06AF9F" unitRef="usd">100000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-7BF1197626F3A20C8EC635CB08393F14" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="FD2018Q1YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-27E24301D8625FC8B73BA9FE8F698E07" unitRef="usd">93600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
	<biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-C48735A6B4BD50358A16CD238242CF02" unitRef="usd">126600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2019Q1YTD" decimals="-5" id="Fact-87D969CDDD37597C8C0DC7DAE45236B3" unitRef="usd">294800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-7E338DA7B2895B82B755A58B9235FC65" unitRef="usd">233900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-A18329DAE37A53F38FDFB1813142A97F" unitRef="usd">60800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-C9A0A9E9C1F05338A132DE32B061CEFD" unitRef="usd">100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2019Q1YTD" decimals="-5" id="Fact-331C923D1EB15907A989DFF3C7622AB8" unitRef="usd">474800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-9A64C1184757596ABFBCE31B45E993BE" unitRef="usd">378100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-E617D0F8D477583FA3E7D7E7D07628EB" unitRef="usd">92100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2019Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-08E465D1D4C051ED9F90D690DD42C7B0" unitRef="usd">4600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PercentageoffuturedevelopmentcostsrelatedtoEisai contextRef="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="INF" id="Fact-FBA5B5F661C45450A2C5F7A5D31FDF14" unitRef="number">0.15</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
	<biib:PercentageoffuturedevelopmentcostsrelatedtoEisai contextRef="FD2019Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="INF" id="Fact-07E3C12003F55755A085DF058D4AD73F" unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E807474B00C95EE08CD8D1132AE7A867" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2BE11A6F1D6451CA9F2E369DA272A8E9" unitRef="usd">25400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7130013DDE5C5208A430F38803F187A4" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0F3FBDCD5F97568D8E0F3B7377D8AC1D" unitRef="usd">25400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-136623B745875876B50017649AD9AB12" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-71245DFD32BB539896482933CC727012" unitRef="usd">29400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2CA94D69555458C58162F9540A9F02BD" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1B76CEE830FD5B9FB60C75C236917BDB" unitRef="usd">29400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:Purchaseofcommonstock contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-900B3A32C06963F7B9B3C59C17744C17" unitRef="usd">625000000</biib:Purchaseofcommonstock>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2018Q1YTD" decimals="-5" id="Fact-B71FEC47027F59D08A7CB96DD3817529" unitRef="usd">47000000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2019Q1YTD" decimals="-5" id="Fact-DA73B72BF434519DBA3B170B9BF02658" unitRef="usd">46200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareOfCoPromotionProfits contextRef="FD2018Q1YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-8B99E1622258597696205462B14F54DB" unitRef="usd">349600000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-B3CF02EDFB4858B886B53070F42296B6" unitRef="usd">390800000</biib:ShareOfCoPromotionProfits>
	<biib:StrategicInvestmentPortfolio contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-FF8C924A6DA6528F90389A09EE330918" unitRef="usd">676300000</biib:StrategicInvestmentPortfolio>
	<biib:StrategicInvestmentPortfolio contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-570F4674C829C212EEFD4BA79FF8967D" unitRef="usd">90100000</biib:StrategicInvestmentPortfolio>
	<biib:StrategicInvestmentPortfolio contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-8F3D102BE7FC5DBC9C3C5D26DAB6D5D7" unitRef="usd">1049700000</biib:StrategicInvestmentPortfolio>
	<biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="FI2018Q4" decimals="-5" id="Fact-CF75EF60460B52C7AA2A1BE006B6D594" unitRef="usd">27300000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
	<biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="FI2019Q1" decimals="-5" id="Fact-439275875BE15102A5D05BCDDC07F9CA" unitRef="usd">-44300000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FD2019Q1YTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" decimals="-5" id="Fact-8F2DB9741F3FF0F17DFBCAB868C10175" unitRef="usd">74000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<dei:AmendmentFlag contextRef="FD2019Q1YTD" id="Fact-5AEC11519995536DA8B4A44AFCDDD6A8">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2019Q1YTD" id="Fact-7061D1199F395A7FBEEFBAB569961286">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2019Q1YTD" id="Fact-E56C76C621B959ACAB4E65B25AC40B80">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2019Q1YTD" id="Fact-E94436ED26E75816A622D4E66743C474">2019</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2019Q1YTD" id="Fact-18C17C5692795980ACAFE9F685E8F7B4">2019-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2019Q1YTD" id="Fact-3D44FBDBBAB65E50B4B8BD2E8765DB80">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2019Q1YTD" id="Fact-E0E38D860E4251D3914B27541754CBDF">0000875045</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2019Q1SharesOutstanding" decimals="0" id="Fact-6E94DDD64AE45545A00A88015E31DECB" unitRef="shares">193893397</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityEmergingGrowthCompany contextRef="FD2019Q1YTD" id="Fact-0DF380410D415A4DAAD24721EF8A044C">false</dei:EntityEmergingGrowthCompany>
	<dei:EntityFilerCategory contextRef="FD2019Q1YTD" id="Fact-6B012EB2396D5A68AF911D10AD9FAD6F">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2019Q1YTD" id="Fact-31D2E309D88B5ACEB43A892D88836FAE">BIOGEN INC.</dei:EntityRegistrantName>
	<dei:EntitySmallBusiness contextRef="FD2019Q1YTD" id="Fact-5C13C3E443D755E38F3595B47174039B">false</dei:EntitySmallBusiness>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-B1E54A1F716B5E5C91FA7A67FAAD131D" unitRef="usd">92200000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-E4F1F65793CA5A3E9E30DF641F709F66" unitRef="usd">131400000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-94415F15D44C53C89AB368AEB066C2E7" unitRef="usd">1701400000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-BDE6C2F9F185588187A882957316F1AE" unitRef="usd">215300000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-8D7AC173527D1F508C37C5A4D7970052" unitRef="usd">98800000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-BF97FFEF48365B3D9D63F82476CF0581" unitRef="usd">2239100000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-D83AB823C2825871A8D29E4EC008ADA2" unitRef="usd">735100000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2019Q1_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-18ACB53A046D58DCBBC68940F16A381A" unitRef="usd">72200000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2019Q1_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-955D796DD4D9502FADCDFFB94A35A86C" unitRef="usd">99200000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2019Q1_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-5891C3524E7B55DE8C2308F607058E70" unitRef="usd">1722200000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2019Q1_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-61FF8CF25E4A55179A5F9C4544ECCABE" unitRef="usd">170900000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2019Q1_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-C6E2B723DAA65A72A7C8C5A480460A29" unitRef="usd">79500000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2019Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-A68A72DC79BC55E48D9B9187BD6A31D4" unitRef="usd">2144000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2019Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-88EDFB10436A546BA4AD27472FFBF44F" unitRef="usd">675000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2019Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-7FEB35B9DF2056E2AA913D551CA534DD" unitRef="usd">895000000</invest:DerivativeNotionalAmount>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-1B28D37FA5585E15A088878266CE535E" unitRef="usd">370500000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-FAE883D309275133B6F2145C408E8777" unitRef="usd">378000000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-2F04048E1526576C93C665350A1538B0" unitRef="usd">1958500000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-9584B1B4580D5712A61782757876D4F5" unitRef="usd">2088900000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedIncomeTaxesNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-3B20FAFA72255BB79A6022DDF6CED135" unitRef="usd">791400000</us-gaap:AccruedIncomeTaxesNoncurrent>
	<us-gaap:AccruedIncomeTaxesNoncurrent contextRef="FI2019Q1" decimals="-5" id="Fact-E4FA58062EB75F73B30281314A9F10C5" unitRef="usd">796100000</us-gaap:AccruedIncomeTaxesNoncurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-9B700A98B0B55509BD9245A40C19094E" unitRef="usd">224700000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-AA083E5A57BF5D8CA5015827E00E1943" unitRef="usd">195000000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-5" id="Fact-6105E5020F1D542F87B1E9AAB5A5A70D" unitRef="usd">1797400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2019Q1" decimals="-5" id="Fact-746C1372A32D5CC8BD8095DCC62BD4A9" unitRef="usd">1841000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4" decimals="-5" id="Fact-D5808ACFF43A57BD852A861ECB7AFF39" unitRef="usd">-318400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-2BF3500EEE475DF38D0CC456F9A27EAD" unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-6B426A04399055A3AB22F49C5D915B12" unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-E89A751083DF52D498F793898724EA67" unitRef="usd">-1600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-A97D72A3B37200C648D2CA76EB706C82" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-FC972D1A1003570DB5B7E84854DC9D62" unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q1" decimals="-5" id="Fact-F0B11AC2612F53CEB30DB6FFFA3F59E8" unitRef="usd">-303900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-A85D15FEC24B592A9B40C2D6CFC13FD6" unitRef="usd">-37300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-9567A1DCADA65F6AA9974F9F4C8F98F9" unitRef="usd">-133500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B5174A5817125E7194ACF71C2EA7D54E" unitRef="usd">-2300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-9E44F0D51AA6DFBFF0A6CA76F19FF74A" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-4CAC7E5A5E7B58F5826408623008503C" unitRef="usd">-130800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="-5" id="Fact-BF34BAE315055340B9816A44D7A6380E" unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-7EA5D11FD0A451B7862A3ECBAE6D3BD1" unitRef="usd">-31300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-8D373BA479075E21BF3AD6DDCF81CCDA" unitRef="usd">34700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-455B83FFD2C556F9A7A1FDACB5358810" unitRef="usd">-4000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-4B08E143062686D4B598CA7655853781" unitRef="usd">3500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-04B97586551D5FD38DCC2301EE5DA87E" unitRef="usd">-243300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q1" decimals="-5" id="Fact-CF67966620275601B018C433BFB6A8CD" unitRef="usd">-219800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-0CD360730C9E59D7A6A732082DDADB2B" unitRef="usd">-30700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-C36CD2D9A5265DC5B45B3F3477EE5789" unitRef="usd">51600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-343D5FF968DB5DB4A4EDB33948BDA975" unitRef="usd">2900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-16FDF9983A906EE258CBCA7659699679" unitRef="usd">17500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-B0ADE180CE945202B81CAA301C91692C" unitRef="usd">-261100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate" decimals="-5" id="Fact-4AF195EAB297DFCEE50DCA77528468B4" unitRef="usd">-316900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-287BB74690B28F06B422CA774F901AD3" unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-303F78E7D4E3153FBDC0CA774D184CC6" unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-955304119D714479FA36CA774BA958CC" unitRef="usd">-100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="0" id="Fact-767154880BFEBAB3ED3DCA76EDBCFB28" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-286B88664A97863DD85ECA7751008AF3" unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2018Q4" decimals="-5" id="Fact-15BCC867D919516589311A0DF96B65CA" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2019Q1" decimals="-5" id="Fact-86CA24006C6752DCAD8794FA77F1F6FA" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentForAmortization contextRef="FD2019Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-00CBDDAE85DED812AC9F36CAEED061BA" unitRef="usd">14700000</us-gaap:AdjustmentForAmortization>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-312B5853E1D6DD591C40C4914AADFC06" unitRef="usd">46700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-310E681194BD5FF38FED3C87C9B6498F" unitRef="usd">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-1A28AAC12CB1576AA134670FEF2A190A" unitRef="usd">3900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-AE95B52E1A5F562582B413B9E7F421C7" unitRef="usd">6100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="-5" id="Fact-172A49CC8BBC59E09643DF8470CF9916" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-D4B613A5C83F575A9F99E3BEDC5B98CA" unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-C7B6591DDA0554EFBC89F5B149211A7B" unitRef="usd">36100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-B146DD3FB23858CA9244582665A772BC" unitRef="usd">-800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-F3E184475DA05653A8BDC96239C6C82F" unitRef="usd">39400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-7F9FEDB95DBA54D498D6A39F1FF49D8B" unitRef="usd">21900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-698AE8EF187758C8B30DD0AED5744CB8" unitRef="usd">28500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-2241CEAD54BF991170E1C49143D61E67" unitRef="usd">46700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD" decimals="-5" id="Fact-8C96F7FBBE5750EB8413C4893D10E0D8" unitRef="usd">49000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-56B18CA51451597E997045D8DB30C916" unitRef="usd">-1000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-03C467FA21285792AA0654B7170916B5" unitRef="usd">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-999683708C475AACA68477B62AB9696C" unitRef="usd">7700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="-5" id="Fact-2E387A9D1E9357BBB9A2ED9EA7F8950D" unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-9765DF6288E25AF6A2BC020C86797D6E" unitRef="usd">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-1E31708899065C13B51312FA14530B1A" unitRef="usd">34700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-0764DB7DDE015EA3A3DDACD7FD49CA34" unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-28192A8EB152543DB0B46614234EA81D" unitRef="usd">38800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-62FA2C0DE7F155F6BDD625063F4CDEFB" unitRef="usd">21700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-72DD0C92715A5DD094829D2A5A293780" unitRef="usd">27800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-2A4E6687D6E6951E5B87C48936646DFB" unitRef="usd">49000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-10071AF1B9B35656B6EF0B077A2C81AC" unitRef="usd">50400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2019Q1YTD" decimals="-5" id="Fact-28D2C15382E05F1B841D9C2ED4B96691" unitRef="usd">49500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q1YTD" decimals="-5" id="Fact-A60E307813165FD79B8194E3A5799950" unitRef="usd">103900000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2019Q1YTD" decimals="-5" id="Fact-C2B193708B65527080192684270032D0" unitRef="usd">68200000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax contextRef="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" decimals="-5" id="Fact-F429FAB59BCAFB81F527C5AA94E235E8" unitRef="usd">7300000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
	<us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax contextRef="FI2019Q1_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" decimals="-5" id="Fact-036B706D0840705EF392C5AAA78B2801" unitRef="usd">9500000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
	<us-gaap:AssetImpairmentCharges contextRef="FD2019Q1YTD" decimals="-6" id="Fact-B35BCC93D67F5B25AB9752668F6A1DD6" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="-5" id="Fact-31036DA434E0543FB9F024B6F404F091" unitRef="usd">25288900000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2019Q1" decimals="-5" id="Fact-216C73C80F5454F483F6BE0CD82B495E" unitRef="usd">26445500000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-A9FC77769AF0585C930E1038E9782658" unitRef="usd">7640900000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-1929CF97BE275FB4ABA2DCB5750073F3" unitRef="usd">8942600000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-792F192CD0F35AE4A96712415CBFA9E1" unitRef="usd">51700000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8B1739DB2AB65A1A8FD8CA8BDE7E566D" unitRef="usd">5050800000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F51F0C4C4F215885995E20E9F0C7B519" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-963D16B7BC895C3D935424DDDBB2DC45" unitRef="usd">5102500000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-46AE00A884715A5F967260923FFB4B67" unitRef="usd">19500000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-533F1635E97754B4A30CB356D3D948BD" unitRef="usd">5938700000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-75CE2BF7CD345F95ACE6D18FE614E893" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B39B4ED1485655F9A5674D878C85A802" unitRef="usd">5958200000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-7C79328C51FA9AF53678C46F7826187E" unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
	<us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-233F2E2274E0D64DF635C46F4EDD59ED" unitRef="usd">682000000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-504DE80DFB5F2EC85D02DE30285436DD" unitRef="usd">682000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4" decimals="-5" id="Fact-8C1C6C4C0AC45580AB9D44B3AFC8C0A2" unitRef="usd">1300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-FA32C217BBBA5E7C9C4C296DCEB8F43C" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-44A7F723585B5CE2914A383AED515664" unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-CFC851543ED15DEDB5627C0189C4F576" unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-2D40D0AEB80B56A8944D2E5E5F38BA0F" unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-1E60B72EEB4259169AE2C119842FAD8A" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-9308FECED01F5775B5BB5B91C18CBBB4" unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q1" decimals="-5" id="Fact-71CC6BF2EFB9566D9635D503D2F903C8" unitRef="usd">4600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-F1B76CD0859B547FB92B4ECCBF4B18BB" unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-66EF6AFC5D7E51F4AA1BD4835B8F1EE9" unitRef="usd">2800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-F0D44527AF2C558CBBDDE04C25110FF5" unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-053A7D6C9D075B48BD6405D7DAF07C13" unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-57FA6072DE2E50F7A954BDED58737DFB" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-5752745BCD5959D3A11941A3533DEB53" unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4" decimals="-5" id="Fact-5587CD41F2D65CFCB35B2C6C03F61927" unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-23E73696E82250E68E11655F0FFFACE0" unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-DE72D81D64EA5749A6D2A8C75B9C281F" unitRef="usd">3900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-4035EBDFBC9E575F9F60B814A59F8C7C" unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-2FAA08278F0D57E6A3A13170D9D2D092" unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-073F207752B15B4DBA2390BB7E3A9901" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-1DE53A5B20B65E2EA87C28AFF04AE992" unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q1" decimals="-5" id="Fact-05D4AA6EE91456299CF0D81403F61C97" unitRef="usd">1200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-A20D446E50555D57A70612283E403EE6" unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-3BF9F2F7B80F5612ABE179B94B556572" unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-A2CC3710A9225E52A6D2DE298B0D9865" unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-CD9171E30ACE59DEBD9BC3FF19902868" unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-4379FAAA050953BAB289B4CB0C4DCF5A" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-A2E06017E4205138BF34C8582C95A5DA" unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4" decimals="-5" id="Fact-147F3519FD0DB19D7D2636182B46B945" unitRef="usd">3694000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-6A56C5126CC158BEBA63CC74921D52B4" unitRef="usd">1608400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-9F5F8430B7B158358561B7634B393751" unitRef="usd">854900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-7D620B6FF9455096AA702C4E8080CFB2" unitRef="usd">706100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-A00377133EF359F0B9D1495370443802" unitRef="usd">264000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-BF5CCC752E9653E2BC940C5692187809" unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-778F0EE7B8C35EC68521CC2A97DF978D" unitRef="usd">260500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q1" decimals="-5" id="Fact-9700E9E87B0CA8D504B9361640689875" unitRef="usd">3035100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-DB9837E0D7FB5B58B3F6A764098E64C9" unitRef="usd">981000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-FCD27663DC635F1883D386FB145F4471" unitRef="usd">852000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-02D8BD4C76F6529BB6724CB35432F95F" unitRef="usd">683600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-9E54DF74B43B5806A916A8DE786BA8FB" unitRef="usd">237500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-0E2F8C0C74FF52A781902CAF1EADD77E" unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-1DC7DBD2DBF957F480F1605B1F8918C0" unitRef="usd">280300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4" decimals="-5" id="Fact-FE26170DEC3853769015271C30F7DE04" unitRef="usd">3689300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-06100BBC20315CFAA3CD74FE833D4998" unitRef="usd">615400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2019Q1" decimals="-5" id="Fact-0BDC1BA850FF52CE9AD3E9FD80239C25" unitRef="usd">3038500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-ECC7760E1A48577CA4165D522410600D" unitRef="usd">904000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-FB388216466D5F2F845038708D8BC579" unitRef="usd">127700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-4DECC560E7C95A8ABF378FDE49B44AC0" unitRef="usd">421700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-97C77FF2DF605842B06C6399864BC138" unitRef="usd">8500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-05F73B6DAAF25E9FBC9DC91919AC63C8" unitRef="usd">7000000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-7ADEF9EA53B95568B8A4FDE9880D8839" unitRef="usd">496200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-6360503366A15C0CB980463D43029D2D" unitRef="usd">489300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2018Q4" decimals="-5" id="Fact-9ABF81FDBE775F039C8820B354D02248" unitRef="usd">1235900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2019Q1" decimals="-5" id="Fact-4B690F710D1B5647BB0BC2243BD7B081" unitRef="usd">1234800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2018Q4" decimals="-5" id="Fact-0643E61359CE58EDBDBF4763AAA872D6" unitRef="usd">1232700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2019Q1" decimals="-5" id="Fact-DAF61666AC755ADAB0E6912F01A8453D" unitRef="usd">1237800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2018Q4" decimals="-5" id="Fact-4347F4BEEDA75D20BE7F5CCC26554D0C" unitRef="usd">2314600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2019Q1" decimals="-5" id="Fact-3224CD4BBFD85830B435F467A16B057B" unitRef="usd">1665300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2018Q4" decimals="-5" id="Fact-E9B249C6F7F1521BA5D1C95B05E4376A" unitRef="usd">2313400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2019Q1" decimals="-5" id="Fact-0991AABC3E275C06AECCB485CDBBF017" unitRef="usd">1665800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4" decimals="-5" id="Fact-30409E584E7F500FAB7B60C2BF4EEA81" unitRef="usd">3689300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FC85F31F8D5F567A96F4285A98B0935B" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-020F2E1719445C9797E2B6458F9357BE" unitRef="usd">260500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2846A4BFADDD54FF9AFAA145F3356F20" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C6AC8935346D51ADB6E2EC7CD7402768" unitRef="usd">260500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F6E3972011005CE2ACB47D6270A7F561" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F8B6E2082C97511D877A4186FC05D4EF" unitRef="usd">2459200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-72F464F722345A9BB1215C28D361E95D" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-791ECB8928775B408B1FA04934346CFE" unitRef="usd">2459200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2CED87B8954453279B7138998B26845F" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-79FDFC549B7E5E668F16AC2E3E829E63" unitRef="usd">969600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4FF7639C6AAC57DEBD050F25A1608128" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8449D056B4C25308BA089FE6BD6197C3" unitRef="usd">969600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-7DF4A730BAC354BEB91CEAC8BF57D9FD" unitRef="usd">1607500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-D27E9D1EC491533399439087A43436E6" unitRef="usd">851700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-22969FEBC288541FA19BC51BBE356432" unitRef="usd">705800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-439F87F908205D16B66338FD5B002AD8" unitRef="usd">263800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-E63EB53208B65AD9B0A403BEA351CC33" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-ACEB30CB301E5E4791D900F39F780363" unitRef="usd">260400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1" decimals="-5" id="Fact-423A408E3AD250F098D7F9A428252329" unitRef="usd">3038500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8187C743FE3D58799756B7383CFF0ACB" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7C633C64A96C54238CBE8B324A037AE0" unitRef="usd">281500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-51BC84CC835A5E9089887AC5A2812C6E" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-72B07A10A660545493EC0331498A3F4D" unitRef="usd">281500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C1E78A544CC65B9DA7975DB204CEEE60" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BCAB8D33D21D5344955FC34B65E84B53" unitRef="usd">1835700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D4D264DDEA45539DA1C94CD7C9B4D47E" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8D168696931D5EC8A3060D8162025A81" unitRef="usd">1835700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E34940BCBBB654EDA9ABB51F34A8D794" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1D5749FCA54C5B17BC7741CC3968376D" unitRef="usd">921300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-11884CC469C65960A1C91C2E96C0CAE0" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-468336AE0F4655E986CE768582E3410A" unitRef="usd">921300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-AFAECAB0B9755770AED6ED286A1B5D78" unitRef="usd">981400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-622EE59A19DF524488391F5A7FCFB1D9" unitRef="usd">854300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-65295362632456AAB8326E6FC4F24FB2" unitRef="usd">683700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-E872D79B251B5C429B7DD5DB8939971F" unitRef="usd">237600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-ECEC7AC04A265AA380F5FCD3CEBBB011" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q1_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-3E473D76980652B7B8AB829512C6FB92" unitRef="usd">280800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-1BF2B16A6EB75B9CBBA23D15AB0F7B54" unitRef="usd">2313400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-25FA4127EEB85264B9EFC9E36FCD6F0B" unitRef="usd">1665800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-F9A18912235E5990A297B5322158D646" unitRef="usd">1375900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="FI2019Q1" decimals="-5" id="Fact-BBDFED9E46325ECBA8FF2F0A80F6E4CA" unitRef="usd">1372700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
	<us-gaap:BusinessAcquisitionSharePrice contextRef="FI2019Q1_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" decimals="2" id="Fact-5EA8710FAA4EB2B31A65C4D90E5C0C78" unitRef="usdPerShare">25.50</us-gaap:BusinessAcquisitionSharePrice>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-93AA80046C435E5E8B8970A1779EB90F" unitRef="usd">523600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D4249C53CF625091ADB0292912711D5F" unitRef="usd">498000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4AB6F70F15E75C7180F77F165D00FE95" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-919B74289B005AD280242ADF42F7CF39" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B3C5BCE091DC5F009D38A4A7F431BF37" unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A3681DB9CA5F565EBD9C219422EE1A26" unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F88C9F643DD95C378157DDB003F6DC4B" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B8F706538FBF53D5B92B4DE7B09FC9F6" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-258157B44D125927A1658FB29D54F23F" unitRef="usd">421300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-07A8708FFC4154C4BD3B9F8A9873BBFC" unitRef="usd">421300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-73199C921928521D8A5B2D67A4AE87AD" unitRef="usd">444800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-0118AB85E99E5A438BD8582C4D3A7CDC" unitRef="usd">147300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-E0E86C87B1C05D5BBEF3DDA4DFC3F0D7" unitRef="usd">265000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2019Q1" decimals="-5" id="Fact-6E8E1C60F8FF5C58A7A404B939B527D3" unitRef="usd">274000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-5" id="Fact-D455B5F8D1E95C61B3F860A39E6A287B" unitRef="usd">1573800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q1" decimals="-5" id="Fact-CF3322FDCF235CFD9B5920A42BC9E533" unitRef="usd">4108000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-5" id="Fact-9888AA88B44959AB91D0FCA84AAEA95A" unitRef="usd">1224600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2019Q1" decimals="-5" id="Fact-2577C93DC00F562EACDA3C813EFBAAD8" unitRef="usd">2243200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-80BE6D1F4F335845BA0E2F1060028920" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F364BA279F5051209715F24FA810161B" unitRef="usd">705500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9C58FBDC311A54FFAEFE3E7945E7D2AC" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A2B5B19E1DF65C45BDB0963F4B4A9315" unitRef="usd">705500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5241C5141BFF59DCBFDB4C7B940BC196" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2F0B4D7D45E55CAC9E9491E4E11892FE" unitRef="usd">1881900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F9BE2D5D2A64545FB84421C96391BEE9" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E997AAEC17025ADDBC2E22D28C96D165" unitRef="usd">1881900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2018Q1YTD" decimals="-5" id="Fact-3FDA50EA29575BAA83461D8942104D50" unitRef="usd">2535100000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2019Q1YTD" decimals="-5" id="Fact-447C8B00354654AFBABF19F2517F246E" unitRef="usd">1019000000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-5" id="Fact-7BAF41EEAD0B57A98077B8C5C4B71A37" unitRef="usd">705500000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-8A85A10150B55C8F8DEED201807D1B20" unitRef="usd">231200000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-42787B4FD3E05E32BAD77F7B4CD20A93" unitRef="usd">194800000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-D0541BDD1FEF5C24AFDD9502C41D6326" unitRef="usd">279500000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-E63724382A605219B8389670A3EC409B" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2019Q1" decimals="-5" id="Fact-B8D6F813130E509580D79F689C78E97D" unitRef="usd">1881900000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2019Q1_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-9B9BCAFD86565449BCD5C9DA5AE501D6" unitRef="usd">446000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2019Q1_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-E0F9465DFEE55E0792E5BCA1126BBC49" unitRef="usd">168800000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2019Q1_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-66E04D81C2F05CBB969DED5A91B0CABC" unitRef="usd">1074400000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2019Q1_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-2B196033417B5E8F9F92F65502F9FB03" unitRef="usd">192700000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-1A8BB1C7FFE6527094F6281EB54FCB90" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2019Q1" id="Fact-EBD277F5A01057AE91BB075AAC667677" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-68D70C94EE105E3791D10086E4D94B9F" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2019Q1" decimals="INF" id="Fact-39107509394056A1A89D9F130DE97EC6" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="-5" id="Fact-EEC99D9DBC2A51C899CAB75241642B7D" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2019Q1" decimals="-5" id="Fact-486760A2D70B5951B07047479FF2A4F5" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-29E6E38F50A15C8682A2629DA42B1E85" unitRef="usd">1185900000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q1YTD" decimals="-5" id="Fact-636AE5CB56EE53CD86745E812E9460EA" unitRef="usd">1429400000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2018Q1YTD" decimals="-5" id="Fact-9656E759536D5E899FB0DE4F23D39F66" unitRef="usd">1700000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2019Q1YTD" decimals="-5" id="Fact-564F2E83B5A15DB28BE8D74E58E46788" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2018Q1YTD" decimals="-5" id="Fact-86F4358F31C653C18B8E20C1FE39DF81" unitRef="usd">1184200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2019Q1YTD" decimals="-5" id="Fact-1CAE2EC373595334BC4F5E2C1AF995FA" unitRef="usd">1429400000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ConstructionInProgressGross contextRef="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" decimals="-8" id="Fact-B1B3A9EE57A85B4180B382F556A11D2D" unitRef="usd">1600000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2019Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" decimals="-8" id="Fact-D0C72261FB05553EBEE17BD5EC5D401E" unitRef="usd">1700000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-832D81F092F5562B81690D321D99CCBA" unitRef="usd">125200000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2019Q1" decimals="-5" id="Fact-F8F8B4F107FA51C6B49BC406C736CAF2" unitRef="usd">99700000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2018Q1YTD" decimals="-5" id="Fact-C33D9E839E5F5E0E80BED725F20BE249" unitRef="usd">446000000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2019Q1YTD" decimals="-5" id="Fact-EB2F470119395DECB8A955530F009834" unitRef="usd">602000000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostsAndExpenses contextRef="FD2018Q1YTD" decimals="-5" id="Fact-3BBE54A293D45D719608A5A949E02371" unitRef="usd">1596400000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2019Q1YTD" decimals="-5" id="Fact-5E429871FECF57A8AEB34375AFC52E93" unitRef="usd">1987100000</us-gaap:CostsAndExpenses>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member" decimals="-5" id="Fact-BB606362161FEEB8D1FDCA774AB0D34C" unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-8DEF63E391F2066A44F6CA7746C7FC9C" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-3EC91B4550A2A28DDFEECA7743542A86" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-AD3471A5A6BC712A0EC2CA77419258B6" unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-CE1C7CE7E1D27B3DE006CA76EC6A5445" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-DA144EE92A822417DF1CCA7748DC9586" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2018Q4" decimals="-5" id="Fact-67709B625479598BB691E658276C0DA2" unitRef="usd">6037600000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2019Q1" decimals="-5" id="Fact-312AC5C7F9A75D0AAF7314CF309D358F" unitRef="usd">6155800000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-AE56A3CE203159B7BB4649D1FEC7D287" unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-276B61DDCDAF55AA9D3546BCD0E05180" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-E63900A09E825FB995B404E4519F1661" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-C1FFE1EB359D5D90A13B12DB4831AC67" unitRef="number">0.029</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="FD2018Q1YTD" decimals="-5" id="Fact-69B8D11909D850CE860680EEA11FD205" unitRef="usd">1800000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
	<us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="FD2019Q1YTD" decimals="-5" id="Fact-06F47CAFC0FC5E78B9A1E5F59FE48176" unitRef="usd">600000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
	<us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="FD2018Q1YTD" decimals="-5" id="Fact-25832B149C7E572F9A21136E64E8A450" unitRef="usd">9400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="FD2019Q1YTD" decimals="-5" id="Fact-457E7F46553E562A9312EEE64A25F506" unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q1YTD" decimals="-5" id="Fact-B96528CF046157FA9F67E9078BC1EEF4" unitRef="usd">53100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2019Q1YTD" decimals="-5" id="Fact-7CF5DD7148C053A591590FB911852379" unitRef="usd">228000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-9D9D74B8962F5B4386ED0523A9BB355D" unitRef="usd">2153900000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2019Q1" decimals="-5" id="Fact-0F449BE45EAC543790023C3FCDA063A9" unitRef="usd">2074400000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-8336DCE7801D51BD901CD9F8325F0C28" unitRef="usd">1636200000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2019Q1" decimals="-5" id="Fact-1DB113CDBA0B5D8EB63A6823AC11C788" unitRef="usd">1741700000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:Depreciation contextRef="FD2018Q1YTD" decimals="-5" id="Fact-786C6CF8DB638EBC80533666E51F5927" unitRef="usd">65000000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2019Q1YTD" decimals="-5" id="Fact-72D61211F976F4EEFD593666C350A2B7" unitRef="usd">52900000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q1YTD" decimals="-5" id="Fact-64997318CC075D7B95F351F77A33FE5B" unitRef="usd">168900000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2019Q1YTD" decimals="-5" id="Fact-19373E226020530D82C404878596ECC2" unitRef="usd">121100000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-AC38A4A43769571AB496C48EA1992EE7" unitRef="usd">65800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-7A39B7D34D215D83B76A66DBE0F6C4AA" unitRef="usd">1100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-FBACE50EE04D523BA534618390B3EBCE" unitRef="usd">101400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-8C808C8D81875568831D60CC05D8D31B" unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-FC19FC211ABF5F9392722948E0506E36" unitRef="usd">6900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-D7A9743ADDE85F2DA088F1E2F6ACE013" unitRef="usd">3200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-BB3A7033D27BF7DDC54344E02BF5F1E4" unitRef="usd">14500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-6864722E50A15DCA97BB743192AD41FF" unitRef="usd">6600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-7E14F441E7FE5716895B3F70F8ED09B5" unitRef="usd">8200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-6ECF846273BE50F4A62334E7B72D1B22" unitRef="usd">9300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-F6F8EAE06561596999665460A38376C9" unitRef="usd">1300000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-C8D04FD11D6F567EA0D3136D22CE8ECC" unitRef="usd">-32900000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-7E11A178A943587CBB0A5C19837C86BC" unitRef="usd">-500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-CCC6CB91E7F6573383D88C03BC331579" unitRef="usd">14800000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-018D63711C7DBF9AFBCCC5A7384882CC" unitRef="usd">-300000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-AF913E1A3B170CF93B9BC5A732D03D9E" unitRef="usd">-900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2018Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-E15F90E14D29095DAFBBC5AB313A671B" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-09675255E90C57AFBE91313CA4888F1A" unitRef="usd">-900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-A3F1EFD2436E506E8DB90FEA2B3170FB" unitRef="usd">3700000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2019Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-F430F3B512EF7EA33B43C5AB03B9CAB9" unitRef="usd">2200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2019Q1YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-CD53C86FD13B5DD2958527230528E1A3">P12M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2019Q1YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-A11B830BC554555BB59F2250CD680B99">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeTermOfContract contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" id="Fact-D38E62BF25E162CE46CEC5A9BFC2021B">P7M</us-gaap:DerivativeTermOfContract>
	<us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax contextRef="FD2019Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-9F9F5D52E2963A9E54CE46AC7DE30597" unitRef="usd">174600000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
	<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="FD2019Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-5B658A8D1FD90E5D2AC3DE4447F51100" unitRef="usd">59100000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-C52257F30A121EF16AFEDE31C02BA306" unitRef="usd">49000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-E3EB2E76BB7DD2548A57C54F9E28DE50" unitRef="usd">890000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-8C724EF0E593F894C6D8CAA2CE01A8BA" unitRef="usd">46500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-E0E398E3D9E9A8B01A98DE2C0D2C9D6A" unitRef="usd">69500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1 contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-6F5D5F1EE23869BF139D35D4AC8A1C72" unitRef="usd">27000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1 contextRef="FI2019Q1_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember" decimals="-5" id="Fact-FCD399395D74EAB1D604360AE08EE765" unitRef="usd">27000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-5A808B67D6E5ABB77F2BDE2EEEF82390" unitRef="usd">68800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense contextRef="FD2019Q1YTD" decimals="-5" id="Fact-24851D98743B2E5E53B535EF3157CC72" unitRef="usd">10000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities contextRef="FI2018Q4" decimals="-5" id="Fact-3EB42474AFC4A311548235AAA0253B4A" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities contextRef="FI2019Q1" decimals="-5" id="Fact-3C50C27A97359205D1EC35AA876F3CB0" unitRef="usd">97200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-F74C9463032F1FD35C64C97B8AFC8730" unitRef="usd">629700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="FI2019Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" decimals="-5" id="Fact-C69EED069C627BECA99CC97C27D2EC55" unitRef="usd">312800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="FI2019Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" decimals="-5" id="Fact-A2E6459239AE25FDF88CC97CEC88EB2D" unitRef="usd">286500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
	<us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown contextRef="FD2018Q1YTD" decimals="-5" id="Fact-1989FCA20FD35AC622F8C464F6679D4C" unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
	<us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown contextRef="FD2019Q1YTD" decimals="-5" id="Fact-2E46A87A160D0C320ACDC464C584D4E5" unitRef="usd">115500000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
	<us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown contextRef="FD2019Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-16A58B2F010ED9BFDF90DE36813F631F" unitRef="usd">115500000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q1YTD" decimals="2" id="Fact-12A56B70C2345D9B8B266EDCB83BAC58" unitRef="usdPerShare">5.55</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2019Q1YTD" decimals="2" id="Fact-5052278F32F252D9B47E8AF41FAA2FEB" unitRef="usdPerShare">7.17</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q1YTD" decimals="2" id="Fact-16B2E7CC350751D99F5072A313562FC8" unitRef="usdPerShare">5.54</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2019Q1YTD" decimals="2" id="Fact-50E6FD09C81C5D84BE6FE41A090D8AC1" unitRef="usdPerShare">7.15</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2018Q1YTD" decimals="-5" id="Fact-A8BB4A103B895604AE0945E252884C0D" unitRef="usd">-900000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2019Q1YTD" decimals="-5" id="Fact-67777BA463495031B4725543D2113444" unitRef="usd">-400000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2018Q1YTD" decimals="3" id="Fact-0E4074636D9C5D6EBBF90305D873FB1B" unitRef="number">0.216</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2019Q1YTD" decimals="3" id="Fact-DF34FE85A7D5525B81E1CADCECD81563" unitRef="number">0.227</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q1YTD" decimals="INF" id="Fact-0E52B1B71E34541D95C0747C3B784DD0" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2019Q1YTD" decimals="3" id="Fact-61E9001144EE5C948E21D90D3583A22F" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets contextRef="FD2018Q1YTD" decimals="INF" id="Fact-C08DBEC95CB5CDFEB91936ABA55C57D5" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
	<us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets contextRef="FD2019Q1YTD" decimals="3" id="Fact-F7293DA7CE04F939D3FA36AB800F79A8" unitRef="number">0.043</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2018Q1YTD" decimals="3" id="Fact-63130F09B22558C98723962C2509BFD8" unitRef="number">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2019Q1YTD" decimals="3" id="Fact-D712F1DB342B5AD6A2379B2A6B1FB485" unitRef="number">-0.046</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2018Q1YTD" decimals="3" id="Fact-4DBF99F3433C5727899324D95976BFC8" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2019Q1YTD" decimals="3" id="Fact-F578B13947F85CCEAAF94D77238F945D" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2018Q1YTD" decimals="3" id="Fact-A91895C45D245592A1C167C095475DE2" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2019Q1YTD" decimals="3" id="Fact-ACE0EFF5807A5B33A7DF7DBC0655D62F" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2018Q1YTD" decimals="3" id="Fact-F5FBF650B6795A919832777B251EAA0A" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2019Q1YTD" decimals="3" id="Fact-24A33233FFCA54288CD313A121F3B9F5" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2018Q1YTD" decimals="3" id="Fact-FF8F49E902CE57A38D97D7718892CCF7" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2019Q1YTD" decimals="3" id="Fact-7200C9885AF65368A03FEA1C37B70335" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2018Q1YTD" decimals="3" id="Fact-D37F632898C55FE298F6D326B948E778" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2019Q1YTD" decimals="3" id="Fact-8845E090DC6E557E87D0A81E7C5A7F2D" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-C898EB26A90D5AD0A310EEBA8F6CFA2D" unitRef="usd">320900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-9548E6A7C41550EDB0D0A4120DD79624" unitRef="usd">160800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2018Q1YTD" decimals="-5" id="Fact-2CD5E1AC368D50498B35AF68FE7752F1" unitRef="usd">3400000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2019Q1YTD" decimals="-5" id="Fact-B8EAD4FB496A5C4E8C3836C0AFA6CCBF" unitRef="usd">3300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-F13F731F4289509B81789CA19C390E87" unitRef="usd">7600000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2019Q1YTD" decimals="-5" id="Fact-95B81586464E571E8DD57D639B241E73" unitRef="usd">7400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-6" id="Fact-6B7C6FC4FDE6F1EEEE1136B677FC8BC5" unitRef="usd">675000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
	<us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember" decimals="-6" id="Fact-484A57A5AD3056CF8A0836BCAA4DEA48" unitRef="usd">225000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
	<us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-6" id="Fact-1E301EE0E40FAD3B440436BB6A907CC6" unitRef="usd">615000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
	<us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-6" id="Fact-4B5D740D6F18D402944E36BC0F63CCA0" unitRef="usd">170000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
	<us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember" decimals="-6" id="Fact-338C175423E0B65C9BED36B85F199AE3" unitRef="usd">115000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2019Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="3" id="Fact-CD1B29A7231156568180631343122912" unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestments contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-FCC728E3ACF186728C62CACB26B4ACE3" unitRef="KRW">759500000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-BCAF5B37455F673B5A98CAA675BA0E91" unitRef="usd">680600000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2019Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-2E622EE3DD41B17B289CCAA689529123" unitRef="usd">642100000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2019Q1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-F582B45898DB713009F8CACB3E55F821" unitRef="KRW">729900000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="FD2018Q1YTD" decimals="-5" id="Fact-7697D489EEAC767A50A735B4B898825D" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
	<us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="FD2019Q1YTD" decimals="-5" id="Fact-89B4DD59C527D4CEAE8C35B483D887A5" unitRef="usd">375000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2018Q1YTD" decimals="-5" id="Fact-1A10F6E0066559878CC8A38872154A44" unitRef="usd">5600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2019Q1YTD" decimals="-5" id="Fact-34A8AF9A268F59A0945C4CC3156D9E94" unitRef="usd">-11500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2018Q1YTD" decimals="-5" id="Fact-35BC0BDD01E858A3B786203F28CC7BAA" unitRef="usd">20000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2019Q1YTD" decimals="-5" id="Fact-CE12E2EC33EF5EB880377452B87715C7" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" id="Fact-5E463719213D5C229231F1253DC13E58">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" id="Fact-46BDEB8879D7540081198812D92F6879">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" id="Fact-8C0C8F87437E5CCC9D42FBC08C6864A4">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" id="Fact-EE49E48BEA09535FBFA014F2E37DA932">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" id="Fact-E121F86633815EFC84D0FA41485A7A33">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" id="Fact-36F49BF5E8A15B7F8571CC13CA34D4DA">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4" decimals="-5" id="Fact-E3ED680D54E25608865B6C2CC7357D73" unitRef="usd">4607300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-0A7A84ADEE04566BAC146E95EEE8C361" unitRef="usd">1330200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-830E4F7E8456569E83068ED5BEE63763" unitRef="usd">542300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-1F978EBDEA7F5A7FB9DD83C8B1D880F9" unitRef="usd">2734800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-794B5B16425A5394B75877AF9241A9B0" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-B38DEEAC90C55C9DAB05470D59E0B687" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q1" decimals="-5" id="Fact-69F993880E5D50798C3F5EDA8CC7C5C7" unitRef="usd">4675600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-CD7858F397865B90B5656B6EB7822CF5" unitRef="usd">1389100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-EDD2128A9BEC5B56AAAC97B27D1C94D4" unitRef="usd">542400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-E6F4B28428C356F5B9D3C60DE6D2D6A9" unitRef="usd">2744100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-A68DE7F963AF5B6CBF0A071E32F03BC4" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-AC5E51BBD64059F996AF66B4BA37FFC2" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2019Q1" decimals="-5" id="Fact-1A25AF9202645586A931B491D84E4B6E" unitRef="usd">290000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="FI2019Q1" decimals="-5" id="Fact-D3476492FB375C998EC0C936F6DC236F" unitRef="usd">200000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2019Q1" decimals="-5" id="Fact-10DE55516DA3533D986FCEB2EBFEB5BC" unitRef="usd">190000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2019Q1" decimals="-5" id="Fact-A6C0AECF01535193833A50C02D746C16" unitRef="usd">230000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2019Q1" decimals="-5" id="Fact-E2EBB1E8BAEF5AFE9521F2D476F79424" unitRef="usd">250000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2019Q1" decimals="-5" id="Fact-6871820D03265D9FA09B8F50527EE14B" unitRef="usd">250000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-9653E28EA09D5F7DA88AAC7FA5628C0E" unitRef="usd">3638700000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-F29DAA25C2E158B8A15C7C43525D81D0" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-3DD99631899B58ADA06F9232B72DD0A5" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-8E33AC4D3E1A55388E9FAB85003DFE72" unitRef="usd">3638700000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-476ECF116EA55FD0B88D9F0E70D6ACBF" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-A193976C4CAB51C8B12FF0DDBCED77A2" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-A464224BDF465641B3AF0580C02C840A" unitRef="usd">2308500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-2AC180337677574EB1A33CEC0FBCD0A4" unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-74CC4DF3D0D751A9BA3D84A15D841A6A" unitRef="usd">270500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q1_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-24CED83B3E285281B82962E1C6ED0DA7" unitRef="usd">256200000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q1_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-BC5D7EF7B3AB5CB4BFF12E900946BF0B" unitRef="usd">63100000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q1_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-A2D90956AAC350B6A4488CB9B808BA38" unitRef="usd">1980800000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-2A036465C6935CA29A546C91EEC67DAF" unitRef="usd">2249600000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-7DB351C3E034586BB910056DAF87818A" unitRef="usd">900000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-510257EFB11256F39D9E6033E3CA8BC6" unitRef="usd">261200000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-00DDB9A0FD4857AEB8E91F55DB3B9F00" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CC0AC25EDE185CCFB08C87D9B885531F" unitRef="usd">66900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D13073B5CB275DF19ECAFA3114C8EF2E" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-49B86915F4DD5899B959BBA89CE8631E" unitRef="usd">66900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-29ADDFEE7AB457F1B0892661563477D4" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DC6991113A585680B43D9FCCB15FFFD9" unitRef="usd">104400000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7195A928C895557DB6EF779497925F2C" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F7847719E0A15965A903F9B963521B83" unitRef="usd">104400000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-54F041FA334B53DAA7A361F53A06AB55" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-70233DAB28415CF3A32B10C5A13A8FCE" unitRef="usd">24600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C542E072A9745D75BB20917B9F280145" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3A0871167A8F5C65AED7CA0CABDBE421" unitRef="usd">24600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C3769FC4E686546DB39CA8689615D1FD" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5EAA1A4D1C7153F98446194018D58015" unitRef="usd">24100000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DC57D2C5DA3B5E5395276D2A0B95DE3C" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-820937861165524494FDAE86638E12A3" unitRef="usd">24100000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-1D6B47DEF99D54BCADC8F72BC1CF34E4" unitRef="usd">-1000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2019Q1YTD" decimals="-5" id="Fact-B6A7994C02995DE5BA69B8675E68893D" unitRef="usd">-2200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions contextRef="FI2018Q4" decimals="-5" id="Fact-7398A2E3B73802522B1536785DD4CB88" unitRef="usd">182800000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter contextRef="FI2018Q4" decimals="-5" id="Fact-5A36191B5B77491CF28036785C8DA749" unitRef="usd">58400000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears contextRef="FI2018Q4" decimals="-5" id="Fact-A1B9FF551D3E970468B936785B8C9475" unitRef="usd">24300000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears contextRef="FI2018Q4" decimals="-5" id="Fact-CD166EDB96D28260EF1536785A65F894" unitRef="usd">24000000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear contextRef="FI2018Q4" decimals="-5" id="Fact-188CA7162786FF48BCF336785700EFB5" unitRef="usd">26800000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears contextRef="FI2018Q4" decimals="-5" id="Fact-00249FDAB8F40BA4E48636785928AFC4" unitRef="usd">23700000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears contextRef="FI2018Q4" decimals="-5" id="Fact-828529649DAD3E6D885036785800DE6B" unitRef="usd">25600000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2018Q1YTD" decimals="-5" id="Fact-620C8283324D5F7EB1DAEDD07E003926" unitRef="usd">-5600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2019Q1YTD" decimals="-5" id="Fact-F6A8B86057B454709A4BD288C0872778" unitRef="usd">4800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:Goodwill contextRef="FI2018Q4" decimals="-5" id="Fact-1C3E19FB785F57F1887924C18A141D97" unitRef="usd">5706400000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2019Q1" decimals="-5" id="Fact-C928A962BC4C53809512D323FA77FAEB" unitRef="usd">5639700000</us-gaap:Goodwill>
	<us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="FI2019Q1" decimals="-6" id="Fact-AB6913B2685B52B99D7464469CB59EF8" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
	<us-gaap:GoodwillOtherIncreaseDecrease contextRef="FD2019Q1YTD" decimals="-5" id="Fact-643262C0ED8C5BB398F6406D17479AB5" unitRef="usd">2800000</us-gaap:GoodwillOtherIncreaseDecrease>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2018Q1YTD" decimals="-5" id="Fact-604B7F4167F7543286E6F3CC3744366D" unitRef="usd">1493700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2019Q1YTD" decimals="-5" id="Fact-034BEFFE2DF15B04A2D7338B9649ADFE" unitRef="usd">1860000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2018Q1YTD" decimals="-5" id="Fact-2EDE148AFBB75C92869DECCE2370DE85" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2019Q1YTD" decimals="-5" id="Fact-AC9620D1A3DD5179864B20378D98DE35" unitRef="usd">-28700000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2019Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-BDFAA7F58280EBFAD60B36C7FDC99457" unitRef="usd">14000000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions contextRef="FD2019Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-02BA17A0436B45610097CACDBE400745" unitRef="usd">28700000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
	<us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-B3C244B509E8743F47BBC4804325F1D0" unitRef="usd">0</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
	<us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax contextRef="FD2019Q1YTD" decimals="-5" id="Fact-E190576DE6A7268A9F5BC48027ADA338" unitRef="usd">-115500000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="FI2019Q1_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" decimals="-5" id="Fact-68DDE0F789575769AD2067C6651277CE" unitRef="usd">60000000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q1YTD" decimals="-5" id="Fact-D7F9972951F95649849451BC3CA10730" unitRef="usd">322500000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-E376E72DF5A5541BAE46AB8D9190B7BF" unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-0C5B1355CD065DA792FB7338831398BF" unitRef="usd">1600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-DD5DFC57661E2ADB9AF2CA8C8503B18F" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q1YTD" decimals="-5" id="Fact-60B920913C405764BCB9D67E4E528C0D" unitRef="usd">422500000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-00A43983D6B7516089DDBE2DF255A08F" unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-3459B22AD06F57FFB5963E1E94C95BFC" unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-B25470C7F2901B41FC6ACA8CA5D26C5B" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2018Q1YTD" decimals="-5" id="Fact-685576F3BDD85B70A296E1FE15810D16" unitRef="usd">134000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2019Q1YTD" decimals="-5" id="Fact-2196B250897F5DCE9D146214FC39B37F" unitRef="usd">136600000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2018Q1YTD" decimals="-5" id="Fact-260EC75FCEB4567B83FEF22CA6A53502" unitRef="usd">257600000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2019Q1YTD" decimals="-5" id="Fact-0B52DD1A3CF2559294A73B0CECEDA967" unitRef="usd">170300000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-74E649260B205307B2481C37570687DE" unitRef="usd">-121800000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2019Q1YTD" decimals="-5" id="Fact-9869632326575C3A95C772E2C1CA51E5" unitRef="usd">-138400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2018Q1YTD" decimals="-5" id="Fact-C58346FE6EA151E29845B8D5F018600A" unitRef="usd">-2600000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2019Q1YTD" decimals="-5" id="Fact-91EA28308BCF50A8AA7A04D46CC9D842" unitRef="usd">-129000000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2018Q1YTD" decimals="-5" id="Fact-42F1B137594F5BD097FE67EFF35A5282" unitRef="usd">20000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2019Q1YTD" decimals="-5" id="Fact-A8503E33BB655284BE2AF440BC061C18" unitRef="usd">171100000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-16046B91A6C65C948EF2CCE4E9AAF1B8" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-DD2DCF59D6F9517598993D3B27006CB1" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-F5096C6CC8485E3CA6D28525F3F2E58E" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-6E10854E133F503C8DC3634C556A3AAC" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-F55F3C7DB28B5AC5BCDA3FEF8DA38059" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-02ED6921A24A5640A75C17BC6A795FEC" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-6673497EC85751729A3DC85FE4E3AC91" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-B85B67DC9A565E0FB27A86F2B861F9D7" unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-CD191FF2504457A3A5F6D6E649C0C58C" unitRef="usd">476000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-09D5ECC879835CCCB6659AD4D89F228C" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2019Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-D55D3BE54D3C593C835E7407C9E84B64" unitRef="usd">480500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2019Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-7B55FA36CB0E534A95A41F5A6AC45B73" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2018Q4" decimals="-5" id="Fact-8851807BFBCC559B9DD52672264C69F0" unitRef="usd">7727300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2019Q1" decimals="-5" id="Fact-28F0A500942C5380A70C5E328CB55DA6" unitRef="usd">7731800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2018Q4" decimals="-5" id="Fact-A67FBF885AA656B5A82E92036C188AFA" unitRef="usd">3120000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2019Q1" decimals="-5" id="Fact-35D59535881D52EF95C3BBD98B481C75" unitRef="usd">3056200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-CE939BE117435A549C82A45007C84B4F" unitRef="usd">50500000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q1YTD" decimals="-5" id="Fact-847C72A2F9525B2292E5F5E1BDE1F659" unitRef="usd">47900000</us-gaap:InterestExpense>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2018Q4" decimals="-5" id="Fact-F6C41A7F5BD15CE5A63FF010E90263CB" unitRef="usd">133500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2019Q1" decimals="-5" id="Fact-11A415FAB0BD5F42BCF780AFE5A9FA5C" unitRef="usd">108200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2018Q4" decimals="-5" id="Fact-BA96969D9E81595D95E1F0E3B3D50A06" unitRef="usd">929900000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2019Q1" decimals="-5" id="Fact-6F7119A300D65B519D9C350E27FEBAA2" unitRef="usd">770200000</us-gaap:InventoryNet>
	<us-gaap:InventoryNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-D232702F445957CEB378A8173104DC93" unitRef="usd">6600000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryNoncurrent contextRef="FI2019Q1" decimals="-5" id="Fact-6C92AC1B60285FA38BF22D3027F6D5C0" unitRef="usd">0</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2018Q4" decimals="-5" id="Fact-E651BBD229E657D781EE04F442AD0FDD" unitRef="usd">196300000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2019Q1" decimals="-5" id="Fact-2A5CA8F09FE050A5981FB0481F557E3B" unitRef="usd">199700000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2018Q4" decimals="-5" id="Fact-16842C9CEFC658F8913F732AC3F3ECCC" unitRef="usd">606700000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2019Q1" decimals="-5" id="Fact-C6DEAEB708B6523ABBC2DB916E6D44A6" unitRef="usd">462300000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2018Q1YTD" decimals="-5" id="Fact-E98E1C53D87B5C2D8330EFA4B517E9EB" unitRef="usd">26700000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2019Q1YTD" decimals="-5" id="Fact-C62B18A43EB65C81A06E1FA71B1D032B" unitRef="usd">31200000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1DBF99FF7300573EBE4FDE17365A6D2C" unitRef="usd">51700000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-19E6D356F24D5DDA8FE98EB429D877ED" unitRef="usd">563700000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-388556981D8854BC90A506F41A8D315F" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A40972F71B515054B4228DA9848747E4" unitRef="usd">615400000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DAC00146418A5F849574E8E63D968A35" unitRef="usd">19500000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D57C14C4EAA054B795C30EEA6F32C212" unitRef="usd">884500000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-32AED88FD99D52CA9BBC205E1D952431" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-02763870CC91529191EDEB16E490B888" unitRef="usd">904000000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="FI2019Q1" decimals="-5" id="Fact-622CEA5D1FA4EBDF46C6C9FE553CFC94" unitRef="usd">577200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="FI2019Q1" decimals="-5" id="Fact-746600B560F65EDD2A37C9FA19AA0D7A" unitRef="usd">146200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="FI2019Q1" decimals="-5" id="Fact-3135E177AA4A2E7E2CA8C9F676C6DAC1" unitRef="usd">81700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="FI2019Q1" decimals="-5" id="Fact-F5C6E3794D79FDEC3C1DC9F932D409F0" unitRef="usd">66100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="FI2019Q1" decimals="-5" id="Fact-5BE5F4E8ACE6B459E500C9F7A01E8EBF" unitRef="usd">68600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="FI2019Q1" decimals="-5" id="Fact-75B9E836C1D4900B2E69C9F6FD40665C" unitRef="usd">69200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="FI2019Q1" decimals="-5" id="Fact-3963668C861061993324C9F6BEBCFA10" unitRef="usd">76000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="FI2019Q1" decimals="-5" id="Fact-FF7E574BE4222B36B64CC9F452072D77" unitRef="usd">69400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
	<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="FI2019Q1" decimals="-5" id="Fact-7AC09E8A84D488115EB7C9FFC032821E" unitRef="usd">68600000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
	<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="FI2019Q1_srt_RangeAxis_srt_MaximumMember" id="Fact-DF35CD325D32E799A93AC9A029F554F6">P6Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
	<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="FI2019Q1_srt_RangeAxis_srt_MinimumMember" id="Fact-341603DB3B3ED809397DC99FDD319C36">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
	<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="FI2019Q1_srt_RangeAxis_srt_MaximumMember" id="Fact-30913A156DF6C49D2F4DC9A8E6063983">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
	<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="FI2019Q1_srt_RangeAxis_srt_MinimumMember" id="Fact-63484BB524DA202EAAF9C9A8C9AE8FED">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="-5" id="Fact-119158BAE9A05AAE9E91304086A1A691" unitRef="usd">12257300000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2019Q1" decimals="-5" id="Fact-29206795CD325F6792E9CF554A315C89" unitRef="usd">12623500000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="-5" id="Fact-FB668D833D1055669632CDF92D060A6A" unitRef="usd">25288900000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2019Q1" decimals="-5" id="Fact-DE843ACBB25955589B4791EEEA3103C4" unitRef="usd">26445500000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-6C0F39A725475AA48874CA267419439F" unitRef="usd">3295200000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-3DCBC2DA25335D1E8B458F150BDFF8F7" unitRef="usd">3148700000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-19C39BB29CD056219244249342253FC8" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DD603BEBAF3F586EBCE5EF115131AE7D" unitRef="usd">24600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1EDD4B1375E35DC9A432EE938389AAC4" unitRef="usd">409800000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5326A1EBDD815CABA1C059559F91DD39" unitRef="usd">434400000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8880C6CF007657809D8B56F605C0C4B2" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F368C736FD7851728FA7A71EE282D3CD" unitRef="usd">24100000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-83C73BCA0D175582B4832C3EEA29474F" unitRef="usd">421300000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3492C31156F4579EB0E79A6BA832F710" unitRef="usd">445400000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-E3C4EC307090F260DDACDE32532B0805" unitRef="usd">97200000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:LongTermDebt contextRef="FI2018Q4" decimals="-5" id="Fact-8F1D97A6C3475F71B3767C3D688BE5F0" unitRef="usd">5936500000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2019Q1" decimals="-5" id="Fact-88E225309B84554FAFADCFB4206F1528" unitRef="usd">5943200000</us-gaap:LongTermDebt>
	<us-gaap:LossContingencyDamagesSought contextRef="FD2019Q1YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR" id="Fact-A9DEA188FA7D51C38D08A3CCAFC52FA9">70.0</us-gaap:LossContingencyDamagesSought>
	<us-gaap:LossOnContractTermination contextRef="FD2019Q1YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-051EB9E57606A79BA5B7CAB2DCBC1D8C" unitRef="usd">45000000</us-gaap:LossOnContractTermination>
	<us-gaap:MinorityInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-54D99DA6A2BE653221D0C48E87FF6C98" unitRef="usd">-14700000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-769E33CC501C7D987B16C491FC155BB6" unitRef="usd">-16200000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2018Q4" decimals="-5" id="Fact-C73042EBC3465F5A8EA1EC7EA972AAF9" unitRef="usd">-8000000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-CEFC359E9ECEEFEE59CDC4867B4B0531" unitRef="usd">-8000000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2019Q1" decimals="-5" id="Fact-158939068BF1510EB0C644BDB939F4CA" unitRef="usd">-7900000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-8F5A0ACEA7C1EC631EF3C489AFC67525" unitRef="usd">-7900000</us-gaap:MinorityInterest>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-198F16AD9E3A58958214AFB04DE70971" unitRef="usd">-268600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2019Q1YTD" decimals="-5" id="Fact-5FAE67B2C65E594BB112F9D6951ACD82" unitRef="usd">-679300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-99270EFAFD0C5193800E78CDD6700B23" unitRef="usd">1346600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2019Q1YTD" decimals="-5" id="Fact-9A32694893A557A09E51F8D22ADB9CB1" unitRef="usd">238800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-1D1CF6B6AA005A26A8968605EBB5D7DA" unitRef="usd">1457100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q1YTD" decimals="-5" id="Fact-5AA15C9643195168A7BCF2F218CD9289" unitRef="usd">1459500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1YTD" decimals="-5" id="Fact-2F3EB2FE962B5D08933474A1A51D8BE0" unitRef="usd">1172900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-CAC8BB789E525F129058A28AC5306156" unitRef="usd">-37400000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-B913924DAEA5A96F60ECC48EDBD98A08" unitRef="usd">1172900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q1YTD" decimals="-5" id="Fact-3FBBF65F3A36548E93E66D16FABAFE9F" unitRef="usd">1408800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-45865DCA5D425AEB84D63C4CDB7C1519" unitRef="usd">16700000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-14BF72DF9A75F5474DD3C486DBA53D92" unitRef="usd">1408800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2018Q1YTD" decimals="-5" id="Fact-16ECCC7B274455EBA1FE24B2F6042B85" unitRef="usd">-1700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-63A96E63F3D66AC359EEC48EE27C09EC" unitRef="usd">-1700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2019Q1YTD" decimals="-5" id="Fact-9909DA8513375735AB3121A70EE6541F" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-96748CB1B52C6317A1E6C486E195F0AC" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-A385E164828F5693968C9D28AA4695E6" unitRef="usd">-41000000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-659B970D9D975BD8A83FC2FC8080903B" unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-4FFB412D37F5572DBCD8511D35CA6EA8" unitRef="usd">-7600000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-391B7280F096DF887089CA8C83B71F93" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2019Q1YTD" decimals="-5" id="Fact-C57E200856FF56A7B30EECC05AECB863" unitRef="usd">357300000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-8F026108C2825830956599CF8FB89583" unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-D1D9A0ED4AA1570283A900C1E9C03F9B" unitRef="usd">300000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-ECABC9FE6C31AB812BE2CA8CA483398D" unitRef="usd">2200000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NotesPayable contextRef="FI2018Q4" decimals="-5" id="Fact-2F91EC03041C5FC4B765CFB65CDC9732" unitRef="usd">5936500000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-B6CA65683E69535EAEED2F3E7A1D09F0" unitRef="usd">1722400000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-3644710D5AEA5C0386D7FC4BC2AC0956" unitRef="usd">1737800000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-6465ACEEA48C539395B3DE35FA0DE768" unitRef="usd">995500000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-31EA72C4D4305F018EBF7EFB5ABC5C80" unitRef="usd">1480800000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2019Q1" decimals="-5" id="Fact-C036F845A1CA50C49AEE36406087FAE3" unitRef="usd">5943200000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-A9E1C8C8944F5BEF8BBD612E4C893580" unitRef="usd">1722600000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-082FC9D17E285F36B20A36FB8DF29D54" unitRef="usd">1738200000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-F71C30BAA3655BA4A07D15A875FD9DF6" unitRef="usd">995800000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-DB0079F48F28549797C54BCEC8E4700A" unitRef="usd">1486600000</us-gaap:NotesPayable>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-A1467B1895B35C2CBE5D645AF9B39D62" unitRef="usd">1802600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-677124CF8F2B50C1AE58581B66DD6139" unitRef="usd">1745100000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-0E0FFD2F737A5491AA4330CB1BB7C9D6" unitRef="usd">1000400000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-8A4320E5CCEC58B0B261FB18527E78DD" unitRef="usd">1489500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-415416A156C45E459223D080FDC6E37B" unitRef="usd">1838000000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-EB2901F7D3E55EE9A57DA67F8F52DF8F" unitRef="usd">1795100000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-ABF2FA458DD5576AB8C59581E6ECD93B" unitRef="usd">1022000000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-A3C1437A499450C783E74DE292D13F8F" unitRef="usd">1500700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NumberOfReportableSegments contextRef="FD2019Q1YTD" decimals="0" id="Fact-6813E1343F3753BE90FB5133F57A5F31" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-5603DF5EDFAD5855847C6D8D71EDE718" unitRef="usd">1300000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-5F098D55BB6A5B528BBA5187B6063FF8" unitRef="usd">500000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q1YTD" decimals="-5" id="Fact-6B89EF91C0D05443A4425F93045DD45F" unitRef="usd">1534700000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q1YTD" decimals="-5" id="Fact-8371D4A985DE527190343B55F0063B14" unitRef="usd">1502700000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeaseCost contextRef="FD2019Q1YTD" decimals="-5" id="Fact-92B8609DCF23BA4F20DFC9ED5643D115" unitRef="usd">15700000</us-gaap:OperatingLeaseCost>
	<us-gaap:OperatingLeaseCost contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-D9E5F7FAF14AFA9332B6C9E4F6FDD1C8" unitRef="usd">300000</us-gaap:OperatingLeaseCost>
	<us-gaap:OperatingLeaseCost contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-D4516A7D43161C735BE1C9E63B5D4B14" unitRef="usd">23500000</us-gaap:OperatingLeaseCost>
	<us-gaap:OperatingLeaseLiability contextRef="FI2019Q1" decimals="-5" id="Fact-0EF7E2C543812FBD68C2C9D9FD1F1BB4" unitRef="usd">508600000</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiability contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-5" id="Fact-1F3B625AB42D1E2ECEA335D205F545F8" unitRef="usd">526000000</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember" decimals="-5" id="Fact-7F0605B05EDF878F1E33C9D7EBE9CCCF" unitRef="usd">72500000</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-E5A9088D5F0BFBABA50AC4755D1E50CC" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q1" decimals="-5" id="Fact-BCC907973300CE242D27C4752A516ABB" unitRef="usd">436100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember" decimals="-5" id="Fact-6FF0594D68C781F91503C9D9715357D7" unitRef="usd">436100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeasePayments contextRef="FD2019Q1YTD" decimals="-5" id="Fact-C09EE9E2AAAF51EEB633CA0E7D7C98E2" unitRef="usd">19400000</us-gaap:OperatingLeasePayments>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2018Q4" decimals="-5" id="Fact-1C895C834B0D49D8B376C4707B50CB31" unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q1" decimals="-5" id="Fact-3A356BA0A7CF6872D26EC470567D2B37" unitRef="usd">447800000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember" decimals="-5" id="Fact-870D99CB7C3F3C707902C9D662BB0CBB" unitRef="usd">447800000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-5" id="Fact-DD16CD409C29361619DAC4CD9A525E17" unitRef="usd">463000000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="FI2019Q1" decimals="INF" id="Fact-118C539A0D3877219791CA0D015BC0F1" unitRef="number">0.0333</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
	<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="FI2019Q1" id="Fact-2F9F409F38653EE3CD7DCA0BF6EE2C57">P7Y10M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2018Q4" decimals="-5" id="Fact-42A8D6D2471482533ED136785658E319" unitRef="usd">601600000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-BA90B5D27AA6CD338BEB36784F826D9D" unitRef="usd">87000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2018Q4" decimals="-5" id="Fact-8BA89F2F7A4043F9CE473678541166CF" unitRef="usd">71000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2018Q4" decimals="-5" id="Fact-AD3A0522883B7106ADAD367852D55E67" unitRef="usd">71700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2018Q4" decimals="-5" id="Fact-50661301997B05406958367851BBAA54" unitRef="usd">75900000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2018Q4" decimals="-5" id="Fact-BB94DE13B019F4637639367850830CF1" unitRef="usd">80700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2018Q4" decimals="-5" id="Fact-57A09091BBB8035786CC3678550FA610" unitRef="usd">215300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-21EF0CE443EB1777E08AC9E9CF6619A0" unitRef="usd">1000000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
	<us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-2E8B9779305200BDFFB3C9E760AE94D9" unitRef="usd">7100000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-764A8151D614559ABA487F87C0CBE4FC" unitRef="usd">609300000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-9DDE082F2E475EF99032EFA44C869328" unitRef="usd">708000000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-DFD0A98DA5015E148C6356A575EF8E6B" unitRef="usd">687600000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-D8009403DEB45D9AA790498F03B8821F" unitRef="usd">965400000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-CC9CBDFB15635C43BFE73B13EC9DE4C0" unitRef="usd">1690600000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2019Q1" decimals="-5" id="Fact-C79CF9BB384E51FFBD9184BC8F418FE3" unitRef="usd">1898300000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherCommitment contextRef="FI2019Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" decimals="-5" id="Fact-A3FA4359C98A5E0C8A391D40AA498814" unitRef="usd">92000000</us-gaap:OtherCommitment>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-3676AE6BA0905F718D3A691ADF0A0900" unitRef="usd">-2200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2019Q1YTD" decimals="-5" id="Fact-7EE70BDF83D25C7EAF6A1FF9FBF3E84C" unitRef="usd">6900000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-9BAB9190F71953D08A532E8F4F5D97B3" unitRef="usd">-24400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-642DF399A9D354B1B37E071949A74BBD" unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-048E6F0A9B6B5C11B0C00DDC68F9EFBB" unitRef="usd">-60400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-455404E860AD5EC183BCD2282CE3B8C2" unitRef="usd">-8200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-DE7D847A81A0BBDB6CDDCA76EEB612E6" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-79BED03D3FD358E09265CBAB01FC63A0" unitRef="usd">44700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2019Q1YTD" decimals="-5" id="Fact-77D6759FECFA56B2A43B913DCCDF7305" unitRef="usd">37300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-4E6835384D695C4A9A5F91ED985D3FC2" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-F943A6FFA9975B81B3B85C4548D163BE" unitRef="usd">31200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-8818CB23FA475AC997FA1DB66B60CFFE" unitRef="usd">7100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-9F83040B0CE00B1CE33ECA76567B4D93" unitRef="usd">16200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-630CB225800E5DB7A75FAFAA8AEB9469" unitRef="usd">-17800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-60FBBE033B435D09AC6DC4A76A2CFDBC" unitRef="usd">-29000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2019Q1YTD" decimals="-5" id="Fact-6597654F3362526081AAAA7FD0B56E77" unitRef="usd">16900000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-5E7D4CCAEADA5C6F8334C83362A88712" unitRef="usd">44700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2019Q1YTD" decimals="-5" id="Fact-54D7925A4C3A5F039BB823FC21C1FC62" unitRef="usd">-17800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-40507E43E756C41F8EEDC48F2ED2A4FE" unitRef="usd">13200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-A92C01DCD0BB5673B6821D9BD391C899" unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-824B5B869AE459338B05B0542662BA56" unitRef="usd">-29000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-29042F32F75B5606B50DFDC7AC829040" unitRef="usd">-2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-ED3B0C96A026F3EF90CACA76F0A582A4" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-9DB79EA8AA7C58C8A445681025C120C5" unitRef="usd">44700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-EBE1A371D805FEA5579DC48F2B5F0E48" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q1YTD" decimals="-5" id="Fact-78576A0739996FF0F507C4873F77B0E8" unitRef="usd">20600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-8279416674BE5FB9BEA6D7951E490DC9" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-3950084B541357B4B10212261B0D5A1D" unitRef="usd">16900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-637A0735BC2F5A6B95C4F15706209DB3" unitRef="usd">6900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-02D897753EBC4AE6EFFBCA76586E0AAC" unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-B97236BC3CFC5DF3AD7C3CB4A3A76A21" unitRef="usd">-17800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-F935063B7A187092D4FEC4873CCC317F" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2018Q1YTD" decimals="-5" id="Fact-2AA1403080775671A3D2D8DFEF015D59" unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-9961E0ACBAC5636FE006C48F248826ED" unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2019Q1YTD" decimals="-5" id="Fact-CFC7A6AC0DC15732B2C42BC62CD6DE94" unitRef="usd">20600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-68CA4EA2D2BDA6E23167C48735D3F8CB" unitRef="usd">20600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-C6363B0B97EA5480BDF4E6E1BF3DCAE3" unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2019Q1YTD" decimals="-5" id="Fact-A95989DD94B552679459C9C67BF07E04" unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-684D67E9595E53049DCD445BFD145A0F" unitRef="usd">2861200000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-C73056CBA39E53DC9902A4F03452C429" unitRef="usd">2435000000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-8A3698EE8B5D5BB7BC54D7BF6936745F" unitRef="usd">1389400000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2019Q1" decimals="-5" id="Fact-85B8D6BFFF55525AACBE234BCCB84D53" unitRef="usd">1353800000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-1897F6431556598F919B65700074E28B" unitRef="usd">-31700000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2019Q1YTD" decimals="-5" id="Fact-7FA0D78B944B518FAC1B64550410F15D" unitRef="usd">-50700000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-27B37FFE34085D0381C3983F6FDA6422" unitRef="usd">-1800000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q1YTD" decimals="-5" id="Fact-8E8234DD321E5FE6B48BA0163014B499" unitRef="usd">-200000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-69EB5361D4CF58FE974727E13B2FF74F" unitRef="usd">-1600000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2019Q1YTD" decimals="-5" id="Fact-12BDA5FB97275A7581AEEDBE1FF0A9C4" unitRef="usd">-1700000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="D2019Q1Sharerepurchases_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-6E5296236749FD4DD1783696E8278B91" unitRef="usd">491600000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2018Q1YTD" decimals="-5" id="Fact-C67B206CC5E85157A58B1FBBDBA2F633" unitRef="usd">250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-5" id="Fact-80D4661678705FB2957056D52D9D5245" unitRef="usd">250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2019Q1YTD" decimals="-5" id="Fact-DC0A9F9484895E7EA4195035D954AF29" unitRef="usd">655800000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" decimals="-5" id="Fact-21CAE95825FD7072BE11CA6F13BB77CC" unitRef="usd">655800000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2018Q1YTD" decimals="-5" id="Fact-6C5FB84301B05ED7BF49F8B57B751D3E" unitRef="usd">21200000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2019Q1YTD" decimals="-5" id="Fact-A8528C30B24F5E9CA6343CEAFB61C0DE" unitRef="usd">32200000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2018Q1YTD" decimals="-5" id="Fact-B6A6DA486A035EF198B9BAA8E54CDEFB" unitRef="usd">1919200000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2019Q1YTD" decimals="-5" id="Fact-37680F2B6D1D5CE797AA957F1F03F129" unitRef="usd">825000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2019Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" decimals="-5" id="Fact-949A15D8DFBAF16EA849C4DCD944E3E6" unitRef="usd">800000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-BA50AF869FFE17587DD0C5A9252AE143" unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
	<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-BD28EA7BA334AECFC7C4C5A9723B3D61" unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
	<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2018Q1YTD" decimals="-5" id="Fact-2D767AA6CFD85F859578FA912F55FEB0" unitRef="usd">10000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
	<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2019Q1YTD" decimals="-5" id="Fact-1ADF0BDACACA50218685A9EAB97C26B3" unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2018Q1YTD" decimals="-5" id="Fact-2C160DF051055870B302E7167880B6F5" unitRef="usd">600000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2019Q1YTD" decimals="-5" id="Fact-7B068388C8A7568F9A0326959AC698A1" unitRef="usd">300000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q1YTD" decimals="-5" id="Fact-E0643DEA8A7059C49B16169315AAE94C" unitRef="usd">194700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2019Q1YTD" decimals="-5" id="Fact-F768164E97935C2895D3E73DCB8A9485" unitRef="usd">127100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-535205F9B1795421A379126DD31A2D83" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2019Q1" decimals="INF" id="Fact-81EDA21BFCBF5489A7849630DA43A5E5" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4" decimals="-5" id="Fact-5504F76CBEBE54A8AC76FA3B313BF1D3" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2019Q1" decimals="-5" id="Fact-69D8CEE53B595AB09FAA2585032D21AF" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" decimals="-5" id="Fact-C6763C9A18C8206B86D4CAC1C5DA556A" unitRef="usd">35500000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-C80453CE020E5C8F85569BA99C5399EA" unitRef="usd">2600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2019Q1YTD" decimals="-5" id="Fact-FDA1CEC99E29548DA0DB8762216A1E80" unitRef="usd">8700000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-198799200D4E547DA83E31BDDD048FC3" unitRef="usd">4068900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2019Q1YTD" decimals="-5" id="Fact-C291BA1ED5575A0D836C0405C1CA69B0" unitRef="usd">1489200000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProfitLoss contextRef="FD2018Q1YTD" decimals="-5" id="Fact-5B26FF9654F15D8CA99A516C75CDC9EF" unitRef="usd">1171200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2019Q1YTD" decimals="-5" id="Fact-0919051202CD51DEAF4773BDB6E3F07A" unitRef="usd">1408800000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="-5" id="Fact-62E40465ECE0563EA6F1A4D767B5ED23" unitRef="usd">3601200000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q1" decimals="-5" id="Fact-D6966D68130A5BCE8CFA32D03FDE8F87" unitRef="usd">3013800000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted contextRef="FI2019Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" decimals="-5" id="Fact-4087A95B3A5E28C66C10DE47702A04C6" unitRef="usd">120000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
	<us-gaap:RealizedInvestmentGainsLosses contextRef="FD2018Q1YTD" decimals="-5" id="Fact-3A3BF304887A514BB203AFC2CC48EAAC" unitRef="usd">-14400000</us-gaap:RealizedInvestmentGainsLosses>
	<us-gaap:RealizedInvestmentGainsLosses contextRef="FD2019Q1YTD" decimals="-5" id="Fact-23163381335655A487BC6E9F9C423962" unitRef="usd">376400000</us-gaap:RealizedInvestmentGainsLosses>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-D049CF4069045F82B062EA703D3E5AC4" unitRef="usd">37400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-759B4B4CF1BE5CEF9554EB900DC47B00" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-5A13A0676BB45A38B304658A9F18F804" unitRef="usd">31400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-4CED491BA644566A91A29181A19B427C" unitRef="usd">6000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-EC5A31BEBA0B488638A8CA76EFABA03B" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-A8EB4CC009EE56F2BE66E33EEE7FB647" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2019Q1YTD" decimals="-5" id="Fact-4D0510813FA3519DA930AFBEA23A81F8" unitRef="usd">-16700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-31573B0856AC586180F4FC913847DB7B" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-3AD38815AD8E5C6C8783BAA8F3AFB38A" unitRef="usd">-14300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-BD02695495AB517EAD1389CC42AF794E" unitRef="usd">-200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-A9DE0E173D1D56369A73CA7657743078" unitRef="usd">-2200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-B16D0A97044950C79EA78C6F7B12DD71" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q1YTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" decimals="-5" id="Fact-B682486D95BD87C05E1DCAC0218EA583" unitRef="usd">38500000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q1YTD" decimals="-5" id="Fact-6D3BDC6062D85A638EB5D8AB1C3B6B05" unitRef="usd">496700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2019Q1YTD" decimals="-5" id="Fact-A98BEC0B13F3503FBEAE14AF64BCABBD" unitRef="usd">563700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2018Q1YTD" decimals="-5" id="Fact-91F24A778DB95ECAA6F06EF6062F9605" unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2019Q1YTD" decimals="-5" id="Fact-07EFBBEFD78957D8BFA78CF785EB9BEB" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:RestructuringCharges contextRef="FD2018Q1YTD" decimals="-5" id="Fact-E428C16CBF99577EA56A1B5A20CD6F1D" unitRef="usd">1600000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2019Q1YTD" decimals="-5" id="Fact-7ED7793A00B552FB8338A9034486DFF5" unitRef="usd">400000</us-gaap:RestructuringCharges>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-5" id="Fact-89FC2259182853C6B22AF7E9D2ED1F91" unitRef="usd">16257000000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2019Q1" decimals="-5" id="Fact-2A01DCBC91B55FE1940F4F8B7B67BDF2" unitRef="usd">17026700000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2018Q1YTD" decimals="-5" id="Fact-117957BAB22350FEADC23F2E7EDBFFCB" unitRef="usd">3131100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-598EDF91782C5628B61688E2A453309E" unitRef="usd">4700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-D6F93983C6AEA99C85E8360C3DFBDCCD" unitRef="usd">47000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-A59FCF1536E257729A1F499CDD88F8D8" unitRef="usd">17900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-D83F86984A4F54EE95866CDB785F18B2" unitRef="usd">120900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-4F4D69A0D01C567BA1BE434610C68321" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-AE154DCFE15150059678D8942C4AEE22" unitRef="usd">120900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" decimals="-5" id="Fact-C48192D7E141FC84CC8EC4EDD03DA368" unitRef="usd">127500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-DBA5FE33FAA7D358EFF2C4EDC672A6F6" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-7FEF5C5DD6E0F20A77CFC4EDCB54335B" unitRef="usd">127500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-79A9917B38D955DEB67E076E9B97C66E" unitRef="usd">24400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-88249B798C095D62AA7C360CBBE467F1" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-5FD173B1B47352E0A1B709D3BEBE42FE" unitRef="usd">24400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-0B873BA1CB545E768E708D77646E40DE" unitRef="usd">6600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-C3449AEFEDDA5D659CB0F9CD7BEAC581" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-FD55211621A55C618A4647534AC92541" unitRef="usd">6600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-E7D7927852E782B40103C4EDDB285A41" unitRef="usd">7000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-1DF18BBFB67E59FF8D368E0E4576C614" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-8CA77B2605F1502393D57153887FBDD9" unitRef="usd">7000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" decimals="-5" id="Fact-816E8ED4607CE28DCFD1C4EDC24934EF" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-900915CADE22ED3F8C63C4EDB7CC2C8B" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-9FC27EE1F1237AB054D9C4EDBCF00BF8" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_InterferonMember" decimals="-5" id="Fact-E7D232342BAE5339900DA1A20BECD997" unitRef="usd">550300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-7AABEE1079F95B6FAC14519731FA6DB1" unitRef="usd">371400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-9C735CB04573592A98D4D846A61BC785" unitRef="usd">178900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" decimals="-5" id="Fact-BD122934814FD9383270C4ED9F619904" unitRef="usd">2025100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-EF5DC3C38110D38DCAB2C4ED9530F240" unitRef="usd">1350000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-72ED6F3BDC5793EAB098C4ED9A13F018" unitRef="usd">675100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" decimals="-5" id="Fact-A4B9834028C65B2A976DCA467375FBA1" unitRef="usd">140600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-39B540A051A7546198B96CCDB41DC5E7" unitRef="usd">443200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-8DCCC643DA2758829FA5000D422074CA" unitRef="usd">363900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-0E5FCDA20A63501AA42B0A43B6BB616E" unitRef="usd">188000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-91F0F9525FE3550ABD7D1DA52FDAC4F0" unitRef="usd">175900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-E7710308A3EF5DBC8442D1388EA5DB3D" unitRef="usd">986900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-EB82F9A339EC51678A2AD07345804842" unitRef="usd">728900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-2CBD331583855474ADE2617E90546EC8" unitRef="usd">258000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" decimals="-5" id="Fact-7569CAB798E357B29D33FCF80E40A3ED" unitRef="usd">462100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-8FCB1FE49D3D5324A76498093A57652D" unitRef="usd">249700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-46CBBD00E5D25C05A0DC6E13DEDB8AA4" unitRef="usd">212400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-E07801D344D25802A2BC8A6C858FC884" unitRef="usd">1400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-9B63FA7A2B3056B4922884C1D6384211" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-B933D786582F530A90A9C6D2695622B1" unitRef="usd">1400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-64C20DA058F25CB5BCC2CB23499BFFA2" unitRef="usd">164400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-9B695073543D57269FDB20411D498CCB" unitRef="usd">2523500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-609CC880BE1353EB91CA1BB431DF6AE3" unitRef="usd">1538000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-21CF32AAC87F52DAB810CCC4A668CC7B" unitRef="usd">985500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" decimals="-5" id="Fact-EB7F64D35C695359B5B33F2B7534B291" unitRef="usd">10600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-14375E78625A5F4C8478376757F4D8F5" unitRef="usd">17900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-3AEA691C915A568F8609E3D2B81E9716" unitRef="usd">32900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD" decimals="-5" id="Fact-86AA168EC14951418A1CBA4B63E537DC" unitRef="usd">3489800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-60A9628E8E6F51C5B484A1AFFE0C2FFE" unitRef="usd">400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-339A13C7A375E8469D89C52213DE3BF8" unitRef="usd">206800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-9AF845E39DC353CE811EC6A326C996F2" unitRef="usd">24800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-99A7491CC5AE51D99EAE5D137285B318" unitRef="usd">124000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-4EB7B1CD3B4D5B4F867CDC1E3792F512" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-90FAA65B67915597831D0DF82252217C" unitRef="usd">124000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" decimals="-5" id="Fact-EAC9208CFAA63C74C2A6C4EBE47480D5" unitRef="usd">174400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-FB9B457F6E23D20B9B24C4EAFFCEA86D" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-D64A5133F41C8A2F1922C4EB789ACA17" unitRef="usd">174400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-A09C9982F517516F80EC0D6100C6ED2C" unitRef="usd">22900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-3474481413EB52519A13FB429DD68307" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-F5B5F0A19FB253D1BDC55C9A3556385D" unitRef="usd">22900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-836F930DD26C58F796F120022C8953F4" unitRef="usd">14700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-42FB4F5D19555614883C90A735C9998A" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-C43310061AE25AF8AF81A98C4ECA5D14" unitRef="usd">14700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-7A603B10807CE0005046C4EC982D3454" unitRef="usd">4100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-C4C60B17CFEB5FBDB5719CB87DAD8B4D" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-E62B2D383A825C95B7AB15F0241795B6" unitRef="usd">4100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" decimals="-5" id="Fact-D4695D1BFBC481DE9E57C4EBE1B397A3" unitRef="usd">35700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-C0D03A8BFAAB8FE9C2D0C4EAFB03CB8A" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-75644483C8ED7FCAE94AC4EB74B10ECC" unitRef="usd">35700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_InterferonMember" decimals="-5" id="Fact-C8C63C1EC2725A75907C49A6C7FF724B" unitRef="usd">500900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-572AF914C1EF5B18B4894CFC26F8F604" unitRef="usd">327300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-AC1426F73B685EE8A29FFDC692BC1C4A" unitRef="usd">173600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" decimals="-5" id="Fact-FC518D4F37B1BCF6FA13C4EA1E4C67C2" unitRef="usd">1983000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-076EFC8B21DFE4670A11C4E92D3FA2EF" unitRef="usd">1290000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-280D7E75E1927659DDA4C4E993AA3FE0" unitRef="usd">693000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" decimals="-5" id="Fact-763FC2B272DF5374AE5868FAA8261DE5" unitRef="usd">264100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-54EB1515B70C5A64AF666988DAA42ABE" unitRef="usd">517400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-CE65D8A6B1DB5775B1701B59BCAD93A7" unitRef="usd">518500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-022917B06262527B8EC4C46D7513679C" unitRef="usd">223300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-B72AF6605F335072A5AD74140DF7D9EC" unitRef="usd">295200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-71B691B1E2D257C089E6A2CCAF251C2E" unitRef="usd">998800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-8B6523563FA955B280407D8DB7B65B3C" unitRef="usd">717700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-96A952182DB65498ACC22701812C893B" unitRef="usd">281100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" decimals="-5" id="Fact-D3C4FB9716615238ABA16AFA06AD31C2" unitRef="usd">460400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-31C11014AC6659C9B73E32A1D60899A8" unitRef="usd">245000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-38166AC778DE5D6FAAB454EE601F71FD" unitRef="usd">215400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-8C95C8924E635A6A975DAA1FB76F7084" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-8F2DCEBC60245FD29943EFED2C970D86" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-25ADB32B045F5F8C9611E6B955917F62" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-3688A571EB0C58BFAD05722F740299F1" unitRef="usd">292400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-08F037F145AD501FBA99B43C54C9F3AA" unitRef="usd">2680000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-BF766B17554E54B59E6CCCCCD82D7F9C" unitRef="usd">1513300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-FC6768E73FD050679DB274A27613931D" unitRef="usd">1166700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" decimals="-5" id="Fact-442053A6B32D56389BA17EE6C61C6B7A" unitRef="usd">3900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-FD7236B182515AC687022AC560D0E69E" unitRef="usd">24800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-175D4E4717B35F3C91E81E1820C6F5AA" unitRef="usd">14800000</us-gaap:Revenues>
	<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="FD2019Q1YTD" decimals="-5" id="Fact-21B1DE13D698D5BE4562CA100D245630" unitRef="usd">5400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-98CDF8774E86517883D89E04E6CE0A4D" unitRef="usd">501300000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2019Q1YTD" decimals="-5" id="Fact-C60A5B7D30C954718A590C3320CB55A1" unitRef="usd">567700000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs contextRef="FD2019Q1YTD" id="Fact-B8F01ACCCCDD54E8BDA1EFD681772F15">0</us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q1YTD" decimals="-5" id="Fact-6231317BB1F557E18A7215226EC13E16" unitRef="usd">43400000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2019Q1YTD" decimals="-5" id="Fact-19755C89E65B5AB5809CB56D732590C2" unitRef="usd">45700000</us-gaap:ShareBasedCompensation>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-6823011837813D6883F3C48E71674E66" unitRef="shares">235300000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-D9ED06A31EFD7528B123C48E6ACBE2E8" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-65DAF963BFD0FA5FB550C48E7F73E03B" unitRef="shares">23800000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-91730478DB1495668AC7C491E6944EE7" unitRef="shares">234800000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-48694197E70029C17ED4C491E108049D" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-A380F74BC1CD94FE348CC491F4216A1E" unitRef="shares">23800000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-95B83960133EF09A629BC48663FF0F04" unitRef="shares">221000000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-476EB5DF4BAAA1C9690DC4865D798B01" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-DC09528A2CCF12EFC586C48673F3B38A" unitRef="shares">23800000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-DD51CE1C97E25113AAAFC4899B6CE7B9" unitRef="shares">219000000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-ACEA1B7C86FAE8845418C489965BA747" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-0352A3134AE9DD4A94E1C489A8EE872F" unitRef="shares">23800000</us-gaap:SharesIssued>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-005F305C0826DD1698EDC490EF855806" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-9BFAA351A450E73B6423C488DE3CCAB0" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-3A3588F34E4BBD949F43C49083D14415" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-F04238F0291587F0E9EFC4886FDC1F99" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q1YTD" decimals="-5" id="Fact-3F41A975D5D572AF2FA4C491001FCCA9" unitRef="usd">37800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-4C7D06EB5AB9E05A672AC490F539AB51" unitRef="usd">37800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-5D99A6D6D093DCE2862DC490F21ED25A" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q1YTD" decimals="-5" id="Fact-94F20FAC7F72B2D7A269C488EC4C8184" unitRef="usd">48900000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-A18E5CC554B1D3AB31B9C488E4AE43B0" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-AE218AE9FBC2D44C3E87C488E1E810BF" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-1E59ACF78A0D24047EDE35CC4B4C95AF" unitRef="usd">48900000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2018Q1YTD" decimals="-5" id="Fact-0B75251375B845488295C49094BDE9E0" unitRef="usd">16200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-C931B3F6E6300BF8979BC490896E8908" unitRef="usd">16200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-0204717D69A85707040FC49087112C95" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2019Q1YTD" decimals="-5" id="Fact-FB972EF56FC6D6F5BBE8C4887ECA59DE" unitRef="usd">16600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-90E5BB0534C57A3D9F53C48875A4E5DB" unitRef="usd">16600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-0436D839F7F7BEDBF5C8C4887346685B" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-8" id="Fact-88D3AE6C56A3FE66C02CCA6D1A82808F" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" decimals="-8" id="Fact-7E1D70ABEB0EEFCCBF85CA39974A41B4" unitRef="usd">3500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" decimals="-8" id="Fact-E74BD3AF5FC3350B61CECA649927B643" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="I2019Q1remainingrepurchaseamount_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-8" id="Fact-B949A688E540D42CF42136983E9B669A" unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-567CFA2334B2B658D8E8C4900DC7CB89" unitRef="shares">900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-CF2A88D0B2095FE70970C490212D4DED" unitRef="shares">900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-7FA35DCC53B780F6E25FC48813F68CBF" unitRef="shares">2400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-25BA50141B6B7C177DCEC4881D7F3118" unitRef="shares">2400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-5" id="Fact-D3C3684DF940E79247DDC48E863D2240" unitRef="usd">12612800000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1" decimals="-5" id="Fact-2B844CA95E46122E0F2EC491FA7404FC" unitRef="usd">14053700000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="-5" id="Fact-C351896C7E5751E7AD369B26C5CE8579" unitRef="usd">13039600000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1" decimals="-5" id="Fact-C614332CCF965A39804C65B62FD778E8" unitRef="usd">13829900000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4" decimals="-5" id="Fact-8360BF62166C8512A150C48E8AD7DD3A" unitRef="usd">12598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-64F0707AA3B94FAA7A5FC48E7951AE33" unitRef="usd">-318400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-D7A3B7FEA23B48267D4BC48E76FF79BD" unitRef="usd">97800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-59639B59B2685C04ABA6C48E740A0D33" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-5C7B5E2602C66D82F214C48E6E450C55" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-E9A059C9FEB7D5E7E7DCC48E7C7939A1" unitRef="usd">15810400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-180486D0614928A41153C48E82A9A707" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q1" decimals="-5" id="Fact-9B55376E39D2E6CAC403C491FF55A4FE" unitRef="usd">14037500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-E3D0B5962EB046C09DD7C491EE12821F" unitRef="usd">-303900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-425C894F49CC0C38097BC491EBCA2E19" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-A22DF126CFBEEC6E2BB6C491E8DB5252" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-D808676666B26393EBCAC491E3A37528" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-D0ADC40DE82CF4533934C491F11E5ED0" unitRef="usd">17334600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-689382EC59315D71BAACC491F77F7363" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4" decimals="-5" id="Fact-3FC619AE59DA5A5C8DBC1873488E6B93" unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-B7C061A4B1AC306D5DF5C4866D3B284B" unitRef="usd">-240400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-7E920C48695F28126182C4866A539148" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-8D54564E5CD8DCFFF319C486670DAD2D" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-984CF37CD1AB0FB511FBC4866115AAD0" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-4F4360408C8C893DCA4AC486705D78D0" unitRef="usd">16257000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-E54616FCA2D591D45A13C4867753CD07" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q1" decimals="-5" id="Fact-639B6151284F540680BD7C7C04B44008" unitRef="usd">13822000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-62365ECE740FC1C52327C489A3B3AE47" unitRef="usd">-219800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-CC990E81DD0CB757184AC489A0C33D18" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-C82A14B005164C1AF73AC4899DE456B1" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-319343250B1748F89097C4899917B28E" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-6E1174F7CF95483F0C07C489A62DEFF4" unitRef="usd">17026700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-64FBA60E0508AFB015E1C489AB5FB58B" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityOther contextRef="FD2018Q1YTD" decimals="-5" id="Fact-6CDA80B79DEA99B0FABBC4919EB91507" unitRef="usd">479900000</us-gaap:StockholdersEquityOther>
	<us-gaap:StockholdersEquityOther contextRef="FD2018Q1YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-2C37ECB4732CB5FD51EEC49193A01AAB" unitRef="usd">1500000</us-gaap:StockholdersEquityOther>
	<us-gaap:StockholdersEquityOther contextRef="FD2018Q1YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-4B25FC99BFAD54B61340C4919868B7E4" unitRef="usd">478400000</us-gaap:StockholdersEquityOther>
	<us-gaap:TaxesPayableCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-0D19A2E6E5FC5C38A7BE81E738CC9DFA" unitRef="usd">63500000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2019Q1" decimals="-5" id="Fact-4633BF01640A54A78F3F8076886F002A" unitRef="usd">238500000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease contextRef="FD2018Q1YTD" decimals="-5" id="Fact-57B556290879BB5F1FD3C46AA1FD7CBC" unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
	<us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease contextRef="FD2018Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" decimals="-5" id="Fact-ACE56041D67939E3D56EC5AB30400741" unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
	<us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease contextRef="FD2019Q1YTD" decimals="-5" id="Fact-6E7D5DCDE5B5EB46E025C46A7E7798A7" unitRef="usd">14000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
	<us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease contextRef="FD2019Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" decimals="-5" id="Fact-BBA7F59BC5A190B99296C5AA1BD9709B" unitRef="usd">11800000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-5" id="Fact-88322B24931B9CA602EDC4902D8C9981" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-F2F84E8499D770DE6980C49016FC8977" unitRef="usd">122900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-4B86A6E3F2929F2BA64CC4901291F4F4" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-2D3C076F4C6EB65FC036C4901CF12859" unitRef="usd">127100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-2AC45BF19BAA0BBE5BE4C490258AF3FE" unitRef="usd">250000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" decimals="-5" id="Fact-29E57A480EF2E0763909C4881FBBC635" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-A23A9A5554F1136E7E20C4881A689EEA" unitRef="usd">65600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-B176A50B1EA82335C8C7C4881826F59E" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-324A970A793DF39B58E0C4881B5FEEFD" unitRef="usd">590200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-E97BF893EA3E061E1E8EC4881E5D2B55" unitRef="usd">655800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockSharesAcquired contextRef="D2019Q1Sharerepurchases_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-8" id="Fact-ECFD5BE61E57D81A9D2D3696075537E9" unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-5" id="Fact-4138CF49B3995E92A108EEB6275D51D0" unitRef="shares">900000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-6D71D940F39597DAD461C48FB1531E8B" unitRef="shares">900000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" decimals="-5" id="Fact-192791A5B9ED849DEBD9CA6EC43AB305" unitRef="shares">2400000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-EC91DDD5A4BAE2AA0BE4C487A8844DA9" unitRef="shares">2400000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockValue contextRef="FI2018Q4" decimals="-5" id="Fact-117F084132F850058A71F3129C7B5AC0" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2019Q1" decimals="-5" id="Fact-EB2933582F215184B5C61142DCA2EEC3" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-5" id="Fact-2732C87AE7413D0097F5C48FBF636710" unitRef="usd">250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-8527A1A74D6490F9A4B4C48FB6942D27" unitRef="usd">250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" decimals="-5" id="Fact-F477E0C659ADAE9B0B6EC487B25C3E18" unitRef="usd">655800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2019Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-D80D66B4564F02C0BA47C487AF31C3CE" unitRef="usd">655800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" decimals="-5" id="Fact-FEA83624CDF456B3F26DC5AA65B5CF0A" unitRef="usd">3800000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2019Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" decimals="-5" id="Fact-20B81D606D0CFB44FAD23622CA17572C" unitRef="usd">8000000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4" decimals="-5" id="Fact-EC7768BF53165E88B4ECC13A8D93DAE3" unitRef="usd">1051300000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-52440EB0B02C5A0C95AB48DD351B8586" unitRef="usd">176600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-5F14A7A95A7055689C9432DC77828797" unitRef="usd">874700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-296CC502BA81542A9D3C2A325F62BCE7" unitRef="usd">888800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-3A5AEB3E8AAD529BABD3F2853E8CE349" unitRef="usd">127800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-3A02D51EFD22532B997694643A6ADD93" unitRef="usd">34700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2019Q1" decimals="-5" id="Fact-A20ABF34505F5AA8A5999514540B1270" unitRef="usd">1083400000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-1838D616EA245EB0BDD02EC62FE9EB42" unitRef="usd">175800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-7B6D82DBF28B58A7844C78A056C48E47" unitRef="usd">907600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2019Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-3795D6E5EB58516AB509AFABE36F99D3" unitRef="usd">932000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2019Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-FE70172A12465242AC9F9118918887DA" unitRef="usd">116400000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2019Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-F2EB8FC37E885494BC7BEE67807C223F" unitRef="usd">35000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2018Q1YTD" decimals="-5" id="Fact-A62F481F67C65CFC990A04B048C9A5FE" unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2019Q1YTD" decimals="-5" id="Fact-D2826698022259FEB0DD8B3C1D713DB4" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2018Q1YTD" decimals="-5" id="Fact-4F8D595D59DD5FED918802A1D872C1D7" unitRef="shares">211700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2019Q1YTD" decimals="-5" id="Fact-6236A77908D854EC9F7F80C3B9AC2019" unitRef="shares">197000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2018Q1YTD" decimals="-5" id="Fact-F8F60CF1950B51DF9651E242A3E714F4" unitRef="shares">211400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2019Q1YTD" decimals="-5" id="Fact-1785465F82185599A781022B39F47072" unitRef="shares">196600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="FD2019Q1YTD" id="Fact-C21515F44FC752E19C7FC3F2C9F9AE04">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;127.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;888.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,051.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;141.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;680.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;826.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(24.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(60.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(233.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(294.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(92.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(378.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(474.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;116.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;932.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,083.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
	<biib:AssetsandLiabilitiesHeldForSalePolicyTextBlock contextRef="FD2019Q1YTD" id="Fact-7F97CA133DD7635EDE0135D06A693E4A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Assets and Liabilities Held For Sale&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held-for-sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:AssetsandLiabilitiesHeldForSalePolicyTextBlock>
	<biib:BusinessOverviewPolicyTextBlock contextRef="FD2019Q1YTD" id="Fact-0D5283AF163251B88F31F576CA8F6CD7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also commercialize biosimilars of advanced biologics.&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; For additional information on our collaboration arrangements with Genentech, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our Annual Report on Form&amp;#160;10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including Parkinson's disease, ALS, progressive supranuclear palsy, AD, stroke, epilepsy, cognitive impairment associated with schizophrenia and pain.&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the European Union (E.U.).&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
	<biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="FD2019Q1YTD" id="Fact-BC1C9BB5DF9E53C69D7BA0871A1E8F34">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(542.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(542.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2,744.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;261.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,734.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;270.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;480.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;480.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;476.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;476.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&amp;#160;and&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&amp;#160;rights&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&amp;#160;patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,638.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1,389.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,249.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,638.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,330.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,308.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,731.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4,675.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,056.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,727.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4,607.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
	<biib:LesseeLeaseTableTableTextBlock contextRef="FD2019Q1YTD" id="Fact-3FBF6C2BEDB760A82496C9B2A8C6760E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance sheet location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;447.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;72.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;436.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:LesseeLeaseTableTableTextBlock>
	<biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock contextRef="FD2019Q1YTD" id="Fact-DEC25C380D64F781CCFFC9C6F2B56ECA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets obtained in exchange for lease obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock>
	<biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock contextRef="FD2019Q1YTD" id="Fact-1702FE9EC1DFE34FEB4FC9C40AA21352">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average remaining lease term in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average discount rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock>
	<biib:OtherrevenuesTableTextBlock contextRef="FD2019Q1YTD" id="Fact-5D1D024BEBA4518F92BFF2AA6C141CD1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;264.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;140.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;292.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;164.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
	<biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock contextRef="FD2019Q1YTD" id="Fact-B180D211AEEE53C4AAF92AA64658F390">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&amp;#8217;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;390.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;349.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;126.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;93.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;517.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;443.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
	<biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="FD2019Q1YTD" id="Fact-BFDA4E781C18554EA1A401A0EAF57660">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;175.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;176.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;907.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;874.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,083.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,051.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
	<biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock contextRef="FD2019Q1YTD" id="Fact-26B04D468F085B4E9E1812CD654E97C7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;162.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;89.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense our condensed consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
	<biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock contextRef="FD2019Q1YTD" id="Fact-743B43A92791596CABED0B39ABDCF4B8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;68.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;52.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
	<us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-E344A5C978A758E1ACADC21FBA48FE91">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Other Consolidated Financial Statement Detail&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(47.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(50.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;376.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;357.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(41.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, gain (loss) on investments, net, as reflected in the table above, substantially relate to marketable equity securities held at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The increase in gain (loss) on investments, net, compared to the prior year period, was primarily due to an increase in the fair value in our investment in Ionis' common stock as well as an increase in the value of a non-marketable equity security.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements. For additional information on our investment in Ionis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2018 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;907.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;874.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;216.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;261.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;195.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;224.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;160.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;320.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;147.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;444.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;99.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;125.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;708.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;609.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,435.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,861.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Long-term Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,353.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,389.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and included accrued income taxes totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$796.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$791.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2019Q1YTD" id="Fact-7E1C09E870CC5BDB9C21675C1D006361">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2019 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br clear="none"/&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;981.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;981.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;852.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;854.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;683.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;683.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;237.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;237.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;280.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;280.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,035.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,038.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;489.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;421.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;904.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,608.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,607.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;854.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;851.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;706.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;705.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;264.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;263.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;260.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;260.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,694.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,689.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;496.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;127.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;615.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2019Q1YTD" id="Fact-B5243C0399D85CF0A9581CCB1C1AC9E4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&amp;#160;GAAP). The information included in this quarterly report on Form&amp;#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2018 Form&amp;#160;10-K. Our accounting policies are described in the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8221; in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&amp;#160;GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-8FFBC1A429EC5BDD93F63778751EFFB8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Acquisitions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proposed Acquisition of Nightstar Therapeutics plc&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into an agreement to acquire Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. NST's lead asset is NSR-REP1 for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder, which leads to blindness and has no approved treatments. NST&amp;#8217;s second clinical program is NSR-RPGR for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no approved treatments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the proposed acquisition, we would pay NST shareholders &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.50&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash for each issued and outstanding NST share, which represents an expected total transaction value of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$800.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on a fully diluted basis, after expected transaction expenses and anticipated cash acquired at closing. We plan to fund the proposed acquisition of NST through available cash and to account for it as an acquisition of a business. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is intended that the proposed acquisition will be implemented by means of a U.K. Court-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006. The proposed acquisition remains subject to customary closing conditions, including the approval by NST shareholders and the issuance of an order by the U.K. Court. We expect to complete the proposed acquisition by mid-year 2019.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="FD2019Q1YTD" id="Fact-E8D50B30B326513A8719EF713651576A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&amp;#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;446.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;192.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,074.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;279.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;168.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;194.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,881.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;705.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2019 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br clear="none"/&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;981.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;981.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;852.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;854.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;683.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;683.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;237.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;237.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;280.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;280.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,035.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,038.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;489.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;421.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;904.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,608.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,607.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;854.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;851.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;706.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;705.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;264.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;263.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;260.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;260.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,694.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,689.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;496.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;127.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;615.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br clear="none"/&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;br clear="none"/&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br clear="none"/&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,665.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,665.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,314.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,313.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,234.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,237.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,235.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,232.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;135.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;134.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;143.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;143.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,035.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,038.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,694.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,689.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, were approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,489.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,068.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,049.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$90.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was reflected as a component of other current assets in our condensed consolidated balance sheet, with the remaining balance included in investments and other assets. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$676.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is included in investments and other assets in our condensed consolidated balance sheet. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our investments in equity securities include approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of Ionis' common stock, acquired in June 2018 at a cost of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$625.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is remeasured each reporting period and carried at fair value. This investment is classified as a Level 2 marketable security due to certain holding period restrictions. The remainder of our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1. The effect of the holding period restrictions on our Ionis stock valuation are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis' common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in our strategic investment portfolio primarily reflects an increase in the fair value in our investment in Ionis' common stock as well as an increase in the value of a non-marketable equity security.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our June 2018 investment in Ionis' common stock, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2018 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-23BED99157D85BEF901FA7019E56DB40">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Co., Ltd.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BAN2401 and Elenbecestat Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the treatment of AD (the BAN2401 and Elenbecestat Collaboration).&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our BAN2401 and Elenbecestat Collaboration, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2018 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration were immaterial. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;68.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;52.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Aducanumab Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;of aducanumab development expense incurred and, beginning January 1, 2019, is reimbursing us for&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;45%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;of aducanumab development expense incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019, following the results of a futility analysis conducted by an independent data monitoring committee, we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia. As a result of this decision, in the first quarter of 2019, we accrued approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the termination of various clinical trials and research and development contracts net of the expected &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;45%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sales and marketing expense incurred were shared in proportion to the same region-based profit split that would have been utilized to co-promote aducanumab had it been commercialized. For additional information on the Aducanumab Collaboration Agreement, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2018 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;162.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;89.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense our condensed consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Research and Discovery Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Skyhawk Therapeutics, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments as well as potential royalties on net commercial sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this agreement, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$74.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Skyhawk, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$38.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as research and development expense in our condensed consolidated statements of income and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&amp;#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;759.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$676.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership percentage remained at approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$675 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, consisting of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$115 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to inventory, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$615 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to developed technology and approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$170 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to in-process research and development. A deferred tax liability of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$225 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years, respectively, one quarter in arrears. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a loss on our investment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$28.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflecting our share of losses for the fourth quarter of 2018 totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$14.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and amortization of basis differences of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$14.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investment in Samsung Bioepis totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;729.9 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$642.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;759.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$680.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Commercial Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We reflect revenues on sales of BENEPALI, FLIXABI and IMRALDI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2017 the European Commission granted a marketing authorization in the E.U. for IMRALDI. In April 2018 we and Samsung Bioepis entered into an agreement with AbbVie for the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales in our condensed consolidated statements of income. We began to recognize revenues on sales of IMRALDI to third parties in the E.U. in the fourth quarter of 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We share &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net profit-sharing expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect Samsung Bioepis' &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration profits, compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$43.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in revenues in relation to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangement with Samsung Bioepis and our other significant collaboration arrangements, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2019Q1YTD" id="Fact-71AC61860E0F5DD18D9349D86E26A4A4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-E372103EA7EF59C4AF527C035B15BD33">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&amp;#160;dollar. The value of revenues and operating expenses measured in U.S.&amp;#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had durations of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,722.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,701.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;170.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;131.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;79.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;98.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;72.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;92.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,144.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,239.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$44.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect the net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$44.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to be settled over the next &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&amp;#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:22%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, we entered into interest rate swaps with an aggregate notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$675.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. The carrying value of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes as of March 31 2019 and December&amp;#160;31, 2018, includes approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Net Investment Hedges - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;759.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$676.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had remaining durations of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;seven months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of March 31, 2019 and December&amp;#160;31, 2018, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:22%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$895.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$735.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts were recognized as a component of other income (expense), net for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash Flow Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;101.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
	<us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="FD2019Q1YTD" id="Fact-5ACEC18BDE615D3389DA4BD829E89BF2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis (MS):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;717.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;281.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;998.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;728.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;258.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;986.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;327.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;173.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;500.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;371.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;178.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;550.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;245.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;215.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;460.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;249.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;462.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;22.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;22.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: MS product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,290.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;693.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,983.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,350.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;675.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,025.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;223.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;295.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;518.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;188.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;175.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;363.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biosimilars:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;124.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;124.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;120.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;120.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IMRALDI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: Biosimilar product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;174.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;174.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;127.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;127.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,513.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,166.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,680.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,538.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;985.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,523.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2019Q1YTD" id="Fact-B9AC5A09172F515696E948C77718177A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Share-based Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;27.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;49.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;38.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;49.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&amp;#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock contextRef="FD2019Q1YTD" id="Fact-28099658BDFF1EDDBE98DE2892679428">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table presents information related to the carrying value of the major classes of assets and liabilities that were reclassified as held for sale in our condensed consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;27.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;629.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;69.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;68.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance on disposal group on assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(115.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;682.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;49.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;97.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock>
	<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-3C489FFFC84E5584F13CDE25F1EDD5ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Divestitures&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proposed Divestiture of Hiller&amp;#248;d, Denmark Manufacturing Operations &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&amp;#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$890.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash, subject to certain working capital adjustments and other contractual terms. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of the proposed transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with such guarantees. We may adjust this estimate based upon changes in business conditions, which may result in the recognition of additional losses. We are also obligated to indemnify FUJIFILM for liabilities that may exist relating to certain business activities incurred prior to the closing of the proposed transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&amp;#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we have not included these contingent payments in our estimate of the fair value of the operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of the proposed transaction, we also expect to enter into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM would use the Hiller&amp;#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determined that the operations to be disposed of in the proposed transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2019 the assets and liabilities related to our Hiller&amp;#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale. The following table presents information related to the carrying value of the major classes of assets and liabilities that were reclassified as held for sale in our condensed consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;27.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;629.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;69.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;68.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance on disposal group on assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(115.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;682.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;49.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;97.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the first quarter of 2019 we recorded a loss of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$174.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our condensed consolidated statements of income. This estimated loss includes a pre-tax loss of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$115.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reflecting our current estimated fair value of the assets and liabilities held for sale, adjusting for our expected costs to sell our Hiller&amp;#248;d, Denmark manufacturing operations of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and our estimate of the fair value of an adverse commitment of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with the guarantee of future minimum batch production at the Hiller&amp;#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$59.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the proposed transaction. Our total estimated loss is based on current exchange rates and business conditions, and any changes to these factors through the closing date of the transaction will result in adjustments to the carrying values of the related assets and liabilities as well as a corresponding adjustment to the loss amount recognized on the sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our estimate of the fair value of assets and liabilities expected to be sold to FUJIFILM is a Level 3 measurement and is based on the expected consideration from the sale, including the valuation of the adverse commitment, as discussed above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proposed transaction remains subject to customary closing conditions, including filings and clearances under the Danish Competition Act. We expect to complete the proposed transaction in the second half of 2019. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&amp;#248;d facility to FUJIFILM at carrying value.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2019Q1YTD" id="Fact-A3AB2198C12F5FA0B294396D20A1BB5C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Earnings&amp;#160;per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,408.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,172.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;196.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;197.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2019Q1YTD" id="Fact-00D2FAA23A055ED7A09E7D6183C1B098">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2019 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,881.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,881.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,835.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,835.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;921.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;921.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;281.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;281.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;904.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;884.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;104.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;104.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;29.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;29.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,958.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,938.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;421.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;421.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;445.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;421.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;705.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;705.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,459.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,459.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;969.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;969.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;260.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;260.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;615.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;563.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;66.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;66.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,102.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,050.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;434.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There have been &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairments of our assets measured and carried at fair value during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, there were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our agreement with Ionis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2018 Form 10-K. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,500.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,486.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,489.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,480.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,022.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;995.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,000.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;995.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,795.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,738.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,745.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,737.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,838.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,722.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,802.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,722.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,155.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,943.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,037.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,936.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our 2018 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence Pharmaceuticals Ltd., Stromedix Inc. and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;421.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;498.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$265.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to changes in the expected timing of the achievement of certain remaining development milestones, a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to an increase in the interest rate used to revalue our contingent consideration liabilities during the period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2019Q1YTD" id="Fact-F6FBD4182F0D52A1BEB4FBB8CD95BA9E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;421.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;498.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-4358356359D2549BA77B541680741857">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(542.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(542.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2,744.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;261.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,734.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;270.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;480.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;480.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;476.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;476.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&amp;#160;and&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&amp;#160;rights&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&amp;#160;patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,638.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1,389.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,249.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,638.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,330.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,308.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,731.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4,675.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,056.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,727.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4,607.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amortization and impairment of acquired intangible assets totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$68.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$103.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period. The decrease in amortization and impairment of acquired intangible asset was primarily due to a net overall decrease in our expected rate of amortization for acquired intangible assets. This was primarily due to lower amortization subsequent to the impairment in the fourth quarter of 2018 of the U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and higher expected lifetime revenues of TYSABRI. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and 2018, we had no impairment charges.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Developed Technology&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$256.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired and In-licensed Rights and Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. Acquired and in-licensed rights and patents also includes our rest of world license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. The net book value of the TYSABRI asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,980.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and the net book value of the TECFIDERA asset as of March 31, 2019, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$63.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on our TECFIDERA license rights, please read Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2018 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our most recent long-range planning cycle was completed in the third quarter of 2018. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 (remaining nine months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;200.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;290.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;250.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;250.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;230.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;190.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,706.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reclassification of goodwill to assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(69.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,639.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The reclassification of goodwill to assets held for sale relates to an allocation based upon the relative fair value of the proposed divestiture of our Hiller&amp;#248;d, Denmark manufacturing operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the three months ended March 31, 2019, goodwill was reviewed for impairment due to the proposed divestiture of our Hiller&amp;#248;d, Denmark manufacturing operations, and based upon this review, no impairments were recognized. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the proposed divestiture of our Hiller&amp;#248;d, Denmark manufacturing operations, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other includes changes related to foreign currency exchange rate fluctuations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-7840F7F754F95A1C84C2B2CD9E4AC90D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Denmark assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Global Intangible Low-Taxed Income (GILTI)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;22.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Changes in Tax Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the three months ended March&amp;#160;31, 2019, compared to the same period in 2018, the increase in our effective tax rate was primarily due to a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$59.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; tax expense related to the proposed divestiture of our subsidiary that owns our Hiller&amp;#248;d, Denmark manufacturing operations.&amp;#160;Although we are recognizing a loss on the proposed divestiture of such subsidiary, the proposed divestiture requires us to write off certain deferred tax assets upon the classification of our Hiller&amp;#248;d, Denmark manufacturing operations as held for sale and results in a taxable gain in certain jurisdictions.&amp;#160;The effect of this increase to our 2019 effective tax rate was partially offset by a higher effective tax rate in 2018 resulting from the sale of inventory, the tax effect of which had been included within prepaid taxes at December 31, 2017, at a higher effective tax rate. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the proposed divestiture of our Hiller&amp;#248;d, Denmark manufacturing operations, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;International Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have made payments totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to the Danish Tax Authority (SKAT) for assessments received for 2009, 2011 and 2013 regarding withholding taxes on certain payments made by our subsidiary that owns our biologics manufacturing operations in Hiller&amp;#248;d, Denmark. We continue to dispute the assessments for all of these periods and believe that the tax positions taken related to these payments are valid. Any amount refunded by SKAT associated with this withholding tax receivable will be paid to our subsidiary that owns our biologics manufacturing operations in Hiller&amp;#248;d, Denmark.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&amp;#248;d, Denmark. This withholding tax receivable from SKAT will be included within the assets that will be transferred to FUJIFILM as part of the proposed transaction. Under the share purchase agreement, FUJIFILM is required to remit any future proceeds refunded by SKAT to us. We have assessed the collectability of the receivable from FUJIFILM and regard it as a contingent gain, which does not meet the probable threshold for recognition under ASC 450, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Contingencies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and therefore we have recorded a pre-tax charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to write the asset down to zero as a component of the loss on assets and liabilities held for sale in the first quarter of 2019. For additional information on the proposed divestiture of our Hiller&amp;#248;d, Denmark manufacturing operations, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Federal and State Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proposed Divestiture of Hiller&amp;#248;d, Denmark Manufacturing Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&amp;#248;d, Denmark. As a result, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$46.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our deferred tax liability was reclassified to liabilities held for sale in our condensed consolidated balance sheets as of March 31, 2019. For additional information on the proposed divestiture of our Hiller&amp;#248;d, Denmark manufacturing operations, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-906190AF326754EF8F31061A5CE8DF2D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;199.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;462.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;606.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;108.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;133.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;770.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;936.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;770.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;929.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;770.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;936.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the three months ended March 31, 2019, we sold hemophilia related inventory to Bioverativ with a cost basis totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$173.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; pursuant to the terms of the manufacture and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proposed Divestiture of Hiller&amp;#248;d, Denmark Manufacturing Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&amp;#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$890.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash, subject to certain working capital adjustments and other contractual terms. As a result, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of work in process inventory was reclassified to assets held for sale in our condensed consolidated balance sheets as of March 31, 2019. Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred. In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&amp;#248;d facility to FUJIFILM at carrying value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the proposed divestiture of our Hiller&amp;#248;d, Denmark manufacturing operations, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="FD2019Q1YTD" id="Fact-06E93D7F42185FF8A515D2D627E3E07C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br clear="none"/&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;br clear="none"/&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br clear="none"/&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,665.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,665.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,314.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,313.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,234.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,237.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,235.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,232.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;135.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;134.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;143.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;143.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,035.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,038.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,694.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,689.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:LeaseCostTableTextBlock contextRef="FD2019Q1YTD" id="Fact-C3FE772D7F0EB65C2F18C9B5DC50D192">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of lease costs in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;23.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sublease income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other (income) expense, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net lease cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;15.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
	<us-gaap:LegalMattersAndContingenciesTextBlock contextRef="FD2019Q1YTD" id="Fact-78252122D7C95775AA9023D129D04531">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&amp;#8217; legal theories; and (v) the parties' settlement positions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IMRALDI Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 Fresenius Kabi Deutschland GmbH&amp;#160;(Fresenius Kabi)&amp;#160;commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen commercializes in Europe, infringes the French counterpart of European Patent No. 3 148 510&amp;#160;(the &amp;#8216;510 Patent), which was issued in June 2018 and expires in May 2035. In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of the Danish Utility Models. In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &amp;#8216;510 Patent, and against Biogen GmbH in the Dusseldorf Regional Court relating to the German counterpart of the &amp;#8216;510 Patent. A hearing has been scheduled for May 2019 in the proceeding in Denmark.  No hearing has been scheduled in the other proceedings. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom counterpart of the &amp;#8216;510 Patent. Fresenius Kabi has filed a counterclaim asserting infringement of the United Kingdom counterpart of the &amp;#8216;510 Patent and seeking damages and an injunction to restrain infringement if the patent is found valid and infringed. A trial has been set for July 2019. In December 2018 Biogen B.V. and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the &amp;#8216;510 Patent. A trial has been set for October 2019. An estimate of the possible loss or range of loss in the above matters cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 Gedeon Richter PLC asserted to Biogen and Samsung Bioepis UK Limited that IMRALDI infringes European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035. We dispute the assertion. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&amp;#8217; fees and costs. Our motion to dismiss was denied in part. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 we and certain other drug manufacturers and pharmacy benefit managers were served with a qui tam action filed by John Borzilleri on behalf of the U.S. and certain states in the U.S. District Court for the District of Rhode Island. The case was filed under seal in January 2014 and unsealed in April 2018 after the U.S. declined to intervene. The case alleges agreements with pharmacy benefit managers in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys' fees and costs. We, the other defendants and the U.S. have moved to dismiss the case and the motions are pending. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Securities Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers are defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &amp;#167;78j(b) and &amp;#167;78t(a) and 17 C.F.R. &amp;#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. In March 2018 the court dismissed the complaint with prejudice. The plaintiff's appeal is pending. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2017, 2018 and 2019 we initiated patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Patent infringement proceedings pursuant to the Hatch-Waxman Act are pending against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Banner Life Sciences LLC, Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shipla Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware and against Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A trial date has not been set in the Delaware actions against Banner Life Sciences LLC or Zydus Pharmaceuticals (USA) Inc. A December 2019 trial date has been set for the other Delaware actions, and a trial date has been set for February 2020 in the West Virginia action against Mylan Pharmaceuticals Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Petition for Inter Partes Review&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 Mylan Pharmaceuticals Inc. filed a petition with the U.S. Patent Trial and Appeal Board seeking &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. On February 6, 2019, the U.S. Patent Trial and Appeal Board instituted &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of the '514 Patent.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2016 the European Patent Office (EPO) revoked our European patent number 2 137 537 (the '537 Patent), which includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for March 2020.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2018 the EPO revoked Forward Pharma&amp;#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and the appeal is pending. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Boards of Appeal and the Enlarged Board of Appeal, if applicable, to make a final determination.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;TYSABRI Patent Revocation Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish &amp;#8216;263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU &amp;#8216;127 Patent) (&amp;#8220;Administration of agents to treat inflammation&amp;#8221;).  The Polish &amp;#8216;263 Patent concerns administration of natalizumab (TYSABRI) to treat MS. The Polish &amp;#8216;263 Patent expires in February 2023. A hearing has been scheduled for May 2019. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of The Hague (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which also concerns administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. The Dutch and German counterparts were ruled invalid and we have appealed. No date for a hearing on the merits has been set in the Italian action.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May&amp;#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&amp;#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. In October 2018 EMD Serono and Pfizer filed an appeal from the judgment in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&amp;#160;We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2017 we learned that the Prosecution Office of Milan was investigating our interactions with certain healthcare providers in Italy.&amp;#160;In January 2019 the Prosecution Office dismissed the proceeding. We consider the matter closed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Matter&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$70.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; including interest and penalties.&amp;#160;We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending.&amp;#160;We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
	<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="FD2019Q1YTD" id="Fact-0AAE5787CD29EECBF5E24F52A310C7C8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The minimum lease payments, net of income from subleases, for the next five years and thereafter is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 (remaining nine months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;69.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;81.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;76.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;69.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;68.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;66.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;146.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;577.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;68.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Present value of operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
	<us-gaap:LesseeOperatingLeasesTextBlock contextRef="FD2019Q1YTD" id="Fact-740D79F5653F51DAB000C9967F918143">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We lease real estate, including laboratory and office space, and certain equipment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our leases have remaining lease terms ranging from less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; year to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one year&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; year to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years. Our subleases do not include an option to renew as they are coterminous with our operating leases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All of our leases qualify as operating leases. The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance sheet location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;447.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;72.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;436.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of lease costs in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;23.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sublease income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other (income) expense, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net lease cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;15.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The minimum lease payments, net of income from subleases, for the next five years and thereafter is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 (remaining nine months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;69.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;81.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;76.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;69.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;68.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;66.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;146.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;577.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;68.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Present value of operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the prior lease guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&amp;#160;31, 2018, were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;87.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;80.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;75.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;601.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(26.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(24.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(24.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(182.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;52.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;46.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;156.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;418.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average remaining lease term in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average discount rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets obtained in exchange for lease obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proposed Divestiture of Hiller&amp;#248;d, Denmark Manufacturing Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&amp;#248;d, Denmark. As a result, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of operating lease assets and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of operating lease liabilities were reclassified to assets held for sale in our condensed consolidated balance sheets as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on the proposed divestiture of our Hiller&amp;#248;d, Denmark manufacturing operations, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2019Q1YTD" id="Fact-EFD8F7F45B8C53FEA7F66B279FDB96D1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Narrow-Scope Improvement for Lessors&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and ASU No. 2019-01, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Codification Improvements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$463.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a corresponding operating lease liability of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$526.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the adoption of the new leasing standards, please read Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Credit Losses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard will become effective for us on January 1, 2020, and requires adoption using a modified retrospective approach, with certain exceptions. Based on the composition of our investment portfolio, current market conditions and historical credit loss activity, the adoption of this standard is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Derivative Instruments and Hedging Activities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 the FASB issued ASU No. 2018-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative and Hedging&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard makes targeted improvements for collaborative arrangements as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-FC50B954E0FA5EF18E74212698F48C59">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,841.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,797.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, depreciation expense totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$52.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$65.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.7 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.6 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to this facility. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$92.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; outstanding related to the construction of this facility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proposed Divestiture of Hiller&amp;#248;d, Denmark Manufacturing Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&amp;#248;d, Denmark. As a result, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$629.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of property, plant and equipment, which is primarily comprised of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$312.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for buildings and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$286.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for machinery and equipment, was reclassified to assets held for sale in our condensed consolidated balance sheets as of March 31, 2019. Additionally, we ceased recording depreciation on these assets as depreciation is not recorded during the period in which a long-lived asset or disposal group is classified as held for sale, even if the asset or disposal group continues to generate revenue during the period. For additional information on the proposed divestiture of our Hiller&amp;#248;d, Denmark manufacturing operations, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="FD2019Q1YTD" id="Fact-1DCE47EB22EA5D0DB564BC5E93100717">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,489.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,068.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="FD2019Q1YTD" id="Fact-0919C42D56865F1B8A57B257D8067CDC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:39%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
	<us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="FD2019Q1YTD" id="Fact-FAE8F797A3145BF785C0F4F100054636">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis (MS):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;717.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;281.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;998.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;728.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;258.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;986.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;327.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;173.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;500.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;371.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;178.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;550.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;245.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;215.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;460.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;249.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;462.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;22.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;22.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: MS product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,290.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;693.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,983.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,350.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;675.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,025.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;223.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;295.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;518.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;188.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;175.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;363.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biosimilars:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;124.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;124.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;120.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;120.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IMRALDI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: Biosimilar product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;174.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;174.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;127.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;127.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,513.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,166.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,680.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,538.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;985.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,523.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognized revenues from two wholesalers accounting for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.3%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;127.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;888.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,051.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;141.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;680.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;826.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(24.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(60.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(233.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(294.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(92.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(378.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(474.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;116.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;932.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,083.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;175.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;176.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;907.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;874.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,083.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,051.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&amp;#8217;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;390.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;349.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;126.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;93.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;517.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;443.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Genentech, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2018 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Other Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;264.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;140.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;292.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;164.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the three months ended March 31, 2019 and 2018, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$206.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these condensed consolidated financial statements. For additional information on our collaboration arrangement with AbbVie Inc. (AbbVie), please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2018 Form 10-K. For additional information on our contract manufacturing agreements with Bioverativ, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2018 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2019Q1YTD" id="Fact-4DE212CE453F587BA02C59B8FE19291B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;907.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;874.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;216.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;261.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;195.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;224.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;160.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;320.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;147.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;444.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;99.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;125.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;708.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;609.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,435.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,861.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2019Q1YTD" id="Fact-B92587116CCD5836AFD25A3F9A317A2E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(31.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(243.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(240.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;16.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(17.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;16.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(17.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;51.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(30.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(261.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(219.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(318.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(316.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(60.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;44.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(29.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;44.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(133.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(130.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(303.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="FD2019Q1YTD" id="Fact-E08CE4E3C74C58288279DB67E6267F21">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,500.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,486.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,489.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,480.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,022.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;995.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,000.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;995.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,795.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,738.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,745.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,737.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,838.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,722.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,802.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,722.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,155.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,943.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,037.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,936.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="FD2019Q1YTD" id="Fact-01E435A344E05D2688E948F5F6976C7D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&amp;#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;446.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;192.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,074.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;279.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;168.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;194.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,881.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;705.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2019Q1YTD" id="Fact-B306E9E1E6DE51E1BD99BBD8EED34418">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;49.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="FD2019Q1YTD" id="Fact-3CAF103F407F5A5CAC3DA9AEADE09101">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:22%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="FD2019Q1YTD" id="Fact-9703A37B9AA852A79A9D065F18978A8E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash Flow Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;101.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2019Q1YTD" id="Fact-82E3DE1E5F2D53E390E6953E0513BBB6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,408.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,172.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;196.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;197.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2019Q1YTD" id="Fact-1D287E7B2F2C5611BB0C406317970E9E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Denmark assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Global Intangible Low-Taxed Income (GILTI)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;22.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2019Q1YTD" id="Fact-26A3177DC02856898BEC4618030C166C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;27.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;49.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;38.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2019Q1YTD" id="Fact-2DA3A643BE0B576489D386B5BE2D588F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2019 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,881.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,881.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,835.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,835.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;921.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;921.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;281.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;281.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;904.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;884.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;104.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;104.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;29.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;29.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,958.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,938.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;421.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;421.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;445.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;421.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;705.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;705.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,459.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,459.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;969.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;969.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;260.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;260.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;615.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;563.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;66.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;66.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,102.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,050.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;434.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2019Q1YTD" id="Fact-27E07A0241C2FB9838EFC9B6AF958897">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the prior lease guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&amp;#160;31, 2018, were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;87.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;80.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;75.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;601.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(26.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(24.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(24.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(182.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;52.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;46.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;156.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;418.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfGoodwillTextBlock contextRef="FD2019Q1YTD" id="Fact-F939134709545615B19FFA27CCAEDF44">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,706.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reclassification of goodwill to assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(69.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,639.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2019Q1YTD" id="Fact-4CCD5ECE0C8D5C6BAAD220BACE30971A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;199.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;462.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;606.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;108.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;133.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;770.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;936.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;770.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;929.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;770.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;936.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2019Q1YTD" id="Fact-ECF806630AFAE000942BC5ABA54B7AE8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:22%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="FD2019Q1YTD" id="Fact-5524116239735F309F4484F47E308A79">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,722.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,701.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;170.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;131.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;79.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;98.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;72.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;92.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,144.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,239.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
	<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="FD2019Q1YTD" id="Fact-07A597C416555DA197230E81AB7B9821">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(47.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(50.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;376.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;357.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(41.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2019Q1YTD" id="Fact-E73E439D436259D3A923C603FEBE49F0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 (remaining nine months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;200.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;290.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;250.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;250.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;230.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;190.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2019Q1YTD" id="Fact-D6F90C49BEC955F186B09ED9D4C878BA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also commercialize biosimilars of advanced biologics.&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; For additional information on our collaboration arrangements with Genentech, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our Annual Report on Form&amp;#160;10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including Parkinson's disease, ALS, progressive supranuclear palsy, AD, stroke, epilepsy, cognitive impairment associated with schizophrenia and pain.&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the European Union (E.U.).&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&amp;#160;GAAP). The information included in this quarterly report on Form&amp;#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2018 Form&amp;#160;10-K. Our accounting policies are described in the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8221; in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&amp;#160;GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Assets and Liabilities Held For Sale&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held-for-sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Narrow-Scope Improvement for Lessors&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and ASU No. 2019-01, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Codification Improvements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$463.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a corresponding operating lease liability of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$526.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the adoption of the new leasing standards, please read Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Credit Losses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard will become effective for us on January 1, 2020, and requires adoption using a modified retrospective approach, with certain exceptions. Based on the composition of our investment portfolio, current market conditions and historical credit loss activity, the adoption of this standard is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Derivative Instruments and Hedging Activities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 the FASB issued ASU No. 2018-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative and Hedging&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard makes targeted improvements for collaborative arrangements as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-2D1122FD00DE115F9A30CA3CE7B3F6FA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2019 Share Repurchase Program). Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. We did not repurchase any shares of our common stock under our 2019 Share Repurchase Program during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2018 Share Repurchase Program). Our 2018 Share Repurchase Program does not have an expiration date. All share repurchases under our 2018 Share Repurchase Program will be retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$655.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From April 1, 2019 through April 24, 2019, we repurchased and retired approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$491.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under our 2018 Share Repurchase Program. Approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; remained available under our 2018 Share Repurchase Program as of April 24, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(31.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(243.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(240.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;16.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(17.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;16.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(17.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;51.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(30.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(261.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(219.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(318.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(316.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(60.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;44.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(29.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;44.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(133.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(130.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(303.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:39%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2019Q1YTD" id="Fact-A926DAF247E25C4D91D72D1A1800E5C5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-A37317574A025FB08082E691949F6898">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD, including aducanumab. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&amp;#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019, following the results of a futility analysis conducted by an independent data monitoring committee, we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development costs for which we reimbursed Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amounts reimbursed were immaterial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$112.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$28.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>biib-20190331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20190331" xmlns:biib="http://www.biogenidec.com/20190331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20190331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20190331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20190331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20190331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2106100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsBusinessAcquisitionDetailsTextual" roleURI="http://www.biogenidec.com/role/AcquisitionsBusinessAcquisitionDetailsTextual">
        <link:definition>2406401 - Disclosure - Acquisitions Business Acquisition (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2134100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails">
        <link:definition>2434402 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2434403 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables">
        <link:definition>2334301 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement">
        <link:definition>1005000 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2123100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2423402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2323301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDivestitures" roleURI="http://www.biogenidec.com/role/DivestituresDivestitures">
        <link:definition>2114100 - Disclosure - Divestitures Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDivestituresDetails" roleURI="http://www.biogenidec.com/role/DivestituresDivestituresDetails">
        <link:definition>2414402 - Disclosure - Divestitures Divestitures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDivestituresDetailsTextual" roleURI="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual">
        <link:definition>2414403 - Disclosure - Divestitures Divestitures (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDivestituresTables" roleURI="http://www.biogenidec.com/role/DivestituresDivestituresTables">
        <link:definition>2314301 - Disclosure - Divestitures Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2130100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2430402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2330301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2429403 - Disclosure - Equity Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2329301 - Disclosure - Equity Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityEquityNotes" roleURI="http://www.biogenidec.com/role/EquityEquityNotes">
        <link:definition>2129100 - Disclosure - Equity Equity (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2429404 - Disclosure - Equity Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/EquityShareRepurchasesDetails">
        <link:definition>2429402 - Disclosure - Equity Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2121100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2421402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2421403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2421404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2421405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2321301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2122100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2422402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2422403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2422404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2422405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2422406 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2322301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2132100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2432402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2432403 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2332301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2120100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2420402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2320301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2119100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2419402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryInventoryDetailsTextual" roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual">
        <link:definition>2419403 - Disclosure - Inventory Inventory (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryProposedDivestitureOfDenmarkManufacturingOperationsDetails" roleURI="http://www.biogenidec.com/role/InventoryProposedDivestitureOfDenmarkManufacturingOperationsDetails">
        <link:definition>2419404 - Disclosure - Inventory Proposed Divestiture of Denmark Manufacturing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2319301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2135100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2435401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.biogenidec.com/role/LeasesDetails">
        <link:definition>2428402 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeases" roleURI="http://www.biogenidec.com/role/LeasesLeases">
        <link:definition>2128100 - Disclosure - Leases Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasesDetailsTextual" roleURI="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual">
        <link:definition>2428403 - Disclosure - Leases Leases (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasesTables" roleURI="http://www.biogenidec.com/role/LeasesLeasesTables">
        <link:definition>2328301 - Disclosure - Leases Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2136100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationLitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails">
        <link:definition>2436401 - Disclosure - Litigation Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2133100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2433402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2433403 - Disclosure - Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2333301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment">
        <link:definition>2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails">
        <link:definition>2424401 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>2418406 - Disclosure - Revenues Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesForDiscountsAndAllowancesDetails1" roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1">
        <link:definition>2418403 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesForDiscountsAndAllowancesDetails2" roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2">
        <link:definition>2418404 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenues" roleURI="http://www.biogenidec.com/role/RevenuesRevenues">
        <link:definition>2118100 - Disclosure - Revenues Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesByProductDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails">
        <link:definition>2418402 - Disclosure - Revenues Revenues by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDetailsTextual" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual">
        <link:definition>2418407 - Disclosure - Revenues Revenues (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails">
        <link:definition>2418405 - Disclosure - Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesTables">
        <link:definition>2318301 - Disclosure - Revenues Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2131100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2431402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2431403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2331301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A2016ShareRepurchaseProgramMember" name="A2016ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2018ShareRepurchaseProgramMember" name="A2018ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2019ShareRepurchaseProgramMember" name="A2019ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AbbVieMember" name="AbbVieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AcquisitionsAbstract" name="AcquisitionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AducanumabMember" name="AducanumabMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock" name="AssetsandLiabilitiesHeldForSalePolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BENEPALIMember" name="BENEPALIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogenshareofcopromotionprofitsorlosses" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiosimilarsMember" name="BiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BioverativMember" name="BioverativMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Collaborationexpensesaccrual" name="Collaborationexpensesaccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Collaborationprofitlosssharing" name="Collaborationprofitlosssharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DeferredtaxliabilityMember" name="DeferredtaxliabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DenmarkManufacturingOperationsMember" name="DenmarkManufacturingOperationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_DisposalGroupOperatingLeaseAssets" name="DisposalGroupOperatingLeaseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_DisposalGroupOperatingleaseliabilities" name="DisposalGroupOperatingleaseliabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DistributorOneMember" name="DistributorOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorTwoMember" name="DistributorTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DivestituresAbstract" name="DivestituresAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DuefromantiCD20therapeuticprograms" name="DuefromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_E2609andBAN2401Member" name="E2609andBAN2401Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveTaxRateReconciliationGILTItax" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Expenseincurredbythecollaboration" name="Expenseincurredbythecollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Expensereflectedwithinstatementsofincome" name="Expensereflectedwithinstatementsofincome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FAMPYRAMember" name="FAMPYRAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FLIXABIMember" name="FLIXABIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FUMADERMMember" name="FUMADERMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IMRALDIMember" name="IMRALDIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InterferonMember" name="InterferonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InventoryAbstract" name="InventoryAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InventorysoldtoBioverativcost" name="InventorysoldtoBioverativcost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentInVariableInterestEntitiesTextualAbstract" name="InvestmentInVariableInterestEntitiesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Investmentincommonstocksharespurchased" name="Investmentincommonstocksharespurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IonisPharmaceuticalsMember" name="IonisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_LesseeLeaseTableTableTextBlock" name="LesseeLeaseTableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_LongtermoperatingleaseliabilitiesMember" name="LongtermoperatingleaseliabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MSProductRevenuesMember" name="MSProductRevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NetMinimumLeasePayments" name="NetMinimumLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsThereafter" name="NetMinimumLeasePaymentsThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFiveYear" name="NetMinimumLeasePaymentsWithInFiveYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFourYear" name="NetMinimumLeasePaymentsWithInFourYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInOneYear" name="NetMinimumLeasePaymentsWithInOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInThreeYear" name="NetMinimumLeasePaymentsWithInThreeYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInTwoYear" name="NetMinimumLeasePaymentsWithInTwoYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_NightstarMember" name="NightstarMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OperatingleaseassetsMember" name="OperatingleaseassetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" name="OperatingleasesupplementalcashflowdisclosureTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" name="OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OthercorporaterevenuesMember" name="OthercorporaterevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherrevenuesAbstract" name="OtherrevenuesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesTableTextBlock" name="OtherrevenuesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinCashMember" name="PerformanceStockUnitsSettledinCashMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinStockMember" name="PerformanceStockUnitsSettledinStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_Purchaseofcommonstock" name="Purchaseofcommonstock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReserveforCashDiscountsMember" name="ReserveforCashDiscountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_Revenuesfromanticd20therapeuticprogramsMember" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RocheGroupGenentechMember" name="RocheGroupGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SPINRAZAMember" name="SPINRAZAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareOfCoPromotionProfits" name="ShareOfCoPromotionProfits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SkyhawkTherapeuticsMember" name="SkyhawkTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnSwitzerlandMember" name="SolothurnSwitzerlandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TaxcontingencyAbstract" name="TaxcontingencyAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_WorkinprocessMember" name="WorkinprocessMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>biib-20190331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20190331.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsBusinessAcquisitionDetailsTextual" xlink:href="biib-20190331.xsd#AcquisitionsBusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20190331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20190331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20190331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:href="biib-20190331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20190331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20190331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20190331.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20190331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20190331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20190331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20190331.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20190331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20190331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20190331.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestituresDetails" xlink:href="biib-20190331.xsd#DivestituresDivestituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual" xlink:href="biib-20190331.xsd#DivestituresDivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestituresTables" xlink:href="biib-20190331.xsd#DivestituresDivestituresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20190331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20190331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20190331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20190331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190331.xsd#EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20190331.xsd#EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityEquityNotes" xlink:href="biib-20190331.xsd#EquityEquityNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190331.xsd#EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityShareRepurchasesDetails" xlink:href="biib-20190331.xsd#EquityShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20190331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20190331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20190331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20190331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20190331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20190331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20190331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20190331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20190331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20190331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20190331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20190331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20190331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20190331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20190331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20190331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20190331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20190331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20190331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20190331.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:href="biib-20190331.xsd#InventoryProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20190331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20190331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20190331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetails" xlink:href="biib-20190331.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeases" xlink:href="biib-20190331.xsd#LeasesLeases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual" xlink:href="biib-20190331.xsd#LeasesLeasesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesTables" xlink:href="biib-20190331.xsd#LeasesLeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20190331.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:href="biib-20190331.xsd#LitigationLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20190331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20190331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20190331.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20190331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20190331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20190331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:href="biib-20190331.xsd#RevenuesOtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20190331.xsd#RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20190331.xsd#RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20190331.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails" xlink:href="biib-20190331.xsd#RevenuesRevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual" xlink:href="biib-20190331.xsd#RevenuesRevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20190331.xsd#RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesTables" xlink:href="biib-20190331.xsd#RevenuesRevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20190331.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20190331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20190331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20190331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20190331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20190331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20190331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsBusinessAcquisitionDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_6ba80206-8cc8-5086-d0db-3c30ef22aeb8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_6ba80206-8cc8-5086-d0db-3c30ef22aeb8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_84156f77-ffd5-075d-6239-6cd45f85e5f7" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_84156f77-ffd5-075d-6239-6cd45f85e5f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_79aabdc0-b963-1fd1-4e81-8c0801b1ebca" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_OtherAssetsCurrent_79aabdc0-b963-1fd1-4e81-8c0801b1ebca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5be77b8d-fe95-a009-6655-0f33965794f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5be77b8d-fe95-a009-6655-0f33965794f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_5ee94de1-09b5-a281-d50f-420352002a69" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_5ee94de1-09b5-a281-d50f-420352002a69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_70b30340-b55c-aed7-73f5-36d397294f84" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_TreasuryStockValue_70b30340-b55c-aed7-73f5-36d397294f84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_a9feabf5-0bf0-3efe-740e-f5e41a4b3194" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_MinorityInterest_a9feabf5-0bf0-3efe-740e-f5e41a4b3194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_e11f4ed8-bba4-2471-6835-a5baa4d63b38" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_TaxesPayableCurrent_e11f4ed8-bba4-2471-6835-a5baa4d63b38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_1a328a3d-d1e5-fe0c-24cb-adc4362e6b5c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_1a328a3d-d1e5-fe0c-24cb-adc4362e6b5c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_6b1efbc2-e859-9fbd-c572-2f4147498390" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_6b1efbc2-e859-9fbd-c572-2f4147498390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c85c86db-a830-0e07-1d7a-6fc2a37081a4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c85c86db-a830-0e07-1d7a-6fc2a37081a4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a8656384-f7ca-f6e9-7877-ac1b97f5601a" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a8656384-f7ca-f6e9-7877-ac1b97f5601a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_d723d1eb-c04b-1442-45e1-e3c4c46a2f9c" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_d723d1eb-c04b-1442-45e1-e3c4c46a2f9c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7dc79878-6c70-80cd-fdf9-04f13ac557f6" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7dc79878-6c70-80cd-fdf9-04f13ac557f6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e69a15cf-ab4b-cbea-dc70-0b76971b08a1" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e69a15cf-ab4b-cbea-dc70-0b76971b08a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a9646808-098c-8496-e17a-df690055019e" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a9646808-098c-8496-e17a-df690055019e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c4aa0718-f1b7-8481-8382-216f94e41c89" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c4aa0718-f1b7-8481-8382-216f94e41c89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a6cca43-79c5-34f3-6172-5859b13486b1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a6cca43-79c5-34f3-6172-5859b13486b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_9bee6818-2a16-d4ae-2725-dfdc5464a350" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_9bee6818-2a16-d4ae-2725-dfdc5464a350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_1d9f6b21-7968-bfc5-a1a6-0a5c2f012b31" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_1d9f6b21-7968-bfc5-a1a6-0a5c2f012b31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_54e087e7-dea1-4188-710c-f95dcb130e6e" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_54e087e7-dea1-4188-710c-f95dcb130e6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d4a92697-d008-996b-823a-bd9a56a04b3a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d4a92697-d008-996b-823a-bd9a56a04b3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_38e7f3e2-9d1a-8772-e4aa-fb2cb7d8adc0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_38e7f3e2-9d1a-8772-e4aa-fb2cb7d8adc0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7f6d9e2c-c748-5cf7-7279-5c01f0cb27b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7f6d9e2c-c748-5cf7-7279-5c01f0cb27b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_f44275a4-2994-4281-73e3-0fa77d53374b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_f44275a4-2994-4281-73e3-0fa77d53374b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_38cb4275-1b57-cd6d-2284-94c39e717048" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_38cb4275-1b57-cd6d-2284-94c39e717048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e83cd656-9fce-43ca-6f7c-1be78bef4068" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e83cd656-9fce-43ca-6f7c-1be78bef4068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7f6d9e2c-c748-5cf7-7279-5c01f0cb27b7" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_f44275a4-2994-4281-73e3-0fa77d53374b" xlink:type="arc" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_38cb4275-1b57-cd6d-2284-94c39e717048" xlink:type="arc" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e83cd656-9fce-43ca-6f7c-1be78bef4068" xlink:type="arc" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ff106bf5-082b-8f58-cc36-c7f91866b7d3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ff106bf5-082b-8f58-cc36-c7f91866b7d3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6b6667ca-75d4-9e60-6c7f-ed168ded3470" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6b6667ca-75d4-9e60-6c7f-ed168ded3470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_40e09388-8f81-ef72-b788-b42e34e21b0a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_40e09388-8f81-ef72-b788-b42e34e21b0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_c58675d3-1913-24cc-82bd-3c30ef81434c" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_biib_Collaborationprofitlosssharing_c58675d3-1913-24cc-82bd-3c30ef81434c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c85c86db-a830-0e07-1d7a-6fc2a37081a4" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c85c86db-a830-0e07-1d7a-6fc2a37081a4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a8656384-f7ca-f6e9-7877-ac1b97f5601a" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a8656384-f7ca-f6e9-7877-ac1b97f5601a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_e04ca6ce-4142-8baf-2785-53947ccd390b" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_RestructuringCharges_e04ca6ce-4142-8baf-2785-53947ccd390b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d01a4d5f-b660-27b4-db84-9a80227862fc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d01a4d5f-b660-27b4-db84-9a80227862fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f5ae002e-8316-7bc0-1b41-6cd171b53db3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f5ae002e-8316-7bc0-1b41-6cd171b53db3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestituresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_197c47d4-bc5c-2203-067f-02363a4fbfd8" xlink:type="locator" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_D53A4B3400744F8EA44235E5D5B764D2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_197c47d4-bc5c-2203-067f-02363a4fbfd8" xlink:to="loc_biib_DisposalGroupOperatingleaseliabilities_D53A4B3400744F8EA44235E5D5B764D2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestituresTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dd9a981-e559-d141-f1c2-4db79f71a7ef" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dd9a981-e559-d141-f1c2-4db79f71a7ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d342f32b-4cc6-0bef-3743-616005090121" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d342f32b-4cc6-0bef-3743-616005090121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e52bef3f-d63a-d129-8b6a-48192f5d97b3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d342f32b-4cc6-0bef-3743-616005090121" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e52bef3f-d63a-d129-8b6a-48192f5d97b3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityEquityNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityShareRepurchasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6bae24fb-c89c-2c1d-91e1-c77efe1775f1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eed137f7-f4cf-61e8-5dd4-67d3dd178f58" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6bae24fb-c89c-2c1d-91e1-c77efe1775f1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eed137f7-f4cf-61e8-5dd4-67d3dd178f58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e0ab27ec-5a16-e4fe-975d-b94bfcaf7d5b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6bae24fb-c89c-2c1d-91e1-c77efe1775f1" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e0ab27ec-5a16-e4fe-975d-b94bfcaf7d5b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0c37b992-ed63-c343-3bce-40db48c88fa6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ca3fdc92-5bc4-ace2-ea95-801ea8b509c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0c37b992-ed63-c343-3bce-40db48c88fa6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ca3fdc92-5bc4-ace2-ea95-801ea8b509c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f3b99f95-1768-5254-1fcc-c01c9fbbdc02" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0c37b992-ed63-c343-3bce-40db48c88fa6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f3b99f95-1768-5254-1fcc-c01c9fbbdc02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_097e1b01-70b4-1050-9921-ba329e565fb9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0c37b992-ed63-c343-3bce-40db48c88fa6" xlink:to="loc_us-gaap_AvailableForSaleSecurities_097e1b01-70b4-1050-9921-ba329e565fb9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_097e1b01-70b4-1050-9921-ba329e565fb9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_329a232f-6b5a-4dfb-de74-33d6f53aa8f1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_097e1b01-70b4-1050-9921-ba329e565fb9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_329a232f-6b5a-4dfb-de74-33d6f53aa8f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bb6f3730-d49d-30bc-8e52-6eba94f7dba4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_097e1b01-70b4-1050-9921-ba329e565fb9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bb6f3730-d49d-30bc-8e52-6eba94f7dba4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_a0eef5af-7e85-59ef-908d-3c30ef035fc5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_097e1b01-70b4-1050-9921-ba329e565fb9" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_a0eef5af-7e85-59ef-908d-3c30ef035fc5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a97722c4-c88e-0258-6d8c-8f5c45929660" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a97722c4-c88e-0258-6d8c-8f5c45929660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ad47d869-5bf7-62ba-8427-e58f9319b050" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ad47d869-5bf7-62ba-8427-e58f9319b050" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_a8e80998-108a-0f34-f1b4-3c30eef430a9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_a8e80998-108a-0f34-f1b4-3c30eef430a9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2159a283-2879-8644-198d-34cde06e5374" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2159a283-2879-8644-198d-34cde06e5374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_928f8c54-624a-8542-b4e3-59da2a4e6af6" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_928f8c54-624a-8542-b4e3-59da2a4e6af6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_8b4dec44-978c-8cf6-a303-372686bd69be" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_8b4dec44-978c-8cf6-a303-372686bd69be" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_524f9585-abae-136f-fab7-d63a54c889d8" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_524f9585-abae-136f-fab7-d63a54c889d8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_A7FB9E41C5A89E43CA12824CBFD9A0D2" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_A7FB9E41C5A89E43CA12824CBFD9A0D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_a279d92b-35df-23ba-dc61-ed7f6f1d81e3" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_a279d92b-35df-23ba-dc61-ed7f6f1d81e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_00f37689-1982-1c68-c80b-43003f810247" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_00f37689-1982-1c68-c80b-43003f810247" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99bd5160-e32a-dcfc-e4fd-38dda5d465b0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99bd5160-e32a-dcfc-e4fd-38dda5d465b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a49df76-38f6-6baa-87dd-2e9a7efd8303" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a49df76-38f6-6baa-87dd-2e9a7efd8303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e52879aa-5fc1-863a-9bc7-07b154238ef5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e52879aa-5fc1-863a-9bc7-07b154238ef5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_90e6c96b-092c-3a0f-bace-3c30ef22b935" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a979ceab-3c76-a4d5-9d1d-ca902d5e8595" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_90e6c96b-092c-3a0f-bace-3c30ef22b935" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a979ceab-3c76-a4d5-9d1d-ca902d5e8595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_02cb866c-0b1c-51f5-8ed3-3272dfc8c769" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_90e6c96b-092c-3a0f-bace-3c30ef22b935" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_02cb866c-0b1c-51f5-8ed3-3272dfc8c769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c2dd0840-de07-383b-bde9-fb229532490d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_90e6c96b-092c-3a0f-bace-3c30ef22b935" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c2dd0840-de07-383b-bde9-fb229532490d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_c856a5b8-7326-6510-a9c4-fbb7de57c364" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_c856a5b8-7326-6510-a9c4-fbb7de57c364" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1ee37125-97ae-9676-6b51-158110f0eb00" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_c856a5b8-7326-6510-a9c4-fbb7de57c364" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1ee37125-97ae-9676-6b51-158110f0eb00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d0e3c4ab-df94-52c6-3761-ce2ed0f2f507" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d0e3c4ab-df94-52c6-3761-ce2ed0f2f507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_198c3642-781c-a7d4-6f7d-8400ab29b18c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_198c3642-781c-a7d4-6f7d-8400ab29b18c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_861baece-48d3-d217-cb0f-fbb7dafd8c6c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_861baece-48d3-d217-cb0f-fbb7dafd8c6c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_680b734e-be2b-a9ae-6215-216b28f8aa8f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_861baece-48d3-d217-cb0f-fbb7dafd8c6c" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_680b734e-be2b-a9ae-6215-216b28f8aa8f" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_32bc1315-87c2-c86c-da91-fbb7de47f51c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_32bc1315-87c2-c86c-da91-fbb7de47f51c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_46feb484-9dc8-7708-8880-ab3ae4fa5724" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_32bc1315-87c2-c86c-da91-fbb7de47f51c" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_46feb484-9dc8-7708-8880-ab3ae4fa5724" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_22720713-ca9c-247b-a99c-fbb7db1c1755" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_36c616b1-40de-90d4-3c05-7e224ce1169a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_22720713-ca9c-247b-a99c-fbb7db1c1755" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_36c616b1-40de-90d4-3c05-7e224ce1169a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_162c926d-b086-ad25-0cf5-12fa6d69e9cc" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_22720713-ca9c-247b-a99c-fbb7db1c1755" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_162c926d-b086-ad25-0cf5-12fa6d69e9cc" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_a93e93be-c9cb-1eb4-fb13-fbb7db8a78b6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_a93e93be-c9cb-1eb4-fb13-fbb7db8a78b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_55b5e968-aed9-5993-81a1-3f801185e617" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_a93e93be-c9cb-1eb4-fb13-fbb7db8a78b6" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_55b5e968-aed9-5993-81a1-3f801185e617" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_0e6a6b77-8b3f-2437-6dc2-fbb7db0d73ef" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_fe404cae-7fcc-3489-844f-4d90e9776180" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_0e6a6b77-8b3f-2437-6dc2-fbb7db0d73ef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_fe404cae-7fcc-3489-844f-4d90e9776180" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7c60d6bd-e7c2-9f1e-0267-8a8e2f2cc01a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_0e6a6b77-8b3f-2437-6dc2-fbb7db0d73ef" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7c60d6bd-e7c2-9f1e-0267-8a8e2f2cc01a" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_ccca83bb-f7af-cbfd-5aa5-fbb7dace1846" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5b651b24-1278-4eab-c840-7002c6d68546" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_ccca83bb-f7af-cbfd-5aa5-fbb7dace1846" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5b651b24-1278-4eab-c840-7002c6d68546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_f195cc05-55eb-d65f-3b51-acb21f092efc" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_ccca83bb-f7af-cbfd-5aa5-fbb7dace1846" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_f195cc05-55eb-d65f-3b51-acb21f092efc" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesLeases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_769dfb75-9711-aaea-9277-d2bbd807826d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_769dfb75-9711-aaea-9277-d2bbd807826d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743ecb1a-adc1-2b63-ff24-350f33c715bd" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743ecb1a-adc1-2b63-ff24-350f33c715bd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="locator" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_140e4b0f-9eba-1bed-3fdc-3c30ef039ec3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:to="loc_biib_ShareOfCoPromotionProfits_140e4b0f-9eba-1bed-3fdc-3c30ef039ec3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_dadfdc90-3d93-b6e5-db26-cb6831e09e51" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ea9db312-1fc1-b02e-da79-91cf6a5f5686" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_dadfdc90-3d93-b6e5-db26-cb6831e09e51" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ea9db312-1fc1-b02e-da79-91cf6a5f5686" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_124f8086-9e7a-7a28-7a00-3c30eecfd4e1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_dadfdc90-3d93-b6e5-db26-cb6831e09e51" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_124f8086-9e7a-7a28-7a00-3c30eecfd4e1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>biib-20190331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20190331.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsBusinessAcquisitionDetailsTextual" xlink:href="biib-20190331.xsd#AcquisitionsBusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20190331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20190331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20190331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:href="biib-20190331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20190331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20190331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20190331.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20190331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20190331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20190331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20190331.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20190331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20190331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20190331.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestituresDetails" xlink:href="biib-20190331.xsd#DivestituresDivestituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual" xlink:href="biib-20190331.xsd#DivestituresDivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestituresTables" xlink:href="biib-20190331.xsd#DivestituresDivestituresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20190331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20190331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20190331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20190331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190331.xsd#EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20190331.xsd#EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityEquityNotes" xlink:href="biib-20190331.xsd#EquityEquityNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190331.xsd#EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityShareRepurchasesDetails" xlink:href="biib-20190331.xsd#EquityShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20190331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20190331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20190331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20190331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20190331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20190331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20190331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20190331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20190331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20190331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20190331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20190331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20190331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20190331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20190331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20190331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20190331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20190331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20190331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20190331.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:href="biib-20190331.xsd#InventoryProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20190331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20190331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20190331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetails" xlink:href="biib-20190331.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeases" xlink:href="biib-20190331.xsd#LeasesLeases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual" xlink:href="biib-20190331.xsd#LeasesLeasesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesTables" xlink:href="biib-20190331.xsd#LeasesLeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20190331.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:href="biib-20190331.xsd#LitigationLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20190331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20190331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20190331.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20190331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20190331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20190331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:href="biib-20190331.xsd#RevenuesOtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20190331.xsd#RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20190331.xsd#RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20190331.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails" xlink:href="biib-20190331.xsd#RevenuesRevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual" xlink:href="biib-20190331.xsd#RevenuesRevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20190331.xsd#RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesTables" xlink:href="biib-20190331.xsd#RevenuesRevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20190331.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20190331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20190331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20190331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20190331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20190331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20190331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsBusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_89A797D89F3C3640019450341DD40447" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762" xlink:to="loc_biib_NightstarMember_89A797D89F3C3640019450341DD40447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_6E93ABBB4405264E23BD50341DD648BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_6E93ABBB4405264E23BD50341DD648BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_DFDAE727CD8A5A6877D150341DD6FAB2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_DFDAE727CD8A5A6877D150341DD6FAB2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C6837A6C5309CBF9952050341BE9159E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C6837A6C5309CBF9952050341BE9159E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F91D93124EB69C252DE850341BEACFF6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C6837A6C5309CBF9952050341BE9159E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F91D93124EB69C252DE850341BEACFF6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F91D93124EB69C252DE850341BEACFF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C6837A6C5309CBF9952050341BE9159E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F91D93124EB69C252DE850341BEACFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_D424C9AA4E8256AAD5C150341BEAD498" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F91D93124EB69C252DE850341BEACFF6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_D424C9AA4E8256AAD5C150341BEAD498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9CE664D880FCD69C6B9750341BEAC64D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F91D93124EB69C252DE850341BEACFF6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9CE664D880FCD69C6B9750341BEAC64D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6B8CAEE193FA2BDED6A150341BEA7B4C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6B8CAEE193FA2BDED6A150341BEA7B4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A0814B93C2E284FCDF750341BEBE319_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6B8CAEE193FA2BDED6A150341BEA7B4C" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A0814B93C2E284FCDF750341BEBE319_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A0814B93C2E284FCDF750341BEBE319" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6B8CAEE193FA2BDED6A150341BEA7B4C" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A0814B93C2E284FCDF750341BEBE319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_32D6ECBB29751A3C7B9650341BEBB6AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A0814B93C2E284FCDF750341BEBE319" xlink:to="loc_us-gaap_CollaborativeArrangementMember_32D6ECBB29751A3C7B9650341BEBB6AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A0814B93C2E284FCDF750341BEBE319" xlink:to="loc_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A0814B93C2E284FCDF750341BEBE319" xlink:to="loc_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0F86EE6399B005780AAA50341BEC9F00" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:to="loc_srt_ProductOrServiceAxis_0F86EE6399B005780AAA50341BEC9F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D0E88BBCA9EB8D33E7AD50341BEC3F8A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0F86EE6399B005780AAA50341BEC9F00" xlink:to="loc_srt_ProductsAndServicesDomain_D0E88BBCA9EB8D33E7AD50341BEC3F8A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D0E88BBCA9EB8D33E7AD50341BEC3F8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0F86EE6399B005780AAA50341BEC9F00" xlink:to="loc_srt_ProductsAndServicesDomain_D0E88BBCA9EB8D33E7AD50341BEC3F8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D0E88BBCA9EB8D33E7AD50341BEC3F8A" xlink:to="loc_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D0E88BBCA9EB8D33E7AD50341BEC3F8A" xlink:to="loc_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_371EE82620FCC2B2C78350341BED167D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_us-gaap_LossOnContractTermination_371EE82620FCC2B2C78350341BED167D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3324AFE6251A7B54551350341BEEEE6C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3324AFE6251A7B54551350341BEEEE6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_029B7EED9D9DA55DA79E50341BEE622D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_029B7EED9D9DA55DA79E50341BEE622D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_EAF23263AE1F0111393C50341BD32ABF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_EAF23263AE1F0111393C50341BD32ABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_EAF23263AE1F0111393C50341BD32ABF" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_EAF23263AE1F0111393C50341BD32ABF" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_14BF10286CA1912E56A150341BD479D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:to="loc_us-gaap_InventoriesMember_14BF10286CA1912E56A150341BD479D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_407B8BF784C831BED9B550341BD4FAB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_407B8BF784C831BED9B550341BD4FAB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5C358B576FFF1084ADF950341BD44AB9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5C358B576FFF1084ADF950341BD44AB9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:to="loc_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_D58490FEB2C6D780891F50341BD5C955" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C" xlink:to="loc_us-gaap_CollaborativeArrangementMember_D58490FEB2C6D780891F50341BD5C955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BEC47F8945D77790D6A350341BD7C94D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BEC47F8945D77790D6A350341BD7C94D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_AA252EDBD5A67D6E277250341BD70783" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_AA252EDBD5A67D6E277250341BD70783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A019E11F28D700E50EB050341BD79AFF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A019E11F28D700E50EB050341BD79AFF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_204DBD5C65E5519BCB6B50341BD7C6CC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_204DBD5C65E5519BCB6B50341BD7C6CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_B31DCBA4892D231219C050341BD70005" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_B31DCBA4892D231219C050341BD70005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_CE5946D4776FFFFAD83450341BD8F4FE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_AdjustmentForAmortization_CE5946D4776FFFFAD83450341BD8F4FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_89252967489160CA731D50341BD86228" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_EquityMethodInvestments_89252967489160CA731D50341BD86228" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F1CC8F96A78BE2C066D950341BD8A506" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_Revenues_F1CC8F96A78BE2C066D950341BD8A506" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_463F31C09EE2C5DBD42550341DE8D7ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StatementTable_463F31C09EE2C5DBD42550341DE8D7ED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_A1AC1C5D0268EB6244A850341DE8FC03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_463F31C09EE2C5DBD42550341DE8D7ED" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_A1AC1C5D0268EB6244A850341DE8FC03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_D8C4E6C622748BAA18DF50341DE91438_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_A1AC1C5D0268EB6244A850341DE8FC03" xlink:to="loc_us-gaap_AccountingGuidanceMember_D8C4E6C622748BAA18DF50341DE91438_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_D8C4E6C622748BAA18DF50341DE91438" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_A1AC1C5D0268EB6244A850341DE8FC03" xlink:to="loc_us-gaap_AccountingGuidanceMember_D8C4E6C622748BAA18DF50341DE91438" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_226BAA62D5F3E210843B50341DE98304" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_D8C4E6C622748BAA18DF50341DE91438" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_226BAA62D5F3E210843B50341DE98304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_2D0D5617566737A3452350341DE9F1DC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_D8C4E6C622748BAA18DF50341DE91438" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_2D0D5617566737A3452350341DE9F1DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_50BC0D26BEAA90584D1250341DE9D2B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_463F31C09EE2C5DBD42550341DE8D7ED" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_50BC0D26BEAA90584D1250341DE9D2B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_588982A3EDB5E520788250341DEA2C9E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_50BC0D26BEAA90584D1250341DE9D2B1" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_588982A3EDB5E520788250341DEA2C9E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_588982A3EDB5E520788250341DEA2C9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_50BC0D26BEAA90584D1250341DE9D2B1" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_588982A3EDB5E520788250341DEA2C9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_8AD383771E8190EB9CFE50341DEA2300" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_588982A3EDB5E520788250341DEA2C9E" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_8AD383771E8190EB9CFE50341DEA2300" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_E2ED2F284F11B0DC979550341DEAECC2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_588982A3EDB5E520788250341DEA2C9E" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_E2ED2F284F11B0DC979550341DEAECC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8F4B90EE3D3192504D1950341DEAA286" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_463F31C09EE2C5DBD42550341DE8D7ED" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8F4B90EE3D3192504D1950341DEAA286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8F4B90EE3D3192504D1950341DEAA286" xlink:to="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8F4B90EE3D3192504D1950341DEAA286" xlink:to="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_7518A54EF68570101F9350341DEBEDF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_PreferredStockMember_7518A54EF68570101F9350341DEBEDF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FEFC8C73EB1F6D64D09D50341DEB2D0F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_CommonStockMember_FEFC8C73EB1F6D64D09D50341DEB2D0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7803110D46BB009C13BC50341DEB8FC3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7803110D46BB009C13BC50341DEB8FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28B1E2AF18B42DF1715D50341DEB11BD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28B1E2AF18B42DF1715D50341DEB11BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_30021A544F7EAD4E960950341DEB08FC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_RetainedEarningsMember_30021A544F7EAD4E960950341DEB08FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_4EBB2FBB185D79456C4550341DECC259" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_TreasuryStockMember_4EBB2FBB185D79456C4550341DECC259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2EF810A1DF8F8864C7C250341DEC4051" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2EF810A1DF8F8864C7C250341DEC4051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_7C73E3AE093C8793B1C150341DECCC8C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_ParentMember_7C73E3AE093C8793B1C150341DECCC8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27C84723C10D5E9C11CF50341DECAAC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27C84723C10D5E9C11CF50341DECAAC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_9B9863D29CEA347AA76350341DEC4D9F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_SharesIssued_9B9863D29CEA347AA76350341DEC4D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0E2A87766C2222E1119150341DED6E72" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockholdersEquity_0E2A87766C2222E1119150341DED6E72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_F94B3D08254412A6DF4250341DED00E8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_MinorityInterest_F94B3D08254412A6DF4250341DED00E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E1FE448972157735EAD150341DED41AC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_NetIncomeLoss_E1FE448972157735EAD150341DED41AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D99F11812A495BFF41D750341DED1B27" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D99F11812A495BFF41D750341DED1B27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_A4B83D2974C8012F516C50341DED2C5C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_ProfitLoss_A4B83D2974C8012F516C50341DED2C5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9F9FFEE92DE7D78921A050341DEE2EC9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9F9FFEE92DE7D78921A050341DEE2EC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19DD85D2D8BA870B5FF750341DEE7913" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19DD85D2D8BA870B5FF750341DEE7913" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_392863B878F168E6294950341DEEF8D1" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_392863B878F168E6294950341DEEF8D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_DDFB00A32A502A80F1E950341DEE62B2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_DDFB00A32A502A80F1E950341DEE62B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_2C7F96E52C1509AE18FA50341DEE8C3D" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_2C7F96E52C1509AE18FA50341DEE8C3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5349E05E8557FF9164B950341DEE9C0D" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5349E05E8557FF9164B950341DEE9C0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_EBA27CFF411CD04E8E4650341DEF4C40" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_EBA27CFF411CD04E8E4650341DEF4C40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECDF24632B07A66E594150341DEF1325" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECDF24632B07A66E594150341DEF1325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0D0A0D00D7DB44200F1150341DEF244A" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0D0A0D00D7DB44200F1150341DEF244A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6C4050238115C76BCE4E50341DEF482F" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6C4050238115C76BCE4E50341DEF482F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_983ED9122DC173FC506A50341DEF145B" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_983ED9122DC173FC506A50341DEF145B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_DA725461851D6C900B2F50341DEF361C" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockholdersEquityOther_DA725461851D6C900B2F50341DEF361C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EF8ADB7037EFA630EFCD50341E35D3DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_18E017E864391CE8495B50341E339B10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_EF8ADB7037EFA630EFCD50341E35D3DD" xlink:to="loc_us-gaap_StatementTable_18E017E864391CE8495B50341E339B10" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4AE3363FB6BC781C664B50341E336440" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_18E017E864391CE8495B50341E339B10" xlink:to="loc_srt_ProductOrServiceAxis_4AE3363FB6BC781C664B50341E336440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_93055A1EB81D2663122550341E341825_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4AE3363FB6BC781C664B50341E336440" xlink:to="loc_srt_ProductsAndServicesDomain_93055A1EB81D2663122550341E341825_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_93055A1EB81D2663122550341E341825" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4AE3363FB6BC781C664B50341E336440" xlink:to="loc_srt_ProductsAndServicesDomain_93055A1EB81D2663122550341E341825" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_377EB457FAF7729AF61F50341E343738" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_93055A1EB81D2663122550341E341825" xlink:to="loc_us-gaap_ProductMember_377EB457FAF7729AF61F50341E343738" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_817E973C55E074F2F78450341E349F1D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_93055A1EB81D2663122550341E341825" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_817E973C55E074F2F78450341E349F1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_B34841D8C496E056489F50341E354038" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_93055A1EB81D2663122550341E341825" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_B34841D8C496E056489F50341E354038" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_71D815950DE9B379D84C50341CD3AD3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_71D815950DE9B379D84C50341CD3AD3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_D83C8DE287E72E7CA68050341CD30D09_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_71D815950DE9B379D84C50341CD3AD3E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_D83C8DE287E72E7CA68050341CD30D09_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_D83C8DE287E72E7CA68050341CD30D09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_71D815950DE9B379D84C50341CD3AD3E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_D83C8DE287E72E7CA68050341CD30D09" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_475891820946D73D4AB050341CD43EFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_D83C8DE287E72E7CA68050341CD30D09" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_475891820946D73D4AB050341CD43EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A24B95A84EB7BAE9D8F050341CD4150D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_DebtInstrumentAxis_A24B95A84EB7BAE9D8F050341CD4150D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DEF54E59E5E4C5F0EB5550341CD4CC1C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_A24B95A84EB7BAE9D8F050341CD4150D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DEF54E59E5E4C5F0EB5550341CD4CC1C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DEF54E59E5E4C5F0EB5550341CD4CC1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_A24B95A84EB7BAE9D8F050341CD4150D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DEF54E59E5E4C5F0EB5550341CD4CC1C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_43AE34C27C83CB7ED3D550341CD5486B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DEF54E59E5E4C5F0EB5550341CD4CC1C" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_43AE34C27C83CB7ED3D550341CD5486B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6" xlink:to="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6" xlink:to="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_86FAE39A62DCA19C646B50341CD5507E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:to="loc_currency_EUR_86FAE39A62DCA19C646B50341CD5507E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_72452122B4031A42C61D50341CD5A2AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:to="loc_currency_GBP_72452122B4031A42C61D50341CD5A2AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_953F7F0879AF64D433B750341CD6FCD2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:to="loc_currency_CHF_953F7F0879AF64D433B750341CD6FCD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_7A6099150B62C65ECB8150341CD674E6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:to="loc_currency_JPY_7A6099150B62C65ECB8150341CD674E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_56E571175FA19E6F40D150341CD65DE0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:to="loc_currency_CAD_56E571175FA19E6F40D150341CD65DE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A5C7EEBBD2CA555D8E8E50341CD60E6A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A5C7EEBBD2CA555D8E8E50341CD60E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_193AEB999046DF73AA3A50341CD6E9D4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A5C7EEBBD2CA555D8E8E50341CD60E6A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_193AEB999046DF73AA3A50341CD6E9D4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_193AEB999046DF73AA3A50341CD6E9D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A5C7EEBBD2CA555D8E8E50341CD60E6A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_193AEB999046DF73AA3A50341CD6E9D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_F156FD779DE2CD1B40DC50341CD7F4DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_193AEB999046DF73AA3A50341CD6E9D4" xlink:to="loc_us-gaap_SalesMember_F156FD779DE2CD1B40DC50341CD7F4DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_22625E856FFEA2B719E650341CD79F76" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_193AEB999046DF73AA3A50341CD6E9D4" xlink:to="loc_us-gaap_OperatingExpenseMember_22625E856FFEA2B719E650341CD79F76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4C54E5DA646436F6B91050341CD7C6A3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_193AEB999046DF73AA3A50341CD6E9D4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4C54E5DA646436F6B91050341CD7C6A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:to="loc_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:to="loc_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1E8D7E8007CF2704BFCF50341CD88669" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_1E8D7E8007CF2704BFCF50341CD88669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_A933B2892412785CC26550341CD86FA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:to="loc_us-gaap_ForeignExchangeContractMember_A933B2892412785CC26550341CD86FA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_892FF2A53C01509A43D850341CD9B5DA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:to="loc_us-gaap_InterestRateSwapMember_892FF2A53C01509A43D850341CD9B5DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9CD275240E628DC6BC7450341CD91BAB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9CD275240E628DC6BC7450341CD91BAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_A63681164D39861BF5EB50341CD9A274_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9CD275240E628DC6BC7450341CD91BAB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_A63681164D39861BF5EB50341CD9A274_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_A63681164D39861BF5EB50341CD9A274" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9CD275240E628DC6BC7450341CD91BAB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_A63681164D39861BF5EB50341CD9A274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_6839ECE6403CC893C93150341CD9CC03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A63681164D39861BF5EB50341CD9A274" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_6839ECE6403CC893C93150341CD9CC03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_0F38687CF9BEA6AD1CEA50341CDAAC8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A63681164D39861BF5EB50341CD9A274" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_0F38687CF9BEA6AD1CEA50341CDAAC8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9AA06A89656BE383A5A850341CDA615A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A63681164D39861BF5EB50341CD9A274" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9AA06A89656BE383A5A850341CDA615A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063" xlink:to="loc_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063" xlink:to="loc_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4F0E8A927E74F0F74C6450341CDA622F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4F0E8A927E74F0F74C6450341CDA622F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_1656706986FFE6C932E350341CDB1AB5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:to="loc_us-gaap_NondesignatedMember_1656706986FFE6C932E350341CDB1AB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D21278FA02098235E1FE50341CDBA367" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_srt_RangeAxis_D21278FA02098235E1FE50341CDBA367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B3C702BC9D2523EB580250341CDBD6B2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_D21278FA02098235E1FE50341CDBA367" xlink:to="loc_srt_RangeMember_B3C702BC9D2523EB580250341CDBD6B2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B3C702BC9D2523EB580250341CDBD6B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_D21278FA02098235E1FE50341CDBA367" xlink:to="loc_srt_RangeMember_B3C702BC9D2523EB580250341CDBD6B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_15882690C4C0BEEF043650341CDB6284" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_B3C702BC9D2523EB580250341CDBD6B2" xlink:to="loc_srt_MinimumMember_15882690C4C0BEEF043650341CDB6284" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C6791E0F50355A80D0CB50341CDC03B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_B3C702BC9D2523EB580250341CDBD6B2" xlink:to="loc_srt_MaximumMember_C6791E0F50355A80D0CB50341CDC03B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_115187616BF10480151950341CDCC92A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_115187616BF10480151950341CDCC92A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_0D3C5482C15A7D44F65050341CDC20F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_invest_DerivativeNotionalAmount_0D3C5482C15A7D44F65050341CDC20F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1EB175CE6A0F048BABC450341CDD6BE9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1EB175CE6A0F048BABC450341CDD6BE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_EB7717D811579C774A8250341CDDEDB4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_EB7717D811579C774A8250341CDDEDB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_748968EA1BBE4A0BD74F50341CDD8AF8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_748968EA1BBE4A0BD74F50341CDD8AF8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C59FFADCD4551CFB451150341CDDCB0E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C59FFADCD4551CFB451150341CDDCB0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC47F08124C31B138B8250341CDDF051" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC47F08124C31B138B8250341CDDF051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_5B4969B9D16820D8DC6E50341CDD5D92" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_5B4969B9D16820D8DC6E50341CDD5D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_2353C5E21067DA954BCE50341CDD53F1" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DerivativeTermOfContract_2353C5E21067DA954BCE50341CDD53F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4648CE094E82971C5F6950341CDEF25C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4648CE094E82971C5F6950341CDEF25C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_4454C4F625C5F5F5029250341CDEAC57" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_4454C4F625C5F5F5029250341CDEAC57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_9BC79249EEDEA3FAC61E50341CDE4B4A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_9BC79249EEDEA3FAC61E50341CDE4B4A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6A14F9C2AC80AA4F456F50341CDE268A" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6A14F9C2AC80AA4F456F50341CDE268A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_01B88489A6F34AEFC48C50341CDE5A57" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_01B88489A6F34AEFC48C50341CDE5A57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_718C2C037F25D4CA48CC50341CDF12B0" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_718C2C037F25D4CA48CC50341CDF12B0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestituresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_04577A5B6524D7EADFB250341DC9A246" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_04577A5B6524D7EADFB250341DC9A246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_05F6FF5F70D53BCCD49D50341DC9D712_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_04577A5B6524D7EADFB250341DC9A246" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_05F6FF5F70D53BCCD49D50341DC9D712_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_05F6FF5F70D53BCCD49D50341DC9D712" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_04577A5B6524D7EADFB250341DC9A246" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_05F6FF5F70D53BCCD49D50341DC9D712" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_431D9BDDD8A37C443B8E50341DC91ACA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_05F6FF5F70D53BCCD49D50341DC9D712" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_431D9BDDD8A37C443B8E50341DC91ACA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EA8F10FDDA163CBAE21E50341DCA0C9A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EA8F10FDDA163CBAE21E50341DCA0C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08C7187296508DEC55D750341DCAD8A5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EA8F10FDDA163CBAE21E50341DCA0C9A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08C7187296508DEC55D750341DCAD8A5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08C7187296508DEC55D750341DCAD8A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EA8F10FDDA163CBAE21E50341DCA0C9A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08C7187296508DEC55D750341DCAD8A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_25B5C8BF6173194B156950341DCA5533" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08C7187296508DEC55D750341DCAD8A5" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_25B5C8BF6173194B156950341DCA5533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_3C459CC78EE7AAE9ED2E50341DCAC9E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_3C459CC78EE7AAE9ED2E50341DCAC9E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_B10CCB00F16F797F287250341DCB1035" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_B10CCB00F16F797F287250341DCB1035" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_F8CF60889625FCCF206550341DCB25EB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_biib_DisposalGroupOperatingLeaseAssets_F8CF60889625FCCF206550341DCB25EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F318E9AD32901F9BD0F150341DCB3AF5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F318E9AD32901F9BD0F150341DCB3AF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_7554577D987AEC21A8CF50341DCBED14" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_7554577D987AEC21A8CF50341DCBED14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6E3430F999DF181E7F7650341DCB38D5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6E3430F999DF181E7F7650341DCB38D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3ED87FC3532E4F3ABE5150341DCB01E9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3ED87FC3532E4F3ABE5150341DCB01E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8F45560488E0BB72F39850341DCC01FF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8F45560488E0BB72F39850341DCC01FF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_7BC7F26493F37C9DDF9D50341DCCDB09" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_biib_DisposalGroupOperatingleaseliabilities_7BC7F26493F37C9DDF9D50341DCCDB09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_D5E6B5943714B2638B0050341DCC3AD5" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_D5E6B5943714B2638B0050341DCC3AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4F45AD3E5B915056C86450341DCC9515" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4F45AD3E5B915056C86450341DCC9515" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65E2CDE1CE782BCE876550341DC10517" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65E2CDE1CE782BCE876550341DC10517" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3E1D57D126B9CE678250341DC185B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65E2CDE1CE782BCE876550341DC10517" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3E1D57D126B9CE678250341DC185B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3294244EA963447CE4CD50341DC28546_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3E1D57D126B9CE678250341DC185B5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3294244EA963447CE4CD50341DC28546_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3294244EA963447CE4CD50341DC28546" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3E1D57D126B9CE678250341DC185B5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3294244EA963447CE4CD50341DC28546" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_6B15596E39C8906A367750341DC29E9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3294244EA963447CE4CD50341DC28546" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_6B15596E39C8906A367750341DC29E9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_8480CB7302B243C1CEAE50341DC2FDF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_8480CB7302B243C1CEAE50341DC2FDF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_75B3A5F25419D5C995E850341DC3E357" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_75B3A5F25419D5C995E850341DC3E357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B74BD8F85AC1754C8E9650341DC3CB9E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B74BD8F85AC1754C8E9650341DC3CB9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_9F8162F4A85BBBD8FF4750341DC3B72C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_9F8162F4A85BBBD8FF4750341DC3B72C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_5FB8C7CF2102C12CD74050341DC35563" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_5FB8C7CF2102C12CD74050341DC35563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_82EB6BBA78ACB7A0B4DD50341DC317A9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_82EB6BBA78ACB7A0B4DD50341DC317A9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestituresTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E822C05D14685AA23E8450341C6D7D7B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_E822C05D14685AA23E8450341C6D7D7B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_96E6C030DCE03340BD9B50341C6E4818" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:to="loc_biib_MarketStockUnitsMember_96E6C030DCE03340BD9B50341C6E4818" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_096698B10B3A2F36DF0650341C6E1671" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_096698B10B3A2F36DF0650341C6E1671" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:to="loc_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7AF792EAEE76E3B0977750341C6F1109" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC" xlink:to="loc_us-gaap_NetIncomeLoss_7AF792EAEE76E3B0977750341C6F1109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9CCDF3DEA691FCC94CC250341C6F9EE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9CCDF3DEA691FCC94CC250341C6F9EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_461BC72E4CA3328DF47350341C70FA67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_461BC72E4CA3328DF47350341C70FA67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ADEE9F5DCC29A02056BD50341C709F63" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ADEE9F5DCC29A02056BD50341C709F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4B2B6C126B0E1AE4850B50341C70A6CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4B2B6C126B0E1AE4850B50341C70A6CC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_6FDA16312FDE92AA92A950341C89B4DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_6FDA16312FDE92AA92A950341C89B4DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA" xlink:to="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA" xlink:to="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F614CF3ABDBF161BFE1D50341C8A67B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F614CF3ABDBF161BFE1D50341C8A67B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D464FEA35A9F13F1B34950341C8A7EAD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D464FEA35A9F13F1B34950341C8A7EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_A97CCFA47B7FF1D181F250341C8A8B9A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_A97CCFA47B7FF1D181F250341C8A8B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8B999E285F96CEBA8F6550341C8B7A88" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8B999E285F96CEBA8F6550341C8B7A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_D6117A08D7057E31494F50341C8B35C1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_D6117A08D7057E31494F50341C8B35C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_567791BCDB2465E13B0B50341C8B6E11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_567791BCDB2465E13B0B50341C8B6E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F7D723B83D422C5D9AD650341C8B819A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F7D723B83D422C5D9AD650341C8B819A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DB9E2836E4AF7ED1D41950341C8CE93F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DB9E2836E4AF7ED1D41950341C8CE93F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_68C59A828B18CA2BC2BE50341C8C1978" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_68C59A828B18CA2BC2BE50341C8C1978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3FD1E6D36764929B7C3450341C8C7FCF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3FD1E6D36764929B7C3450341C8C7FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0C8AD967CDDEC731E66C50341C8C20F6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0C8AD967CDDEC731E66C50341C8C20F6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityEquityNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_62847CD42CD1E3EE6B4B50341C80C540" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_62847CD42CD1E3EE6B4B50341C80C540" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8737377FD88A5A36C38850341C81B4A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62847CD42CD1E3EE6B4B50341C80C540" xlink:to="loc_us-gaap_EquityComponentDomain_8737377FD88A5A36C38850341C81B4A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8737377FD88A5A36C38850341C81B4A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62847CD42CD1E3EE6B4B50341C80C540" xlink:to="loc_us-gaap_EquityComponentDomain_8737377FD88A5A36C38850341C81B4A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_463EA8496A6A58D69E8150341C815B88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8737377FD88A5A36C38850341C81B4A9" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_463EA8496A6A58D69E8150341C815B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_612BBD5E6965837B24E050341C819A62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8737377FD88A5A36C38850341C81B4A9" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_612BBD5E6965837B24E050341C819A62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_D4D12BB02DB979546D2450341C81BD62" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8737377FD88A5A36C38850341C81B4A9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_D4D12BB02DB979546D2450341C81BD62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F043CE7482427013079350341C82F239" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F043CE7482427013079350341C82F239" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_560C0F76F1C966D77CE950341C829B69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_560C0F76F1C966D77CE950341C829B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0BEB533ABC7423388D5750341C83DC64" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0BEB533ABC7423388D5750341C83DC64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BB1EC58272F270E1BF5650341C831D34" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:to="loc_us-gaap_Revenues_BB1EC58272F270E1BF5650341C831D34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D96354BACAEB9AE0D28A50341C83C53C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:to="loc_us-gaap_OperatingExpenses_D96354BACAEB9AE0D28A50341C83C53C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_96341332A819F0BFA65150341C837E8B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:to="loc_us-gaap_NetIncomeLoss_96341332A819F0BFA65150341C837E8B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5E77A20C7B76BE05D5E650341C920D31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20" xlink:to="loc_us-gaap_SubsequentEventMember_5E77A20C7B76BE05D5E650341C920D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:to="loc_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D5C26CDF4C2CDFB08C450341C9396B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D5C26CDF4C2CDFB08C450341C9396B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_88AFE672B2C39A33413550341C94EE57" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_88AFE672B2C39A33413550341C94EE57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_FD1318FAAEB206EAAB2050341C947478" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_FD1318FAAEB206EAAB2050341C947478" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5BB9A6DA7ABBD8D2768250341D533BF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5BB9A6DA7ABBD8D2768250341D533BF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DA8123818CEFB2ED9E4D50341D53484B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_DA8123818CEFB2ED9E4D50341D53484B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_432B89A3054E6837CFF250341D53BDCF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_432B89A3054E6837CFF250341D53BDCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B68C4F467868B3B74B7C50341D538485" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B68C4F467868B3B74B7C50341D538485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_13761BDEF761B33EAD9150341D549D59_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B68C4F467868B3B74B7C50341D538485" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_13761BDEF761B33EAD9150341D549D59_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_13761BDEF761B33EAD9150341D549D59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B68C4F467868B3B74B7C50341D538485" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_13761BDEF761B33EAD9150341D549D59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_95C3236DDAA89955BB7D50341D5415C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_13761BDEF761B33EAD9150341D549D59" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_95C3236DDAA89955BB7D50341D5415C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5428556BAA0780B53B7350341D548B4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5428556BAA0780B53B7350341D548B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_2045245CA4747DC5B01F50341D55B9C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_2045245CA4747DC5B01F50341D55B9C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_849F1A2DF8631040068550341D55AD59" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_849F1A2DF8631040068550341D55AD59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_890E675788CF70B8AB5150341D56DAD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_890E675788CF70B8AB5150341D56DAD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F2065EE935B035D421250341D56F598" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F2065EE935B035D421250341D56F598" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_F2861A2216C0D5CE509750341D56C347" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_F2861A2216C0D5CE509750341D56C347" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C57E8A59E4C2435EE59150341D567CD5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C57E8A59E4C2435EE59150341D567CD5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_881379112A8F9A47062850341D576319" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_881379112A8F9A47062850341D576319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1FDAEE0C0148DB5FAC4150341D573CF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1FDAEE0C0148DB5FAC4150341D573CF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9146131949D7B568B16D50341D5761C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9146131949D7B568B16D50341D5761C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_10375D785976EF2B814650341D57EF32" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_10375D785976EF2B814650341D57EF32" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:to="loc_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD" xlink:to="loc_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_A3681F682B47E158D62050341D4B3AA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_A3681F682B47E158D62050341D4B3AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_8507B37540F736C281E150341D4B1855" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:to="loc_us-gaap_NotesPayable_8507B37540F736C281E150341D4B1855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_22B052E0159989880A2350341D4BC053" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:to="loc_us-gaap_DebtInstrumentFairValue_22B052E0159989880A2350341D4BC053" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_C7BC491984034B9E46A950341D4543C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_C7BC491984034B9E46A950341D4543C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2C88029FB015B3C83C2650341D4530F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2C88029FB015B3C83C2650341D4530F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5667EAB5C3DB7F6F34250341D4561BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5667EAB5C3DB7F6F34250341D4561BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C1C3BC9B36ADD19294F250341D46ED39" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C1C3BC9B36ADD19294F250341D46ED39" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F69FAE961FB09736AFC050341D40B4A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_51B80CBFD40A03EF29EA50341D3E5365" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F69FAE961FB09736AFC050341D40B4A3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_51B80CBFD40A03EF29EA50341D3E5365" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_201DABB462C8E191150E50341D3E0C9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_51B80CBFD40A03EF29EA50341D3E5365" xlink:to="loc_us-gaap_DebtInstrumentAxis_201DABB462C8E191150E50341D3E0C9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_201DABB462C8E191150E50341D3E0C9B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_201DABB462C8E191150E50341D3E0C9B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_21D51968BD0A92E8D8D550341D3F2906" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_21D51968BD0A92E8D8D550341D3F2906" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A6B997816AD93D9B882450341D3FDC83" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A6B997816AD93D9B882450341D3FDC83" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5470BF38093AA8FBAFF050341D3F55AB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5470BF38093AA8FBAFF050341D3F55AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_33B260760A1B2E442A3B50341D3FB475" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_33B260760A1B2E442A3B50341D3FB475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_171BCD1E74E294CAB01650341D40B269" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F69FAE961FB09736AFC050341D40B4A3" xlink:to="loc_us-gaap_AssetImpairmentCharges_171BCD1E74E294CAB01650341D40B269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs" xlink:label="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_72DDFED369147BAE7BCC50341D40114F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F69FAE961FB09736AFC050341D40B4A3" xlink:to="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_72DDFED369147BAE7BCC50341D40114F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_33A92CEDAD733B4FC47750341D4010BC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F69FAE961FB09736AFC050341D40B4A3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_33A92CEDAD733B4FC47750341D4010BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13F6A6C5BEB4E2AF97DC50341D40B4D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F69FAE961FB09736AFC050341D40B4A3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13F6A6C5BEB4E2AF97DC50341D40B4D1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77" xlink:to="loc_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_EC10271382C48A2E872150341D346804" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:to="loc_us-gaap_CommercialPaperMember_EC10271382C48A2E872150341D346804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_97A501FCD30580B8493650341D343491" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_97A501FCD30580B8493650341D343491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1E6C947DA6C2B58DCDDE50341D34B4A5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1E6C947DA6C2B58DCDDE50341D34B4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_2FE385869DFC836B6E0150341D34C3D9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:to="loc_us-gaap_DebtSecuritiesMember_2FE385869DFC836B6E0150341D34C3D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_158954D2724EB5F8ADB250341D3585B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_158954D2724EB5F8ADB250341D3585B1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_EE36D6999EF07B0E539C50341D2BCEBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01" xlink:to="loc_us-gaap_FinancialInstrumentAxis_EE36D6999EF07B0E539C50341D2BCEBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_EE36D6999EF07B0E539C50341D2BCEBA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_EE36D6999EF07B0E539C50341D2BCEBA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_3202D972F02F4CAF89CD50341D2DE89A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_us-gaap_EquitySecuritiesMember_3202D972F02F4CAF89CD50341D2DE89A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_043242D26AC0671C346750341D2D9532" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_043242D26AC0671C346750341D2D9532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAC5111EC817B92E1BDA50341D2D5503" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAC5111EC817B92E1BDA50341D2D5503" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4B3A57A65B79B0ACA88950341D2E61BF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4B3A57A65B79B0ACA88950341D2E61BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3147B7F5A416F7B6F26F50341D2E393B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3147B7F5A416F7B6F26F50341D2E393B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_998D1ECA3F5D384DBAFD50341D2E41FC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_998D1ECA3F5D384DBAFD50341D2E41FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B40066506ED9777EAF4B50341D2E40AA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B40066506ED9777EAF4B50341D2E40AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F09C2DC2A4FDCADA8BCB50341D2EE71D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F09C2DC2A4FDCADA8BCB50341D2EE71D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_4E34EF54C1F3016BBF5450341D2EA778" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleSecurities_4E34EF54C1F3016BBF5450341D2EA778" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2ED78F9F8F2526CE7A7950341CEF7421" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3321B20B2A8D74A3FA0150341CEC347B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ED78F9F8F2526CE7A7950341CEF7421" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3321B20B2A8D74A3FA0150341CEC347B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_349BEED5489CDF7BF60F50341CED2ED2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3321B20B2A8D74A3FA0150341CEC347B" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_349BEED5489CDF7BF60F50341CED2ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_B2CEDF9F6C4D3A43E08850341CED0733_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_349BEED5489CDF7BF60F50341CED2ED2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_B2CEDF9F6C4D3A43E08850341CED0733_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_B2CEDF9F6C4D3A43E08850341CED0733" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_349BEED5489CDF7BF60F50341CED2ED2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_B2CEDF9F6C4D3A43E08850341CED0733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_A99091C1DF4392776EC150341CEDBA6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_B2CEDF9F6C4D3A43E08850341CED0733" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_A99091C1DF4392776EC150341CEDBA6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_CDF89CEA4213AD9EDCA050341CED43DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_B2CEDF9F6C4D3A43E08850341CED0733" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_CDF89CEA4213AD9EDCA050341CED43DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_EE5C4C666F43EC53E41050341CEE6B4F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3321B20B2A8D74A3FA0150341CEC347B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_EE5C4C666F43EC53E41050341CEE6B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1019DE58F93F799FE00850341CEEF91C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EE5C4C666F43EC53E41050341CEE6B4F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1019DE58F93F799FE00850341CEEF91C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1019DE58F93F799FE00850341CEEF91C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EE5C4C666F43EC53E41050341CEE6B4F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1019DE58F93F799FE00850341CEEF91C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1019DE58F93F799FE00850341CEEF91C" xlink:to="loc_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3321B20B2A8D74A3FA0150341CEC347B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C" xlink:to="loc_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ED78F9F8F2526CE7A7950341CEF7421" xlink:to="loc_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ED78F9F8F2526CE7A7950341CEF7421" xlink:to="loc_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ED78F9F8F2526CE7A7950341CEF7421" xlink:to="loc_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0329C7DEE63E6559352B50341C29FF38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_8EBA9EB64FC11A6E2B3750341C279F5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0329C7DEE63E6559352B50341C29FF38" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_8EBA9EB64FC11A6E2B3750341C279F5A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDEF518332E7FCE0392C50341C27440A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8EBA9EB64FC11A6E2B3750341C279F5A" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDEF518332E7FCE0392C50341C27440A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D915A1A936B5D6BAD9D950341C27B3E2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDEF518332E7FCE0392C50341C27440A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D915A1A936B5D6BAD9D950341C27B3E2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D915A1A936B5D6BAD9D950341C27B3E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDEF518332E7FCE0392C50341C27440A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D915A1A936B5D6BAD9D950341C27B3E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_F2DDEDD49BB1734BA06D50341C28730C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D915A1A936B5D6BAD9D950341C27B3E2" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_F2DDEDD49BB1734BA06D50341C28730C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6301A1B7469640C03CEE50341C280103" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8EBA9EB64FC11A6E2B3750341C279F5A" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6301A1B7469640C03CEE50341C280103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1B5C7FC792B15A4E865550341C28BCE6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6301A1B7469640C03CEE50341C280103" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1B5C7FC792B15A4E865550341C28BCE6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1B5C7FC792B15A4E865550341C28BCE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6301A1B7469640C03CEE50341C280103" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1B5C7FC792B15A4E865550341C28BCE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_CD2BB919752524EB64D850341C2954A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1B5C7FC792B15A4E865550341C28BCE6" xlink:to="loc_us-gaap_ForeignCountryMember_CD2BB919752524EB64D850341C2954A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_D1712653C0BD6E23C52250341C297D9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0329C7DEE63E6559352B50341C29FF38" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_D1712653C0BD6E23C52250341C297D9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_F4A5BA05DF7C17B6425650341C29676A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0329C7DEE63E6559352B50341C29FF38" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_F4A5BA05DF7C17B6425650341C29676A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_EA90AAB936343C42BF0550341C293AC9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0329C7DEE63E6559352B50341C29FF38" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_EA90AAB936343C42BF0550341C293AC9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_70D8D10389941E21893450341D6DB3E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_70D8D10389941E21893450341D6DB3E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_901DFA416EF73BB75D0F50341D6EE600" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_901DFA416EF73BB75D0F50341D6EE600" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:to="loc_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_A607027B00A08157D3E650341D6F4F7D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_A607027B00A08157D3E650341D6F4F7D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:to="loc_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_FCC8FD16B1A16C17408150341D6F9705" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:to="loc_srt_ProductOrServiceAxis_FCC8FD16B1A16C17408150341D6F9705" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7091C7BDFCA77E1225F550341D6F213F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_FCC8FD16B1A16C17408150341D6F9705" xlink:to="loc_srt_ProductsAndServicesDomain_7091C7BDFCA77E1225F550341D6F213F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7091C7BDFCA77E1225F550341D6F213F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_FCC8FD16B1A16C17408150341D6F9705" xlink:to="loc_srt_ProductsAndServicesDomain_7091C7BDFCA77E1225F550341D6F213F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7091C7BDFCA77E1225F550341D6F213F" xlink:to="loc_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7091C7BDFCA77E1225F550341D6F213F" xlink:to="loc_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7091C7BDFCA77E1225F550341D6F213F" xlink:to="loc_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_AC2125D4359889BB5DA050341D703A04" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:to="loc_srt_RangeAxis_AC2125D4359889BB5DA050341D703A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D68CC406FC3B6642734750341D70AADD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_AC2125D4359889BB5DA050341D703A04" xlink:to="loc_srt_RangeMember_D68CC406FC3B6642734750341D70AADD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D68CC406FC3B6642734750341D70AADD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_AC2125D4359889BB5DA050341D703A04" xlink:to="loc_srt_RangeMember_D68CC406FC3B6642734750341D70AADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_22E0C219A37DFA7312F950341D7026BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D68CC406FC3B6642734750341D70AADD" xlink:to="loc_srt_MinimumMember_22E0C219A37DFA7312F950341D7026BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_480D9D4225DF191B262950341D71A9EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D68CC406FC3B6642734750341D70AADD" xlink:to="loc_srt_MaximumMember_480D9D4225DF191B262950341D71A9EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E9947141E18D1B3C35E450341D71501E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E9947141E18D1B3C35E450341D71501E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4A62DA896A475518A46050341D7208F6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4A62DA896A475518A46050341D7208F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7CCA33BB2602BC5A446050341D7291E0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7CCA33BB2602BC5A446050341D7291E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_56B959373432C49023E250341D72E061" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_56B959373432C49023E250341D72E061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2CF890C29238B75AFAB850341D724ED7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2CF890C29238B75AFAB850341D724ED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E49E83160EB71F20A70250341D72F892" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E49E83160EB71F20A70250341D72F892" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F66AE7CB60E1584F699D50341D738A6A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F66AE7CB60E1584F699D50341D738A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D81870406F0B518E876A50341D7384D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_D81870406F0B518E876A50341D7384D3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_FC7714D77672D52D1D2150341D6366CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_FC7714D77672D52D1D2150341D6366CD" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3AD75C4374C19F6BC75250341D63D2A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3AD75C4374C19F6BC75250341D63D2A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1B827952347D75411CE350341D63FE6F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3AD75C4374C19F6BC75250341D63D2A5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1B827952347D75411CE350341D63FE6F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1B827952347D75411CE350341D63FE6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3AD75C4374C19F6BC75250341D63D2A5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1B827952347D75411CE350341D63FE6F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_8364344276BF93D7FB9250341D63C745" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1B827952347D75411CE350341D63FE6F" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_8364344276BF93D7FB9250341D63C745" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31" xlink:to="loc_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_BB3B859BE5B7707F4DAE50341D86477D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4" xlink:to="loc_srt_MajorCustomersAxis_BB3B859BE5B7707F4DAE50341D86477D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FCD7C9A8AFD62C0487EE50341D8671EE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_BB3B859BE5B7707F4DAE50341D86477D" xlink:to="loc_srt_NameOfMajorCustomerDomain_FCD7C9A8AFD62C0487EE50341D8671EE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FCD7C9A8AFD62C0487EE50341D8671EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_BB3B859BE5B7707F4DAE50341D86477D" xlink:to="loc_srt_NameOfMajorCustomerDomain_FCD7C9A8AFD62C0487EE50341D8671EE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_5B1CD7BC98F6DD8F75F850341D8778EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FCD7C9A8AFD62C0487EE50341D8671EE" xlink:to="loc_biib_BioverativMember_5B1CD7BC98F6DD8F75F850341D8778EB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_InventorysoldtoBioverativcost" xlink:label="loc_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31" xlink:to="loc_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015" xlink:to="loc_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7BB0CE5AAD5E9524182650479ED0CDD5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7BB0CE5AAD5E9524182650479ED0CDD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96196DB046FF07B3E8E150479ED02180_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7BB0CE5AAD5E9524182650479ED0CDD5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96196DB046FF07B3E8E150479ED02180_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96196DB046FF07B3E8E150479ED02180" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7BB0CE5AAD5E9524182650479ED0CDD5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96196DB046FF07B3E8E150479ED02180" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_3B5D129A91C71AE21EF450479ED00896" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96196DB046FF07B3E8E150479ED02180" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_3B5D129A91C71AE21EF450479ED00896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_04A9E5D7DCA1309BD19A50479ED15D38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_04A9E5D7DCA1309BD19A50479ED15D38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_E84C18AA15F6FABAB2FC50479ED1DE39" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_E84C18AA15F6FABAB2FC50479ED1DE39" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_OperatingleaseassetsMember" xlink:label="loc_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:to="loc_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_CDC8638FCAEE232CAE465092023796B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_CDC8638FCAEE232CAE465092023796B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_EEB2C9F35E321AD356ED5092023808FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_EEB2C9F35E321AD356ED5092023808FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87A396A3E7DE768378B350920238D911" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87A396A3E7DE768378B350920238D911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_044325660A40282AD80750920238E3AC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_044325660A40282AD80750920238E3AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7BAF9651F8A3D698AA9C5092023916F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7BAF9651F8A3D698AA9C5092023916F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_AE706E91E585A4475520509202399285" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_AE706E91E585A4475520509202399285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_54BB693B93E409E1A09750920239C876" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_54BB693B93E409E1A09750920239C876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_BCD93A9A69596DF501465092023998F5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseLiability_BCD93A9A69596DF501465092023998F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_3D55A5BFE3A1095A63A45092023905A7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseCost_3D55A5BFE3A1095A63A45092023905A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_671FBAB40AC520F044065092023AD8CA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_671FBAB40AC520F044065092023AD8CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_DFEDEB385CA08D9CF55A5092023AC055" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_DFEDEB385CA08D9CF55A5092023AC055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3FB05D0351E2DF0FA10C5092023A2AFE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3FB05D0351E2DF0FA10C5092023A2AFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C880875D94F76599AB3F5092023AC37D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C880875D94F76599AB3F5092023AC37D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3D80712892620F4358435092023A5C35" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3D80712892620F4358435092023A5C35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D837E26EE2DEC0A699F05092023B7620" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D837E26EE2DEC0A699F05092023B7620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3DBBE8D9D7F4F9E78FC05092023B23FD" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3DBBE8D9D7F4F9E78FC05092023B23FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CAA485D5A2F953870ECF5092023B8AE2" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CAA485D5A2F953870ECF5092023B8AE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73CCD8956E3D2A6BBBAE5092023B4936" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73CCD8956E3D2A6BBBAE5092023B4936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_B42A4B48793EF9C3B7645092023BD210" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_B42A4B48793EF9C3B7645092023BD210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_330FCA5C36AC184BC3AE5092023C46A2" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_330FCA5C36AC184BC3AE5092023C46A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6F579D6F0E3A400F3F315092023C36B5" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6F579D6F0E3A400F3F315092023C36B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_45ECDAEED5AA559FE17A5092023C50D8" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_45ECDAEED5AA559FE17A5092023C50D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_640BFF691FA0A3169C785092023C4BE6" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_640BFF691FA0A3169C785092023C4BE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ED53CEDDF92FFC86BFAA5092023CE6D8" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ED53CEDDF92FFC86BFAA5092023CE6D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7DA9F4D36C47FFC808035092023C5CE1" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7DA9F4D36C47FFC808035092023C5CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4E96ED8142CAC25585705092023CC1C5" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4E96ED8142CAC25585705092023CC1C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_A396502DB1C3B25651275092023DCD26" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_A396502DB1C3B25651275092023DCD26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7911D3BDFBD91140938C5092023DD5B3" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7911D3BDFBD91140938C5092023DD5B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_E620BEBD10BCCCEB88B85092023D95A3" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_E620BEBD10BCCCEB88B85092023D95A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7CCA02D07CA46482870D5092023D80E0" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7CCA02D07CA46482870D5092023D80E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_79BC7775A578815642485092023D94CE" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_79BC7775A578815642485092023D94CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_ABFD003E6060DA843A405092023DF9E3" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_ABFD003E6060DA843A405092023DF9E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_1F32F9B1A357D4F8EF1C5092023E9EE2" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_1F32F9B1A357D4F8EF1C5092023E9EE2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1" xlink:type="locator" />
    <link:definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41393617AA4BAE5B364E5092023FD899" xlink:type="locator" />
    <link:definitionArc order="38" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41393617AA4BAE5B364E5092023FD899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0CF5C58A161B55514D935092023FA752" xlink:type="locator" />
    <link:definitionArc order="39" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0CF5C58A161B55514D935092023FA752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_D9C60146487C27B36F4D5092023F9909" xlink:type="locator" />
    <link:definitionArc order="40" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasePayments_D9C60146487C27B36F4D5092023F9909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D50E09170BC0EB0717BA5092023F0467" xlink:type="locator" />
    <link:definitionArc order="41" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D50E09170BC0EB0717BA5092023F0467" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesLeases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:to="loc_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66" xlink:to="loc_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66" xlink:to="loc_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A8CDC0CB430396E5050A50341C9E86C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:to="loc_srt_MinimumMember_A8CDC0CB430396E5050A50341C9E86C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7D8E5E9096470E42FDF050341C9E4A10" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:to="loc_srt_MaximumMember_7D8E5E9096470E42FDF050341C9E4A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_FC5266AE273FDB11727650341C9E8AA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_FC5266AE273FDB11727650341C9E8AA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_00942F6E1A5A8A8F23E350341C9FBED4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_00942F6E1A5A8A8F23E350341C9FBED4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:to="loc_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:to="loc_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_7157EE5D3B3D41B1B27950341BB5E9A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC" xlink:to="loc_country_BR_7157EE5D3B3D41B1B27950341BB5E9A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesSought" xlink:label="loc_us-gaap_LossContingencyDamagesSought_1E6930C51F37A7D2E13150341BB6B423" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623" xlink:to="loc_us-gaap_LossContingencyDamagesSought_1E6930C51F37A7D2E13150341BB6B423" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1359408756425F18C2BD50341C0E924C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_058B80D7C06740173C9E50341C0DD103" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1359408756425F18C2BD50341C0E924C" xlink:to="loc_us-gaap_StatementTable_058B80D7C06740173C9E50341C0DD103" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_57606D4AEF0A175D33A250341C0D41CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_058B80D7C06740173C9E50341C0DD103" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_57606D4AEF0A175D33A250341C0D41CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_64CC3BE4C5A4D772476150341C0D968C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_57606D4AEF0A175D33A250341C0D41CB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_64CC3BE4C5A4D772476150341C0D968C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_64CC3BE4C5A4D772476150341C0D968C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_57606D4AEF0A175D33A250341C0D41CB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_64CC3BE4C5A4D772476150341C0D968C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_614CFD7B516D4C70FC2050341C0E89FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_64CC3BE4C5A4D772476150341C0D968C" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_614CFD7B516D4C70FC2050341C0E89FD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_0080631896C76882045B50341CC5A808" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:to="loc_us-gaap_BuildingMember_0080631896C76882045B50341CC5A808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_03E5CA31CB3653F33CA750341CC67BFE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_03E5CA31CB3653F33CA750341CC67BFE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:to="loc_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:to="loc_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:to="loc_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D" xlink:to="loc_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6FCB59BDD30627AE1D8950341CC7AE29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6FCB59BDD30627AE1D8950341CC7AE29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2D229B0D260D0E346E5950341CC762D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:to="loc_us-gaap_Depreciation_2D229B0D260D0E346E5950341CC762D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_DA9184A532ABD63B467850341CC72DBA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:to="loc_us-gaap_ConstructionInProgressGross_DA9184A532ABD63B467850341CC72DBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_DAE0A79D564AEEC4DACE50341CC7B32E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:to="loc_us-gaap_OtherCommitment_DAE0A79D564AEEC4DACE50341CC7B32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_45697A9112DBF9AD3E9850341CC8366F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_45697A9112DBF9AD3E9850341CC8366F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_C3CEBA838E6C15E4504B50341D9DE22C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_07941233BCEFB97749ED50341D9A65D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C3CEBA838E6C15E4504B50341D9DE22C" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_07941233BCEFB97749ED50341D9A65D1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F6DC8E2B44788456771D50341D9ABE79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07941233BCEFB97749ED50341D9A65D1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F6DC8E2B44788456771D50341D9ABE79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_228F71C33C9E10F0301E50341D9A29D2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F6DC8E2B44788456771D50341D9ABE79" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_228F71C33C9E10F0301E50341D9A29D2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_228F71C33C9E10F0301E50341D9A29D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F6DC8E2B44788456771D50341D9ABE79" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_228F71C33C9E10F0301E50341D9A29D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_92ACC1C2D7B7978FDBF350341D9B42BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_228F71C33C9E10F0301E50341D9A29D2" xlink:to="loc_us-gaap_CollaborativeArrangementMember_92ACC1C2D7B7978FDBF350341D9B42BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_93182FC3211353E0112850341D9B57B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07941233BCEFB97749ED50341D9A65D1" xlink:to="loc_srt_ProductOrServiceAxis_93182FC3211353E0112850341D9B57B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D301526AC0EA9B44A9AE50341D9B2998_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_93182FC3211353E0112850341D9B57B1" xlink:to="loc_srt_ProductsAndServicesDomain_D301526AC0EA9B44A9AE50341D9B2998_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D301526AC0EA9B44A9AE50341D9B2998" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_93182FC3211353E0112850341D9B57B1" xlink:to="loc_srt_ProductsAndServicesDomain_D301526AC0EA9B44A9AE50341D9B2998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_1C76F2D9B99CAF82283350341D9B6CE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D301526AC0EA9B44A9AE50341D9B2998" xlink:to="loc_us-gaap_RoyaltyMember_1C76F2D9B99CAF82283350341D9B6CE4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D301526AC0EA9B44A9AE50341D9B2998" xlink:to="loc_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_D32454A96220C3F435B250341D9CF53F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D301526AC0EA9B44A9AE50341D9B2998" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_D32454A96220C3F435B250341D9CF53F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6ADA9179B17A8DAD084850341D9C3E31" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07941233BCEFB97749ED50341D9A65D1" xlink:to="loc_srt_MajorCustomersAxis_6ADA9179B17A8DAD084850341D9C3E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B80E5078C6B522C985A750341D9CD7B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6ADA9179B17A8DAD084850341D9C3E31" xlink:to="loc_srt_NameOfMajorCustomerDomain_B80E5078C6B522C985A750341D9CD7B4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B80E5078C6B522C985A750341D9CD7B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6ADA9179B17A8DAD084850341D9C3E31" xlink:to="loc_srt_NameOfMajorCustomerDomain_B80E5078C6B522C985A750341D9CD7B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B80E5078C6B522C985A750341D9CD7B4" xlink:to="loc_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_EA66143A87A29281623A50341D9D1EBB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B80E5078C6B522C985A750341D9CD7B4" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_EA66143A87A29281623A50341D9D1EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BB74B116BD55C2CDEA8150341D9DBF01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C3CEBA838E6C15E4504B50341D9DE22C" xlink:to="loc_us-gaap_Revenues_BB74B116BD55C2CDEA8150341D9DBF01" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:to="loc_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:to="loc_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_0373028E48B7B64830F450341DADD115" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_0373028E48B7B64830F450341DADD115" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_F08C83C23EE0E82A649C50341DADA25D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_F08C83C23EE0E82A649C50341DADA25D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1238C008F850F7D8BBB750341DA8688B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_62ABC13BDF5C8301A1F150341DA63FE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1238C008F850F7D8BBB750341DA8688B" xlink:to="loc_us-gaap_StatementTable_62ABC13BDF5C8301A1F150341DA63FE9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DD484539990109DFD1F850341DA74F3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_62ABC13BDF5C8301A1F150341DA63FE9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_DD484539990109DFD1F850341DA74F3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0E15E2280BBF279D735A50341DA768D3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DD484539990109DFD1F850341DA74F3F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0E15E2280BBF279D735A50341DA768D3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0E15E2280BBF279D735A50341DA768D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DD484539990109DFD1F850341DA74F3F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0E15E2280BBF279D735A50341DA768D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_FFC8AE394AD79EAB53CA50341DA7E365" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0E15E2280BBF279D735A50341DA768D3" xlink:to="loc_us-gaap_AccountsReceivableMember_FFC8AE394AD79EAB53CA50341DA7E365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_DC9FACDC8AC42B2B6CE350341DA8F5D8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0E15E2280BBF279D735A50341DA768D3" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_DC9FACDC8AC42B2B6CE350341DA8F5D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_A1944DF82ACD270E270450341DA865FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1238C008F850F7D8BBB750341DA8688B" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_A1944DF82ACD270E270450341DA865FC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_A8DE0C7A3EBAF07551F750341DB69132" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1D0833FFB235D450783A50341DB3241E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_A8DE0C7A3EBAF07551F750341DB69132" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1D0833FFB235D450783A50341DB3241E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_6289A804C25F3A5544D250341DB30F78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1D0833FFB235D450783A50341DB3241E" xlink:to="loc_srt_ProductOrServiceAxis_6289A804C25F3A5544D250341DB30F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6289A804C25F3A5544D250341DB30F78" xlink:to="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6289A804C25F3A5544D250341DB30F78" xlink:to="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_071C52429D0F888E643750341DB30917" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_TecfideraMember_071C52429D0F888E643750341DB30917" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_234967298917AF5963A950341DB48F93" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_TysabriProductMember_234967298917AF5963A950341DB48F93" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_E3A967439BF488B9461A50341DB523C8" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_us-gaap_ProductMember_E3A967439BF488B9461A50341DB523C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1D0833FFB235D450783A50341DB3241E" xlink:to="loc_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371" xlink:to="loc_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371" xlink:to="loc_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_CF1D32479306C996872950341DB6F978" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:to="loc_country_US_CF1D32479306C996872950341DB6F978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_88A531458F8782A5A51D50341DB6F5AD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:to="loc_us-gaap_NonUsMember_88A531458F8782A5A51D50341DB6F5AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33BBA40772D2B7AD244A50341DB75796" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_A8DE0C7A3EBAF07551F750341DB69132" xlink:to="loc_us-gaap_Revenues_33BBA40772D2B7AD244A50341DB75796" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:to="loc_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB" xlink:to="loc_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB" xlink:to="loc_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_B126FCC4CC41A5E0FF6750341D943DF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_B126FCC4CC41A5E0FF6750341D943DF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:to="loc_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7" xlink:to="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7" xlink:to="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:to="loc_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:to="loc_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:to="loc_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C47D536FE5827B45124A50341D957214" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:to="loc_us-gaap_Revenues_C47D536FE5827B45124A50341D957214" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7AE38F45B117444E8F3850341DA32CA8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_CBA021E90B8369E01CFB50341DA1A970" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7AE38F45B117444E8F3850341DA32CA8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_CBA021E90B8369E01CFB50341DA1A970" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_6D8E94A3B00437E236F050341DA1E9A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CBA021E90B8369E01CFB50341DA1A970" xlink:to="loc_srt_ProductOrServiceAxis_6D8E94A3B00437E236F050341DA1E9A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_28C482D6AACAA694D12950341DA23055_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6D8E94A3B00437E236F050341DA1E9A6" xlink:to="loc_srt_ProductsAndServicesDomain_28C482D6AACAA694D12950341DA23055_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_28C482D6AACAA694D12950341DA23055" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6D8E94A3B00437E236F050341DA1E9A6" xlink:to="loc_srt_ProductsAndServicesDomain_28C482D6AACAA694D12950341DA23055" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_28C482D6AACAA694D12950341DA23055" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F14ED69D858BFD94039750341DA2A0F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CBA021E90B8369E01CFB50341DA1A970" xlink:to="loc_srt_MajorCustomersAxis_F14ED69D858BFD94039750341DA2A0F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_78D8BC2256D4E704441150341DA3366C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_F14ED69D858BFD94039750341DA2A0F7" xlink:to="loc_srt_NameOfMajorCustomerDomain_78D8BC2256D4E704441150341DA3366C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_78D8BC2256D4E704441150341DA3366C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_F14ED69D858BFD94039750341DA2A0F7" xlink:to="loc_srt_NameOfMajorCustomerDomain_78D8BC2256D4E704441150341DA3366C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_78D8BC2256D4E704441150341DA3366C" xlink:to="loc_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7AE38F45B117444E8F3850341DA32CA8" xlink:to="loc_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7AE38F45B117444E8F3850341DA32CA8" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C506768B91715A80636F50341DA4E2A8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7AE38F45B117444E8F3850341DA32CA8" xlink:to="loc_us-gaap_Revenues_C506768B91715A80636F50341DA4E2A8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_387F000625C1084F19BA50341C580C04" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B30A892AD7B0693299BB50341C5610AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_387F000625C1084F19BA50341C580C04" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B30A892AD7B0693299BB50341C5610AA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0844CCB1E81B4AF8230950341C56B1D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B30A892AD7B0693299BB50341C5610AA" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0844CCB1E81B4AF8230950341C56B1D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_30788EA50A4E5EAC212950341C578D2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0844CCB1E81B4AF8230950341C56B1D4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_30788EA50A4E5EAC212950341C578D2A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_30788EA50A4E5EAC212950341C578D2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0844CCB1E81B4AF8230950341C56B1D4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_30788EA50A4E5EAC212950341C578D2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4FEA027559756A73D8A050341C577DE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_30788EA50A4E5EAC212950341C578D2A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4FEA027559756A73D8A050341C577DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_762F53614C50EA2DA9A250341C579A91" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_30788EA50A4E5EAC212950341C578D2A" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_762F53614C50EA2DA9A250341C579A91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_B01604F5BDB6EF379A3B50341C58DA90" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_30788EA50A4E5EAC212950341C578D2A" xlink:to="loc_us-gaap_ParentMember_B01604F5BDB6EF379A3B50341C58DA90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_387F000625C1084F19BA50341C580C04" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D447C48875D15EDA7E7750341C5848D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D447C48875D15EDA7E7750341C5848D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DC0E3E942B765BA6295D50341C588392" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DC0E3E942B765BA6295D50341C588392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_1A5BCFA678B325E7023950341C584200" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_1A5BCFA678B325E7023950341C584200" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3C11B5B8166B2FDC9F4350341C591BE1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3C11B5B8166B2FDC9F4350341C591BE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_EF3D6E15F32FE0986DB650341C5966F5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_EF3D6E15F32FE0986DB650341C5966F5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15" xlink:to="loc_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_0260FFB12CF5A11FF7D750341C4A373A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_us-gaap_PerformanceSharesMember_0260FFB12CF5A11FF7D750341C4A373A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_81F1F5DD749A122F377350341C4B98F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_81F1F5DD749A122F377350341C4B98F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B4CF1F7BDC7C9756748A50341C4B193C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B4CF1F7BDC7C9756748A50341C4B193C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2691337E9AC2C6B6B78350341C4C8006" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2691337E9AC2C6B6B78350341C4C8006" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_BB7C3A110FF2D36EA53750341DDC92E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DEB5AA07FDFBF3DAC9A250341DDB682D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_BB7C3A110FF2D36EA53750341DDC92E9" xlink:to="loc_us-gaap_StatementTable_DEB5AA07FDFBF3DAC9A250341DDB682D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_DEB5AA07FDFBF3DAC9A250341DDB682D" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25" xlink:to="loc_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25" xlink:to="loc_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_01EABCE5075EFE98076D50341DDCBA58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_01EABCE5075EFE98076D50341DDCBA58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_66838BA516EB05DFDD0950341DDC6EFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BB7C3A110FF2D36EA53750341DDC92E9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_66838BA516EB05DFDD0950341DDC6EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_BE902D9963ED555D4BAC50341DDCAD67" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BB7C3A110FF2D36EA53750341DDC92E9" xlink:to="loc_us-gaap_OperatingLeaseLiability_BE902D9963ED555D4BAC50341DDCAD67" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>biib-20190331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_CBBE6EEE69473AC762CB50341D9024BE_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_CBBE6EEE69473AC762CB50341D9024BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_CBBE6EEE69473AC762CB50341D9024BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_CBBE6EEE69473AC762CB50341D9024BE" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_CBBE6EEE69473AC762CB50341D9024BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_44DA30E888D0608ADD0550341D90800F_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_44DA30E888D0608ADD0550341D90800F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_44DA30E888D0608ADD0550341D90800F_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_44DA30E888D0608ADD0550341D90800F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_44DA30E888D0608ADD0550341D90800F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_44DA30E888D0608ADD0550341D90800F" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_44DA30E888D0608ADD0550341D90800F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_FB6A457A49982B872ACE50341C9CC576_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_FB6A457A49982B872ACE50341C9CC576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_FB6A457A49982B872ACE50341C9CC576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_FB6A457A49982B872ACE50341C9CC576" xlink:to="lab_us-gaap_LeasesAbstract_FB6A457A49982B872ACE50341C9CC576" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B" xlink:type="arc" />
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58_terseLabel_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58_label_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58_documentation_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58" xlink:to="lab_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66_label_en-US" xlink:label="lab_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66" xlink:to="lab_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4_terseLabel_en-US" xlink:label="lab_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4_label_en-US" xlink:label="lab_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:to="lab_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_A8CDC0CB430396E5050A50341C9E86C7_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_A8CDC0CB430396E5050A50341C9E86C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_A8CDC0CB430396E5050A50341C9E86C7_label_en-US" xlink:label="lab_srt_MinimumMember_A8CDC0CB430396E5050A50341C9E86C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A8CDC0CB430396E5050A50341C9E86C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_A8CDC0CB430396E5050A50341C9E86C7" xlink:to="lab_srt_MinimumMember_A8CDC0CB430396E5050A50341C9E86C7" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_7D8E5E9096470E42FDF050341C9E4A10_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_7D8E5E9096470E42FDF050341C9E4A10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_7D8E5E9096470E42FDF050341C9E4A10_label_en-US" xlink:label="lab_srt_MaximumMember_7D8E5E9096470E42FDF050341C9E4A10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7D8E5E9096470E42FDF050341C9E4A10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_7D8E5E9096470E42FDF050341C9E4A10" xlink:to="lab_srt_MaximumMember_7D8E5E9096470E42FDF050341C9E4A10" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_FC5266AE273FDB11727650341C9E8AA3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_FC5266AE273FDB11727650341C9E8AA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_FC5266AE273FDB11727650341C9E8AA3_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_FC5266AE273FDB11727650341C9E8AA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_FC5266AE273FDB11727650341C9E8AA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_FC5266AE273FDB11727650341C9E8AA3" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_FC5266AE273FDB11727650341C9E8AA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_00942F6E1A5A8A8F23E350341C9FBED4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_00942F6E1A5A8A8F23E350341C9FBED4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_00942F6E1A5A8A8F23E350341C9FBED4_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_00942F6E1A5A8A8F23E350341C9FBED4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_00942F6E1A5A8A8F23E350341C9FBED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_00942F6E1A5A8A8F23E350341C9FBED4" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_00942F6E1A5A8A8F23E350341C9FBED4" xlink:type="arc" />
    <link:label id="lab_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4_terseLabel_en-US" xlink:label="lab_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4_label_en-US" xlink:label="lab_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Operating Lease Assets</link:label>
    <link:label id="lab_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4_documentation_en-US" xlink:label="lab_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Operating Lease Assets</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4" xlink:to="lab_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4" xlink:type="arc" />
    <link:label id="lab_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6_terseLabel_en-US" xlink:label="lab_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6_label_en-US" xlink:label="lab_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Operating lease liabilities</link:label>
    <link:label id="lab_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6_documentation_en-US" xlink:label="lab_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Operating lease liabilities</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6" xlink:to="lab_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8F40884C82F7DB9622E150341CE9E48D_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8F40884C82F7DB9622E150341CE9E48D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8F40884C82F7DB9622E150341CE9E48D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8F40884C82F7DB9622E150341CE9E48D" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8F40884C82F7DB9622E150341CE9E48D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E7458F7FD500B9D894F50341CE91962_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E7458F7FD500B9D894F50341CE91962" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E7458F7FD500B9D894F50341CE91962_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E7458F7FD500B9D894F50341CE91962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E7458F7FD500B9D894F50341CE91962" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E7458F7FD500B9D894F50341CE91962" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E7458F7FD500B9D894F50341CE91962" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_5FA54196FE2C41605CCC50341CC457C2_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_5FA54196FE2C41605CCC50341CC457C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5FA54196FE2C41605CCC50341CC457C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5FA54196FE2C41605CCC50341CC457C2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_5FA54196FE2C41605CCC50341CC457C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_0080631896C76882045B50341CC5A808_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_0080631896C76882045B50341CC5A808" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_0080631896C76882045B50341CC5A808_label_en-US" xlink:label="lab_us-gaap_BuildingMember_0080631896C76882045B50341CC5A808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_0080631896C76882045B50341CC5A808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_0080631896C76882045B50341CC5A808" xlink:to="lab_us-gaap_BuildingMember_0080631896C76882045B50341CC5A808" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_03E5CA31CB3653F33CA750341CC67BFE_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_03E5CA31CB3653F33CA750341CC67BFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_03E5CA31CB3653F33CA750341CC67BFE_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_03E5CA31CB3653F33CA750341CC67BFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_03E5CA31CB3653F33CA750341CC67BFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_03E5CA31CB3653F33CA750341CC67BFE" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_03E5CA31CB3653F33CA750341CC67BFE" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:to="lab_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D" xlink:to="lab_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B" xlink:to="lab_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6FCB59BDD30627AE1D8950341CC7AE29_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6FCB59BDD30627AE1D8950341CC7AE29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6FCB59BDD30627AE1D8950341CC7AE29_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6FCB59BDD30627AE1D8950341CC7AE29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6FCB59BDD30627AE1D8950341CC7AE29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6FCB59BDD30627AE1D8950341CC7AE29" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6FCB59BDD30627AE1D8950341CC7AE29" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_2D229B0D260D0E346E5950341CC762D7_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_2D229B0D260D0E346E5950341CC762D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_2D229B0D260D0E346E5950341CC762D7_label_en-US" xlink:label="lab_us-gaap_Depreciation_2D229B0D260D0E346E5950341CC762D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2D229B0D260D0E346E5950341CC762D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_2D229B0D260D0E346E5950341CC762D7" xlink:to="lab_us-gaap_Depreciation_2D229B0D260D0E346E5950341CC762D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_DA9184A532ABD63B467850341CC72DBA_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_DA9184A532ABD63B467850341CC72DBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_DA9184A532ABD63B467850341CC72DBA_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_DA9184A532ABD63B467850341CC72DBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_DA9184A532ABD63B467850341CC72DBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_DA9184A532ABD63B467850341CC72DBA" xlink:to="lab_us-gaap_ConstructionInProgressGross_DA9184A532ABD63B467850341CC72DBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_DAE0A79D564AEEC4DACE50341CC7B32E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_DAE0A79D564AEEC4DACE50341CC7B32E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual commitments for the construction of the facility</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_DAE0A79D564AEEC4DACE50341CC7B32E_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_DAE0A79D564AEEC4DACE50341CC7B32E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_DAE0A79D564AEEC4DACE50341CC7B32E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_DAE0A79D564AEEC4DACE50341CC7B32E" xlink:to="lab_us-gaap_OtherCommitment_DAE0A79D564AEEC4DACE50341CC7B32E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_45697A9112DBF9AD3E9850341CC8366F_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_45697A9112DBF9AD3E9850341CC8366F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_45697A9112DBF9AD3E9850341CC8366F_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_45697A9112DBF9AD3E9850341CC8366F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_45697A9112DBF9AD3E9850341CC8366F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_45697A9112DBF9AD3E9850341CC8366F" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_45697A9112DBF9AD3E9850341CC8366F" xlink:type="arc" />
    <link:label id="lab_biib_AcquisitionsAbstract_A0EC34392985DCD415A050341DD47E7E_label_en-US" xlink:label="lab_biib_AcquisitionsAbstract_A0EC34392985DCD415A050341DD47E7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_A0EC34392985DCD415A050341DD47E7E_documentation_en-US" xlink:label="lab_biib_AcquisitionsAbstract_A0EC34392985DCD415A050341DD47E7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_A0EC34392985DCD415A050341DD47E7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcquisitionsAbstract_A0EC34392985DCD415A050341DD47E7E" xlink:to="lab_biib_AcquisitionsAbstract_A0EC34392985DCD415A050341DD47E7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762" xlink:type="arc" />
    <link:label id="lab_biib_NightstarMember_89A797D89F3C3640019450341DD40447_terseLabel_en-US" xlink:label="lab_biib_NightstarMember_89A797D89F3C3640019450341DD40447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nightstar</link:label>
    <link:label id="lab_biib_NightstarMember_89A797D89F3C3640019450341DD40447_label_en-US" xlink:label="lab_biib_NightstarMember_89A797D89F3C3640019450341DD40447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:label id="lab_biib_NightstarMember_89A797D89F3C3640019450341DD40447_documentation_en-US" xlink:label="lab_biib_NightstarMember_89A797D89F3C3640019450341DD40447" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_89A797D89F3C3640019450341DD40447" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NightstarMember_89A797D89F3C3640019450341DD40447" xlink:to="lab_biib_NightstarMember_89A797D89F3C3640019450341DD40447" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_6E93ABBB4405264E23BD50341DD648BF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_6E93ABBB4405264E23BD50341DD648BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_6E93ABBB4405264E23BD50341DD648BF_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_6E93ABBB4405264E23BD50341DD648BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_6E93ABBB4405264E23BD50341DD648BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_6E93ABBB4405264E23BD50341DD648BF" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_6E93ABBB4405264E23BD50341DD648BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_DFDAE727CD8A5A6877D150341DD6FAB2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_DFDAE727CD8A5A6877D150341DD6FAB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total transaction value</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_DFDAE727CD8A5A6877D150341DD6FAB2_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_DFDAE727CD8A5A6877D150341DD6FAB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_DFDAE727CD8A5A6877D150341DD6FAB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_DFDAE727CD8A5A6877D150341DD6FAB2" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_DFDAE727CD8A5A6877D150341DD6FAB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_46142A1BF6ABAA7DEFC950341D21D03F_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_46142A1BF6ABAA7DEFC950341D21D03F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_46142A1BF6ABAA7DEFC950341D21D03F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_46142A1BF6ABAA7DEFC950341D21D03F" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_46142A1BF6ABAA7DEFC950341D21D03F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C2ED01E2C88A9571C04250341D226F51_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C2ED01E2C88A9571C04250341D226F51" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C2ED01E2C88A9571C04250341D226F51_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C2ED01E2C88A9571C04250341D226F51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C2ED01E2C88A9571C04250341D226F51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C2ED01E2C88A9571C04250341D226F51" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C2ED01E2C88A9571C04250341D226F51" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FA31DAC519FB58F886D850341D22576B_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FA31DAC519FB58F886D850341D22576B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FA31DAC519FB58F886D850341D22576B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FA31DAC519FB58F886D850341D22576B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FA31DAC519FB58F886D850341D22576B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FA31DAC519FB58F886D850341D22576B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FA31DAC519FB58F886D850341D22576B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7B99B2EF0F879FC1E45D50341D23DAB5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7B99B2EF0F879FC1E45D50341D23DAB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7B99B2EF0F879FC1E45D50341D23DAB5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7B99B2EF0F879FC1E45D50341D23DAB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7B99B2EF0F879FC1E45D50341D23DAB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7B99B2EF0F879FC1E45D50341D23DAB5" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7B99B2EF0F879FC1E45D50341D23DAB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8627E231BC18445B0CDB50341D230638_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8627E231BC18445B0CDB50341D230638" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8627E231BC18445B0CDB50341D230638_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8627E231BC18445B0CDB50341D230638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8627E231BC18445B0CDB50341D230638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8627E231BC18445B0CDB50341D230638" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8627E231BC18445B0CDB50341D230638" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CAC025A953CEC430EDCC50341D234D08_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CAC025A953CEC430EDCC50341D234D08" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CAC025A953CEC430EDCC50341D234D08_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CAC025A953CEC430EDCC50341D234D08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CAC025A953CEC430EDCC50341D234D08_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CAC025A953CEC430EDCC50341D234D08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CAC025A953CEC430EDCC50341D234D08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CAC025A953CEC430EDCC50341D234D08" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CAC025A953CEC430EDCC50341D234D08" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_E93CC65C40CC549DB67850341D2487A5_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_E93CC65C40CC549DB67850341D2487A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_E93CC65C40CC549DB67850341D2487A5_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_E93CC65C40CC549DB67850341D2487A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_E93CC65C40CC549DB67850341D2487A5_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_E93CC65C40CC549DB67850341D2487A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_E93CC65C40CC549DB67850341D2487A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_E93CC65C40CC549DB67850341D2487A5" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_E93CC65C40CC549DB67850341D2487A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_954D897ECE64A4D1EEB950341D241BEC_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_954D897ECE64A4D1EEB950341D241BEC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_954D897ECE64A4D1EEB950341D241BEC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_954D897ECE64A4D1EEB950341D241BEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_954D897ECE64A4D1EEB950341D241BEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_954D897ECE64A4D1EEB950341D241BEC" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_954D897ECE64A4D1EEB950341D241BEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_1D55DABF271B648EB34450341D24837A_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_1D55DABF271B648EB34450341D24837A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_1D55DABF271B648EB34450341D24837A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_1D55DABF271B648EB34450341D24837A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_1D55DABF271B648EB34450341D24837A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_1D55DABF271B648EB34450341D24837A" xlink:to="lab_us-gaap_AvailableForSaleSecurities_1D55DABF271B648EB34450341D24837A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C205E65B17B68660392450341D7C9903_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C205E65B17B68660392450341D7C9903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C205E65B17B68660392450341D7C9903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C205E65B17B68660392450341D7C9903" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C205E65B17B68660392450341D7C9903" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_48DAA0E9F5259C800E5850341D7D199C_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_48DAA0E9F5259C800E5850341D7D199C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_48DAA0E9F5259C800E5850341D7D199C_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_48DAA0E9F5259C800E5850341D7D199C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_48DAA0E9F5259C800E5850341D7D199C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_48DAA0E9F5259C800E5850341D7D199C" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_48DAA0E9F5259C800E5850341D7D199C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8A628EFCABC7FFFB024550341C492746_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8A628EFCABC7FFFB024550341C492746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8A628EFCABC7FFFB024550341C492746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8A628EFCABC7FFFB024550341C492746" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8A628EFCABC7FFFB024550341C492746" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288" xlink:to="lab_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68" xlink:to="lab_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A" xlink:to="lab_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_0260FFB12CF5A11FF7D750341C4A373A_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_0260FFB12CF5A11FF7D750341C4A373A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_0260FFB12CF5A11FF7D750341C4A373A_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_0260FFB12CF5A11FF7D750341C4A373A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_0260FFB12CF5A11FF7D750341C4A373A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_0260FFB12CF5A11FF7D750341C4A373A" xlink:to="lab_us-gaap_PerformanceSharesMember_0260FFB12CF5A11FF7D750341C4A373A" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_81F1F5DD749A122F377350341C4B98F0_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_81F1F5DD749A122F377350341C4B98F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_81F1F5DD749A122F377350341C4B98F0_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_81F1F5DD749A122F377350341C4B98F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_81F1F5DD749A122F377350341C4B98F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_81F1F5DD749A122F377350341C4B98F0" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_81F1F5DD749A122F377350341C4B98F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B4CF1F7BDC7C9756748A50341C4B193C_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B4CF1F7BDC7C9756748A50341C4B193C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B4CF1F7BDC7C9756748A50341C4B193C_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B4CF1F7BDC7C9756748A50341C4B193C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B4CF1F7BDC7C9756748A50341C4B193C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B4CF1F7BDC7C9756748A50341C4B193C" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B4CF1F7BDC7C9756748A50341C4B193C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2691337E9AC2C6B6B78350341C4C8006_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2691337E9AC2C6B6B78350341C4C8006" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2691337E9AC2C6B6B78350341C4C8006_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2691337E9AC2C6B6B78350341C4C8006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2691337E9AC2C6B6B78350341C4C8006" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2691337E9AC2C6B6B78350341C4C8006" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2691337E9AC2C6B6B78350341C4C8006" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF_label_en-US" xlink:label="lab_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:to="lab_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:type="arc" />
    <link:label id="lab_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC_terseLabel_en-US" xlink:label="lab_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC_label_en-US" xlink:label="lab_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease assets [Member]</link:label>
    <link:label id="lab_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC_documentation_en-US" xlink:label="lab_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease assets [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_OperatingleaseassetsMember" xlink:label="loc_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC" xlink:to="lab_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_CDC8638FCAEE232CAE465092023796B6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_CDC8638FCAEE232CAE465092023796B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_CDC8638FCAEE232CAE465092023796B6_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_CDC8638FCAEE232CAE465092023796B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_CDC8638FCAEE232CAE465092023796B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_CDC8638FCAEE232CAE465092023796B6" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_CDC8638FCAEE232CAE465092023796B6" xlink:type="arc" />
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8_terseLabel_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8_label_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities [Member]</link:label>
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8_documentation_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8" xlink:to="lab_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_EEB2C9F35E321AD356ED5092023808FB_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_EEB2C9F35E321AD356ED5092023808FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_EEB2C9F35E321AD356ED5092023808FB_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_EEB2C9F35E321AD356ED5092023808FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_EEB2C9F35E321AD356ED5092023808FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_EEB2C9F35E321AD356ED5092023808FB" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_EEB2C9F35E321AD356ED5092023808FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87A396A3E7DE768378B350920238D911_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87A396A3E7DE768378B350920238D911" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87A396A3E7DE768378B350920238D911_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87A396A3E7DE768378B350920238D911" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87A396A3E7DE768378B350920238D911" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87A396A3E7DE768378B350920238D911" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87A396A3E7DE768378B350920238D911" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_044325660A40282AD80750920238E3AC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_044325660A40282AD80750920238E3AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_044325660A40282AD80750920238E3AC_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_044325660A40282AD80750920238E3AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_044325660A40282AD80750920238E3AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_044325660A40282AD80750920238E3AC" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_044325660A40282AD80750920238E3AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="lab_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7BAF9651F8A3D698AA9C5092023916F5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_7BAF9651F8A3D698AA9C5092023916F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7BAF9651F8A3D698AA9C5092023916F5_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_7BAF9651F8A3D698AA9C5092023916F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7BAF9651F8A3D698AA9C5092023916F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_7BAF9651F8A3D698AA9C5092023916F5" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_7BAF9651F8A3D698AA9C5092023916F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_AE706E91E585A4475520509202399285_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_AE706E91E585A4475520509202399285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_AE706E91E585A4475520509202399285_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_AE706E91E585A4475520509202399285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_AE706E91E585A4475520509202399285" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_AE706E91E585A4475520509202399285" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_AE706E91E585A4475520509202399285" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_54BB693B93E409E1A09750920239C876_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_54BB693B93E409E1A09750920239C876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_54BB693B93E409E1A09750920239C876_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_54BB693B93E409E1A09750920239C876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_54BB693B93E409E1A09750920239C876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_54BB693B93E409E1A09750920239C876" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_54BB693B93E409E1A09750920239C876" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_BCD93A9A69596DF501465092023998F5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_BCD93A9A69596DF501465092023998F5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_BCD93A9A69596DF501465092023998F5_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_BCD93A9A69596DF501465092023998F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_BCD93A9A69596DF501465092023998F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_BCD93A9A69596DF501465092023998F5" xlink:to="lab_us-gaap_OperatingLeaseLiability_BCD93A9A69596DF501465092023998F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_3D55A5BFE3A1095A63A45092023905A7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_3D55A5BFE3A1095A63A45092023905A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_3D55A5BFE3A1095A63A45092023905A7_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_3D55A5BFE3A1095A63A45092023905A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_3D55A5BFE3A1095A63A45092023905A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_3D55A5BFE3A1095A63A45092023905A7" xlink:to="lab_us-gaap_OperatingLeaseCost_3D55A5BFE3A1095A63A45092023905A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_671FBAB40AC520F044065092023AD8CA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_671FBAB40AC520F044065092023AD8CA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_671FBAB40AC520F044065092023AD8CA_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_671FBAB40AC520F044065092023AD8CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Income Statement, Sublease Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_671FBAB40AC520F044065092023AD8CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_671FBAB40AC520F044065092023AD8CA" xlink:to="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_671FBAB40AC520F044065092023AD8CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_71D2D66EA34125E59F1C5092023AF5D9_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_71D2D66EA34125E59F1C5092023AF5D9" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net lease cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_71D2D66EA34125E59F1C5092023AF5D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_71D2D66EA34125E59F1C5092023AF5D9" xlink:to="lab_us-gaap_OperatingLeaseCost_71D2D66EA34125E59F1C5092023AF5D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_DFEDEB385CA08D9CF55A5092023AC055_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_DFEDEB385CA08D9CF55A5092023AC055" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments 2019 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_DFEDEB385CA08D9CF55A5092023AC055_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_DFEDEB385CA08D9CF55A5092023AC055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_DFEDEB385CA08D9CF55A5092023AC055" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_DFEDEB385CA08D9CF55A5092023AC055" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_DFEDEB385CA08D9CF55A5092023AC055" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3FB05D0351E2DF0FA10C5092023A2AFE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3FB05D0351E2DF0FA10C5092023A2AFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3FB05D0351E2DF0FA10C5092023A2AFE_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3FB05D0351E2DF0FA10C5092023A2AFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3FB05D0351E2DF0FA10C5092023A2AFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3FB05D0351E2DF0FA10C5092023A2AFE" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3FB05D0351E2DF0FA10C5092023A2AFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C880875D94F76599AB3F5092023AC37D_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C880875D94F76599AB3F5092023AC37D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C880875D94F76599AB3F5092023AC37D_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C880875D94F76599AB3F5092023AC37D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C880875D94F76599AB3F5092023AC37D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C880875D94F76599AB3F5092023AC37D" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C880875D94F76599AB3F5092023AC37D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3D80712892620F4358435092023A5C35_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3D80712892620F4358435092023A5C35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3D80712892620F4358435092023A5C35_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3D80712892620F4358435092023A5C35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3D80712892620F4358435092023A5C35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3D80712892620F4358435092023A5C35" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3D80712892620F4358435092023A5C35" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D837E26EE2DEC0A699F05092023B7620_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D837E26EE2DEC0A699F05092023B7620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D837E26EE2DEC0A699F05092023B7620_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D837E26EE2DEC0A699F05092023B7620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D837E26EE2DEC0A699F05092023B7620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D837E26EE2DEC0A699F05092023B7620" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D837E26EE2DEC0A699F05092023B7620" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3DBBE8D9D7F4F9E78FC05092023B23FD_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3DBBE8D9D7F4F9E78FC05092023B23FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3DBBE8D9D7F4F9E78FC05092023B23FD_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3DBBE8D9D7F4F9E78FC05092023B23FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3DBBE8D9D7F4F9E78FC05092023B23FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3DBBE8D9D7F4F9E78FC05092023B23FD" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3DBBE8D9D7F4F9E78FC05092023B23FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CAA485D5A2F953870ECF5092023B8AE2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CAA485D5A2F953870ECF5092023B8AE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CAA485D5A2F953870ECF5092023B8AE2_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CAA485D5A2F953870ECF5092023B8AE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CAA485D5A2F953870ECF5092023B8AE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CAA485D5A2F953870ECF5092023B8AE2" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CAA485D5A2F953870ECF5092023B8AE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73CCD8956E3D2A6BBBAE5092023B4936_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73CCD8956E3D2A6BBBAE5092023B4936" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73CCD8956E3D2A6BBBAE5092023B4936_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73CCD8956E3D2A6BBBAE5092023B4936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73CCD8956E3D2A6BBBAE5092023B4936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73CCD8956E3D2A6BBBAE5092023B4936" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73CCD8956E3D2A6BBBAE5092023B4936" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_B42A4B48793EF9C3B7645092023BD210_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_B42A4B48793EF9C3B7645092023BD210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_B42A4B48793EF9C3B7645092023BD210_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_B42A4B48793EF9C3B7645092023BD210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_B42A4B48793EF9C3B7645092023BD210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_B42A4B48793EF9C3B7645092023BD210" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_B42A4B48793EF9C3B7645092023BD210" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_330FCA5C36AC184BC3AE5092023C46A2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_330FCA5C36AC184BC3AE5092023C46A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2019 (remaining 9 months)</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_330FCA5C36AC184BC3AE5092023C46A2_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_330FCA5C36AC184BC3AE5092023C46A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_330FCA5C36AC184BC3AE5092023C46A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_330FCA5C36AC184BC3AE5092023C46A2" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_330FCA5C36AC184BC3AE5092023C46A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6F579D6F0E3A400F3F315092023C36B5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6F579D6F0E3A400F3F315092023C36B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6F579D6F0E3A400F3F315092023C36B5_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6F579D6F0E3A400F3F315092023C36B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6F579D6F0E3A400F3F315092023C36B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6F579D6F0E3A400F3F315092023C36B5" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6F579D6F0E3A400F3F315092023C36B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_45ECDAEED5AA559FE17A5092023C50D8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_45ECDAEED5AA559FE17A5092023C50D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_45ECDAEED5AA559FE17A5092023C50D8_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_45ECDAEED5AA559FE17A5092023C50D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_45ECDAEED5AA559FE17A5092023C50D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_45ECDAEED5AA559FE17A5092023C50D8" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_45ECDAEED5AA559FE17A5092023C50D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_640BFF691FA0A3169C785092023C4BE6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_640BFF691FA0A3169C785092023C4BE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_640BFF691FA0A3169C785092023C4BE6_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_640BFF691FA0A3169C785092023C4BE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_640BFF691FA0A3169C785092023C4BE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_640BFF691FA0A3169C785092023C4BE6" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_640BFF691FA0A3169C785092023C4BE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ED53CEDDF92FFC86BFAA5092023CE6D8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ED53CEDDF92FFC86BFAA5092023CE6D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 940 - Minimum lease payments, 2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ED53CEDDF92FFC86BFAA5092023CE6D8_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ED53CEDDF92FFC86BFAA5092023CE6D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ED53CEDDF92FFC86BFAA5092023CE6D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ED53CEDDF92FFC86BFAA5092023CE6D8" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ED53CEDDF92FFC86BFAA5092023CE6D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7DA9F4D36C47FFC808035092023C5CE1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7DA9F4D36C47FFC808035092023C5CE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7DA9F4D36C47FFC808035092023C5CE1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7DA9F4D36C47FFC808035092023C5CE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7DA9F4D36C47FFC808035092023C5CE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7DA9F4D36C47FFC808035092023C5CE1" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7DA9F4D36C47FFC808035092023C5CE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4E96ED8142CAC25585705092023CC1C5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4E96ED8142CAC25585705092023CC1C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4E96ED8142CAC25585705092023CC1C5_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4E96ED8142CAC25585705092023CC1C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4E96ED8142CAC25585705092023CC1C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4E96ED8142CAC25585705092023CC1C5" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4E96ED8142CAC25585705092023CC1C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_A396502DB1C3B25651275092023DCD26_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_A396502DB1C3B25651275092023DCD26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2019 (remaining 9 months)</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_A396502DB1C3B25651275092023DCD26_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_A396502DB1C3B25651275092023DCD26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_A396502DB1C3B25651275092023DCD26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_A396502DB1C3B25651275092023DCD26" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_A396502DB1C3B25651275092023DCD26" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7911D3BDFBD91140938C5092023DD5B3_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7911D3BDFBD91140938C5092023DD5B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2020</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7911D3BDFBD91140938C5092023DD5B3_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7911D3BDFBD91140938C5092023DD5B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7911D3BDFBD91140938C5092023DD5B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7911D3BDFBD91140938C5092023DD5B3" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7911D3BDFBD91140938C5092023DD5B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_E620BEBD10BCCCEB88B85092023D95A3_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_E620BEBD10BCCCEB88B85092023D95A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2021</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_E620BEBD10BCCCEB88B85092023D95A3_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_E620BEBD10BCCCEB88B85092023D95A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_E620BEBD10BCCCEB88B85092023D95A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_E620BEBD10BCCCEB88B85092023D95A3" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_E620BEBD10BCCCEB88B85092023D95A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7CCA02D07CA46482870D5092023D80E0_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7CCA02D07CA46482870D5092023D80E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2022</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7CCA02D07CA46482870D5092023D80E0_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7CCA02D07CA46482870D5092023D80E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7CCA02D07CA46482870D5092023D80E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7CCA02D07CA46482870D5092023D80E0" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7CCA02D07CA46482870D5092023D80E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_79BC7775A578815642485092023D94CE_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_79BC7775A578815642485092023D94CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2023</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_79BC7775A578815642485092023D94CE_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_79BC7775A578815642485092023D94CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_79BC7775A578815642485092023D94CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_79BC7775A578815642485092023D94CE" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_79BC7775A578815642485092023D94CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_ABFD003E6060DA843A405092023DF9E3_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_ABFD003E6060DA843A405092023DF9E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, thereafter</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_ABFD003E6060DA843A405092023DF9E3_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_ABFD003E6060DA843A405092023DF9E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_ABFD003E6060DA843A405092023DF9E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_ABFD003E6060DA843A405092023DF9E3" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_ABFD003E6060DA843A405092023DF9E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_1F32F9B1A357D4F8EF1C5092023E9EE2_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_1F32F9B1A357D4F8EF1C5092023E9EE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income total</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_1F32F9B1A357D4F8EF1C5092023E9EE2_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_1F32F9B1A357D4F8EF1C5092023E9EE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_1F32F9B1A357D4F8EF1C5092023E9EE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_1F32F9B1A357D4F8EF1C5092023E9EE2" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_1F32F9B1A357D4F8EF1C5092023E9EE2" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments 2019 (remaining 9 months)</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In One Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in one year.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2020</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Two Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in two year.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2021</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Three Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in three year.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2022</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Four Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in four year.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2023</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Five Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in five year.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments Thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments thereafter.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4" xlink:to="lab_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments total</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1_label_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments total.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1" xlink:to="lab_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41393617AA4BAE5B364E5092023FD899_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41393617AA4BAE5B364E5092023FD899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term in years</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41393617AA4BAE5B364E5092023FD899_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41393617AA4BAE5B364E5092023FD899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41393617AA4BAE5B364E5092023FD899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41393617AA4BAE5B364E5092023FD899" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41393617AA4BAE5B364E5092023FD899" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0CF5C58A161B55514D935092023FA752_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0CF5C58A161B55514D935092023FA752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0CF5C58A161B55514D935092023FA752_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0CF5C58A161B55514D935092023FA752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0CF5C58A161B55514D935092023FA752" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0CF5C58A161B55514D935092023FA752" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0CF5C58A161B55514D935092023FA752" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_D9C60146487C27B36F4D5092023F9909_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_D9C60146487C27B36F4D5092023F9909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_D9C60146487C27B36F4D5092023F9909_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_D9C60146487C27B36F4D5092023F9909" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_D9C60146487C27B36F4D5092023F9909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_D9C60146487C27B36F4D5092023F9909" xlink:to="lab_us-gaap_OperatingLeasePayments_D9C60146487C27B36F4D5092023F9909" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D50E09170BC0EB0717BA5092023F0467_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D50E09170BC0EB0717BA5092023F0467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D50E09170BC0EB0717BA5092023F0467_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D50E09170BC0EB0717BA5092023F0467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D50E09170BC0EB0717BA5092023F0467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D50E09170BC0EB0717BA5092023F0467" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D50E09170BC0EB0717BA5092023F0467" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_C34E6804B2BD55426FBE50341DDFE1CB_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_C34E6804B2BD55426FBE50341DDFE1CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C34E6804B2BD55426FBE50341DDFE1CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C34E6804B2BD55426FBE50341DDFE1CB" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_C34E6804B2BD55426FBE50341DDFE1CB" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_FF6A614655909E1C5B2250341DDF1059_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_FF6A614655909E1C5B2250341DDF1059" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_FF6A614655909E1C5B2250341DDF1059_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_FF6A614655909E1C5B2250341DDF1059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_FF6A614655909E1C5B2250341DDF1059_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_FF6A614655909E1C5B2250341DDF1059" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_FF6A614655909E1C5B2250341DDF1059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_FF6A614655909E1C5B2250341DDF1059" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_FF6A614655909E1C5B2250341DDF1059" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87E221C7457F947F248650341DDFC867_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87E221C7457F947F248650341DDFC867" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87E221C7457F947F248650341DDFC867_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87E221C7457F947F248650341DDFC867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87E221C7457F947F248650341DDFC867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87E221C7457F947F248650341DDFC867" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87E221C7457F947F248650341DDFC867" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_D71D4B61EF6EB6E2983D50341DDFE9ED_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_D71D4B61EF6EB6E2983D50341DDFE9ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_D71D4B61EF6EB6E2983D50341DDFE9ED_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_D71D4B61EF6EB6E2983D50341DDFE9ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_D71D4B61EF6EB6E2983D50341DDFE9ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_D71D4B61EF6EB6E2983D50341DDFE9ED" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_D71D4B61EF6EB6E2983D50341DDFE9ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_A712D7A8BDE0FF6C265B50341DDF9BCE_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_A712D7A8BDE0FF6C265B50341DDF9BCE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_A712D7A8BDE0FF6C265B50341DDF9BCE_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_A712D7A8BDE0FF6C265B50341DDF9BCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_A712D7A8BDE0FF6C265B50341DDF9BCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_A712D7A8BDE0FF6C265B50341DDF9BCE" xlink:to="lab_us-gaap_UseOfEstimates_A712D7A8BDE0FF6C265B50341DDF9BCE" xlink:type="arc" />
    <link:label id="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_06161641FBD001B2FE2950341DDFCAC2_terseLabel_en-US" xlink:label="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_06161641FBD001B2FE2950341DDFCAC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities held for sale</link:label>
    <link:label id="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_06161641FBD001B2FE2950341DDFCAC2_label_en-US" xlink:label="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_06161641FBD001B2FE2950341DDFCAC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Held For Sale [Policy Text Block]</link:label>
    <link:label id="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_06161641FBD001B2FE2950341DDFCAC2_documentation_en-US" xlink:label="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_06161641FBD001B2FE2950341DDFCAC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Held For Sale [Policy Text Block]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock" xlink:label="loc_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_06161641FBD001B2FE2950341DDFCAC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_06161641FBD001B2FE2950341DDFCAC2" xlink:to="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_06161641FBD001B2FE2950341DDFCAC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0DD3AA3ECABE7806097550341DDF5093_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0DD3AA3ECABE7806097550341DDF5093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0DD3AA3ECABE7806097550341DDF5093_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0DD3AA3ECABE7806097550341DDF5093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0DD3AA3ECABE7806097550341DDF5093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0DD3AA3ECABE7806097550341DDF5093" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0DD3AA3ECABE7806097550341DDF5093" xlink:type="arc" />
    <link:label id="lab_biib_TaxcontingencyAbstract_2BDFDA40DE2CCAFBE14C50341BB1ED32_label_en-US" xlink:label="lab_biib_TaxcontingencyAbstract_2BDFDA40DE2CCAFBE14C50341BB1ED32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax contingency [Abstract]</link:label>
    <link:label id="lab_biib_TaxcontingencyAbstract_2BDFDA40DE2CCAFBE14C50341BB1ED32_documentation_en-US" xlink:label="lab_biib_TaxcontingencyAbstract_2BDFDA40DE2CCAFBE14C50341BB1ED32" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax contingency [Abstract]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_TaxcontingencyAbstract" xlink:label="loc_biib_TaxcontingencyAbstract_2BDFDA40DE2CCAFBE14C50341BB1ED32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TaxcontingencyAbstract_2BDFDA40DE2CCAFBE14C50341BB1ED32" xlink:to="lab_biib_TaxcontingencyAbstract_2BDFDA40DE2CCAFBE14C50341BB1ED32" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC" xlink:type="arc" />
    <link:label id="lab_country_BR_7157EE5D3B3D41B1B27950341BB5E9A2_terseLabel_en-US" xlink:label="lab_country_BR_7157EE5D3B3D41B1B27950341BB5E9A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_7157EE5D3B3D41B1B27950341BB5E9A2_label_en-US" xlink:label="lab_country_BR_7157EE5D3B3D41B1B27950341BB5E9A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_7157EE5D3B3D41B1B27950341BB5E9A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR_7157EE5D3B3D41B1B27950341BB5E9A2" xlink:to="lab_country_BR_7157EE5D3B3D41B1B27950341BB5E9A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesSought_1E6930C51F37A7D2E13150341BB6B423_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSought_1E6930C51F37A7D2E13150341BB6B423" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil tax assessment, including interest and penalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSought_1E6930C51F37A7D2E13150341BB6B423_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSought_1E6930C51F37A7D2E13150341BB6B423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesSought" xlink:label="loc_us-gaap_LossContingencyDamagesSought_1E6930C51F37A7D2E13150341BB6B423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSought_1E6930C51F37A7D2E13150341BB6B423" xlink:to="lab_us-gaap_LossContingencyDamagesSought_1E6930C51F37A7D2E13150341BB6B423" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_3F469D00D50A8479208450341BC1EB58_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_3F469D00D50A8479208450341BC1EB58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_3F469D00D50A8479208450341BC1EB58_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_3F469D00D50A8479208450341BC1EB58" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_3F469D00D50A8479208450341BC1EB58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_3F469D00D50A8479208450341BC1EB58" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_3F469D00D50A8479208450341BC1EB58" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_CD671B1ACDC982A63D0650341BC12046_terseLabel_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_CD671B1ACDC982A63D0650341BC12046" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual)</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_CD671B1ACDC982A63D0650341BC12046_label_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_CD671B1ACDC982A63D0650341BC12046" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_CD671B1ACDC982A63D0650341BC12046_documentation_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_CD671B1ACDC982A63D0650341BC12046" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_CD671B1ACDC982A63D0650341BC12046" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_CD671B1ACDC982A63D0650341BC12046" xlink:to="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_CD671B1ACDC982A63D0650341BC12046" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_337868DC24EAC83D2AB250341BC2E79B_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_337868DC24EAC83D2AB250341BC2E79B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_337868DC24EAC83D2AB250341BC2E79B_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_337868DC24EAC83D2AB250341BC2E79B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_337868DC24EAC83D2AB250341BC2E79B_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_337868DC24EAC83D2AB250341BC2E79B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_337868DC24EAC83D2AB250341BC2E79B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_337868DC24EAC83D2AB250341BC2E79B" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_337868DC24EAC83D2AB250341BC2E79B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_8860918FDAD093E414CE50341D5E8783_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_8860918FDAD093E414CE50341D5E8783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8860918FDAD093E414CE50341D5E8783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8860918FDAD093E414CE50341D5E8783" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_8860918FDAD093E414CE50341D5E8783" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_A17173CEC5A703F56D9150341D5E4088_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_A17173CEC5A703F56D9150341D5E4088" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_A17173CEC5A703F56D9150341D5E4088_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_A17173CEC5A703F56D9150341D5E4088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_A17173CEC5A703F56D9150341D5E4088" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_A17173CEC5A703F56D9150341D5E4088" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_A17173CEC5A703F56D9150341D5E4088" xlink:type="arc" />
    <link:label id="lab_biib_DivestituresAbstract_5C9634DD9A8FC20F051050479ECEFDAF_label_en-US" xlink:label="lab_biib_DivestituresAbstract_5C9634DD9A8FC20F051050479ECEFDAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_5C9634DD9A8FC20F051050479ECEFDAF_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract_5C9634DD9A8FC20F051050479ECEFDAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_5C9634DD9A8FC20F051050479ECEFDAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract_5C9634DD9A8FC20F051050479ECEFDAF" xlink:to="lab_biib_DivestituresAbstract_5C9634DD9A8FC20F051050479ECEFDAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015" xlink:type="arc" />
    <link:label id="lab_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012_terseLabel_en-US" xlink:label="lab_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012_label_en-US" xlink:label="lab_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work-in-process [Member]</link:label>
    <link:label id="lab_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012_documentation_en-US" xlink:label="lab_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012" xlink:to="lab_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_04A9E5D7DCA1309BD19A50479ED15D38_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_04A9E5D7DCA1309BD19A50479ED15D38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration expected to be received for sale of Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_04A9E5D7DCA1309BD19A50479ED15D38_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_04A9E5D7DCA1309BD19A50479ED15D38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_04A9E5D7DCA1309BD19A50479ED15D38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_04A9E5D7DCA1309BD19A50479ED15D38" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_04A9E5D7DCA1309BD19A50479ED15D38" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_E84C18AA15F6FABAB2FC50479ED1DE39_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_E84C18AA15F6FABAB2FC50479ED1DE39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory expected to be sold to FUJIFILM</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_E84C18AA15F6FABAB2FC50479ED1DE39_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_E84C18AA15F6FABAB2FC50479ED1DE39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_E84C18AA15F6FABAB2FC50479ED1DE39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_E84C18AA15F6FABAB2FC50479ED1DE39" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_E84C18AA15F6FABAB2FC50479ED1DE39" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4A7076D34C036F4F5B1E50341DE29011_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4A7076D34C036F4F5B1E50341DE29011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4A7076D34C036F4F5B1E50341DE29011_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4A7076D34C036F4F5B1E50341DE29011" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4A7076D34C036F4F5B1E50341DE29011" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4A7076D34C036F4F5B1E50341DE29011" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4A7076D34C036F4F5B1E50341DE29011" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_75072A4BCF35B896CBE350341C6CD9B0_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_75072A4BCF35B896CBE350341C6CD9B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_75072A4BCF35B896CBE350341C6CD9B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_75072A4BCF35B896CBE350341C6CD9B0" xlink:to="lab_us-gaap_EarningsPerShareAbstract_75072A4BCF35B896CBE350341C6CD9B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC" xlink:to="lab_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_7AF792EAEE76E3B0977750341C6F1109_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_7AF792EAEE76E3B0977750341C6F1109" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7AF792EAEE76E3B0977750341C6F1109_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_7AF792EAEE76E3B0977750341C6F1109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7AF792EAEE76E3B0977750341C6F1109" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_7AF792EAEE76E3B0977750341C6F1109" xlink:to="lab_us-gaap_NetIncomeLoss_7AF792EAEE76E3B0977750341C6F1109" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9CCDF3DEA691FCC94CC250341C6F9EE0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9CCDF3DEA691FCC94CC250341C6F9EE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9CCDF3DEA691FCC94CC250341C6F9EE0_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9CCDF3DEA691FCC94CC250341C6F9EE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9CCDF3DEA691FCC94CC250341C6F9EE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9CCDF3DEA691FCC94CC250341C6F9EE0" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9CCDF3DEA691FCC94CC250341C6F9EE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_461BC72E4CA3328DF47350341C70FA67_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_461BC72E4CA3328DF47350341C70FA67" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_461BC72E4CA3328DF47350341C70FA67_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_461BC72E4CA3328DF47350341C70FA67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_461BC72E4CA3328DF47350341C70FA67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_461BC72E4CA3328DF47350341C70FA67" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_461BC72E4CA3328DF47350341C70FA67" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ADEE9F5DCC29A02056BD50341C709F63_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ADEE9F5DCC29A02056BD50341C709F63" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ADEE9F5DCC29A02056BD50341C709F63_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ADEE9F5DCC29A02056BD50341C709F63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ADEE9F5DCC29A02056BD50341C709F63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ADEE9F5DCC29A02056BD50341C709F63" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ADEE9F5DCC29A02056BD50341C709F63" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4B2B6C126B0E1AE4850B50341C70A6CC_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4B2B6C126B0E1AE4850B50341C70A6CC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4B2B6C126B0E1AE4850B50341C70A6CC_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4B2B6C126B0E1AE4850B50341C70A6CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4B2B6C126B0E1AE4850B50341C70A6CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4B2B6C126B0E1AE4850B50341C70A6CC" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4B2B6C126B0E1AE4850B50341C70A6CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_B77186C5A59D1C79622950341DBB7DE7_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_B77186C5A59D1C79622950341DBB7DE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B77186C5A59D1C79622950341DBB7DE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B77186C5A59D1C79622950341DBB7DE7" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_B77186C5A59D1C79622950341DBB7DE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_32B35608AA0E5DE8068450341DBB043A_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_32B35608AA0E5DE8068450341DBB043A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_32B35608AA0E5DE8068450341DBB043A_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_32B35608AA0E5DE8068450341DBB043A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_32B35608AA0E5DE8068450341DBB043A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_32B35608AA0E5DE8068450341DBB043A" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_32B35608AA0E5DE8068450341DBB043A" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6E7A238D60516343570650341DBBA9E4_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6E7A238D60516343570650341DBBA9E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6E7A238D60516343570650341DBBA9E4_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6E7A238D60516343570650341DBBA9E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6E7A238D60516343570650341DBBA9E4_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6E7A238D60516343570650341DBBA9E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6E7A238D60516343570650341DBBA9E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6E7A238D60516343570650341DBBA9E4" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6E7A238D60516343570650341DBBA9E4" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D5F8FFF00849FB5664C650341DBBA9BD_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D5F8FFF00849FB5664C650341DBBA9BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D5F8FFF00849FB5664C650341DBBA9BD_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D5F8FFF00849FB5664C650341DBBA9BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D5F8FFF00849FB5664C650341DBBA9BD_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D5F8FFF00849FB5664C650341DBBA9BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D5F8FFF00849FB5664C650341DBBA9BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D5F8FFF00849FB5664C650341DBBA9BD" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D5F8FFF00849FB5664C650341DBBA9BD" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2C7E9C62C6CFF564824C50341DBB916B_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2C7E9C62C6CFF564824C50341DBB916B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2C7E9C62C6CFF564824C50341DBB916B_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2C7E9C62C6CFF564824C50341DBB916B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2C7E9C62C6CFF564824C50341DBB916B_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2C7E9C62C6CFF564824C50341DBB916B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2C7E9C62C6CFF564824C50341DBB916B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2C7E9C62C6CFF564824C50341DBB916B" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2C7E9C62C6CFF564824C50341DBB916B" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_522C8CEDA905D672A72C50341DBCFC2C_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_522C8CEDA905D672A72C50341DBCFC2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_522C8CEDA905D672A72C50341DBCFC2C_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_522C8CEDA905D672A72C50341DBCFC2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_522C8CEDA905D672A72C50341DBCFC2C_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_522C8CEDA905D672A72C50341DBCFC2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_522C8CEDA905D672A72C50341DBCFC2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock_522C8CEDA905D672A72C50341DBCFC2C" xlink:to="lab_biib_OtherrevenuesTableTextBlock_522C8CEDA905D672A72C50341DBCFC2C" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_64D80C5E04233ECDF53D50341DABC22D_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract_64D80C5E04233ECDF53D50341DABC22D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_64D80C5E04233ECDF53D50341DABC22D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_64D80C5E04233ECDF53D50341DABC22D" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract_64D80C5E04233ECDF53D50341DABC22D" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:type="arc" />
    <link:label id="lab_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2" xlink:to="lab_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D" xlink:to="lab_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_0373028E48B7B64830F450341DADD115_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_0373028E48B7B64830F450341DADD115" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_0373028E48B7B64830F450341DADD115_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_0373028E48B7B64830F450341DADD115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_0373028E48B7B64830F450341DADD115" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_0373028E48B7B64830F450341DADD115" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_0373028E48B7B64830F450341DADD115" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_F08C83C23EE0E82A649C50341DADA25D_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_F08C83C23EE0E82A649C50341DADA25D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_F08C83C23EE0E82A649C50341DADA25D_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_F08C83C23EE0E82A649C50341DADA25D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_F08C83C23EE0E82A649C50341DADA25D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_F08C83C23EE0E82A649C50341DADA25D" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_F08C83C23EE0E82A649C50341DADA25D" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_0206B18605BEEB6D329050341DAE2DE0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_0206B18605BEEB6D329050341DAE2DE0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0206B18605BEEB6D329050341DAE2DE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_0206B18605BEEB6D329050341DAE2DE0" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_0206B18605BEEB6D329050341DAE2DE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138" xlink:to="lab_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_B7267DCC11E86487861D50341D8B3909_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_B7267DCC11E86487861D50341D8B3909" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_B7267DCC11E86487861D50341D8B3909_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_B7267DCC11E86487861D50341D8B3909" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_B7267DCC11E86487861D50341D8B3909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_B7267DCC11E86487861D50341D8B3909" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_B7267DCC11E86487861D50341D8B3909" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_16F3F8379DB24A24C18E50341D8B895E_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_16F3F8379DB24A24C18E50341D8B895E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_16F3F8379DB24A24C18E50341D8B895E_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_16F3F8379DB24A24C18E50341D8B895E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_16F3F8379DB24A24C18E50341D8B895E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_16F3F8379DB24A24C18E50341D8B895E" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_16F3F8379DB24A24C18E50341D8B895E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_8DFF10C352574445B3CA50341D8B2AE8_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_8DFF10C352574445B3CA50341D8B2AE8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_8DFF10C352574445B3CA50341D8B2AE8_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_8DFF10C352574445B3CA50341D8B2AE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8DFF10C352574445B3CA50341D8B2AE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8DFF10C352574445B3CA50341D8B2AE8" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_8DFF10C352574445B3CA50341D8B2AE8" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_883E53EFAD4AF65C1C4E50341D8BFCCA_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_883E53EFAD4AF65C1C4E50341D8BFCCA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_883E53EFAD4AF65C1C4E50341D8BFCCA_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_883E53EFAD4AF65C1C4E50341D8BFCCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_883E53EFAD4AF65C1C4E50341D8BFCCA_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_883E53EFAD4AF65C1C4E50341D8BFCCA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_883E53EFAD4AF65C1C4E50341D8BFCCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_883E53EFAD4AF65C1C4E50341D8BFCCA" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_883E53EFAD4AF65C1C4E50341D8BFCCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_72E3B35BF504BBE8BC7350341D8BC7FF_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_72E3B35BF504BBE8BC7350341D8BC7FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_72E3B35BF504BBE8BC7350341D8BC7FF_label_en-US" xlink:label="lab_us-gaap_InventoryNet_72E3B35BF504BBE8BC7350341D8BC7FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_72E3B35BF504BBE8BC7350341D8BC7FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_72E3B35BF504BBE8BC7350341D8BC7FF" xlink:to="lab_us-gaap_InventoryNet_72E3B35BF504BBE8BC7350341D8BC7FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_A86DEDAB834401352E1250341D8CECB8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_A86DEDAB834401352E1250341D8CECB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_A86DEDAB834401352E1250341D8CECB8_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_A86DEDAB834401352E1250341D8CECB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_A86DEDAB834401352E1250341D8CECB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_A86DEDAB834401352E1250341D8CECB8" xlink:to="lab_us-gaap_InventoryNoncurrent_A86DEDAB834401352E1250341D8CECB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD" xlink:to="lab_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60" xlink:to="lab_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:to="lab_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_A3681F682B47E158D62050341D4B3AA7_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_A3681F682B47E158D62050341D4B3AA7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_A3681F682B47E158D62050341D4B3AA7_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_A3681F682B47E158D62050341D4B3AA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_A3681F682B47E158D62050341D4B3AA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_A3681F682B47E158D62050341D4B3AA7" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_A3681F682B47E158D62050341D4B3AA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_8507B37540F736C281E150341D4B1855_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_8507B37540F736C281E150341D4B1855" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_8507B37540F736C281E150341D4B1855_label_en-US" xlink:label="lab_us-gaap_NotesPayable_8507B37540F736C281E150341D4B1855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_8507B37540F736C281E150341D4B1855" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_8507B37540F736C281E150341D4B1855" xlink:to="lab_us-gaap_NotesPayable_8507B37540F736C281E150341D4B1855" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_22B052E0159989880A2350341D4BC053_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_22B052E0159989880A2350341D4BC053" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_22B052E0159989880A2350341D4BC053_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_22B052E0159989880A2350341D4BC053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_22B052E0159989880A2350341D4BC053" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_22B052E0159989880A2350341D4BC053" xlink:to="lab_us-gaap_DebtInstrumentFairValue_22B052E0159989880A2350341D4BC053" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4FEA027559756A73D8A050341C577DE4_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4FEA027559756A73D8A050341C577DE4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4FEA027559756A73D8A050341C577DE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4FEA027559756A73D8A050341C577DE4" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4FEA027559756A73D8A050341C577DE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_762F53614C50EA2DA9A250341C579A91_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_762F53614C50EA2DA9A250341C579A91" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_762F53614C50EA2DA9A250341C579A91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_762F53614C50EA2DA9A250341C579A91" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_762F53614C50EA2DA9A250341C579A91" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_B01604F5BDB6EF379A3B50341C58DA90_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_B01604F5BDB6EF379A3B50341C58DA90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_B01604F5BDB6EF379A3B50341C58DA90_label_en-US" xlink:label="lab_us-gaap_ParentMember_B01604F5BDB6EF379A3B50341C58DA90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_B01604F5BDB6EF379A3B50341C58DA90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_B01604F5BDB6EF379A3B50341C58DA90" xlink:to="lab_us-gaap_ParentMember_B01604F5BDB6EF379A3B50341C58DA90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DC0E3E942B765BA6295D50341C588392_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DC0E3E942B765BA6295D50341C588392" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DC0E3E942B765BA6295D50341C588392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DC0E3E942B765BA6295D50341C588392" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DC0E3E942B765BA6295D50341C588392" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_EF3D6E15F32FE0986DB650341C5966F5_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_EF3D6E15F32FE0986DB650341C5966F5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_EF3D6E15F32FE0986DB650341C5966F5_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_EF3D6E15F32FE0986DB650341C5966F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_EF3D6E15F32FE0986DB650341C5966F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_EF3D6E15F32FE0986DB650341C5966F5" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_EF3D6E15F32FE0986DB650341C5966F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_84F889DFF94FEE7E829B50341C96D607_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_84F889DFF94FEE7E829B50341C96D607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_84F889DFF94FEE7E829B50341C96D607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_84F889DFF94FEE7E829B50341C96D607" xlink:to="lab_us-gaap_EquityAbstract_84F889DFF94FEE7E829B50341C96D607" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8EAA1522F282962357F550341C9714C4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8EAA1522F282962357F550341C9714C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8EAA1522F282962357F550341C9714C4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8EAA1522F282962357F550341C9714C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8EAA1522F282962357F550341C9714C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8EAA1522F282962357F550341C9714C4" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8EAA1522F282962357F550341C9714C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3F30927C6EA8609F735C50341C9738FF_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3F30927C6EA8609F735C50341C9738FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3F30927C6EA8609F735C50341C9738FF_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3F30927C6EA8609F735C50341C9738FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3F30927C6EA8609F735C50341C9738FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3F30927C6EA8609F735C50341C9738FF" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3F30927C6EA8609F735C50341C9738FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_C0A7DB26518AB6C5011A50341E154E2E_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_C0A7DB26518AB6C5011A50341E154E2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_C0A7DB26518AB6C5011A50341E154E2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C0A7DB26518AB6C5011A50341E154E2E" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_C0A7DB26518AB6C5011A50341E154E2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:to="lab_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:to="lab_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_13AF11C939B22D2B4F5750341E16A686_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_13AF11C939B22D2B4F5750341E16A686" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_13AF11C939B22D2B4F5750341E16A686_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_13AF11C939B22D2B4F5750341E16A686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13AF11C939B22D2B4F5750341E16A686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13AF11C939B22D2B4F5750341E16A686" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_13AF11C939B22D2B4F5750341E16A686" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6F12DCA58915B2197C2550341E17059F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6F12DCA58915B2197C2550341E17059F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6F12DCA58915B2197C2550341E17059F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6F12DCA58915B2197C2550341E17059F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6F12DCA58915B2197C2550341E17059F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6F12DCA58915B2197C2550341E17059F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6F12DCA58915B2197C2550341E17059F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_67E8AE1569AAA07A63A050341E179514_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_67E8AE1569AAA07A63A050341E179514" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_67E8AE1569AAA07A63A050341E179514_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_67E8AE1569AAA07A63A050341E179514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_67E8AE1569AAA07A63A050341E179514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_67E8AE1569AAA07A63A050341E179514" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_67E8AE1569AAA07A63A050341E179514" xlink:type="arc" />
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_60CC89118407F8AB6A6F50341E17A1A1_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_60CC89118407F8AB6A6F50341E17A1A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_60CC89118407F8AB6A6F50341E17A1A1_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_60CC89118407F8AB6A6F50341E17A1A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_60CC89118407F8AB6A6F50341E17A1A1_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_60CC89118407F8AB6A6F50341E17A1A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_60CC89118407F8AB6A6F50341E17A1A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms_60CC89118407F8AB6A6F50341E17A1A1" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms_60CC89118407F8AB6A6F50341E17A1A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_2468BA285723AB38F42850341E174EA6_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_2468BA285723AB38F42850341E174EA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2468BA285723AB38F42850341E174EA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_2468BA285723AB38F42850341E174EA6" xlink:to="lab_us-gaap_InventoryNet_2468BA285723AB38F42850341E174EA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_DCEB253E6FD7185232D050341E173799_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_DCEB253E6FD7185232D050341E173799" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_DCEB253E6FD7185232D050341E173799_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_DCEB253E6FD7185232D050341E173799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_DCEB253E6FD7185232D050341E173799" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_DCEB253E6FD7185232D050341E173799" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_DCEB253E6FD7185232D050341E173799" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_F386BA784B73474C981650341E1788FE_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_F386BA784B73474C981650341E1788FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_F386BA784B73474C981650341E1788FE_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_F386BA784B73474C981650341E1788FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_F386BA784B73474C981650341E1788FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_F386BA784B73474C981650341E1788FE" xlink:to="lab_us-gaap_OtherAssetsCurrent_F386BA784B73474C981650341E1788FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_0C9F99766AF647BB38B550341E1774A8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_0C9F99766AF647BB38B550341E1774A8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_0C9F99766AF647BB38B550341E1774A8_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_0C9F99766AF647BB38B550341E1774A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0C9F99766AF647BB38B550341E1774A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_0C9F99766AF647BB38B550341E1774A8" xlink:to="lab_us-gaap_AssetsCurrent_0C9F99766AF647BB38B550341E1774A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FE0AE6DCDBFF9E6E4B3050341E180A47_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FE0AE6DCDBFF9E6E4B3050341E180A47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FE0AE6DCDBFF9E6E4B3050341E180A47_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FE0AE6DCDBFF9E6E4B3050341E180A47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FE0AE6DCDBFF9E6E4B3050341E180A47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FE0AE6DCDBFF9E6E4B3050341E180A47" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FE0AE6DCDBFF9E6E4B3050341E180A47" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8EAF6D348322CDA50C4B50341E181BD8_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_8EAF6D348322CDA50C4B50341E181BD8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8EAF6D348322CDA50C4B50341E181BD8_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_8EAF6D348322CDA50C4B50341E181BD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8EAF6D348322CDA50C4B50341E181BD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8EAF6D348322CDA50C4B50341E181BD8" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_8EAF6D348322CDA50C4B50341E181BD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_E1A3E7484956C35BA3F650341E18C8DB_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_E1A3E7484956C35BA3F650341E18C8DB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_E1A3E7484956C35BA3F650341E18C8DB_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_E1A3E7484956C35BA3F650341E18C8DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_E1A3E7484956C35BA3F650341E18C8DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_E1A3E7484956C35BA3F650341E18C8DB" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_E1A3E7484956C35BA3F650341E18C8DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_06072BF23720A01C9EF850341E180EB3_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_06072BF23720A01C9EF850341E180EB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_06072BF23720A01C9EF850341E180EB3_label_en-US" xlink:label="lab_us-gaap_Goodwill_06072BF23720A01C9EF850341E180EB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_06072BF23720A01C9EF850341E180EB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_06072BF23720A01C9EF850341E180EB3" xlink:to="lab_us-gaap_Goodwill_06072BF23720A01C9EF850341E180EB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_985AE365607445A9AD5D50341E1814E5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_985AE365607445A9AD5D50341E1814E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_985AE365607445A9AD5D50341E1814E5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_985AE365607445A9AD5D50341E1814E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_985AE365607445A9AD5D50341E1814E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_985AE365607445A9AD5D50341E1814E5" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_985AE365607445A9AD5D50341E1814E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_AB1156FCBD18BB2CB59A50341E19DEDB_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_AB1156FCBD18BB2CB59A50341E19DEDB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_AB1156FCBD18BB2CB59A50341E19DEDB_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_AB1156FCBD18BB2CB59A50341E19DEDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_AB1156FCBD18BB2CB59A50341E19DEDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_AB1156FCBD18BB2CB59A50341E19DEDB" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_AB1156FCBD18BB2CB59A50341E19DEDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_D7AB0F5C032324350C1E50341E196001_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_D7AB0F5C032324350C1E50341E196001" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_D7AB0F5C032324350C1E50341E196001_label_en-US" xlink:label="lab_us-gaap_Assets_D7AB0F5C032324350C1E50341E196001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D7AB0F5C032324350C1E50341E196001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_D7AB0F5C032324350C1E50341E196001" xlink:to="lab_us-gaap_Assets_D7AB0F5C032324350C1E50341E196001" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_04510D520C1B0E13E93650341E194FB4_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_04510D520C1B0E13E93650341E194FB4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_04510D520C1B0E13E93650341E194FB4_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_04510D520C1B0E13E93650341E194FB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_04510D520C1B0E13E93650341E194FB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_04510D520C1B0E13E93650341E194FB4" xlink:to="lab_us-gaap_TaxesPayableCurrent_04510D520C1B0E13E93650341E194FB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_CDDA9BB22F54AEB05E8E50341E1A038F_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_CDDA9BB22F54AEB05E8E50341E1A038F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_CDDA9BB22F54AEB05E8E50341E1A038F_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_CDDA9BB22F54AEB05E8E50341E1A038F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_CDDA9BB22F54AEB05E8E50341E1A038F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_CDDA9BB22F54AEB05E8E50341E1A038F" xlink:to="lab_us-gaap_AccountsPayableCurrent_CDDA9BB22F54AEB05E8E50341E1A038F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_F20851E2522FD1A91E0050341E1A7A3E_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_F20851E2522FD1A91E0050341E1A7A3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_F20851E2522FD1A91E0050341E1A7A3E_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_F20851E2522FD1A91E0050341E1A7A3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_F20851E2522FD1A91E0050341E1A7A3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_F20851E2522FD1A91E0050341E1A7A3E" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_F20851E2522FD1A91E0050341E1A7A3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_2E4F42205F7BFFBAC29150341E1A1F9E_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_2E4F42205F7BFFBAC29150341E1A1F9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_2E4F42205F7BFFBAC29150341E1A1F9E_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_2E4F42205F7BFFBAC29150341E1A1F9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2E4F42205F7BFFBAC29150341E1A1F9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_2E4F42205F7BFFBAC29150341E1A1F9E" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_2E4F42205F7BFFBAC29150341E1A1F9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_E8624D6F93A9870C75F650341E1A34D4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_E8624D6F93A9870C75F650341E1A34D4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_E8624D6F93A9870C75F650341E1A34D4_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_E8624D6F93A9870C75F650341E1A34D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_E8624D6F93A9870C75F650341E1A34D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_E8624D6F93A9870C75F650341E1A34D4" xlink:to="lab_us-gaap_LiabilitiesCurrent_E8624D6F93A9870C75F650341E1A34D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_A4DA15C989C3B4F74FF450341E1ADDFF_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_A4DA15C989C3B4F74FF450341E1ADDFF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_A4DA15C989C3B4F74FF450341E1ADDFF_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_A4DA15C989C3B4F74FF450341E1ADDFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_A4DA15C989C3B4F74FF450341E1ADDFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_A4DA15C989C3B4F74FF450341E1ADDFF" xlink:to="lab_us-gaap_LongTermDebt_A4DA15C989C3B4F74FF450341E1ADDFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_169A262647DBBB8FAF2750341E1AE0BD_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_169A262647DBBB8FAF2750341E1AE0BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_169A262647DBBB8FAF2750341E1AE0BD_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_169A262647DBBB8FAF2750341E1AE0BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_169A262647DBBB8FAF2750341E1AE0BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_169A262647DBBB8FAF2750341E1AE0BD" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_169A262647DBBB8FAF2750341E1AE0BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_CCD02E1E41AE2FABD34450341E1BF1F5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_CCD02E1E41AE2FABD34450341E1BF1F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_CCD02E1E41AE2FABD34450341E1BF1F5_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_CCD02E1E41AE2FABD34450341E1BF1F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_CCD02E1E41AE2FABD34450341E1BF1F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_CCD02E1E41AE2FABD34450341E1BF1F5" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_CCD02E1E41AE2FABD34450341E1BF1F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_871B583AAD93CC5B52E550341E1B50DA_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_871B583AAD93CC5B52E550341E1B50DA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_871B583AAD93CC5B52E550341E1B50DA_label_en-US" xlink:label="lab_us-gaap_Liabilities_871B583AAD93CC5B52E550341E1B50DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_871B583AAD93CC5B52E550341E1B50DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_871B583AAD93CC5B52E550341E1B50DA" xlink:to="lab_us-gaap_Liabilities_871B583AAD93CC5B52E550341E1B50DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_C07E22F6C92AB6D4577350341E1B82DD_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_C07E22F6C92AB6D4577350341E1B82DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_C07E22F6C92AB6D4577350341E1B82DD_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_C07E22F6C92AB6D4577350341E1B82DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_C07E22F6C92AB6D4577350341E1B82DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_C07E22F6C92AB6D4577350341E1B82DD" xlink:to="lab_us-gaap_CommitmentsAndContingencies_C07E22F6C92AB6D4577350341E1B82DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9531ABCB8FA033E8CC3350341E1B04DA_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9531ABCB8FA033E8CC3350341E1B04DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9531ABCB8FA033E8CC3350341E1B04DA_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9531ABCB8FA033E8CC3350341E1B04DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9531ABCB8FA033E8CC3350341E1B04DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9531ABCB8FA033E8CC3350341E1B04DA" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9531ABCB8FA033E8CC3350341E1B04DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:to="lab_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_C511BA7C1DFD94677B3950341E1C84C1_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_C511BA7C1DFD94677B3950341E1C84C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_C511BA7C1DFD94677B3950341E1C84C1_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_C511BA7C1DFD94677B3950341E1C84C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_C511BA7C1DFD94677B3950341E1C84C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_C511BA7C1DFD94677B3950341E1C84C1" xlink:to="lab_us-gaap_PreferredStockValue_C511BA7C1DFD94677B3950341E1C84C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_EF1D2F5BA031BFD3E3D850341E1C6C46_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_EF1D2F5BA031BFD3E3D850341E1C6C46" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_EF1D2F5BA031BFD3E3D850341E1C6C46_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_EF1D2F5BA031BFD3E3D850341E1C6C46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_EF1D2F5BA031BFD3E3D850341E1C6C46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_EF1D2F5BA031BFD3E3D850341E1C6C46" xlink:to="lab_us-gaap_CommonStockValue_EF1D2F5BA031BFD3E3D850341E1C6C46" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_F60BF6C45C8EAD23B7CE50341E1C2BC4_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_F60BF6C45C8EAD23B7CE50341E1C2BC4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_F60BF6C45C8EAD23B7CE50341E1C2BC4_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_F60BF6C45C8EAD23B7CE50341E1C2BC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_F60BF6C45C8EAD23B7CE50341E1C2BC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_F60BF6C45C8EAD23B7CE50341E1C2BC4" xlink:to="lab_us-gaap_AdditionalPaidInCapital_F60BF6C45C8EAD23B7CE50341E1C2BC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4E52D1BE66D27B078C1850341E1DA0A4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4E52D1BE66D27B078C1850341E1DA0A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4E52D1BE66D27B078C1850341E1DA0A4_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4E52D1BE66D27B078C1850341E1DA0A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4E52D1BE66D27B078C1850341E1DA0A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4E52D1BE66D27B078C1850341E1DA0A4" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4E52D1BE66D27B078C1850341E1DA0A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A66F5C0181FA24962C4850341E1D982D_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A66F5C0181FA24962C4850341E1D982D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A66F5C0181FA24962C4850341E1D982D_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A66F5C0181FA24962C4850341E1D982D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_A66F5C0181FA24962C4850341E1D982D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_A66F5C0181FA24962C4850341E1D982D" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A66F5C0181FA24962C4850341E1D982D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_1401AAAAF25BF933B8E950341E1D0333_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_1401AAAAF25BF933B8E950341E1D0333" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_1401AAAAF25BF933B8E950341E1D0333_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_1401AAAAF25BF933B8E950341E1D0333" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_1401AAAAF25BF933B8E950341E1D0333" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_1401AAAAF25BF933B8E950341E1D0333" xlink:to="lab_us-gaap_TreasuryStockValue_1401AAAAF25BF933B8E950341E1D0333" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_51CE42B20E629F0CF63250341E1D4D77_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_51CE42B20E629F0CF63250341E1D4D77" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_51CE42B20E629F0CF63250341E1D4D77_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_51CE42B20E629F0CF63250341E1D4D77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_51CE42B20E629F0CF63250341E1D4D77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_51CE42B20E629F0CF63250341E1D4D77" xlink:to="lab_us-gaap_StockholdersEquity_51CE42B20E629F0CF63250341E1D4D77" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_DC09532B8316910E0C3750341E1D939B_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_DC09532B8316910E0C3750341E1D939B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_DC09532B8316910E0C3750341E1D939B_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_DC09532B8316910E0C3750341E1D939B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_DC09532B8316910E0C3750341E1D939B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_DC09532B8316910E0C3750341E1D939B" xlink:to="lab_us-gaap_MinorityInterest_DC09532B8316910E0C3750341E1D939B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FE5272672A0C41869F2B50341E1DF3D9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FE5272672A0C41869F2B50341E1DF3D9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FE5272672A0C41869F2B50341E1DF3D9_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FE5272672A0C41869F2B50341E1DF3D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FE5272672A0C41869F2B50341E1DF3D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FE5272672A0C41869F2B50341E1DF3D9" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FE5272672A0C41869F2B50341E1DF3D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3C2BB250A71B6BD6219C50341E1E1ED0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_3C2BB250A71B6BD6219C50341E1E1ED0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3C2BB250A71B6BD6219C50341E1E1ED0_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_3C2BB250A71B6BD6219C50341E1E1ED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3C2BB250A71B6BD6219C50341E1E1ED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3C2BB250A71B6BD6219C50341E1E1ED0" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_3C2BB250A71B6BD6219C50341E1E1ED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB" xlink:to="lab_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8" xlink:to="lab_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_B126FCC4CC41A5E0FF6750341D943DF4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_B126FCC4CC41A5E0FF6750341D943DF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_B126FCC4CC41A5E0FF6750341D943DF4_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_B126FCC4CC41A5E0FF6750341D943DF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_B126FCC4CC41A5E0FF6750341D943DF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_B126FCC4CC41A5E0FF6750341D943DF4" xlink:to="lab_us-gaap_ProductAndServiceOtherMember_B126FCC4CC41A5E0FF6750341D943DF4" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7" xlink:to="lab_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:to="lab_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB_label_en-US" xlink:label="lab_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB_documentation_en-US" xlink:label="lab_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB" xlink:to="lab_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F_label_en-US" xlink:label="lab_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F" xlink:to="lab_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F" xlink:type="arc" />
    <link:label id="lab_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1_terseLabel_en-US" xlink:label="lab_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1_label_en-US" xlink:label="lab_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:label id="lab_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1_documentation_en-US" xlink:label="lab_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1" xlink:to="lab_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_C47D536FE5827B45124A50341D957214_netLabel_en-US" xlink:label="lab_us-gaap_Revenues_C47D536FE5827B45124A50341D957214" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_C47D536FE5827B45124A50341D957214_label_en-US" xlink:label="lab_us-gaap_Revenues_C47D536FE5827B45124A50341D957214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C47D536FE5827B45124A50341D957214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_C47D536FE5827B45124A50341D957214" xlink:to="lab_us-gaap_Revenues_C47D536FE5827B45124A50341D957214" xlink:type="arc" />
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7533365DDC9D8731046250341C7B2DDE_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_7533365DDC9D8731046250341C7B2DDE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7533365DDC9D8731046250341C7B2DDE_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_7533365DDC9D8731046250341C7B2DDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7533365DDC9D8731046250341C7B2DDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_7533365DDC9D8731046250341C7B2DDE" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_7533365DDC9D8731046250341C7B2DDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_320F3197F7F3D4B0093A50341DBE1DED_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_320F3197F7F3D4B0093A50341DBE1DED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_320F3197F7F3D4B0093A50341DBE1DED_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_320F3197F7F3D4B0093A50341DBE1DED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_320F3197F7F3D4B0093A50341DBE1DED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_320F3197F7F3D4B0093A50341DBE1DED" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_320F3197F7F3D4B0093A50341DBE1DED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_70D8D10389941E21893450341D6DB3E3_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_70D8D10389941E21893450341D6DB3E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_70D8D10389941E21893450341D6DB3E3_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_70D8D10389941E21893450341D6DB3E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_70D8D10389941E21893450341D6DB3E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_70D8D10389941E21893450341D6DB3E3" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_70D8D10389941E21893450341D6DB3E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_901DFA416EF73BB75D0F50341D6EE600_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_901DFA416EF73BB75D0F50341D6EE600" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_901DFA416EF73BB75D0F50341D6EE600_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_901DFA416EF73BB75D0F50341D6EE600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_901DFA416EF73BB75D0F50341D6EE600" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_901DFA416EF73BB75D0F50341D6EE600" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_901DFA416EF73BB75D0F50341D6EE600" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9" xlink:to="lab_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_A607027B00A08157D3E650341D6F4F7D_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_A607027B00A08157D3E650341D6F4F7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_A607027B00A08157D3E650341D6F4F7D_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_A607027B00A08157D3E650341D6F4F7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_A607027B00A08157D3E650341D6F4F7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_A607027B00A08157D3E650341D6F4F7D" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_A607027B00A08157D3E650341D6F4F7D" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F" xlink:to="lab_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767_label_en-US" xlink:label="lab_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767_documentation_en-US" xlink:label="lab_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767" xlink:to="lab_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B_label_en-US" xlink:label="lab_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B" xlink:to="lab_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF_label_en-US" xlink:label="lab_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF_documentation_en-US" xlink:label="lab_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF" xlink:to="lab_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_22E0C219A37DFA7312F950341D7026BF_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember_22E0C219A37DFA7312F950341D7026BF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_22E0C219A37DFA7312F950341D7026BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_22E0C219A37DFA7312F950341D7026BF" xlink:to="lab_srt_MinimumMember_22E0C219A37DFA7312F950341D7026BF" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_480D9D4225DF191B262950341D71A9EB_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember_480D9D4225DF191B262950341D71A9EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_480D9D4225DF191B262950341D71A9EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_480D9D4225DF191B262950341D71A9EB" xlink:to="lab_srt_MaximumMember_480D9D4225DF191B262950341D71A9EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E9947141E18D1B3C35E450341D71501E_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E9947141E18D1B3C35E450341D71501E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E9947141E18D1B3C35E450341D71501E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E9947141E18D1B3C35E450341D71501E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E9947141E18D1B3C35E450341D71501E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E9947141E18D1B3C35E450341D71501E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E9947141E18D1B3C35E450341D71501E" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4A62DA896A475518A46050341D7208F6_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4A62DA896A475518A46050341D7208F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4A62DA896A475518A46050341D7208F6_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4A62DA896A475518A46050341D7208F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4A62DA896A475518A46050341D7208F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4A62DA896A475518A46050341D7208F6" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4A62DA896A475518A46050341D7208F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7CCA33BB2602BC5A446050341D7291E0_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7CCA33BB2602BC5A446050341D7291E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7CCA33BB2602BC5A446050341D7291E0_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7CCA33BB2602BC5A446050341D7291E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7CCA33BB2602BC5A446050341D7291E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7CCA33BB2602BC5A446050341D7291E0" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7CCA33BB2602BC5A446050341D7291E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_56B959373432C49023E250341D72E061_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_56B959373432C49023E250341D72E061" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_56B959373432C49023E250341D72E061_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_56B959373432C49023E250341D72E061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_56B959373432C49023E250341D72E061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_56B959373432C49023E250341D72E061" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_56B959373432C49023E250341D72E061" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2CF890C29238B75AFAB850341D724ED7_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2CF890C29238B75AFAB850341D724ED7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2CF890C29238B75AFAB850341D724ED7_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2CF890C29238B75AFAB850341D724ED7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2CF890C29238B75AFAB850341D724ED7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2CF890C29238B75AFAB850341D724ED7" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2CF890C29238B75AFAB850341D724ED7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E49E83160EB71F20A70250341D72F892_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E49E83160EB71F20A70250341D72F892" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E49E83160EB71F20A70250341D72F892_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E49E83160EB71F20A70250341D72F892" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E49E83160EB71F20A70250341D72F892" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E49E83160EB71F20A70250341D72F892" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E49E83160EB71F20A70250341D72F892" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_F66AE7CB60E1584F699D50341D738A6A_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_F66AE7CB60E1584F699D50341D738A6A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F66AE7CB60E1584F699D50341D738A6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F66AE7CB60E1584F699D50341D738A6A" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_F66AE7CB60E1584F699D50341D738A6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_D81870406F0B518E876A50341D7384D3_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_D81870406F0B518E876A50341D7384D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_D81870406F0B518E876A50341D7384D3_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_D81870406F0B518E876A50341D7384D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D81870406F0B518E876A50341D7384D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_D81870406F0B518E876A50341D7384D3" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_D81870406F0B518E876A50341D7384D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_B0494225ACBCF3050B4950341D739B2F_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_B0494225ACBCF3050B4950341D739B2F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Textual) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_B0494225ACBCF3050B4950341D739B2F_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_B0494225ACBCF3050B4950341D739B2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_B0494225ACBCF3050B4950341D739B2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_B0494225ACBCF3050B4950341D739B2F" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_B0494225ACBCF3050B4950341D739B2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_228AD7A2F5AB803F97AD50341D731C36_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_228AD7A2F5AB803F97AD50341D731C36" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_228AD7A2F5AB803F97AD50341D731C36_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_228AD7A2F5AB803F97AD50341D731C36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_228AD7A2F5AB803F97AD50341D731C36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_228AD7A2F5AB803F97AD50341D731C36" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_228AD7A2F5AB803F97AD50341D731C36" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7DEC9793BD678B13D00750341D7373D8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7DEC9793BD678B13D00750341D7373D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7DEC9793BD678B13D00750341D7373D8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7DEC9793BD678B13D00750341D7373D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7DEC9793BD678B13D00750341D7373D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7DEC9793BD678B13D00750341D7373D8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7DEC9793BD678B13D00750341D7373D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C309EA02CE72E8A8115C50341D732AC4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C309EA02CE72E8A8115C50341D732AC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C309EA02CE72E8A8115C50341D732AC4_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C309EA02CE72E8A8115C50341D732AC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C309EA02CE72E8A8115C50341D732AC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C309EA02CE72E8A8115C50341D732AC4" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C309EA02CE72E8A8115C50341D732AC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_976C54ADA35B1293BF4F50341D74E272_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_976C54ADA35B1293BF4F50341D74E272" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_976C54ADA35B1293BF4F50341D74E272_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_976C54ADA35B1293BF4F50341D74E272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_976C54ADA35B1293BF4F50341D74E272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_976C54ADA35B1293BF4F50341D74E272" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_976C54ADA35B1293BF4F50341D74E272" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_45E837B19137EB46FC5750341D747546_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_45E837B19137EB46FC5750341D747546" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_45E837B19137EB46FC5750341D747546_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_45E837B19137EB46FC5750341D747546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_45E837B19137EB46FC5750341D747546" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_45E837B19137EB46FC5750341D747546" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_45E837B19137EB46FC5750341D747546" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_FB936E4F9A9F3AE548D450341D741CF9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_FB936E4F9A9F3AE548D450341D741CF9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_FB936E4F9A9F3AE548D450341D741CF9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_FB936E4F9A9F3AE548D450341D741CF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_FB936E4F9A9F3AE548D450341D741CF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_FB936E4F9A9F3AE548D450341D741CF9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_FB936E4F9A9F3AE548D450341D741CF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_54FEEF5C65B0D4E2443F50341D74B92B_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_54FEEF5C65B0D4E2443F50341D74B92B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_54FEEF5C65B0D4E2443F50341D74B92B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_54FEEF5C65B0D4E2443F50341D74B92B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_54FEEF5C65B0D4E2443F50341D74B92B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_54FEEF5C65B0D4E2443F50341D74B92B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_54FEEF5C65B0D4E2443F50341D74B92B" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_BF2CB5C1F9DEF1E2495050341CF3F972_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_BF2CB5C1F9DEF1E2495050341CF3F972" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_BF2CB5C1F9DEF1E2495050341CF3F972_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_BF2CB5C1F9DEF1E2495050341CF3F972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_BF2CB5C1F9DEF1E2495050341CF3F972_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_BF2CB5C1F9DEF1E2495050341CF3F972" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_BF2CB5C1F9DEF1E2495050341CF3F972" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_BF2CB5C1F9DEF1E2495050341CF3F972" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_BF2CB5C1F9DEF1E2495050341CF3F972" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6" xlink:to="lab_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_EC10271382C48A2E872150341D346804_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_EC10271382C48A2E872150341D346804" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_EC10271382C48A2E872150341D346804_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_EC10271382C48A2E872150341D346804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_EC10271382C48A2E872150341D346804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_EC10271382C48A2E872150341D346804" xlink:to="lab_us-gaap_CommercialPaperMember_EC10271382C48A2E872150341D346804" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_97A501FCD30580B8493650341D343491_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_97A501FCD30580B8493650341D343491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_97A501FCD30580B8493650341D343491_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_97A501FCD30580B8493650341D343491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_97A501FCD30580B8493650341D343491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_97A501FCD30580B8493650341D343491" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_97A501FCD30580B8493650341D343491" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_1E6C947DA6C2B58DCDDE50341D34B4A5_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_1E6C947DA6C2B58DCDDE50341D34B4A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_1E6C947DA6C2B58DCDDE50341D34B4A5_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_1E6C947DA6C2B58DCDDE50341D34B4A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1E6C947DA6C2B58DCDDE50341D34B4A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_1E6C947DA6C2B58DCDDE50341D34B4A5" xlink:to="lab_us-gaap_MoneyMarketFundsMember_1E6C947DA6C2B58DCDDE50341D34B4A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_2FE385869DFC836B6E0150341D34C3D9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_2FE385869DFC836B6E0150341D34C3D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_2FE385869DFC836B6E0150341D34C3D9_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_2FE385869DFC836B6E0150341D34C3D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_2FE385869DFC836B6E0150341D34C3D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_2FE385869DFC836B6E0150341D34C3D9" xlink:to="lab_us-gaap_DebtSecuritiesMember_2FE385869DFC836B6E0150341D34C3D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_158954D2724EB5F8ADB250341D3585B1_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_158954D2724EB5F8ADB250341D3585B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_158954D2724EB5F8ADB250341D3585B1_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_158954D2724EB5F8ADB250341D3585B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_158954D2724EB5F8ADB250341D3585B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_158954D2724EB5F8ADB250341D3585B1" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_158954D2724EB5F8ADB250341D3585B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_DC428B08EFA5DBA7C54650341BC492F8_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_DC428B08EFA5DBA7C54650341BC492F8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_DC428B08EFA5DBA7C54650341BC492F8_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_DC428B08EFA5DBA7C54650341BC492F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_DC428B08EFA5DBA7C54650341BC492F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_DC428B08EFA5DBA7C54650341BC492F8" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_DC428B08EFA5DBA7C54650341BC492F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2930664614C1CDDE9DB750341C3955D0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_2930664614C1CDDE9DB750341C3955D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2930664614C1CDDE9DB750341C3955D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2930664614C1CDDE9DB750341C3955D0" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_2930664614C1CDDE9DB750341C3955D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_19B5F12D7471A23B690550341C396266_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_19B5F12D7471A23B690550341C396266" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_19B5F12D7471A23B690550341C396266_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_19B5F12D7471A23B690550341C396266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_19B5F12D7471A23B690550341C396266" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_19B5F12D7471A23B690550341C396266" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_19B5F12D7471A23B690550341C396266" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D" xlink:to="lab_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_6FDA16312FDE92AA92A950341C89B4DA_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_6FDA16312FDE92AA92A950341C89B4DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_6FDA16312FDE92AA92A950341C89B4DA_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_6FDA16312FDE92AA92A950341C89B4DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_6FDA16312FDE92AA92A950341C89B4DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member_6FDA16312FDE92AA92A950341C89B4DA" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member_6FDA16312FDE92AA92A950341C89B4DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:to="lab_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F614CF3ABDBF161BFE1D50341C8A67B5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F614CF3ABDBF161BFE1D50341C8A67B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F614CF3ABDBF161BFE1D50341C8A67B5_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F614CF3ABDBF161BFE1D50341C8A67B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F614CF3ABDBF161BFE1D50341C8A67B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F614CF3ABDBF161BFE1D50341C8A67B5" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F614CF3ABDBF161BFE1D50341C8A67B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D464FEA35A9F13F1B34950341C8A7EAD_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D464FEA35A9F13F1B34950341C8A7EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D464FEA35A9F13F1B34950341C8A7EAD_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D464FEA35A9F13F1B34950341C8A7EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D464FEA35A9F13F1B34950341C8A7EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D464FEA35A9F13F1B34950341C8A7EAD" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D464FEA35A9F13F1B34950341C8A7EAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_A97CCFA47B7FF1D181F250341C8A8B9A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_A97CCFA47B7FF1D181F250341C8A8B9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_A97CCFA47B7FF1D181F250341C8A8B9A_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_A97CCFA47B7FF1D181F250341C8A8B9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_A97CCFA47B7FF1D181F250341C8A8B9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_A97CCFA47B7FF1D181F250341C8A8B9A" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_A97CCFA47B7FF1D181F250341C8A8B9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8B999E285F96CEBA8F6550341C8B7A88_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8B999E285F96CEBA8F6550341C8B7A88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8B999E285F96CEBA8F6550341C8B7A88_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8B999E285F96CEBA8F6550341C8B7A88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8B999E285F96CEBA8F6550341C8B7A88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8B999E285F96CEBA8F6550341C8B7A88" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8B999E285F96CEBA8F6550341C8B7A88" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_D6117A08D7057E31494F50341C8B35C1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_D6117A08D7057E31494F50341C8B35C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_D6117A08D7057E31494F50341C8B35C1_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_D6117A08D7057E31494F50341C8B35C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_D6117A08D7057E31494F50341C8B35C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_D6117A08D7057E31494F50341C8B35C1" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_D6117A08D7057E31494F50341C8B35C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_567791BCDB2465E13B0B50341C8B6E11_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_567791BCDB2465E13B0B50341C8B6E11" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_567791BCDB2465E13B0B50341C8B6E11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_567791BCDB2465E13B0B50341C8B6E11" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_567791BCDB2465E13B0B50341C8B6E11" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F7D723B83D422C5D9AD650341C8B819A_verboseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F7D723B83D422C5D9AD650341C8B819A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect of new accounting principle in period of adoption</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F7D723B83D422C5D9AD650341C8B819A_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F7D723B83D422C5D9AD650341C8B819A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F7D723B83D422C5D9AD650341C8B819A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F7D723B83D422C5D9AD650341C8B819A" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F7D723B83D422C5D9AD650341C8B819A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1CA3A6C4AB0D3FC0C1C50341C8BED6C_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1CA3A6C4AB0D3FC0C1C50341C8BED6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1CA3A6C4AB0D3FC0C1C50341C8BED6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1CA3A6C4AB0D3FC0C1C50341C8BED6C" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1CA3A6C4AB0D3FC0C1C50341C8BED6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DB9E2836E4AF7ED1D41950341C8CE93F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DB9E2836E4AF7ED1D41950341C8CE93F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DB9E2836E4AF7ED1D41950341C8CE93F_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DB9E2836E4AF7ED1D41950341C8CE93F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DB9E2836E4AF7ED1D41950341C8CE93F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DB9E2836E4AF7ED1D41950341C8CE93F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DB9E2836E4AF7ED1D41950341C8CE93F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_68C59A828B18CA2BC2BE50341C8C1978_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_68C59A828B18CA2BC2BE50341C8C1978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_68C59A828B18CA2BC2BE50341C8C1978_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_68C59A828B18CA2BC2BE50341C8C1978" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_68C59A828B18CA2BC2BE50341C8C1978" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_68C59A828B18CA2BC2BE50341C8C1978" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_68C59A828B18CA2BC2BE50341C8C1978" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3FD1E6D36764929B7C3450341C8C7FCF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3FD1E6D36764929B7C3450341C8C7FCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3FD1E6D36764929B7C3450341C8C7FCF_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3FD1E6D36764929B7C3450341C8C7FCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3FD1E6D36764929B7C3450341C8C7FCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3FD1E6D36764929B7C3450341C8C7FCF" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3FD1E6D36764929B7C3450341C8C7FCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE62CF9B57EF800CD11850341C8CD2EE_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE62CF9B57EF800CD11850341C8CD2EE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE62CF9B57EF800CD11850341C8CD2EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE62CF9B57EF800CD11850341C8CD2EE" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE62CF9B57EF800CD11850341C8CD2EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0C8AD967CDDEC731E66C50341C8C20F6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0C8AD967CDDEC731E66C50341C8C20F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0C8AD967CDDEC731E66C50341C8C20F6_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0C8AD967CDDEC731E66C50341C8C20F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0C8AD967CDDEC731E66C50341C8C20F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0C8AD967CDDEC731E66C50341C8C20F6" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0C8AD967CDDEC731E66C50341C8C20F6" xlink:type="arc" />
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_60C57E6C36361F643C1750341C803F46_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_60C57E6C36361F643C1750341C803F46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_60C57E6C36361F643C1750341C803F46_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_60C57E6C36361F643C1750341C803F46" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_60C57E6C36361F643C1750341C803F46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_60C57E6C36361F643C1750341C803F46" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_60C57E6C36361F643C1750341C803F46" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F043CE7482427013079350341C82F239_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F043CE7482427013079350341C82F239" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F043CE7482427013079350341C82F239_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F043CE7482427013079350341C82F239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F043CE7482427013079350341C82F239" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F043CE7482427013079350341C82F239" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F043CE7482427013079350341C82F239" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_560C0F76F1C966D77CE950341C829B69_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_560C0F76F1C966D77CE950341C829B69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_560C0F76F1C966D77CE950341C829B69_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_560C0F76F1C966D77CE950341C829B69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_560C0F76F1C966D77CE950341C829B69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_560C0F76F1C966D77CE950341C829B69" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_560C0F76F1C966D77CE950341C829B69" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0BEB533ABC7423388D5750341C83DC64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0BEB533ABC7423388D5750341C83DC64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0BEB533ABC7423388D5750341C83DC64_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0BEB533ABC7423388D5750341C83DC64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0BEB533ABC7423388D5750341C83DC64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0BEB533ABC7423388D5750341C83DC64" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0BEB533ABC7423388D5750341C83DC64" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_BB1EC58272F270E1BF5650341C831D34_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_BB1EC58272F270E1BF5650341C831D34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BB1EC58272F270E1BF5650341C831D34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_BB1EC58272F270E1BF5650341C831D34" xlink:to="lab_us-gaap_Revenues_BB1EC58272F270E1BF5650341C831D34" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_D96354BACAEB9AE0D28A50341C83C53C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_D96354BACAEB9AE0D28A50341C83C53C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_D96354BACAEB9AE0D28A50341C83C53C_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_D96354BACAEB9AE0D28A50341C83C53C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D96354BACAEB9AE0D28A50341C83C53C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_D96354BACAEB9AE0D28A50341C83C53C" xlink:to="lab_us-gaap_OperatingExpenses_D96354BACAEB9AE0D28A50341C83C53C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_DB32B9FC046CCBBA096750341DCFA75B_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_DB32B9FC046CCBBA096750341DCFA75B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_DB32B9FC046CCBBA096750341DCFA75B_label_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_DB32B9FC046CCBBA096750341DCFA75B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Long Lived Assets Held-for-sale [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_DB32B9FC046CCBBA096750341DCFA75B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_DB32B9FC046CCBBA096750341DCFA75B" xlink:to="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_DB32B9FC046CCBBA096750341DCFA75B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_3FC585AF44E0E68BA1AC50341DD83F93_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_3FC585AF44E0E68BA1AC50341DD83F93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3FC585AF44E0E68BA1AC50341DD83F93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3FC585AF44E0E68BA1AC50341DD83F93" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_3FC585AF44E0E68BA1AC50341DD83F93" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_785C4F73C9BD8E74C95450341DD81955_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_785C4F73C9BD8E74C95450341DD81955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_785C4F73C9BD8E74C95450341DD81955_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_785C4F73C9BD8E74C95450341DD81955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_785C4F73C9BD8E74C95450341DD81955" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_785C4F73C9BD8E74C95450341DD81955" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_785C4F73C9BD8E74C95450341DD81955" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_FFC8AE394AD79EAB53CA50341DA7E365_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_FFC8AE394AD79EAB53CA50341DA7E365" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_FFC8AE394AD79EAB53CA50341DA7E365_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_FFC8AE394AD79EAB53CA50341DA7E365" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_FFC8AE394AD79EAB53CA50341DA7E365" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_FFC8AE394AD79EAB53CA50341DA7E365" xlink:to="lab_us-gaap_AccountsReceivableMember_FFC8AE394AD79EAB53CA50341DA7E365" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_DC9FACDC8AC42B2B6CE350341DA8F5D8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_DC9FACDC8AC42B2B6CE350341DA8F5D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_DC9FACDC8AC42B2B6CE350341DA8F5D8_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_DC9FACDC8AC42B2B6CE350341DA8F5D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_DC9FACDC8AC42B2B6CE350341DA8F5D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_DC9FACDC8AC42B2B6CE350341DA8F5D8" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_DC9FACDC8AC42B2B6CE350341DA8F5D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_A1944DF82ACD270E270450341DA865FC_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_A1944DF82ACD270E270450341DA865FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_A1944DF82ACD270E270450341DA865FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_A1944DF82ACD270E270450341DA865FC" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_A1944DF82ACD270E270450341DA865FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2FE80794F70C7343FB1A50341C0C2010_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2FE80794F70C7343FB1A50341C0C2010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2FE80794F70C7343FB1A50341C0C2010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2FE80794F70C7343FB1A50341C0C2010" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2FE80794F70C7343FB1A50341C0C2010" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_A189441A3DD48BCFA71150341C0E73DD_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_A189441A3DD48BCFA71150341C0E73DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_A189441A3DD48BCFA71150341C0E73DD_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_A189441A3DD48BCFA71150341C0E73DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_A189441A3DD48BCFA71150341C0E73DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_A189441A3DD48BCFA71150341C0E73DD" xlink:to="lab_us-gaap_InvestmentIncomeInterest_A189441A3DD48BCFA71150341C0E73DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_F158006AF3B9EF917E3E50341C10636A_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_F158006AF3B9EF917E3E50341C10636A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_F158006AF3B9EF917E3E50341C10636A_label_en-US" xlink:label="lab_us-gaap_InterestExpense_F158006AF3B9EF917E3E50341C10636A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_F158006AF3B9EF917E3E50341C10636A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_F158006AF3B9EF917E3E50341C10636A" xlink:to="lab_us-gaap_InterestExpense_F158006AF3B9EF917E3E50341C10636A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_29DBCA19467E700927BF50341C10D2BE_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_29DBCA19467E700927BF50341C10D2BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_29DBCA19467E700927BF50341C10D2BE_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_29DBCA19467E700927BF50341C10D2BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_29DBCA19467E700927BF50341C10D2BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses_29DBCA19467E700927BF50341C10D2BE" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses_29DBCA19467E700927BF50341C10D2BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F39587F620662C3E5FE750341C10AB0F_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F39587F620662C3E5FE750341C10AB0F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F39587F620662C3E5FE750341C10AB0F_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F39587F620662C3E5FE750341C10AB0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F39587F620662C3E5FE750341C10AB0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F39587F620662C3E5FE750341C10AB0F" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F39587F620662C3E5FE750341C10AB0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_51A91BE906E765A4745950341C109E3F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_51A91BE906E765A4745950341C109E3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_51A91BE906E765A4745950341C109E3F_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_51A91BE906E765A4745950341C109E3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_51A91BE906E765A4745950341C109E3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_51A91BE906E765A4745950341C109E3F" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_51A91BE906E765A4745950341C109E3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_F47A751D993719D8F79850341C11B15C_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_F47A751D993719D8F79850341C11B15C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_F47A751D993719D8F79850341C11B15C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_F47A751D993719D8F79850341C11B15C" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_F47A751D993719D8F79850341C11B15C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_B6F625CAEE58B1F386CF50341C1173E7_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_B6F625CAEE58B1F386CF50341C1173E7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_B6F625CAEE58B1F386CF50341C1173E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_B6F625CAEE58B1F386CF50341C1173E7" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_B6F625CAEE58B1F386CF50341C1173E7" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationexpensesaccrual_6CB9BB7D3D56BA951ED950341C117D82_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_6CB9BB7D3D56BA951ED950341C117D82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_6CB9BB7D3D56BA951ED950341C117D82_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_6CB9BB7D3D56BA951ED950341C117D82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_6CB9BB7D3D56BA951ED950341C117D82_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_6CB9BB7D3D56BA951ED950341C117D82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_6CB9BB7D3D56BA951ED950341C117D82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual_6CB9BB7D3D56BA951ED950341C117D82" xlink:to="lab_biib_Collaborationexpensesaccrual_6CB9BB7D3D56BA951ED950341C117D82" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_75ACB5CCD5DACC8529C750341C117229_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_75ACB5CCD5DACC8529C750341C117229" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_75ACB5CCD5DACC8529C750341C117229_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_75ACB5CCD5DACC8529C750341C117229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_75ACB5CCD5DACC8529C750341C117229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_75ACB5CCD5DACC8529C750341C117229" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_75ACB5CCD5DACC8529C750341C117229" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3A4B1C1ED52F3325100150341C118582_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3A4B1C1ED52F3325100150341C118582" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3A4B1C1ED52F3325100150341C118582_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3A4B1C1ED52F3325100150341C118582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3A4B1C1ED52F3325100150341C118582" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3A4B1C1ED52F3325100150341C118582" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3A4B1C1ED52F3325100150341C118582" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_84967CC53325E367BD9A50341C12DF66_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_84967CC53325E367BD9A50341C12DF66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_84967CC53325E367BD9A50341C12DF66_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_84967CC53325E367BD9A50341C12DF66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_84967CC53325E367BD9A50341C12DF66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_84967CC53325E367BD9A50341C12DF66" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_84967CC53325E367BD9A50341C12DF66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_2B54086FF191E4D1831B50341C121BE1_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_2B54086FF191E4D1831B50341C121BE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_2B54086FF191E4D1831B50341C121BE1_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_2B54086FF191E4D1831B50341C121BE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_2B54086FF191E4D1831B50341C121BE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_2B54086FF191E4D1831B50341C121BE1" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_2B54086FF191E4D1831B50341C121BE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D7F96A07FCB2D4C698E050341C12F58F_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D7F96A07FCB2D4C698E050341C12F58F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D7F96A07FCB2D4C698E050341C12F58F_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D7F96A07FCB2D4C698E050341C12F58F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_D7F96A07FCB2D4C698E050341C12F58F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_D7F96A07FCB2D4C698E050341C12F58F" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D7F96A07FCB2D4C698E050341C12F58F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3F6A67AFA9E2EBA16AF150341C1217E8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_3F6A67AFA9E2EBA16AF150341C1217E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3F6A67AFA9E2EBA16AF150341C1217E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_3F6A67AFA9E2EBA16AF150341C1217E8" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_3F6A67AFA9E2EBA16AF150341C1217E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_C7BC491984034B9E46A950341D4543C4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_C7BC491984034B9E46A950341D4543C4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_C7BC491984034B9E46A950341D4543C4_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_C7BC491984034B9E46A950341D4543C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_C7BC491984034B9E46A950341D4543C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_C7BC491984034B9E46A950341D4543C4" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_C7BC491984034B9E46A950341D4543C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2C88029FB015B3C83C2650341D4530F8_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2C88029FB015B3C83C2650341D4530F8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2C88029FB015B3C83C2650341D4530F8_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2C88029FB015B3C83C2650341D4530F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2C88029FB015B3C83C2650341D4530F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2C88029FB015B3C83C2650341D4530F8" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2C88029FB015B3C83C2650341D4530F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5667EAB5C3DB7F6F34250341D4561BB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5667EAB5C3DB7F6F34250341D4561BB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5667EAB5C3DB7F6F34250341D4561BB_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5667EAB5C3DB7F6F34250341D4561BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5667EAB5C3DB7F6F34250341D4561BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5667EAB5C3DB7F6F34250341D4561BB" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5667EAB5C3DB7F6F34250341D4561BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C1C3BC9B36ADD19294F250341D46ED39_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C1C3BC9B36ADD19294F250341D46ED39" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C1C3BC9B36ADD19294F250341D46ED39_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C1C3BC9B36ADD19294F250341D46ED39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C1C3BC9B36ADD19294F250341D46ED39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C1C3BC9B36ADD19294F250341D46ED39" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C1C3BC9B36ADD19294F250341D46ED39" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7B7921DC12848FCE078750341D46EA83_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7B7921DC12848FCE078750341D46EA83" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7B7921DC12848FCE078750341D46EA83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7B7921DC12848FCE078750341D46EA83" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7B7921DC12848FCE078750341D46EA83" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25_terseLabel_en-US" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25_label_en-US" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25" xlink:to="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Guidance [Domain]</link:label>
    <link:label id="lab_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9_label_en-US" xlink:label="lab_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Guidance [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9" xlink:to="lab_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_01EABCE5075EFE98076D50341DDCBA58_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_01EABCE5075EFE98076D50341DDCBA58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_01EABCE5075EFE98076D50341DDCBA58_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_01EABCE5075EFE98076D50341DDCBA58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_01EABCE5075EFE98076D50341DDCBA58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_01EABCE5075EFE98076D50341DDCBA58" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_01EABCE5075EFE98076D50341DDCBA58" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_BE902D9963ED555D4BAC50341DDCAD67_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_BE902D9963ED555D4BAC50341DDCAD67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_BE902D9963ED555D4BAC50341DDCAD67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_BE902D9963ED555D4BAC50341DDCAD67" xlink:to="lab_us-gaap_OperatingLeaseLiability_BE902D9963ED555D4BAC50341DDCAD67" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_FAF996A51371F086027A50341DDCB2D9_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_FAF996A51371F086027A50341DDCB2D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_FAF996A51371F086027A50341DDCB2D9_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_FAF996A51371F086027A50341DDCB2D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_FAF996A51371F086027A50341DDCB2D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_FAF996A51371F086027A50341DDCB2D9" xlink:to="lab_us-gaap_NumberOfReportableSegments_FAF996A51371F086027A50341DDCB2D9" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_05EEE8369694B5912CF350341DDC684C_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_05EEE8369694B5912CF350341DDC684C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_05EEE8369694B5912CF350341DDC684C_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_05EEE8369694B5912CF350341DDC684C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_05EEE8369694B5912CF350341DDC684C_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_05EEE8369694B5912CF350341DDC684C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_05EEE8369694B5912CF350341DDC684C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_05EEE8369694B5912CF350341DDC684C" xlink:to="lab_biib_InterestInSubsidiary_05EEE8369694B5912CF350341DDC684C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_B51043C682363A6C96F450341DD1FE0D_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_B51043C682363A6C96F450341DD1FE0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_B51043C682363A6C96F450341DD1FE0D_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_B51043C682363A6C96F450341DD1FE0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_B51043C682363A6C96F450341DD1FE0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_B51043C682363A6C96F450341DD1FE0D" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_B51043C682363A6C96F450341DD1FE0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C9E0730B2A2A5B581BBB50341D8E1CC4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C9E0730B2A2A5B581BBB50341D8E1CC4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C9E0730B2A2A5B581BBB50341D8E1CC4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C9E0730B2A2A5B581BBB50341D8E1CC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C9E0730B2A2A5B581BBB50341D8E1CC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C9E0730B2A2A5B581BBB50341D8E1CC4" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C9E0730B2A2A5B581BBB50341D8E1CC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ECB06C7A3090C6B6A81550341D386489_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ECB06C7A3090C6B6A81550341D386489" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ECB06C7A3090C6B6A81550341D386489_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ECB06C7A3090C6B6A81550341D386489" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ECB06C7A3090C6B6A81550341D386489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ECB06C7A3090C6B6A81550341D386489" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ECB06C7A3090C6B6A81550341D386489" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_45AE493B647F1132DAA550341D38656A_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_45AE493B647F1132DAA550341D38656A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_45AE493B647F1132DAA550341D38656A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_45AE493B647F1132DAA550341D38656A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_45AE493B647F1132DAA550341D38656A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_45AE493B647F1132DAA550341D38656A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_45AE493B647F1132DAA550341D38656A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B14E07A812A2CE356E1750341D38CFA0_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B14E07A812A2CE356E1750341D38CFA0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B14E07A812A2CE356E1750341D38CFA0_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B14E07A812A2CE356E1750341D38CFA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B14E07A812A2CE356E1750341D38CFA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B14E07A812A2CE356E1750341D38CFA0" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B14E07A812A2CE356E1750341D38CFA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_435AE8F5D8EA1AB5842B50341D38D222_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_435AE8F5D8EA1AB5842B50341D38D222" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_435AE8F5D8EA1AB5842B50341D38D222_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_435AE8F5D8EA1AB5842B50341D38D222" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_435AE8F5D8EA1AB5842B50341D38D222" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_435AE8F5D8EA1AB5842B50341D38D222" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_435AE8F5D8EA1AB5842B50341D38D222" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_75B3A5F25419D5C995E850341DC3E357_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_75B3A5F25419D5C995E850341DC3E357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on assets and liabilities held for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_75B3A5F25419D5C995E850341DC3E357_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_75B3A5F25419D5C995E850341DC3E357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_75B3A5F25419D5C995E850341DC3E357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_75B3A5F25419D5C995E850341DC3E357" xlink:to="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_75B3A5F25419D5C995E850341DC3E357" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B74BD8F85AC1754C8E9650341DC3CB9E_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B74BD8F85AC1754C8E9650341DC3CB9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on assets and liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B74BD8F85AC1754C8E9650341DC3CB9E_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B74BD8F85AC1754C8E9650341DC3CB9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B74BD8F85AC1754C8E9650341DC3CB9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B74BD8F85AC1754C8E9650341DC3CB9E" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B74BD8F85AC1754C8E9650341DC3CB9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_9F8162F4A85BBBD8FF4750341DC3B72C_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_9F8162F4A85BBBD8FF4750341DC3B72C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected costs to sell disposal group</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_9F8162F4A85BBBD8FF4750341DC3B72C_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_9F8162F4A85BBBD8FF4750341DC3B72C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_9F8162F4A85BBBD8FF4750341DC3B72C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_9F8162F4A85BBBD8FF4750341DC3B72C" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_9F8162F4A85BBBD8FF4750341DC3B72C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_5FB8C7CF2102C12CD74050341DC35563_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_5FB8C7CF2102C12CD74050341DC35563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum batch production for Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_5FB8C7CF2102C12CD74050341DC35563_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_5FB8C7CF2102C12CD74050341DC35563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_5FB8C7CF2102C12CD74050341DC35563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_5FB8C7CF2102C12CD74050341DC35563" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_5FB8C7CF2102C12CD74050341DC35563" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_82EB6BBA78ACB7A0B4DD50341DC317A9_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_82EB6BBA78ACB7A0B4DD50341DC317A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense on disposal group</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_82EB6BBA78ACB7A0B4DD50341DC317A9_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_82EB6BBA78ACB7A0B4DD50341DC317A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_82EB6BBA78ACB7A0B4DD50341DC317A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_82EB6BBA78ACB7A0B4DD50341DC317A9" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_82EB6BBA78ACB7A0B4DD50341DC317A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5BB9A6DA7ABBD8D2768250341D533BF2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_5BB9A6DA7ABBD8D2768250341D533BF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5BB9A6DA7ABBD8D2768250341D533BF2_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_5BB9A6DA7ABBD8D2768250341D533BF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5BB9A6DA7ABBD8D2768250341D533BF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_5BB9A6DA7ABBD8D2768250341D533BF2" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_5BB9A6DA7ABBD8D2768250341D533BF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_DA8123818CEFB2ED9E4D50341D53484B_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_DA8123818CEFB2ED9E4D50341D53484B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_DA8123818CEFB2ED9E4D50341D53484B_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_DA8123818CEFB2ED9E4D50341D53484B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DA8123818CEFB2ED9E4D50341D53484B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_DA8123818CEFB2ED9E4D50341D53484B" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_DA8123818CEFB2ED9E4D50341D53484B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_432B89A3054E6837CFF250341D53BDCF_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_432B89A3054E6837CFF250341D53BDCF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_432B89A3054E6837CFF250341D53BDCF_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_432B89A3054E6837CFF250341D53BDCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_432B89A3054E6837CFF250341D53BDCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_432B89A3054E6837CFF250341D53BDCF" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_432B89A3054E6837CFF250341D53BDCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_5428556BAA0780B53B7350341D548B4F_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_5428556BAA0780B53B7350341D548B4F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_5428556BAA0780B53B7350341D548B4F_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_5428556BAA0780B53B7350341D548B4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5428556BAA0780B53B7350341D548B4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_5428556BAA0780B53B7350341D548B4F" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_5428556BAA0780B53B7350341D548B4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_2045245CA4747DC5B01F50341D55B9C5_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_2045245CA4747DC5B01F50341D55B9C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_2045245CA4747DC5B01F50341D55B9C5_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_2045245CA4747DC5B01F50341D55B9C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_2045245CA4747DC5B01F50341D55B9C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_2045245CA4747DC5B01F50341D55B9C5" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_2045245CA4747DC5B01F50341D55B9C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_849F1A2DF8631040068550341D55AD59_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_849F1A2DF8631040068550341D55AD59" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_849F1A2DF8631040068550341D55AD59_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_849F1A2DF8631040068550341D55AD59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_849F1A2DF8631040068550341D55AD59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_849F1A2DF8631040068550341D55AD59" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_849F1A2DF8631040068550341D55AD59" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_890E675788CF70B8AB5150341D56DAD5_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_890E675788CF70B8AB5150341D56DAD5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_890E675788CF70B8AB5150341D56DAD5_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_890E675788CF70B8AB5150341D56DAD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_890E675788CF70B8AB5150341D56DAD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_890E675788CF70B8AB5150341D56DAD5" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_890E675788CF70B8AB5150341D56DAD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F2065EE935B035D421250341D56F598_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F2065EE935B035D421250341D56F598" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F2065EE935B035D421250341D56F598_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F2065EE935B035D421250341D56F598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F2065EE935B035D421250341D56F598" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F2065EE935B035D421250341D56F598" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F2065EE935B035D421250341D56F598" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_F2861A2216C0D5CE509750341D56C347_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_F2861A2216C0D5CE509750341D56C347" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_F2861A2216C0D5CE509750341D56C347_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_F2861A2216C0D5CE509750341D56C347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_F2861A2216C0D5CE509750341D56C347" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_F2861A2216C0D5CE509750341D56C347" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_F2861A2216C0D5CE509750341D56C347" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C57E8A59E4C2435EE59150341D567CD5_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C57E8A59E4C2435EE59150341D567CD5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C57E8A59E4C2435EE59150341D567CD5_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C57E8A59E4C2435EE59150341D567CD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C57E8A59E4C2435EE59150341D567CD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C57E8A59E4C2435EE59150341D567CD5" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C57E8A59E4C2435EE59150341D567CD5" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_881379112A8F9A47062850341D576319_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_881379112A8F9A47062850341D576319" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_881379112A8F9A47062850341D576319_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_881379112A8F9A47062850341D576319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_881379112A8F9A47062850341D576319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_881379112A8F9A47062850341D576319" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_881379112A8F9A47062850341D576319" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1FDAEE0C0148DB5FAC4150341D573CF2_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1FDAEE0C0148DB5FAC4150341D573CF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1FDAEE0C0148DB5FAC4150341D573CF2_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1FDAEE0C0148DB5FAC4150341D573CF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1FDAEE0C0148DB5FAC4150341D573CF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1FDAEE0C0148DB5FAC4150341D573CF2" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1FDAEE0C0148DB5FAC4150341D573CF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9146131949D7B568B16D50341D5761C5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9146131949D7B568B16D50341D5761C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9146131949D7B568B16D50341D5761C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9146131949D7B568B16D50341D5761C5" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9146131949D7B568B16D50341D5761C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_10375D785976EF2B814650341D57EF32_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_10375D785976EF2B814650341D57EF32" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_10375D785976EF2B814650341D57EF32_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_10375D785976EF2B814650341D57EF32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_10375D785976EF2B814650341D57EF32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_10375D785976EF2B814650341D57EF32" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_10375D785976EF2B814650341D57EF32" xlink:type="arc" />
    <link:label id="lab_biib_InventoryAbstract_0DE97C1D0DD118100F2050341D85E660_label_en-US" xlink:label="lab_biib_InventoryAbstract_0DE97C1D0DD118100F2050341D85E660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:label id="lab_biib_InventoryAbstract_0DE97C1D0DD118100F2050341D85E660_documentation_en-US" xlink:label="lab_biib_InventoryAbstract_0DE97C1D0DD118100F2050341D85E660" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_InventoryAbstract" xlink:label="loc_biib_InventoryAbstract_0DE97C1D0DD118100F2050341D85E660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryAbstract_0DE97C1D0DD118100F2050341D85E660" xlink:to="lab_biib_InventoryAbstract_0DE97C1D0DD118100F2050341D85E660" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4" xlink:to="lab_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31" xlink:to="lab_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31" xlink:type="arc" />
    <link:label id="lab_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F_terseLabel_en-US" xlink:label="lab_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory sold to Bioverativ, cost</link:label>
    <link:label id="lab_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F_label_en-US" xlink:label="lab_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory sold to Bioverativ, cost</link:label>
    <link:label id="lab_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F_documentation_en-US" xlink:label="lab_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory sold to Bioverativ, cost</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_InventorysoldtoBioverativcost" xlink:label="loc_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F" xlink:to="lab_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_F594207E0630254562D250341CC1F978_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_F594207E0630254562D250341CC1F978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_F594207E0630254562D250341CC1F978_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_F594207E0630254562D250341CC1F978" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_F594207E0630254562D250341CC1F978" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_F594207E0630254562D250341CC1F978" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_F594207E0630254562D250341CC1F978" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_14BF10286CA1912E56A150341BD479D1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_14BF10286CA1912E56A150341BD479D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_14BF10286CA1912E56A150341BD479D1_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_14BF10286CA1912E56A150341BD479D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_14BF10286CA1912E56A150341BD479D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_14BF10286CA1912E56A150341BD479D1" xlink:to="lab_us-gaap_InventoriesMember_14BF10286CA1912E56A150341BD479D1" xlink:type="arc" />
    <link:label id="lab_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425_label_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425" xlink:to="lab_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2" xlink:to="lab_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_D58490FEB2C6D780891F50341BD5C955_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_D58490FEB2C6D780891F50341BD5C955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_D58490FEB2C6D780891F50341BD5C955_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_D58490FEB2C6D780891F50341BD5C955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_D58490FEB2C6D780891F50341BD5C955" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_D58490FEB2C6D780891F50341BD5C955" xlink:to="lab_us-gaap_CollaborativeArrangementMember_D58490FEB2C6D780891F50341BD5C955" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BEC47F8945D77790D6A350341BD7C94D_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BEC47F8945D77790D6A350341BD7C94D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BEC47F8945D77790D6A350341BD7C94D_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BEC47F8945D77790D6A350341BD7C94D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BEC47F8945D77790D6A350341BD7C94D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BEC47F8945D77790D6A350341BD7C94D" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BEC47F8945D77790D6A350341BD7C94D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_AA252EDBD5A67D6E277250341BD70783_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_AA252EDBD5A67D6E277250341BD70783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_AA252EDBD5A67D6E277250341BD70783_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_AA252EDBD5A67D6E277250341BD70783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_AA252EDBD5A67D6E277250341BD70783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_AA252EDBD5A67D6E277250341BD70783" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_AA252EDBD5A67D6E277250341BD70783" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A019E11F28D700E50EB050341BD79AFF_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A019E11F28D700E50EB050341BD79AFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A019E11F28D700E50EB050341BD79AFF_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A019E11F28D700E50EB050341BD79AFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A019E11F28D700E50EB050341BD79AFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A019E11F28D700E50EB050341BD79AFF" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A019E11F28D700E50EB050341BD79AFF" xlink:type="arc" />
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_204DBD5C65E5519BCB6B50341BD7C6CC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_204DBD5C65E5519BCB6B50341BD7C6CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss recorded on Samsung Bioepis joint venture</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_204DBD5C65E5519BCB6B50341BD7C6CC_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_204DBD5C65E5519BCB6B50341BD7C6CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_204DBD5C65E5519BCB6B50341BD7C6CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_204DBD5C65E5519BCB6B50341BD7C6CC" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_204DBD5C65E5519BCB6B50341BD7C6CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_B31DCBA4892D231219C050341BD70005_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_B31DCBA4892D231219C050341BD70005" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Our share of Samsung Bioepis gains (losses)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_B31DCBA4892D231219C050341BD70005_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_B31DCBA4892D231219C050341BD70005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_B31DCBA4892D231219C050341BD70005" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_B31DCBA4892D231219C050341BD70005" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_B31DCBA4892D231219C050341BD70005" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentForAmortization_CE5946D4776FFFFAD83450341BD8F4FE_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_CE5946D4776FFFFAD83450341BD8F4FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_CE5946D4776FFFFAD83450341BD8F4FE_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_CE5946D4776FFFFAD83450341BD8F4FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_CE5946D4776FFFFAD83450341BD8F4FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization_CE5946D4776FFFFAD83450341BD8F4FE" xlink:to="lab_us-gaap_AdjustmentForAmortization_CE5946D4776FFFFAD83450341BD8F4FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_89252967489160CA731D50341BD86228_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_89252967489160CA731D50341BD86228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_89252967489160CA731D50341BD86228_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_89252967489160CA731D50341BD86228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_89252967489160CA731D50341BD86228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_89252967489160CA731D50341BD86228" xlink:to="lab_us-gaap_EquityMethodInvestments_89252967489160CA731D50341BD86228" xlink:type="arc" />
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311" xlink:to="lab_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_F1CC8F96A78BE2C066D950341BD8A506_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_F1CC8F96A78BE2C066D950341BD8A506" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F1CC8F96A78BE2C066D950341BD8A506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_F1CC8F96A78BE2C066D950341BD8A506" xlink:to="lab_us-gaap_Revenues_F1CC8F96A78BE2C066D950341BD8A506" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_82D125F69E6EF5F3C88050341BFC252E_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_82D125F69E6EF5F3C88050341BFC252E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_82D125F69E6EF5F3C88050341BFC252E_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_82D125F69E6EF5F3C88050341BFC252E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_82D125F69E6EF5F3C88050341BFC252E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent_82D125F69E6EF5F3C88050341BFC252E" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent_82D125F69E6EF5F3C88050341BFC252E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_171BCD1E74E294CAB01650341D40B269_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_171BCD1E74E294CAB01650341D40B269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_171BCD1E74E294CAB01650341D40B269_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_171BCD1E74E294CAB01650341D40B269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_171BCD1E74E294CAB01650341D40B269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_171BCD1E74E294CAB01650341D40B269" xlink:to="lab_us-gaap_AssetImpairmentCharges_171BCD1E74E294CAB01650341D40B269" xlink:type="arc" />
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_72DDFED369147BAE7BCC50341D40114F_terseLabel_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_72DDFED369147BAE7BCC50341D40114F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements, changes in valuation inputs</link:label>
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_72DDFED369147BAE7BCC50341D40114F_label_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_72DDFED369147BAE7BCC50341D40114F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servicing Asset at Fair Value, Description of Changes in Valuation Inputs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs" xlink:label="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_72DDFED369147BAE7BCC50341D40114F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_72DDFED369147BAE7BCC50341D40114F" xlink:to="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_72DDFED369147BAE7BCC50341D40114F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_33A92CEDAD733B4FC47750341D4010BC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_33A92CEDAD733B4FC47750341D4010BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_33A92CEDAD733B4FC47750341D4010BC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_33A92CEDAD733B4FC47750341D4010BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_33A92CEDAD733B4FC47750341D4010BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_33A92CEDAD733B4FC47750341D4010BC" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_33A92CEDAD733B4FC47750341D4010BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13F6A6C5BEB4E2AF97DC50341D40B4D1_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13F6A6C5BEB4E2AF97DC50341D40B4D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13F6A6C5BEB4E2AF97DC50341D40B4D1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13F6A6C5BEB4E2AF97DC50341D40B4D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13F6A6C5BEB4E2AF97DC50341D40B4D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13F6A6C5BEB4E2AF97DC50341D40B4D1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13F6A6C5BEB4E2AF97DC50341D40B4D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_4FEEAFC56CCB4F5AB39D50341C1F3A64_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_4FEEAFC56CCB4F5AB39D50341C1F3A64" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_4FEEAFC56CCB4F5AB39D50341C1F3A64_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_4FEEAFC56CCB4F5AB39D50341C1F3A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_4FEEAFC56CCB4F5AB39D50341C1F3A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_4FEEAFC56CCB4F5AB39D50341C1F3A64" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_4FEEAFC56CCB4F5AB39D50341C1F3A64" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_053F2991B7C834C4C48150341CCA02C2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_053F2991B7C834C4C48150341CCA02C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_053F2991B7C834C4C48150341CCA02C2_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_053F2991B7C834C4C48150341CCA02C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_053F2991B7C834C4C48150341CCA02C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_053F2991B7C834C4C48150341CCA02C2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_053F2991B7C834C4C48150341CCA02C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F2651D8DEA848175F1650341BF98419_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F2651D8DEA848175F1650341BF98419" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F2651D8DEA848175F1650341BF98419_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F2651D8DEA848175F1650341BF98419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F2651D8DEA848175F1650341BF98419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F2651D8DEA848175F1650341BF98419" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F2651D8DEA848175F1650341BF98419" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C8461FFE2DDA037563EC50341C34CCD5_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C8461FFE2DDA037563EC50341C34CCD5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C8461FFE2DDA037563EC50341C34CCD5_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C8461FFE2DDA037563EC50341C34CCD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C8461FFE2DDA037563EC50341C34CCD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C8461FFE2DDA037563EC50341C34CCD5" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C8461FFE2DDA037563EC50341C34CCD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9DBC01AAAC94D3AC35F750341C34F44D_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9DBC01AAAC94D3AC35F750341C34F44D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9DBC01AAAC94D3AC35F750341C34F44D_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9DBC01AAAC94D3AC35F750341C34F44D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9DBC01AAAC94D3AC35F750341C34F44D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9DBC01AAAC94D3AC35F750341C34F44D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9DBC01AAAC94D3AC35F750341C34F44D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8FE2DB8B1139AD3287AE50341C3570D9_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8FE2DB8B1139AD3287AE50341C3570D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8FE2DB8B1139AD3287AE50341C3570D9_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8FE2DB8B1139AD3287AE50341C3570D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8FE2DB8B1139AD3287AE50341C3570D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8FE2DB8B1139AD3287AE50341C3570D9" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8FE2DB8B1139AD3287AE50341C3570D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_50A4627F6257E315D79050341C35AA23_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_50A4627F6257E315D79050341C35AA23" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_50A4627F6257E315D79050341C35AA23_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_50A4627F6257E315D79050341C35AA23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_50A4627F6257E315D79050341C35AA23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_50A4627F6257E315D79050341C35AA23" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_50A4627F6257E315D79050341C35AA23" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7374C6A20E30C31BA7E050341C35F788_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7374C6A20E30C31BA7E050341C35F788" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7374C6A20E30C31BA7E050341C35F788_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7374C6A20E30C31BA7E050341C35F788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7374C6A20E30C31BA7E050341C35F788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7374C6A20E30C31BA7E050341C35F788" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7374C6A20E30C31BA7E050341C35F788" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_DAA2BDD27B679355A01650341C35E5C6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_DAA2BDD27B679355A01650341C35E5C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denmark assets held for sale</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_DAA2BDD27B679355A01650341C35E5C6_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_DAA2BDD27B679355A01650341C35E5C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_DAA2BDD27B679355A01650341C35E5C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_DAA2BDD27B679355A01650341C35E5C6" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_DAA2BDD27B679355A01650341C35E5C6" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_744E3BD0C60CAC1FCA2250341C351F98_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_744E3BD0C60CAC1FCA2250341C351F98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_744E3BD0C60CAC1FCA2250341C351F98_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_744E3BD0C60CAC1FCA2250341C351F98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_744E3BD0C60CAC1FCA2250341C351F98_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_744E3BD0C60CAC1FCA2250341C351F98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_744E3BD0C60CAC1FCA2250341C351F98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax_744E3BD0C60CAC1FCA2250341C351F98" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax_744E3BD0C60CAC1FCA2250341C351F98" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_35B8FEC57BB74523C0AA50341C3515A7_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_35B8FEC57BB74523C0AA50341C3515A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_35B8FEC57BB74523C0AA50341C3515A7_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_35B8FEC57BB74523C0AA50341C3515A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_35B8FEC57BB74523C0AA50341C3515A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_35B8FEC57BB74523C0AA50341C3515A7" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_35B8FEC57BB74523C0AA50341C3515A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0E4952AD1E593036AD7E50341C3675CF_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0E4952AD1E593036AD7E50341C3675CF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0E4952AD1E593036AD7E50341C3675CF_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0E4952AD1E593036AD7E50341C3675CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0E4952AD1E593036AD7E50341C3675CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0E4952AD1E593036AD7E50341C3675CF" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0E4952AD1E593036AD7E50341C3675CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CB07AD9CA5C939B1784650341C363FDC_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CB07AD9CA5C939B1784650341C363FDC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CB07AD9CA5C939B1784650341C363FDC_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CB07AD9CA5C939B1784650341C363FDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CB07AD9CA5C939B1784650341C363FDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CB07AD9CA5C939B1784650341C363FDC" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CB07AD9CA5C939B1784650341C363FDC" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_B67A608D3D8EA7932C6650341D7AACCD_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_B67A608D3D8EA7932C6650341D7AACCD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_B67A608D3D8EA7932C6650341D7AACCD_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_B67A608D3D8EA7932C6650341D7AACCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_B67A608D3D8EA7932C6650341D7AACCD_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_B67A608D3D8EA7932C6650341D7AACCD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_B67A608D3D8EA7932C6650341D7AACCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_B67A608D3D8EA7932C6650341D7AACCD" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_B67A608D3D8EA7932C6650341D7AACCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BF032E2F4691264FD3AC50341D7AA0D1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BF032E2F4691264FD3AC50341D7AA0D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BF032E2F4691264FD3AC50341D7AA0D1_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BF032E2F4691264FD3AC50341D7AA0D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BF032E2F4691264FD3AC50341D7AA0D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BF032E2F4691264FD3AC50341D7AA0D1" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BF032E2F4691264FD3AC50341D7AA0D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_A21266AA1FC48F3406B050341D7A8E31_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_A21266AA1FC48F3406B050341D7A8E31" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_A21266AA1FC48F3406B050341D7A8E31_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_A21266AA1FC48F3406B050341D7A8E31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_A21266AA1FC48F3406B050341D7A8E31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_A21266AA1FC48F3406B050341D7A8E31" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_A21266AA1FC48F3406B050341D7A8E31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_917E9D855ACD629F35CF50341C5CA91D_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_917E9D855ACD629F35CF50341C5CA91D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_917E9D855ACD629F35CF50341C5CA91D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_917E9D855ACD629F35CF50341C5CA91D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_917E9D855ACD629F35CF50341C5CA91D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_917E9D855ACD629F35CF50341C5CA91D" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_917E9D855ACD629F35CF50341C5CA91D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_968E3D2378B07AB50A5F50341C5C0102_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_968E3D2378B07AB50A5F50341C5C0102" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_968E3D2378B07AB50A5F50341C5C0102_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_968E3D2378B07AB50A5F50341C5C0102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_968E3D2378B07AB50A5F50341C5C0102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_968E3D2378B07AB50A5F50341C5C0102" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_968E3D2378B07AB50A5F50341C5C0102" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_31474FE83F6A6D3274E650341CECD1C3_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_31474FE83F6A6D3274E650341CECD1C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_31474FE83F6A6D3274E650341CECD1C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_31474FE83F6A6D3274E650341CECD1C3" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_31474FE83F6A6D3274E650341CECD1C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_A99091C1DF4392776EC150341CEDBA6C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_A99091C1DF4392776EC150341CEDBA6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_A99091C1DF4392776EC150341CEDBA6C_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_A99091C1DF4392776EC150341CEDBA6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_A99091C1DF4392776EC150341CEDBA6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_A99091C1DF4392776EC150341CEDBA6C" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_A99091C1DF4392776EC150341CEDBA6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_CDF89CEA4213AD9EDCA050341CED43DB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_CDF89CEA4213AD9EDCA050341CED43DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_CDF89CEA4213AD9EDCA050341CED43DB_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_CDF89CEA4213AD9EDCA050341CED43DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_CDF89CEA4213AD9EDCA050341CED43DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember_CDF89CEA4213AD9EDCA050341CED43DB" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember_CDF89CEA4213AD9EDCA050341CED43DB" xlink:type="arc" />
    <link:label id="lab_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B" xlink:to="lab_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7" xlink:to="lab_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C" xlink:to="lab_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040" xlink:to="lab_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040" xlink:type="arc" />
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57_terseLabel_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57_label_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57_documentation_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57" xlink:to="lab_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57" xlink:type="arc" />
    <link:label id="lab_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78_terseLabel_en-US" xlink:label="lab_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78_label_en-US" xlink:label="lab_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78_documentation_en-US" xlink:label="lab_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78" xlink:to="lab_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_61D89E6572830E2879EE50341BBAA569_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_61D89E6572830E2879EE50341BBAA569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_61D89E6572830E2879EE50341BBAA569" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_61D89E6572830E2879EE50341BBAA569" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_61D89E6572830E2879EE50341BBAA569" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_7BA6E7DB6AF9971E080F50341BBA1214_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_7BA6E7DB6AF9971E080F50341BBA1214" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_7BA6E7DB6AF9971E080F50341BBA1214_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_7BA6E7DB6AF9971E080F50341BBA1214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_7BA6E7DB6AF9971E080F50341BBA1214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_7BA6E7DB6AF9971E080F50341BBA1214" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_7BA6E7DB6AF9971E080F50341BBA1214" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_5E77A20C7B76BE05D5E650341C920D31_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_5E77A20C7B76BE05D5E650341C920D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_5E77A20C7B76BE05D5E650341C920D31_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_5E77A20C7B76BE05D5E650341C920D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5E77A20C7B76BE05D5E650341C920D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_5E77A20C7B76BE05D5E650341C920D31" xlink:to="lab_us-gaap_SubsequentEventMember_5E77A20C7B76BE05D5E650341C920D31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:type="arc" />
    <link:label id="lab_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103_terseLabel_en-US" xlink:label="lab_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103_label_en-US" xlink:label="lab_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103_documentation_en-US" xlink:label="lab_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103" xlink:to="lab_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103" xlink:type="arc" />
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A_terseLabel_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A_label_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A_documentation_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A" xlink:to="lab_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A" xlink:type="arc" />
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F_terseLabel_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F_label_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F_documentation_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F" xlink:to="lab_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:to="lab_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D5C26CDF4C2CDFB08C450341C9396B8_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D5C26CDF4C2CDFB08C450341C9396B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D5C26CDF4C2CDFB08C450341C9396B8_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D5C26CDF4C2CDFB08C450341C9396B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D5C26CDF4C2CDFB08C450341C9396B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D5C26CDF4C2CDFB08C450341C9396B8" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D5C26CDF4C2CDFB08C450341C9396B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_88AFE672B2C39A33413550341C94EE57_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_88AFE672B2C39A33413550341C94EE57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_88AFE672B2C39A33413550341C94EE57_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_88AFE672B2C39A33413550341C94EE57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_88AFE672B2C39A33413550341C94EE57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_88AFE672B2C39A33413550341C94EE57" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_88AFE672B2C39A33413550341C94EE57" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_FD1318FAAEB206EAAB2050341C947478_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_FD1318FAAEB206EAAB2050341C947478" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_FD1318FAAEB206EAAB2050341C947478_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_FD1318FAAEB206EAAB2050341C947478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_FD1318FAAEB206EAAB2050341C947478" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_FD1318FAAEB206EAAB2050341C947478" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_FD1318FAAEB206EAAB2050341C947478" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_CD2BB919752524EB64D850341C2954A1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_CD2BB919752524EB64D850341C2954A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_CD2BB919752524EB64D850341C2954A1_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_CD2BB919752524EB64D850341C2954A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_CD2BB919752524EB64D850341C2954A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_CD2BB919752524EB64D850341C2954A1" xlink:to="lab_us-gaap_ForeignCountryMember_CD2BB919752524EB64D850341C2954A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_F4A5BA05DF7C17B6425650341C29676A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_F4A5BA05DF7C17B6425650341C29676A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax payment, including penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_F4A5BA05DF7C17B6425650341C29676A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_F4A5BA05DF7C17B6425650341C29676A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_F4A5BA05DF7C17B6425650341C29676A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_F4A5BA05DF7C17B6425650341C29676A" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_F4A5BA05DF7C17B6425650341C29676A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_EA90AAB936343C42BF0550341C293AC9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_EA90AAB936343C42BF0550341C293AC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_EA90AAB936343C42BF0550341C293AC9_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_EA90AAB936343C42BF0550341C293AC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_EA90AAB936343C42BF0550341C293AC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_EA90AAB936343C42BF0550341C293AC9" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_EA90AAB936343C42BF0550341C293AC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FE9DF949C1F133FD348850341C990993_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FE9DF949C1F133FD348850341C990993" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FE9DF949C1F133FD348850341C990993_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FE9DF949C1F133FD348850341C990993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FE9DF949C1F133FD348850341C990993" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FE9DF949C1F133FD348850341C990993" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FE9DF949C1F133FD348850341C990993" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_12882A53A29399428C9850341D5C134E_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_12882A53A29399428C9850341D5C134E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_12882A53A29399428C9850341D5C134E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_12882A53A29399428C9850341D5C134E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_12882A53A29399428C9850341D5C134E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_12882A53A29399428C9850341D5C134E" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_12882A53A29399428C9850341D5C134E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_939A0F469303BE7CCE5150341D5C4BC5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_939A0F469303BE7CCE5150341D5C4BC5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_939A0F469303BE7CCE5150341D5C4BC5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_939A0F469303BE7CCE5150341D5C4BC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_939A0F469303BE7CCE5150341D5C4BC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_939A0F469303BE7CCE5150341D5C4BC5" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_939A0F469303BE7CCE5150341D5C4BC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_67BBA209A6413C965ED950341D5CA0F5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_67BBA209A6413C965ED950341D5CA0F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_67BBA209A6413C965ED950341D5CA0F5_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_67BBA209A6413C965ED950341D5CA0F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_67BBA209A6413C965ED950341D5CA0F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_67BBA209A6413C965ED950341D5CA0F5" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_67BBA209A6413C965ED950341D5CA0F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ADC27BA11F8A7B278BCA50341CF51C4A_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ADC27BA11F8A7B278BCA50341CF51C4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ADC27BA11F8A7B278BCA50341CF51C4A_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ADC27BA11F8A7B278BCA50341CF51C4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ADC27BA11F8A7B278BCA50341CF51C4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ADC27BA11F8A7B278BCA50341CF51C4A" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ADC27BA11F8A7B278BCA50341CF51C4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_34FB0DE40722C63B22D750341CF5A0F0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_34FB0DE40722C63B22D750341CF5A0F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_34FB0DE40722C63B22D750341CF5A0F0_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_34FB0DE40722C63B22D750341CF5A0F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_34FB0DE40722C63B22D750341CF5A0F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_34FB0DE40722C63B22D750341CF5A0F0" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_34FB0DE40722C63B22D750341CF5A0F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D815996EDDA0F5F6E50341CF50ED5_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D815996EDDA0F5F6E50341CF50ED5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D815996EDDA0F5F6E50341CF50ED5_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D815996EDDA0F5F6E50341CF50ED5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D815996EDDA0F5F6E50341CF50ED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D815996EDDA0F5F6E50341CF50ED5" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D815996EDDA0F5F6E50341CF50ED5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_337BA15AAD5A678AEF2A50341C401ABF_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_337BA15AAD5A678AEF2A50341C401ABF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_337BA15AAD5A678AEF2A50341C401ABF_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_337BA15AAD5A678AEF2A50341C401ABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_337BA15AAD5A678AEF2A50341C401ABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_337BA15AAD5A678AEF2A50341C401ABF" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_337BA15AAD5A678AEF2A50341C401ABF" xlink:type="arc" />
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D" xlink:to="lab_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0" xlink:to="lab_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_C506768B91715A80636F50341DA4E2A8_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_C506768B91715A80636F50341DA4E2A8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C506768B91715A80636F50341DA4E2A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_C506768B91715A80636F50341DA4E2A8" xlink:to="lab_us-gaap_Revenues_C506768B91715A80636F50341DA4E2A8" xlink:type="arc" />
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_0AEA6A53115A6E7F3F6D50341CBE588C_terseLabel_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock_0AEA6A53115A6E7F3F6D50341CBE588C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of operating leases</link:label>
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_0AEA6A53115A6E7F3F6D50341CBE588C_label_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock_0AEA6A53115A6E7F3F6D50341CBE588C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Lease Table [Table Text Block]</link:label>
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_0AEA6A53115A6E7F3F6D50341CBE588C_documentation_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock_0AEA6A53115A6E7F3F6D50341CBE588C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee Lease Table [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_LesseeLeaseTableTableTextBlock" xlink:label="loc_biib_LesseeLeaseTableTableTextBlock_0AEA6A53115A6E7F3F6D50341CBE588C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LesseeLeaseTableTableTextBlock_0AEA6A53115A6E7F3F6D50341CBE588C" xlink:to="lab_biib_LesseeLeaseTableTableTextBlock_0AEA6A53115A6E7F3F6D50341CBE588C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_952AFEF2A3707AA56FA250341CBE39DC_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_952AFEF2A3707AA56FA250341CBE39DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_952AFEF2A3707AA56FA250341CBE39DC_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_952AFEF2A3707AA56FA250341CBE39DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_952AFEF2A3707AA56FA250341CBE39DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_952AFEF2A3707AA56FA250341CBE39DC" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_952AFEF2A3707AA56FA250341CBE39DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_78ECE54235B58DDF00C350341CBE9A39_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_78ECE54235B58DDF00C350341CBE9A39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_78ECE54235B58DDF00C350341CBE9A39_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_78ECE54235B58DDF00C350341CBE9A39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_78ECE54235B58DDF00C350341CBE9A39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_78ECE54235B58DDF00C350341CBE9A39" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_78ECE54235B58DDF00C350341CBE9A39" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E4D1C8669F0525D5488E50341CBEACD7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E4D1C8669F0525D5488E50341CBEACD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E4D1C8669F0525D5488E50341CBEACD7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E4D1C8669F0525D5488E50341CBEACD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E4D1C8669F0525D5488E50341CBEACD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E4D1C8669F0525D5488E50341CBEACD7" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E4D1C8669F0525D5488E50341CBEACD7" xlink:type="arc" />
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_2F0DE749640E1CC92E4250341CBEB0D6_terseLabel_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_2F0DE749640E1CC92E4250341CBEB0D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease weighted average remaining term and discount rate</link:label>
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_2F0DE749640E1CC92E4250341CBEB0D6_label_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_2F0DE749640E1CC92E4250341CBEB0D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease weighted average remaining term and discount rate [Table Text Block]</link:label>
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_2F0DE749640E1CC92E4250341CBEB0D6_documentation_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_2F0DE749640E1CC92E4250341CBEB0D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease weighted average remaining term and discount rate [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:label="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_2F0DE749640E1CC92E4250341CBEB0D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_2F0DE749640E1CC92E4250341CBEB0D6" xlink:to="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_2F0DE749640E1CC92E4250341CBEB0D6" xlink:type="arc" />
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_DF333E3C94004D48B3B650341CBFF135_terseLabel_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_DF333E3C94004D48B3B650341CBFF135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease supplemental cash flow disclosure</link:label>
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_DF333E3C94004D48B3B650341CBFF135_label_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_DF333E3C94004D48B3B650341CBFF135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease supplemental cash flow disclosure [Table Text Block]</link:label>
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_DF333E3C94004D48B3B650341CBFF135_documentation_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_DF333E3C94004D48B3B650341CBFF135" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease supplemental cash flow disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:label="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_DF333E3C94004D48B3B650341CBFF135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_DF333E3C94004D48B3B650341CBFF135" xlink:to="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_DF333E3C94004D48B3B650341CBFF135" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_FC7714D77672D52D1D2150341D6366CD_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_FC7714D77672D52D1D2150341D6366CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_FC7714D77672D52D1D2150341D6366CD_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_FC7714D77672D52D1D2150341D6366CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_FC7714D77672D52D1D2150341D6366CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_FC7714D77672D52D1D2150341D6366CD" xlink:to="lab_us-gaap_GoodwillLineItems_FC7714D77672D52D1D2150341D6366CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238" xlink:to="lab_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_5D01D5D95369C3799C9450341D64C755_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_5D01D5D95369C3799C9450341D64C755" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5D01D5D95369C3799C9450341D64C755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_5D01D5D95369C3799C9450341D64C755" xlink:to="lab_us-gaap_Goodwill_5D01D5D95369C3799C9450341D64C755" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_510EC9AF43BEE126AD4850341D64CD8C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_510EC9AF43BEE126AD4850341D64CD8C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Goodwill held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_510EC9AF43BEE126AD4850341D64CD8C_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_510EC9AF43BEE126AD4850341D64CD8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_510EC9AF43BEE126AD4850341D64CD8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_510EC9AF43BEE126AD4850341D64CD8C" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_510EC9AF43BEE126AD4850341D64CD8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_FCB4042A740139A85F6E50341D648B10_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_FCB4042A740139A85F6E50341D648B10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_FCB4042A740139A85F6E50341D648B10_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_FCB4042A740139A85F6E50341D648B10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_FCB4042A740139A85F6E50341D648B10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_FCB4042A740139A85F6E50341D648B10" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_FCB4042A740139A85F6E50341D648B10" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_EE3D536650292AA66C9350341D640448_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_EE3D536650292AA66C9350341D640448" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_EE3D536650292AA66C9350341D640448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_EE3D536650292AA66C9350341D640448" xlink:to="lab_us-gaap_Goodwill_EE3D536650292AA66C9350341D640448" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A6CCAFFA0B385C3FBB0D50341E288E86_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A6CCAFFA0B385C3FBB0D50341E288E86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A6CCAFFA0B385C3FBB0D50341E288E86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A6CCAFFA0B385C3FBB0D50341E288E86" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A6CCAFFA0B385C3FBB0D50341E288E86" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_CED567CC41E86290781150341E2830C7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_CED567CC41E86290781150341E2830C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_CED567CC41E86290781150341E2830C7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_CED567CC41E86290781150341E2830C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_CED567CC41E86290781150341E2830C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_CED567CC41E86290781150341E2830C7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_CED567CC41E86290781150341E2830C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_A6258500FB133BB4196450341E2929AC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_A6258500FB133BB4196450341E2929AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_A6258500FB133BB4196450341E2929AC_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_A6258500FB133BB4196450341E2929AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_A6258500FB133BB4196450341E2929AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_A6258500FB133BB4196450341E2929AC" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_A6258500FB133BB4196450341E2929AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_6211BFB18F0C0D826FCF50341E29C206_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_6211BFB18F0C0D826FCF50341E29C206" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_6211BFB18F0C0D826FCF50341E29C206_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_6211BFB18F0C0D826FCF50341E29C206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_6211BFB18F0C0D826FCF50341E29C206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_6211BFB18F0C0D826FCF50341E29C206" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_6211BFB18F0C0D826FCF50341E29C206" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_FE6AFE28A47FAEB9E3A950341E29259C_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_FE6AFE28A47FAEB9E3A950341E29259C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_FE6AFE28A47FAEB9E3A950341E29259C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_FE6AFE28A47FAEB9E3A950341E29259C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_FE6AFE28A47FAEB9E3A950341E29259C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_FE6AFE28A47FAEB9E3A950341E29259C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_FE6AFE28A47FAEB9E3A950341E29259C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5C856F60F2BA0573E5B150341E29745D_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5C856F60F2BA0573E5B150341E29745D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5C856F60F2BA0573E5B150341E29745D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5C856F60F2BA0573E5B150341E29745D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5C856F60F2BA0573E5B150341E29745D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5C856F60F2BA0573E5B150341E29745D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5C856F60F2BA0573E5B150341E29745D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5D23AC4097D11F20AF2B50341E29BB2B_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5D23AC4097D11F20AF2B50341E29BB2B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5D23AC4097D11F20AF2B50341E29BB2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5D23AC4097D11F20AF2B50341E29BB2B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5D23AC4097D11F20AF2B50341E29BB2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8D7C51CFCFEC458B77BF50341E29F2E6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_8D7C51CFCFEC458B77BF50341E29F2E6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8D7C51CFCFEC458B77BF50341E29F2E6_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_8D7C51CFCFEC458B77BF50341E29F2E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8D7C51CFCFEC458B77BF50341E29F2E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_8D7C51CFCFEC458B77BF50341E29F2E6" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_8D7C51CFCFEC458B77BF50341E29F2E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D4200B7923990400955C50341E2AEDC8_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D4200B7923990400955C50341E2AEDC8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D4200B7923990400955C50341E2AEDC8_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D4200B7923990400955C50341E2AEDC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D4200B7923990400955C50341E2AEDC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D4200B7923990400955C50341E2AEDC8" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D4200B7923990400955C50341E2AEDC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3C8359C0A644C8B4655E50341E2A5243_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3C8359C0A644C8B4655E50341E2A5243" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3C8359C0A644C8B4655E50341E2A5243_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3C8359C0A644C8B4655E50341E2A5243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3C8359C0A644C8B4655E50341E2A5243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3C8359C0A644C8B4655E50341E2A5243" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3C8359C0A644C8B4655E50341E2A5243" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="lab_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_377EB457FAF7729AF61F50341E343738_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_377EB457FAF7729AF61F50341E343738" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_377EB457FAF7729AF61F50341E343738_label_en-US" xlink:label="lab_us-gaap_ProductMember_377EB457FAF7729AF61F50341E343738" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_377EB457FAF7729AF61F50341E343738" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_377EB457FAF7729AF61F50341E343738" xlink:to="lab_us-gaap_ProductMember_377EB457FAF7729AF61F50341E343738" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_7F50F5AA38DE826DFB2650341E3543F8_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_7F50F5AA38DE826DFB2650341E3543F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_7F50F5AA38DE826DFB2650341E3543F8_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_7F50F5AA38DE826DFB2650341E3543F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7F50F5AA38DE826DFB2650341E3543F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_7F50F5AA38DE826DFB2650341E3543F8" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_7F50F5AA38DE826DFB2650341E3543F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_20A59E3725418BADBD2B50341E351729_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_20A59E3725418BADBD2B50341E351729" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_20A59E3725418BADBD2B50341E351729_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_20A59E3725418BADBD2B50341E351729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_20A59E3725418BADBD2B50341E351729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_20A59E3725418BADBD2B50341E351729" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_20A59E3725418BADBD2B50341E351729" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_56838F60446E734FDDA950341E36536A_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_56838F60446E734FDDA950341E36536A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_56838F60446E734FDDA950341E36536A_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_56838F60446E734FDDA950341E36536A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_56838F60446E734FDDA950341E36536A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_56838F60446E734FDDA950341E36536A" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_56838F60446E734FDDA950341E36536A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_90338D23E973F7F467E750341E36984A_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_90338D23E973F7F467E750341E36984A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_90338D23E973F7F467E750341E36984A_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_90338D23E973F7F467E750341E36984A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_90338D23E973F7F467E750341E36984A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_90338D23E973F7F467E750341E36984A" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_90338D23E973F7F467E750341E36984A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BB4101A9D49D9A06389950341E36C3A2_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BB4101A9D49D9A06389950341E36C3A2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on fair value remeasurement of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BB4101A9D49D9A06389950341E36C3A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BB4101A9D49D9A06389950341E36C3A2" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BB4101A9D49D9A06389950341E36C3A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_F59BE80A5326F3B2DC8250341E37B0A7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_F59BE80A5326F3B2DC8250341E37B0A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_F59BE80A5326F3B2DC8250341E37B0A7_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_F59BE80A5326F3B2DC8250341E37B0A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_F59BE80A5326F3B2DC8250341E37B0A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_F59BE80A5326F3B2DC8250341E37B0A7" xlink:to="lab_us-gaap_RestructuringCharges_F59BE80A5326F3B2DC8250341E37B0A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_C341C8C89DC769A3D74450341E37B954_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_C341C8C89DC769A3D74450341E37B954" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_C341C8C89DC769A3D74450341E37B954_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_C341C8C89DC769A3D74450341E37B954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_C341C8C89DC769A3D74450341E37B954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_C341C8C89DC769A3D74450341E37B954" xlink:to="lab_us-gaap_CostsAndExpenses_C341C8C89DC769A3D74450341E37B954" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_E17B10A484C3AB77A64350341E371801_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_E17B10A484C3AB77A64350341E371801" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_E17B10A484C3AB77A64350341E371801_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_E17B10A484C3AB77A64350341E371801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E17B10A484C3AB77A64350341E371801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_E17B10A484C3AB77A64350341E371801" xlink:to="lab_us-gaap_OperatingIncomeLoss_E17B10A484C3AB77A64350341E371801" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9AA5C9446148092C268D50341E37915D_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_9AA5C9446148092C268D50341E37915D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9AA5C9446148092C268D50341E37915D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9AA5C9446148092C268D50341E37915D" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_9AA5C9446148092C268D50341E37915D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_AC0B5128DC3FB25A877A50341E3742C1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_AC0B5128DC3FB25A877A50341E3742C1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_AC0B5128DC3FB25A877A50341E3742C1_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_AC0B5128DC3FB25A877A50341E3742C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_AC0B5128DC3FB25A877A50341E3742C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_AC0B5128DC3FB25A877A50341E3742C1" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_AC0B5128DC3FB25A877A50341E3742C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5F293530BAED37500E2250341E380075_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_5F293530BAED37500E2250341E380075" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5F293530BAED37500E2250341E380075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5F293530BAED37500E2250341E380075" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_5F293530BAED37500E2250341E380075" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_ECC3B3F3386F1355B17D50341E38D712_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_ECC3B3F3386F1355B17D50341E38D712" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ECC3B3F3386F1355B17D50341E38D712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ECC3B3F3386F1355B17D50341E38D712" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_ECC3B3F3386F1355B17D50341E38D712" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_337709C008C7F5CF1E4A50341E384AAA_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_337709C008C7F5CF1E4A50341E384AAA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_337709C008C7F5CF1E4A50341E384AAA_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_337709C008C7F5CF1E4A50341E384AAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_337709C008C7F5CF1E4A50341E384AAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_337709C008C7F5CF1E4A50341E384AAA" xlink:to="lab_us-gaap_ProfitLoss_337709C008C7F5CF1E4A50341E384AAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2A08D72225D301A2867950341E383A56_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2A08D72225D301A2867950341E383A56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2A08D72225D301A2867950341E383A56_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2A08D72225D301A2867950341E383A56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2A08D72225D301A2867950341E383A56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2A08D72225D301A2867950341E383A56" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2A08D72225D301A2867950341E383A56" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_66B95749C8F84E7AC18350341E38BE4F_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_66B95749C8F84E7AC18350341E38BE4F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_66B95749C8F84E7AC18350341E38BE4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_66B95749C8F84E7AC18350341E38BE4F" xlink:to="lab_us-gaap_NetIncomeLoss_66B95749C8F84E7AC18350341E38BE4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9FA920E38DC443A52F6450341E388C3A_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_9FA920E38DC443A52F6450341E388C3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9FA920E38DC443A52F6450341E388C3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9FA920E38DC443A52F6450341E388C3A" xlink:to="lab_us-gaap_EarningsPerShareAbstract_9FA920E38DC443A52F6450341E388C3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_92A00B6C5F75C09F27DC50341E399EC0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_92A00B6C5F75C09F27DC50341E399EC0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_92A00B6C5F75C09F27DC50341E399EC0_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_92A00B6C5F75C09F27DC50341E399EC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_92A00B6C5F75C09F27DC50341E399EC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_92A00B6C5F75C09F27DC50341E399EC0" xlink:to="lab_us-gaap_EarningsPerShareBasic_92A00B6C5F75C09F27DC50341E399EC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_FCD62B42D45E2920E9E150341E39E0A8_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_FCD62B42D45E2920E9E150341E39E0A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_FCD62B42D45E2920E9E150341E39E0A8_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_FCD62B42D45E2920E9E150341E39E0A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_FCD62B42D45E2920E9E150341E39E0A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_FCD62B42D45E2920E9E150341E39E0A8" xlink:to="lab_us-gaap_EarningsPerShareDiluted_FCD62B42D45E2920E9E150341E39E0A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A74ABE19408A8F090CFA50341E39536F_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A74ABE19408A8F090CFA50341E39536F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A74ABE19408A8F090CFA50341E39536F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A74ABE19408A8F090CFA50341E39536F" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A74ABE19408A8F090CFA50341E39536F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9D843D4EB1328683213350341E3995D8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9D843D4EB1328683213350341E3995D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9D843D4EB1328683213350341E3995D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9D843D4EB1328683213350341E3995D8" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9D843D4EB1328683213350341E3995D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_1AD9AF8B14F1027E8AF750341DB251D1_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract_1AD9AF8B14F1027E8AF750341DB251D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_1AD9AF8B14F1027E8AF750341DB251D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_1AD9AF8B14F1027E8AF750341DB251D1" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract_1AD9AF8B14F1027E8AF750341DB251D1" xlink:type="arc" />
    <link:label id="lab_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553_terseLabel_en-US" xlink:label="lab_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553_label_en-US" xlink:label="lab_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553_documentation_en-US" xlink:label="lab_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553" xlink:to="lab_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553" xlink:type="arc" />
    <link:label id="lab_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA_label_en-US" xlink:label="lab_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA" xlink:to="lab_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC" xlink:to="lab_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC" xlink:type="arc" />
    <link:label id="lab_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01" xlink:to="lab_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01" xlink:type="arc" />
    <link:label id="lab_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B_label_en-US" xlink:label="lab_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B" xlink:to="lab_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B" xlink:type="arc" />
    <link:label id="lab_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0_label_en-US" xlink:label="lab_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0_documentation_en-US" xlink:label="lab_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0" xlink:to="lab_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0" xlink:type="arc" />
    <link:label id="lab_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85_label_en-US" xlink:label="lab_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85_documentation_en-US" xlink:label="lab_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85" xlink:to="lab_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85" xlink:type="arc" />
    <link:label id="lab_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC_label_en-US" xlink:label="lab_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC_documentation_en-US" xlink:label="lab_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC" xlink:to="lab_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC" xlink:type="arc" />
    <link:label id="lab_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70_label_en-US" xlink:label="lab_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70" xlink:to="lab_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70" xlink:type="arc" />
    <link:label id="lab_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14_label_en-US" xlink:label="lab_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14_documentation_en-US" xlink:label="lab_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14" xlink:to="lab_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371" xlink:to="lab_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:to="lab_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:type="arc" />
    <link:label id="lab_country_US_CF1D32479306C996872950341DB6F978_terseLabel_en-US" xlink:label="lab_country_US_CF1D32479306C996872950341DB6F978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_CF1D32479306C996872950341DB6F978_label_en-US" xlink:label="lab_country_US_CF1D32479306C996872950341DB6F978" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_CF1D32479306C996872950341DB6F978" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_CF1D32479306C996872950341DB6F978" xlink:to="lab_country_US_CF1D32479306C996872950341DB6F978" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_88A531458F8782A5A51D50341DB6F5AD_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_88A531458F8782A5A51D50341DB6F5AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_88A531458F8782A5A51D50341DB6F5AD_label_en-US" xlink:label="lab_us-gaap_NonUsMember_88A531458F8782A5A51D50341DB6F5AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_88A531458F8782A5A51D50341DB6F5AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_88A531458F8782A5A51D50341DB6F5AD" xlink:to="lab_us-gaap_NonUsMember_88A531458F8782A5A51D50341DB6F5AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_72DA4C3D6DFB60E762D750341E0AB3F7_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_72DA4C3D6DFB60E762D750341E0AB3F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_72DA4C3D6DFB60E762D750341E0AB3F7_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_72DA4C3D6DFB60E762D750341E0AB3F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_72DA4C3D6DFB60E762D750341E0AB3F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_72DA4C3D6DFB60E762D750341E0AB3F7" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_72DA4C3D6DFB60E762D750341E0AB3F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9963D3EA0164343F91BB50341E0AED1C_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_9963D3EA0164343F91BB50341E0AED1C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9963D3EA0164343F91BB50341E0AED1C_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_9963D3EA0164343F91BB50341E0AED1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9963D3EA0164343F91BB50341E0AED1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_9963D3EA0164343F91BB50341E0AED1C" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_9963D3EA0164343F91BB50341E0AED1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9_label_en-US" xlink:label="lab_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9_documentation_en-US" xlink:label="lab_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9" xlink:to="lab_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9" xlink:type="arc" />
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE_terseLabel_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE_label_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE_documentation_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE" xlink:to="lab_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE" xlink:type="arc" />
    <link:label id="lab_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BAN2401 and Elenbecestat</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329" xlink:to="lab_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329" xlink:type="arc" />
    <link:label id="lab_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F_terseLabel_en-US" xlink:label="lab_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aducanumab</link:label>
    <link:label id="lab_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F_label_en-US" xlink:label="lab_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F_documentation_en-US" xlink:label="lab_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F" xlink:to="lab_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:type="arc" />
    <link:label id="lab_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C" xlink:to="lab_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C" xlink:type="arc" />
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212" xlink:type="arc" />
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossOnContractTermination_371EE82620FCC2B2C78350341BED167D_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination_371EE82620FCC2B2C78350341BED167D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on research and development contracts terminated with Eisai</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_371EE82620FCC2B2C78350341BED167D_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination_371EE82620FCC2B2C78350341BED167D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_371EE82620FCC2B2C78350341BED167D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination_371EE82620FCC2B2C78350341BED167D" xlink:to="lab_us-gaap_LossOnContractTermination_371EE82620FCC2B2C78350341BED167D" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payment to Skyhawk</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208" xlink:to="lab_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208" xlink:type="arc" />
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3324AFE6251A7B54551350341BEEEE6C_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_3324AFE6251A7B54551350341BEEEE6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3324AFE6251A7B54551350341BEEEE6C_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_3324AFE6251A7B54551350341BEEEE6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3324AFE6251A7B54551350341BEEEE6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_3324AFE6251A7B54551350341BEEEE6C" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_3324AFE6251A7B54551350341BEEEE6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_029B7EED9D9DA55DA79E50341BEE622D_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_029B7EED9D9DA55DA79E50341BEE622D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_029B7EED9D9DA55DA79E50341BEE622D_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_029B7EED9D9DA55DA79E50341BEE622D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_029B7EED9D9DA55DA79E50341BEE622D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_029B7EED9D9DA55DA79E50341BEE622D" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets_029B7EED9D9DA55DA79E50341BEE622D" xlink:type="arc" />
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9_label_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9_documentation_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="lab_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_CF7FC7422BF20EFA25C950341E404B82_label_en-US" xlink:label="lab_dei_EntityRegistrantName_CF7FC7422BF20EFA25C950341E404B82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_CF7FC7422BF20EFA25C950341E404B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_CF7FC7422BF20EFA25C950341E404B82" xlink:to="lab_dei_EntityRegistrantName_CF7FC7422BF20EFA25C950341E404B82" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_06D40C7791E93480CE8550341E40CDD7_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_06D40C7791E93480CE8550341E40CDD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_06D40C7791E93480CE8550341E40CDD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_06D40C7791E93480CE8550341E40CDD7" xlink:to="lab_dei_EntityCentralIndexKey_06D40C7791E93480CE8550341E40CDD7" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1252999A02411C32C00D50341E40E207_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_1252999A02411C32C00D50341E40E207" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_1252999A02411C32C00D50341E40E207" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_1252999A02411C32C00D50341E40E207" xlink:to="lab_dei_CurrentFiscalYearEndDate_1252999A02411C32C00D50341E40E207" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_4941F326D5E047A4CE7050341E407AD8_label_en-US" xlink:label="lab_dei_EntityFilerCategory_4941F326D5E047A4CE7050341E407AD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_4941F326D5E047A4CE7050341E407AD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_4941F326D5E047A4CE7050341E407AD8" xlink:to="lab_dei_EntityFilerCategory_4941F326D5E047A4CE7050341E407AD8" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_AA4B665085520F078EE350341E404FD9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_AA4B665085520F078EE350341E404FD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_AA4B665085520F078EE350341E404FD9_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_AA4B665085520F078EE350341E404FD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_AA4B665085520F078EE350341E404FD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_AA4B665085520F078EE350341E404FD9" xlink:to="lab_dei_EntitySmallBusiness_AA4B665085520F078EE350341E404FD9" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_405F5AF3FFB58880EE7E50341E4103DD_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_405F5AF3FFB58880EE7E50341E4103DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_405F5AF3FFB58880EE7E50341E4103DD_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_405F5AF3FFB58880EE7E50341E4103DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_405F5AF3FFB58880EE7E50341E4103DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_405F5AF3FFB58880EE7E50341E4103DD" xlink:to="lab_dei_EntityEmergingGrowthCompany_405F5AF3FFB58880EE7E50341E4103DD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_867DD9B40F2475A0E8D650341E414A69_label_en-US" xlink:label="lab_dei_DocumentType_867DD9B40F2475A0E8D650341E414A69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_867DD9B40F2475A0E8D650341E414A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_867DD9B40F2475A0E8D650341E414A69" xlink:to="lab_dei_DocumentType_867DD9B40F2475A0E8D650341E414A69" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_2CD4864A866B8C22DDEE50341E41B5D4_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_2CD4864A866B8C22DDEE50341E41B5D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_2CD4864A866B8C22DDEE50341E41B5D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_2CD4864A866B8C22DDEE50341E41B5D4" xlink:to="lab_dei_DocumentPeriodEndDate_2CD4864A866B8C22DDEE50341E41B5D4" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_998D1AB5B5018270F95F50341E41DE4D_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_998D1AB5B5018270F95F50341E41DE4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_998D1AB5B5018270F95F50341E41DE4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_998D1AB5B5018270F95F50341E41DE4D" xlink:to="lab_dei_DocumentFiscalYearFocus_998D1AB5B5018270F95F50341E41DE4D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_37ACE2B6CBEA92DDFE8D50341E418C4E_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_37ACE2B6CBEA92DDFE8D50341E418C4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_37ACE2B6CBEA92DDFE8D50341E418C4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_37ACE2B6CBEA92DDFE8D50341E418C4E" xlink:to="lab_dei_DocumentFiscalPeriodFocus_37ACE2B6CBEA92DDFE8D50341E418C4E" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_3F51C4240A5A8B9378CD50341E4135E9_label_en-US" xlink:label="lab_dei_AmendmentFlag_3F51C4240A5A8B9378CD50341E4135E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3F51C4240A5A8B9378CD50341E4135E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_3F51C4240A5A8B9378CD50341E4135E9" xlink:to="lab_dei_AmendmentFlag_3F51C4240A5A8B9378CD50341E4135E9" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_D591C581371C3CBD5CA150341E420B94_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_D591C581371C3CBD5CA150341E420B94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_D591C581371C3CBD5CA150341E420B94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_D591C581371C3CBD5CA150341E420B94" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_D591C581371C3CBD5CA150341E420B94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long Lived Assets Held-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long Lived Assets Held-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:to="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Lived Assets and Liabilities Held-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Lived Assets Held-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_3C459CC78EE7AAE9ED2E50341DCAC9E3_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_3C459CC78EE7AAE9ED2E50341DCAC9E3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_3C459CC78EE7AAE9ED2E50341DCAC9E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_3C459CC78EE7AAE9ED2E50341DCAC9E3" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_3C459CC78EE7AAE9ED2E50341DCAC9E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_B10CCB00F16F797F287250341DCB1035_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_B10CCB00F16F797F287250341DCB1035" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_B10CCB00F16F797F287250341DCB1035" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_B10CCB00F16F797F287250341DCB1035" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_B10CCB00F16F797F287250341DCB1035" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F318E9AD32901F9BD0F150341DCB3AF5_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F318E9AD32901F9BD0F150341DCB3AF5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F318E9AD32901F9BD0F150341DCB3AF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F318E9AD32901F9BD0F150341DCB3AF5" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F318E9AD32901F9BD0F150341DCB3AF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_7554577D987AEC21A8CF50341DCBED14_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_7554577D987AEC21A8CF50341DCBED14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_7554577D987AEC21A8CF50341DCBED14_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_7554577D987AEC21A8CF50341DCBED14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_7554577D987AEC21A8CF50341DCBED14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_7554577D987AEC21A8CF50341DCBED14" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_7554577D987AEC21A8CF50341DCBED14" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6E3430F999DF181E7F7650341DCB38D5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6E3430F999DF181E7F7650341DCB38D5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on assets and liabilities held for sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6E3430F999DF181E7F7650341DCB38D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6E3430F999DF181E7F7650341DCB38D5" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6E3430F999DF181E7F7650341DCB38D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3ED87FC3532E4F3ABE5150341DCB01E9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3ED87FC3532E4F3ABE5150341DCB01E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3ED87FC3532E4F3ABE5150341DCB01E9_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3ED87FC3532E4F3ABE5150341DCB01E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3ED87FC3532E4F3ABE5150341DCB01E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3ED87FC3532E4F3ABE5150341DCB01E9" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3ED87FC3532E4F3ABE5150341DCB01E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8F45560488E0BB72F39850341DCC01FF_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8F45560488E0BB72F39850341DCC01FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8F45560488E0BB72F39850341DCC01FF_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8F45560488E0BB72F39850341DCC01FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8F45560488E0BB72F39850341DCC01FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8F45560488E0BB72F39850341DCC01FF" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8F45560488E0BB72F39850341DCC01FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_D5E6B5943714B2638B0050341DCC3AD5_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_D5E6B5943714B2638B0050341DCC3AD5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_D5E6B5943714B2638B0050341DCC3AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_D5E6B5943714B2638B0050341DCC3AD5" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_D5E6B5943714B2638B0050341DCC3AD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4F45AD3E5B915056C86450341DCC9515_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4F45AD3E5B915056C86450341DCC9515" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4F45AD3E5B915056C86450341DCC9515_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4F45AD3E5B915056C86450341DCC9515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4F45AD3E5B915056C86450341DCC9515" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4F45AD3E5B915056C86450341DCC9515" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4F45AD3E5B915056C86450341DCC9515" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:type="arc" />
    <link:label id="lab_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6_label_en-US" xlink:label="lab_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6" xlink:to="lab_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:to="lab_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:type="arc" />
    <link:label id="lab_currency_EUR_86FAE39A62DCA19C646B50341CD5507E_verboseLabel_en-US" xlink:label="lab_currency_EUR_86FAE39A62DCA19C646B50341CD5507E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_86FAE39A62DCA19C646B50341CD5507E_label_en-US" xlink:label="lab_currency_EUR_86FAE39A62DCA19C646B50341CD5507E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_86FAE39A62DCA19C646B50341CD5507E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_86FAE39A62DCA19C646B50341CD5507E" xlink:to="lab_currency_EUR_86FAE39A62DCA19C646B50341CD5507E" xlink:type="arc" />
    <link:label id="lab_currency_GBP_72452122B4031A42C61D50341CD5A2AE_terseLabel_en-US" xlink:label="lab_currency_GBP_72452122B4031A42C61D50341CD5A2AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_72452122B4031A42C61D50341CD5A2AE_label_en-US" xlink:label="lab_currency_GBP_72452122B4031A42C61D50341CD5A2AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_72452122B4031A42C61D50341CD5A2AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_72452122B4031A42C61D50341CD5A2AE" xlink:to="lab_currency_GBP_72452122B4031A42C61D50341CD5A2AE" xlink:type="arc" />
    <link:label id="lab_currency_CHF_953F7F0879AF64D433B750341CD6FCD2_terseLabel_en-US" xlink:label="lab_currency_CHF_953F7F0879AF64D433B750341CD6FCD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_953F7F0879AF64D433B750341CD6FCD2_label_en-US" xlink:label="lab_currency_CHF_953F7F0879AF64D433B750341CD6FCD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_953F7F0879AF64D433B750341CD6FCD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_953F7F0879AF64D433B750341CD6FCD2" xlink:to="lab_currency_CHF_953F7F0879AF64D433B750341CD6FCD2" xlink:type="arc" />
    <link:label id="lab_currency_JPY_7A6099150B62C65ECB8150341CD674E6_terseLabel_en-US" xlink:label="lab_currency_JPY_7A6099150B62C65ECB8150341CD674E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_7A6099150B62C65ECB8150341CD674E6_label_en-US" xlink:label="lab_currency_JPY_7A6099150B62C65ECB8150341CD674E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_7A6099150B62C65ECB8150341CD674E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY_7A6099150B62C65ECB8150341CD674E6" xlink:to="lab_currency_JPY_7A6099150B62C65ECB8150341CD674E6" xlink:type="arc" />
    <link:label id="lab_currency_CAD_56E571175FA19E6F40D150341CD65DE0_verboseLabel_en-US" xlink:label="lab_currency_CAD_56E571175FA19E6F40D150341CD65DE0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_56E571175FA19E6F40D150341CD65DE0_label_en-US" xlink:label="lab_currency_CAD_56E571175FA19E6F40D150341CD65DE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_56E571175FA19E6F40D150341CD65DE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_56E571175FA19E6F40D150341CD65DE0" xlink:to="lab_currency_CAD_56E571175FA19E6F40D150341CD65DE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_F156FD779DE2CD1B40DC50341CD7F4DC_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_F156FD779DE2CD1B40DC50341CD7F4DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_F156FD779DE2CD1B40DC50341CD7F4DC_label_en-US" xlink:label="lab_us-gaap_SalesMember_F156FD779DE2CD1B40DC50341CD7F4DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_F156FD779DE2CD1B40DC50341CD7F4DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_F156FD779DE2CD1B40DC50341CD7F4DC" xlink:to="lab_us-gaap_SalesMember_F156FD779DE2CD1B40DC50341CD7F4DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_22625E856FFEA2B719E650341CD79F76_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_22625E856FFEA2B719E650341CD79F76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_22625E856FFEA2B719E650341CD79F76_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_22625E856FFEA2B719E650341CD79F76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_22625E856FFEA2B719E650341CD79F76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_22625E856FFEA2B719E650341CD79F76" xlink:to="lab_us-gaap_OperatingExpenseMember_22625E856FFEA2B719E650341CD79F76" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:to="lab_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F" xlink:to="lab_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2" xlink:to="lab_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_1E8D7E8007CF2704BFCF50341CD88669_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_1E8D7E8007CF2704BFCF50341CD88669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_1E8D7E8007CF2704BFCF50341CD88669_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_1E8D7E8007CF2704BFCF50341CD88669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1E8D7E8007CF2704BFCF50341CD88669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember_1E8D7E8007CF2704BFCF50341CD88669" xlink:to="lab_us-gaap_NetInvestmentHedgingMember_1E8D7E8007CF2704BFCF50341CD88669" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_A933B2892412785CC26550341CD86FA3_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_A933B2892412785CC26550341CD86FA3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_A933B2892412785CC26550341CD86FA3_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_A933B2892412785CC26550341CD86FA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_A933B2892412785CC26550341CD86FA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_A933B2892412785CC26550341CD86FA3" xlink:to="lab_us-gaap_ForeignExchangeContractMember_A933B2892412785CC26550341CD86FA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_892FF2A53C01509A43D850341CD9B5DA_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_892FF2A53C01509A43D850341CD9B5DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_892FF2A53C01509A43D850341CD9B5DA_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_892FF2A53C01509A43D850341CD9B5DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_892FF2A53C01509A43D850341CD9B5DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_892FF2A53C01509A43D850341CD9B5DA" xlink:to="lab_us-gaap_InterestRateSwapMember_892FF2A53C01509A43D850341CD9B5DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9AA06A89656BE383A5A850341CDA615A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9AA06A89656BE383A5A850341CDA615A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9AA06A89656BE383A5A850341CDA615A_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9AA06A89656BE383A5A850341CDA615A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9AA06A89656BE383A5A850341CDA615A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9AA06A89656BE383A5A850341CDA615A" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9AA06A89656BE383A5A850341CDA615A" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063" xlink:to="lab_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:to="lab_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4F0E8A927E74F0F74C6450341CDA622F_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4F0E8A927E74F0F74C6450341CDA622F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4F0E8A927E74F0F74C6450341CDA622F_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4F0E8A927E74F0F74C6450341CDA622F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4F0E8A927E74F0F74C6450341CDA622F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4F0E8A927E74F0F74C6450341CDA622F" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4F0E8A927E74F0F74C6450341CDA622F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_1656706986FFE6C932E350341CDB1AB5_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_1656706986FFE6C932E350341CDB1AB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_1656706986FFE6C932E350341CDB1AB5_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_1656706986FFE6C932E350341CDB1AB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_1656706986FFE6C932E350341CDB1AB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_1656706986FFE6C932E350341CDB1AB5" xlink:to="lab_us-gaap_NondesignatedMember_1656706986FFE6C932E350341CDB1AB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_115187616BF10480151950341CDCC92A_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_115187616BF10480151950341CDCC92A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_115187616BF10480151950341CDCC92A_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_115187616BF10480151950341CDCC92A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_115187616BF10480151950341CDCC92A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_115187616BF10480151950341CDCC92A" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_115187616BF10480151950341CDCC92A" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_0D3C5482C15A7D44F65050341CDC20F1_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_0D3C5482C15A7D44F65050341CDC20F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate notional amount</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_0D3C5482C15A7D44F65050341CDC20F1_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_0D3C5482C15A7D44F65050341CDC20F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_0D3C5482C15A7D44F65050341CDC20F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_0D3C5482C15A7D44F65050341CDC20F1" xlink:to="lab_invest_DerivativeNotionalAmount_0D3C5482C15A7D44F65050341CDC20F1" xlink:type="arc" />
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5_negatedLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1EB175CE6A0F048BABC450341CDD6BE9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1EB175CE6A0F048BABC450341CDD6BE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on reclassification of cash flow hedges, effective portion</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1EB175CE6A0F048BABC450341CDD6BE9_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1EB175CE6A0F048BABC450341CDD6BE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1EB175CE6A0F048BABC450341CDD6BE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1EB175CE6A0F048BABC450341CDD6BE9" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1EB175CE6A0F048BABC450341CDD6BE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_EB7717D811579C774A8250341CDDEDB4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_EB7717D811579C774A8250341CDDEDB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) recognized in net income, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_EB7717D811579C774A8250341CDDEDB4_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_EB7717D811579C774A8250341CDDEDB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_EB7717D811579C774A8250341CDDEDB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_EB7717D811579C774A8250341CDDEDB4" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_EB7717D811579C774A8250341CDDEDB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC47F08124C31B138B8250341CDDF051_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC47F08124C31B138B8250341CDDF051" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC47F08124C31B138B8250341CDDF051" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC47F08124C31B138B8250341CDDF051" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC47F08124C31B138B8250341CDDF051" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeTermOfContract_2353C5E21067DA954BCE50341CDD53F1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_2353C5E21067DA954BCE50341CDD53F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining duration of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_2353C5E21067DA954BCE50341CDD53F1_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_2353C5E21067DA954BCE50341CDD53F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_2353C5E21067DA954BCE50341CDD53F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract_2353C5E21067DA954BCE50341CDD53F1" xlink:to="lab_us-gaap_DerivativeTermOfContract_2353C5E21067DA954BCE50341CDD53F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4648CE094E82971C5F6950341CDEF25C_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4648CE094E82971C5F6950341CDEF25C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on net investment hedges in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4648CE094E82971C5F6950341CDEF25C_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4648CE094E82971C5F6950341CDEF25C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4648CE094E82971C5F6950341CDEF25C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4648CE094E82971C5F6950341CDEF25C" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4648CE094E82971C5F6950341CDEF25C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_4454C4F625C5F5F5029250341CDEAC57_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_4454C4F625C5F5F5029250341CDEAC57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative qualifying as net investment hedge, excluded component</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_4454C4F625C5F5F5029250341CDEAC57_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_4454C4F625C5F5F5029250341CDEAC57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_4454C4F625C5F5F5029250341CDEAC57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_4454C4F625C5F5F5029250341CDEAC57" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_4454C4F625C5F5F5029250341CDEAC57" xlink:type="arc" />
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6A14F9C2AC80AA4F456F50341CDE268A_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6A14F9C2AC80AA4F456F50341CDE268A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6A14F9C2AC80AA4F456F50341CDE268A_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6A14F9C2AC80AA4F456F50341CDE268A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6A14F9C2AC80AA4F456F50341CDE268A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6A14F9C2AC80AA4F456F50341CDE268A" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6A14F9C2AC80AA4F456F50341CDE268A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_01B88489A6F34AEFC48C50341CDE5A57_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_01B88489A6F34AEFC48C50341CDE5A57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_01B88489A6F34AEFC48C50341CDE5A57_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_01B88489A6F34AEFC48C50341CDE5A57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_01B88489A6F34AEFC48C50341CDE5A57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_01B88489A6F34AEFC48C50341CDE5A57" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_01B88489A6F34AEFC48C50341CDE5A57" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_718C2C037F25D4CA48CC50341CDF12B0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_718C2C037F25D4CA48CC50341CDF12B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_718C2C037F25D4CA48CC50341CDF12B0_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_718C2C037F25D4CA48CC50341CDF12B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_718C2C037F25D4CA48CC50341CDF12B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_718C2C037F25D4CA48CC50341CDF12B0" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_718C2C037F25D4CA48CC50341CDF12B0" xlink:type="arc" />
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7E4236CFBDACE765154A50341BF28D5C_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7E4236CFBDACE765154A50341BF28D5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7E4236CFBDACE765154A50341BF28D5C_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7E4236CFBDACE765154A50341BF28D5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7E4236CFBDACE765154A50341BF28D5C_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7E4236CFBDACE765154A50341BF28D5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7E4236CFBDACE765154A50341BF28D5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7E4236CFBDACE765154A50341BF28D5C" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7E4236CFBDACE765154A50341BF28D5C" xlink:type="arc" />
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_A97E717B482C7F8B74D450341BF29CCA_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_A97E717B482C7F8B74D450341BF29CCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_A97E717B482C7F8B74D450341BF29CCA_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_A97E717B482C7F8B74D450341BF29CCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_A97E717B482C7F8B74D450341BF29CCA_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_A97E717B482C7F8B74D450341BF29CCA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_A97E717B482C7F8B74D450341BF29CCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_A97E717B482C7F8B74D450341BF29CCA" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_A97E717B482C7F8B74D450341BF29CCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9105810D373D90CBF61F50341C17BB65_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9105810D373D90CBF61F50341C17BB65" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9105810D373D90CBF61F50341C17BB65_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9105810D373D90CBF61F50341C17BB65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9105810D373D90CBF61F50341C17BB65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9105810D373D90CBF61F50341C17BB65" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9105810D373D90CBF61F50341C17BB65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EE0FF13B28E0CCE9E31450341C17E97B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EE0FF13B28E0CCE9E31450341C17E97B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EE0FF13B28E0CCE9E31450341C17E97B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EE0FF13B28E0CCE9E31450341C17E97B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EE0FF13B28E0CCE9E31450341C17E97B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EE0FF13B28E0CCE9E31450341C17E97B" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EE0FF13B28E0CCE9E31450341C17E97B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9159B126911D47C26E9050341C63C1A0_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9159B126911D47C26E9050341C63C1A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9159B126911D47C26E9050341C63C1A0_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9159B126911D47C26E9050341C63C1A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9159B126911D47C26E9050341C63C1A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9159B126911D47C26E9050341C63C1A0" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9159B126911D47C26E9050341C63C1A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_DE9E896790D65B9CD85F50341DE88623_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_DE9E896790D65B9CD85F50341DE88623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_DE9E896790D65B9CD85F50341DE88623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_DE9E896790D65B9CD85F50341DE88623" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_DE9E896790D65B9CD85F50341DE88623" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201616Member_2D0D5617566737A3452350341DE9F1DC_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member_2D0D5617566737A3452350341DE9F1DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-16</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201616Member_2D0D5617566737A3452350341DE9F1DC_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member_2D0D5617566737A3452350341DE9F1DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-16 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_2D0D5617566737A3452350341DE9F1DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201616Member_2D0D5617566737A3452350341DE9F1DC" xlink:to="lab_us-gaap_AccountingStandardsUpdate201616Member_2D0D5617566737A3452350341DE9F1DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_7518A54EF68570101F9350341DEBEDF8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_7518A54EF68570101F9350341DEBEDF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_7518A54EF68570101F9350341DEBEDF8_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_7518A54EF68570101F9350341DEBEDF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_7518A54EF68570101F9350341DEBEDF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_7518A54EF68570101F9350341DEBEDF8" xlink:to="lab_us-gaap_PreferredStockMember_7518A54EF68570101F9350341DEBEDF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_FEFC8C73EB1F6D64D09D50341DEB2D0F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_FEFC8C73EB1F6D64D09D50341DEB2D0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_FEFC8C73EB1F6D64D09D50341DEB2D0F_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_FEFC8C73EB1F6D64D09D50341DEB2D0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FEFC8C73EB1F6D64D09D50341DEB2D0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_FEFC8C73EB1F6D64D09D50341DEB2D0F" xlink:to="lab_us-gaap_CommonStockMember_FEFC8C73EB1F6D64D09D50341DEB2D0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7803110D46BB009C13BC50341DEB8FC3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_7803110D46BB009C13BC50341DEB8FC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7803110D46BB009C13BC50341DEB8FC3_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_7803110D46BB009C13BC50341DEB8FC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7803110D46BB009C13BC50341DEB8FC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_7803110D46BB009C13BC50341DEB8FC3" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_7803110D46BB009C13BC50341DEB8FC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28B1E2AF18B42DF1715D50341DEB11BD_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28B1E2AF18B42DF1715D50341DEB11BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28B1E2AF18B42DF1715D50341DEB11BD_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28B1E2AF18B42DF1715D50341DEB11BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28B1E2AF18B42DF1715D50341DEB11BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28B1E2AF18B42DF1715D50341DEB11BD" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28B1E2AF18B42DF1715D50341DEB11BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_30021A544F7EAD4E960950341DEB08FC_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_30021A544F7EAD4E960950341DEB08FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_30021A544F7EAD4E960950341DEB08FC_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_30021A544F7EAD4E960950341DEB08FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_30021A544F7EAD4E960950341DEB08FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_30021A544F7EAD4E960950341DEB08FC" xlink:to="lab_us-gaap_RetainedEarningsMember_30021A544F7EAD4E960950341DEB08FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_4EBB2FBB185D79456C4550341DECC259_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_4EBB2FBB185D79456C4550341DECC259" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_4EBB2FBB185D79456C4550341DECC259_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_4EBB2FBB185D79456C4550341DECC259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_4EBB2FBB185D79456C4550341DECC259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_4EBB2FBB185D79456C4550341DECC259" xlink:to="lab_us-gaap_TreasuryStockMember_4EBB2FBB185D79456C4550341DECC259" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_2EF810A1DF8F8864C7C250341DEC4051_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_2EF810A1DF8F8864C7C250341DEC4051" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_2EF810A1DF8F8864C7C250341DEC4051_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_2EF810A1DF8F8864C7C250341DEC4051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2EF810A1DF8F8864C7C250341DEC4051" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_2EF810A1DF8F8864C7C250341DEC4051" xlink:to="lab_us-gaap_NoncontrollingInterestMember_2EF810A1DF8F8864C7C250341DEC4051" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_7C73E3AE093C8793B1C150341DECCC8C_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_7C73E3AE093C8793B1C150341DECCC8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_7C73E3AE093C8793B1C150341DECCC8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_7C73E3AE093C8793B1C150341DECCC8C" xlink:to="lab_us-gaap_ParentMember_7C73E3AE093C8793B1C150341DECCC8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27C84723C10D5E9C11CF50341DECAAC4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27C84723C10D5E9C11CF50341DECAAC4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27C84723C10D5E9C11CF50341DECAAC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27C84723C10D5E9C11CF50341DECAAC4" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27C84723C10D5E9C11CF50341DECAAC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_9B9863D29CEA347AA76350341DEC4D9F_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_9B9863D29CEA347AA76350341DEC4D9F" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesIssued_9B9863D29CEA347AA76350341DEC4D9F_label_en-US" xlink:label="lab_us-gaap_SharesIssued_9B9863D29CEA347AA76350341DEC4D9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_9B9863D29CEA347AA76350341DEC4D9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_9B9863D29CEA347AA76350341DEC4D9F" xlink:to="lab_us-gaap_SharesIssued_9B9863D29CEA347AA76350341DEC4D9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_0E2A87766C2222E1119150341DED6E72_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_0E2A87766C2222E1119150341DED6E72" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0E2A87766C2222E1119150341DED6E72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_0E2A87766C2222E1119150341DED6E72" xlink:to="lab_us-gaap_StockholdersEquity_0E2A87766C2222E1119150341DED6E72" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_F94B3D08254412A6DF4250341DED00E8_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_F94B3D08254412A6DF4250341DED00E8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_F94B3D08254412A6DF4250341DED00E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_F94B3D08254412A6DF4250341DED00E8" xlink:to="lab_us-gaap_MinorityInterest_F94B3D08254412A6DF4250341DED00E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D99F11812A495BFF41D750341DED1B27_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D99F11812A495BFF41D750341DED1B27" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interest, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D99F11812A495BFF41D750341DED1B27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D99F11812A495BFF41D750341DED1B27" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D99F11812A495BFF41D750341DED1B27" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_A4B83D2974C8012F516C50341DED2C5C_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_A4B83D2974C8012F516C50341DED2C5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_A4B83D2974C8012F516C50341DED2C5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_A4B83D2974C8012F516C50341DED2C5C" xlink:to="lab_us-gaap_ProfitLoss_A4B83D2974C8012F516C50341DED2C5C" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_392863B878F168E6294950341DEEF8D1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_392863B878F168E6294950341DEEF8D1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_392863B878F168E6294950341DEEF8D1_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_392863B878F168E6294950341DEEF8D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_392863B878F168E6294950341DEEF8D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_392863B878F168E6294950341DEEF8D1" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_392863B878F168E6294950341DEEF8D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_DDFB00A32A502A80F1E950341DEE62B2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_DDFB00A32A502A80F1E950341DEE62B2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_DDFB00A32A502A80F1E950341DEE62B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_DDFB00A32A502A80F1E950341DEE62B2" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_DDFB00A32A502A80F1E950341DEE62B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_2C7F96E52C1509AE18FA50341DEE8C3D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_2C7F96E52C1509AE18FA50341DEE8C3D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Progams, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_2C7F96E52C1509AE18FA50341DEE8C3D_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_2C7F96E52C1509AE18FA50341DEE8C3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_2C7F96E52C1509AE18FA50341DEE8C3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_2C7F96E52C1509AE18FA50341DEE8C3D" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_2C7F96E52C1509AE18FA50341DEE8C3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5349E05E8557FF9164B950341DEE9C0D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5349E05E8557FF9164B950341DEE9C0D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5349E05E8557FF9164B950341DEE9C0D_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5349E05E8557FF9164B950341DEE9C0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5349E05E8557FF9164B950341DEE9C0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5349E05E8557FF9164B950341DEE9C0D" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5349E05E8557FF9164B950341DEE9C0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_EBA27CFF411CD04E8E4650341DEF4C40_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_EBA27CFF411CD04E8E4650341DEF4C40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_EBA27CFF411CD04E8E4650341DEF4C40_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_EBA27CFF411CD04E8E4650341DEF4C40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_EBA27CFF411CD04E8E4650341DEF4C40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_EBA27CFF411CD04E8E4650341DEF4C40" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_EBA27CFF411CD04E8E4650341DEF4C40" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECDF24632B07A66E594150341DEF1325_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECDF24632B07A66E594150341DEF1325" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECDF24632B07A66E594150341DEF1325_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECDF24632B07A66E594150341DEF1325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECDF24632B07A66E594150341DEF1325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECDF24632B07A66E594150341DEF1325" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECDF24632B07A66E594150341DEF1325" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0D0A0D00D7DB44200F1150341DEF244A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0D0A0D00D7DB44200F1150341DEF244A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0D0A0D00D7DB44200F1150341DEF244A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0D0A0D00D7DB44200F1150341DEF244A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0D0A0D00D7DB44200F1150341DEF244A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0D0A0D00D7DB44200F1150341DEF244A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0D0A0D00D7DB44200F1150341DEF244A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6C4050238115C76BCE4E50341DEF482F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6C4050238115C76BCE4E50341DEF482F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6C4050238115C76BCE4E50341DEF482F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6C4050238115C76BCE4E50341DEF482F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6C4050238115C76BCE4E50341DEF482F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6C4050238115C76BCE4E50341DEF482F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6C4050238115C76BCE4E50341DEF482F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_983ED9122DC173FC506A50341DEF145B_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_983ED9122DC173FC506A50341DEF145B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_983ED9122DC173FC506A50341DEF145B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_983ED9122DC173FC506A50341DEF145B" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_983ED9122DC173FC506A50341DEF145B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityOther_DA725461851D6C900B2F50341DEF361C_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_DA725461851D6C900B2F50341DEF361C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of new accounting guidance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_DA725461851D6C900B2F50341DEF361C_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_DA725461851D6C900B2F50341DEF361C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_DA725461851D6C900B2F50341DEF361C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther_DA725461851D6C900B2F50341DEF361C" xlink:to="lab_us-gaap_StockholdersEquityOther_DA725461851D6C900B2F50341DEF361C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BEC1F7B3F088118528CB50341DF08491_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BEC1F7B3F088118528CB50341DF08491" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BEC1F7B3F088118528CB50341DF08491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BEC1F7B3F088118528CB50341DF08491" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BEC1F7B3F088118528CB50341DF08491" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_EB1ACA3D5DF87A65AEDA50341DF0D117_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_EB1ACA3D5DF87A65AEDA50341DF0D117" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_EB1ACA3D5DF87A65AEDA50341DF0D117" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_EB1ACA3D5DF87A65AEDA50341DF0D117" xlink:to="lab_us-gaap_StockholdersEquity_EB1ACA3D5DF87A65AEDA50341DF0D117" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_7FE01C5293BA4480400150341DF09D0A_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_7FE01C5293BA4480400150341DF09D0A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_7FE01C5293BA4480400150341DF09D0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_7FE01C5293BA4480400150341DF09D0A" xlink:to="lab_us-gaap_MinorityInterest_7FE01C5293BA4480400150341DF09D0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_16BC87CC915066DA05FF50341DF05EA1_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_16BC87CC915066DA05FF50341DF05EA1" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_16BC87CC915066DA05FF50341DF05EA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_16BC87CC915066DA05FF50341DF05EA1" xlink:to="lab_us-gaap_SharesIssued_16BC87CC915066DA05FF50341DF05EA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_3202D972F02F4CAF89CD50341D2DE89A_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_3202D972F02F4CAF89CD50341D2DE89A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_3202D972F02F4CAF89CD50341D2DE89A_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_3202D972F02F4CAF89CD50341D2DE89A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_3202D972F02F4CAF89CD50341D2DE89A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_3202D972F02F4CAF89CD50341D2DE89A" xlink:to="lab_us-gaap_EquitySecuritiesMember_3202D972F02F4CAF89CD50341D2DE89A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAC5111EC817B92E1BDA50341D2D5503_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAC5111EC817B92E1BDA50341D2D5503" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAC5111EC817B92E1BDA50341D2D5503_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAC5111EC817B92E1BDA50341D2D5503" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAC5111EC817B92E1BDA50341D2D5503" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAC5111EC817B92E1BDA50341D2D5503" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAC5111EC817B92E1BDA50341D2D5503" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4B3A57A65B79B0ACA88950341D2E61BF_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4B3A57A65B79B0ACA88950341D2E61BF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4B3A57A65B79B0ACA88950341D2E61BF_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4B3A57A65B79B0ACA88950341D2E61BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4B3A57A65B79B0ACA88950341D2E61BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4B3A57A65B79B0ACA88950341D2E61BF" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4B3A57A65B79B0ACA88950341D2E61BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3147B7F5A416F7B6F26F50341D2E393B_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3147B7F5A416F7B6F26F50341D2E393B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3147B7F5A416F7B6F26F50341D2E393B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3147B7F5A416F7B6F26F50341D2E393B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3147B7F5A416F7B6F26F50341D2E393B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_998D1ECA3F5D384DBAFD50341D2E41FC_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_998D1ECA3F5D384DBAFD50341D2E41FC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_998D1ECA3F5D384DBAFD50341D2E41FC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_998D1ECA3F5D384DBAFD50341D2E41FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_998D1ECA3F5D384DBAFD50341D2E41FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_998D1ECA3F5D384DBAFD50341D2E41FC" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_998D1ECA3F5D384DBAFD50341D2E41FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B40066506ED9777EAF4B50341D2E40AA_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B40066506ED9777EAF4B50341D2E40AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B40066506ED9777EAF4B50341D2E40AA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B40066506ED9777EAF4B50341D2E40AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B40066506ED9777EAF4B50341D2E40AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B40066506ED9777EAF4B50341D2E40AA" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B40066506ED9777EAF4B50341D2E40AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F09C2DC2A4FDCADA8BCB50341D2EE71D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F09C2DC2A4FDCADA8BCB50341D2EE71D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F09C2DC2A4FDCADA8BCB50341D2EE71D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F09C2DC2A4FDCADA8BCB50341D2EE71D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F09C2DC2A4FDCADA8BCB50341D2EE71D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F09C2DC2A4FDCADA8BCB50341D2EE71D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F09C2DC2A4FDCADA8BCB50341D2EE71D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_4E34EF54C1F3016BBF5450341D2EA778_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_4E34EF54C1F3016BBF5450341D2EA778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_4E34EF54C1F3016BBF5450341D2EA778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_4E34EF54C1F3016BBF5450341D2EA778" xlink:to="lab_us-gaap_AvailableForSaleSecurities_4E34EF54C1F3016BBF5450341D2EA778" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3AE9209802CC485B5D4F50341D3B6A32_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3AE9209802CC485B5D4F50341D3B6A32" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3AE9209802CC485B5D4F50341D3B6A32_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3AE9209802CC485B5D4F50341D3B6A32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3AE9209802CC485B5D4F50341D3B6A32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3AE9209802CC485B5D4F50341D3B6A32" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3AE9209802CC485B5D4F50341D3B6A32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_07D799DD9D760792D8E650341CE6CBD9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_07D799DD9D760792D8E650341CE6CBD9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_07D799DD9D760792D8E650341CE6CBD9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_07D799DD9D760792D8E650341CE6CBD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_07D799DD9D760792D8E650341CE6CBD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_07D799DD9D760792D8E650341CE6CBD9" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_07D799DD9D760792D8E650341CE6CBD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_88AFF27065163A2197D250341CE63F35_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_88AFF27065163A2197D250341CE63F35" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_88AFF27065163A2197D250341CE63F35_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_88AFF27065163A2197D250341CE63F35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_88AFF27065163A2197D250341CE63F35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_88AFF27065163A2197D250341CE63F35" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_88AFF27065163A2197D250341CE63F35" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B4C38FA3B8FEE28C378B50341CE652F0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B4C38FA3B8FEE28C378B50341CE652F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B4C38FA3B8FEE28C378B50341CE652F0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B4C38FA3B8FEE28C378B50341CE652F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B4C38FA3B8FEE28C378B50341CE652F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B4C38FA3B8FEE28C378B50341CE652F0" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B4C38FA3B8FEE28C378B50341CE652F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_F92BA920CA674CD070A150341CE6E13E_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_F92BA920CA674CD070A150341CE6E13E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_F92BA920CA674CD070A150341CE6E13E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_F92BA920CA674CD070A150341CE6E13E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_F92BA920CA674CD070A150341CE6E13E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_F92BA920CA674CD070A150341CE6E13E" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_F92BA920CA674CD070A150341CE6E13E" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesAbstract_D58ED4E2810AEA032A0650341D9984A0_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract_D58ED4E2810AEA032A0650341D9984A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_D58ED4E2810AEA032A0650341D9984A0_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract_D58ED4E2810AEA032A0650341D9984A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_OtherrevenuesAbstract" xlink:label="loc_biib_OtherrevenuesAbstract_D58ED4E2810AEA032A0650341D9984A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract_D58ED4E2810AEA032A0650341D9984A0" xlink:to="lab_biib_OtherrevenuesAbstract_D58ED4E2810AEA032A0650341D9984A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyMember_1C76F2D9B99CAF82283350341D9B6CE4_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember_1C76F2D9B99CAF82283350341D9B6CE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_1C76F2D9B99CAF82283350341D9B6CE4_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember_1C76F2D9B99CAF82283350341D9B6CE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_1C76F2D9B99CAF82283350341D9B6CE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember_1C76F2D9B99CAF82283350341D9B6CE4" xlink:to="lab_us-gaap_RoyaltyMember_1C76F2D9B99CAF82283350341D9B6CE4" xlink:type="arc" />
    <link:label id="lab_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8" xlink:to="lab_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8" xlink:type="arc" />
    <link:label id="lab_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E_terseLabel_en-US" xlink:label="lab_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E_label_en-US" xlink:label="lab_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E_documentation_en-US" xlink:label="lab_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20190331.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E" xlink:to="lab_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_BB74B116BD55C2CDEA8150341D9DBF01_negatedLabel_en-US" xlink:label="lab_us-gaap_Revenues_BB74B116BD55C2CDEA8150341D9DBF01" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BB74B116BD55C2CDEA8150341D9DBF01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_BB74B116BD55C2CDEA8150341D9DBF01" xlink:to="lab_us-gaap_Revenues_BB74B116BD55C2CDEA8150341D9DBF01" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2410E3178B5EA4E4D31650341DFEF84A_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2410E3178B5EA4E4D31650341DFEF84A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2410E3178B5EA4E4D31650341DFEF84A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2410E3178B5EA4E4D31650341DFEF84A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2410E3178B5EA4E4D31650341DFEF84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2410E3178B5EA4E4D31650341DFEF84A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2410E3178B5EA4E4D31650341DFEF84A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_713B0E7A01BA213A845150341DFE34CE_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_713B0E7A01BA213A845150341DFE34CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_713B0E7A01BA213A845150341DFE34CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_713B0E7A01BA213A845150341DFE34CE" xlink:to="lab_us-gaap_ProfitLoss_713B0E7A01BA213A845150341DFE34CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_E5C6773628065BD3933150341DFF9EB6_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_E5C6773628065BD3933150341DFF9EB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairments</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_E5C6773628065BD3933150341DFF9EB6_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_E5C6773628065BD3933150341DFF9EB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_E5C6773628065BD3933150341DFF9EB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_E5C6773628065BD3933150341DFF9EB6" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_E5C6773628065BD3933150341DFF9EB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_B440A446481D543D444950341DFFA3DD_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_B440A446481D543D444950341DFFA3DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_B440A446481D543D444950341DFFA3DD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_B440A446481D543D444950341DFFA3DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_B440A446481D543D444950341DFFA3DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_B440A446481D543D444950341DFFA3DD" xlink:to="lab_us-gaap_ShareBasedCompensation_B440A446481D543D444950341DFFA3DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2D504C1CFC7C2A3BA45B50341DFFB4E1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2D504C1CFC7C2A3BA45B50341DFFB4E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2D504C1CFC7C2A3BA45B50341DFFB4E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2D504C1CFC7C2A3BA45B50341DFFB4E1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2D504C1CFC7C2A3BA45B50341DFFB4E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_D7A2A0E5F158FAD39CDF50341DFFB9B1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_D7A2A0E5F158FAD39CDF50341DFFB9B1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on assets and liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_D7A2A0E5F158FAD39CDF50341DFFB9B1_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_D7A2A0E5F158FAD39CDF50341DFFB9B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_D7A2A0E5F158FAD39CDF50341DFFB9B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_D7A2A0E5F158FAD39CDF50341DFFB9B1" xlink:to="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_D7A2A0E5F158FAD39CDF50341DFFB9B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_65DEF2CCE382D2E6F48D50341E0058B4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_65DEF2CCE382D2E6F48D50341E0058B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_65DEF2CCE382D2E6F48D50341E0058B4_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_65DEF2CCE382D2E6F48D50341E0058B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_65DEF2CCE382D2E6F48D50341E0058B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_65DEF2CCE382D2E6F48D50341E0058B4" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_65DEF2CCE382D2E6F48D50341E0058B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_807EE326C2277652A76D50341E00C683_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_807EE326C2277652A76D50341E00C683" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_807EE326C2277652A76D50341E00C683_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_807EE326C2277652A76D50341E00C683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_807EE326C2277652A76D50341E00C683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_807EE326C2277652A76D50341E00C683" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_807EE326C2277652A76D50341E00C683" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_6F89A32008E8861AECF950341E005DE8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_6F89A32008E8861AECF950341E005DE8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_6F89A32008E8861AECF950341E005DE8_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_6F89A32008E8861AECF950341E005DE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6F89A32008E8861AECF950341E005DE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_6F89A32008E8861AECF950341E005DE8" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_6F89A32008E8861AECF950341E005DE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B0D95E23F074A426C66350341E0051C1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B0D95E23F074A426C66350341E0051C1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B0D95E23F074A426C66350341E0051C1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B0D95E23F074A426C66350341E0051C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B0D95E23F074A426C66350341E0051C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B0D95E23F074A426C66350341E0051C1" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B0D95E23F074A426C66350341E0051C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0ADB4F100D306B49A55050341E011B29_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_0ADB4F100D306B49A55050341E011B29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0ADB4F100D306B49A55050341E011B29_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_0ADB4F100D306B49A55050341E011B29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0ADB4F100D306B49A55050341E011B29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_0ADB4F100D306B49A55050341E011B29" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_0ADB4F100D306B49A55050341E011B29" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_087167DD2471F89B3E3B50341E01C231_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_087167DD2471F89B3E3B50341E01C231" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_087167DD2471F89B3E3B50341E01C231_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_087167DD2471F89B3E3B50341E01C231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_087167DD2471F89B3E3B50341E01C231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_087167DD2471F89B3E3B50341E01C231" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_087167DD2471F89B3E3B50341E01C231" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_CA321112B2CB18459A7450341E0195D3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_CA321112B2CB18459A7450341E0195D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_CA321112B2CB18459A7450341E0195D3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_CA321112B2CB18459A7450341E0195D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_CA321112B2CB18459A7450341E0195D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_CA321112B2CB18459A7450341E0195D3" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_CA321112B2CB18459A7450341E0195D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_24D3C8650AEEB5BD4B3050341E011AE4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_24D3C8650AEEB5BD4B3050341E011AE4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_24D3C8650AEEB5BD4B3050341E011AE4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_24D3C8650AEEB5BD4B3050341E011AE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_24D3C8650AEEB5BD4B3050341E011AE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_24D3C8650AEEB5BD4B3050341E011AE4" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_24D3C8650AEEB5BD4B3050341E011AE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3DE6E2DE4DBEE4CE6F7C50341E01249B_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3DE6E2DE4DBEE4CE6F7C50341E01249B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3DE6E2DE4DBEE4CE6F7C50341E01249B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3DE6E2DE4DBEE4CE6F7C50341E01249B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3DE6E2DE4DBEE4CE6F7C50341E01249B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3DE6E2DE4DBEE4CE6F7C50341E01249B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3DE6E2DE4DBEE4CE6F7C50341E01249B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_94B4C1B52DED0A46FB9C50341E02ACB6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_94B4C1B52DED0A46FB9C50341E02ACB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_94B4C1B52DED0A46FB9C50341E02ACB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_94B4C1B52DED0A46FB9C50341E02ACB6" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_94B4C1B52DED0A46FB9C50341E02ACB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_004998BBA8D63F46900250341E02D4AD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_004998BBA8D63F46900250341E02D4AD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_004998BBA8D63F46900250341E02D4AD_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_004998BBA8D63F46900250341E02D4AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_004998BBA8D63F46900250341E02D4AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_004998BBA8D63F46900250341E02D4AD" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_004998BBA8D63F46900250341E02D4AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_C40CED6676B1FAFF575450341E028B60_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_C40CED6676B1FAFF575450341E028B60" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration paid related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_C40CED6676B1FAFF575450341E028B60_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_C40CED6676B1FAFF575450341E028B60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_C40CED6676B1FAFF575450341E028B60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_C40CED6676B1FAFF575450341E028B60" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_C40CED6676B1FAFF575450341E028B60" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C55EEACADCC483F41ACA50341E023298_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C55EEACADCC483F41ACA50341E023298" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C55EEACADCC483F41ACA50341E023298_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C55EEACADCC483F41ACA50341E023298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C55EEACADCC483F41ACA50341E023298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C55EEACADCC483F41ACA50341E023298" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C55EEACADCC483F41ACA50341E023298" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_327D7EB2E6380EF6875850341E028510_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_327D7EB2E6380EF6875850341E028510" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_327D7EB2E6380EF6875850341E028510_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_327D7EB2E6380EF6875850341E028510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_327D7EB2E6380EF6875850341E028510" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_327D7EB2E6380EF6875850341E028510" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_327D7EB2E6380EF6875850341E028510" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BD2CE108DBC10CDD811650341E02B046_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BD2CE108DBC10CDD811650341E02B046" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BD2CE108DBC10CDD811650341E02B046_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BD2CE108DBC10CDD811650341E02B046" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BD2CE108DBC10CDD811650341E02B046" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BD2CE108DBC10CDD811650341E02B046" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BD2CE108DBC10CDD811650341E02B046" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_08350C103E0C3D2E461250341E0301EC_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_08350C103E0C3D2E461250341E0301EC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_08350C103E0C3D2E461250341E0301EC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_08350C103E0C3D2E461250341E0301EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_08350C103E0C3D2E461250341E0301EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_08350C103E0C3D2E461250341E0301EC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_08350C103E0C3D2E461250341E0301EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_DB3158854D63429948D750341E033E5F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_DB3158854D63429948D750341E033E5F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_DB3158854D63429948D750341E033E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_DB3158854D63429948D750341E033E5F" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_DB3158854D63429948D750341E033E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A4A4FAA27F36C5429FD250341E03D2ED_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A4A4FAA27F36C5429FD250341E03D2ED" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A4A4FAA27F36C5429FD250341E03D2ED_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A4A4FAA27F36C5429FD250341E03D2ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A4A4FAA27F36C5429FD250341E03D2ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A4A4FAA27F36C5429FD250341E03D2ED" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A4A4FAA27F36C5429FD250341E03D2ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_68BA4107054952286C6C50341E034EBF_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_68BA4107054952286C6C50341E034EBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_68BA4107054952286C6C50341E034EBF_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_68BA4107054952286C6C50341E034EBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_68BA4107054952286C6C50341E034EBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_68BA4107054952286C6C50341E034EBF" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_68BA4107054952286C6C50341E034EBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BFA11418B6CCC8A92EF450341E0316BD_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BFA11418B6CCC8A92EF450341E0316BD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BFA11418B6CCC8A92EF450341E0316BD_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BFA11418B6CCC8A92EF450341E0316BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BFA11418B6CCC8A92EF450341E0316BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BFA11418B6CCC8A92EF450341E0316BD" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BFA11418B6CCC8A92EF450341E0316BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EB6AA4C46D8FC2631C1950341E041967_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EB6AA4C46D8FC2631C1950341E041967" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EB6AA4C46D8FC2631C1950341E041967_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EB6AA4C46D8FC2631C1950341E041967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EB6AA4C46D8FC2631C1950341E041967" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EB6AA4C46D8FC2631C1950341E041967" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EB6AA4C46D8FC2631C1950341E041967" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D250E7D3885CEA85225750341E04070E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D250E7D3885CEA85225750341E04070E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D250E7D3885CEA85225750341E04070E_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D250E7D3885CEA85225750341E04070E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D250E7D3885CEA85225750341E04070E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D250E7D3885CEA85225750341E04070E" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D250E7D3885CEA85225750341E04070E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_37FDEE3420F945EE059E50341E04DA16_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_37FDEE3420F945EE059E50341E04DA16" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37FDEE3420F945EE059E50341E04DA16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37FDEE3420F945EE059E50341E04DA16" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_37FDEE3420F945EE059E50341E04DA16" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_42D1D5F3D718CE5244A250341E046804_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_42D1D5F3D718CE5244A250341E046804" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42D1D5F3D718CE5244A250341E046804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42D1D5F3D718CE5244A250341E046804" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_42D1D5F3D718CE5244A250341E046804" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_49D386C591C516AD118150341C79A5C1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_49D386C591C516AD118150341C79A5C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_49D386C591C516AD118150341C79A5C1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_49D386C591C516AD118150341C79A5C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_49D386C591C516AD118150341C79A5C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_49D386C591C516AD118150341C79A5C1" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_49D386C591C516AD118150341C79A5C1" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>biib-20190331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20190331.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsBusinessAcquisitionDetailsTextual" xlink:href="biib-20190331.xsd#AcquisitionsBusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20190331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20190331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20190331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:href="biib-20190331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20190331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20190331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20190331.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20190331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20190331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20190331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20190331.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20190331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20190331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20190331.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestituresDetails" xlink:href="biib-20190331.xsd#DivestituresDivestituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual" xlink:href="biib-20190331.xsd#DivestituresDivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestituresTables" xlink:href="biib-20190331.xsd#DivestituresDivestituresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20190331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20190331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20190331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20190331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190331.xsd#EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20190331.xsd#EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityEquityNotes" xlink:href="biib-20190331.xsd#EquityEquityNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190331.xsd#EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityShareRepurchasesDetails" xlink:href="biib-20190331.xsd#EquityShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20190331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20190331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20190331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20190331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20190331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20190331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20190331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20190331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20190331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20190331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20190331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20190331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20190331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20190331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20190331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20190331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20190331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20190331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20190331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20190331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20190331.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:href="biib-20190331.xsd#InventoryProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20190331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20190331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20190331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetails" xlink:href="biib-20190331.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeases" xlink:href="biib-20190331.xsd#LeasesLeases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual" xlink:href="biib-20190331.xsd#LeasesLeasesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesLeasesTables" xlink:href="biib-20190331.xsd#LeasesLeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20190331.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:href="biib-20190331.xsd#LitigationLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20190331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20190331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20190331.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20190331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20190331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20190331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:href="biib-20190331.xsd#RevenuesOtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20190331.xsd#RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20190331.xsd#RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20190331.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails" xlink:href="biib-20190331.xsd#RevenuesRevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual" xlink:href="biib-20190331.xsd#RevenuesRevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20190331.xsd#RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesTables" xlink:href="biib-20190331.xsd#RevenuesRevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20190331.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20190331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20190331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20190331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20190331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20190331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20190331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3FC585AF44E0E68BA1AC50341DD83F93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_785C4F73C9BD8E74C95450341DD81955" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3FC585AF44E0E68BA1AC50341DD83F93" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_785C4F73C9BD8E74C95450341DD81955" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsBusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_A0EC34392985DCD415A050341DD47E7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_A0EC34392985DCD415A050341DD47E7E" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FFB9695AB23DE743A66D50341DD43CE1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_89A797D89F3C3640019450341DD40447" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E58264B6228E9901E5A50341DD43762" xlink:to="loc_biib_NightstarMember_89A797D89F3C3640019450341DD40447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46774B99348730C28A7850341DD4C888" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_6E93ABBB4405264E23BD50341DD648BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_6E93ABBB4405264E23BD50341DD648BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_DFDAE727CD8A5A6877D150341DD6FAB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BF0536ED84263B66345750341DD45BDB" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_DFDAE727CD8A5A6877D150341DD6FAB2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5688C56C3102349A783150341BF9C1ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F2651D8DEA848175F1650341BF98419" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5688C56C3102349A783150341BF9C1ED" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F2651D8DEA848175F1650341BF98419" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2BE731C5D895091B395C50341BE93E25" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2BE731C5D895091B395C50341BE93E25" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C6837A6C5309CBF9952050341BE9159E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C6837A6C5309CBF9952050341BE9159E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F91D93124EB69C252DE850341BEACFF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C6837A6C5309CBF9952050341BE9159E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F91D93124EB69C252DE850341BEACFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_D424C9AA4E8256AAD5C150341BEAD498" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F91D93124EB69C252DE850341BEACFF6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_D424C9AA4E8256AAD5C150341BEAD498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9CE664D880FCD69C6B9750341BEAC64D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F91D93124EB69C252DE850341BEACFF6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9CE664D880FCD69C6B9750341BEAC64D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6B8CAEE193FA2BDED6A150341BEA7B4C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6B8CAEE193FA2BDED6A150341BEA7B4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A0814B93C2E284FCDF750341BEBE319" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6B8CAEE193FA2BDED6A150341BEA7B4C" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A0814B93C2E284FCDF750341BEBE319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_32D6ECBB29751A3C7B9650341BEBB6AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A0814B93C2E284FCDF750341BEBE319" xlink:to="loc_us-gaap_CollaborativeArrangementMember_32D6ECBB29751A3C7B9650341BEBB6AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A0814B93C2E284FCDF750341BEBE319" xlink:to="loc_biib_EisaiMember_A1EF7E6B4377450CDA4950341BEBFFA9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6A0814B93C2E284FCDF750341BEBE319" xlink:to="loc_biib_SkyhawkTherapeuticsMember_10D698D883C1AA28FB0D50341BEB33FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0F86EE6399B005780AAA50341BEC9F00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:to="loc_srt_ProductOrServiceAxis_0F86EE6399B005780AAA50341BEC9F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D0E88BBCA9EB8D33E7AD50341BEC3F8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0F86EE6399B005780AAA50341BEC9F00" xlink:to="loc_srt_ProductsAndServicesDomain_D0E88BBCA9EB8D33E7AD50341BEC3F8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D0E88BBCA9EB8D33E7AD50341BEC3F8A" xlink:to="loc_biib_E2609andBAN2401Member_4C0AF48ECBCD44DF569D50341BEC7329" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D0E88BBCA9EB8D33E7AD50341BEC3F8A" xlink:to="loc_biib_AducanumabMember_E21168F4AD8C5B5DD25D50341BEC952F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62182A66DEE5A2C7C8E050341BE9ECB2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_biib_Expenseincurredbythecollaboration_749AF0622106AA3533B050341BEC973C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_9588FD8BCAB35F2D69EA50341BED0212" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_36F2F37BF85B7FE88AF550341BED6BA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_371EE82620FCC2B2C78350341BED167D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_us-gaap_LossOnContractTermination_371EE82620FCC2B2C78350341BED167D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_biib_AdditionalMilestonePayment_4B0434A5C94BAFC9277950341BEDC208" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_060C92426921B460D53850341BED1C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3324AFE6251A7B54551350341BEEEE6C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3324AFE6251A7B54551350341BEEEE6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_029B7EED9D9DA55DA79E50341BEE622D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2E3F78BCC67ECAC8CE3050341BECF2F6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_029B7EED9D9DA55DA79E50341BEE622D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C6C3E7598BA4B9F2768E50341BD3D515" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C6C3E7598BA4B9F2768E50341BD3D515" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_EAF23263AE1F0111393C50341BD32ABF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_EAF23263AE1F0111393C50341BD32ABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_EAF23263AE1F0111393C50341BD32ABF" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_14BF10286CA1912E56A150341BD479D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:to="loc_us-gaap_InventoriesMember_14BF10286CA1912E56A150341BD479D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_407B8BF784C831BED9B550341BD4FAB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_407B8BF784C831BED9B550341BD4FAB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5C358B576FFF1084ADF950341BD44AB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5C358B576FFF1084ADF950341BD44AB9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3E68B0BA0BD957117F1750341BD44EED" xlink:to="loc_biib_DeferredtaxliabilityMember_3DEBCF580FA27F75DEAF50341BD5C425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2D754AA4BD4C42F58DBB50341BD519B2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_D58490FEB2C6D780891F50341BD5C955" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F7A6C985C229211693250341BD55D9C" xlink:to="loc_us-gaap_CollaborativeArrangementMember_D58490FEB2C6D780891F50341BD5C955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_BD1C48AE0461E54D55AE50341BD5857E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_79C5BA6A4B1A970F056750341BD525A6" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_27FCBA1569731783ACBF50341BD6268E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7BC538B85FE6E88BB4AD50341BD303FF" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7F2CB34B88F58619E58650341BD621EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BEC47F8945D77790D6A350341BD7C94D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BEC47F8945D77790D6A350341BD7C94D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_AA252EDBD5A67D6E277250341BD70783" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_AA252EDBD5A67D6E277250341BD70783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A019E11F28D700E50EB050341BD79AFF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A019E11F28D700E50EB050341BD79AFF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A37084D7941FDE5B283250341BD79559" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_204DBD5C65E5519BCB6B50341BD7C6CC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_204DBD5C65E5519BCB6B50341BD7C6CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_B31DCBA4892D231219C050341BD70005" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_B31DCBA4892D231219C050341BD70005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_CE5946D4776FFFFAD83450341BD8F4FE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_AdjustmentForAmortization_CE5946D4776FFFFAD83450341BD8F4FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_89252967489160CA731D50341BD86228" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_EquityMethodInvestments_89252967489160CA731D50341BD86228" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_6CD9CD6A267516562ED150341BD8C57A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_biib_Collaborationprofitlosssharing_4FFDAD494D66F622F61750341BD8A311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F1CC8F96A78BE2C066D950341BD8A506" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3535423D312F59D6AFC850341BD65C60" xlink:to="loc_us-gaap_Revenues_F1CC8F96A78BE2C066D950341BD8A506" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FF8C2B1D86343371D30750341BF2C06C" xlink:type="locator" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7E4236CFBDACE765154A50341BF28D5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FF8C2B1D86343371D30750341BF2C06C" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7E4236CFBDACE765154A50341BF28D5C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_A97E717B482C7F8B74D450341BF29CCA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FF8C2B1D86343371D30750341BF2C06C" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_A97E717B482C7F8B74D450341BF29CCA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_C0A7DB26518AB6C5011A50341E154E2E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C0A7DB26518AB6C5011A50341E154E2E" xlink:to="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13AF11C939B22D2B4F5750341E16A686" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13AF11C939B22D2B4F5750341E16A686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6F12DCA58915B2197C2550341E17059F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6F12DCA58915B2197C2550341E17059F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_67E8AE1569AAA07A63A050341E179514" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_67E8AE1569AAA07A63A050341E179514" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_60CC89118407F8AB6A6F50341E17A1A1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_60CC89118407F8AB6A6F50341E17A1A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2468BA285723AB38F42850341E174EA6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:to="loc_us-gaap_InventoryNet_2468BA285723AB38F42850341E174EA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_DCEB253E6FD7185232D050341E173799" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_DCEB253E6FD7185232D050341E173799" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_F386BA784B73474C981650341E1788FE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:to="loc_us-gaap_OtherAssetsCurrent_F386BA784B73474C981650341E1788FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0C9F99766AF647BB38B550341E1774A8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5CB404A546EE3C04016C50341E16B501" xlink:to="loc_us-gaap_AssetsCurrent_0C9F99766AF647BB38B550341E1774A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FE0AE6DCDBFF9E6E4B3050341E180A47" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FE0AE6DCDBFF9E6E4B3050341E180A47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8EAF6D348322CDA50C4B50341E181BD8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8EAF6D348322CDA50C4B50341E181BD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6891B4BC579313A40A3E50341E189DA8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6891B4BC579313A40A3E50341E189DA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_E1A3E7484956C35BA3F650341E18C8DB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_E1A3E7484956C35BA3F650341E18C8DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_06072BF23720A01C9EF850341E180EB3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:to="loc_us-gaap_Goodwill_06072BF23720A01C9EF850341E180EB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_985AE365607445A9AD5D50341E1814E5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_985AE365607445A9AD5D50341E1814E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_AB1156FCBD18BB2CB59A50341E19DEDB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_AB1156FCBD18BB2CB59A50341E19DEDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D7AB0F5C032324350C1E50341E196001" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42EA4AA78DC0D816BBCF50341E160496" xlink:to="loc_us-gaap_Assets_D7AB0F5C032324350C1E50341E196001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C0A7DB26518AB6C5011A50341E154E2E" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_04510D520C1B0E13E93650341E194FB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB" xlink:to="loc_us-gaap_TaxesPayableCurrent_04510D520C1B0E13E93650341E194FB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_CDDA9BB22F54AEB05E8E50341E1A038F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB" xlink:to="loc_us-gaap_AccountsPayableCurrent_CDDA9BB22F54AEB05E8E50341E1A038F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_F20851E2522FD1A91E0050341E1A7A3E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_F20851E2522FD1A91E0050341E1A7A3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2E4F42205F7BFFBAC29150341E1A1F9E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2E4F42205F7BFFBAC29150341E1A1F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_E8624D6F93A9870C75F650341E1A34D4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_918EDE1B436BF77AE26A50341E192EBB" xlink:to="loc_us-gaap_LiabilitiesCurrent_E8624D6F93A9870C75F650341E1A34D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_A4DA15C989C3B4F74FF450341E1ADDFF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:to="loc_us-gaap_LongTermDebt_A4DA15C989C3B4F74FF450341E1ADDFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_169A262647DBBB8FAF2750341E1AE0BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_169A262647DBBB8FAF2750341E1AE0BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_387B633B3CF67B91FE6650341E1BBC91" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_387B633B3CF67B91FE6650341E1BBC91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_CCD02E1E41AE2FABD34450341E1BF1F5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_CCD02E1E41AE2FABD34450341E1BF1F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_871B583AAD93CC5B52E550341E1B50DA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:to="loc_us-gaap_Liabilities_871B583AAD93CC5B52E550341E1B50DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_C07E22F6C92AB6D4577350341E1B82DD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_C07E22F6C92AB6D4577350341E1B82DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9531ABCB8FA033E8CC3350341E1B04DA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9531ABCB8FA033E8CC3350341E1B04DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9531ABCB8FA033E8CC3350341E1B04DA" xlink:to="loc_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_C511BA7C1DFD94677B3950341E1C84C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:to="loc_us-gaap_PreferredStockValue_C511BA7C1DFD94677B3950341E1C84C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_EF1D2F5BA031BFD3E3D850341E1C6C46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:to="loc_us-gaap_CommonStockValue_EF1D2F5BA031BFD3E3D850341E1C6C46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_F60BF6C45C8EAD23B7CE50341E1C2BC4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:to="loc_us-gaap_AdditionalPaidInCapital_F60BF6C45C8EAD23B7CE50341E1C2BC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4E52D1BE66D27B078C1850341E1DA0A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4E52D1BE66D27B078C1850341E1DA0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_A66F5C0181FA24962C4850341E1D982D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_A66F5C0181FA24962C4850341E1D982D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_1401AAAAF25BF933B8E950341E1D0333" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:to="loc_us-gaap_TreasuryStockValue_1401AAAAF25BF933B8E950341E1D0333" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_51CE42B20E629F0CF63250341E1D4D77" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03601EBF859586DDB58650341E1CB1AC" xlink:to="loc_us-gaap_StockholdersEquity_51CE42B20E629F0CF63250341E1D4D77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_DC09532B8316910E0C3750341E1D939B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9531ABCB8FA033E8CC3350341E1B04DA" xlink:to="loc_us-gaap_MinorityInterest_DC09532B8316910E0C3750341E1D939B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FE5272672A0C41869F2B50341E1DF3D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9531ABCB8FA033E8CC3350341E1B04DA" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_FE5272672A0C41869F2B50341E1DF3D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3C2BB250A71B6BD6219C50341E1E1ED0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E5056B8E96290A7D54E650341E1999E8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3C2BB250A71B6BD6219C50341E1E1ED0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_BC53169C8CBCA6926FB650341E0A8688" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_72DA4C3D6DFB60E762D750341E0AB3F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_BC53169C8CBCA6926FB650341E0A8688" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_72DA4C3D6DFB60E762D750341E0AB3F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9963D3EA0164343F91BB50341E0AED1C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_BC53169C8CBCA6926FB650341E0A8688" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9963D3EA0164343F91BB50341E0AED1C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_DE9E896790D65B9CD85F50341DE88623" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_463F31C09EE2C5DBD42550341DE8D7ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_DE9E896790D65B9CD85F50341DE88623" xlink:to="loc_us-gaap_StatementTable_463F31C09EE2C5DBD42550341DE8D7ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_A1AC1C5D0268EB6244A850341DE8FC03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_463F31C09EE2C5DBD42550341DE8D7ED" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_A1AC1C5D0268EB6244A850341DE8FC03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_D8C4E6C622748BAA18DF50341DE91438" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_A1AC1C5D0268EB6244A850341DE8FC03" xlink:to="loc_us-gaap_AccountingGuidanceMember_D8C4E6C622748BAA18DF50341DE91438" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_226BAA62D5F3E210843B50341DE98304" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_D8C4E6C622748BAA18DF50341DE91438" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_226BAA62D5F3E210843B50341DE98304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_2D0D5617566737A3452350341DE9F1DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_D8C4E6C622748BAA18DF50341DE91438" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_2D0D5617566737A3452350341DE9F1DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_50BC0D26BEAA90584D1250341DE9D2B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_463F31C09EE2C5DBD42550341DE8D7ED" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_50BC0D26BEAA90584D1250341DE9D2B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_588982A3EDB5E520788250341DEA2C9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_50BC0D26BEAA90584D1250341DE9D2B1" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_588982A3EDB5E520788250341DEA2C9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_8AD383771E8190EB9CFE50341DEA2300" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_588982A3EDB5E520788250341DEA2C9E" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_8AD383771E8190EB9CFE50341DEA2300" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_E2ED2F284F11B0DC979550341DEAECC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_588982A3EDB5E520788250341DEA2C9E" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_E2ED2F284F11B0DC979550341DEAECC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8F4B90EE3D3192504D1950341DEAA286" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_463F31C09EE2C5DBD42550341DE8D7ED" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8F4B90EE3D3192504D1950341DEAA286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8F4B90EE3D3192504D1950341DEAA286" xlink:to="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_7518A54EF68570101F9350341DEBEDF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_PreferredStockMember_7518A54EF68570101F9350341DEBEDF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FEFC8C73EB1F6D64D09D50341DEB2D0F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_CommonStockMember_FEFC8C73EB1F6D64D09D50341DEB2D0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7803110D46BB009C13BC50341DEB8FC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7803110D46BB009C13BC50341DEB8FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28B1E2AF18B42DF1715D50341DEB11BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28B1E2AF18B42DF1715D50341DEB11BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_30021A544F7EAD4E960950341DEB08FC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_RetainedEarningsMember_30021A544F7EAD4E960950341DEB08FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_4EBB2FBB185D79456C4550341DECC259" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_TreasuryStockMember_4EBB2FBB185D79456C4550341DECC259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2EF810A1DF8F8864C7C250341DEC4051" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2EF810A1DF8F8864C7C250341DEC4051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_7C73E3AE093C8793B1C150341DECCC8C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_386B27E1D37EC8B01BA250341DEAC1A8" xlink:to="loc_us-gaap_ParentMember_7C73E3AE093C8793B1C150341DECCC8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_463F31C09EE2C5DBD42550341DE8D7ED" xlink:to="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27C84723C10D5E9C11CF50341DECAAC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27C84723C10D5E9C11CF50341DECAAC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_9B9863D29CEA347AA76350341DEC4D9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_SharesIssued_9B9863D29CEA347AA76350341DEC4D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0E2A87766C2222E1119150341DED6E72" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockholdersEquity_0E2A87766C2222E1119150341DED6E72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_F94B3D08254412A6DF4250341DED00E8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_MinorityInterest_F94B3D08254412A6DF4250341DED00E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E1FE448972157735EAD150341DED41AC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_NetIncomeLoss_E1FE448972157735EAD150341DED41AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D99F11812A495BFF41D750341DED1B27" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D99F11812A495BFF41D750341DED1B27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_A4B83D2974C8012F516C50341DED2C5C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_ProfitLoss_A4B83D2974C8012F516C50341DED2C5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9F9FFEE92DE7D78921A050341DEE2EC9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9F9FFEE92DE7D78921A050341DEE2EC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19DD85D2D8BA870B5FF750341DEE7913" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19DD85D2D8BA870B5FF750341DEE7913" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_5538D38A09D41FF82DE350341DEE3988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_392863B878F168E6294950341DEEF8D1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_392863B878F168E6294950341DEEF8D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_DDFB00A32A502A80F1E950341DEE62B2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_DDFB00A32A502A80F1E950341DEE62B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_2C7F96E52C1509AE18FA50341DEE8C3D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_2C7F96E52C1509AE18FA50341DEE8C3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5349E05E8557FF9164B950341DEE9C0D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5349E05E8557FF9164B950341DEE9C0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_EBA27CFF411CD04E8E4650341DEF4C40" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_EBA27CFF411CD04E8E4650341DEF4C40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECDF24632B07A66E594150341DEF1325" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ECDF24632B07A66E594150341DEF1325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0D0A0D00D7DB44200F1150341DEF244A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0D0A0D00D7DB44200F1150341DEF244A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6C4050238115C76BCE4E50341DEF482F" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6C4050238115C76BCE4E50341DEF482F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_983ED9122DC173FC506A50341DEF145B" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_983ED9122DC173FC506A50341DEF145B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_DA725461851D6C900B2F50341DEF361C" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockholdersEquityOther_DA725461851D6C900B2F50341DEF361C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BEC1F7B3F088118528CB50341DF08491" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BEC1F7B3F088118528CB50341DF08491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_EB1ACA3D5DF87A65AEDA50341DF0D117" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_StockholdersEquity_EB1ACA3D5DF87A65AEDA50341DF0D117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_7FE01C5293BA4480400150341DF09D0A" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_MinorityInterest_7FE01C5293BA4480400150341DF09D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_16BC87CC915066DA05FF50341DF05EA1" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1AD09307E8644871086150341DECA1B6" xlink:to="loc_us-gaap_SharesIssued_16BC87CC915066DA05FF50341DF05EA1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2410E3178B5EA4E4D31650341DFEF84A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2410E3178B5EA4E4D31650341DFEF84A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_713B0E7A01BA213A845150341DFE34CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2410E3178B5EA4E4D31650341DFEF84A" xlink:to="loc_us-gaap_ProfitLoss_713B0E7A01BA213A845150341DFE34CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2410E3178B5EA4E4D31650341DFEF84A" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_E5C6773628065BD3933150341DFF9EB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_E5C6773628065BD3933150341DFF9EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_24AD6308822A9C27ECEA50341DFFC2CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_24AD6308822A9C27ECEA50341DFFC2CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_B440A446481D543D444950341DFFA3DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:to="loc_us-gaap_ShareBasedCompensation_B440A446481D543D444950341DFFA3DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2D504C1CFC7C2A3BA45B50341DFFB4E1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2D504C1CFC7C2A3BA45B50341DFFB4E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_D7A2A0E5F158FAD39CDF50341DFFB9B1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_D7A2A0E5F158FAD39CDF50341DFFB9B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_65DEF2CCE382D2E6F48D50341E0058B4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_65DEF2CCE382D2E6F48D50341E0058B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_807EE326C2277652A76D50341E00C683" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_807EE326C2277652A76D50341E00C683" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6F89A32008E8861AECF950341E005DE8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_6F89A32008E8861AECF950341E005DE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B0D95E23F074A426C66350341E0051C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B0D95E23F074A426C66350341E0051C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0ADB4F100D306B49A55050341E011B29" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0ADB4F100D306B49A55050341E011B29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_087167DD2471F89B3E3B50341E01C231" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_087167DD2471F89B3E3B50341E01C231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_CA321112B2CB18459A7450341E0195D3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_CA321112B2CB18459A7450341E0195D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_24D3C8650AEEB5BD4B3050341E011AE4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AFC1E5C41FDFB4E96BEF50341E00D8D3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_24D3C8650AEEB5BD4B3050341E011AE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3DE6E2DE4DBEE4CE6F7C50341E01249B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4F31E46FFB7D1205A73E50341DFF2287" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3DE6E2DE4DBEE4CE6F7C50341E01249B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_94B4C1B52DED0A46FB9C50341E02ACB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_94B4C1B52DED0A46FB9C50341E02ACB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_004998BBA8D63F46900250341E02D4AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_004998BBA8D63F46900250341E02D4AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_C40CED6676B1FAFF575450341E028B60" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_C40CED6676B1FAFF575450341E028B60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C55EEACADCC483F41ACA50341E023298" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C55EEACADCC483F41ACA50341E023298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_327D7EB2E6380EF6875850341E028510" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_327D7EB2E6380EF6875850341E028510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BD2CE108DBC10CDD811650341E02B046" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_BD2CE108DBC10CDD811650341E02B046" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_08350C103E0C3D2E461250341E0301EC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5524EC645BF249F7266050341E0121E4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_08350C103E0C3D2E461250341E0301EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_DB3158854D63429948D750341E033E5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_DB3158854D63429948D750341E033E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A4A4FAA27F36C5429FD250341E03D2ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_A4A4FAA27F36C5429FD250341E03D2ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_68BA4107054952286C6C50341E034EBF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_68BA4107054952286C6C50341E034EBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BFA11418B6CCC8A92EF450341E0316BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47B4CCDBE79080CD583850341E030404" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BFA11418B6CCC8A92EF450341E0316BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EB6AA4C46D8FC2631C1950341E041967" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EB6AA4C46D8FC2631C1950341E041967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D250E7D3885CEA85225750341E04070E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D250E7D3885CEA85225750341E04070E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37FDEE3420F945EE059E50341E04DA16" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37FDEE3420F945EE059E50341E04DA16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42D1D5F3D718CE5244A250341E046804" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_549202FFC6E3F23BAD6650341DFEDDD0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42D1D5F3D718CE5244A250341E046804" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A6CCAFFA0B385C3FBB0D50341E288E86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0DE7462C366C08D67FC950341E28FA93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A6CCAFFA0B385C3FBB0D50341E288E86" xlink:to="loc_us-gaap_NetIncomeLoss_0DE7462C366C08D67FC950341E28FA93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A6CCAFFA0B385C3FBB0D50341E288E86" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_CED567CC41E86290781150341E2830C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_CED567CC41E86290781150341E2830C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_A6258500FB133BB4196450341E2929AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_A6258500FB133BB4196450341E2929AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_6211BFB18F0C0D826FCF50341E29C206" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_6211BFB18F0C0D826FCF50341E29C206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_FE6AFE28A47FAEB9E3A950341E29259C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_FE6AFE28A47FAEB9E3A950341E29259C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5C856F60F2BA0573E5B150341E29745D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5C856F60F2BA0573E5B150341E29745D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5D23AC4097D11F20AF2B50341E29BB2B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5D23AC4097D11F20AF2B50341E29BB2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8D7C51CFCFEC458B77BF50341E29F2E6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8D7C51CFCFEC458B77BF50341E29F2E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D4200B7923990400955C50341E2AEDC8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D4200B7923990400955C50341E2AEDC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3C8359C0A644C8B4655E50341E2A5243" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8EB005479CB24AD286CD50341E28D489" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3C8359C0A644C8B4655E50341E2A5243" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_18E017E864391CE8495B50341E339B10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_StatementTable_18E017E864391CE8495B50341E339B10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4AE3363FB6BC781C664B50341E336440" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18E017E864391CE8495B50341E339B10" xlink:to="loc_srt_ProductOrServiceAxis_4AE3363FB6BC781C664B50341E336440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_93055A1EB81D2663122550341E341825" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4AE3363FB6BC781C664B50341E336440" xlink:to="loc_srt_ProductsAndServicesDomain_93055A1EB81D2663122550341E341825" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_377EB457FAF7729AF61F50341E343738" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_93055A1EB81D2663122550341E341825" xlink:to="loc_us-gaap_ProductMember_377EB457FAF7729AF61F50341E343738" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_817E973C55E074F2F78450341E349F1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_93055A1EB81D2663122550341E341825" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_817E973C55E074F2F78450341E349F1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_B34841D8C496E056489F50341E354038" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_93055A1EB81D2663122550341E341825" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_B34841D8C496E056489F50341E354038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EF8ADB7037EFA630EFCD50341E35D3DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18E017E864391CE8495B50341E339B10" xlink:to="loc_us-gaap_StatementLineItems_EF8ADB7037EFA630EFCD50341E35D3DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_0B85A7DFF9A70243475E50341E351469" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_Revenues_0B85A7DFF9A70243475E50341E351469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7F50F5AA38DE826DFB2650341E3543F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7F50F5AA38DE826DFB2650341E3543F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_20A59E3725418BADBD2B50341E351729" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_20A59E3725418BADBD2B50341E351729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_56838F60446E734FDDA950341E36536A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_56838F60446E734FDDA950341E36536A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_8DCFF79A2CD482CAE4FE50341E363DB5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_8DCFF79A2CD482CAE4FE50341E363DB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_611539F5FFECCC07BE6450341E360F39" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_611539F5FFECCC07BE6450341E360F39" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_DAD34E8834F37ACA2F0650341E365E6A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:to="loc_biib_Collaborationprofitlosssharing_DAD34E8834F37ACA2F0650341E365E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_90338D23E973F7F467E750341E36984A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_90338D23E973F7F467E750341E36984A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BB4101A9D49D9A06389950341E36C3A2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BB4101A9D49D9A06389950341E36C3A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_F59BE80A5326F3B2DC8250341E37B0A7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:to="loc_us-gaap_RestructuringCharges_F59BE80A5326F3B2DC8250341E37B0A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_C341C8C89DC769A3D74450341E37B954" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0D7492EDCABE075B13AA50341E35709C" xlink:to="loc_us-gaap_CostsAndExpenses_C341C8C89DC769A3D74450341E37B954" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E17B10A484C3AB77A64350341E371801" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_OperatingIncomeLoss_E17B10A484C3AB77A64350341E371801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9AA5C9446148092C268D50341E37915D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9AA5C9446148092C268D50341E37915D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_AC0B5128DC3FB25A877A50341E3742C1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_AC0B5128DC3FB25A877A50341E3742C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5F293530BAED37500E2250341E380075" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5F293530BAED37500E2250341E380075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ECC3B3F3386F1355B17D50341E38D712" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ECC3B3F3386F1355B17D50341E38D712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_337709C008C7F5CF1E4A50341E384AAA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_ProfitLoss_337709C008C7F5CF1E4A50341E384AAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2A08D72225D301A2867950341E383A56" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2A08D72225D301A2867950341E383A56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_66B95749C8F84E7AC18350341E38BE4F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_NetIncomeLoss_66B95749C8F84E7AC18350341E38BE4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9FA920E38DC443A52F6450341E388C3A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_EarningsPerShareAbstract_9FA920E38DC443A52F6450341E388C3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_92A00B6C5F75C09F27DC50341E399EC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9FA920E38DC443A52F6450341E388C3A" xlink:to="loc_us-gaap_EarningsPerShareBasic_92A00B6C5F75C09F27DC50341E399EC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_FCD62B42D45E2920E9E150341E39E0A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9FA920E38DC443A52F6450341E388C3A" xlink:to="loc_us-gaap_EarningsPerShareDiluted_FCD62B42D45E2920E9E150341E39E0A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3BA8C3C3C5B947A2C7C550341E39312C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_445B5C2844D6188641D150341E33E2B3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3BA8C3C3C5B947A2C7C550341E39312C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A74ABE19408A8F090CFA50341E39536F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3BA8C3C3C5B947A2C7C550341E39312C" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A74ABE19408A8F090CFA50341E39536F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9D843D4EB1328683213350341E3995D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3BA8C3C3C5B947A2C7C550341E39312C" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9D843D4EB1328683213350341E3995D8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8F40884C82F7DB9622E150341CE9E48D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E7458F7FD500B9D894F50341CE91962" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8F40884C82F7DB9622E150341CE9E48D" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E7458F7FD500B9D894F50341CE91962" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_541C2667115872BDE7EA50341CD3E563" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_541C2667115872BDE7EA50341CD3E563" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_71D815950DE9B379D84C50341CD3AD3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_71D815950DE9B379D84C50341CD3AD3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_D83C8DE287E72E7CA68050341CD30D09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_71D815950DE9B379D84C50341CD3AD3E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_D83C8DE287E72E7CA68050341CD30D09" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_475891820946D73D4AB050341CD43EFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_D83C8DE287E72E7CA68050341CD30D09" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_475891820946D73D4AB050341CD43EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A24B95A84EB7BAE9D8F050341CD4150D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_DebtInstrumentAxis_A24B95A84EB7BAE9D8F050341CD4150D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DEF54E59E5E4C5F0EB5550341CD4CC1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_A24B95A84EB7BAE9D8F050341CD4150D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DEF54E59E5E4C5F0EB5550341CD4CC1C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_43AE34C27C83CB7ED3D550341CD5486B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DEF54E59E5E4C5F0EB5550341CD4CC1C" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_43AE34C27C83CB7ED3D550341CD5486B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_7718C88725D805A71F8650341CD5EDD6" xlink:to="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_86FAE39A62DCA19C646B50341CD5507E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:to="loc_currency_EUR_86FAE39A62DCA19C646B50341CD5507E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_72452122B4031A42C61D50341CD5A2AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:to="loc_currency_GBP_72452122B4031A42C61D50341CD5A2AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_953F7F0879AF64D433B750341CD6FCD2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:to="loc_currency_CHF_953F7F0879AF64D433B750341CD6FCD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_7A6099150B62C65ECB8150341CD674E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:to="loc_currency_JPY_7A6099150B62C65ECB8150341CD674E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_56E571175FA19E6F40D150341CD65DE0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_F246766FFE449699516F50341CD59992" xlink:to="loc_currency_CAD_56E571175FA19E6F40D150341CD65DE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A5C7EEBBD2CA555D8E8E50341CD60E6A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A5C7EEBBD2CA555D8E8E50341CD60E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_193AEB999046DF73AA3A50341CD6E9D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A5C7EEBBD2CA555D8E8E50341CD60E6A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_193AEB999046DF73AA3A50341CD6E9D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_F156FD779DE2CD1B40DC50341CD7F4DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_193AEB999046DF73AA3A50341CD6E9D4" xlink:to="loc_us-gaap_SalesMember_F156FD779DE2CD1B40DC50341CD7F4DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_22625E856FFEA2B719E650341CD79F76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_193AEB999046DF73AA3A50341CD6E9D4" xlink:to="loc_us-gaap_OperatingExpenseMember_22625E856FFEA2B719E650341CD79F76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4C54E5DA646436F6B91050341CD7C6A3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_193AEB999046DF73AA3A50341CD6E9D4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4C54E5DA646436F6B91050341CD7C6A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D78BFD3867F73FA7DEE950341CD777CC" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:to="loc_biib_CashflowsrevenueMember_6E7B053DA0382819AE1050341CD74D5F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:to="loc_biib_CashflowsoperatingexpensesMember_0DDBE5D5EBC484551AED50341CD8F6F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1E8D7E8007CF2704BFCF50341CD88669" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C7A2888386E1CB6ADA950341CD735C4" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_1E8D7E8007CF2704BFCF50341CD88669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_F7615CD549B573FBCD2250341CD850F5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_A933B2892412785CC26550341CD86FA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:to="loc_us-gaap_ForeignExchangeContractMember_A933B2892412785CC26550341CD86FA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_892FF2A53C01509A43D850341CD9B5DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9E6310C421F156D1456950341CD8937B" xlink:to="loc_us-gaap_InterestRateSwapMember_892FF2A53C01509A43D850341CD9B5DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9CD275240E628DC6BC7450341CD91BAB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9CD275240E628DC6BC7450341CD91BAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_A63681164D39861BF5EB50341CD9A274" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9CD275240E628DC6BC7450341CD91BAB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_A63681164D39861BF5EB50341CD9A274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_6839ECE6403CC893C93150341CD9CC03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A63681164D39861BF5EB50341CD9A274" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_6839ECE6403CC893C93150341CD9CC03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_0F38687CF9BEA6AD1CEA50341CDAAC8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A63681164D39861BF5EB50341CD9A274" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_0F38687CF9BEA6AD1CEA50341CDAAC8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9AA06A89656BE383A5A850341CDA615A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A63681164D39861BF5EB50341CD9A274" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9AA06A89656BE383A5A850341CDA615A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_CCDF04A203790A33C69150341CDA8063" xlink:to="loc_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4F0E8A927E74F0F74C6450341CDA622F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4F0E8A927E74F0F74C6450341CDA622F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_1656706986FFE6C932E350341CDB1AB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_9A5F1F6238A7CD18CEB250341CDA0879" xlink:to="loc_us-gaap_NondesignatedMember_1656706986FFE6C932E350341CDB1AB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D21278FA02098235E1FE50341CDBA367" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_srt_RangeAxis_D21278FA02098235E1FE50341CDBA367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B3C702BC9D2523EB580250341CDBD6B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_D21278FA02098235E1FE50341CDBA367" xlink:to="loc_srt_RangeMember_B3C702BC9D2523EB580250341CDBD6B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_15882690C4C0BEEF043650341CDB6284" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_B3C702BC9D2523EB580250341CDBD6B2" xlink:to="loc_srt_MinimumMember_15882690C4C0BEEF043650341CDB6284" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C6791E0F50355A80D0CB50341CDC03B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_B3C702BC9D2523EB580250341CDBD6B2" xlink:to="loc_srt_MaximumMember_C6791E0F50355A80D0CB50341CDC03B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D65C9153D880DA02C6A750341CD340DC" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_115187616BF10480151950341CDCC92A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_115187616BF10480151950341CDCC92A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_0D3C5482C15A7D44F65050341CDC20F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_invest_DerivativeNotionalAmount_0D3C5482C15A7D44F65050341CDC20F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8B8752FA777E2C590CCE50341CDC62D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1EB175CE6A0F048BABC450341CDD6BE9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1EB175CE6A0F048BABC450341CDD6BE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_EB7717D811579C774A8250341CDDEDB4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_EB7717D811579C774A8250341CDDEDB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_748968EA1BBE4A0BD74F50341CDD8AF8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_748968EA1BBE4A0BD74F50341CDD8AF8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C59FFADCD4551CFB451150341CDDCB0E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C59FFADCD4551CFB451150341CDDCB0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC47F08124C31B138B8250341CDDF051" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC47F08124C31B138B8250341CDDF051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_5B4969B9D16820D8DC6E50341CDD5D92" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_5B4969B9D16820D8DC6E50341CDD5D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_2353C5E21067DA954BCE50341CDD53F1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DerivativeTermOfContract_2353C5E21067DA954BCE50341CDD53F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4648CE094E82971C5F6950341CDEF25C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4648CE094E82971C5F6950341CDEF25C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_4454C4F625C5F5F5029250341CDEAC57" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_4454C4F625C5F5F5029250341CDEAC57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_9BC79249EEDEA3FAC61E50341CDE4B4A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_9BC79249EEDEA3FAC61E50341CDE4B4A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_84DE2C896E12A07A69C650341CDE756E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6A14F9C2AC80AA4F456F50341CDE268A" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6A14F9C2AC80AA4F456F50341CDE268A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_01B88489A6F34AEFC48C50341CDE5A57" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_01B88489A6F34AEFC48C50341CDE5A57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_718C2C037F25D4CA48CC50341CDF12B0" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_199DBC38EF4B60325B3D50341CDC0EF3" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_718C2C037F25D4CA48CC50341CDF12B0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_45273C1A300F4CE85FF750341CE6D66F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_07D799DD9D760792D8E650341CE6CBD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_45273C1A300F4CE85FF750341CE6D66F" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_07D799DD9D760792D8E650341CE6CBD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_88AFF27065163A2197D250341CE63F35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_45273C1A300F4CE85FF750341CE6D66F" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_88AFF27065163A2197D250341CE63F35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B4C38FA3B8FEE28C378B50341CE652F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_45273C1A300F4CE85FF750341CE6D66F" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_B4C38FA3B8FEE28C378B50341CE652F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_F92BA920CA674CD070A150341CE6E13E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_45273C1A300F4CE85FF750341CE6D66F" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_F92BA920CA674CD070A150341CE6E13E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_F927951FD547E8FC040650341DD16251" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_B51043C682363A6C96F450341DD1FE0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_F927951FD547E8FC040650341DD16251" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_B51043C682363A6C96F450341DD1FE0D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestituresDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_AF5663C2F90E4859FCCA50341DC8FEC5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_AF5663C2F90E4859FCCA50341DC8FEC5" xlink:to="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_04577A5B6524D7EADFB250341DC9A246" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_04577A5B6524D7EADFB250341DC9A246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_05F6FF5F70D53BCCD49D50341DC9D712" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_04577A5B6524D7EADFB250341DC9A246" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_05F6FF5F70D53BCCD49D50341DC9D712" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_431D9BDDD8A37C443B8E50341DC91ACA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_05F6FF5F70D53BCCD49D50341DC9D712" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_431D9BDDD8A37C443B8E50341DC91ACA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EA8F10FDDA163CBAE21E50341DCA0C9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EA8F10FDDA163CBAE21E50341DCA0C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08C7187296508DEC55D750341DCAD8A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EA8F10FDDA163CBAE21E50341DCA0C9A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08C7187296508DEC55D750341DCAD8A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_25B5C8BF6173194B156950341DCA5533" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08C7187296508DEC55D750341DCAD8A5" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_25B5C8BF6173194B156950341DCA5533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_D9B35458838E2F8BD78450341DC800EE" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_3C459CC78EE7AAE9ED2E50341DCAC9E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_3C459CC78EE7AAE9ED2E50341DCAC9E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_B10CCB00F16F797F287250341DCB1035" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_B10CCB00F16F797F287250341DCB1035" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_F8CF60889625FCCF206550341DCB25EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_biib_DisposalGroupOperatingLeaseAssets_F8CF60889625FCCF206550341DCB25EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F318E9AD32901F9BD0F150341DCB3AF5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F318E9AD32901F9BD0F150341DCB3AF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_7554577D987AEC21A8CF50341DCBED14" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_7554577D987AEC21A8CF50341DCBED14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6E3430F999DF181E7F7650341DCB38D5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6E3430F999DF181E7F7650341DCB38D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3ED87FC3532E4F3ABE5150341DCB01E9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3ED87FC3532E4F3ABE5150341DCB01E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8F45560488E0BB72F39850341DCC01FF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8F45560488E0BB72F39850341DCC01FF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_7BC7F26493F37C9DDF9D50341DCCDB09" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_biib_DisposalGroupOperatingleaseliabilities_7BC7F26493F37C9DDF9D50341DCCDB09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_D5E6B5943714B2638B0050341DCC3AD5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_D5E6B5943714B2638B0050341DCC3AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4F45AD3E5B915056C86450341DCC9515" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_B276EDE6BA3770D7078B50341DCAAED6" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4F45AD3E5B915056C86450341DCC9515" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_B614E93A19D59F61582150341DC185F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65E2CDE1CE782BCE876550341DC10517" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_B614E93A19D59F61582150341DC185F8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65E2CDE1CE782BCE876550341DC10517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3E1D57D126B9CE678250341DC185B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65E2CDE1CE782BCE876550341DC10517" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3E1D57D126B9CE678250341DC185B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3294244EA963447CE4CD50341DC28546" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1B3E1D57D126B9CE678250341DC185B5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3294244EA963447CE4CD50341DC28546" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_6B15596E39C8906A367750341DC29E9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3294244EA963447CE4CD50341DC28546" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_6B15596E39C8906A367750341DC29E9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65E2CDE1CE782BCE876550341DC10517" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_8480CB7302B243C1CEAE50341DC2FDF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_8480CB7302B243C1CEAE50341DC2FDF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_75B3A5F25419D5C995E850341DC3E357" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_75B3A5F25419D5C995E850341DC3E357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B74BD8F85AC1754C8E9650341DC3CB9E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_B74BD8F85AC1754C8E9650341DC3CB9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_9F8162F4A85BBBD8FF4750341DC3B72C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_9F8162F4A85BBBD8FF4750341DC3B72C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_5FB8C7CF2102C12CD74050341DC35563" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_5FB8C7CF2102C12CD74050341DC35563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_82EB6BBA78ACB7A0B4DD50341DC317A9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_DC2DCD1E7BE342EA913250341DC2500A" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_82EB6BBA78ACB7A0B4DD50341DC317A9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestituresTables" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_CD0D0E6306A581ABFDB050341DCFE6C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_DB32B9FC046CCBBA096750341DCFA75B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_CD0D0E6306A581ABFDB050341DCFE6C4" xlink:to="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_DB32B9FC046CCBBA096750341DCFA75B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_CF7FC7422BF20EFA25C950341E404B82" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="loc_dei_EntityRegistrantName_CF7FC7422BF20EFA25C950341E404B82" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_06D40C7791E93480CE8550341E40CDD7" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="loc_dei_EntityCentralIndexKey_06D40C7791E93480CE8550341E40CDD7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_1252999A02411C32C00D50341E40E207" xlink:type="locator" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="loc_dei_CurrentFiscalYearEndDate_1252999A02411C32C00D50341E40E207" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_4941F326D5E047A4CE7050341E407AD8" xlink:type="locator" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="loc_dei_EntityFilerCategory_4941F326D5E047A4CE7050341E407AD8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_AA4B665085520F078EE350341E404FD9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="loc_dei_EntitySmallBusiness_AA4B665085520F078EE350341E404FD9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_405F5AF3FFB58880EE7E50341E4103DD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="loc_dei_EntityEmergingGrowthCompany_405F5AF3FFB58880EE7E50341E4103DD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_867DD9B40F2475A0E8D650341E414A69" xlink:type="locator" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="loc_dei_DocumentType_867DD9B40F2475A0E8D650341E414A69" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_2CD4864A866B8C22DDEE50341E41B5D4" xlink:type="locator" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="loc_dei_DocumentPeriodEndDate_2CD4864A866B8C22DDEE50341E41B5D4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_998D1AB5B5018270F95F50341E41DE4D" xlink:type="locator" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="loc_dei_DocumentFiscalYearFocus_998D1AB5B5018270F95F50341E41DE4D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_37ACE2B6CBEA92DDFE8D50341E418C4E" xlink:type="locator" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_37ACE2B6CBEA92DDFE8D50341E418C4E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3F51C4240A5A8B9378CD50341E4135E9" xlink:type="locator" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="loc_dei_AmendmentFlag_3F51C4240A5A8B9378CD50341E4135E9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_D591C581371C3CBD5CA150341E420B94" xlink:type="locator" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_6CA4C8E8AB63E33D2AE550341E4067B9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_D591C581371C3CBD5CA150341E420B94" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_CA1065D98B33094D321250341C7BA7C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7533365DDC9D8731046250341C7B2DDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CA1065D98B33094D321250341C7BA7C3" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7533365DDC9D8731046250341C7B2DDE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_75072A4BCF35B896CBE350341C6CD9B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_75072A4BCF35B896CBE350341C6CD9B0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2759C5B0168FFEB0A92250341C6DD360" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_482D49CA5B5221E4A68D50341C6DBF9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E822C05D14685AA23E8450341C6D7D7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_E822C05D14685AA23E8450341C6D7D7B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_96E6C030DCE03340BD9B50341C6E4818" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:to="loc_biib_MarketStockUnitsMember_96E6C030DCE03340BD9B50341C6E4818" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_096698B10B3A2F36DF0650341C6E1671" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6F656292916E204A654A50341C6D3964" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_096698B10B3A2F36DF0650341C6E1671" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C2BD201AEBC91733050341C6CBDDB" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64B96B4994170053373F50341C6EA810" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:to="loc_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7AF792EAEE76E3B0977750341C6F1109" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_E525F5C52EBB2D19B5F350341C6E4CEC" xlink:to="loc_us-gaap_NetIncomeLoss_7AF792EAEE76E3B0977750341C6F1109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4E60D992037304575BC450341C6E5E76" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9CCDF3DEA691FCC94CC250341C6F9EE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9CCDF3DEA691FCC94CC250341C6F9EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_461BC72E4CA3328DF47350341C70FA67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_461BC72E4CA3328DF47350341C70FA67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ADEE9F5DCC29A02056BD50341C709F63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_5ADDEE989F2A04E9286D50341C6F3637" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ADEE9F5DCC29A02056BD50341C709F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4B2B6C126B0E1AE4850B50341C70A6CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B223C6F1C6E54367807850341C6F17E0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4B2B6C126B0E1AE4850B50341C70A6CC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_A7F142758BCA541D55FC50341C78937A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_49D386C591C516AD118150341C79A5C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A7F142758BCA541D55FC50341C78937A" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_49D386C591C516AD118150341C79A5C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_78E1D95F7824186A1F2750341C88FB0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78E1D95F7824186A1F2750341C88FB0C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8EBC727EF12FFBBF7A9B50341C89DBE1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_6FDA16312FDE92AA92A950341C89B4DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0F20AC2A82704891D7ED50341C89294D" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_6FDA16312FDE92AA92A950341C89B4DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8FA7B0ABE616579BC96050341C89BFAA" xlink:to="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F614CF3ABDBF161BFE1D50341C8A67B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F614CF3ABDBF161BFE1D50341C8A67B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D464FEA35A9F13F1B34950341C8A7EAD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_D464FEA35A9F13F1B34950341C8A7EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_A97CCFA47B7FF1D181F250341C8A8B9A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_A97CCFA47B7FF1D181F250341C8A8B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8B999E285F96CEBA8F6550341C8B7A88" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8B999E285F96CEBA8F6550341C8B7A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_D6117A08D7057E31494F50341C8B35C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A9B3E8A8A82FEC2E046C50341C8AF6AE" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_D6117A08D7057E31494F50341C8B35C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_EB1EA8EC1D45F741BCDD50341C882CDB" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_567791BCDB2465E13B0B50341C8B6E11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_567791BCDB2465E13B0B50341C8B6E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F7D723B83D422C5D9AD650341C8B819A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F7D723B83D422C5D9AD650341C8B819A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1CA3A6C4AB0D3FC0C1C50341C8BED6C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1CA3A6C4AB0D3FC0C1C50341C8BED6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DB9E2836E4AF7ED1D41950341C8CE93F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DB9E2836E4AF7ED1D41950341C8CE93F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_68C59A828B18CA2BC2BE50341C8C1978" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_68C59A828B18CA2BC2BE50341C8C1978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3FD1E6D36764929B7C3450341C8C7FCF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3FD1E6D36764929B7C3450341C8C7FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE62CF9B57EF800CD11850341C8CD2EE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE62CF9B57EF800CD11850341C8CD2EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0C8AD967CDDEC731E66C50341C8C20F6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_BAE21E5F3DD23CFBDFBB50341C8BA937" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0C8AD967CDDEC731E66C50341C8C20F6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_84F889DFF94FEE7E829B50341C96D607" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8EAA1522F282962357F550341C9714C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_84F889DFF94FEE7E829B50341C96D607" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8EAA1522F282962357F550341C9714C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3F30927C6EA8609F735C50341C9738FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_84F889DFF94FEE7E829B50341C96D607" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3F30927C6EA8609F735C50341C9738FF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityEquityNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_C2098B36F8AAC4260A3D50341C993BF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FE9DF949C1F133FD348850341C990993" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C2098B36F8AAC4260A3D50341C993BF5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FE9DF949C1F133FD348850341C990993" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_60C57E6C36361F643C1750341C803F46" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_60C57E6C36361F643C1750341C803F46" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_62847CD42CD1E3EE6B4B50341C80C540" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_62847CD42CD1E3EE6B4B50341C80C540" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8737377FD88A5A36C38850341C81B4A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62847CD42CD1E3EE6B4B50341C80C540" xlink:to="loc_us-gaap_EquityComponentDomain_8737377FD88A5A36C38850341C81B4A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_463EA8496A6A58D69E8150341C815B88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8737377FD88A5A36C38850341C81B4A9" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_463EA8496A6A58D69E8150341C815B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_612BBD5E6965837B24E050341C819A62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8737377FD88A5A36C38850341C81B4A9" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_612BBD5E6965837B24E050341C819A62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_D4D12BB02DB979546D2450341C81BD62" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8737377FD88A5A36C38850341C81B4A9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_D4D12BB02DB979546D2450341C81BD62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47283081F04FD6032C5C50341C825D40" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F043CE7482427013079350341C82F239" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_261D434D8871B2E0B6F350341C82F1C3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_F043CE7482427013079350341C82F239" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_A31FCA3552EEBD5C702750341C80A70F" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_560C0F76F1C966D77CE950341C829B69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_560C0F76F1C966D77CE950341C829B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0BEB533ABC7423388D5750341C83DC64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0BEB533ABC7423388D5750341C83DC64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BB1EC58272F270E1BF5650341C831D34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:to="loc_us-gaap_Revenues_BB1EC58272F270E1BF5650341C831D34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D96354BACAEB9AE0D28A50341C83C53C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:to="loc_us-gaap_OperatingExpenses_D96354BACAEB9AE0D28A50341C83C53C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_96341332A819F0BFA65150341C837E8B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_24BED2017A06914AC7CE50341C82C872" xlink:to="loc_us-gaap_NetIncomeLoss_96341332A819F0BFA65150341C837E8B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_FA286945AF4B3B7112E050341C91E4E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_FA286945AF4B3B7112E050341C91E4E3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_E88AAB99335B94E79FB650341C911A4F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5E77A20C7B76BE05D5E650341C920D31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4EB668A1B5045AA7028B50341C925A20" xlink:to="loc_us-gaap_SubsequentEventMember_5E77A20C7B76BE05D5E650341C920D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_C2AF86799A3CE8A2849850341C9273CB" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:to="loc_biib_A2019ShareRepurchaseProgramMember_DF2253E292743B86EADB50341C92F103" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_893CA2F03456623AF14650341C93868A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1815220BC537E0684B6E50341C9239FD" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_4DC45988166728C9750150341C93375F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72ACBFD0AA40A9537B950341C912B2C" xlink:to="loc_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D5C26CDF4C2CDFB08C450341C9396B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D5C26CDF4C2CDFB08C450341C9396B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_88AFE672B2C39A33413550341C94EE57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_88AFE672B2C39A33413550341C94EE57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_FD1318FAAEB206EAAB2050341C947478" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6E2B092E224988B9426450341C933156" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_FD1318FAAEB206EAAB2050341C947478" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8860918FDAD093E414CE50341D5E8783" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_A17173CEC5A703F56D9150341D5E4088" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8860918FDAD093E414CE50341D5E8783" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_A17173CEC5A703F56D9150341D5E4088" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_48AC4DF8C12E84064D5550341D52CA66" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_48AC4DF8C12E84064D5550341D52CA66" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_35C47B6395FAE7646E5E50341D52F934" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5BB9A6DA7ABBD8D2768250341D533BF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5BB9A6DA7ABBD8D2768250341D533BF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DA8123818CEFB2ED9E4D50341D53484B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_DA8123818CEFB2ED9E4D50341D53484B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_432B89A3054E6837CFF250341D53BDCF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41EF6F6C56937862A08B50341D5252E2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_432B89A3054E6837CFF250341D53BDCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B68C4F467868B3B74B7C50341D538485" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B68C4F467868B3B74B7C50341D538485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_13761BDEF761B33EAD9150341D549D59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B68C4F467868B3B74B7C50341D538485" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_13761BDEF761B33EAD9150341D549D59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_95C3236DDAA89955BB7D50341D5415C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_13761BDEF761B33EAD9150341D549D59" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_95C3236DDAA89955BB7D50341D5415C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8109C440A49326F3D6A850341D541E06" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5428556BAA0780B53B7350341D548B4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5428556BAA0780B53B7350341D548B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_2045245CA4747DC5B01F50341D55B9C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_2045245CA4747DC5B01F50341D55B9C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_849F1A2DF8631040068550341D55AD59" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_716E87AEB512DD4D3E0450341D545A46" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_849F1A2DF8631040068550341D55AD59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C7800600320225A9C41750341D52B101" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9FA64AF247F70FD09E9050341D557F8C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_890E675788CF70B8AB5150341D56DAD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_890E675788CF70B8AB5150341D56DAD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F2065EE935B035D421250341D56F598" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6F2065EE935B035D421250341D56F598" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_F2861A2216C0D5CE509750341D56C347" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_F2861A2216C0D5CE509750341D56C347" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C57E8A59E4C2435EE59150341D567CD5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C57E8A59E4C2435EE59150341D567CD5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_89FD89A52D5B5C4AB4FC50341D5751FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_881379112A8F9A47062850341D576319" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13AF498A24640739F80750341D5613ED" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_881379112A8F9A47062850341D576319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1FAF928918C9E689040050341D555EDA" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1FDAEE0C0148DB5FAC4150341D573CF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1FDAEE0C0148DB5FAC4150341D573CF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9146131949D7B568B16D50341D5761C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9146131949D7B568B16D50341D5761C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_10375D785976EF2B814650341D57EF32" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_82E7155C917DE3D9755C50341D57BF4E" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_10375D785976EF2B814650341D57EF32" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_45DBBB3B76D2F91483A250341D495FCF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_45DBBB3B76D2F91483A250341D495FCF" xlink:to="loc_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD" xlink:to="loc_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2DA4C48F22B95C104C7C50341D493F60" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4B25136CCAF2D000184B50341D4A5480" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3A82BAAA2D2EC5963AD850341D4A1E8E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_38E82426AAF5434D51BF50341D4B8723" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2A1F4518C98F81F9B70E50341D4AC588" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D575649604C69782A27150341D4BE585" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1DD177C544B8E14B435750341D4915DD" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_A3681F682B47E158D62050341D4B3AA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_A3681F682B47E158D62050341D4B3AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_8507B37540F736C281E150341D4B1855" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:to="loc_us-gaap_NotesPayable_8507B37540F736C281E150341D4B1855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_22B052E0159989880A2350341D4BC053" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9A2FD64D6516A2E7816B50341D4B78C0" xlink:to="loc_us-gaap_DebtInstrumentFairValue_22B052E0159989880A2350341D4BC053" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_69F28114EC96E02F016050341D448BBE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_69F28114EC96E02F016050341D448BBE" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9EA386EB1E9B2BF8E28450341D44E746" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_C7BC491984034B9E46A950341D4543C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7936B2B2531B00CACD8850341D4415C2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_C7BC491984034B9E46A950341D4543C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6150EB4396647F9FDB4B50341D44E3EA" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2C88029FB015B3C83C2650341D4530F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2C88029FB015B3C83C2650341D4530F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5667EAB5C3DB7F6F34250341D4561BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5667EAB5C3DB7F6F34250341D4561BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C1C3BC9B36ADD19294F250341D46ED39" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C1C3BC9B36ADD19294F250341D46ED39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7B7921DC12848FCE078750341D46EA83" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_D4FB42918B6C09CD448B50341D455324" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7B7921DC12848FCE078750341D46EA83" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5ADA869AA4728086EE4C50341D3E873E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_51B80CBFD40A03EF29EA50341D3E5365" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5ADA869AA4728086EE4C50341D3E873E" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_51B80CBFD40A03EF29EA50341D3E5365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_201DABB462C8E191150E50341D3E0C9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_51B80CBFD40A03EF29EA50341D3E5365" xlink:to="loc_us-gaap_DebtInstrumentAxis_201DABB462C8E191150E50341D3E0C9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_201DABB462C8E191150E50341D3E0C9B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_21D51968BD0A92E8D8D550341D3F2906" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_21D51968BD0A92E8D8D550341D3F2906" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A6B997816AD93D9B882450341D3FDC83" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A6B997816AD93D9B882450341D3FDC83" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5470BF38093AA8FBAFF050341D3F55AB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5470BF38093AA8FBAFF050341D3F55AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_33B260760A1B2E442A3B50341D3FB475" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BC84731136867D8518C550341D3F7008" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_33B260760A1B2E442A3B50341D3FB475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F69FAE961FB09736AFC050341D40B4A3" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_51B80CBFD40A03EF29EA50341D3E5365" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F69FAE961FB09736AFC050341D40B4A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_171BCD1E74E294CAB01650341D40B269" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F69FAE961FB09736AFC050341D40B4A3" xlink:to="loc_us-gaap_AssetImpairmentCharges_171BCD1E74E294CAB01650341D40B269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs" xlink:label="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_72DDFED369147BAE7BCC50341D40114F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F69FAE961FB09736AFC050341D40B4A3" xlink:to="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_72DDFED369147BAE7BCC50341D40114F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_33A92CEDAD733B4FC47750341D4010BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F69FAE961FB09736AFC050341D40B4A3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_33A92CEDAD733B4FC47750341D4010BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13F6A6C5BEB4E2AF97DC50341D40B4D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F69FAE961FB09736AFC050341D40B4A3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13F6A6C5BEB4E2AF97DC50341D40B4D1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DA5F983B760013BC2C0C50341D5C7B57" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_12882A53A29399428C9850341D5C134E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DA5F983B760013BC2C0C50341D5C7B57" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_12882A53A29399428C9850341D5C134E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_939A0F469303BE7CCE5150341D5C4BC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DA5F983B760013BC2C0C50341D5C7B57" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_939A0F469303BE7CCE5150341D5C4BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_67BBA209A6413C965ED950341D5CA0F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DA5F983B760013BC2C0C50341D5C7B57" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_67BBA209A6413C965ED950341D5CA0F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8FE732794D25E48C07EE50341D3B4C2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3AE9209802CC485B5D4F50341D3B6A32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8FE732794D25E48C07EE50341D3B4C2D" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3AE9209802CC485B5D4F50341D3B6A32" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2A5C715B61E6478C734E50341D336468" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2A5C715B61E6478C734E50341D336468" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77" xlink:to="loc_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_799E548F27E0235311EA50341D3358B6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_EC10271382C48A2E872150341D346804" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:to="loc_us-gaap_CommercialPaperMember_EC10271382C48A2E872150341D346804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_97A501FCD30580B8493650341D343491" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_97A501FCD30580B8493650341D343491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1E6C947DA6C2B58DCDDE50341D34B4A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1E6C947DA6C2B58DCDDE50341D34B4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_2FE385869DFC836B6E0150341D34C3D9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DC06F6ADDE6B4B2746A050341D33C1F0" xlink:to="loc_us-gaap_DebtSecuritiesMember_2FE385869DFC836B6E0150341D34C3D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E0175679AC0FFB82071B50341D33CB77" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F3B539FCA82592DD9E4250341D34B855" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_158954D2724EB5F8ADB250341D3585B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9ED5BEC82FAB521B87C550341D352640" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_158954D2724EB5F8ADB250341D3585B1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_875408A98DC3C5270A6750341D2BB03D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_875408A98DC3C5270A6750341D2BB03D" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_EE36D6999EF07B0E539C50341D2BCEBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01" xlink:to="loc_us-gaap_FinancialInstrumentAxis_EE36D6999EF07B0E539C50341D2BCEBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_EE36D6999EF07B0E539C50341D2BCEBA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_D3B8DBC110675C38B4F450341D2C052D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_3F33ACB4C0326141AE3350341D2CAC3F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_3278E9447F03148DF2D850341D2CD8A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_13EB1111BBC5B81C790350341D2C0094" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_249B700B7322816881D450341D2CB76E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_43FD69613245171C19C850341D2D1E4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_3202D972F02F4CAF89CD50341D2DE89A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2AD4DC93C9B9FBEAE81350341D2B697C" xlink:to="loc_us-gaap_EquitySecuritiesMember_3202D972F02F4CAF89CD50341D2DE89A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B2C9B8995CF613C8BC4550341D2B3B01" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_043242D26AC0671C346750341D2D9532" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_043242D26AC0671C346750341D2D9532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAC5111EC817B92E1BDA50341D2D5503" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_EAC5111EC817B92E1BDA50341D2D5503" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4B3A57A65B79B0ACA88950341D2E61BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4B3A57A65B79B0ACA88950341D2E61BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3147B7F5A416F7B6F26F50341D2E393B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3147B7F5A416F7B6F26F50341D2E393B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_998D1ECA3F5D384DBAFD50341D2E41FC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_998D1ECA3F5D384DBAFD50341D2E41FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B40066506ED9777EAF4B50341D2E40AA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B40066506ED9777EAF4B50341D2E40AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F09C2DC2A4FDCADA8BCB50341D2EE71D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F09C2DC2A4FDCADA8BCB50341D2EE71D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_4E34EF54C1F3016BBF5450341D2EA778" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_32E7D5894FB727CC339B50341D2D0407" xlink:to="loc_us-gaap_AvailableForSaleSecurities_4E34EF54C1F3016BBF5450341D2EA778" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_46142A1BF6ABAA7DEFC950341D21D03F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_46142A1BF6ABAA7DEFC950341D21D03F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C2ED01E2C88A9571C04250341D226F51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C2ED01E2C88A9571C04250341D226F51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FA31DAC519FB58F886D850341D22576B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_FA31DAC519FB58F886D850341D22576B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7B99B2EF0F879FC1E45D50341D23DAB5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7B99B2EF0F879FC1E45D50341D23DAB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8627E231BC18445B0CDB50341D230638" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8627E231BC18445B0CDB50341D230638" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CAC025A953CEC430EDCC50341D234D08" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CAC025A953CEC430EDCC50341D234D08" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_E93CC65C40CC549DB67850341D2487A5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_E93CC65C40CC549DB67850341D2487A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_954D897ECE64A4D1EEB950341D241BEC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_954D897ECE64A4D1EEB950341D241BEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_1D55DABF271B648EB34450341D24837A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7B934889AC567516EE5350341D22AC9A" xlink:to="loc_us-gaap_AvailableForSaleSecurities_1D55DABF271B648EB34450341D24837A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0BA2F25F042C831ACA0350341CF56553" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ADC27BA11F8A7B278BCA50341CF51C4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0BA2F25F042C831ACA0350341CF56553" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ADC27BA11F8A7B278BCA50341CF51C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_34FB0DE40722C63B22D750341CF5A0F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0BA2F25F042C831ACA0350341CF56553" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_34FB0DE40722C63B22D750341CF5A0F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D815996EDDA0F5F6E50341CF50ED5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0BA2F25F042C831ACA0350341CF56553" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_A46D815996EDDA0F5F6E50341CF50ED5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_05195103AC5962BD0F8150341CF2F3F5" xlink:type="locator" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_BF2CB5C1F9DEF1E2495050341CF3F972" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_05195103AC5962BD0F8150341CF2F3F5" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_BF2CB5C1F9DEF1E2495050341CF3F972" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_31474FE83F6A6D3274E650341CECD1C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3321B20B2A8D74A3FA0150341CEC347B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_31474FE83F6A6D3274E650341CECD1C3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3321B20B2A8D74A3FA0150341CEC347B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_349BEED5489CDF7BF60F50341CED2ED2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3321B20B2A8D74A3FA0150341CEC347B" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_349BEED5489CDF7BF60F50341CED2ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_B2CEDF9F6C4D3A43E08850341CED0733" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_349BEED5489CDF7BF60F50341CED2ED2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_B2CEDF9F6C4D3A43E08850341CED0733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_A99091C1DF4392776EC150341CEDBA6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_B2CEDF9F6C4D3A43E08850341CED0733" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_A99091C1DF4392776EC150341CEDBA6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_CDF89CEA4213AD9EDCA050341CED43DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_B2CEDF9F6C4D3A43E08850341CED0733" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_CDF89CEA4213AD9EDCA050341CED43DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_EE5C4C666F43EC53E41050341CEE6B4F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3321B20B2A8D74A3FA0150341CEC347B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_EE5C4C666F43EC53E41050341CEE6B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1019DE58F93F799FE00850341CEEF91C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EE5C4C666F43EC53E41050341CEE6B4F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1019DE58F93F799FE00850341CEEF91C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1019DE58F93F799FE00850341CEEF91C" xlink:to="loc_biib_IonisPharmaceuticalsMember_728A2412633883F652A250341CEE369B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3321B20B2A8D74A3FA0150341CEC347B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2442821458BCD74D299450341CEEC2D7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A9A77E44FE4C62E3114750341CEE5C8C" xlink:to="loc_biib_StrategicInvestmentsMember_8DC3341A962932187DCC50341CEF4B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2ED78F9F8F2526CE7A7950341CEF7421" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3321B20B2A8D74A3FA0150341CEC347B" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2ED78F9F8F2526CE7A7950341CEF7421" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ED78F9F8F2526CE7A7950341CEF7421" xlink:to="loc_biib_StrategicInvestmentPortfolio_C14AC9324A2D2449A45750341CEF5040" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ED78F9F8F2526CE7A7950341CEF7421" xlink:to="loc_biib_Investmentincommonstocksharespurchased_356FCAD90244D4F9E8CF50341CEF7F57" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ED78F9F8F2526CE7A7950341CEF7421" xlink:to="loc_biib_Purchaseofcommonstock_E9D6FBC76EFFCF5D190350341CF02E78" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0F34DE34AC75BA3BD2E450341D38CE8F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ECB06C7A3090C6B6A81550341D386489" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0F34DE34AC75BA3BD2E450341D38CE8F" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ECB06C7A3090C6B6A81550341D386489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_45AE493B647F1132DAA550341D38656A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0F34DE34AC75BA3BD2E450341D38CE8F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_45AE493B647F1132DAA550341D38656A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B14E07A812A2CE356E1750341D38CFA0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0F34DE34AC75BA3BD2E450341D38CE8F" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B14E07A812A2CE356E1750341D38CFA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_435AE8F5D8EA1AB5842B50341D38D222" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0F34DE34AC75BA3BD2E450341D38CE8F" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_435AE8F5D8EA1AB5842B50341D38D222" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_21E76E3E928AE2130D4F50341C40BE48" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_337BA15AAD5A678AEF2A50341C401ABF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21E76E3E928AE2130D4F50341C40BE48" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_337BA15AAD5A678AEF2A50341C401ABF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4F77D5D35EEF8545758650341C34DE94" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4F77D5D35EEF8545758650341C34DE94" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C8461FFE2DDA037563EC50341C34CCD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C8461FFE2DDA037563EC50341C34CCD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9DBC01AAAC94D3AC35F750341C34F44D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9DBC01AAAC94D3AC35F750341C34F44D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8FE2DB8B1139AD3287AE50341C3570D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8FE2DB8B1139AD3287AE50341C3570D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_50A4627F6257E315D79050341C35AA23" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_50A4627F6257E315D79050341C35AA23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7374C6A20E30C31BA7E050341C35F788" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7374C6A20E30C31BA7E050341C35F788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_DAA2BDD27B679355A01650341C35E5C6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_DAA2BDD27B679355A01650341C35E5C6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_744E3BD0C60CAC1FCA2250341C351F98" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_744E3BD0C60CAC1FCA2250341C351F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_35B8FEC57BB74523C0AA50341C3515A7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_35B8FEC57BB74523C0AA50341C3515A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0E4952AD1E593036AD7E50341C3675CF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0E4952AD1E593036AD7E50341C3675CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CB07AD9CA5C939B1784650341C363FDC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_47C0E69B94FE247D4EEF50341C340A61" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_CB07AD9CA5C939B1784650341C363FDC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7B49D5039E16BEB1E86650341C224AF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_8EBA9EB64FC11A6E2B3750341C279F5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7B49D5039E16BEB1E86650341C224AF5" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_8EBA9EB64FC11A6E2B3750341C279F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDEF518332E7FCE0392C50341C27440A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8EBA9EB64FC11A6E2B3750341C279F5A" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDEF518332E7FCE0392C50341C27440A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D915A1A936B5D6BAD9D950341C27B3E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDEF518332E7FCE0392C50341C27440A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D915A1A936B5D6BAD9D950341C27B3E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_F2DDEDD49BB1734BA06D50341C28730C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D915A1A936B5D6BAD9D950341C27B3E2" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_F2DDEDD49BB1734BA06D50341C28730C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6301A1B7469640C03CEE50341C280103" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8EBA9EB64FC11A6E2B3750341C279F5A" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6301A1B7469640C03CEE50341C280103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1B5C7FC792B15A4E865550341C28BCE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6301A1B7469640C03CEE50341C280103" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1B5C7FC792B15A4E865550341C28BCE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_CD2BB919752524EB64D850341C2954A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1B5C7FC792B15A4E865550341C28BCE6" xlink:to="loc_us-gaap_ForeignCountryMember_CD2BB919752524EB64D850341C2954A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0329C7DEE63E6559352B50341C29FF38" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8EBA9EB64FC11A6E2B3750341C279F5A" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_0329C7DEE63E6559352B50341C29FF38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_D1712653C0BD6E23C52250341C297D9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0329C7DEE63E6559352B50341C29FF38" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_D1712653C0BD6E23C52250341C297D9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_F4A5BA05DF7C17B6425650341C29676A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0329C7DEE63E6559352B50341C29FF38" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_F4A5BA05DF7C17B6425650341C29676A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_EA90AAB936343C42BF0550341C293AC9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0329C7DEE63E6559352B50341C29FF38" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_EA90AAB936343C42BF0550341C293AC9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2930664614C1CDDE9DB750341C3955D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_19B5F12D7471A23B690550341C396266" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2930664614C1CDDE9DB750341C3955D0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_19B5F12D7471A23B690550341C396266" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C205E65B17B68660392450341D7C9903" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_48DAA0E9F5259C800E5850341D7D199C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C205E65B17B68660392450341D7C9903" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_48DAA0E9F5259C800E5850341D7D199C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8EC81B7D8A5C0EE86D2750341D6DA8B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8EC81B7D8A5C0EE86D2750341D6DA8B2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_EC686898BCF25ED8524E50341D6D3F2C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_70D8D10389941E21893450341D6DB3E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_70D8D10389941E21893450341D6DB3E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_901DFA416EF73BB75D0F50341D6EE600" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C1C4FB0224AD750823E50341D6D94DD" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_901DFA416EF73BB75D0F50341D6EE600" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CDBCD8ED6B254EF5FD2E50341D6EFFA7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:to="loc_biib_OutLicensedPatentsMember_1C6A1EB0B6D9531BFD4750341D6EA1F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_A607027B00A08157D3E650341D6F4F7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_A607027B00A08157D3E650341D6F4F7D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F5BCE5C32C346DBDEBD250341D6E9D6F" xlink:to="loc_biib_InLicensedPatentsMember_B41E221B94AE4EE4B0BB50341D6FA80F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_FCC8FD16B1A16C17408150341D6F9705" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:to="loc_srt_ProductOrServiceAxis_FCC8FD16B1A16C17408150341D6F9705" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7091C7BDFCA77E1225F550341D6F213F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_FCC8FD16B1A16C17408150341D6F9705" xlink:to="loc_srt_ProductsAndServicesDomain_7091C7BDFCA77E1225F550341D6F213F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7091C7BDFCA77E1225F550341D6F213F" xlink:to="loc_biib_AVONEXMember_1BD4D212037ECEC0BB0D50341D6F8767" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7091C7BDFCA77E1225F550341D6F213F" xlink:to="loc_biib_TysabriProductMember_3F4DAD8737C1B54DEF8650341D705D5B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7091C7BDFCA77E1225F550341D6F213F" xlink:to="loc_biib_TecfideraMember_151B6A2F5886F42BAE5650341D7001CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_AC2125D4359889BB5DA050341D703A04" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:to="loc_srt_RangeAxis_AC2125D4359889BB5DA050341D703A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D68CC406FC3B6642734750341D70AADD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_AC2125D4359889BB5DA050341D703A04" xlink:to="loc_srt_RangeMember_D68CC406FC3B6642734750341D70AADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_22E0C219A37DFA7312F950341D7026BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D68CC406FC3B6642734750341D70AADD" xlink:to="loc_srt_MinimumMember_22E0C219A37DFA7312F950341D7026BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_480D9D4225DF191B262950341D71A9EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D68CC406FC3B6642734750341D70AADD" xlink:to="loc_srt_MaximumMember_480D9D4225DF191B262950341D71A9EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_04A53C1DDAE0811A2FBA50341D6D830A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E9947141E18D1B3C35E450341D71501E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E9947141E18D1B3C35E450341D71501E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_D1FB7DD597533AA8CD3250341D726579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4A62DA896A475518A46050341D7208F6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4A62DA896A475518A46050341D7208F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7CCA33BB2602BC5A446050341D7291E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7CCA33BB2602BC5A446050341D7291E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_56B959373432C49023E250341D72E061" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_56B959373432C49023E250341D72E061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2CF890C29238B75AFAB850341D724ED7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2CF890C29238B75AFAB850341D724ED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E49E83160EB71F20A70250341D72F892" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E49E83160EB71F20A70250341D72F892" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F66AE7CB60E1584F699D50341D738A6A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_74BDAB5DAE4DCD3B073650341D71531B" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F66AE7CB60E1584F699D50341D738A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D81870406F0B518E876A50341D7384D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8D63687DA934A3BFA55050341D713BE1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_D81870406F0B518E876A50341D7384D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_B0494225ACBCF3050B4950341D739B2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8EC81B7D8A5C0EE86D2750341D6DA8B2" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_B0494225ACBCF3050B4950341D739B2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_228AD7A2F5AB803F97AD50341D731C36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_B0494225ACBCF3050B4950341D739B2F" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_228AD7A2F5AB803F97AD50341D731C36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7DEC9793BD678B13D00750341D7373D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8EC81B7D8A5C0EE86D2750341D6DA8B2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7DEC9793BD678B13D00750341D7373D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C309EA02CE72E8A8115C50341D732AC4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8EC81B7D8A5C0EE86D2750341D6DA8B2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C309EA02CE72E8A8115C50341D732AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_976C54ADA35B1293BF4F50341D74E272" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8EC81B7D8A5C0EE86D2750341D6DA8B2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_976C54ADA35B1293BF4F50341D74E272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_45E837B19137EB46FC5750341D747546" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8EC81B7D8A5C0EE86D2750341D6DA8B2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_45E837B19137EB46FC5750341D747546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_FB936E4F9A9F3AE548D450341D741CF9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8EC81B7D8A5C0EE86D2750341D6DA8B2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_FB936E4F9A9F3AE548D450341D741CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_54FEEF5C65B0D4E2443F50341D74B92B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8EC81B7D8A5C0EE86D2750341D6DA8B2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_54FEEF5C65B0D4E2443F50341D74B92B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E43C7704C78A1FE0763050341D62D178" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E43C7704C78A1FE0763050341D62D178" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3AD75C4374C19F6BC75250341D63D2A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3AD75C4374C19F6BC75250341D63D2A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1B827952347D75411CE350341D63FE6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3AD75C4374C19F6BC75250341D63D2A5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1B827952347D75411CE350341D63FE6F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_8364344276BF93D7FB9250341D63C745" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1B827952347D75411CE350341D63FE6F" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_8364344276BF93D7FB9250341D63C745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_FC7714D77672D52D1D2150341D6366CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_EBCF08DC3FF77828A27F50341D62787E" xlink:to="loc_us-gaap_GoodwillLineItems_FC7714D77672D52D1D2150341D6366CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E43C7704C78A1FE0763050341D62D178" xlink:to="loc_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5D01D5D95369C3799C9450341D64C755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238" xlink:to="loc_us-gaap_Goodwill_5D01D5D95369C3799C9450341D64C755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_510EC9AF43BEE126AD4850341D64CD8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_510EC9AF43BEE126AD4850341D64CD8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_FCB4042A740139A85F6E50341D648B10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_FCB4042A740139A85F6E50341D648B10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_EE3D536650292AA66C9350341D640448" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_750C234192FCB9F4737750341D634238" xlink:to="loc_us-gaap_Goodwill_EE3D536650292AA66C9350341D640448" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_939FF8AAF45AFC966BF650341D7930F8" xlink:type="locator" />
    <link:loc xlink:href="biib-20190331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_B67A608D3D8EA7932C6650341D7AACCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_939FF8AAF45AFC966BF650341D7930F8" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_B67A608D3D8EA7932C6650341D7AACCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BF032E2F4691264FD3AC50341D7AA0D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_939FF8AAF45AFC966BF650341D7930F8" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BF032E2F4691264FD3AC50341D7AA0D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_A21266AA1FC48F3406B050341D7A8E31" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_939FF8AAF45AFC966BF650341D7930F8" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_A21266AA1FC48F3406B050341D7A8E31" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_CBBE6EEE69473AC762CB50341D9024BE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_44DA30E888D0608ADD0550341D90800F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_CBBE6EEE69473AC762CB50341D9024BE" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_44DA30E888D0608ADD0550341D90800F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2290C07F1EA458D069B550341D8AE6B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2290C07F1EA458D069B550341D8AE6B6" xlink:to="loc_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_B7267DCC11E86487861D50341D8B3909" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_B7267DCC11E86487861D50341D8B3909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_16F3F8379DB24A24C18E50341D8B895E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_16F3F8379DB24A24C18E50341D8B895E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8DFF10C352574445B3CA50341D8B2AE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8DFF10C352574445B3CA50341D8B2AE8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_883E53EFAD4AF65C1C4E50341D8BFCCA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_F12A3228E08A889F9C3450341D8A1138" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_883E53EFAD4AF65C1C4E50341D8BFCCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_72E3B35BF504BBE8BC7350341D8BC7FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2290C07F1EA458D069B550341D8AE6B6" xlink:to="loc_us-gaap_InventoryNet_72E3B35BF504BBE8BC7350341D8BC7FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_A86DEDAB834401352E1250341D8CECB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2290C07F1EA458D069B550341D8AE6B6" xlink:to="loc_us-gaap_InventoryNoncurrent_A86DEDAB834401352E1250341D8CECB8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_InventoryAbstract" xlink:label="loc_biib_InventoryAbstract_0DE97C1D0DD118100F2050341D85E660" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InventoryAbstract_0DE97C1D0DD118100F2050341D85E660" xlink:to="loc_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_BB3B859BE5B7707F4DAE50341D86477D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4" xlink:to="loc_srt_MajorCustomersAxis_BB3B859BE5B7707F4DAE50341D86477D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FCD7C9A8AFD62C0487EE50341D8671EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_BB3B859BE5B7707F4DAE50341D86477D" xlink:to="loc_srt_NameOfMajorCustomerDomain_FCD7C9A8AFD62C0487EE50341D8671EE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_5B1CD7BC98F6DD8F75F850341D8778EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FCD7C9A8AFD62C0487EE50341D8671EE" xlink:to="loc_biib_BioverativMember_5B1CD7BC98F6DD8F75F850341D8778EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_AE687759526218A3DC3550341D8640F4" xlink:to="loc_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_InventorysoldtoBioverativcost" xlink:label="loc_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_A360F34F48C4B6939CC750341D878A31" xlink:to="loc_biib_InventorysoldtoBioverativcost_FA15117522A3126512CA50341D87F10F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_5C9634DD9A8FC20F051050479ECEFDAF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_5C9634DD9A8FC20F051050479ECEFDAF" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_B7302165B2515FC10E0350479ECF83DD" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_97F4260E38F0A902C6D450479ECFF015" xlink:to="loc_biib_WorkinprocessMember_0C5C7628FDB7FD700C1A50479ECF1012" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7BB0CE5AAD5E9524182650479ED0CDD5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7BB0CE5AAD5E9524182650479ED0CDD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96196DB046FF07B3E8E150479ED02180" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7BB0CE5AAD5E9524182650479ED0CDD5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96196DB046FF07B3E8E150479ED02180" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_3B5D129A91C71AE21EF450479ED00896" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96196DB046FF07B3E8E150479ED02180" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_3B5D129A91C71AE21EF450479ED00896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_D7601B91119B041A11E250479ECED6A7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_04A9E5D7DCA1309BD19A50479ED15D38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_04A9E5D7DCA1309BD19A50479ED15D38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_E84C18AA15F6FABAB2FC50479ED1DE39" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3C93EFAB0A84953E4C4050479ED0766C" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_E84C18AA15F6FABAB2FC50479ED1DE39" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_149D838CDA6A607427C050341D8E79A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C9E0730B2A2A5B581BBB50341D8E1CC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_149D838CDA6A607427C050341D8E79A1" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C9E0730B2A2A5B581BBB50341D8E1CC4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_672A9B0A53F000538D3550341BC499D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_DC428B08EFA5DBA7C54650341BC492F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_672A9B0A53F000538D3550341BC499D5" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_DC428B08EFA5DBA7C54650341BC492F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_3F469D00D50A8479208450341BC1EB58" xlink:type="locator" />
    <link:loc xlink:href="biib-20190331.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_CD671B1ACDC982A63D0650341BC12046" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_3F469D00D50A8479208450341BC1EB58" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_CD671B1ACDC982A63D0650341BC12046" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_337868DC24EAC83D2AB250341BC2E79B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_CD671B1ACDC982A63D0650341BC12046" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_337868DC24EAC83D2AB250341BC2E79B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_C8325E2B0754E251A58F509202364845" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C8325E2B0754E251A58F509202364845" xlink:to="loc_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DB85C62991C2DF539B7E50920236E6D6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_OperatingleaseassetsMember" xlink:label="loc_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:to="loc_biib_OperatingleaseassetsMember_68C50A5F2AC618E2233150920237EFAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_CDC8638FCAEE232CAE465092023796B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_CDC8638FCAEE232CAE465092023796B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8265E0141B3B5FD0112C5092023774CB" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_ECC0C0E1914F175450BF50920237C3F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F8A4366C27BCF3A8F19F50920237DCE4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_EEB2C9F35E321AD356ED5092023808FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_EEB2C9F35E321AD356ED5092023808FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87A396A3E7DE768378B350920238D911" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87A396A3E7DE768378B350920238D911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_044325660A40282AD80750920238E3AC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3BA76150482191587AB250920238A0E1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_044325660A40282AD80750920238E3AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A90EF63A6AB8224CBED750920236E6AF" xlink:to="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7BAF9651F8A3D698AA9C5092023916F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7BAF9651F8A3D698AA9C5092023916F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_AE706E91E585A4475520509202399285" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_AE706E91E585A4475520509202399285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_54BB693B93E409E1A09750920239C876" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_54BB693B93E409E1A09750920239C876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_BCD93A9A69596DF501465092023998F5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseLiability_BCD93A9A69596DF501465092023998F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_3D55A5BFE3A1095A63A45092023905A7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseCost_3D55A5BFE3A1095A63A45092023905A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_671FBAB40AC520F044065092023AD8CA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_671FBAB40AC520F044065092023AD8CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_71D2D66EA34125E59F1C5092023AF5D9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseCost_71D2D66EA34125E59F1C5092023AF5D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_DFEDEB385CA08D9CF55A5092023AC055" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_DFEDEB385CA08D9CF55A5092023AC055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3FB05D0351E2DF0FA10C5092023A2AFE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3FB05D0351E2DF0FA10C5092023A2AFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C880875D94F76599AB3F5092023AC37D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_C880875D94F76599AB3F5092023AC37D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3D80712892620F4358435092023A5C35" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3D80712892620F4358435092023A5C35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D837E26EE2DEC0A699F05092023B7620" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D837E26EE2DEC0A699F05092023B7620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3DBBE8D9D7F4F9E78FC05092023B23FD" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3DBBE8D9D7F4F9E78FC05092023B23FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CAA485D5A2F953870ECF5092023B8AE2" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_CAA485D5A2F953870ECF5092023B8AE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73CCD8956E3D2A6BBBAE5092023B4936" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73CCD8956E3D2A6BBBAE5092023B4936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_B42A4B48793EF9C3B7645092023BD210" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_B42A4B48793EF9C3B7645092023BD210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_330FCA5C36AC184BC3AE5092023C46A2" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_330FCA5C36AC184BC3AE5092023C46A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6F579D6F0E3A400F3F315092023C36B5" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6F579D6F0E3A400F3F315092023C36B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_45ECDAEED5AA559FE17A5092023C50D8" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_45ECDAEED5AA559FE17A5092023C50D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_640BFF691FA0A3169C785092023C4BE6" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_640BFF691FA0A3169C785092023C4BE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ED53CEDDF92FFC86BFAA5092023CE6D8" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_ED53CEDDF92FFC86BFAA5092023CE6D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7DA9F4D36C47FFC808035092023C5CE1" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7DA9F4D36C47FFC808035092023C5CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4E96ED8142CAC25585705092023CC1C5" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4E96ED8142CAC25585705092023CC1C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_A396502DB1C3B25651275092023DCD26" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_A396502DB1C3B25651275092023DCD26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7911D3BDFBD91140938C5092023DD5B3" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_7911D3BDFBD91140938C5092023DD5B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_E620BEBD10BCCCEB88B85092023D95A3" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_E620BEBD10BCCCEB88B85092023D95A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7CCA02D07CA46482870D5092023D80E0" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7CCA02D07CA46482870D5092023D80E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_79BC7775A578815642485092023D94CE" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_79BC7775A578815642485092023D94CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_ABFD003E6060DA843A405092023DF9E3" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_ABFD003E6060DA843A405092023DF9E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_1F32F9B1A357D4F8EF1C5092023E9EE2" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_1F32F9B1A357D4F8EF1C5092023E9EE2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInOneYear_159E0B42228562EBE1105092023E5CAD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_02456BE6DDD46E0788FE5092023EEA2A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_F3735205DC11B789D25B5092023EE283" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFourYear_BD8B9F6B09B213EA863D5092023E79DD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_323B401178DED50A0F4D5092023ECF41" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePaymentsThereafter_19F6860AB44A17BED8655092023E9FE4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_biib_NetMinimumLeasePayments_2FDCA20333376609DCA65092023FAAF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41393617AA4BAE5B364E5092023FD899" xlink:type="locator" />
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41393617AA4BAE5B364E5092023FD899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0CF5C58A161B55514D935092023FA752" xlink:type="locator" />
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0CF5C58A161B55514D935092023FA752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_D9C60146487C27B36F4D5092023F9909" xlink:type="locator" />
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_OperatingLeasePayments_D9C60146487C27B36F4D5092023F9909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D50E09170BC0EB0717BA5092023F0467" xlink:type="locator" />
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_28DA079ACE63E810AC075092023941B0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_D50E09170BC0EB0717BA5092023F0467" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesLeases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_D403F7CAC222E301BB6350341CC17233" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_F594207E0630254562D250341CC1F978" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D403F7CAC222E301BB6350341CC17233" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_F594207E0630254562D250341CC1F978" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_FB6A457A49982B872ACE50341C9CC576" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_FB6A457A49982B872ACE50341C9CC576" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D6615AD8CE51B8A593AB50341C9D3CC3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_104277911B8B6C25E45050341C9DA06B" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_B7E763012A214A2A6A8F50341C9D0C58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:to="loc_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_AB16B9BA92761EC48DCD50341C9ECC66" xlink:to="loc_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A8CDC0CB430396E5050A50341C9E86C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:to="loc_srt_MinimumMember_A8CDC0CB430396E5050A50341C9E86C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7D8E5E9096470E42FDF050341C9E4A10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_49E472D339C73E60F6E150341C9E3BD4" xlink:to="loc_srt_MaximumMember_7D8E5E9096470E42FDF050341C9E4A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C93312082CE1EA6D381950341C9C8D13" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_FC5266AE273FDB11727650341C9E8AA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_FC5266AE273FDB11727650341C9E8AA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_00942F6E1A5A8A8F23E350341C9FBED4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_00942F6E1A5A8A8F23E350341C9FBED4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:to="loc_biib_DisposalGroupOperatingLeaseAssets_9138F1127B077EB3B5F950341C9FC6C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_8B0ACF8FA5D18EA2953E50341C9E5044" xlink:to="loc_biib_DisposalGroupOperatingleaseliabilities_8B512DADEBD7D1F8F4EA50341C9FC3C6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesLeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_006ECF5C96B607C20BA150341CBD7ABE" xlink:type="locator" />
    <link:loc xlink:href="biib-20190331.xsd#biib_LesseeLeaseTableTableTextBlock" xlink:label="loc_biib_LesseeLeaseTableTableTextBlock_0AEA6A53115A6E7F3F6D50341CBE588C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_006ECF5C96B607C20BA150341CBD7ABE" xlink:to="loc_biib_LesseeLeaseTableTableTextBlock_0AEA6A53115A6E7F3F6D50341CBE588C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_952AFEF2A3707AA56FA250341CBE39DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_006ECF5C96B607C20BA150341CBD7ABE" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_952AFEF2A3707AA56FA250341CBE39DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_78ECE54235B58DDF00C350341CBE9A39" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_006ECF5C96B607C20BA150341CBD7ABE" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_78ECE54235B58DDF00C350341CBE9A39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E4D1C8669F0525D5488E50341CBEACD7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_006ECF5C96B607C20BA150341CBD7ABE" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_E4D1C8669F0525D5488E50341CBEACD7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:label="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_2F0DE749640E1CC92E4250341CBEB0D6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_006ECF5C96B607C20BA150341CBD7ABE" xlink:to="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_2F0DE749640E1CC92E4250341CBEB0D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:label="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_DF333E3C94004D48B3B650341CBFF135" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_006ECF5C96B607C20BA150341CBD7ABE" xlink:to="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_DF333E3C94004D48B3B650341CBFF135" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_61D89E6572830E2879EE50341BBAA569" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_7BA6E7DB6AF9971E080F50341BBA1214" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_61D89E6572830E2879EE50341BBAA569" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_7BA6E7DB6AF9971E080F50341BBA1214" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_TaxcontingencyAbstract" xlink:label="loc_biib_TaxcontingencyAbstract_2BDFDA40DE2CCAFBE14C50341BB1ED32" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxcontingencyAbstract_2BDFDA40DE2CCAFBE14C50341BB1ED32" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3FA2AD3B0A893A01D83950341BB48112" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_7157EE5D3B3D41B1B27950341BB5E9A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_E31E7077E5CCDBCFF75850341BB571BC" xlink:to="loc_country_BR_7157EE5D3B3D41B1B27950341BB5E9A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_9A024F0FEC15C300CD2D50341BB3B499" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesSought" xlink:label="loc_us-gaap_LossContingencyDamagesSought_1E6930C51F37A7D2E13150341BB6B423" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_926970ABE23132CA9F1650341BB52623" xlink:to="loc_us-gaap_LossContingencyDamagesSought_1E6930C51F37A7D2E13150341BB6B423" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E44D2E76986452C129150341C1E8903" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_4FEEAFC56CCB4F5AB39D50341C1F3A64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E44D2E76986452C129150341C1E8903" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_4FEEAFC56CCB4F5AB39D50341C1F3A64" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2FE80794F70C7343FB1A50341C0C2010" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_058B80D7C06740173C9E50341C0DD103" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2FE80794F70C7343FB1A50341C0C2010" xlink:to="loc_us-gaap_StatementTable_058B80D7C06740173C9E50341C0DD103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_57606D4AEF0A175D33A250341C0D41CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_058B80D7C06740173C9E50341C0DD103" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_57606D4AEF0A175D33A250341C0D41CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_64CC3BE4C5A4D772476150341C0D968C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_57606D4AEF0A175D33A250341C0D41CB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_64CC3BE4C5A4D772476150341C0D968C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_614CFD7B516D4C70FC2050341C0E89FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_64CC3BE4C5A4D772476150341C0D968C" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_614CFD7B516D4C70FC2050341C0E89FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1359408756425F18C2BD50341C0E924C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_058B80D7C06740173C9E50341C0DD103" xlink:to="loc_us-gaap_StatementLineItems_1359408756425F18C2BD50341C0E924C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2FE80794F70C7343FB1A50341C0C2010" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_A189441A3DD48BCFA71150341C0E73DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:to="loc_us-gaap_InvestmentIncomeInterest_A189441A3DD48BCFA71150341C0E73DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_F158006AF3B9EF917E3E50341C10636A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:to="loc_us-gaap_InterestExpense_F158006AF3B9EF917E3E50341C10636A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_29DBCA19467E700927BF50341C10D2BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_29DBCA19467E700927BF50341C10D2BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F39587F620662C3E5FE750341C10AB0F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F39587F620662C3E5FE750341C10AB0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_51A91BE906E765A4745950341C109E3F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_51A91BE906E765A4745950341C109E3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_F47A751D993719D8F79850341C11B15C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_E3A533ECCEFC92C5AC6350341C0EB77A" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_F47A751D993719D8F79850341C11B15C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2FE80794F70C7343FB1A50341C0C2010" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_B6F625CAEE58B1F386CF50341C1173E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_B6F625CAEE58B1F386CF50341C1173E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_6CB9BB7D3D56BA951ED950341C117D82" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:to="loc_biib_Collaborationexpensesaccrual_6CB9BB7D3D56BA951ED950341C117D82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_75ACB5CCD5DACC8529C750341C117229" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_75ACB5CCD5DACC8529C750341C117229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3A4B1C1ED52F3325100150341C118582" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3A4B1C1ED52F3325100150341C118582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_84967CC53325E367BD9A50341C12DF66" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_84967CC53325E367BD9A50341C12DF66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_2B54086FF191E4D1831B50341C121BE1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_2B54086FF191E4D1831B50341C121BE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_D7F96A07FCB2D4C698E050341C12F58F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_D7F96A07FCB2D4C698E050341C12F58F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3F6A67AFA9E2EBA16AF150341C1217E8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5EDAAFF393D26136D5C150341C1168DC" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3F6A67AFA9E2EBA16AF150341C1217E8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56783149AA5832A6CEBE50341BFB7CC2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_51A275C9032A084B243150341BFCC73D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56783149AA5832A6CEBE50341BFB7CC2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_51A275C9032A084B243150341BFCC73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_82D125F69E6EF5F3C88050341BFC252E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56783149AA5832A6CEBE50341BFB7CC2" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_82D125F69E6EF5F3C88050341BFC252E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EBBC8A39F47FCB4DC24850341C17AEC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9105810D373D90CBF61F50341C17BB65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EBBC8A39F47FCB4DC24850341C17AEC4" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9105810D373D90CBF61F50341C17BB65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EE0FF13B28E0CCE9E31450341C17E97B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EBBC8A39F47FCB4DC24850341C17AEC4" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EE0FF13B28E0CCE9E31450341C17E97B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_67A57D538BD3EB9B68AE50341CCAB311" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_053F2991B7C834C4C48150341CCA02C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_67A57D538BD3EB9B68AE50341CCAB311" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_053F2991B7C834C4C48150341CCA02C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5FA54196FE2C41605CCC50341CC457C2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5FA54196FE2C41605CCC50341CC457C2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2890FCEE600825A453B850341CC57949" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_0080631896C76882045B50341CC5A808" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:to="loc_us-gaap_BuildingMember_0080631896C76882045B50341CC5A808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_03E5CA31CB3653F33CA750341CC67BFE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_832182805475A2CB35F750341CC51A6A" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_03E5CA31CB3653F33CA750341CC67BFE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:to="loc_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_5BDAA670D9171488B71250341CC669E6" xlink:to="loc_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_CA7FDE8A2315BBD8104650341CC6CF5D" xlink:to="loc_biib_SolothurnSwitzerlandMember_D3E93C8DE8ED4AB2D36750341CC6FF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52DEE4D59A9D21D5079E50341CC5302B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6FCB59BDD30627AE1D8950341CC7AE29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6FCB59BDD30627AE1D8950341CC7AE29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2D229B0D260D0E346E5950341CC762D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:to="loc_us-gaap_Depreciation_2D229B0D260D0E346E5950341CC762D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_DA9184A532ABD63B467850341CC72DBA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:to="loc_us-gaap_ConstructionInProgressGross_DA9184A532ABD63B467850341CC72DBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_DAE0A79D564AEEC4DACE50341CC7B32E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:to="loc_us-gaap_OtherCommitment_DAE0A79D564AEEC4DACE50341CC7B32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_45697A9112DBF9AD3E9850341CC8366F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D883DA3F5A2664D34C4950341CC75EB4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_45697A9112DBF9AD3E9850341CC8366F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190331.xsd#biib_OtherrevenuesAbstract" xlink:label="loc_biib_OtherrevenuesAbstract_D58ED4E2810AEA032A0650341D9984A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_07941233BCEFB97749ED50341D9A65D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_D58ED4E2810AEA032A0650341D9984A0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_07941233BCEFB97749ED50341D9A65D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F6DC8E2B44788456771D50341D9ABE79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07941233BCEFB97749ED50341D9A65D1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F6DC8E2B44788456771D50341D9ABE79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_228F71C33C9E10F0301E50341D9A29D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F6DC8E2B44788456771D50341D9ABE79" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_228F71C33C9E10F0301E50341D9A29D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_92ACC1C2D7B7978FDBF350341D9B42BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_228F71C33C9E10F0301E50341D9A29D2" xlink:to="loc_us-gaap_CollaborativeArrangementMember_92ACC1C2D7B7978FDBF350341D9B42BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_93182FC3211353E0112850341D9B57B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07941233BCEFB97749ED50341D9A65D1" xlink:to="loc_srt_ProductOrServiceAxis_93182FC3211353E0112850341D9B57B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D301526AC0EA9B44A9AE50341D9B2998" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_93182FC3211353E0112850341D9B57B1" xlink:to="loc_srt_ProductsAndServicesDomain_D301526AC0EA9B44A9AE50341D9B2998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_1C76F2D9B99CAF82283350341D9B6CE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D301526AC0EA9B44A9AE50341D9B2998" xlink:to="loc_us-gaap_RoyaltyMember_1C76F2D9B99CAF82283350341D9B6CE4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D301526AC0EA9B44A9AE50341D9B2998" xlink:to="loc_biib_OthercorporaterevenuesMember_62A23117FBB03736E58C50341D9C7BB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_D32454A96220C3F435B250341D9CF53F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D301526AC0EA9B44A9AE50341D9B2998" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_D32454A96220C3F435B250341D9CF53F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6ADA9179B17A8DAD084850341D9C3E31" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07941233BCEFB97749ED50341D9A65D1" xlink:to="loc_srt_MajorCustomersAxis_6ADA9179B17A8DAD084850341D9C3E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B80E5078C6B522C985A750341D9CD7B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6ADA9179B17A8DAD084850341D9C3E31" xlink:to="loc_srt_NameOfMajorCustomerDomain_B80E5078C6B522C985A750341D9CD7B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B80E5078C6B522C985A750341D9CD7B4" xlink:to="loc_biib_AbbVieMember_E0558320DDC252083AE250341D9CF17E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_EA66143A87A29281623A50341D9D1EBB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B80E5078C6B522C985A750341D9CD7B4" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_EA66143A87A29281623A50341D9D1EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_C3CEBA838E6C15E4504B50341D9DE22C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07941233BCEFB97749ED50341D9A65D1" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_C3CEBA838E6C15E4504B50341D9DE22C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BB74B116BD55C2CDEA8150341D9DBF01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C3CEBA838E6C15E4504B50341D9DE22C" xlink:to="loc_us-gaap_Revenues_BB74B116BD55C2CDEA8150341D9DBF01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_64D80C5E04233ECDF53D50341DABC22D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_64D80C5E04233ECDF53D50341DABC22D" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_A609E4682258169B3DE450341DAC6B78" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:to="loc_biib_ReserveforCashDiscountsMember_86AC925D1274DD83706D50341DACCEB2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:to="loc_biib_ContractualAdjustmentsMember_759B500C0FCB0B5D04D050341DAC026D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_0373028E48B7B64830F450341DADD115" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3DEE312F36183522EF3050341DAC1D56" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_0373028E48B7B64830F450341DADD115" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1DCFAE3859C8F04B171B50341DAB74E5" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_F08C83C23EE0E82A649C50341DADA25D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_F08C83C23EE0E82A649C50341DADA25D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_65DF8443E50C6C3BBC9350341DAD9BFD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_CC84F9E4A521421EA04E50341DAD73B7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D70AF6BE83554BC9DC1750341DAEC5CE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_1AB9F3BFF3E006B264E250341DAE00D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0206B18605BEEB6D329050341DAE2DE0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09557253595781D5400950341DAD3F50" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_0206B18605BEEB6D329050341DAE2DE0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_C8F98FCE09AB5482A6FB50341DA6B014" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_62ABC13BDF5C8301A1F150341DA63FE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_C8F98FCE09AB5482A6FB50341DA6B014" xlink:to="loc_us-gaap_StatementTable_62ABC13BDF5C8301A1F150341DA63FE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DD484539990109DFD1F850341DA74F3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_62ABC13BDF5C8301A1F150341DA63FE9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_DD484539990109DFD1F850341DA74F3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0E15E2280BBF279D735A50341DA768D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DD484539990109DFD1F850341DA74F3F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0E15E2280BBF279D735A50341DA768D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_FFC8AE394AD79EAB53CA50341DA7E365" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0E15E2280BBF279D735A50341DA768D3" xlink:to="loc_us-gaap_AccountsReceivableMember_FFC8AE394AD79EAB53CA50341DA7E365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_DC9FACDC8AC42B2B6CE350341DA8F5D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0E15E2280BBF279D735A50341DA768D3" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_DC9FACDC8AC42B2B6CE350341DA8F5D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1238C008F850F7D8BBB750341DA8688B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_62ABC13BDF5C8301A1F150341DA63FE9" xlink:to="loc_us-gaap_StatementLineItems_1238C008F850F7D8BBB750341DA8688B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_A1944DF82ACD270E270450341DA865FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1238C008F850F7D8BBB750341DA8688B" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_A1944DF82ACD270E270450341DA865FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C5E53A8D9248448C12FB50341DBE948D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_320F3197F7F3D4B0093A50341DBE1DED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C5E53A8D9248448C12FB50341DBE948D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_320F3197F7F3D4B0093A50341DBE1DED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_1AD9AF8B14F1027E8AF750341DB251D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1D0833FFB235D450783A50341DB3241E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_1AD9AF8B14F1027E8AF750341DB251D1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1D0833FFB235D450783A50341DB3241E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_6289A804C25F3A5544D250341DB30F78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1D0833FFB235D450783A50341DB3241E" xlink:to="loc_srt_ProductOrServiceAxis_6289A804C25F3A5544D250341DB30F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6289A804C25F3A5544D250341DB30F78" xlink:to="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_071C52429D0F888E643750341DB30917" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_TecfideraMember_071C52429D0F888E643750341DB30917" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_InterferonMember_66846603EF2BB06FD7C950341DB4D553" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_234967298917AF5963A950341DB48F93" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_TysabriProductMember_234967298917AF5963A950341DB48F93" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_FAMPYRAMember_0924BD32D84A352A790C50341DB4B4EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_ZINBRYTAMember_58A1D25C71C45B46191750341DB4B9FC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_MSProductRevenuesMember_4CC9EDBCCF9FFFEB155150341DB4BD01" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_SPINRAZAMember_400350C131F57825653650341DB4C59B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_BENEPALIMember_2B8E393565A5A6B4180550341DB536F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_FLIXABIMember_4D4F149F4D5513E2A9F350341DB55D85" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_IMRALDIMember_5A0F7F8F6CA765B4D8E050341DB5BCFC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_BiosimilarsMember_32923643FA460226C80050341DB5CF70" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_biib_FUMADERMMember_7F96BE889B4AC1DFB61F50341DB57A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_E3A967439BF488B9461A50341DB523C8" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39CD77A2B417BD0B962450341DB3FEDE" xlink:to="loc_us-gaap_ProductMember_E3A967439BF488B9461A50341DB523C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1D0833FFB235D450783A50341DB3241E" xlink:to="loc_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_035AA60DB61B846A842F50341DB62371" xlink:to="loc_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_CF1D32479306C996872950341DB6F978" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:to="loc_country_US_CF1D32479306C996872950341DB6F978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_88A531458F8782A5A51D50341DB6F5AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6A10393E45A0174118C450341DB64BD1" xlink:to="loc_us-gaap_NonUsMember_88A531458F8782A5A51D50341DB6F5AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_A8DE0C7A3EBAF07551F750341DB69132" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1D0833FFB235D450783A50341DB3241E" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_A8DE0C7A3EBAF07551F750341DB69132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33BBA40772D2B7AD244A50341DB75796" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_A8DE0C7A3EBAF07551F750341DB69132" xlink:to="loc_us-gaap_Revenues_33BBA40772D2B7AD244A50341DB75796" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3B49390B53B10351FEF750341D9376B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3B49390B53B10351FEF750341D9376B5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:to="loc_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0C9A1EDB1981BE167F4A50341D9488AB" xlink:to="loc_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_B126FCC4CC41A5E0FF6750341D943DF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0D26EF2D5C559A148A9450341D9477B8" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_B126FCC4CC41A5E0FF6750341D943DF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:to="loc_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_2EA11218E1359BCE522750341D94F4F7" xlink:to="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:to="loc_biib_DistributorOneMember_702ECA5A4C42603B99A550341D9577BB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:to="loc_biib_DistributorTwoMember_74283544F4E708DC44EC50341D95DB7F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7A590085D2C44538D82A50341D95DDB3" xlink:to="loc_biib_BioverativMember_A873E84E6E12189CB30C50341D95EFA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E67F05A17A6412CD34EA50341D939631" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C47D536FE5827B45124A50341D957214" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:to="loc_us-gaap_Revenues_C47D536FE5827B45124A50341D957214" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3412F2AFC59242C0C77750341D95E50C" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_03974431955A15385C8650341D965FF7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4E887A8F89855EB224D950341DA177EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_CBA021E90B8369E01CFB50341DA1A970" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4E887A8F89855EB224D950341DA177EA" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_CBA021E90B8369E01CFB50341DA1A970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_6D8E94A3B00437E236F050341DA1E9A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CBA021E90B8369E01CFB50341DA1A970" xlink:to="loc_srt_ProductOrServiceAxis_6D8E94A3B00437E236F050341DA1E9A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_28C482D6AACAA694D12950341DA23055" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6D8E94A3B00437E236F050341DA1E9A6" xlink:to="loc_srt_ProductsAndServicesDomain_28C482D6AACAA694D12950341DA23055" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_28C482D6AACAA694D12950341DA23055" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_C8DE174AC58147E3FA2A50341DA2F522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F14ED69D858BFD94039750341DA2A0F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CBA021E90B8369E01CFB50341DA1A970" xlink:to="loc_srt_MajorCustomersAxis_F14ED69D858BFD94039750341DA2A0F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_78D8BC2256D4E704441150341DA3366C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_F14ED69D858BFD94039750341DA2A0F7" xlink:to="loc_srt_NameOfMajorCustomerDomain_78D8BC2256D4E704441150341DA3366C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_78D8BC2256D4E704441150341DA3366C" xlink:to="loc_biib_RocheGroupGenentechMember_E2FA3955120314C0101950341DA39C6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7AE38F45B117444E8F3850341DA32CA8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CBA021E90B8369E01CFB50341DA1A970" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7AE38F45B117444E8F3850341DA32CA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7AE38F45B117444E8F3850341DA32CA8" xlink:to="loc_biib_ShareOfCoPromotionProfits_E28DB24914D5FE25620550341DA36BB0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7AE38F45B117444E8F3850341DA32CA8" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0FF55B7195AD9D989F4350341DA3BEC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C506768B91715A80636F50341DA4E2A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7AE38F45B117444E8F3850341DA32CA8" xlink:to="loc_us-gaap_Revenues_C506768B91715A80636F50341DA4E2A8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B77186C5A59D1C79622950341DBB7DE7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_32B35608AA0E5DE8068450341DBB043A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B77186C5A59D1C79622950341DBB7DE7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_32B35608AA0E5DE8068450341DBB043A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6E7A238D60516343570650341DBBA9E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B77186C5A59D1C79622950341DBB7DE7" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6E7A238D60516343570650341DBBA9E4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D5F8FFF00849FB5664C650341DBBA9BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B77186C5A59D1C79622950341DBB7DE7" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D5F8FFF00849FB5664C650341DBBA9BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2C7E9C62C6CFF564824C50341DBB916B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B77186C5A59D1C79622950341DBB7DE7" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2C7E9C62C6CFF564824C50341DBB916B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_522C8CEDA905D672A72C50341DBCFC2C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B77186C5A59D1C79622950341DBB7DE7" xlink:to="loc_biib_OtherrevenuesTableTextBlock_522C8CEDA905D672A72C50341DBCFC2C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4B53F45BE4675B52869B50341C635D7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9159B126911D47C26E9050341C63C1A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4B53F45BE4675B52869B50341C635D7D" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9159B126911D47C26E9050341C63C1A0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_55B9A9F0004D93179C3E50341C567287" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B30A892AD7B0693299BB50341C5610AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_55B9A9F0004D93179C3E50341C567287" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B30A892AD7B0693299BB50341C5610AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0844CCB1E81B4AF8230950341C56B1D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B30A892AD7B0693299BB50341C5610AA" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0844CCB1E81B4AF8230950341C56B1D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_30788EA50A4E5EAC212950341C578D2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0844CCB1E81B4AF8230950341C56B1D4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_30788EA50A4E5EAC212950341C578D2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4FEA027559756A73D8A050341C577DE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_30788EA50A4E5EAC212950341C578D2A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4FEA027559756A73D8A050341C577DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_762F53614C50EA2DA9A250341C579A91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_30788EA50A4E5EAC212950341C578D2A" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_762F53614C50EA2DA9A250341C579A91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_B01604F5BDB6EF379A3B50341C58DA90" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_30788EA50A4E5EAC212950341C578D2A" xlink:to="loc_us-gaap_ParentMember_B01604F5BDB6EF379A3B50341C58DA90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_387F000625C1084F19BA50341C580C04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B30A892AD7B0693299BB50341C5610AA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_387F000625C1084F19BA50341C580C04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_387F000625C1084F19BA50341C580C04" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D447C48875D15EDA7E7750341C5848D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D447C48875D15EDA7E7750341C5848D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DC0E3E942B765BA6295D50341C588392" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DC0E3E942B765BA6295D50341C588392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_1A5BCFA678B325E7023950341C584200" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_1A5BCFA678B325E7023950341C584200" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3C11B5B8166B2FDC9F4350341C591BE1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3C11B5B8166B2FDC9F4350341C591BE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_EF3D6E15F32FE0986DB650341C5966F5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_BB5E26615E8F7592586450341C58CFCA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_EF3D6E15F32FE0986DB650341C5966F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8A628EFCABC7FFFB024550341C492746" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8A628EFCABC7FFFB024550341C492746" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15" xlink:to="loc_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2BBA398E5BBC829B00B950341C497288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_biib_MarketStockUnitsMember_743DE21B2106FBAC78C350341C4A6B68" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_E5D63BA26901B14405D750341C4A066C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_biib_CashSettledPerformanceSharesMember_B027CB5901DFDC44A24150341C4A077A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_0260FFB12CF5A11FF7D750341C4A373A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_us-gaap_PerformanceSharesMember_0260FFB12CF5A11FF7D750341C4A373A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_BCEFBBB186E9EBCF985450341C4AFF4F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_FB244A12EF1AD0A1EB7550341C4BC941" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA95289B72F56086FDDA50341C49AFF3" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_44C2364964DD0D5D612250341C4B5BE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1DC5D6EB120877BB5FB450341C492B15" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9B90F20F7D8ABD09A58050341C4B2D28" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_81F1F5DD749A122F377350341C4B98F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_81F1F5DD749A122F377350341C4B98F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B4CF1F7BDC7C9756748A50341C4B193C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B4CF1F7BDC7C9756748A50341C4B193C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2691337E9AC2C6B6B78350341C4C8006" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2691337E9AC2C6B6B78350341C4C8006" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FF3457B0295765C68EB050341C4B2BE6" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_78BCCDC23CDDB896A0A750341C4C9FCC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B4B5EE20792C552DEF9F50341C5C06A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_917E9D855ACD629F35CF50341C5CA91D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B4B5EE20792C552DEF9F50341C5C06A6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_917E9D855ACD629F35CF50341C5CA91D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_968E3D2378B07AB50A5F50341C5C0102" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B4B5EE20792C552DEF9F50341C5C06A6" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_968E3D2378B07AB50A5F50341C5C0102" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1BF2EE55C9B0BB91161050341DE2F0A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4A7076D34C036F4F5B1E50341DE29011" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1BF2EE55C9B0BB91161050341DE2F0A4" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4A7076D34C036F4F5B1E50341DE29011" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CECB719F9E8F6A5A156C50341DDB409B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DEB5AA07FDFBF3DAC9A250341DDB682D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CECB719F9E8F6A5A156C50341DDB409B" xlink:to="loc_us-gaap_StatementTable_DEB5AA07FDFBF3DAC9A250341DDB682D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DEB5AA07FDFBF3DAC9A250341DDB682D" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_CE022A3C860E8A832D7250341DDBBD25" xlink:to="loc_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_01EABCE5075EFE98076D50341DDCBA58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_537285BBCBE9791DEE3950341DDB41C9" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_01EABCE5075EFE98076D50341DDCBA58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_BB7C3A110FF2D36EA53750341DDC92E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DEB5AA07FDFBF3DAC9A250341DDB682D" xlink:to="loc_us-gaap_StatementLineItems_BB7C3A110FF2D36EA53750341DDC92E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_66838BA516EB05DFDD0950341DDC6EFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BB7C3A110FF2D36EA53750341DDC92E9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_66838BA516EB05DFDD0950341DDC6EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_BE902D9963ED555D4BAC50341DDCAD67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BB7C3A110FF2D36EA53750341DDC92E9" xlink:to="loc_us-gaap_OperatingLeaseLiability_BE902D9963ED555D4BAC50341DDCAD67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_FAF996A51371F086027A50341DDCB2D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CECB719F9E8F6A5A156C50341DDB409B" xlink:to="loc_us-gaap_NumberOfReportableSegments_FAF996A51371F086027A50341DDCB2D9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_05EEE8369694B5912CF350341DDC684C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CECB719F9E8F6A5A156C50341DDB409B" xlink:to="loc_biib_InterestInSubsidiary_05EEE8369694B5912CF350341DDC684C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C34E6804B2BD55426FBE50341DDFE1CB" xlink:type="locator" />
    <link:loc xlink:href="biib-20190331.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_FF6A614655909E1C5B2250341DDF1059" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C34E6804B2BD55426FBE50341DDFE1CB" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_FF6A614655909E1C5B2250341DDF1059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87E221C7457F947F248650341DDFC867" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C34E6804B2BD55426FBE50341DDFE1CB" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87E221C7457F947F248650341DDFC867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_D71D4B61EF6EB6E2983D50341DDFE9ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C34E6804B2BD55426FBE50341DDFE1CB" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_D71D4B61EF6EB6E2983D50341DDFE9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_A712D7A8BDE0FF6C265B50341DDF9BCE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C34E6804B2BD55426FBE50341DDFE1CB" xlink:to="loc_us-gaap_UseOfEstimates_A712D7A8BDE0FF6C265B50341DDF9BCE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190331.xsd#biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock" xlink:label="loc_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_06161641FBD001B2FE2950341DDFCAC2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C34E6804B2BD55426FBE50341DDFE1CB" xlink:to="loc_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_06161641FBD001B2FE2950341DDFCAC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0DD3AA3ECABE7806097550341DDF5093" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C34E6804B2BD55426FBE50341DDFE1CB" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0DD3AA3ECABE7806097550341DDF5093" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>amortofacquireintanassets.jpg
<TEXT>
begin 644 amortofacquireintanassets.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M;_V:M97X./!\1XKSP1JOA?0O@YX;\8^(M&T!_'&JZ1XA^+OAY9VMO"6FV_\
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M)+JX\RXD"@/(P H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y@^-/[6G
MPR^!'QG_ &5_@5XSL/%]WXR_:^^('CCX;_"ZZ\/Z5IE]H&G:]\/_ (;:U\4M
M;N/&=]>ZWIEYI.ER^'M"NK73I]*T[7KJXU>:VMIK*UM&GOX/IX$, PZ$ CZ$
M9K\/?^"EKO'_ ,%(/^"%3I#)<,/VKOVG0(HFB61@W['GC]6(,\L,6$4F1@TB
MDJI"!G*JW[2QZIJ'EI_Q3>K_ '%_Y>= ]!_U&Z -ZBL3^U-0_P"A;U?_ ,"?
M#_\ \NZ/[4U#_H6]7_\  GP__P#+N@#;HK$_M34/^A;U?_P)\/\ _P NZ/[4
MU#_H6]7_ / GP_\ _+N@#;HK$_M34/\ H6]7_P# GP__ /+NC^U-0_Z%O5__
M  )\/_\ R[H VZ*Q/[4U#_H6]7_\"?#_ /\ +NC^U-0_Z%O5_P#P)\/_ /R[
MH VZ*Q/[4U#_ *%O5_\ P)\/_P#R[H_M34/^A;U?_P "?#__ ,NZ -NBL3^U
M-0_Z%O5__ GP_P#_ "[H_M34/^A;U?\ \"?#_P#\NZ -NBL3^U-0_P"A;U?_
M ,"?#_\ \NZ/[4U#_H6]7_\  GP__P#+N@"SJ.LZ3I A.JZG8:<+@N(#>W4-
MJ)C$%,@B\YTWF,.A?;G:&7.,BLO_ (33PA_T,^@_^#6R_P#CU>'_ !RNKBYA
M\,^?IEYI^R;5MANI=/D\[='8;A']AOKP@I@%O-$8.X;"Q#!?GVOR?B?Q#QV1
M9WC,JHY=A*]/"K#<M6K5K1G+V^%H8AWC#W5RNJXJVZBKZM@?>7_":>$/^AGT
M'_P:V7_QZC_A-/"'_0SZ#_X-;+_X]7P;2$X!."< G ZG'8>Y[5X'_$6\S_Z%
M& _\'8C^N_\ 3T>GG]W_  ?7^GI]Y_\ ":>$/^AGT'_P:V7_ ,>H_P"$T\(?
M]#/H/_@ULO\ X]7X3Z#^UUK>M_MD>-/V99/"7@31M*\)>&[V^BM]?^(MQH/Q
MQ\3-ICZG<2^/_!'PRUCPO9:+X^^&.KVMO96VD+X/\7ZGXBM[>:3Q3K#V=K#J
M7AO1KNE?M8>+KSX=?%+Q/K/P8?PGX]\+_M.^'?V8/ 7POUOQSIMW>:UXL\?_
M /"HX/A[<_$+Q3X<L==T3PE*[_%6/5?']EX6_P"$UM?"FF>'M3TW1M4\5ZPD
M4MUZ,O$;B&+IQ>29=S5:6%K0C]=?,Z>,DHT)<KJ)J,I:2DTHT_==1P4HMEM+
MZ_=ITN]^E_G^7[E_\)IX0_Z&?0?_  :V7_QZC_A-/"'_ $,^@_\ @ULO_CU?
M@WXE_:L^(/A+PY\3H_%>C_L[> /%'P*\<Z=X6^,?CGXC?%KQKX?^!&BZ%XN^
M'_AKXA_"KQ7X<N;/P'J7Q-U0_%&R\3IX>@T"^T2UG\!^(/#WB9]8U3Q+:IX>
MMM?]*\0?M)WFC?LQ?#O]H&3P/::'K7Q+T_X&Q:=X/\;^+[?0?#/@OQ#\=M?\
M)^&=&E^(WQ!M]*N8=$\!^%M0\66VH>(_%L&A-<S:1#;0VNCVFL:M!9VLOQ(S
M^/L?^$7+FL16IT*3CC)24ZE:,9TDFIV2J4YQJ1E)I*G.G4GRPJTY2+>?W6=K
M6\_/3NU;?;]FO^$T\(?]#/H/_@ULO_CU'_":>$/^AGT'_P &ME_\>K\C/@+\
M:KCXL3_%SPOKL'@N+QU\#/B1;?#3QU/\-O$M_P"+?A]JFH:KX&\*_$/1-7\+
M:QJVGZ9K,"3Z%XLM]-\0>'-:MI-4\*>*M(UK1;C4-4CAM[Z7Z!KEK>*F;X>I
M*E5R? 1G%0DU[>NTXU(0J4Y)IM.,Z<XSB^L91>E]#3S^[_@^O]/3[R_X33PA
M_P!#/H/_ (-;+_X]1_PFGA#_ *&?0>.3_P 36RZ#J?\ 7=J^#:1ONN/5''_C
MIZ^WKU]@:R?BWF:3?]D8#17_ (V(_KO_ $]!)-I:ZM?I_P '^GI^B\;I*B2Q
MNLD<B*\;H0R.C@,KJPR&5E(*D$@@@CBG5R>D:G?KI.EJOAW5I%73;$!UN-!"
MN!:Q#<H?65<*>HW*K8QN53D#>L[JXN?,\_3;S3]FW;]JET^3S=V[=L^PWUYC
M9@;O-\O.]=F[#;?W.C-U*5*HTDZE.$VELG**DTO)7$7J***T **** "BBB@
MHHHH **** /Q _X*3_\ *23_ ((4_P#9UO[4'_K'/Q!K]O(_]7'_ +B_^@BO
MQ#_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^XO\ Z"* 'T444 %%%% !
M1110 4444 %%%% !1110 4444 ?._P ?O]3X5_Z[:Q_Z+TZOF^OI#X_?ZGPK
M_P!=M8_]%Z=7S?7\R>(G_)89MZ8#_P!5F# *",@CGD8X.#^!'(/O117Q0'RC
MJG[*.D:Y\?;/XY:U\4?BAK-KH7V/7O!GPRUG4?#^K^#_  3\1K#4/&EY8^+_
M  ]J-_X>E\9P:#I7_"<ZU=Z/\,V\4'P59:S=7,\MG=: ]GX8T_EO#O['&H6N
MG?%C2?'7[1GQ-^(UI\5_B#HWQDDN'\ _!7X?:SX%^-GABZ^'-YX5^*G@;6?
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MZ]5^9^@VB_\ (&TG_L&6'_I+%6G69HO_ "!M)_[!EA_Z2Q5IU_96%_W;#_\
M7BC_ .FXB"BBBMP"BBB@ HHHH **** "BBB@#\0/^"D__*23_@A3_P!G6_M0
M?^L<_$&OV\C_ -7'_N+_ .@BOQ#_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O
M(_\ 5Q_[B_\ H(H ?1110 4444 %%%% !1110 4444 %%%% !1110!\[_'[_
M %/A7_KMK'_HO3J^;Z^D/C]_J?"O_7;6/_1>G5\WU_,GB)_R6&;>F _]5F#
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M% &!_;DO_0#UW_P"@_\ DVC^W)?^@'KO_@%!_P#)M;]% &!_;DO_ $ ]=_\
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M1R:MX1M9?B[H?BWQCK&B>%?"LOP\A\07WB#6]?\ #EOIFGW%MXCT&[U+XO\
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M^70=!Q0!^(/_  4G_P"4DG_!"G_LZW]J#_UCGX@U^WD?^KC_ -Q?_017X?\
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ML]0MK_S/LZW8\K;O^U:??V/W]VW9]MMK?S?NG=Y>_9QOV[ES_96%_P!VP_\
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M:'X]3U^O\O3VZT ?B!_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\
MT$5^(?\ P4G_ .4DG_!"G_LZW]J#_P!8Y^(-?MY'_JX_]Q?_ $$4 ? /B#_D
M/Z[_ -AG5/\ TNN*R*U_$'_(?UW_ +#.J?\ I=<5D5_&^+_WO%?]A%;_ -.2
M ****YP"BBB@ HHHH **** "O6_@K_R.R?\ 8(U/_P!#LZ\DKUOX*_\ ([)_
MV"-3_P#0[.OH>$_^2FR+_L9X3_T[$:VEZ?JCZ]HHHK^KQ'SO\?O]3X5_Z[:Q
M_P"B].KYOKZ0^/W^I\*_]=M8_P#1>G5\WU_,GB)_R6&;>F _]5F# ****^*
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M=L<<]J\NKUOX*_\ ([)_V"-3_P#0[.OH>$_^2FR+_L9X3_T[$:Z^GZH^GO\
MA*- _P"@E%_W[G_^-4?\)1H'_02B_P"_<_\ \:K>P/?\S_C1@>_YG_&OZO$?
M-'QPU73]2A\-"QN4N##+JQEVK(NP2)8!,[T7.XJV,9Z'-?/]?2'Q^&(?"O7_
M %VL=23_ ,L].]:^;Z_F3Q$_Y+#-O3 ?^JS!@%%%%?% %%%% !1110 4444
M%(WW6]T<?B5('ZTM(WW7_P!Q_P#T TI;/T?Y#6Z]5^9]U:1XET./2=+C?4(E
M=-.L59=DYPRVL0()$1&0>#@UT%CJEAJ7F_8;E+CR=GF[5D79YF[9G>BYW;&Q
MC/0YJ+11_P 2;2>O_(,L.Y_Y]8O>M3&/7\23_.O[*PO^[8?_ *\4O_3<1!11
M16X!1110 4444 %%%% !1110!^('_!2?_E))_P $*?\ LZW]J#_UCGX@U^WD
M?^KC_P!Q?_017XA_\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MY'_ *N/_<7_ -!%
M 'P#X@_Y#^N_]AG5/_2ZXK(K7\0?\A_7?^PSJG_I=<5D5_&^+_WO%?\ 816_
M].2 ****YP"BBB@ HHHH **** "O6_@K_P CLG_8(U/_ -#LZ\DKUOX*_P#(
M[)_V"-3_ /0[.OH>$_\ DILB_P"QGA/_ $[$:VEZ?JCZ]HHHK^KQ'SO\?O\
M4^%?^NVL?^B].KYOKZ0^/W^I\*_]=M8_]%Z=7S?7\R>(G_)89MZ8#_U68, H
MHHKXH HHHH **** "BBB@ I&^Z_^X_\ Z :6D;[K_P"X_P#Z :4MGZ/\AQW7
MJOS/T&T7_D#:3_V#+#_TEBK3K,T7_D#:3_V#+#_TEBK3K^RL+_NV'_Z\4?\
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MO^'X?_!*/_H\SP7_ .&X^/\ _P#.@K^=>/,GS;%<59I7PN5YCB:%18'DK8?
MXJM2GRY?A(2Y:E.E*$N6<91E:3M*,D[-.P?JU17Y2_\ #\/_ ()1_P#1YG@O
M_P -Q\?_ /YT%'_#\/\ X)1_]'F>"_\ PW'Q_P#_ )T%?'_V!GW_ $),X_\
M#9C?_E'G^?9@?JU17Y2_\/P_^"4?_1YG@O\ \-Q\?_\ YT%'_#\/_@E'_P!'
MF>"__#<?'_\ ^=!1_8&??]"3./\ PV8W_P"4>?Y]F!^K5%?E&O\ P7&_X)0M
MNV_MG^"&V,4<+\.OCZQ1P 2CA?A"3'(%96,;[7"LK%0&4EW_  _#_P""4?\
MT>9X+_\ #<?'_P#^=!1_8&??]"3./_#9C?\ Y1Y_GV8'ZM45^4O_  _#_P""
M4?\ T>9X+_\ #<?'_P#^=!1_P_#_ ."4?_1YG@O_ ,-Q\?\ _P"=!1_8&??]
M"3./_#9C?_E'G^?9@?JU2-]U_P#<?_T U^4W_#\/_@E'_P!'F>"__#<?'_\
M^=!2-_P7$_X)1[6_XS,\%G*L!CX;_'_J5('_ #2"A\/Y]9_\(F<;/_F68W_Y
M1Y_U9C6Z]5^9_3!HO_(&TG_L&6'_ *2Q5IU^)>F?\'#/_!'&VTW3[>7]MOP<
M)8+&TAD'_"MOCQQ)%;QHX_Y)1V92.<'CD \#[>_9!_X*)_L:?MZ/X_C_ &2_
MC?HWQC?X7#PR?'@TGPUX]\/?\(\/&/\ ;G_"-F<^-O"?A@7?]J?\(YK7E_V:
M;WR/L+_:_L_FV_G?UIADUAZ":::HTDTU9IJ$4TT]4T]&GL(^UJ***V ****
M"BBB@ HHHH **** $*AL9'0Y' .#@C/((S@GGK2;1_D+_P#$TZB@!FQ?0?\
M?*__ !-'EKZ#_OE?_B:?10 SRU]!_P!\K_\ $T>6OH/^^5_^)I]% #/+7T'_
M 'RO_P 37RU^VE\+O&'QB_9H^*'PX\ :;!JOBWQ-8>'H-'L)[_3]*BN)+#QK
MX7UFZ#W^HS6UE;B.PTR[F!GF19&C6)"99(U/U0"#T(.#@X['T^M% $21  Y
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M%% !1110 4444 %%%% !1110 4444 %%%% !7C_[0OQ$USX1? 3XV_%?PQH
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M[NI9?LB0+<7%S<74ZRW,TDK 'RC\1[G]I_X0^(/V*]$U7X\6'B;0M<_:&L?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>anticd20revenues.jpg
<TEXT>
begin 644 anticd20revenues.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %: 3T# 2(  A$! Q$!_\0
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MQKIUO%ICB\\&Z/J_AVRU+7-$+ZI'%<^*;&QN?#=A]AUN2ZU)8M"U5K6/Q/\
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M],T>SDM/'4D$FD:Q#XFOEU66^?4=,\27>AV6J-%H?@OPG'?>)_$D-_:?+T?
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M3_Q%7C=?[.Y+_P B;*?^Q9@/_46D?\UO%7_)3\1?]CS-O_4^N%=%X3\6>(O
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M5Q/$GM,1F.,KU.7,<"H\];$SJ344\I;4>:323;LK)MZW^P/^%P^!?^?[4O\
MP37?_P 51_PN'P+_ ,_VI?\ @FN__BJ^/Z*[/^(I\3?\^<I_\)<3Y?\ 4=Y?
MB^YYO_$N?A__ -!/$O\ X<L!Y?\ 4I\OQ];_ &!_PN'P+_S_ &I?^":[_P#B
MJ/\ A</@7_G^U+_P37?_ ,57Q_11_P 13XF_Y\Y3_P"$N)\O^H[R_%]P_P")
M<_#_ /Z">)?_  Y8#R_ZE/E^/K?[ _X7#X%_Y_M2_P#!-=__ !5'_"X? O\
MS_:E_P"":[_^*KX_HH_XBGQ-_P ^<I_\)<3Y?]1WE^+[A_Q+GX?_ /03Q+_X
M<L!Y?]2GR_'UO]@?\+A\"_\ /]J7_@FN_P#XJC_A</@7_G^U+_P37?\ \57Q
M_11_Q%/B;_GSE/\ X2XGR_ZCO+\7W#_B7/P__P"@GB7_ ,.6 \O^I3Y?CZW^
MP/\ A</@7_G^U+_P37?_ ,57[)?\$*/B)X6\2?MWVNE:3<WLMZWP6^*%V%GT
MZ>VB\FVN?!ZRDRR$J&!GCVIC+@DC[IS_ #6U^YW_  ;P_P#*1:Q_[('\8O\
MTM\ 5\AQ_P"(N?YGP5Q/@,13RU4,7DV-H572P^(C44)T7%N,I8R<5+JFXR5[
MZ'Z#X4>!?!7#_B1P5G> Q&?RQF6<0Y;B\/'$8_!U*#JTL13Y55A#+*4Y0O\
M%&-2#:VDGJ?WI4445_ Q_J2?SD?\'!O_ ""/V4O^PK\9O_3?\-Z_FFK^E?\
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M.OXFQ?\ O6(_Z_5/_2V?Z$8+_<\)_P!@U#_TU ****YSI"BBB@ HHHH *0X
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M:+]CWQ_*ARI5N'13C.#C# J2#^T,7AK1HE@D2TP\;0.A^TWAPR.C*<-<D'!
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M9E@\/C8XK!5Z>)H2GCJLX*K2DIP<H-6DE))N+T?W6_%__A[Q\4_^D-'_  6
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MT\F@^*M/TS1M:O-#U%1X\'E7T&E>(=%OF1=\;6^HV[I(Q+A.F_X87_X*3_\
M2,K]MO\ \-[X/_\ F]K_ $E/@E\&KWX5ZY\?M6U#5K#6(_C%\>?$/Q>TZ&UM
M)X'T6PUKP)\-O"*:1>M<,ZW-[%<>!KF\DN;<);O#?6\:IYD,K-[WY,7_ #RC
M_P"^%_PH_P"(I<6_]!&"_P#"&EY>?K]_D'_$'."?^@;,/_#A6_R_J_H?Y>'_
M  PO_P %)_\ I&5^VW_X;WP?_P#-[1_PPO\ \%)_^D97[;?_ (;WP?\ _-[7
M^H?Y,7_/*/\ [X7_  H\F+_GE'_WPO\ A1_Q%+B[_H(P7_A#2\O/R?W^0?\
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M[9MEI?@SQ%X1\<_'#6/VR?ACXAL_'NA_%_Q3=?$C3_V3_$5AH.L^,OA3J?P
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M&]*^+DNE> _VMOB'X=\77?CZ/7?%&D:EHWBGX1Z?XNUMH?&7C_PYHNM>*?\
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M79>/]&BL_$-_9S>&/AG8>'O%]I\8;Z:\BG\#:GX4GL&MM1_X27P WBZKK_\
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MIX \3>$;_P#9[UC2?&D/P]^'FI?$/Q'K.E>'6^/-G\2M/T&VAL+7PBNL^)/
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MH:-<:RUMXMT77==T6&\\1>%+R[TU1I5]JFF:7K5EJ-Q:^(+']"Z* /S/U/\
MX)UIXCL/C5=^)_C!-?>-?C_\&?VI?AE\1/$.F^ +;2M&'B#]IVY^%T-YXI\,
M>&'\6ZB^C:!X"\,_"/PGX7T#P=?Z_KFHZS:V\FJ^)?&VH:W<WU]>?3FD_LZC
M1]2_:AU/3OB%XFT2]_:4N-%N1J_A:"VT/Q+\-+G1?@=X3^"UKJ?A369)=2BF
MURT3PM#XMTG4KO3HH]-U>6&W:RO(;,3W'TI10!^5_P (O^"9.D_#7XD>'/BI
M??$?P]=^)M*\7? +Q;K=KX.^$</@K1O%6H? /P/^TOX'TS5]9;4OB!XX\3:E
MXS\9VG[1D^K^,_&?B#Q1X@U"]UKPC!+96UG8:NECHU^;_@FXMOI$NC:'\9I;
M"VU[X<?&WX9>-IM0^'L6J3ZKH?Q2_:"\1_M%>&[WPVT'C;2H_#6M>"?%OB6^
MT>_N-0B\56'B_P /%HSIWAO4_L^HVOZ@T4 ?">N?L46GA/QO9_$K]E[QMI_[
M/?C2Y\)?$'P'XON+CP+_ ,+2T+Q3X;^('C)_B+)J1T;7/&&@76F>.O!WCJ[U
MOQ%X%UT:U?\ A:PE\4>(].\2>!/%.DW6GV6E^?Z[^P5X_P!9F^-/@R7]I2[N
M?@9^T3;_  JT[XR>']:^&7]L_'/Q;I'@#X2^ O@[XLTMOCFWQ%LO#MG%\7/"
M_@*WB\<:D/@K<>(+8^(O$TGAG5]&U"ZTO4M(_2RB@#\\(OV,OBAXG^+WQ0\;
M?&WXU?#/XQ_#_P")NE?$[X>+X*U;X!>)="\7?#_X#_$/2+[1C\'?AGXXLOV@
M[SPGX1M9H7TJ\^('C>#X2W/C+XI7VEV__"0ZC:Z;IWA/2_"?I_P/_9A\3?#G
MQII/C[XE_%^\^+_B3P1\'K7X!_#*_D\'6G@N30/AL-9T;7=>O?%(L_$&OQ^,
M/B7XXU#PGX(?QKXNLH_"7AR]C\&Z,OA[P#X9>?69-3^P** /@[PG^Q,_AGXN
MV/Q%E^)BZEX?\-_%+]ISXG^#?"C>!X[75M)N?VJ[6&]^(&DZOXN'BNYAUJ#2
MO&,NL:UX6O;/POH%S::%J:>&-4359;)=?N/#/A;_ ,$IO 'PO^('PS\90^*_
M#OBJ#P9IW[/=YXB;Q1\,GU#Q=K7C[]G/X/\ @3X/^$O$_A'Q&?B OAWP+H^H
M:=\,O!?B&]T2[\!>,_$>B>(+"[NO!OCSPX-0?R/UDHH _)KXQ_\ !+FQ^+?P
M;^'GP.OOC#$W@CP7^RKH7[,DNG^)_AC:>,+'3+OPWIT-I8?&CX5Z%<>-M)\-
M?#?XJ:G+;VUIXBUS5=%^(,LOAK3=(T7PS-X4OK2ZUW4&>)/^"<VN?'?3?BQX
M*^/'Q%FA^$'B?XO_ +6?Q \)> /#&@:1'XCL=3^/WAGQK\,M(\2ZA\0DU*2.
M^T30O!'CSQ1KNE> KOPA%>+XQUICXK\5^(O#&G6'A2']:** /S,\#?\ !/6Z
M^'(\+^+/!/Q"^'_@WXP>&?B[-\2E\7>$O@?=V7@_4],O_A)KWP9U3PYJO@O7
MOB_XF\3:I?GPSXFU;6="\0ZM\3]2M?#/BO[&=+\,CP2E_P""=2N_#G_@GQ/\
M-=$\*>%-+^,DFJ>&](^%_P"Q7X'\2#6?A_$_B'Q)XC_8D^)^C>//!'B^SUC3
M_&=AIN@6GC71K+5/#?C;PS_PCVK 7]]IOB/P[KFCQZ7>Z!K?Z344 ?*W[-/[
M._BO]GS2+3P5=?%RX\<?#3P1X6L/ 'P?\(R> _#WAN_\)^"]+UG5-0TX>,O%
MEM>ZMJOC_P 76FEW.D>%EUVPB\"^'KC0_#]E>7G@JY\5WNK^)+WZIHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *\^^(?PM\$?%2S\/Z;X[T6+7]-\-^*-
M-\7V&FW4CG3Y]7TJTU*QMUU2RR;;5M-DM-7OX+S2=0BGT^]CFV7,$BJH'H-%
M '-6?@SPCI]@=+L?"_AZSTT^'+#P>;"UT32[>S/A/2X[R'3?#)M8;1(#X>T^
M'4;^*RT0QG3+2*]O([>UC2ZG$GS%\6_V(/@E\5SX2_T36/A[#X/\(Z_\/-.T
MWX;'PSH/AZ7X?^*-0L=5U[PBWA/5O"OB+PIIEI?:AI]M<)K7AO0]!\7V ^T6
M^F^)+.UN[F"7["HH \NTGX)_";1O WASX;6WP^\*W7@CPFGA;^PM UK1K+Q'
M:VEUX*T[3-)\+:K+)XABU2YO]?T:QT;2XK/Q%J,]WKRO907#:BUP@EKJ(? W
M@NW54M_"7AB!5N-"NE6'P_I$:BY\+SFY\-W "62@3^'[@F?1)@/-TF;][I[6
MTGS5U-% '$:A\,_AUJUWH%_JG@/P7J-[X5U[4O%/AB\O_"N@7EUX=\3:S>S:
MEJ_B'0;BYTZ6;1]=U34+B>^U'6-->UU&^O)I;J[N9IY'D/;T44 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biogenlogostandardrgbr.jpg
<TEXT>
begin 644 biogenlogostandardrgbr.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8
M,0  86-S<$U31E0     245#('-21T(                  /;6  $
MTRU(4" @
M           18W!R=    5     S9&5S8P   80   !L=W1P=    ?     4
M8FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D
M   49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P
M ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E12
M0P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M        $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V
M,3DV-BTR+C$
M                 %A96B        #S40 !     1;,6%E:(
M          !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4
M !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO
M+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M
M9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ
M  !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@
M  !,"58 4    %<?YVUE87,          0                        */
M     G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ",
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M P,# P,# P,# P,# P,# P,# P,#_\  $0@!(@-A P$1  (1 0,1 ?_$ /P
M 0 " P$  P$!           )"@8'" 4#! L" 0$!  $% 0$!
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M'ZB B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MT7Y,^[+$^JD]O*I$!%2D] 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M?^4%['_SK-%_OB8]_A@S#]5O,;Z$R7XA_P"\L3_69R^^F<=^.9^^G\H+V/\
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M7BKZXL)02R1D3W,< 2"0X"AH01Y0L3R&N]&8J\?C\ED[*"^B(#XWRM:YI(!
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M:]A+7-/:"""ND5M<P7EM'>6K@^VE8U['#<YK@'-<.P@@A>N/!>Z B B B B
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M("*^5Z3_ -7KVT_-C*/I$S$<S^=WO3S'KH_81+HOR9]V6)]5)[>52("*E)Z
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MKO/EQ*VKKF),Z=*<X/I;:;4L^/ AX75U:V-N^[O9(X;2-M7/>X,8T#I<YQ
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M76F&G'WW&V666UNO/.K2VTTTVDUN...+,D(;0@C,S,R(B+DQ^M:7$-:"7$T
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MJ$7&PY#KB#6E2XK<_"HJ%<$KA;J.2X/DI_\ #7BA?\QQ>N'HV5C-*#]D[@@
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MIZ5+IZ^3(>4G867H2;K[T=;KADA)$7)GX$1#FSSKO;V+FCEXXII6L$T= 'N
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MS_NR9G]*FF!K;XH_=_9_YQ%_AKM;#>&G_OJ[_P IE_Q%JKA T,6\" B B B
MBHN>L=]8_P!QG^J+Z"-8#I)R"]TN)_O7^,N%SRYY^]/*?W;_  ENHR!,*B9
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MH9N?(,T.\(-Q*/>3[_0D_<$B8[Q5861H_.V)NH7=/<RQRCS!XAZ-M*]E3O6
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M?_T8[(_Q=#$"^)#W92_VR#^45.'A[]X\7]DG_DA75AST6^R B B B B B B
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M8>2XI./:+I+RIR+<GRZQ%PT@\%FR$^6"L!]FNXQ'"D% 1 1 1 1 1 1 1 1
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M+D=S2OGAL>)EC;TF22&,#[N0$[^@$GH&PJAO.='+.R;Q/RD;W=4<<TA/W$9
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MF,EZ.;M?,O*^8;FO\7=4I*XZW[C)(A2W&'4J0_7ULM!^TN84Y\:U9I/0TUI
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MP<;G+7#G]R[?G<:-7XAG%E+*.DS6C;) *GBV;W0U)[8R[:>!H51,;U+2A 1
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MN=0C>_E5RFLM VWYQOBV?4\T='O'Q(FFA,<5=^T#CD.UU-@:W896A":F1 1
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MR%A>9.?)W\#YX(;R"R%M>,B:Y\C(W6Q[ZV<X,<(B>)H=1K@1M6R/YP-VU?\
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M2 ]RRAV.!DXAMHTD44IZ8Y+Z]U*]KQ:.LK$G;+<UB%.ML9'>NJ/BD,X3LJX
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M^ ;^C<7PQ36IQ&5MV@?/&W,3G'I+',<&>8.;)\)W=-B\:H+:% 1 1 1 1 1
M1 14FO6?[9L1[>>[%%QKZKAT.&[HQ-G8;6/UT9,.LH<J*UL:;+8-5%:23$>N
MG2H3-DEM!I0R[/<:;0VTAM(Z(>'W6%]JK1!@RCW2Y#'SF O<:N?'PM?$7$[2
MX F.IVD,!)+B2M!.?&D[+3&L^_QC&QV-_")N!HHUDG$YL@:-P:2 ^@V O(
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M.2U'*TALTC((SV1@OD/:"7QBO6TCK5D,:DK:= 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 10X>M[V_V.X>SYW.\=@.
M3LCT'DS.PGFF&O-E.X-+A/TN<I:+P-#-;&D1;:0OGA,:K</@SX$^^'35$6 U
MZ,;=.#;3)PF $[ )@0^'SN(=$T?72!09X@--2YS0YR-JTNNL;*)B!O,1!9+Y
MF@MD<?K8RJ6@Z$+0Q 1 1=-]LG>!O[M%RMW*-)YO*HVK!3/[8L2LF_QOA&6,
ML'^#:R'&I#B8DA]I'4AJ8R;%A'0M9,OMDM7.'ZPT'IC75D++45LV1S*]W*WT
M9HB?K)!M Z2T\3'$#B::!9;I+7&I-$WAN\!<&-KJ<<;O2BD ^OC.PGH#A1[0
M3PN%2K%&A_M NG\@APZSN(U5E6O+TFVFI.2Z^4SFF'R7^?PTQVIGR:K**&,9
M'[K#17"RX\7#&J6I?"[GK61TVE;V"[MJDB.>L4H'0 YH=&\]I[H=BV?TYXE<
M'<L;%J>SFM;BFV2&DL1/2>$ELC!V#O3VJ2[!/4R[#=B,LO4?<]K*K\[DO*SN
MREZS>:6E!*6AY&Q(.,='3SQU<FA1_>J4(@R7)_F9BG%MSAKQ].F%HN!YNX,G
M[_6%*^.YL<N<FT.M\O:,K_3.,!\_?B/][J72-/OG1N0I970;GU/>(DOHBQUT
M^Q<0LTR)3AMDW&95"N'R=?6;J>$)Y4?47!>)#$9],ZDM21=8^^C(%3Q02MH.
MLU8*#9O650:CT]= &VO[*0$T'#/$ZIZA1QV]BS']NV&?];L8_P"GZK_"Q0?F
M[(?T$WW#OWE7?G"P_IX?NV_OK!KWN%T%B[3S^3;QT_CK,<Y"7WKW9>%U#3"H
MB5+E$\Y874=#9QD(,W.HRZ"(S/C@7*VTKJ>](;9XV_E<:4#+>5U:[J<+#OZ.
MM6ZXU-INS!==Y"QB:*U+YXFTIOKQ/&[IZER5L[U7NPG5L>4<[?V.YG8Q^29J
M-8P[78,B>X1^+<6UQZ'*Q=OP(S);]@RT?P*Y,B/.<-R1YFYIS>[Q<MO$=[K@
MM@#?*UY$GF:PGL6%Y?G+RXQ#3WF2BGE&YMN'3$^1S 8_.7@=J@[[Q_74V%M.
MEN-?]K^,V^G<9M&WX4[9%]-BN;1FUSQ.-+;HHE2]*J,$>?97PJ0S+L)J#X4P
M_'6GJ/8[0/ALQ6%N(\IK*:._O&$$6[ ?FX<-OIEP#I@#\DM8P[G-<-BU]USX
MA\GF('XW2,3[&T>"#.\CYP6G9Z :2V$D?*#GO'R7-.U0 K6MU:W'%J<<<4I;
MCBU&M:UK,U*6M2C-2E*4?)F?B9C:   4&P!:V$DFIVDK^ 7XMJZ2TSGW<'M/
M#=/ZRJ%7.8YM;-UE<R?6B'!82A<FSN[:0VVZ<*DHJUEV7,?Z5>5'96HB4?"3
MLNHM08S2V%N,]F).[L+9G$X]).YK&C95[W$-:.EQ&[>KQI_ Y+4V8@P>)9WE
M]</X6CH WN>X]#&-!<X]#0=^Y?H,=N.BL2[:-(ZZTAA1*71X#C[5:JP=1Y<F
M\NI3SUGDF1S4=;A-3,BR";)FN-I/RVE/^6V1-I2DN6VK=2WVK]1W>H\C_P!3
M=2EW"-S& !L<8[(V!K =YI4[22NE^EM.V6E-/VNG[#_I[:(-J=[W$ESWGM>\
MN>1N%:#8 MVC'5?T!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!%]2? A6L&;5V<2//KK*))@6$&8RW(B384QE<>5$E1
MW4J:?CR6'%(6A1&E25&1EP8^XI9(9&S0N+96.#FD&A!!J""-Q!V@KXDCCFC=
M#*T.B>TAP(J""*$$=((V$*E'ZG/IGY=VBYG;[,UQ4V.0]MF46SDJJM(K3LQ_
M5T^TE+4UA>5*0;C[-2R^X3-59N_@Y#:FV'E_*BY>Z'<G>;]CKK'QX?+/9%JZ
M%E'-)H+AK1MECZ"XC;)&-K35S1P?%T'YM<I[W1-^_+8ICI=*3/JUPVFW+C_-
M2=(:#LCD.QPHUQX_C1&"=%"B B B B B B B B B B BW!H[0NV>X[/ZK6>G
M,-M<QRFT<0:VH3)HK:6!YB6W[O)+=TDU]!1PS67F2I+C;9*-*$FIQ:$*L.H]
M38/26+?F,_<,M[)@WD^D]W0R-OQGO/0UH)WDT )%[T_IS,ZIR3,3@X'SWCST
M#T6CI>]WQ6,'2YQ Z-I(!NK^G=Z=6!]C>%2IK\J+F6[\SKH36?9X3!IB08[:
M6I*L-PMM]M$B%BT2P3YCCRTHE6CR$//I0EN/'C\\^:W-?)\R,BV-K76^G+=Y
M,,-=KCN[V6FPR%NP 5;&"6MJ2]S]]^6'*_'<O; R.(GU!.T=]-38!O[J*NT1
M@[231TA <X !K6R1B)%*B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MC$DL>V1H>P@L(J"-H(["H\<US'%CP0\':#L(\H7PCZ7R@(@(@(@(@(NA]/\
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MV]MO=3:YY^ND>:O>[J+B:#8*"@6[1CJOZ B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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'@(@(@(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biosimilars.jpg
<TEXT>
begin 644 biosimilars.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KY%_;._::N?V5_AAX9\<V>G?#JZNO%?Q<^&/PIAU+XN?$J3X1_#/P
MRWQ%UYM'_P"$F\9>.XO"WC&72-*TH1GRXTT.<ZAJ%Q96'VBT%P;A/KJO%_C-
M\%])^,T?PSBU?5KW2T^&GQC^'OQBL5L[:TNEU/5/AY?7E_8:1>+=@B*QO9;L
M_:+B ?:H3%&\&'Y !XC\.?VVOA3K!^'GA7Q[XX^&[_$;QPWA.V>_^".K>//C
M%\ [/5/B;=7TGPDT1/V@8_ASX9\$6FN?$W1X+*Y\'Z+XG?PUJOB+4+^SL?#]
MIJL6K>'+O7)/&?[=?P9T']D7X@_MG^$;3Q_\3OA'X&\,77BFT;PC\.O'":[X
MUTZWBTQUO/!NCZMX=LM2UW1"^J1Q7/BFPL;GPUIYL=;DN]32+0=6>TA\3_L9
MZ5K_ ,5=7\9VGQ-\6Z%\./&GQ*^#'QG^(_P=T_1O"[Z)XM^*G[/\?@N'X;:[
M:^);C37\2>&M%)^&GPUG\7^&=+:2V\1S^ =!-G?Z!:7_ (MM?$_:2_LK>$KS
M]CY?V.M2U_7KCP>?@5#\"Y?%5O'IUGXE.F0>$H_"T7B.& 6\^D1:U$8HM52W
MDM+C2VO$$,]K/:-)$X!Q'@O]NOX2>(?B[XX^$'B2/7O NMZ%\2O!WPZ\*7GB
M+PIX^L+#7+WQM^SS\./V@-$M?&FHZGX,TS0_A#XRU+3?&FN:)H_P\\?ZUIGB
MG5[CP;?R6MH-0NAH]M[%\'/VEO@_\>IM0M_AGXBU/4Y[+0_#_BVVCUWP9XW\
M$-XA\#>+)-1B\*_$+P8OC?P[X>/C?X=>)Y-)U)/#OCSPF-8\*ZPUI)]CU217
M@:7PZ?\ 8DTWQ'9:Q)\1/B+JWB[7_%_Q[^%O[0/CW4[3PWI?AFQ\2^)?AW\$
M? _P1U+1K;2-/O[M]"T'Q?HW@L:K>+9ZG/J.CWNK74&EWGE6UI*J?L<?L'_#
M7]CD:Q_PAB^$;R:?PEX1^'6C:EH?P7^$/PQUZ/P+X&-X="@\8>(?AYX6T;6_
MB!XLNS=1/XA\2:Y?6^FZC<Z=9ZAIOA30]3N-:O=8 /$]3_;N^._P^\4?';_A
M;WP4^"NA_#KX!?&#]GGX1^*/$W@SXY?$/Q3XDU"X_:/\4_!K3O"OB'3?"VI?
ML^>'+9K3P]X=^+UO?Z[I2:[<:K?>(-%;P]H$.H1ZI:ZG']06?[<G[,]VWAB%
MO'NH:;=^*+3XJWXT_7O ?Q#\.:EX4T_X&:QH^A_&/4/B7I^O>%=.O/A3I_PS
MOO$&A/XRO_B3#X6LM&T[6]&U:>X.F:MIMW=P>)_V1?#/BC6?C)J]QXNURWD^
M,?QO_9B^-VIPQ6.G/%I&J_LR:E\(-2T'1=/>3YKG3O$LGPATR/6+BX)NK)=7
MOS88:"VKE9OV#OAOJ^J_&2X\3^(O$6NZ!\</"_[57@OQCX?\G3M/3_A'/VLK
M[X53^-K33M3@CEN[>;1[3X6VEEHMTR2;QK%U<WD4DEI:*0#K[3]N/]G2^\./
MXBMO$7C5IW\0>&O#&F>"Y?@W\9+7XJ>(]5\::#KWBOP=_P (G\([OP%!\3/%
M6F^*?"GA7Q5XIT36]!\*W^BW?AWPIXLU=M0AL_"WB&33%^.G[4L?@C]E'7OV
MF_@;X4L_C^1I?A/4/ ?@VS\27'@L^.[KQ5XU\/\ @VWT.'5KSPYK5_H.O1W>
MM3VW]CZIX<&I0>(;$^&]7M-)O3=26/R4O_!)/X+_ /"#V6AW7_"K+CQ9H'C_
M ,->//#FKP_LI_LZZ5X%N9O"G@/QM\-;*S^(GPIT7P?IV@_$E]6\+?$3Q?=Z
MWJVN:O9WMCXMU%/$7P__ .$ CADTFY^W/#W[-?A#PI\"?A_\!/#EY%HGA[X>
MZY\,?$.G7F@^$_!?A6";5/AO\4O#?Q:#Q>%/!F@^&O!.BP^(/$?A^3^T+'0-
M!TVSM8=3NI;6V-P/-E /G[Q#_P %$OAOI'QD^$_A*TT_3KCX)^//V9O&W[2W
MB_X]ZCXE?3-*^'N@:1X8T#Q[X)TFY\,IH5]/JK^+/ %UXB\6:O>MK&F3^&+/
M3?#MO#I>O2^+(6T[TJZ_;T_9LLH[&&[U[XA0>)-1\2>*?"%O\.W^!?QQ'Q93
MQ-X.\ Z;\5-;T2[^$O\ PKO_ (6-97Z?#76-.\>Z='=^&H4UOPG<C6M'DO;2
M.=HO!U_X):?" >'M2\)?\)]\14\-7^K_ +3%W:VL<^B_;O#.D_'ZV\)Z=X5\
M->$=0N=/NDT?1/V?=)\"^#])^$5C<66J6MM9^'[&W\0VVK0O?0W?K/@7]BU=
M$^*FB?'3QQ\6O$OQ$^+$/B'Q?X@\4^(;KPQX9\+Z9X@.O?"?0_@[H.CV7AS0
MXQ:^&](\)^&M%DU.VC@N-1O]7\2:_K^H:CJ'V"?2]+TD \LU_P#X*B?"*U^(
M&H>#?"WA/QOXHT32OB3^RMX,/Q$B\,>,XO WBWP_^U=X.OO&/@GQ3\*M7T_P
M=J\?Q-O8K1-(L[3PCX;,^N>(;O6(QI"-':7++]":;^W!^SEK$O@2VTCQ7XFU
M>]\?V3:C:6&D?"OXL:IJ'A*RB\>:I\++JZ^*MA8>"+B]^#T%A\3="U[P!J<G
MQ1M_"8TOQ7X?\0Z5J7V1_#^M26'AG@O_ ()P^&? NL_".XT?XI^)Y?#WPQTG
M]E W>@7OA[09I?$WB[]D?P;J?P[\$^*&UE)HKC18?$G@W57L/%>@06M_9MJ-
MAINK:)=:5(-3M]47QM_P3F\/^+8O"]I%\5M=T6VT'Q[\7?'"ZQ9^ /AS-\1O
M#-Y\7/VAO%7[0^K7_P '?BRVCQ?$;X/>*8-9\3GP?=:[H'B#5-)UKPCIEE]M
M\)1Z_P";K3 'UK\8_P!H_P"$GP&DT2W^(^NZQ9WVOZ=XDUVQTKPSX)\<?$#6
M8O"W@M-+D\:^-=4T;P!X<\3:IHO@7P;'K>C?\)5XTU>TLO#>A2ZQI-M?ZE%>
M:G86]QQ=I^VG^S9>^.=3\ 0?$3&J:-X@UGPGJ>OW'A7QG:_#FR\4Z%\*M.^.
M5YX=G^*UQX>C^&B:U/\ ![4HOB7I>GGQ7]HUGP9;:CKNE)=V>FWCQ>?_ +6W
M["GPU_:N\1^ _&?B4^&K?Q5X(\,^.O -O<^,OA+\,_C5HD_@CXDW_A75/$T-
MCX4^*F@Z]HFB^+[#4_!NAZAX4\96,#OI,JZA8ZYHWBK0=1N-'JAK'[ /PMUW
M0M5\(:CK.K?\(9KGQTUWXR:AX9T[3M)T>P_LWQ#^RQJ/[)][\/K$Z1%91Z1X
M?C\#:E-J.GWFEP65QINI1V]IIUM:Z;;PV\8!7\._\%%O@9X@\6^.--6/QC:>
M%?#W@[]G[7?!^J3_  X^+,7CSXH>(OC_ *K\=(/#OA;P+\&KSX>6?Q&\2;O#
MWP5N/&.BZSX<T?7+'Q#X8U/4]<5=.T7PKJFIL_XR?\%$/@A\.?A_'XO\&7.I
M?%#5[[P]X#\5:?H.C^&_B!9Z?I^A^/OBY:_!O2)?B!XIA\#:KI/PGU&Z\7V_
MBW1=,T/XD#PUK.I^)? OBOPQ'8PZIH>K+8>5^*_^"8VA?$BS;4/BU\7;SXO>
M.='7X()X.UCXE_"/X4^*?!FF0_ /3/CKX9\(V_BGX77.CIX4\;Q>(?"7[07C
MNQ\<-?/I=W>:]/:^*/"%UX'N+'2+#2M:\_X)I>$(/#2>"?!7Q2UWX?\ @SQ'
MX*^&/A'XK^&/"'PX^$OAW0_'DWP@^)FN_%?P5K>CZ/X:\*>'M$^'$\GB3Q9X
MET[Q39>#]*CLO$GAR]M()!9>)+*?Q5J !^FZMN!.,89U_P"^'9<_CMS3J:J[
M01G/S,W_ 'TQ8C\"<4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *8_P!T?[\?M_RT7^?0^HXI]% '\M/CGXG?%;2?V2/B]^S/
M%\2OB5%JUSX>UK]O;0?B(/&WBV+Q+8_!&X\=W^LZW\-K3XBG68O$%D^G_M=6
M-OX8MO#\.O 0_!3Q'%X9AL8?!EHUFGU;\2O^"D_QI\+_ !-^/N@^![OP#XKT
M7P]X _;CG\'6FN:+X5T"\\"^/_V4;*[N?#5GXJ\-:%\7/&GQ2DT7Q/J&F:UI
M6MZE\0_"?PS/B>S@L/%OP^T33M$N;"TUO]UWT?2I(F@?3;!X7MFLVB:RM6B:
MT:7SFMFC:(HUNTO[UH2IB,GSE"W-0GP_H33WUR=&THW&J-OU*X;3K)I]0?[&
M-/WWTK0&2[86 %D&N6E(L_\ 11^X_=T ?C!^T/\ M)?&W18?VK/A'XI^/'PE
M\.>(OAQ\)/B-X4TOP%9>#->\)_%KXP?VW^Q[XL^-,OQQ^%VIZ=XXU34?!FB>
M$_%C7OA+09#H^O\ AS3K7X3^/9O$_CB/Q=J.F'PU]@?L>?%/XPZ]XJ^(/PB^
M+VN^$O%EWX%^$W[,7Q*T'Q)X8\/:OX;ECLOC1X6\<PZEX2U6+5O$GB:?7G\.
MZU\,KN[L?%DLVEW^M67B+[-J>CPW6F?;+[[DN=&TB\NOMUWIFGW-Z;"YTO[7
M<65M-<_V;>LCWFG^?+$\OV&Z>*-[FSW_ &:X>-&FB=D4BU%9VD$LDT-M;Q32
MQ6\$DL<$4<DD-J)1;0O(B*[Q6XFF$$;,4A$L@B5 [Y /Q"^&7CSPK8_M;SCX
M8?M S7'PW\?_  "_:)U76OB/HO[0GB;XR^,M&\0:)<> M<?XG_M3?"+XR:3:
M?#_]G(_"'4G\4^&OAD;'1[K3WGNY?A]XPTSPQH%I#X:E^E_V _C_ /!H_ W5
M]#NOVG?"OQ.N]$_:J_:"^&&G^*_%_P :?#'COQAK][XL_:E^,.C?!S2M6UR/
M6)FN]:\>:3ID4'@#2+2WL;+5K"TBTWP/I$&A:?8Z?:?HHWAOP\_]M;M#TAO^
M$DB,/B'=IEBW]NPFV:S\K6MUN?[6C^R.UKLU#[2OV=F@QY3,AY>#X2_#*U%J
M++P#X0T];+6M"\10)IGAW2=+C&M^&#=-X=U*6/3;2TCNKK0I+RXFTA[I9QIU
MQ)]ILUAG1)% /S+_ ."BOC+X-67BJV\"R_M WW@[]J'Q?\+DA^"7AF[_ &D_
M^%(^!_@#%<>(=;TX_M<>,+.T\3>%H;RQT?7KRRTT6WB>/QS>?$A?!2_##X>^
M"Y++5OBG=R^:Z5XWU#_A>'A75[+XH>+-0_; NO\ @H!XR^&?C/X57'CWQ%!9
MR_L@6FI^-8]*FE^"_P#;TWA?3/A-!^SI;^"_C?X<^(</A5$G^)=]IT\7BQ]9
M\4WT&H_LCXA^'O@/Q;<PWGBGP7X3\275O"EO!<Z_X:T36;B&"-I62&*?4["Z
MECB1IIF6-'5%,LA"@R.6Z!-(TN/4#JJ:=8IJ;6*:8=06TMUOCIL<K3QZ>;P1
MBY-C',S3)9F7[,DK-*L0D):@#\-= ^+6EZE\)_\ @H]X'\!?MJZ'\3_&/A/X
MW^ /&TOC/Q)^T7X2T77;CX6Q_"']DS6/C#I6@>+? +2Z9\"/!OB%]1\=?#70
MO%?@SPYH/@_X3>)?$PUI[K3=:L]8U\_17["7Q)U&6S_:SUG2+;6--_9R\$^*
M/"][\(-&G^(EW^T1=>%;BU^#^EZ]\6_"FE^-O#GB3XA6GB@:3XF6SO+GPA\.
MO''CWP]X=\3ZMKGA70=<_MU-7\/:)^CNB_#GP!X;N9KWP_X(\(:%>7%I/I\]
MWHWAC0M*N9K&YE6>YLY;C3]/MII+2XG19I[9W:":51))&S@$=+IVF:=I%C;:
M9I5C9Z;IUG$L%I8:?:P65E:PIG;%;6EK'%;V\2DDK'#&B DD*"2: /P1^%__
M  43_:2^)VM67@WPWXB^%>H/XT\;?L:2^&?B)<^&?!NIVFF>%/VE/$GQU\/>
M-](N?!GPN^.?Q+L-+UGPE9_"G2=8\,Z!XJ\?Q^--,O-:;3/'4%Q;26]V.6_:
M-_;0^/GB+X#?&#P;K?Q7^&?PK\1>$?A!\7-/L]5L?#&O^'_%O[2'COP%^UG\
M;_V:M97X./!\1XKSP1JOA?0O@YX;\8^(M&T!_'&JZ1XA^+OAY9VMO"6FV_\
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M)+JX\RXD"@/(P H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMZ_T]/X)Q^05GCL8_K-/7%8A_!+9U9/O_7RU_6/8_P#=;_OD_P"%&QCU1O\
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MZQ_\ET?\)]X]_P"AT\6_^%#K'_R77J_VY2_Y\5/_  ./^7K_ $]/#_U?K?\
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MK@::;3333LT]&FMTUT:/4332::::333NFGJFFM&FM4UN%%%%(84444 %%%%
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M?%7_ $,NO\ +_P A>_\ NAS(%S]HSM$A,@7.T2$N!O)-/?QCXOD $GBKQ)(
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M_B36O7[-+C^,UYC5:]_X\K[_ *\KS_TFEIQQ%>Z_?5-U]M]_4/J>&_Y\4O\
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M=$W[\KG?G;M^7&37X%5_BU?^OD__ $IG]-8?^!0_Z\TO_2(FA11169L%%%%
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M#ZDD >I.*_;=98C'$!)&21"  ZDDDI@ 9Y)H _SH_P!HO_DX7X^?]EP^+_\
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M?1UO];O_ !MJVI^*M/E\/>%M)T/4-1UNUAO18+->QP6=QXY8?MN_#W7?A+\
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MA3Q!IE[H_B>]O6AM_#VHQ+:ZR]E+/;+. >[45\Y77[7O[+MCX(T_XD7WQ_\
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M=X!FU(W:"W0QZE%;& 26TDLWO-% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>collabprofitshare.jpg
<TEXT>
begin 644 collabprofitshare.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MLQ>%O!::7)XU\:ZIHW@#PYXFU31? O@V/6]&_P"$J\::O:67AO0I=8TFVO\
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M_P!G6_M0?^L<_$&OV\C_ -7'_N+_ .@BOQ#_ ."D_P#RDD_X(4_]G6_M0?\
MK'/Q!K]O(_\ 5Q_[B_\ H(H ^ ?$'_(?UW_L,ZI_Z77%9%:_B#_D/Z[_ -AG
M5/\ TNN*R*_C?%_[WBO^PBM_Z<D 4445S@>8#X)_" ?%.;XW_P#"L? A^+UQ
MX9_X0Z?XCGPKHK>+IO#IEED>PEUIK(W<DDL,TFFSZB\AU2XT-AX>GO9-!5--
M7)T+]G/]G[POHGB_PSX<^!_PFT/PY\0(8;7QQH&F^ ?#<&C>++*UFDN;/3=;
MTW[ UI=:1IUU--=Z1HJQ1:/HE[+)>Z-86%X[3GV6BM_K.)LE]8KV4:<4O;5+
M*-&7-1BES64:4O>I*UJ;NX6; \B\/?L__ SPE:^&;'PO\(/AWX?M?!GB'7O%
MOA2/2?#%A:2Z!XK\4^%+_P ">)?$]A>(GV\^(M>\$ZIJ/A'5=<N[JZU2[\-7
MDNBR77V!8H8\GX6?LQ_L[_ _6]8\2?!WX+^ /AIX@\06CV.O:SX1TJYT_4-9
MM'DL)7BU2:6^N1>L\FE:86N)T>[9-/LH3<&"VAB3W.BAXK$R4XRQ.(DJBM44
MJU1JHN9SM-.34USRE.TK^]*4MY-L"BBBL "O6_@K_P CLG_8(U/_ -#LZ\DK
MUOX*_P#([)_V"-3_ /0[.OH>$_\ DILB_P"QGA/_ $[$:VEZ?JCZ]HHHK^KQ
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'X@?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MY'_ *N/_<7_ -!%?B'_ ,%)
M_P#E))_P0I_[.M_:@_\ 6.?B#7[>1_ZN/_<7_P!!% 'P#X@_Y#^N_P#89U3_
M -+KBLBM?Q!_R']=_P"PSJG_ *77%9%?QOB_][Q7_816_P#3D@"BBBN< HHH
MH **** "BBB@ KUOX*_\CLG_ &"-3_\ 0[.O)*];^"O_ ".R?]@C4_\ T.SK
MZ'A/_DILB_[&>$_].Q&MI>GZH^O:***_J\04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !17+3^./!EMX@A\)W'BSPU!XIN$
M5[?PW-KVDQ>()T=0R-#HDEXNJ2AU(93':,&4@J2"*ZG_ #Z?SH _$#_@I/\
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M -!% 'P#X@_Y#^N_]AG5/_2ZXK(K7\0?\A_7?^PSJG_I=<5D5_&^+_WO%?\
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M[)_V"-3_ /0[.OH>$_\ DILB_P"QGA/_ $[$:VEZ?JCZ]HHHK^KQ'SO\?O\
M4^%?^NVL?^B].KYOKZ0^/W^I\*_]=M8_]%Z=7S?7\R>(G_)89MZ8#_U68, H
MHHKXH HHHH **** "BBB@ I&^Z_^X_\ Z :6D;[K_P"X_P#Z :4MGZ/\AQW7
MJOS/T&T7_D#:3_V#+#_TEBK3K,T7_D#:3_V#+#_TEBK3K^RL+_NV'_Z\4?\
MTW$04445N 4444 %%%% !2'H<<G!P/P]^/SI:0Y )'4 X^O;IS^5 'YFK\,/
MC7HO[2GQ/\0Q^&?VCU\%>+?B[X.\4:+J'PE^(G[.O@/X27'A^'PWX,TG5+SQ
M9X&USQ8_Q"US51?Z1JC>.]>FLE\0^,]*2PM=+L((],TJS7],Q_CU^O\ G'M7
MYRWGC_XZ-^T5X\\/>)M5_:ET#PAIGQ/\(6'P]A^%/P!^'.N_!?7_ (?WNA>$
M99F\1>//%O@/Q5XX.HKXDD\56GQ UJSUSP]IFEZ6]A_PB"0&PNM5E_1H?CU/
M7Z_R]/;K0!^('_!2?_E))_P0I_[.M_:@_P#6.?B#7[>1_P"KC_W%_P#017XA
M_P#!2?\ Y22?\$*?^SK?VH/_ %CGX@U^WD?^KC_W%_\ 010!\ ^(/^0_KO\
MV&=4_P#2ZXK(K7\0?\A_7?\ L,ZI_P"EUQ617\;XO_>\5_V$5O\ TY( HHHK
MG **** "BBB@ HHHH *];^"O_([)_P!@C4__ $.SKR2O6_@K_P CLG_8(U/_
M -#LZ^AX3_Y*;(O^QGA/_3L1K:7I^J/KVBBBOZO$?._Q^_U/A7_KMK'_ *+T
MZOF^OI#X_?ZGPK_UVUC_ -%Z=7S?7\R>(G_)89MZ8#_U68, HHHKXH HHHH
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M_@.:6D;[K_[C_P#H!I2V?H_R&MUZK\S[JTC4=672=+5- E=5TZQ"O_:6GIO
MM8L-M:7<H8<@'D9Y -=!8W-Y<^;]KTY[#9L\O==6USYN[=NQ]G9MFS"YWXW;
MOES@XCT7_D#:3_V#+#_TEBK3K^RL+_NV'_Z\4O\ TW$04445N 4444 %%%%
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M86$*VVGSN99][JD$4\T7MD?_  </_P#!&X(@/[;G@X850?\ BVWQX)&  ?\
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M_P""4?\ T>9X+_\ #<?'_P#^=!7H7PR_X+Q?\$D?#GBA-1U7]M'P;#:#3KZ
MR#X;_'P_O9FMC&OS_".-?F\MOXL^@/2O>X7R7.:'$62UJV49I1I4\QPLZE6K
ME^+ITZ<(U(N4YSG1C&$4M7*326MWHQKKYK]4?T845^+'_$1!_P $;?\ H]SP
M=_X;;X\?_.HH_P"(B#_@C;_T>YX._P##;?'C_P"=17]."/T?^/W^I\*_]=M8
M_P#1>G5\WU\'?%S_ (+Y_P#!(?Q5'H"Z/^VKX-G-C+J37&?AM\>_E%PEF(ON
M?"23[QA<<XZ<9KQ;_A^'_P $H_\ H\SP7_X;CX__ /SH*_G7CS)\VQ7%6:5\
M+E>8XFA46!Y*V'P.*K4I\N7X2$N6I3I2A+EG&496D[2C).S3L'ZM45^4O_#\
M/_@E'_T>9X+_ /#<?'__ .=!1_P_#_X)1_\ 1YG@O_PW'Q__ /G05\?_ &!G
MW_0DSC_PV8W_ .4>?Y]F!^K5%?E+_P /P_\ @E'_ -'F>"__  W'Q_\ _G04
M?\/P_P#@E'_T>9X+_P##<?'_ /\ G04?V!GW_0DSC_PV8W_Y1Y_GV8'ZM45^
M4:_\%QO^"4+;MO[9_@AMC%'"_#KX^L4< $HX7X0DQR!65C&^UPK*Q4!E)=_P
M_#_X)1_]'F>"_P#PW'Q__P#G04?V!GW_ $),X_\ #9C?_E'G^?9@?JU17Y2_
M\/P_^"4?_1YG@O\ \-Q\?_\ YT%'_#\/_@E'_P!'F>"__#<?'_\ ^=!1_8&?
M?]"3./\ PV8W_P"4>?Y]F!^K5(WW7_W'_P#0#7Y3?\/P_P#@E'_T>9X+_P##
M<?'_ /\ G04C?\%Q/^"4>UO^,S/!9RK 8^&_Q_ZE2!_S2"A\/Y]9_P#")G&S
M_P"99C?_ )1Y_P!68UNO5?F?TP:+_P @;2?^P98?^DL5:=?B7IG_  <,_P#!
M'&VTW3[>7]MOP<)8+&TAD'_"MOCQQ)%;QHX_Y)1V92.<'CD \#[>_9!_X*)_
ML:?MZ/X_C_9+^-^C?&-_A</#)\>#2?#7CWP]_P (\/&/]N?\(V9SXV\)^&!=
M_P!J?\(YK7E_V:;WR/L+_:_L_FV_G?UIADUAZ":::HTDTU9IJ$4TT]4T]&GL
M(^UJ***V **** "BBB@ HHHH **** $*AL9'0Y' .#@C/((S@GGK2;1_D+_\
M33J* &;%]!_WRO\ \31Y:^@_[Y7_ .)I]% #/+7T'_?*_P#Q-'EKZ#_OE?\
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MOH/^^5_^)I]% #/+7T'_ 'RO_P 31Y:^@_[Y7_XFGT4 -VC_ "%_^)I0,?\
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MN/[6;PK;6_A:;7<_VY<>&8(?#UQJ4NCQ)9* >T*254G!)4$D=,D=O;TIU%%
M!1110 4444 %%%% !1110!^1G[0OQB^-5_XP_;SUKPW\:-<^"5A^P_\ !KP1
MX_\ ASX>L=(\$7OA+X@ZSK'PF\9_%K4O&7Q?B\1^&/$/B/Q%\.=:U/0Q\)=.
MT3PSJO@F6PD\+>/=1TS5+KQ?/HFI>&_>/ WQ&^.>K?MD^#-*\7^)HM*^%GQ'
M_9"USXG:%\%[7PC;Z;=^!O%.D>./@?I]W>>,O%E]-?:_XF\8B?QWXHT1X;)?
M"OAG2M"LM,@'ABZU[^U=>NO6_P!H;]D?X1?M'S^%M=\7:/:Z5\0/ ^LZ!K/A
M'XDZ5X>\%ZMXJTH>'M6DUFUT*\A\;>&/%?ASQ-X2GOY[B]E\*>*]"UK1+766
MM?%.D6NE^+=)T?7M/FU+]CC]F;5_C/;_ +0^I?![PI>?&JTU2RUBU^(\HU7_
M (22WO=/73A:F&Y34T@CM4;2-+FDT];8:=<W.GVEW=6DUU!', #K_'/A7XR7
M?C"3Q+\/_B9H>@:0/AMK/A6R\&^*O"$WB7PW'X_U;Q?X8O\ 2?B/J::5K'AO
M7]37PWX9L?$.C1^%K3Q'HEIJ\NL1O=:E9>0+J/\ +-_CW^TIK7[)G[$&GZ)X
MS^)?Q+^-/Q?\>^,M*^(]E\,(/@UX#^.OQ7\ _#RS^*$7BK7_  )X@^).G:1\
M"/AU<^'M2L? GB;Q8NN?\(K%JWAF*]\)>!==L/%>L:1!J/[%^.O WA3XE>$=
M>\">-]&M_$'A/Q/I[Z7KNC7<EU#;ZA82/'(]O++97%K=QJ7BC8/;W,,JL@*N
M*^=O#O["7[(?A3P#J'PO\/\ P ^'6F> -1\16GBU_"T.E3R:79>*+&QO=,M?
M$.BI<WD\_A[68=/U/4[,:CX?GTNZ>WU34XI)734;T3@%K]BGXE^*?BQ^SAX&
M\5^.]4U'4?'D&H^//"?CBVUW2[+1_%?AKQ9X%^(?BKP;K/@?QS:Z1IFC>'KG
MQ_X$GT1?"/CK7/"6F6?@?Q1XLT;5_$_@6(^#]8T21_JNN8\&>"O"'PZ\,:/X
M*\!>&-!\&^$?#UJ;+0_#/AC2;'1-#TFU,TMP\-AIFG0V]I;++<SSW,QCB#SW
M4\]S.TEQ-+(_3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>costofsales.jpg
<TEXT>
begin 644 costofsales.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M;_V:M97X./!\1XKSP1JOA?0O@YX;\8^(M&T!_'&JZ1XA^+OAY9VMO"6FV_\
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M)+JX\RXD"@/(P H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+J?5)+>WELK>U:6]A^AUUBZ?:1X?UH!]N"PT@ ;L8)/]L\#GD]J_%W_@I/\
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M4?\ NQ_^RTX[KU7Y@?SC?$?_ )*)X_\ ^QY\8?\ J2:G7&5V?Q'_ .2B>/\
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M7_3OS_JZOX?17N'_  SY\1/^>?A__P 'J?\ R'1_PSW\1/\ GGX?_P#!XO\
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M^$/\18P.1@?8\ ^XYZ<\"OY1M#^.WQ.UFZMO#>L^+O&/PYT+3_B'XM\):_\
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MRXXPF(K8:='ANI/#U949SHX+,73<Z;49J#JX^E-I2C*-W3BF[N-XM2?[:_\
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M !Y?"+_K\\;_ /I+X9K\O:_4+_@HQ_QY?"+_ *_/&_\ Z2^&:_+VOZA\.?\
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MV5'X=3T&.Y_7U/<\T ?B#_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?MY'_JX_\
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MA_\  _Q[X&\&^#?CMX@^%/ACX5>'?!VK>&OC=IGC+4+K6?@VGQ*@_P"$>NO
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M/_2ZXK(K7\0?\A_7?^PSJG_I=<5D5_&^+_WO%?\ 816_].2 ****YP"BBB@
MHHHH **** "O6_@K_P CLG_8(U/_ -#LZ\DKUOX*_P#([)_V"-3_ /0[.OH>
M$_\ DILB_P"QGA/_ $[$:VEZ?JCZ]HHHK^KQ'SO\?O\ 4^%?^NVL?^B].KYO
MKZ0^/W^I\*_]=M8_]%Z=7S?7\R>(G_)89MZ8#_U68, HHHKXH HHHH ****
M"BBB@ I&^Z_^X_\ Z :6D;[K_P"X_P#Z :4MGZ/\AQW7JOS/T&T7_D#:3_V#
M+#_TEBK3K,T7_D#:3_V#+#_TEBK3K^RL+_NV'_Z\4?\ TW$04445N 4444 %
M%%% !1110 4444 ?B!_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\
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M^K$\TO\ PXE^&7_21#_@L!_XL(^(7_S/5^YG^?SZT4?V7EG_ $+L!_X28?\
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M$4]S#\9OA)XC^-NK-XK\3>$=?\02:U\-/$NF^)M,M/"%W!)<2^'=7O[M+VQ
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M^?'ZT?DG#_P29^%EAX;U#3M!UKPWX2\6_$#P5^U]\,?CG\1?"'PN\.:)XO\
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M3I&@Z#J7PJ^'WCSP]J.A_M3_  ]\?:]K7C:ZO?''A_XV^!=7\2?#OP!!X%\
M66J>&;_Q/:W_ (GEFC\-6?B=/UBHH 9%&D4:1HBQHBA5C0 (B@85$   1  J
M*  J@    4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>equityinlossofinvestee.jpg
<TEXT>
begin 644 equityinlossofinvestee.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #5 3T# 2(  A$! Q$!_\0
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M3]G2^\./XAMO$7C5IW\0^&O#&F>"Y?@W\9+7XJ>(]5\::#KWBOP:?"?PCN_
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M/Q%;IIOA[2M+C&M^&3=-X=U*6/3;6TCN;K0WO+B;27NEG&G7$GVBT6&=$D4
M_,C_ (**^,_@O8^*[;P+-^T#>>#OVHO%_P +DB^"/AN^_:2_X4CX%_9_@N/$
M.MZ:?VN/%UI:>)_"L-W9Z1KUY9Z:MMXD3QS>_$E?!2?##X?^#&T_5/BI>2>;
M:3XVO_\ A>/A75[+XG>*[_\ ;!N?V_\ QE\-?&GPLN/'GB&"TE_8^M-4\:II
M4\OP9_MZ7PQIGPD@_9TM_!?QM\-_$*'PJD4_Q-OM.FA\6/K?BF^@U+]DM?\
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MP8#<:3IDQM9KZXM3+86DOV:?4Q.NHSP;X6$,U^MS<+>RQ[9+M9YEN6E$L@8
M^!OV^_'7[/G@?P_\.)/CQ\1?$=I=ZUK?B[3?A=\!O#WQOMO@>WQV\<)I$-Q&
M-4\1)XI\!7T6D?#;2XKKQ#<^(=7\<Z#\/_ G]IIXM\4Q:CKUAX&2V_.+QIXM
M\3Z)\.?'$/Q6_:4U7Q+^T%\+?V,?V?=:_8A\8_#_ .,7B";2/C=\<+S1/'Z:
MIXE^&EGHNM:=IW[1OB#QC\9[+P7\*?&<7B#PYXJOM;\ )X6E\1Z3I=K\3M=&
ML?T$^(?"'A7Q;%;P>*?#6@>(X;1I'M8=>T72]9BMWE,9E>"/4[2Z2%I##$7:
M)4+F*,L3L7$UOX9\.V<&BVUIH6CVMOX<!7P_!;:78P0Z&I@>U(T>*&W2/2PU
MK));,+!;?-N[P',3,A /R5MOCOX3\$?MG?M7:%J?[3>L^.O%US^R+H'B.Q^$
MGA7Q[X#\8>+O _CWPOXS_:&O-6^''P*^"]B=/L=2^(7A[P]I5A(+#5/#VI>.
M/&M];Z/-XZU2]TV+1K+2?./^"7GBWQM'\5)/!7BWQWX+\<SZY^S'X0\=:CK/
MP7_:/\9_M*^$O$/BW3?%>FZ5XB\;_'NY^(.H7=]\&?CQXLBU_33H?@SP4^M^
M#?%^F6'Q*=?&/B#_ (5YHMOI/[/1_#[P+#KA\30^#/"D7B,WL^HG7HO#>B1Z
MT=0N8F@N;[^UDL%U'[9/"[1377VG[1+$S1R2,A(.[I^CZ3I+7C:7IEAIS:A=
MRZA?FQL[:S-[?SA1->WAMHHC=7DH51+=7'F7$@4!Y& H TJ*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#Y?^-7[6OPR^ _QH_96^!/C/3O&%WXR_:_\ B!XY
M^&_PONO#^E:7?:!INN_#_P"&VM?%+6[GQG?7VNZ9>Z3I<OA[0KJTTZ?2=-U^
MZN-8FM;>>RM;-I[^#Z?!# ,.A (^A&:_$'_@I/\ \I)/^"%/_9UO[4'_ *QS
M\0:_;R/_ %<?^XO_ *"* 'T5\2:YXS\70ZUK,,/B76XH8=6U***)-0N%2...
M]G6.-%# *B(%1% PJ@ <<5E_\)QXR_Z&G7?_  97/_Q=?E-7Q7RRE5J4GE6/
M;IU)4VU4PUFX2Y6U>=[:-J^NGF/YK\?\OZL_*_W?17PA_P )QXR_Z&G7?_!E
M<_\ Q='_  G'C(=?%.N_^#*X_P#BZC_B+65_]"G,/_!F&\O[_F_N\P^:_'_+
M^K/RO]WT5^2<G[:W@2'XQ:A\"Y_BUX@@\>Z3I-[J6J23:?XOB\%:=>:7!=7^
MK>%M0^([Z4/ =CXSTC1;.X\0ZMX9N_$$%]IVC1M)=>5?QS:=%@Z7^WY\+-4T
M/7_$?_"V_&^CZ5H'A3PUX\C?Q5X)^*OA.^\7>!/&OB2Q\&^"/&WPST7Q!X3L
M-<^*/ACQMXPU71_"7A*_\ Z;K]QKGB37/#^D6]DMUXBT)=2ZEXF4&HO_ %>S
MIJ4:,XM0IM2CB)*-"4;/55I7C2:_B.+4+L+>:_JWY7U[69^Q5%?F;X$_:)F^
M(VF>(-0\.^)_B+:W?A+4Y-$\6^%/%OAOQKX'\?>%M:71K'Q%;Z3X@\">+=+T
MCQ-IU]JF@:II>M:"&L)+;7],U*QN]%NKZ.;Y./\ AC^U[#\5_%GB/P/H4G[0
M7A?Q3X4\-:%XNUK2_BM\(OBE\)VAT'Q-JFJZ/H-U;7/CC1=*M;V?4[_0M:6V
MT^VE>_DMM)U&_6W-C:2W"Y_\12P255O(\U7L%&5:[H+V49N*C*I[WNQDY))N
MR=XV?O(+=;KYZ=G^O3_*_P"L5%?"'_"<>,O^AIUW_P &5S_\71_PG'C+_H:=
M=_\ !E<__%UC_P 1:RO_ *%.8?\ @S#>7]_S?W>8?-?C_E_5GY7^[Z*^$/\
MA./&7_0TZ[_X,KG_ .+KT[X2>)O$6J^+DM-3UO5+^U.EZA*;>[O)IX?,C:U"
M/Y;L5WH';:V,C<<=:[LL\3,NS/,,'E]/+<;2J8W$4L/"I4GAW"$JLHQ4I*,W
M)I-N]E?3S"WX?\#_ #/J&BBBOTL04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%13QK-#+$WF;98I(V\J66"3:Z%3Y<T+QS1/@G
M9+%(DD;8>-U=0P .<F\;^#;;Q!#X3N/%?AJ#Q1<(KV_AN;7M)BU^='4,C0Z+
M)>+JDH92&4QVC!E(*D@BNH_SZ?SK\6OB/KNMZ9\8M=^%'A']B_X5WGA'P?\
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M*4:<;J3N_E\O+R[K^M3X?_9B^%?Q>^"LWBG3[CP4;;P+\4OC#=^*YM&\:?M
MW'QE^)_PC\/_ /"KEM]5U[Q)\5]>T"^\2?'+4?&/Q&T31-&\/>#]3\7ZY>?"
MOP5=[[/Q]J6@:99^"-%]S^"G@+Q%X0;XN^(O&B::WC'XI?'+XB>.+NXTZ[%_
M&G@2SO;?P5\$]"-T$C,:>'/A#X7\*P2:9M$>E:UJ/B%%#7-U>W%Q[;17)B,=
M6Q,JTYQIQEB%2C6E!5.:HJ+O#FE4JU).[C3=1MN56=&G5J.5;VE2H@HHHKC
M*]3^#UY:V7C%)[RY@M81I6HH9;B5(8]S-:%5WR%5W,%;:N<G!P#7EE>M_!7_
M )'9/^P1J?\ Z'9U]#PG_P E-D7_ &,\)_Z=B-=?3]4?47_"2^'O^@WI7_@?
M;?\ QRC_ (27P]_T&]*_\#[;_P".5MT5_5XC$_X27P]_T&]*_P# ^V_^.4?\
M)+X>_P"@WI7_ ('VW_QRMNB@#$_X27P]_P!!O2O_  /MO_CE'_"2^'O^@WI7
M_@?;?_'*VZ* ,3_A)?#W_0;TK_P/MO\ XY1_PDOA[_H-Z5_X'VW_ ,<K;HH
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M-:D1E='U?4W1T8,CHU[.RNK D,K*0RL"00002#657\;XO_>\5_V$5O\ TY(
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M>7'_ ,\T_P"^5_PH\N/_ )YI_P!\K_A3Z*_J\0SRX_\ GFG_ 'RO^%'EQ_\
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MT=&#(Z->SLKJP)#*RD,K D$$$$@UE5K^(.-?US'_ $&=4_\ 2Z>LBOXWQ?\
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M_P!\K_A1Y<?_ #S3_OE?\* ,K_A(= _Z#FC_ /@SLO\ X_1_PD.@?]!S1_\
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M (!_1?17XL_\1$'_  1K_P"CXO O_A ?&_\ ^=;1_P 1$'_!&O\ Z/B\"_\
MA ?&_P#^=;7].B/VFHK\6?\ B(@_X(U_]'Q>!?\ P@/C?_\ .MH_XB(/^"-?
M_1\7@7_P@/C?_P#.MH _::BOQ9_XB(/^"-?_ $?%X%_\(#XW_P#SK:/^(B#_
M ((U_P#1\7@7_P (#XW_ /SK: /VFK\Z/^"EGCOXX^!_@?I]Q\"O$NKZ#KEW
MK\[^)+7X>:U\--*^.6J>&+#1[R8#X00?%U9? ^I7^G^(I?#]UXSM;V%=27P2
MVK/HMW9WY5W^</\ B(@_X(U_]'Q>!?\ P@/C?_\ .MKR7XU?\%JO^"!G[17@
M:\^&WQM_:A^#_P 2/!5[=6M_)H7B?X7_ !JOK>#4;)RUIJ6GS-\+!=Z9J4"M
M+!'J&G3VMX+6XN[3S_LUW<Q2@'=^(_VI?C#XR^'7[0OQC\"_'3Q5X;MOV0_V
M:OAS\6?"WAW6/A_X&\.0_'3QK+!\7+[QU8?&OPMJ/A_6KW3[;7?$_P *]2^
M-EH7PS\4^&(- \?Z'X[U_P .ZIJ4LWA,:1^W=E/)=6EM<RV\UI)<00S/:7 C
M%Q:O+&LC6TXB>2/SK=F,,WER.GF1ML9EP3_/=KG_  6&_P"#>3Q-JOP_UG6?
MC[^SSJ.H_">WT_3OA[*?@I\54C\':=HMY;ZIHFBZ3:6GPEAL[72?#^JVMEK6
M@Z'-;2:;H.LV=AK>DV5EJEM:WJ>ZC_@X?_X(U#I^W%X%_P#" ^-__P ZW\Z
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M?&X X.1D X.",@$$ X)&>N"1G!--\I/[J_\ ?"?_ !-244 1>3%_<3_OA/\
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>financialhighlights.jpg
<TEXT>
begin 644 financialhighlights.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &J 3T# 2(  A$! Q$!_\0
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MM_$_]G1^*-'\/1Q_#[X?:_K_ (,LKA[36O$_@G2+V+5-+TG4O%>A>(NVUO\
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MIOB#4[JWBU!-2TM/#MEH>L/XB;4O$]MH%K[%^TQ^R?X<_:7TC7-.UGQIXO\
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M7)BA0W%Y>7$]W=3%[BYFDFD=VT* "BBB@ HHHH **** "BBB@ HHHH ****
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M[%J'PQ_X+E?!/X%^#/&/Q+TWX.>+?^"9_P >OB1XE^&=Y\5OB;X@\%:SX_\
M#O[1GPQ\/:#XSO/#_B3Q=K&GOXET?0M5U+2-.UE8EO[33[ZZM8)TAF=#^VW_
M  C.D_\ /.[_ /!KJ_\ \GT ;]%8'_",Z3_SSN__  :ZO_\ )]'_  C.D_\
M/.[_ /!KJ_\ \GT ;]%8'_",Z3_SSN__  :ZO_\ )]'_  C.D_\ /.[_ /!K
MJ_\ \GT ;]%8'_",Z3_SSN__  :ZO_\ )]'_  C.D_\ /.[_ /!KJ_\ \GT
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M#]G#_M$W^TE_ZU)\(:_<2OP[\?\ _*Q!^SA_VB;_ &DO_6I/A#7[B4 %%%%
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MV<.O_*)O]I+J2?\ FZ7X0^I-?N+7X=^/_P#E8@_9P_[1-_M)?^M2?"&OW$H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHJ*<2-!,L4@AE,4@CE,8E$;E&"2&(LHD",0YC+*'QM+
M'( 'ET!P64'.,%AG)Z#&>IIU?C-\2OCWX1\*?&"Y\&Q^,_VL?$WBWP[\5K/P
M3X]\;Z3\9?#_ (7TCPCIAUG]GGP8WB_2_@M;6LW@_7M*F^(G[3'@#PIH'A;4
M?AG!?>+8-"\?:WI4VLV6A:6WBO\ 8K2K>\M-,T^TU#4'U:_M;.VMKS5)+:WL
MY-2NH(4BGOY+2T2.TMI+N56GD@M(HK6)Y"EO#%"$C4 OT4A('7OT[D\9P .2
M< G [ TN1C.1CU[?G0 44F1@'L>G!R>_ ZGCG@=.:3<HQR.1GUX]3CH/<\4
M.HHHH _#OQ__ ,K$'[.'_:)O]I+_ -:D^$-?N)7X=^/_ /E8@_9P_P"T3?[2
M7_K4GPAK]Q* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *0YP<=<''U[4M5;ZY6RLKN\:&ZN%M;:XN
M6@LK>2[O)E@A>4Q6EK"&EN;F0(4MX(E,DTS)$@+L!0!^5>L)K-S^UO\ $6'Q
MMHOQ7T>]O?BM\*;[P1<_#?\ 9M^ .N^#?'/@?P5HWA:X\*:YXG\>>-OA]XJ^
M,&L:GX%\5ZCXSMM=\7VFM:/I?@2QO8#\/9=(FM;[59OU='3\_0<9]NWI[5^(
M/CWX63>*_P!I'5M8L_A_XL73?B1\<_@-\9;CXMZ]^QA\5M8^/WPZG\,V'PNN
MK7P+X'^-RWD'A;PWX/@@\.MHEUJVJ)IQ^%FC^)OB7X9U+PIXLFFO+V;]O@,#
M'U_F>GH/0>F* /B+]N'QA\#O!W@_P%=_'?XK>-?!^@7WC6?3O"_PI^'WQ-3X
M6>)_VA_'%QX8UI=!^&MEK5AXC\#>);]-.4W?C.:RL_'_ (,\(Z;_ &#'XJ^)
MVMVW@7P[J<L//_!/Q>=+_95^'_@7XE_M:>"-,^*][\,[OQC?_$?2OBA\.O'O
MB+0_ "?$"'2'UO3?%OC*/4='\?P?#ZRU[P]\)]1^,OB+0-5TS7_&D%IXCUVU
MO-<UI=/N_M#Q=X!\#^/[6VL?'/@[PKXQLK.:2XM+3Q5X<T7Q':VL\L?DR36]
MOK5C?0P2R1?NGEB1'>/Y&8KQ7.'X)?"$Q16S?#3P*UA!X4NO UOI3>%=#;1;
M?PA?ZW;>)+_PY;Z$;$Z-!H]]KUE9:M?6$5@EO>7]C8W-RDLMG;-& ?C'\'?C
M%X9^(G[.G_!.CPS\0?V@M4U7X'^(H?B+X;^/OQ+B^/FKZ?KFL?$/PUX*US4?
M@YX)^+/QJ\.>--)\5Z+/XL\CQ!XJF>]\5:1>^,O%'A'PUHU^U_:ZLVCZCY>G
MQ:U_Q#\+_B'J/QH_:&^*?A.X^'7[*GC/QM^POXP;XF^(_ VO_&'5]&^.G[4?
MA7P'\6$M=+U#PY'\?OB9JOP_\(_LI6T?A'Q1;>.;3Q5IOQ%L=0FT'56^,NIB
M^_?S3/A-\+]%T36/#6D?#GP'I?AWQ#/'=:]H.F^#O#5AHNMW,*0I%<:OI5II
M<.GZG-$EO;I'+?6UPZ+!"$8"*/;U%_X=T#59=(FU/1=)U&;0+V/4]"EO].LK
MR71M1B@DMHM0TF2Y@E?3;Z.WFEMX[RQ,%RD$CQ)*(W92 97@"_\ %&J>!O!N
MI>-M,MM%\9:AX5\.WOBS1K.1I;32?$UWHUE<>(-,MI6):2WT_6)+VSA=B2T4
M*$\FF^./$6O>&-#.J>'/ GB#XBZD+RUMQX=\-:IX/TC4FMYV99[\7GCCQ)X5
MT,6]D%#SQ'51>2*ZBTMKA@RKV%% '\_-[XP\4^)/^#@W]GF]U_X5^,/ -[!_
MP2C_ &D88M(\1ZU\.=4O+V,_M0?":3[9:W/@OQOXHTU;962*W=;V]LKOSY3L
MM'MXVN3^]7]J:E_T+>J?^!>A?_+>OQ7\?_\ *Q!^SA_VB;_:2_\ 6I/A#7[B
M4 8?]J:E_P!"WJG_ (%Z%_\ +>C^U-2_Z%O5/_ O0O\ Y;UN44 8?]J:E_T+
M>J?^!>A?_+>C^U-2_P"A;U3_ ,"]"_\ EO6Y10!A_P!J:E_T+>J?^!>A?_+>
MC^U-2_Z%O5/_  +T+_Y;UN44 8?]J:E_T+>J?^!>A?\ RWH_M34O^A;U3_P+
MT+_Y;UN44 8?]J:E_P!"WJG_ (%Z%_\ +>C^U-2_Z%O5/_ O0O\ Y;UN44 8
M?]J:E_T+>J?^!>A?_+>C^U-2_P"A;U3_ ,"]"_\ EO6Y10!A_P!J:E_T+>J?
M^!>A?_+>C^U-2_Z%O5/_  +T+_Y;UMY'U^G/\NGXUYYXC^+?PS\)SM::_P".
M/#5AJ*OY?]D#5+>\UMW )*1:'I[7>KS. /NQ63MD@8R0" =1_:FI?]"WJG_@
M7H7_ ,MZR]3\7Q:*=.75M-N--;6-4M=%TH7FI>'X#J&KWJS/9Z9:;]7_ 'U[
M<I;SM! OS.(9"/NUPQ^,%YJH=?!'PN^)?BO<@:WU"]T*'P%H<@8X60W_ ,0+
MSP]?20D?-YMCH]^2G*QL2%/Y4_M??'WQEXK^(6E>%IH]+\)R_"K5EOHK;0/$
MK^(!!XS"VERMY=:F=+T6-M2\/*B6'V:VM9K>SNY-2B6\N&>3RP#]H_[4U(_\
MRWJG_@7H7_RWH_M34O\ H6]4_P# O0O_ );UP'P-^*-A\8OACX8\<V;0K=:A
M9_9==LX75AIOB/3R+76K$A68HBW:M<6H8[I+&YM9ONR UZW0!A_VIJ7_ $+>
MJ?\ @7H7_P MZ/[4U+_H6]4_\"]"_P#EO6Y10!A_VIJ7_0MZI_X%Z%_\MZO6
M5U<W/F?:--NM/V;-GVF:PE\W=NW;/L5Y=;=F!N\S9G>-F[#8O44 %%%% !11
M10 4444 %9.OJ6T36%6V:\8Z7J(6U2T:_>Y)LIP+=+);S3VNVG)\I;5;ZS:X
M+B$7=L7\^/6I&Y5A['OCMZ]OK0!^%OACX&ZCX1^*?@""?X#>%$6Q\3?#G5!K
M^E_L:>)?#]M9K=S>'M9>6UUO5_\ @HAJ]QH]WX>>Z>PU#4I/!_B2'0]:TN^\
MO1_$L5@MOJ'[I#^I_F?<_P#U^N!TK\<I='\(6G[7WQ@N_$GA;X):?KVJ_'SP
M%J.E7WQ#_8X^-OQ\\?ZU!'X+^&FG:=X@\-_M%6VH:%X+\%P276G/IGAOPS96
M&M:1\'[[16UC4-7O8]:?2M*_8T?U/;'<_P"2>YYH 6BBB@ HHHH **** /P[
M\?\ _*Q!^SA_VB;_ &DO_6I/A#7[B5^'?C__ )6(/V</^T3?[27_ *U)\(:_
M<2@ HHHH ***S-3UG2=%CBFU;4K+38II#%%+?7,5K&\@4NRK),R+E45G;GY4
M5G/RJ2(J5:=&$JE:I"E3@KRJ5)QA"*;23E.344FVEJUJTNH&G17SC\*?VF_A
MW\43XX\C5=/T4>#_ !-?Z5"VHW\4(UCP_%O_ +,\4VQG$(%CJ7V>]^13(;46
MZ&=P+B+=TG_"]_!^H@#P;I7C;XB.6*J_@KP=K-]I;\X5E\3:K!HWA,I(<[)/
M[=,94%]P0;J4:M*<ZE.%2G*I2Y/:TXSC*=/VD>>'M(IN4.>/O0YDN:.JN@/:
MJ,@=3BO%3XD^-VN;ET7X<>&/!L!==E]X_P#&(U/4!$1DL?#?@:SU.U=QD?NY
M/&%L<Y#%<#(?A]\2M<W?\)7\9-6LH)@3)IGPV\,Z)X.MD)S^[&JZV/&7B,HH
M)42VVJ6,S??RC;=N@'L-W>6EA;RW=]<V]G:P+OFN;J:.VMXD'5Y9YF2*-1GE
MG<#WKRF\^/'PK@NI-/TWQ1'XMU- _P#Q*_ 6G:MX]O\ S$',4D/A"QUE+9\_
M*?M<MNBM\KNI!PVU^ WPO2YCO]8\.OXSU*/8?[1^(.KZSX]NMZ#"R1CQ9?ZK
M:VSCJHM+6W1&Y1%P,>K65A8Z;;166G6=K86<"[8+2RMX;2VA4=%BM[=(XD48
M^ZJ 4 >0#XB_$36MG_")_!G7X8)/E74_B+X@T+P/9*6SB4Z=82>+?%&Q!M8I
M/H5G*QRF$8$@_P"$?^.6N!3J_P 0/"'@F .Y:T\"^$9==U((W"K_ ,)%XVO9
M[!V0<[T\&PY;!V@#!]JP!T %% 'BW_"B_"VHAO\ A,]=\>?$,LRNT/B_QEJ[
MZ2S#!8-X8\/R:!X5='(^:.319$( 7&WBO0_#O@OPAX1A-OX5\+^'O#<+ AX]
M"T;3M*63.,F0V5M"TC,0"S2,S,>6)-=-10 F!Z=/7D_F>:X.X^%7PON[B>[N
M_AOX"NKJZFEN;FYN?!_AZ>XN;BXD::>XN)I=.>6:>>5WEFED9I))'9W9F8D]
M[10!B:'X:\.>&+:6R\-:!HOAZSGG-U/::'I5CI-K-=-''"US+;V$%O%).T44
M433,AD,<<:%BJ*!MT44 %%%% !1110 4444 %%%% !1110 4A. 3Z GMV^N!
M^9 I:JWML;RSNK1;FYLFN;:>W6[LW2*[M6GB>);BUDEBFCCN8"XE@>2&5%F1
M&>.1048 ^$[K]KS4[OX]>-_A%IVI_LQ>$XO /Q%\)^ K_1OBI^T?%X7^,GB&
M+Q#H7A77T\1>'?A=I'@[7HUL-<3Q'<:7X"L]1\1PWGBG4=%NUNET-I&M;7[V
MKXNOO@WX)7XB^"=1O_VH/B;'XAUN^TV7POX.O/'WPF6+QM=?#RRTJV\01V.E
M7/P\/B#7Y+DZ,]_XX&BZA]H@O+_4YU?18WMXK/[1'Y__ %_\\4 8'BGQ7X7\
M#>']5\6^-/$>A>$?"V@VDFH:YXE\3:MI^@Z!HUA$5$M]JNL:K<6FG:=9QEE#
MW-Y<PPJS*I?<R@[^1Z^WXYQC\^/K7YW?\%1/"NC>-_V0_B5X4NO@WX^^-_BS
M6_#_ (KT[X6>%O 7P^UWXDW.E_%"^\$>)K'PGXHU+0]*633M.@T>>ZG_ +,\
M3^((AI_AS7KC3-2L[FQUF+3;R'I/BM\7OBE\:OAO?_#3]G'PCXY^'OQ<^)7P
MOU'QAX?\2_&GP]XO^#NC^#/#5A\4/#_P^\9Z9K.LP^&O%_C#P%\7-1\*ZGXA
MUWX3QWGP]UBR>YL[3Q9=1W&F:5<6-P ?2.I?'_X%Z/X+U;XD:M\9?A9IGP^T
M'Q1K/@C6_'-_\0/"EIX1T?QGX=UZ\\+:]X2U/Q'/JT>D6/B;1?$VGW_A[5M!
MN+M-5T_6[*[TNZM(KVVF@2UXA^.'P9\(CP(WBKXL_#7PVOQ1DM(?AJVO>.O"
MVD)\09;]+&2QC\$O?ZK;IXI:]34],:T.AM?)<_VEIPA9VO[,3_C3\ ?@M^T)
M\#;WP'\1OB1^SG;Z5\/?@I^V7^V3K>E_"3X':YX@^+6L:7X)^,6BWFA?#KXP
M>&="UOP-\-=6\30>%9QKW@VT?1-(U7Q3K/@[XFZCXZGTO3[F/Q!IEM@Z/^SK
M\7_AS\,_C5X5\4?LU>*?&_\ PT_^ROXV^#_P;\%>'+#PEKMG\!+[Q9\>?VKO
MB-X;^!OQ U6'6(M)^'WA/1_"OQX^$L]YXZLKR^\':-=?"?6- AUNXN/"_P -
M[/6P#^@8'/3_ #_GO17)> M&U[P[X'\':!XHUZ7Q1XDT/PKX=T?Q!XEG!$WB
M'6]+T:QL-6UR4,%82:OJ-O<ZBX958-<D,JG("^,[3QS>:,8?A[KWA/PYXA^U
MVKKJ7C/PEK'C31A8JS&\@.BZ'XU\ WS7<Z%%M;L:^L-JP9I;*\#!$ /QG\?_
M /*Q!^SA_P!HF_VDO_6I/A#7[B5_/[J.G_%&S_X.#_V>H_'GBSP#XAU=_P#@
ME'^TB]E=^$?AYXB\':;;V@_:?^$BM;W6G:S\3O'5U>W+7'E3+=Q:I81)")+<
MV3NRW2_O/Y/B/_H):)_X)+__ .:"@#;HK$\GQ'_T$M$_\$E__P#-!1Y/B/\
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M.6VG)ESVMKKE[>MM=;:[;W13_M3Q*O#^%58^L.O63ICTS-!;ON'<>7CIACR
M?VMXC_Z%-S_W&]-_K5SR?$?_ $$M$_\ !)?_ /S04GD^(^G]IZ'GT_L2^_\
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MIRN0#@^H]#]*6B@ HHHH _#OQ_\ \K$'[.'_ &B;_:2_]:D^$-?N)7X=^/\
M_E8@_9P_[1-_M)?^M2?"&OW$H **** "OD_]IC]IC2O@OI3:%H36NJ_$?5K0
MR:;ITA$MIH-I,'2/7=<1&!\O<K_V9II9)M4FC8DQ6,-Q./K"OF?]HS]G/0?C
MAH7VJV^S:/X^TBVD&@>(&CQ'<QC=)_8FN>4IDN-)N)"3%,%DN=)N'-W:!XWN
M[2[]WAJ631SG!//HU)9:JB]JH7<%.Z]D\1&/ORPRG9UXT_?=.]E+6,OE^,X\
M1SX<S*/"DZ,,Y=']PZFE1T[_ +Z.$DVJ<,;*GS+"SK7I1JVYN6ZJ0_.GX!?M
M8^+?AUXLO?\ A.=4U;Q9X0\5:J]]XB^V3/>ZKI.IWKJ)_$&CAB!MSM_M'1(!
M%:SVT:-IT5O=0)'<?J79_''PAK=C;ZCX1TWQQXUL;M#):7WAGP'XIN=,ND#O
M'OMM9U'3M+T69!)'+$SIJ!1)8I(G99$91^8WP(_9 \7^-?&&H+\2-)U+PKX2
M\)ZH]AK<,^ZWO_$.H6I5WTC1+A#M?3'1HY+WQ#:.]NUK*D.E327<SSV'[%Z3
MI.F:%IECHVCV-KINE:9:PV6GZ?90I!:6EI;H(X;>"&,!(XXT4!5 ]68EB2?M
M_$2KPHLRH2R^BL1C_9P^N_4*]&CE_L^2#P_M/9T:BJXAT^6_L)THJERJI*51
MVC^8^#]#CUY-B89MB'A,I5>:R[^U<+7Q&;^U]HUBO9*M7HRI815%/E^MTZ\Y
M5W4=*$*2O/S=_'?CN\"G1O@[XF57QB;Q1XC\%^'H!DG!:.PUKQ+J* ##,&T_
MS%&X>6655<>Y^-]\5,.E?##PW&^"3=:UXJ\77$8P.&@M-'\(P,V<YV7NWYAA
MFV9D]9HK\[^NT8V]GEN!A)7M.7URM+IO&OBZE%M6ZT;?W;-W_8/[-Q,_XV<Y
MG4B[.5.*R_#QTMI&IA<!1Q,5OM7NM[W1Y,WA/XIWL@?4/BO:Z=&QR\/A/P!H
M]@5&3Q'<>*-2\8/G!^\T+'Y4XX?S'#X4K<OOUKXB?%/6PW^LC;QC+X=@<D $
M>3X*LO# 5..$5@!DYR22?5Z*/[3QB_ARH4'MS8;!X/"U/_!F'P].I\^:_6]P
M_L3+W_%CBL2F[N&,S',<;2;\Z.+Q5:E9]N2UG;9*WE4/P1^%:2^==>#M.UJ;
M.3-XGGU'Q9,3SRTOB:]U9V.23R3CMR!7<Z3X8\-Z"H30_#^B:,BC"II6DZ?I
MR*/EX5;.WA 'RKQ_LKZ#&Y16-7'8W$+EKXS%5H[<M6O5J+[IS:.C#Y7EN%ES
MX7+\%AI_S4,+0HR_\"IPB^G?OW88QZ_B2?YT8 Z#%%%<IW67;^OZ2"O,OB#\
M'OAY\49_#]SXW\.6NM3^&M034--ED9XG*A@\VG7C0E6OM'NY%BDO-*N3)97,
MD,321$J=WIM%;X;$XC!UHXC"5ZV&KP4E"M0J3I58J<7":C.#C)*4)2C*SUBV
MGHV<V,P6#S##SPF/PN'QF%J.#J8?%4:=>C-TYQJ4W*E4C*$G"I",XW3M**DM
M4AD<<<,:11(D<4:+'''&JHB(BA41$4!41% 554!54!5   I]%%8;[G2DDK)6
M2T26R78**** "BBB@ HHHH **** "BBB@ HHHH **** "BBN2\=^(-<\*^$M
M;\0>&O WB'XE:YIEJL^G>!O"NH^$-)\0>(YVN(839:9J/CSQ)X0\(VLZ12R7
M32:WXCTJV,-O*D<[W3P6\P!UM%?!OAG]NNQ\2>'M-F7]G[XUVGQ#\3?%_P ?
M?!KP'\(UU+X(:KXH\?ZU\*M$FUGXE>)?#OBK2/C#=_"BV\#^!Y]/UWPSK_B/
MQ%\0=$2+QIH%]X2L[6]UJ]T*UU>G=_\ !1;X.?\ "/IXOT#P9\7?%OA'PY\/
M=-^*7QMU_1/"FCP#]G/P7?>*?&7@J^O/BYHNO>*-&\2#6?#'B/X<?$>#QAX4
M^'NC^/O$OAK2_ 7B/Q!J&FC1?[$N]; /OZBF1R1S(DL3K)'(H>.1&#(Z, 5=
M&4E61U(9&4E64AE)!!I] 'X=^/\ _E8@_9P_[1-_M)?^M2?"&OW$K\._'_\
MRL0?LX?]HF_VDO\ UJ3X0U^XE !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>);?6[
MOP]KMKX:OK/3/$5QH^J0:#J.H6[WECI^M2V-PFDWUY:QD27-K9ZBUM<W$$;*
M\T,3QH0S UMT4 ?G_%^R1XU^'_PY_9"?X0^)?!T?Q=_9,\&3^#+>3QG8ZY_P
M@/Q-TGQCX"TOPM\4X/$4F@%?$>CZKXF\4Z-HWQ&L?%5O::Q>Q:_I4MIJFD7U
MMKVH7%KXE%_P3S^*/A;PC\4_ W@CXK^!I-/_ &LOAYJ_@K]JWQ#X@\&>((M7
M7Q)XP\7?%[Q/\0?B9\&])T[Q'<Z3I^H^)-)^-WB[P7I7A#QA<W6F>'+;0O /
MB:77M>OM%\1Z-XN_6VB@"AI6F66BZ9I^CZ; MKIVE6-IIMA;(SLEO96-O':6
MD"M*[R,L-M#%$&=V=@FYB6)-8?C+P;I'CK1CH6M7GBFQLFNK:\,_@_QQXT^'
MVL>=:,S1(/$/@/7_  WKRVKEB+FQ74A97BA4N[>=$51U=% '\_VH_#CP_P""
MO^#@_P#9ZTO1]1\>7EM>?\$I/VD;J:7Q9\4?B9X\U!)5_:>^$D 2UU;QQXM\
M0ZI8VVR1F:RL;RWLWG"7+P-<HDH_>?\ L&R_Y^-:_P#"BU__ .6=?BKX_P#^
M5B#]G#_M$W^TE_ZU)\(:_<2@#%_L&R_Y^-:_\*+7_P#Y9T?V#9?\_&M?^%%K
M_P#\LZVJ* ,7^P;+_GXUK_PHM?\ _EG1_8-E_P _&M?^%%K_ /\ +.MJB@#%
M_L&R_P"?C6O_  HM?_\ EG1_8-E_S\:U_P"%%K__ ,LZVJ* ,7^P;+_GXUK_
M ,*+7_\ Y9T?V#9?\_&M?^%%K_\ \LZVJ* ,7^P;+_GXUK_PHM?_ /EG1_8-
ME_S\:U_X46O_ /RSK:HH Q?[!LO^?C6O_"BU_P#^6=']@V7_ #\:U_X46O\
M_P LZVJ* ,7^P;+_ )^-:_\ "BU__P"6=']@V7_/QK7_ (46O_\ RSK:HH Q
M?[!LO^?C6O\ PHM?_P#EG1_8-E_S\:U_X46O_P#RSK:HH Q?[!LO^?C6O_"B
MU_\ ^6=']@V7_/QK7_A1:_\ _+.MJB@#%_L&R_Y^-:_\*+7_ /Y9T?V#9?\
M/QK7_A1:_P#_ "SK:HH Q?[!LO\ GXUK_P *+7__ )9U=L[""Q\SR9+V3S=N
M[[9J.H:AC9NQY?VZYN/*SN.[RMF_"[]VU<7:* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _#OQ_\ \K$'[.'_ &B;_:2_]:D^$-?N)7X=^/\
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M%K8FS\(^&M'\;6>K7L NY8S?7$,^MZ>L=A;"2ZG$KM%&PB<J ?GS_P 1#_\
MP1Y_Z._B_P##"_M0?_.2H_XB'_\ @CU_T=_%_P"&%_:@_P#G)5^TT:;413G*
MHH/S$\@ 'G//UIV![_F?\: /Q7_XB'_^"/7_ $=_%_X87]J#_P"<E1_Q$/\
M_!'K_H[^+_PPO[4'_P Y*OVHP/?\S_C1@>_YG_&@#\5_^(A__@CU_P!'?Q?^
M&%_:@_\ G)5]I?L@?\%$_P!CK]O1_'\?[*'QA3XK/\+AX9/CH+X!^*/@C^PQ
MXQ_MS_A'"3\2/!'@X:E_:/\ PCFLX_L<ZA]D^QG[=]E^T6OG_:V![_F?\:7&
M/7\23_.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH .G6DW+C=D8]<C'/3GIS7CWQZCU%_A;XDELOC#%\!;*R_LO4_$_Q4-CX=N[
MSPOX+TO5['4/&3:3=>+A/X8T'6-5\-VVHZ)IGBK6]+UZS\+76HIKJ:!K%Y8V
MMF_YJ^ _$_[0?CKQA\)?@;XE^,_QG^'7PN^+7BG]I[QM\)_B7K^B>%?"7[3'
MC#X4_"#0_@7:?#+PGXG;Q#X"^Q^'M3\3>)/'OQ7^)6FPZ]X#TKXE:S\(?A[X
M,LO'EI!JUQ\0+:] /V,R/7KT]Z3(SC(SC.,\X]<=<5^1GP<^.O[2/Q%O_P#@
MG!XY\1?$O38_!?Q:U+XP^ ?'_ACP]X&TG3?^%P:UX)^%G[0-_I'Q>U+Q+/<7
MZ:;X0\6P_#;P/\0/ GA+P9I'A:VMI_$VK76L:OK^DOX>T30^"^&G[17[0$_[
M5N@:YXKU_P")LG[/OQ%_:M^-WP0\&?$^6Y^%][^SKXQ\/^&;+Q[HO@#X3>%O
MA7INEVOQ^\#?%'2/B!X1UWPUJWQ>\9;/ /B?6_AIXMOK?Q+JWAOXB_#?PU9
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MTVJ:I&)XQJ6KSS:O??:-3EDNV]WHH ^3O#O["?['?A/P5K_PY\/?LW?"'2_
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M_P#V4;?QZFOW7Q"^,VH^ DU+[;_PK.ZU;PXEI-8@^8N@77C"WT*+Q7-I!?\
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MO/A#^V?\4?B]\7/A]\,O%7A74/AEXG\%_M.Z1X#^(-A#H7BGPUIOCGP3X_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBF^8F[;O3=G&W<-V?3&<YH
M=111_7I0 4444 %%%% !110"#R"".>1ST.#^1X/O0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C-M5F()"@L0H)8
MX&< #DD]@.2>!7SZ?VCO"X)'_"!_&\X)&1\%?B$0<'&0?[&Y'H1P1R*^@Z3
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M[42:3=:C\*(_@3_PRCX>\;:MX?T'3/B)#XKT?XWV'QX^,WP@\<V<%[X_\'>
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M4;_:3\.)\/-!\1?LZZUXF\;W'PET'X^_$;3?#WP_^)=K:S>$OB1\:?B7\/?
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MQS^(M2NKB]U62ZN)I)&4?#;X>KXE_P"$S7P/X2'B[^WI?%/_  DX\/:4-?\
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>fvonremeasurementofcc.jpg
<TEXT>
begin 644 fvonremeasurementofcc.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M;_V:M97X./!\1XKSP1JOA?0O@YX;\8^(M&T!_'&JZ1XA^+OAY9VMO"6FV_\
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M)+JX\RXD"@/(P H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M .!$7_Q=5/["T7_H$Z9_X+[/_P",4?V%HO\ T"=,_P#!?9__ !B@"W]NLO\
MG\M?_ B+_P"+H^W67_/Y:_\ @1%_\753^PM%_P"@3IG_ (+[/_XQ1_86B_\
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ME]YNVUU"V\K9G[=936F_?NQY?FJ/,V[?GV_=RN?O"@#0HHHH **** "BBB@
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M_A/1\O[WK^'F!\#?\(IXI_Z%K7__  3ZC_\ (U'_  BGBG_H6M?_ /!/J/\
M\C5]\T4?\0DP/_0XQ?\ X3T?+^]Z_AY@? W_  BGBG_H6M?_ /!/J/\ \C4?
M\(IXI_Z%K7__  3ZC_\ (U??-%'_ !"3 _\ 0XQ?_A/1\O[WK^'F!\#?\(IX
MI_Z%K7__  3ZC_\ (U'_  BGBG_H6M?_ /!/J/\ \C5]\T4?\0DP/_0XQ?\
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M1H7_ (,[3_X[7PA17@?\1:S7_H5X#_P9B/+^]Y/[_(>GG]__  /7^EK]W_\
M"<>#O^AHT+_P9VG_ ,=H_P"$X\'?]#1H7_@SM/\ X[7PA11_Q%K-?^A7@/\
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MW^I\*_\ 7;6/_1>G5\WU](?'[_4^%?\ KMK'_HO3J^;Z_F3Q$_Y+#-O3 ?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>incometaxprovision.jpg
<TEXT>
begin 644 incometaxprovision.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M;_V:M97X./!\1XKSP1JOA?0O@YX;\8^(M&T!_'&JZ1XA^+OAY9VMO"6FV_\
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M)+JX\RXD"@/(P H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(2=MKRBF[7N[7>FK$%%%%6 4444 %%%% !1110 4444 %%%% !1110 4444
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M_(LS5=/[0A_ZBT0*EE8VFGPF"SA6"$NTA12[#>P 9LNS')"COCC@5;HHK]:
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MW@B!+P>"O$-GJNN:[=-=>)WT^P_;0?AU/3ZG]?7WH _$'_@I/_RDD_X(4_\
M9UO[4'_K'/Q!K]O(_P#5Q_[B_P#H(K\0_P#@I/\ \I)/^"%/_9UO[4'_ *QS
M\0:_;N,CRX^1]Q>X_NB@#X4\<?\ (Y>*?^P[J7_I2]<M74^./^1R\4_]AW4O
M_2EZY:OX_P V_P"1KF?_ &,,;_ZDU0"BBBO/ **** "BBB@ HHHH *1ONO\
M[C_^@&EI&^Z_^X__ * :4MGZ/\AQW7JOS/T,TW_D'6'_ %Y6O_HB.KM4=-(_
MLZPY'_'E:]_^F$=7<CU'YBO[,H?P*/\ UZI_^D1$4]2_Y!U__P!>5U_Z(DK\
M\U^ZG^XG_H K]"]2(_LZ_P"1_P >5UW'_/"2OST7[J?[B?\ H K\6\7?]XR'
M_KSF7_I>"'T?JORD+1117XZ(**** "BBB@ HHHH **** .J\#?\ (Y^%_P#L
M.:?_ .CUK[NKX1\#?\CGX7_[#FG_ /H]:^[<CU'YBOW;PE_Y%F:_]C"'_J+1
M 6BC(/0YHK]: **** "BBB@ H)P"?09HJM>QW$MG=1VLK07,EM.EO,C0J\4[
MQ.L,BM<6M[ K1R%75IK.ZB!4&2VN$#0N ?#LW[6FK7WQT\<?";2C^SEX;A\
M?$3PMX#U+3OBG^TFOA#XNZY%X@T'PMKZ>(_#GPIT?X?^)XWTS68O$5QIW@.W
MU3Q78WGB[4=%O5N(]"5]D/W77Y1Q>$_BC8^/-)N_$-U^V5XM\7V6M:1JMS8W
M/P#_ &!]1T#Q"VFW-G</%<?%W2OA;H>E66G7PMEM6U0^*_"?BBULV^TV=GHN
MI011VOZFZ5/?76F:?<ZG8II>I7%E;3W^FQWB:A'I]Y-"DES9)?Q0V\=ZMK,S
MP"ZC@B2X\OS415<4 ?B7_P %+(Q+_P %(?\ @A4A>1 ?VK_VG&+12-$_[O\
M8]\?R;=Z$,%?;LD (+1LRY&:_:&/P_'Y:?\ $VU_[B_\Q>Y]![U^,7_!2?\
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MUX!/' )P*_/I+?XK_$3XY06GQ)_99^(?ACX)_"'Q3\5=3^#6C:#J_P"SS>^
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MOIFJ^*=;T"[MM,T>3P]H?]@^#M1U?Q!?:=I3>>>"_P!FKXM:%XPMOAWKMO\
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MN/\ @DA\8;J>:YG_ ."PW_!4=YIY&EE?_A*_V44W2.<LVU/V6E1<G^%551V
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M+$Y\5_LHN%D0Y5BC_LLLC8/\+JRGH0170?\ #KKX_P#_ $F4_P""HO\ X/\
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M"GPS\2_!.N_$GP=#-/XG\$:5XCTN]\2Z)':R6<-^+_2K>Y>YBDTN;4=,AUB
M*\^C3:II<6JQV4FI6"W !ZG17D.J_'[X):'\1X?@_K'Q6\ :;\4;C2;C7(/
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MPYXG$&EZTK>*;GQQXS\$ZE:ZY/H7BS4K[Q0FI>&^#T#_ ()[?$O2O@S-\/\
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(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>interferon.jpg
<TEXT>
begin 644 interferon.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M;_V:M97X./!\1XKSP1JOA?0O@YX;\8^(M&T!_'&JZ1XA^+OAY9VMO"6FV_\
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M)+JX\RXD"@/(P H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.?L=>(OB;\8/A#8>%_%W[1:_$KQEHG[1_B'XN:_XR^(_@WX=?LW?$WX>^ ?
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M>*M.\!>*;R_UCPI-J=_]]4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=K'@;Q#X \2:/\"_ OCZTUV]L+V:\7Q)92_%"ZTS3/"OBOQ9K%G\-K35Y8?
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M(/\ GA!_WYB_^(KZC_B7_ ?]%-B__#72_P#F[^KORM\Y_P 1RQW_ $3N%_\
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M%_\ RWR7W'VO_P /!?VF/^A@\)?^$5IW_P DT?\ #P7]IC_H8/"7_A%:=_\
M)-?%'7ISGICG/N,=1[BEP3T!/X4?ZC<&_P#1,9%T_P"97@_+_ISY+^K6/]<N
M+/\ HI,[_P##EB__ );Y+[C[6_X>"_M,?]#!X2_\(K3O_DFC_AX+^TQ_T,'A
M+_PBM._^2:^*<'&<''KVHP3T!-'^HW!O_1,9%T_YE>#\O^G/DOZM8_URXL_Z
M*3.__#EB_P#Y;Y+[C[6_X>"_M,?]#!X2_P#"*T[_ .2:/^'@O[3'_0P>$O\
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M /7O_ &'_P"3*/[=D_Z >O?^ ,/_ ,F5_&!_7!^7O_!4?_CQ^"7_ %_>/_\
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MSX;ABU:TUK1M/MM+.EV8O])M-1@U[Q'J-XNKZALL6RI]?\.#XR>(O&MAXO\
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M,CU'YBC(]1^8K\:_^&C?CA_T4G7_ /OUH_\ \JZ/^&C?CA_T4G7_ /OUH_\
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M0?\ K'/Q!K]NE_U4?TB_FE?B+_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?MTO\
MJH_I%_-*<=UZK\P/\Y']HW_DX?X__P#9<_C%_P"K)\3UXU7LO[1O_)P_Q_\
M^RY_&+_U9/B>O&J_UWRG_D599_V+\%_ZC4C_ "FS7_D9YA_V&XK_ -/3"BBB
MO0. **** "BBB@ HHHH *_8O_@A;_P GZ6/_ &13XJ?^E?@ROQTK]B_^"%O_
M "?I8_\ 9%/BI_Z5^#*^!\4_^3<\:_\ 9.YE_P"H\C[KPR_Y.#P?_P!E!EG_
M *E4S^TVBBBO\M3_ $N/YH_^#B__ )!'[(G_ &&/C;_Z;/AI7\P=?T^?\'%_
M_((_9$_[#'QM_P#39\-*_F#K_2/Z/_\ R:;A?_'GO_K19L?YZ>.O_)T>)?3)
MO_6>RD****_93\B"BBB@ HHHH **** "JU[_ ,>5]_UY7G_I-+5FJU[_ ,>5
M]_UY7G_I-+3CNO5?F*6S]'^1_I&? K_DBGP@_P"R7?#W_P!0_1J]5KRKX%?\
MD4^$'_9+OA[_ .H?HU>JU_D)F?\ R,L?_P!AF)_]/3/]7<N_Y%^!_P"P/"_^
MF(!1117"=@4444 %%%% !2$X!/7 )QZX^O%+56^CGFL[N&VE>&XEMIXX)HY(
MX9(II(72*5)9;6^CB>.1E=9'L[M$90S6UPH,+@'P!>_M?:K=?M">./A!;>,?
MV4_ 47@'XC^$/ D_A?XJ?',Z3\9?%EIXBT+PIKT7B+P[X%TJUDLK>+Q"WB*\
MT3P1I-S?WM]JVI:+*=4.F75U)I%C^A(_#J>GL?Y^OO7YE:;X=^/F@:_I%MJ6
MJ_M]^*=<TR]M+^:U;5OV#+_X8:\^GW4,LUO?>-U^'_A+Q!%X<U7R!;W\W]D>
M&O&1TZ6:2PT6TOTMUC_2?3)=0GTZPFU:TMK#5);.VEU&QLKU]2L[*^DA1[NT
MM=1DL].DO[>VG,D,-Y)I]B]U&BS-:6Y<Q( ?B=_P4G_Y22?\$*?^SK?VH/\
MUCGX@U^W2_ZJ/Z1?S2OQ%_X*3_\ *23_ ((4_P#9UO[4'_K'/Q!K]N5(\J/K
MTB['U3VIQW7JOS _SDOVC?\ DX?X_P#_ &7/XQ?^K)\3UXU7LO[1O_)P_P ?
M_P#LN?QB_P#5D^)Z\:K_ %WRG_D599_V+\%_ZC4C_*;-?^1GF'_8;BO_ $],
M*.O2BO6/@9I6B:U\6/!NG^)?!OB'X@^'VN]5N]9\(>%M(O?$.N:M8:;X<UK4
MI)+;PYIFK:!JGB6TT>6TAU_6?#6E:YHVI^(M"TG4]%T_5+&[OHKA.G%8B.%P
MV)Q4XSG##4*V(E"GR\\XT:<JDH0YY0ASR46H\\X0YFN:<8WDN;#4)8K$X?#0
ME&$\37HX>,Y\W)"5:I&E&4^2,Y\D7).7)"<N5/EC)V3\G W8*_,",@K\P([$
M$9!![$<4N"<X!XZ\'CZ^E?JW^T'X&T+X<?M!^+/%-Q\,O@MI?PP\46MLR?$R
MU_9[^+/Q!\&> 4C\=^+-"?4-;_9[U#4=/M-*\8^,[SPKJ'@VSO+1;KP3J^FZ
M--XD^',XUC5=4OK;&O/!'@#X??&7XSZ+XG_9_P#AMX=_9Y\"?&'Q?_PL?QOX
MPBUSQ9KLW@S7/#VGZK\._@K\$-0O+JPUK0/B:VGW9UK0=)\+_:O&.C:EK<%U
M\5=4TKPEX'OH[SX^CQMAL1AZ&(I9?BIO$9>L?3IJI04Y.$L+3KX."J3INICU
MB,90P=# TXRQTL75HPQ>%P-+$X6M7^LK<'8BA7K4*F/PT/88_P"HU*CIUW&,
M9K$5*.+FZ<*BI8%T,+7Q=?&U''!1PM.K/"XC&5</B:-'\O=K8SM./7!QSTYH
M )!(!('4@' ^M?55[K,&F?LJ:1>:_P" ?A7+KWQ,\7W7@3X?:]9?#'PCIGC3
M0_"GPCA\/:AX^\87/C33+"WU[6O%'B?Q+XD\.>!H-0N[F2)M-T_QK<RPRWM_
M8267J/[(_@O0=<\1>&/AW\3OA+X:6T^(7BSQ3X<T?4_&WP@^('B'Q+\4O$5O
MI T=/A5X9^(EM=6^E_ &[\&Z_-INHZGXX@TK^T-&O?$$6J^,!=Z!I$-@?3Q7
M$,<'@,?F%;"3E3P.)Q=!0P]6%:>)IX"#EBZN'BXTYR="I2Q.&J0]G:E6PU6I
M6G3P,*F-AYN&R&6+Q^!P%+%0C/&X?"5G.O2G2AAZF.E!86E6DG.$?;TZN'Q%
M.?/>I1Q%*G2A4QLZ>#G\!T4@22("*8@S1#RIBKI(IFB_=S%9(R8Y%\U7VR1$
MQ2+AXR8V4E:^D6JO^6J/G_P\GNO4*_8O_@A;_P GZ6/_ &13XJ?^E?@ROQTK
M]B_^"%O_ "?G8_\ 9%/BI_Z5^#*^!\4_^3<\:_\ 9.YE_P"H\C[KPR_Y.#P?
M_P!E!EG_ *E4S^TVBDR/?\C_ (49'O\ D?\ "O\ +4_TN/YI/^#B_P#Y!'[(
MG_88^-O_ *;/AI7\P=?T^?\ !Q<<Z1^R+U_Y#'QMZ@C_ )AGPU]:_F#K_2/Z
M/_\ R:;A?_'GO_K19L?YZ>.O_)T>)?3)O_6?RD* ,D#U.**/U_S[5^RGY$?5
MFM?LOMX=_9X\"_'/7OB3H6B7OQ#UBS3PYX6U3PUXUBT.^\/7\-IY4T'Q'M=
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MO\A,S_Y&6/\ ^PS$_P#IZ9_J[EW_ "+\#_V!X7_TQ ****X3L"BBB@ HHHH
M**** $P,YP,],XYQZ9I:** /P\_X*611S_\ !2'_ ((51RHLB']J_P#:<<HP
MRI:/]CWQ_(A(Z':Z*V#P2,$$9%?M%'X:T)%AD73;<.A@=3\YPRLC X+D'!&<
M$$'N*_&'_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OVZ7_51_2+^:4UJU?75 ?Y
MQ_[1*+'^T)\?(T4*D?QP^,$:*.BHGQ'\3*BC/.%4 #//'->.5[+^T;_R</\
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MO]=\I_Y%66?]B_!?^HU(_P ILT_Y&>8?]AN*_P#3TPHHHKT#@"BBB@ HHHH
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M?4GK2_\ $+K^P?\ ]'!_\%$?_$NM4_\ F)K^DO\ S^?6BC_6/B'_ *'V=?\
MAUQ_E_T_\D']@9%_T),H_P##;@O+_IQY(_FT_P"(77]@_P#Z.#_X*(_^)=:I
M_P#,31_Q"Z_L'_\ 1P?_  41_P#$NM4_^8FOZ2Z*/]8^(?\ H?9U_P"'7'^7
M_3_R0?V!D7_0DRC_ ,-N"\O^G'DC^;3_ (A=?V#_ /HX/_@HC_XEUJG_ ,Q-
M=KX!_P"#;[]E/X4^(!XL^%_[7O\ P4^^'7BE;&[TM?$?@G]MKQ/X:UQ=-OS
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M\Q-'_$+K^P?_ -'!_P#!1'_Q+K5/_F)K^DNBMO\ 6/B'_H?9U_X=<?Y?]/\
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MSM+>'05B@MK6WBB@@AC58XHHTC10J@#[<_9!_8IL/V07\?O9?M/?MI?M&?\
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MD>$=?\=^ [ZTM=;UF>QTW2I]0TS3=:OK2^O+5;D ^Q:*^,--_;H^"8^-UO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
J444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>lossonheldforsale.jpg
<TEXT>
begin 644 lossonheldforsale.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MLQ>%O!::7)XU\:ZIHW@#PYXFU31? O@V/6]&_P"$J\::O:67AO0I=8TFVO\
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MC '['GC\N&C2:!F+(&52)5V,0Y#A2C?M+';^(?+C_P")MI&-B\?V#=^@[_\
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MB+_H+:1_X(;O_P":"@#;HK$^S>(O^@MI'_@AN_\ YH*/LWB+_H+:1_X(;O\
M^:"@#;HK$^S>(O\ H+:1_P""&[_^:"C[-XB_Z"VD?^"&[_\ F@H VZ*Q/LWB
M+_H+:1_X(;O_ .:"C[-XB_Z"VD?^"&[_ /F@H VZ*Q/LWB+_ *"VD?\ @AN_
M_F@J[9QZC'YGV^[L[K.WROLMA-8[,;M^_P W4+_S-V5V[?*V;6SOW#: 7J**
M* "BBB@ HHHH **** "BBB@#\0/^"D__ "DD_P""%/\ V=;^U!_ZQS\0:_;R
M/_5Q_P"XO_H(K\0_^"D__*23_@A3_P!G6_M0?^L<_$&OV\C_ -7'_N+_ .@B
M@#X!\0?\A_7?^PSJG_I=<5D5K^(/^0_KO_89U3_TNN*R*_C?%_[WBO\ L(K?
M^G) %%%%<X!1110 4444 %%%% !7K?P5_P"1V3_L$:G_ .AV=>25ZW\%?^1V
M3_L$:G_Z'9U]#PG_ ,E-D7_8SPG_ *=B-;2]/U1]>T445_5X@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN6G\<>#+;Q!
M#X3N/%GAJ#Q3<(KV_AN;7M)B\03HZAD:'1)+Q=4E#J0RF.T8,I!4D$5U/^?3
M^= 'X@?\%)_^4DG_  0I_P"SK?VH/_6.?B#7[>1_ZN/_ '%_]!%?B'_P4G_Y
M22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$4 ? /B#_D/Z[_V&=4_]+KB
MLBM?Q!_R']=_[#.J?^EUQ617\;XO_>\5_P!A%;_TY( HHHKG **** "BBB@
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MK^-\7_O>*_["*W_IR0!1117. 4444 %%%% !1110 5ZW\%?^1V3_ +!&I_\
MH=G7DE>M_!7_ )'9/^P1J?\ Z'9U]#PG_P E-D7_ &,\)_Z=B-;2]/U1]>T4
M45_5X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M0]#CDX.!^'OQ^=+2'(!(Z@''U[=.?RH _,U?AA\:]%_:4^)_B&/PS^T>O@KQ
M;\7?!WBC1=0^$OQ$_9U\!_"2X\/P^&_!FDZI>>+/ VN>+'^(6N:J+_2-4;QW
MKTUDOB'QGI26%KI=A!'IFE6:_IF/\>OU_P X]J_.6\\?_'1OVBO'GA[Q-JO[
M4N@>$-,^)_A"P^'L/PI^ /PYUWX+Z_\ #^]T+PC+,WB+QYXM\!^*O'!U%?$D
MGBJT^(&M6>N>'M,TO2WL/^$02 V%UJLOZ-#\>IZ_7^7I[=: /P\_X*6R-%_P
M4@_X(5.D,D[#]J[]IT"*$Q"1MW['GC]209I(8P$!+OND4[%;:&;:I_::+5KO
M9&/^$=UO[B#._0P.@]=:Z5^+O_!2?_E))_P0I_[.M_:@_P#6.?B#7[>1_P"K
MC_W%_P#010!^?^NL7US6F*-&6U?4F,;[=Z%KV<E'V,Z;D)VML=TR#M9EP3E5
MK^(/^0_KO_89U3_TNN*R*_C?%_[WBO\ L(K?^G) %%%%<X!1110 4444 %%%
M% !7J?P>GDM_&*21VES>L-*U$>1:FV$I!:T)<&[N+6':NT!AYN\EEVJW./+*
M];^"O_([)_V"-3_]#LZ^AX3_ .2FR+_L9X3_ -.Q&NOI^J/J+^UKO_H7=;_[
M[T/_ .75']K7?_0NZW_WWH?_ ,NJVZ*_J\1B?VM=_P#0NZW_ -]Z'_\ +JC^
MUKO_ *%W6_\ OO0__EU6W10!B?VM=_\ 0NZW_P!]Z'_\NJ/[6N_^A=UO_OO0
M_P#Y=5MT4 8G]K7?_0NZW_WWH?\ \NJ/[6N_^A=UO_OO0_\ Y=5MT4 8G]K7
M?_0NZW_WWH?_ ,NJ/[6N_P#H7=;_ .^]#_\ EU6W10!B?VM=_P#0NZW_ -]Z
M'_\ +JC^UKO_ *%W6_\ OO0__EU6W10!B?VM=_\ 0NZW_P!]Z'_\NJ/[6N_^
MA=UO_OO0_P#Y=5MT4 8G]K7?_0NZW_WWH?\ \NJNV=W-=>9YNG7UALV[?MAL
M3YN[=GR_L=[>?<VC?YGE_>7;N^;;>HH **** "BBB@ HHHH *JWUI'?6=W92
MA&BN[:XMI%>-94:.XA>%P\3_ "2*5D(9&^5QE6X)JU10!^7FG?L,2>&?$^EW
M'AKX%?L<))HFLZ9J^B?$N33?BSIFN:1=Z5>6]]INH)\+[6]U'3;J^T^YMXKB
M)(?BYIMI+- NQ;2*3RH?TTTJ"^M=,T^WU2^34]3@LK:+4=2CLTT^._ODA1;N
M]CL(YKA+*.YG$DT=HMQ<"V1Q#]HGV>:]^B@#\0/^"D__ "DD_P""%/\ V=;^
MU!_ZQS\0:_;R/_5Q_P"XO_H(K\0_^"D__*23_@A3_P!G6_M0?^L<_$&OV\C_
M -7'_N+_ .@B@#X!\0?\A_7?^PSJG_I=<5D5K^(/^0_KO_89U3_TNN*R*_C?
M%_[WBO\ L(K?^G) %%%%<X!1110 4444 %%%% !7K?P5_P"1V3_L$:G_ .AV
M=>25ZW\%?^1V3_L$:G_Z'9U]#PG_ ,E-D7_8SPG_ *=B-;2]/U1]>T445_5X
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#\0/^"D__*23_@A3_P!G6_M0?^L<_$&OV\C_ -7'_N+_ .@BOQ#_ ."D
M_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(H ^ ?$'_(?UW_L,ZI_
MZ77%9%:_B#_D/Z[_ -AG5/\ TNN*R*_C?%_[WBO^PBM_Z<D 4445S@%%%% !
M1110 4444 %>M_!7_D=D_P"P1J?_ *'9UY)7K?P5_P"1V3_L$:G_ .AV=?0\
M)_\ )39%_P!C/"?^G8C6TO3]4?7M%%%?U>(**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$#_@I/\ \I)/^"%/_9UO
M[4'_ *QS\0:_;R/_ %<?^XO_ *"*_$/_ (*3_P#*23_@A3_V=;^U!_ZQS\0:
M_;R/_5Q_[B_^@B@#X!\0?\A_7?\ L,ZI_P"EUQ616OX@_P"0_KO_ &&=4_\
M2ZXK(K^-\7_O>*_["*W_ *<D 4445S@%%%% !1110 4444 %>M_!7_D=D_[!
M&I_^AV=>25ZW\%?^1V3_ +!&I_\ H=G7T/"?_)39%_V,\)_Z=B-;2]/U1]>T
M445_5X@HHHH **** "BBB@ HHR/7KT]Z* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH _$#_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\
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M<Z,8PBEJY2:2UN]&-=?-?JC^C"BOQ8_XB(/^"-O_ $>YX._\-M\>/_G44?\
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M\UI)/!#,]I<>7]HM7EC61K:?RI)8_.MV8PS>7(Z&2-BCLN"?Y[]<_P""Q/\
MP;T>)]6^'^M:S\=_@#J.I?">#3].^'DS? GXN!?!EAHMW;ZGHNC:/;6WP?BM
M+/2] U2VL=:T+1)+=].T+6+33];TJRLM3M;2]C]S_P"(B#_@C;_T>YX._P##
M;?'C_P"=10!^T]%?BQ_Q$0?\$;?^CW/!W_AMOCQ_\ZBC_B(@_P""-O\ T>YX
M._\ #;?'C_YU% '[3T5^+'_$1!_P1M_Z/<\'?^&V^/'_ ,ZBC_B(@_X(V_\
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M+4PW*:FD$=JC:1I<TFGK;#3KFYT^TN[JTFNH(Y@ =?XY\*_&2[\82>)?A_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>oie.jpg
<TEXT>
begin 644 oie.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M;_V:M97X./!\1XKSP1JOA?0O@YX;\8^(M&T!_'&JZ1XA^+OAY9VMO"6FV_\
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M)+JX\RXD"@/(P H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y9^.7[7'
MPW^ ?QB_98^!OBW2/&6J>-OVOOB#XV^&WPMD\.:=H]SH.GZ[X!^'&L_%#7;K
MQIJ.IZ]I5SI&DOX<T.[M["?2=.U^\N=7EM;62PM[5IKZ#Z&75=58*1X<N\,
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M4U;_ *%R[_\ !CI'_P FT?VIJW_0N7?_ (,=(_\ DVM^B@# _M35O^A<N_\
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M]7'_ +B_^@BOQ#_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^XO\ Z"*
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M^('_  4G_P"4DG_!"G_LZW]J#_UCGX@U^WD?^KC_ -Q?_017X@?\%*Y(XO\
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MZC^VM(_Z"FG?^!UI_P#'J -.BLS^VM(_Z"FG?^!UI_\ 'J/[:TC_ *"FG?\
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M?0\)_P#)39%_V,\)_P"G8C77T_5'UC_9VG_\^-G_ . T'_Q%']G:?_SXV?\
MX#0?_$5<HK^KQ%/^SM/_ .?&S_\  :#_ .(H_L[3_P#GQL__  &@_P#B*N44
M 4_[.T__ )\;/_P&@_\ B*/[.T__ )\;/_P&@_\ B*N44 4_[.T__GQL_P#P
M&@_^(H_L[3_^?&S_ / :#_XBKE% %/\ L[3_ /GQL_\ P&@_^(H_L[3_ /GQ
ML_\ P&@_^(JY10!3_L[3_P#GQL__  &@_P#B*/[.T_\ Y\;/_P !H/\ XBKE
M% %/^SM/_P"?&S_\!H/_ (BC^SM/_P"?&S_\!H/_ (BKE% %/^SM/_Y\;/\
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M_0R:K_X"Z#_\IZ -NBL3^R]1_P"ADU7_ ,!=!_\ E/1_9>H_]#)JO_@+H/\
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MH?CU/7Z_R]/;K0!^('_!2?\ Y22?\$*?^SK?VH/_ %CGX@U^WD?^KC_W%_\
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M]@C4_P#T.SKZ'A/_ )*;(O\ L9X3_P!.Q&MI>GZH^O:***_J\04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^'G_!2
MQW3_ (*0?\$*6CB,S?\ #5_[3@\M71"5;]CWQ^KL&D*K^[0M)M)!?;L4[F%?
MM!%J>L[(Q_PCLGW$_P"8KIWH/]NOQC_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;
MR/\ U<?^XO\ Z"* /S_UTLVMZRSIY;MJVI,\>X-Y;&]G+(67Y6*$E2R_*<9'
M!%95:_B#_D/Z[_V&=4_]+KBLBOXWQ?\ O>*_["*W_IR0!1117. 4444 %%%%
M !1110 5ZC\()KB#Q@DEK:->RC2M1'DK/%;DJ6M-S^9,0@"X48SD[N.AKRZO
M6_@K_P CLG_8(U/_ -#LZ^AX3_Y*;(O^QGA/_3L1KKZ?JCZ=_M/6?^A=D_\
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M(QN&HU8<\83AS4ZE2,X\T)QG&Z5XM26C5P].HKS'_A<'@+_H+7'_ (*M3_\
MD6C_ (7!X"_Z"UQ_X*M3_P#D6N?_ %HX;_Z'V3]/^9E@^MO^GW]Y?B.S[/\
MK_AU]YZ=17F/_"X/ 7_06N/_  5:G_\ (M'_  N#P%_T%KC_ ,%6I_\ R+1_
MK1PW_P!#[)^G_,RP?6W_ $^_O+\0L^S_ *_X=?>>G45YC_PN#P%_T%KC_P %
M6I__ "+1_P +@\!?]!:X_P#!5J?_ ,BT?ZT<-_\ 0^R?I_S,L'UM_P!/O[R_
M$+/L_P"O^'7WGIU%>8_\+@\!?]!:X_\ !5J?_P BT?\ "X/ 7_06N/\ P5:G
M_P#(M'^M'#?_ $/LGZ?\S+!];?\ 3[^\OQ"S[/\ K_AU]YZ=17F/_"X/ 7_0
M6N/_  5:G_\ (M!^,/@$ DZM<8 )/_$JU/H!D_\ +IZ?C1_K1PW_ -#[)_\
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M_B(6_P""/'_1Z/AG_P -9\?_ /YTE'_$0M_P1X_Z/1\,_P#AK/C_ /\ SI*
M/T8^/W^I\*_]=M8_]%Z=7S?7PK\7/^"]/_!)+Q5'H"Z/^V3X8G-C+J37&?A;
M^T'\HN$LQ%]SX02?>,+CG'3C->+?\/N?^"5W_1X/A;_PUW[0W_SG*_G7CW*,
MVQ7%6:5\+E>98FA46!Y*V'P.*KTI\F782$N6I2I2A+EG&496D[2BXO5-!;^K
MK^OZ\F?JG02 "3P ,D^@%?E9_P /N?\ @E=_T>#X6_\ #7?M#?\ SG*0_P#!
M;G_@E<01_P -@^%>01S\+?VAB/Q'_"G!D>HR,^M?'_V!GW_0DSC_ ,->._\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>otherrevenue.jpg
<TEXT>
begin 644 otherrevenue.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M;_V:M97X./!\1XKSP1JOA?0O@YX;\8^(M&T!_'&JZ1XA^+OAY9VMO"6FV_\
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M)+JX\RXD"@/(P H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ4SVE7K4XX'*'&G5J03=+&7:A-Q3=L:E=I:V25WMIJ'VQ_PM/P#_ -#';_\
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M6!_8D_\ T'M=_P# JR_^5U']B3_]![7?_ JR_P#E=0!OT5@?V)/_ -![7?\
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M&O\ @H?XE\>^ /AUK'@OX/\ B33#K7Q0NH_B%X<\:? _XL:+J5_\0GUHZ9X
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M90L^W]:?YH]_HKP#_A?>G?\ 0MW_ /X'V?\ \12'X^:< 3_PC>H< DXO[0G
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M\0?\A_7?^PSJG_I=<5D5K^(/^0_KO_89U3_TNN*R*_C?%_[WBO\ L(K?^G)
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MY)I]B]U&BS-:6Y<Q( ?B=_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?MY'_JX_\
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M3_Y*;(O^QGA/_3L1KKZ?JC[%HK'_ .$AT#_H.:/_ .#.R_\ C]'_  D.@?\
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M*M.N6T?7]"32-+1]:TE'33;%71M2LU966UB#*RF8%6!!!! (/!K=M-1T^_\
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MOKBXO8[1G-M'>3SW:1+<32R.HCC'2.->-ORQHOR@Y"_*H^4$DA>@)) S3J*
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M[/[CMJ*=L?\ YYR?]^W_ /B:-C_\\Y/^_;__ !-977=?>@L^S^YC:];^"O\
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M?K'HO_(&TG_L&6'_ *2Q5IUB^'+F&[\/Z%=0,SP7&C:7/"Y1T+136,$L;%&
M92R.I*L RDD$ @UM9SZ_B"/YU_2="$Z="C3J1E"<*5.,X23C*,HPBI1E%V:D
MFFFFDTU9GU$91G&,XM2C)*491:<91DKIIK1IIIIK1K4****U&%%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>rdandpercentofrevenue.jpg
<TEXT>
begin 644 rdandpercentofrevenue.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M;_V:M97X./!\1XKSP1JOA?0O@YX;\8^(M&T!_'&JZ1XA^+OAY9VMO"6FV_\
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M)+JX\RXD"@/(P H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRY'>'-7JRY'S1G>-YOE?/"$[JS<X1E\44T"DDDDG))))[DDY)/N2<FDHHKG
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MVH?_ "11_;^O?]!W6O\ P;:A_P#)%9-%<WUO%_\ 03B/_!U3_P"2"[[O^O\
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MXD7Q!\%?AY?;&4Y5K0Z%>^%C%N!83"Z^W!\1F'[.5D\WZFTW_D'6'_7E:_\
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MARPYI2;<813V%>X4445R@=5X&_Y'/PO_ -AS3_\ T>M?=U?"/@;_ )'/PO\
M]AS3_P#T>M?=U?NWA+_R+,U_[&$/_46B 4445^M %%%% !1110 4444 %%%%
M 'R;\?\ ]D#P#^T)\7OV5OCAXB\2^-?#OCO]D#XB>-?B7\+O^$:NO#XT'4]:
M\??#?6OA=KUEXUTO6O#^K7&K:2OAW7;JYT^+2-2\/WUKJ\-M<R7]S:+/83^Y
M#PQXQ4!1\1=1P  /^*:\+= ,?\^%>@44 >$7OP134;RZO[WQ;J,UW>SR7-S+
M_8GA]/,FE8O(^U;0*NYB3A0 .PJK_P *%L_^AIU'_P $V@?_ ")7T#17BSX<
MX>J3G4J9%D\ZDY2G.<\MP<ISG)\TISE*BY2E*7O2DVVWJVV%WW_K^DCY^_X4
M+9_]#3J/_@FT#_Y$H_X4+9_]#3J/_@FT#_Y$KZ!HJ?\ 5GAS_H09+_X;,%_\
MH\E]P[ON_P"O^&7W'S]_PH6S_P"AIU'_ ,$V@?\ R)2CX#V,;Q-)XFU*2,30
M^9&-)T&,R1F5!(@D%FQC+H64.%8H2&"G&#] 4$ ]1GH>?4'(/X'D>]'^K/#G
M_0@R7_PV8+_Y1Y+[@N^[_K_AE]Q^=O['_AC6OC=^S#\#_BOXS\52-XL\>?#_
M $CQ%XBET[PYX;L+";5+V2Z,TEI8P62PV</EI$BP1;D!1G!RY5?I'_A0MG_T
M-.H_^";0/_D2O:M!\/Z#X5T?3O#OA?1-(\-^']'M8[+2="T'3;+1]'TNRBSY
M5IIVF:?#;V5E:Q[F\NWMH(HDR=J#)K7I_P"K/#G_ $(,F_\ #9@O_E'DON"[
M[O\ K_AE]Q\_?\*%L_\ H:=1_P#!-H'_ ,B4?\*%L_\ H:=1_P#!-H'_ ,B5
M] T4O]6>'/\ H09+_P"&S!?_ "CR7W!=]W_7_#+[CY^_X4+9_P#0TZC_ .";
M0/\ Y$H_X4)9G(_X2G4>00?^)-H'0\'_ )=/2OH&BC_5GAS_ *$&2_\ AKP7
M_P H\E]P7?=_U_PR^X\]C\+>+XHXXH_B)J*I$B1HO_"->%SM1%"J,FQSPH Y
M]*?_ ,(UXQ_Z*+J/_A->%O\ Y KOZ*]M)))))))))*R26B22T22V0CSV3PMX
MOECDBD^(FHM'*CQNO_"->%QN1U*L,BQ!&5)&0<UP'_"A+,8'_"4ZCP !_P 2
M;0.@X'_+IZ5] T5Q8S*\MS%TWF&7X+'.DI*D\7A:&)=-3<7-4W6A-P4G"+DH
MVYG&+=[(#Y^_X4+9_P#0TZC_ .";0/\ Y$H_X4+9_P#0TZC_ .";0/\ Y$KZ
M!HKA_P!6>'/^A!DO_ALP7_RCR7W#N^[_ *_X9?<?/W_"A;/_ *&G4?\ P3:!
M_P#(E'_"A;/_ *&G4?\ P3:!_P#(E?0-%'^K/#G_ $(,E_\ #9@O_E'DON"[
M[O\ K_AE]Q^=G[8/AG6O@C^S%\;?BOX,\52+XL\"^!-0U_P]+J/ASPW?6$.I
M6MU8K')=V,]DT-Y#Y,L\9@EPA9UDR6C"M])M\"+"1Y7C\3:E'$9I_*C.DZ#(
M8XA,XC0R&S4R%$"J7*J7(+%03@>TZ_X?T'Q5H^H>'?%&B:1XD\/ZO;/9ZKH6
MOZ;9:QH^IVDA5GM=0TS48;BRO;9RJEX+F"6)BJDJ2!C7P!T&.I_$G)/XGD^]
M'^K/#G_0@R7_ ,-F"_\ E'DON%=]SY^_X4+9_P#0TZC_ .";0/\ Y$H_X4+9
M_P#0TZC_ .";0/\ Y$KZ!HH_U9X<_P"A!DO_ (;,%_\ */)?<.[[O^O^&7W'
MS]_PH6S_ .AIU'_P3:!_\B4?\*%L_P#H:=1_\$V@?_(E?0-%'^K/#G_0@R7_
M ,-F"_\ E'DON"[[O^O^&7W'A%E\$ETZ\M=0LO%NHPW=E/'<VTO]B>'V\N:)
M@T;[6M"K;6 .&!![BNX_X1KQC_T474?_  FO"W_R!7?T5Z&#R_ 9?"=/ 8+"
M8*%27/.&$P]'#1G-)14IQHP@I244HW:;LDMD(R=&LM1L+1H-4UB;7+DSR2"]
MGLK"P=8F5 D'D:=%# 5C*L1(4\QMY#,0JXUJ**[ "BBB@ HHHH **** "BBB
M@ HHHH **** "D)P,G_/L/<] .YI:1AD8]P1]0002,C(! R,C/3- 'QSIW[;
M/PSU'QUH_AM?"OQ)M/ GB?XP>(/V?_"7QWO="T&'X/\ BKXT^&+O7M(U;P#I
M-\OBJ3QU$W_"4^%?$W@G2?&FK> M-^&_B/QSHESX2\/^,=2UF\T:WU3TCX#?
MM)?#K]HT?$R?X<0^*CIOPO\ ']O\/M1U7Q+X8U'PM:>);R[\!^"_B'9>(_!U
MOK(MM6U?P9J6A>.=)&C>)+K3-,M=>>"[O]#CU'0)-+UK4_A&S_9=^+?@/QQ\
M#_V<?L=KK/[(WA[]H[QA^TQH'CCP?I%Y/X]T?Q-IGQ2\2_M!>!O@W\3X-3UZ
M+2_#W@S2?B5XIN-6L?BYX?B\17WB[1O"&C?#;6?!7A;5]:G\;:C]#_LS?#K]
MJ?P5\8/V@/%WQFTOX 6W@_XU^+](^(, ^&7C/XF:]XFT/7?#7PJ^%/P@TO1K
MBU\7_#KPOI-[I5_HOPXF\07^JQ:E!>V>IZE%I,&EWUK ^J, =9\:?VT/A9\!
M?"'QA\9^//#_ ,3Q8?!WQK:>!+S3]!\"WNOZQXZU6X^%WA/XNW6H_#VTL+EX
MM4\+:'X2\5$^)O%FO77AOP_X;O\ PUXKCUK4;*STF.\N[?QG_:[\$?!;Q)XE
M\.ZAX*^)WC:+X<_#VP^+7QDU_P  :%H.JZ)\&_AGJFH>)+'3?%_C0ZSXJ\/:
MMJJ7D7@OQGJ\?ACX=Z3XY\;IX?\ "NL:Y-X9CL?[,?4X/VV_AC\9OC7^SM\0
M_@Y\%$^&$>M_%+PYK_@77=5^*>M^+]'TG0?#OB'0[^QGUG2HO!WA?Q1?:OK-
MI>O9>3I5VFD6,UJ]U*^JQ31107'S9^T-^QY\9OVF;&SN?&%I\$/!GBCXC_![
M7O@G\:]4\)>-OVAGALO"FJZ]XG>"*+2]&U;P!X/_ &B?#NF^&_%.K3>%O 'Q
MM\$:#HW@WQOK&O:U'JWB/PQKFN>#]7 /U!M+NUO[6VOK&Y@O+*\@ANK2[M9H
M[BVNK6XC6:WN;>>%GBF@GA=)898W9)(W5T8JP)L5D:!HECX;T/1_#VF(\>FZ
M'I>G:/I\<CF61+'2[."PLTDD;!DD2VMXE>0@&1@7(&[ UZ "BBB@ HHHH **
M** "BBB@#,UO6M)\.:/JOB#7M1L](T30]-OM8UC5=0N([6PTS2M+M)K[4=0O
M;F9EBM[.QLK>>ZNIY&"0P0R2.0JFOC_P)^W/\+/%TUHWB+PG\4OA/I/B3X1^
M(?CU\-==^)WA;3M.L?BK\(?"DGA__A(_%_@^P\,>(O%OB.QOM(M/%_@_5;KX
M>^.-"\'_ !2.D>*='OX/!$ZG4H]-^F?B?\/?#_Q;^&WQ ^%?BQ;M_"WQ*\$>
M+/ 'B5+"=;6^?P_XS\/ZCX:UE+.Y:.9;>Z.FZI<_9IVBD6*?RY#&X4J?S=^&
MWP?_ &IM+^+W@BS^(.C^"==U/]DG]G3Q)X1_9O\ &VG6GB'P[\+OC7XG\:Z7
MX \(ZIXL^+&LV]YXGU_X8^)]*TCP/'H@^&/AWPCXQTY+?7?$/CVQ\9:Y%-HO
MA7P\ ??/P$^-WA?]HCX5^'?BYX.TCQ?H7A_Q)>^*;"UT?QWH$GA;Q=I]UX0\
M9^(? NK6^N^&Y[BYO-$O$UGPUJ#?V;J+0ZI:6[0Q:K9:=J*W6GVOC<_[;_PF
ML[KX):7?^'OBG8:_\=_B;J_PP\,>'[KP)>+J'AV[TGQ9XT\%KXK^(%W'=2:#
MX.\&:SKO@F\@\+ZCJ6LG5/%*:KHW]@:+J,LFIQZ4S]B7X7_'KX-?##5/A[\<
M8/A"9;'QEX\\3^&-2^$_B+QQK<5]%\2OB7X]^)NMV^NVWC3P;X4?39=$O?&%
MOHNF'3I=635+:RFU&[;3))HM/CQ/VPOA=^TK\3]6^"C? ZP^!L^D_#+XJ>#_
M (Q:M+\6/%_Q$\/ZAJ&N>!Y=9CT[PWIMOX,^'WC&UCTS5K76GDO-=N[M;O39
M[58HM#U.*X,MN =5?_ME?#^Q^*6N_#@>#_B-=Z3X4^+W@?X ^+OBE:Z;X3_X
M0'PS\9_B-H/@_P 1>#_ -[97/C.V^)FHW.JZ?\0/!0E\3>'_ (<ZQX(TRX\1
M6T>I>)K:'3]>N='^N@<@$=" ?SK\DM<_X)]>-_$O[3=E^T#J,_P<M_'4GQ?^
M'GQ7A_:$M[3QFW[1/P[\(^$;71K35_V;O ]S;6^E^#]9^%&M:&OC?P#%?^('
MT^P'@SXA^(;SQ!\,_$7C5Y?$MY^MPX% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 8!P2!D=#Z=N/3CBBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ I,#.<#.,9QSCKC/7&>U+10 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !117G_P 2?$^I>$O#T>J:6MJ]R^I6MH1>1231
M>5-%<NY"1S0-OS$NUMY &[*G((X\PQU#+<%B<?B>?ZOA*4JU7V<>>?)#?EC=
M<S[*Z]0/0**^2/\ A=_C/_GAH7_@!=?_ "QKWCX;>)M2\6>'6U75%M4NAJ-W
M:@6<4D,/E0+"4.R2:=MY+MN._!XPHQS\[DO&V2Y]C?J& >*^L>QJ5_WU#V<.
M2FX1E[RG+6]165M0._HHHKZX HKX3\8?MO1>"OBI\2?"6I_ _P")%S\+?A'\
M6/@_\$O'OQRT[7?AG-X<T?Q_\;-&^$>J>$+>W\#7'C*T^)FL:-!<_&[P#H^K
MZEH_AF_NX+Z_O7T[2=4M=/FFKW6']J#]G6>/XCRQ?&[X6O%\(7EC^)LB^-_#
MY3P0\.IS:'*/$3?;MMALUZVNO#Q+%E_X2.TNO#P)UNVGL$ /=Z*^?KC]J[]F
MFT\/^ O%=U\>/A/;>&_BA?:AIOP_UN?QWX=AT[Q7?:/J,>CZW:Z1<R7ZI/+H
M.M3V^B>(!)Y2Z!K=Q;:/K+6&IW$%I)H3_M+_ +/MMXG\:^#)_C-\-8?%/PYT
M77O$7CK1)/&&BK?^$]'\*62ZEXJO==B-UBP7POISPZAXEAE;[3X?L;BUN]8@
MLK>ZMY) #W&BOG<_M8_LY3W^A:)I/QF^&^O>)?%WAW6_%'@KPOHWC+0+W7_&
MFD:$WB&*YN?"^GI?"35HKJX\)^)K?2IK?=#J[>']<ETQ[NWT?4YK6;]G;]IS
MX/?M.^"-)\8_"SQAH.M7-QX/^'?B[Q+X2M-?T'5?%7@%/B9X3LO%_AS1_&=A
MH>HZC%I6JR6%U<6CA9YK.;4M*UBRL[JXFTN^2  ^@J*^?%_:P_9G<^-\?'GX
M3*GPWGM8/'4\GCOP]%:>%WN_$EMX-B;5[R2^6TMX4\7WEMX5NKD3/:V/B65=
M!OIK;5<VHYOQE^VI^S%X,^%S?%RZ^-7PUU'PI=0>/$\-S:?XX\+K+XOUSX<:
M/JNL>*_"WAPWVJVD-WXBTF+2+FVU&PFEMVTJY>W356LEN(6D /J>BO%6_:!^
M%FE?"?P)\9/'/BS0_AGX-^(&E^!+[1KOQ_K6D>'ME_\ $33M/U#P[X>EGN;T
M6<VO7 U!;<6%C<73RRV]T\!EMK>6=?-/A3^VS^SU\4_#GPCUB/X@^&/!^M?&
M^TO[_P"''@?Q9XH\,VOB_P 2V-KXKUSP?97FEZ=8ZM?1:A:Z_J^A74/ANXL[
MB:'7II(K'2GN]2$MG& ?6M%>(ZK^TG\ M#\)V'CO5OC#\.K#P?JOA'0O'FE^
M([CQ9I"Z3J?A#Q1J5IH_AG7].NQ<LE_I_B/6+ZSTG0)+3SI-:U2YBT_38KF\
M;R1S4_[6/P1LM3\0G4/''ARP\#^'OA)\./C++\5[GQ'X?'PVU#PK\4O&/C7P
M/X432_$<6IR17M_?ZWX*N(+6**-H]2FU?1;#29+W4[I[., ^DZ*^?+W]K+]F
M33K+P7J5]\?OA#:Z=\1;;1[SP+?S?$#PREEXKL]?UF;PYH][HEV=1^SWUG?^
M(;>70(;N.7[.NMJND321:A)';-GZS^V-^RIX>NO%ECKW[1/P:T:\\"2WD/C.
MUU/XA^&;&X\,2Z9XOO\ P%JR:W#<ZA%)IYT7QCI>H>'==\]5&AZI:S0:N;)0
MKL ?2=%>,ZE^T3\"-'\:ZE\.-4^,'PXL/'FC^&KKQ?JOA*Z\8:'%K^G^&[+0
MY/$]UJUWIIO/M$-M;^&(I/$TJN@N%\-HVO\ DG1Q]MKQCQ=_P4%_9 \(:7X,
MUN?XZ> ==TCQS\9/ _P(T?4O"7B#3/$]G;_$3XBZ)>^(_"6GZM-I5W.--L-6
MT.PFU2VU:8&QGLC'/;27"%S& ?9M%>7?$WXV_"'X,6NB7OQ9^)?@CX<6OB/4
M9-*T*?QGXDTKP]'JM]!$+B[ALFU*Y@$Z:?;,+O4[E?\ 1-+L_P#3-1N+6UQ-
M5#4_V@?@CHLNNP:Q\5O .DR^%[_Q#I?B5=3\3Z58?\(]?^%)/!T7B2WUTW5Q
M$ND-HK_$/P$-1?4#;Q6R^-/"SO)LU[2VN@#V"BOG2?\ :[_9>M?"6@>.[K]H
M#X16W@[Q1XAU;PIH/B.X\>^'8-*U/Q'X?G:W\0Z-!<RWZ*FH>')%8^(H)Q"?
M#\0$^LFQMW25NI'[0GP-/Q+_ .%-#XM_#S_A:XN[S3V^'9\6Z*OC!=0L/"^F
M^-[JP?06NQ?K?Q^#M7L/%2V;1"YF\.3-K4$4NG6]U<0 'L5%?.=E^UY^R]J7
MA+Q3XZT[X_\ PCO_  AX)U;3-"\4^(++QWX>NM.T75]=D:+P]IUW+!?2,;KQ
M,ZD>%XH$F/B8 MH!U) 6'N/AOQ+X>\8Z!H_BKPGKFD^)?#7B'3K35]"\0:#J
M-IJVC:SI5]$L]EJ.EZG82SV=]8W<+K+;W-M-)#*C!D8T ;=%%% !1110 444
M4 %%%% !1110 4444 %>._' @>#(,D#_ (GE@.3C_EA>^M>Q5')%%,NR:..5
M,@[9$5UR,X.U@1D9.#C(R:\S.<O>;95C\MC55!XW#SH*LX.HJ?/9<SIJ<'.W
M;GC?N@/SJR/4?F*^N?@@0?!3X(/_ !.M2'!S_#;>E>J_8+'_ )\K3_P&A_\
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MOBK=?"72],^%4/C#18+/4_!/P\T'Q'\0=)\._P!H^+=6B\5ZQXAU/7OV,HH
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M2H)(Y$89#(Z,KJPX*D$<&N=_X0GP=_T*?AK_ ,$.D_\ R'73 !5"J JJ %4
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MWQ3\;?L\:7X,U+QO;?$CP+X/L]#_ &@O#'Q7\17=K)'XHT>Q\2^--0^%-O\
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M_P %K+XTR_##X?:Y8_&#5OA[I/P)\$>#/$_BOQ7\3_#[?$'XX1?!*VO?B_\
M#[2="N-;O[/0Y9XO$.MGX?CS;?Q@S_!.".XUPV/C?4,K6/\ @HC^T'8^%M<U
M^+X$^%]&E^%O[._QV_:'^)UC\0;SQSX%U?7?#W[/?Q;E\$:GI_@?PS>Z3?\
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MZ@TS6[+Y^^,/_!/#XA6X^*WB_P"$OBKP]-J_Q+\%?"+X0W/P_?P=IU[H6G^
M_@7X]^$]W\#=9L9_%7B..6]\1>"-$\/^/;[XI2ZOJ\LGQ8T;7-!\,"?3_P#A
M6O@"6#WOP3^V/X]U_P#:0T#X<>+O &B_#CX;>.-0T_PGX#O_ !(OC34/$?B#
MQ9>?!&P^,LFFKXV\(Z'XG^#FD>.+"XC\8>$=7^"7C/Q'X*\=VVG^"K_XA:'J
MWBG1]7T71+K]$P<C(Z'D4 ?C3\1O^"8?COXD^+O$'Q?USXN>&1\5?B/JWQCL
M_B/I>BK^T)\._A:?!OQ=\,_ GP/+I^@:7\&_VA?AIXVU2[TGPW^SUX,?Q)IG
MC;Q?K?A7XF7FK^(H=7TKP]!!X;N-&^A[?]A*UTS49I=%\3:%I^E_\-7?!W]H
M*VL/^$:NKF0>%/A)^RM\.OV:;#P!>W5WJ]S<ZG+<6G@5]5AU/4;F[ACTK4?[
M#O;>^=;J_NOT/HH _&-O^"8_Q1O/!NC:/J/QRT^UF^%_C?X6>,?@YX)\)ZU^
MTUX5^&WA^]^&G@OXQ?#F\GL-6@_:+OOC9\*[#Q-X,^+ITO0/ /P=^*7A[X9?
M"N3P3X<D\/>%/$%GJ'B2PU3Z]7]E#Q+X<_8WL_V:?AK\0K7P%XIT\66IKXQT
M=/B3_9>HZO-\4%^*/C;3)[S4_BEK?QBT[1_B%=W.O^'-6\1Z?\7W^).B6?B*
M\\0^'_%MKX@M+)H_M^B@#\:$_P""97Q-T7P3J.E>$/C)X2T+QOK_ ,3OCKX\
ME\=VUM^T)8>*? ]O\>] ^%=CJ]EX+\::3^T-:>-_$6G>']>^&L&O:QX&^+>M
M>/OA[\6;F+PNWC'0]+_X1/381]G_ +2/[.WQ-^,N@?"31O#?Q=;2(?!.L22^
M/M-UB+QKX?TWXH:=J'AAO#5Q=ZKJ7P2\<_"7QAI.H:1=37/B:P\/Z5XEM? V
MMWMQ+I7B'0WMK?1-1T'[(HH \*_9@^#<W[/'[.GP/^!%QKZ>*I?@[\+/!'PU
M;Q(EE+IJZZ/!GA^QT%-5&GSWFHS61ODLEN#:RW][) 7,;7=PRF5_=:** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#P_1/V<O@WHGQ5\4?&Y? OAS5/
MBQXG\17'B(>/]:T'0=2\6^&WO/ '@_X;7VD>$O$<FE+K>@Z%?>&_!>G)>:=!
MJ$GGW5_K;--]EU.6S6UX._9S^ 'P\4KX"^"7PF\%JWBFU\<$>%?AYX3\/@^,
MK&TU.PL/%(&DZ3:!=>L+#6M7L;#4UQ=6-GJFHVMI)!!>W$<GLU% 'BS?LX?L
M_-!\2+9O@A\)6M_C%,+CXL0-\.O")A^)<XNIK_SO'<1TC9XJE_M"XN=1\S6A
M>,-2N;G4@1?W$]S)=TWX _ S1O#[^%-)^#OPPTSPS)X'UGX92>'K#P)X9L]%
ME^'7B.^N=4\0^!9=,M],CLY?"6O:G>WFI:UH$D+:9JNH7=U>W]O<75Q-*_KE
M% 'B7B;]FO\ 9Z\9ZIKNM^+O@=\)?%&K^)]<\)>)O$>I^(/A[X4UB^UWQ)X"
MT^ZTCP5X@U:YU#2KB6_UOPKH][=Z/H6JW+27^G:/<S:3;W"Z=(UJ?F7Q%_P3
M;^ NN?&+3OBY83:KX2;3M;^%VO6GA+PKX4^#NFVFC7/P=?PP_@C2? OC^7X7
M7?QH^%?@Z ^%;)M6\#?"[XF>$/"NJ2ZAXFF&F6DOC'Q<VN?H/10!YE\.O@K\
M'_A#)XCE^%?PM^'GPWE\8:B-6\52>!?!OA[PI)XCU))+J6.]UM]"T^Q;4[B*
M6^OI87NS*()+V\>$1O=7!DSX/@!\#+;6O'_B2W^#GPO@\0?%:QN]+^)NMP^
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M")<Z;!I<]M%I]RHN;%+>XS*?6** /+9O@?\ !FXT2+PU/\)_AQ/X=A\)>+/
M46@S>"O#DVCQ^!_'FHZ9J_C;P>FFR:<UDOACQ=JNBZ/J7B70A!_9NMW^E:=>
M:C;7%Q96\D?(7W[)_P"S!J?AO3/!VI?L[_!&_P#">C:^WBK2?#-[\+/!%UH.
MG>)7TRPT277[/29]$DLK?5[C1M+T_2;O4(X5N;W3+*VL;R2XMH4B'T#10!Y;
M;_ _X,VGQ*?XRVOPH^'%M\6Y;!=+D^)L'@KPY#X]DT]--CT9+1_%D>FKKC0K
MH\,6D*#>EAI,46F!OL$:6R^I444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>researchanddev.jpg
<TEXT>
begin 644 researchanddev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )N 3T# 2(  A$! Q$!_\0
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MUS\-_'_P#_:)U76OB/HO[0GB;XR^,M'\0:)/X"UQ_B?^U/\ "+XR:39_#_\
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MP058@@U,6 ..?P4GOCL#C\>V3T!K^7_X">'OAC\0?V.?V9;;XL)\%_A1\*_
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M^*6MW'C*^O=;TV[TG2Y?#VA75KIT^E:=KUU<:O-;6TUE;6C3W\'T\&! 8="
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M1110 4444 %%%% 'X@?\%)_^4DG_  0I_P"SK?VH/_6.?B#7[=I_JH_]V/\
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M<RZ.T*>3:7<TQ#"&3+;-JX^8C(R ?K]1110 4444 %%%(2 "2<  DGT Y)H
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M_P#'Z /ONBO@3_A>O[2W_0&^!G_?7C[_ ./TU_CM^TN$=ET;X%[E1V7+>/\
M&Y5)&<3YQD#..<=* /OVBL[1[BZN])TRZOEMUO;G3[*>\6T\S[*MU-:Q2W"V
MWG$S?9Q,[B'S3YGEA=_S9K1H **** "BBB@ HHHH **** "BBB@#\0/^"D__
M "DD_P""%/\ V=;^U!_ZQS\0:_;R/_5Q_P"XO_H(K\0_^"D__*23_@A3_P!G
M6_M0?^L<_$&OV\C_ -7'_N+_ .@B@#X(U_\ Y#VN_P#8:U;_ -.%Q636MK__
M "'M=_[#6K?^G"XK)H **** "BBB@ HHHH **** "O5_@S_R.B?]@C4__0K2
MO**]7^#/_(Z)_P!@C4__ $*TH ^N:*** /GOX]_ZGPM_UVU?_P!%Z=7SG7T9
M\>_]3X6_Z[:O_P"B].KYSH **** "DP.F!@  #L "6 'H S,P XW,QZDDK10
M =R>Y))/J3U)]2>ISWYHP!T&,# ]ADG'TR2<>I/K110 4444 %-?_5R?]<Y/
M_0&IU-?_ %<G_7.3_P! :@#[_P!%_P"01I?_ &#K#_TDAK3K,T7_ )!&E_\
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MM+5;N;^RM1'E/<+;#:3:[F\QHY1E2%PNSYMW48Y\RKU?X,_\CHG_ &"-3_\
M0K2@#Z9^W>(/^@##_P"#F#_Y"H^W>(/^@##_ .#F#_Y"KH** /FOXV3ZA-%X
M;^W:>EB%EU7RBE['>>:3'8;P0D$/E[ %()W;MV!C!SX'7T9\>_\ 4^%O^NVK
M_P#HO3J^<Z "BBB@ HHHH **** "BBB@ IK_ '']-CY^FTY/;H.<9YIU-?\
MU<G_ %SD_P#0&H ^XM)O==72]-":'"Z#3[$*_P#:\*%E%K" Q4V1*DC!(R<$
MXR<5T%C/J$WF_;K!+';L\K9>I=^9G=OSL@A\O9A<9W;MW&-IRS1?^01I?_8.
ML/\ TDAK3H **** "BBB@ HHHH **** "BBB@#\0/^"D_P#RDD_X(4_]G6_M
M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(K\0_\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]
MO(_]7'_N+_Z"* /@C7_^0]KO_8:U;_TX7%9-:VO_ /(>UW_L-:M_Z<+BLF@
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MP;4DI*5FFTTKIV9X3XCRJ,G%UJB<6XO]Q6=FFD]5!K_AF?=%%?"__#5WBO\
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M&/P[J&@Z+I]LWA/Q'J'VFQGU&2X\RSETE4C"W4KQ;'%PV\[2PPNTCFO8X?\
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MB+_V/_C;_P!2C5JXBNW^)O\ R4KXB_\ 8_\ C;_U*-6KB*_P<SW_ )'>;_\
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M_EE]S_KJOO'9]G_7_#K[QM%.V/\ W6_[Y/\ A1L?^ZW_ 'R?\*.67\LON?\
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M=K^XHZ?B?7U/KZ]2>_7G- 'X@?\ !2EE3_@I'_P0I+,JC_AJ[]IY<L0!N?\
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M*HVD_P! /^$X\:?]#?XH_P#!_JW_ ,ET?\)QXT_Z&_Q1_P"#_5O_ )+KX_\
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MH_AC3/#W@_1I=+O_ ("^ O#^G> _$ T*[T75;V2XU^\UK7_B+:WZZ3XOU?\
MLNPT:QL/T9']3WSW_P \=NE 'X@?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MVG^
MJC_W8_\ V6OQ$_X*3_\ *23_ ((4_P#9UO[4'_K'/Q!K]NT_U4?^['_[+3CN
MO5?F!_.-\1_^2B>/_P#L>?&'_J2:G7&5V?Q'_P"2B>/_ /L>?&'_ *DFIUQE
M?V=@O]SPG_8-0_\ 34#_ #<S+_D88[_L+Q'_ *=F%%%%=)Q!1110 4444 %%
M%% !7V1^PI_R7J'_ +$GQ3_Z.T6OC>OLC]A3_DO4/_8D^*?_ $=HM?.\7?\
M),YY_P!BW$_^FV?8^'W_ "6_"W_8[R__ -2:9^U%%%%?R2?W^?ES_P %+O\
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M_)>H?^Q)\4_^CM%KXWK[(_84_P"2]0_]B3XI_P#1VBU\[Q=_R3.>?]BW$_\
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M/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"*-@/PR\=? 'Q[J'C?QI?V[^'OL]]XO\
M%%Y!YFK2+)Y-WKNH7$/F*+$A7\J1-ZAF"MD!B!FN5_X9U^(?_/3PW_X.)?\
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M3/&;*VM;DS_;H-%1Q)]I9=@C%LI4IRV]MW05\1?\,SZ#_P!#9KG_ (+-+_\
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M (U_ ;P_\3?V8/B3\*]5\.^._#/@?4=9^);_ +5?@:X\4>+?%OPW^)-EX?\
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M_N+_ .@BOQ#_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(H
M^ ?$'_(?UW_L,ZI_Z77%9%:_B#_D/Z[_ -AG5/\ TNN*R*_C?%_[WBO^PBM_
MZ<D 4445S@%%%% !1110 4444 %>M_!7_D=D_P"P1J?_ *'9UY)7K?P5_P"1
MV3_L$:G_ .AV=?0\)_\ )39%_P!C/"?^G8C6TO3]4?7M%%%?U>(^=_C]_J?"
MO_7;6/\ T7IU?-]1_P#!0?\ :Q^#W[+EI\)YOBU=^*;2/QO>>,X-!/AKPO<^
M)F>3P_;>')M1%XMO=VILPJ:M9^07WB<M*%VF([OS3_X>V?L;_P#08^*G_AJ]
M2_\ EM7Y5Q+X0>*/%6=8S/>&^ .+,\R;&_5UA,SRS(\?C,#B7AL+0PF(]CB*
M%&=*I['$T*U"IRR?)5I5(2M*+1\MF7''!V3XVMEV:\39)EV/P_L_;X/&9CAL
M/B*/MJ5.M2]I2J5(SA[2C5IU8<R7-"<9+1W/TPHK\S_^'MG[&_\ T&/BI_X:
MO4O_ );4?\/;/V-_^@Q\5/\ PU>I?_+:O"_X@!XW?]&JX\_\1K-/_F;^K/RO
MP?\ $2_#[_HM.&O_  [X+_Y;Y_GV9^F%%?F?_P /;/V-_P#H,?%3_P -7J7_
M ,MJ/^'MG[&__08^*G_AJ]2_^6U'_$ /&[_HU7'G_B-9I_\ ,W]6?E<_XB7X
M??\ 1:<-?^'?!?\ RWS_ #[,_3"BOS/_ .'MG[&__08^*G_AJ]2_^6U'_#VS
M]C?_ *#'Q4_\-7J7_P MJ/\ B 'C=_T:KCS_ ,1K-/\ YF_JS\KG_$2_#[_H
MM.&O_#O@O_EOG^?9GZ845^9__#VS]C?_ *#'Q4_\-7J7_P MJ/\ A[9^QO\
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M_P#,Q7Y6?%+X+WWPW\2>!-"BUFZUB/XBZ)I.NZ$FO>#/$7PV\7Z9!J_B:_\
M"MO:>,OA[XK:37?"U[-?Z=)J&E&>YO++7_#MUI^NZ5=RVMWLBZ+]H/\ 9\N_
M@'J-II5_J7CS4KJXU[Q/H7VKQ5\$O%?PKT*^/A:\.GWE_P"%M<\1:[J\/BNV
MFNAO6*VMM/NK?39].U6XB6WU*V4]%+Z,GT9JU3 4J? .'E4S..(G@H?VWQW&
M56.$:6)YN;/(_5W2?NRCB?8RYE*,8N4&HX5/%7QCHT\=5J<15(T\MEAX8V?U
M'AEJE+%)/#J/+@7[=54KJ6']M%1DI2<8RBW^F/\ P^P\9?\ 1N?@W_PY/B3_
M .9BC_A]AXR_Z-S\&_\ AR?$G_S,5^(-%>I_Q*5]'G_HW&&_\2/C'R_ZJ+R_
MJRMYG_$;O%'_ **NK_X:LB\O^I7Y?B^Y^WW_  ^P\9?]&Y^#?_#D^)/_ )F*
M^_O^":G_  4G\1?M1?M-VWPJU/X0>'?!5M+\._&OB;^V],\8ZQK=RLFA3^'H
MTLQ8WVB6$!CNAJ3%YOM >+R5"H^]MO\ *'7[%_\ !"W_ )/TL?\ LBGQ4_\
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MK_\ "!^'O_SRJ]G_ (C)X8?]%GE'_@6)_P#F?S7WGD_\0B\2?^B0S7[L/_\
M+_-?>>?5^Q?_  0M_P"3]+'_ +(I\5/_ $K\&5^6O_#,O_!1#_I%[^W7_P"$
M#\/?_GE5]Y_\$X;W]M3]CK]I6W^,_P 1O^"47_!1G7_#D/P\\:^$CI_@GX:?
M"34-;.H^(Y= EL)Q;Z[\9O#MA]BB.DSK=RG4?/C\R)H;:YRZK\;XA^*GAYFW
M W%66Y=Q7EF+QV-R/'X?"8:DZ[J5Z]2A*-.G#FH)<TVTE=I7:NT?7\ ^&7'N
M5\:<,9CF'#&8X7!8/.L!B,5B:BH>SH4*6(ISJ59\M:4N6,5=V3?D?W245^+G
M_#W+XN?](:/^"N__ (9S]G+_ .B=H_X>Y?%S_I#1_P %=_\ PSG[.7_T3M?Y
MZG]YGR-_P<7_ /((_9$_[#'QM_\ 39\-*_F#K]Q?^"JGQS_:S_;LL?@=:_"[
M_@DC_P %,_#,GPPO_B%=:VWC_P"%_P %M.2]3Q=9^$K?3UTK_A'?CIXF:9X'
MT"[-X+L6019;?R&G+R"+\>_^&9?^"B'_ $B]_;K_ /"!^'O_ ,\JO[J\&/$K
M@3A[PWX?RC.N)LNR_,L++-WB,'7=;VM+V^=YCB*//R491_>4*U*K&TG[M2-[
M/1?Q1XO>'7&V?>(.?9KD_#F/Q^7XI95]7Q=!4?95?8Y+EN&JJ//5C+]W7I5*
M<KQ7O1=KJS//J*]!_P"&9?\ @HA_TB]_;K_\('X>_P#SRJ/^&9?^"B'_ $B]
M_;K_ /"!^'O_ ,\JOU+_ (C)X8?]%GE'_@6)_P#F?S7WGYI_Q"+Q)_Z)#-?N
MP_\ \O\ -?>8'A/Q=XI\!^(=.\6>"O$.L^%/$^D-.^EZ_H&H7&F:K8FZMY+2
MY$%W;.D@CN+::2&>%]\,R-B2-BJ%7Z9XU\::+IFO:)HWC/QCI.C>*@1XITC3
M/%?B&PTSQ1N5T=O$MA::E#:>(7D221)I-9AOI)TDD29Y%DD#;G_#,O\ P40_
MZ1>_MU_^$#\/?_GE4']F;_@H@ 2?^"7O[=>!R?\ B@?A[_\ /*K&?BYX45)2
MG/BS(YSFJ49SE"M*4XT)RJT(RD\,W*-&I4E4I)MJG.<I02E)M[0\*O%"$8PA
MPOG4(Q=64(PG2C&,J\(4ZTHI8E).M3A3IU6DG4A&$97C&*6'-XS\97/AW3?"
M%SXP\6W'A'1K[^T]'\)W'B?7I_"^D:EOED&HZ5X<EU!]%TV^62::1;NRL8+A
M))YY$D5YI6>Z_P 1OB));>*K)_B#X\>R\=7DVH^.+-_&GB=K3QKJ%PQ>XO\
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M#^\,CWI0<C(Z'U!'Z'!H B6", YCC)+R,3L7)WNS\Y')^;D]S3O)B_YY1_\
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M0 4444 %>/?M#7/Q.LO@'\;KSX*0"Y^,EI\(OB7<_"6V:*VF2X^)L'@K7)?
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M@4Y(3[H8E@ Q)H 5<[5SG.T9SUSCG/OZ^].HHH **** "BBB@ HHHH ****
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MYM;;SMZR>:;>$R>8B[4?S"F_>B_*K;MRK\JD#B@#Y[^-'@;P+8W6O?&WQ?\
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M.FZ?+X/^(_AZ+Q)XJT[6M2@^-?PTTCXA_LMZUHGB#P=X%TK3/!_BJ]O-7TX
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MFW:*45LDE9'Z%2I4Z%*E0I1Y*5&G"E3C=OEITXJ$(WDW)VBDKR;;M=MO4*3
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M(+J* &[%R3C!88)!()';D'M_#_=R=N,G*+%&F-J*NU0HVC: H& H P @Z[
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M\(6?Q"^+/C?1?V>/"VN_$O\ 9@^%7Q'N9_A;IT-E^S/IOQ._8Z^&'QZ^)7Q
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M^=+JPU*SMK^QN8]WEW%G>0)<VTZ;U5]DT$B2+N56VL-R@Y%7*XCX9_\ ).?
M/_8E>%/_ $PZ?7;U^-8BFJ.(K4HMN-.K4A%NUVHR<4W9)7LM;)*_1']&X2M+
M$83#5YJ*G6P]&M)1NHJ52G&<E%-M\J<FE=MVW;>H4T,&Z!OQ5E_]" I3T/\
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M/&WPN\+>+M<\)^.KOQ9\2]3\#0R@']"H(/(((YY'/0X/Y'@^]%?A!X-_:?\
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MK7"^$/AMX-\":IXWUOPUI=Q;ZS\1O$[^,/&6KZCK.N^(-4UC6CI]GI-LIO\
MQ%J>JW>GZ+I.EV%IIOA[POI4MCX8\-:?$;/P_H^FV\LT<G=44 -VC.>>_P#$
MW?\ 'MV'8Y(P2:HZGI.F:SIU_H^KZ?9ZII.JV5WINIZ9J%O'>:?J&GW]M+9W
MMC>V=PLEO=6=Y:SS6]U;31O#/#+)'*C*[ Z%% '@/PI_9A^#'P6U==>\!>'=
M<AUBW\*V_@72=1\5_$3XE_$BZ\+>!K:\L[^'P-X(D^)/C#Q;_P ('X(6\TS2
MIV\'^#1H?AZ1]'T;S=.D72--%KZQXN\'>&?'F@77A?Q=I%KKN@WLVFW%UIEZ
M9C!/-H^JV.MZ;(YAEAEW6FJZ98WL1$H'G6T>\,FY&Z:B@! H&<#J23R3RQR>
MI/4]N@[8KRWXH_!?X>_&*S\/6OCG3=:DN?"6N2>(_"GB'PKXU\<?#GQIX5UJ
MXT75?#=[?^&/'GPY\1^%/&GA^74O#VN:QH.KKI.O6D.KZ-J=[I>IQ7=E<20G
MU.B@#B?AY\.?!OPJ\(Z;X%\!:*F@^&=+GU>]M[);W4]2N;C4_$&M:CXD\1:S
MJNKZS>ZCK6N:]XC\1:OJNO\ B+7M:U'4-9U[6]3U#5M7OKR_O+BXD[7&!CG\
M22>?<G/^':EHH 0@'KG\R.V.Q_+T/(YYI0,#'IQR23^)/)^IYHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R?Q_\<_A
M/\+M4LM&\?>-=+\,ZGJ%A_:EE9WT6H/)<6'VF6T^TH;.RN8PGVB"6+#.K[D)
MV[<$\&?VP/V;%!8_%GP\ H+$_9];X"@DG_D$]@":^ /^"CQ(^+7@;!(_XMR.
MA_ZF?5Z_.^9F\F;D_P"IF[G_ )YM7\$^*7TJ^.>!N/N*.%,LR+A3%8'(\?'"
MX:OC\-F\\75A+"87$<U>6'SG#T92YJTU>G1IKEY5RW3D_C,QXCQF#QN(PU.C
MAI0HS48RG&JY-<L9:N-6*OJ]DNGS_J6TW4;+5].L-6TVX2[T[4[*UU"PNHPX
MCN;.]@CN;6X0.J.$F@ECD4.BL%8!E5L@7:X3X7?\DT^'G_8C>$?_ %'M.KNZ
M_NG+,3/&Y;E^,J1C&IB\%A,34C!-0C.O0IU9Q@I.4E%2FU%2E)V2NV]3["G)
MSITYNR<X1DTMDY13=O+4*:&!.!N!]U9<_0L #^!/K0YPC')&%)R.HP#R/?T]
MZ_E+^ -S^T'^R]\%OA9\4/ WP?\ AG\/O'>K_P#!/GPMXZ\+S_#.;QIJUI\?
M;CQC\4/@#X<^+OQ4_:,A\1:!HVDV?Q%_9>\ :['\9#:MI/BZXUQ?'OC*\7Q9
M:^$_"GBW2/$O:6?U;45^ OBK]M/]I;0O@CX6\=W_ ,8OASIV@0>._CM::)XI
M\/:W\(O&7CKXP>'O _A?X=:M\/;#1?%^J> ?!G[+GQ&\2GQ/KGCSPUXB^'7P
MUUCX6^)_BW9Z=X8/PB\::'KNA?$FST_KK?\ ;B_:CD_:%^*MGJ6CV6@^$?!U
MY\7[F'X*R66@:S\6E^"O@O\ 9\OOB5X#^*WASX'6WA[3_C/K?Q"\8^+H-*$%
MIXA^(VB?"76+75KCX16=QH?Q0TO^U[P _<RC./Y="?Y?SZ5^#?P2_:Q_:P^*
MWCG0/A-8?%3PS>:!X@^-_P !+.V^-OARQ^'GQ2N;WX;_ !,_9U_:A^(_C_PW
MI.N^$OAMX*^$">(/"_C3X(:%I.G3:=HOCR#P1J.J7>@>*_%OQ"N[>2U>IJ7Q
MN^,_QN^''A8ZE\;;:/XKW?[3W[']SX[^#5I\(KO3[G]E#Q7-^VKHOA2\\#:M
MX@TPZ6VJBT\&Z?-#<>#?B;?:EXK\87FFGXLZ7>0?"+78_#L0!^]]%?FKIG[0
MWQ4\(_L9?'[Q[XSUK6/$/CWX)_$CX]_"FP\=Z/\ #W0;C6M;TSX>?&+5OAUX
M2^(FN^#H[SPQX(L9H/#QTW7_ !UK:'1O .CVNG:[XVFT6R\-65QH"?'OPT_:
MA_;#^*NNR?#>P^+F@Z-IV@^)OVM;.T^+OA?PUX$^+!^(?A;X9? K]E/XL_"?
M7-(\7+\+_AQ\,]?AG\4_&WQ1X>U+7_"/PVTOPWXE\,Z-<Z7HSS>(+:+QU  ?
MO917\_P_:4^+WQ[\>?LRW?C?QU;^#];NOVD/V(/$6F_LZ^'O!4MB=7^%_C?]
MG7P[\4?$_P ;&\073W7C&Z\,7/Q5\:^*? *ZC-J1\ >'X_!%O\/=<TZX^(]_
M-JK>K_\ !1OXL_$I=6^)/PCC^(4OPUT&U^%W[/?B/X6^"K#PK;ZKKG[1GB3Q
M5\?VT[XL0Z7XD$<FN6Z_"'PQX6\,/>Z)X*FTW4?"]OXRE^('Q"EU/P1+IEA"
M ?M5_G_/^>>U%?AO\5OVHOBQ\%X?"UYHWB_P]X&\(GXO_MG:C?\ @7PMX.\+
M/\2OB7K?A?\ ;<\>^'=-L?"WAGXE6>F>'?C&^L^"X-2N-5^&/PC^)'@#X_\
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M:*_G\F_;I_:XUOQ/\$--\)7&A:9I>N> OAW=^$+_ .*<OPY^'(_:1^(6H?M
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M;^)_$FE>'=#US68_-%YJ>D^$Y_$%SX=L;IC(8V@TF?Q3X@EM0L:MNU6Z\UI
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M8U?1Y8_A;\== \;:YXIF\/>+O&G@CXG:CX8TN6PE /U$HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .,\2?#GX?^,;N#4/%O@GPGXFOK6V^QVUYK
M_A_2M7NK>T\UY_LT,]_:SRQ6_G223>2C+'YCN^W<Q)YX_ OX*D$'X2?#8@@@
M@^"O#A!!&""/[.Y!'!'<5ZI10!!:VMM8VUO965O#:6=G!#:VEK;1)!;VUM;Q
MK#!;P0QJL<4,,2)'%$BJD<:JB@* !/110 4F!_DGM_GGUXSG I:* $(!ZY_
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%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>reservesfordisandallow.jpg
<TEXT>
begin 644 reservesfordisandallow.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %T 3T# 2(  A$! Q$!_\0
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M6=7Q1^QGIOB'XIZUXPM/B?XNT'X:>-OB7\&OC3\2O@UINA^$FT3Q9\5?@"/
M*_#?7K+Q//I3>*/"FB[OA1\+9O%GA?19?L7B*3P%I M;O0K75?%MOXD[.3]E
M;PM>_L=Q_L<ZIXE\07?A(? BV^!4WB^"'2[/Q,^F6GA&+PI#XDBMA;3Z)%K$
M0@AU1+1[*?23=1BWEM9K)GA8 XGP3^W=\(?$?Q8\;?"7Q,NN^ -;T3XE>#/A
MUX3F\3^%?'NGV^N7_CC]GCX;?M Z'9^-+W4?!NG:'\(O&6I:9XU\0:'I/P\\
M?:UIOBC5)_ ^J306JWUS'I$/LOP=_:5^#WQYFOK?X9^)-1U::ST'P]XNMH]:
M\'>-O!3>(/ _BV74H?"WQ!\'+XV\.^'CXU^'GB:71]3C\/>//"@U?PIK+V<@
MLM5D5X&E\'NOV(K+Q-8ZV?B%\3-9\4ZUXR^/_P +/V@_'=]8^&-'\-:;XA\0
M?#OX'> _@=JGA^TT:SO+UM$\/^,='\#IK%X;;4[G5='U#5KB#2[_ ,BTLG1_
M[&_[!WPW_8X&LCP:WA2^DN?"WA;P!H^HZ/\ !KX2_#7Q /!?@UKIM'_X3/Q)
MX!\-:7KOQ \7WYGMY/$?B+6;^TTG4;K3;34--\(Z%J5QK%YJH!XWJG[=WQO^
M'WBCX[#XN_!7X+Z#\.O@'\8OV=OA%XH\4^#_ (Z_$+Q3X@O[C]H_Q1\&M-\,
M^(]/\+:C^SQX;@:Q\.^'_B_;ZCK>EIKMQK%_KFB2>'M M=1&J6FHK],VG[<W
M[,=TWAV)OB#?:?>>([?XIW@TW6O /Q&T+5/#-G\#M9T70?C+??$;3M9\)V%Y
M\+=/^%U_XBT%O&VI?$6'PQI^AV&M:1JL]T=,U33[NZJ>)_V0_#WB?6_C+K4O
MC7Q!:2_&/XY_LN_'+4(8-.TIX]$U3]F#4_@]JFAZ%ILDJ;[G3?%4GP?TZ/6;
MNZ+7U@NM7[:8R-;V>.2N/V"?ASK>J_&>;Q7XH\2^(?#OQT\+?M7>"O&7ATPZ
M9IJ#PU^UG>?">7QG9:=JMM%)>P2Z'8_"NVT_0KETE\U-:N[B_BF>RL5 !W-G
M^W#^SC?^'FU^V\4>,#/)KOA[PYIG@R;X._&6U^*GB/5/&&@Z[XJ\(?\ ")?"
M&[\ 6_Q.\6:;XI\+>%_$_B?1-<\/>$]0T.Z\/>%_%6L/J,-EX6\12Z6GQT_:
MEB\#?LI:]^TY\#O"5K^T&$TOPEJ/@3P5IWB6;P7+X^N/%7C7P]X/M]"M=7OO
M#VLWFA^(%NM:GM4TC5?#JW\7B*Q/AK5K;2KUKJ2Q^06_X)%_!>;P-::)J$_P
MUO/&'A_X@>'/'WAK7(_V7/V?-*\$2W'A;P/X[^'-C:?$'X6:)X4T[0OB0VI>
M&/B9XUNM5U/7=7M+JP\5ZA;Z_P"!E\$0V]QI%_\ <>@_LU^%/"_P*\ ? ?P[
M?IH>A> -?^&'B6PU#0?"?@KPM%<ZK\-_BMX;^+K21^%/!V@^'/!6C0^(_$GA
M^8:E9Z#H6GVUK#JEY/:PF['GR '@?B#_ (*(_#32/C!\)?"EI9:?<_!7Q_\
MLT^-/VEO%?Q]U#Q(=*T/X?\ AO2?#.A>._!6F77AP:)>W.J2>+/ 5SXB\6:K
M=MJNFS>&+'3?#T4>FZY-XMM?L/I-Q^WG^S1:"PMKKQ1XX@\1ZGXD\3^#K3X?
MO\$?C?\ \+4/BGPCX#TKXI:UH5S\*1\/#\1;#4$^&NM:=X]T^.]\-01ZSX2N
M!K>D2WMG%,\7S^O_  2P^$B^'[_PD/B/\2E\,WFL?M-7EK:)+X?-]X9T?X_0
M^$M/\'^%O!^HSZ7<)HN@_LZ:-X#\&:'\'+&XLM4@M--\.:?:>(8-7A-Y%=>M
M^!OV+#HGQ9T+X\>-OB_XG\?_ !7AU_Q?KOBS6YO"_A?POH_B(:Y\*=%^$'A[
M1['P[HR/%X:T?PCX=TB;5[:*WO=1OM8\4>(/$&I:C?BPN-+TG20#RK7O^"I7
MP?MO'MUX1\+^#O'WB?0;#XB_LQ^#_P#A92^%_%UOX!\6>'_VHO"5UXM\$>*?
MA5K-AX4U?_A9EY):'2+32_"?A^.36O%%SJZOHH>"QNI%^BM._;B_9LU>X\%6
M>C^,_$&LW_CFS?4+73M&^%WQ7U?4?"EA#X^UGX4W=[\4]/TWP1=7GP>M=/\
MB?X=\0_#[4IOBC#X233?%WA[Q%H]^;>;P]K;6'@?@K_@FYX?\!ZU\&[G1OB[
MXKD\/?"O1_V4_M_A^]\,>&)9O%WC#]DOP5>_#CP9XJFUN/RKW0X/$G@R^EL/
M%'ARRAN]._M*WM-7T6?3)?[0@U&3QO\ \$XM$\70^%K.+XO>(M$M]"^(WQ>^
M(#:WI_@'X=?\+)\/7?Q;_:$\8_M":C<_"/XMQZ1;?$?X2>(K+5_%S>$I]9T;
M7]7TC6O#&C:7+J'A)/$ N=8G /KSXP_M&_"/X$OH\'Q'\0:K8WVN:9XCU^QT
MKPYX+\<>/M:B\+>#%TR3QGXTU31? /ASQ-JFB>!?!T>M:.?%7C76;2P\,:#)
MJVE6NH:I%>:II]M<\7:_MH_LU7GC74O </Q*A75=&\1ZQX/U76;GPUXQL_ %
MAXKT7X56?QRNO#D_Q0NO#\7PW_MJ?X.7B_$W3-/3Q2UQJO@NVO\ 7=.6YM-/
MNFC\X_:W_80^&O[5WB?X?^.?$4GAZS\7^ ?#GC?P-97GB[X5?#?XS:(_@GXB
MZAX5U;Q+%8^%/B?HNM:+H_B^QU3P;H5]X4\86L$W]DM_:5AK6B>)]'U*33$S
M-6_X)\_##7/#NJ>"M1\1:XW@C6OCIKOQBU#PS8:;HND61T;Q#^RIJ7[)EY\.
M;)M(M[)=)\/1>"-2FU?3]0TN"SO=.U>*WMM/@M=*MX+6( D\._\ !13X%:_X
MN\;Z6A\6VWA7P]X,^ 'B'PAJTGPY^+2^.OB=X@^/^K?'2#PWX6\#?!RY^'=K
M\1O$K2>'?@M+XST36/#6CZ[9>(?"^KZCK873=(\*ZOJ%+\9?^"B/P,^''P_3
MQ=X,O;_XHZS>Z%X#\3:?X?T7P]X]M+'3]$\?_%>'X0Z//\0?%$/@C5-+^$VH
M7?BZT\5:%I>A_$E?#6LZKXG\%^)_#"6-OJ6B:N-/\H\:?\$Q=&^*-JVI?%SX
MRZI\7/'6C1_!6+P9K7Q'^$OPG\1^#M(3X%:=\??#?AD>)?AA+HL/A7QN?$GA
M/]HOQ]8^-I-1?3KJZUR6P\3>$[CP9/IVEV&G:U[_ ,$T/"=MX9;P1X(^*WB'
MX>>#_%'@SX;^%/BUX<\(?#GX4:!HWCRY^$WQ*\0_%;PAK6BZ-H'A?0M#^&\U
MSXE\8>)]-\767A+25M/$OAB\L+5FT_Q'8W'BK4@#].5;<"<8PSKZ_<=ES^.W
M/MG'/6G4U5"C _O,W/JS%C^1.![4Z@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *8_W1_OQ^W_+1?Y]#ZCBGT4 ?RS>.?BM\4M*
M_9)^,'[,B?%7XFQ:Y/X<UG]O;P[\1AXZ\8P>*;+X#W7CG4=:UOX;VGQ+&K1Z
M]9G2_P!K[3X?!<'A]?$*>1\#?$]KX9@MH?"-FUDGU;\2?^"E_P :?#/Q-^/>
MA^!IOAWXH\.Z!\/?VW[SP/'XAT'P[X=O/!WQ!_9,MM9?1K'Q1X=T7XR^,OBE
M<>'O$.IZ)J6E:_JWC[P3\+T\468LO%WPUTVVT">QMM7_ '9?1=(D@:UDTO3G
MMGMFLWMWL;1H6M&E\YK5HFA,;6[3?O6@*F(R?.4+_-43^'M!DGU"Y?1=)>YU
M9E?5+AM,L6GU)TL?[+1[^5K<R7C)IO\ Q+U:Y:4K9?Z(/]'_ '= 'XO_ +17
M[3'QMT/3OVL_A/XK^/7P6\,>(/AQ\+OB3X/TKP/9^#O$_@GXP?%M=<_9%\0?
M&I?C=\*-3L?B)JVH>"M)\+>)KG4/!GAZ4Z-XC\.VB?"3XA7OB/QW:^*[_3+?
MPQ]@?L>?%;XOZ]XJ^(/PA^+VO^#?%MYX#^$W[,WQ,T+Q+X3\/ZSX;FBL/C7X
M=\?I>^$M6AUGQ/XINO$+>'=4^&=Q=:?XTGFTC4?$%EX@-OJNA6M[I37NH?<M
MSHND7ERU[=Z7IUU>/IUUI#W5Q8VL]RVE7SQ27NF-/+"\ITZ[D@ADNK$O]EN)
M(HWFA=D4BS#96=O+)/!:VT,\L-M;RS100Q2R068E%I#))&BN\5L)YA;Q,Q2
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M*M.$.J^+?%WBCPW9W%KX1\5Z\/$'A^_T31/T"H **** "BBB@ HHHH ****
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M?$GQ79ZE^>?[0^A?$GXU_"[7_A]I_P 2YM.76[>2WO=-\=:,OQ*\!^)+215
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MJ[Y1_)F/_@[#?_,_]6?E>+<0?\_,G_\ "?&^7_45Z_UO_3!_PM#X:_\ 10O
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MJH_]V/\ ]EH _FA^)?\ R4GXB?\ 8_>-?_4GU6N)KMOB7_R4GXB?]C]XU_\
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MC,R*CF1%<^)M4WJCLD;.JMD*[1QE@ Q1"=HXN@ HHHH **** "BBB@ HHHH
M*^U/V!?^3@X/^Q%\6_\ H_0Z^*Z^S/V#FND^/T!LX;>>;_A!_%8\NYN9+2+9
MYVB;F\Z*TO7W [=J>1ALDEUP P!^YE%8WG^(?^@7HW_@]OO_ )G*//\ $/\
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MVG6WA_3H= N)K5;'4)KK5+:'4I=7O]/T;088[[5-:UBRT33[K4XP#TVBO/\
MP!\0K#Q]%XF@31=>\+^(?!'B3_A$O&7A3Q+'I/\ :V@:Y)H6B>*;%/MWA_5M
M>\/:SIFK^&O$>B:[H^LZ'K%]97MC?JDAM;ZWN[*W] H *BG_ -1/_P!<)O\
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M W2-C<[8&YB3@9Q7%UVWQ+_Y*3\1/^Q^\:_^I/JM<30 4444 %%%% !1110
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MWS]=V%Z8YPO /_(C>#?^Q4\.?^F:RKK: "BBB@ HHHH **** "BBB@ HHHH
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M'_P'MO\ Y+I?VYDG_0XRK_PXX/R_Z?>:"S[/^O\ AU]YYM17I/\ PIWXI?\
M0B>(?_ >V_\ DNC_ (4[\4O^A$\0_P#@/;?_ "71_;F2?]#C*O\ PXX/R_Z?
M>:"S[/\ K_AU]YYM17I/_"G?BE_T(GB'_P ![;_Y+H_X4[\4O^A$\0_^ ]M_
M\ET?VYDG_0XRK_PXX/R_Z?>:"S[/^O\ AU]YYM17I/\ PIWXI?\ 0B>(?_ >
MV_\ DNC_ (4[\4O^A$\0_P#@/;?_ "71_;F2?]#C*O\ PXX/R_Z?>:"S[/\
MK_AU]YYM7VI^P+_R<'!_V(OBW_T?H=?.G_"G?BE_T(GB'_P'MO\ Y+KZ]_8@
M^'OCCPU\=(=3U_POJVDZ>/!?BBV-W>Q0I#Y\\VC&&+,<\C;Y!'(5&W!V-R,<
MW3SC*:U2%*CFF6U:M22C3ITL=A:E2<I648PA"JY2DVTE&*;;>B%9]OZ_IK[S
M]DJ***]$#\N_^"E?_'I\&_\ K\\=_P#I)X8K\JZ_<3]L3X7:/\2K?X>KJVI:
MIIPT:X\3M!_9JV3&8W\&BI)YWVR"8 1_94\OR]I)=MV1C'Q!_P ,M>#O^AD\
M4_\ ?O1?_D*OD<TXXX>R?'5\NQV(KT\5A_9^UC#"5ZL5[6C3KPM.$7%WIU8-
MV>C;3U3"W]77]?UY,^&J*^Y?^&6O!W_0R>*?^_>B_P#R%1_PRUX._P"AD\4_
M]^]%_P#D*O/_ .(E\)_]!>*_\(,5_P#*QV]/O7]=?S[,^&J*^Y?^&6O!W_0R
M>*?^_>B__(5'_#+7@[_H9/%/_?O1?_D*C_B)?"?_ $%XK_P@Q7_RL+>GWK^N
MOY]F?#5%?<O_  RUX._Z&3Q3_P!^]%_^0J/^&6O!W_0R>*?^_>B__(5'_$2^
M$_\ H+Q7_A!BO_E86]/O7]=?S[,^&J*^Y?\ AEKP=_T,GBG_ +]Z+_\ (5'_
M  RUX._Z&3Q3_P!^]%_^0J/^(E\)_P#07BO_  @Q7_RL+>GWK^NOY]F?#513
M_P"HG_ZX3?\ HIZ^ZO\ AEKP=_T,GBG_ +]Z+_\ (5,D_99\'-%*O_"2^*?F
MBD7_ %>B]T89_P"/$^M'_$2^$_\ H+Q7_A#B?_D M_5UY?Y_U9G[$^ ?^1&\
M&_\ 8J>'/_3-95UM87A:TCL/#/AVQB=Y([/0M(M8WDV^8Z6VGV\*,^T!=[+&
M&;: NXG  P*W:^\A-5(0G'X9QC.-]':235UTT8@HHHJ@"BBB@ HHHH ****
M"BBB@#\0/^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(K\0_\
M@I/_ ,I)/^"%/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"* /@#Q !_;^N\#_D,ZIV
M_P"G^XK(P/0?D*V/$'_(?UW_ +#.J?\ I=<5D5_&^+_WO%?]A%;_ -.2 3 ]
M!^0K$\2>)/#G@W0-7\5>+=;TKPSX9T"R?4=;U_6[N.PTG2;"-XXVNKZ[D^6.
M,RRPP1(BR3W-S-!:6D,]W<002;E>8_&;PC+X[^&/BSPG#X2T3QU+JT.CLGA/
M7_&.N?#NSU=])\3:'K\7V+X@>&[6]USP-XFTR;28M<\$^+]/MV?P[XUTOP]J
ML\MI:6UQ>6^=&,)UJ4*C<:<JM.-247",HPE-*;C*I*---1;:=248)VYY1C=H
M_K^MSSS3/VO/V:-4^#=M\?D^,'A+3OA1<ZCI.A?\))K[:AX?O+7Q-KESI=II
M/A"]\+:O86GBZV\97TVMZ2]MX5;0FUJ:RU"VU>*TDT5SJ2^I_$CXH?#WX06O
MAZ\^)?BG3/"%OXL^('A/X5^&FU%+N>36_B%XYUE- \+>%]/M]-M+^YFO=4U2
M00O<F%-+TRW2;4=9O].TR":\C_*>U^"_[5 _8+U7X8>+O@YXN^+?Q-U[3M&T
M;X/^'?%_Q%^!>M?%#X%:$GAGP!#XJ7QW\5O%6H> -,NTUW6]%\8V/A^R\,7G
MB_QGX<\':KIGA#Q5XF\0V(D?3/9OVJ?@9^U-^T%J.A_%3X>WOPZ\&7*ZU\!I
M=!^"OQF\&2>*?%7PJC\,?M->!?BG\5?$L7CKX:_'G3OAWJNJ^*M'\%^&[WQ!
M:V$>L:G?>"_!=E\.O#'B#3M2\1:K=/[D\NRV.*A3>.IPP[QN*H3J+%T*\E1A
M]56&<72I-QNZM9UL15I0PS5&?LF[4I8A^F_]:+>_X'WGIGQ0^'.M?$;Q3\(M
M&\9^'=6^)G@?PUH7B_QGX*TV^2^UOPIX=\3ZEJ.D>'K_ ,0QVRRVVDRZO?:3
MJ"6>E7ES%K36\":C)IT6FW=C>77*^,_C]\+O 7C>Q^'.OWWBZY\97VCZ+X@.
MC^$?A/\ %SXB)IFA^(];U?P[H6K>)-7^'G@3Q5H7A.QU76- UNTLY_%.J:,D
MB:3J%Y\MA:RW2^$>'-,^)>C_ +9_BSQ?9_LT^(=#^&7B;X26/PUU'XGZ3XI^
M ^FZ#K/CFT^+GC;XCZ]\3=1\':?\1I/B//I/BJRUK2[9;[4/#5[X[FU$+#KN
MFBUL1?5PGQK^&?QF^)XN/&WACX(>./ 7QK\?_!3P1H?A;QKHW[7,/AS2OV=?
MBGH.I^-M2L+WXC>%/">M:1X=\>P_#R\\7RZE#XD\#Z1\7+/XG:/<:Q\/-2\*
M^']-FCU#5N:G@L'+$4X5,1&-&>&H2<XXS <T,144%-3<ZB4:4)>TE*"C*M3B
MH0:E.47(TOY?U_5[?(_1EDVLRD+E693@JPRI(.&4E6&1PRDJPP5)!!I,#T'Y
M"E&[ WNLCX >1(5MTE< !Y4ME9UMDE<-(MLKNMNK"%7=4#$KR!"8'H/R%>M_
M!0 >-DP /^)1J?;_ &[.O):];^"O_([)_P!@C4__ $.SKZ'A/_DILB_[&>$_
M].Q&MI>GZH^O:***_J\1\[_'[_4^%?\ KMK'_HO3J^;Z^D/C]_J?"O\ UVUC
M_P!%Z=7S?7\R>(G_ "6&;>F _P#59@P"D) !)X !)/L.32T'H><>_I[U\4!\
MM^'?VIM"\5_M >.O@9H/P\^(.IV'PWM;VT\:?%:RB\+W/@SPUXOTJYOX]6\/
M:]H</B5OB#I&CVT-G#;V/CJ[\)CP[K6NWMKI>F&;3KO3?$&H5=$_:^\ Z[\,
MOBA\4X/!WQ2T_2?AO\6HO@Q9>&==\)1^'?B!\0O&6L1?#@>!X?"?@_Q!J6E7
MND0_$2\^*7A2#PS!\0)?!^HZ=83W&O>-+/PII5K=O:^?:Q^R+XKUS]L/2_VE
M[[QUX$73_"NDV<_A2?3?A?#X=^,,EU:3^.(H?A7XQ^)'A[Q!96GBSX+K9>*[
M3^TQJGABZ\8Z_I6BZ)X6NKNWFT&V\77G-)^R/\9?''AKXZ>%?C5XU_9_U33_
M (K?'+PO^TOX<F\"?#_XIW$?AGXN>"+SX077AS3/%.B>//'%QI_CCX7W<?PE
MCL_%N@B\T;7?$&G>*=:TQ=4L[98I&]]TLD<J'[Y1A[#+WB.5XERC5=:,<;&*
ME2_>S]CS5'*'LJ<+<E.G*=F596\_-^:[>5[Z_<>OZ?\ M5S:S:^#M+\/_!#Q
M]XE^)GCW4_'4'A3X<>'/'7P6UO3_ !#X9^&VG^&+_P 7_$/P_P#&+3_'T_PD
MUOP-977C3PMX0L;ZW\00ZS>_$K5O^$ N=#TR_P!-U?4;#N)_VD/AV?@)H'[1
M&DQ>)=?\'>+M.\)R>$=!TW2;>#QSXB\2^-_$MCX(\-_#^WT/5=2T^PT[QK/X
MZOT\'ZM9ZSK-AH_AO5;+6+K6]:M-$T>^U6/P?PM^R7\0_ ?CZ;X]>!?&OP9\
M*?'#4/$_C74=3\/:1\*/$VG?LX)X5\=>#/A+X3U3PWI7@;1_&^E^-(-=CU;X
M)^ ?B+?>.6\10WOBWQ9;ZOI6N:):Z'J5O<:9IZG^QW<7WP,\._LYGQEX7O\
MX=>!M&^&7BOPEJ/B+P%>:MXGU']H;P%\:;_XU:YX^^(-A;>*].\+^(OA?X^U
MNX^Q:]\*M,M=(OX['6O%5BOC"YL+S3(;*:E/)N?#\M91@\1AWB.18MRC1E4K
M?6H)34^:-&'U94)PESU;XB4Y2?LZ=,TZ=WOOTMK:VK[Z*VZW?TC\(OB9)\5O
M"T_B63P?JO@TV^LWNCK;W?B7P)XZT/6DM(+.X77O!?C_ .&GB+Q/X+\:>&K@
MWC:>VIZ7J,%WIGB#3==\.ZUI>G:GH\R2^HUX%\!_@WJ'PH_X6CK&MWG@7_A(
M?BYX_M?'^O:!\*?!]SX"^%?A>\T_P3X7\!VUEX-\,W^IZOJ37>JZ?X5M=;\9
M>)]5NXM1\5^)+R6\FT_3[>RLX6]]KRL4J"Q%18=IT;Q<+<]HWA%S@G4<IR4)
MN4%*3;FHJ=_>L)VOI_7Y;A2-]U_]Q_\ T TM(WW7_P!Q_P#T US2V?H_R".Z
M]5^9^@VB_P#(&TG_ +!EA_Z2Q5IUF:+_ ,@;2?\ L&6'_I+%6G7]E87_ ';#
M_P#7BC_Z;B(****W **** "BBB@ HHHH **** /Y^O\ @LA\6? G[/7[7O\
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M<D'IC/./%?\ A]=_P3!_Z.DB_P##%_M/_P#SD*_ICVCU;_OM_P#XJC:/5O\
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MVQN&MYC;W*V_P3_:9G:VN%2.1K>Y6+X)N;>X6.6*1K>8),L<L4A0)+&S3?\
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M8_#2W7]L?9S=-JS>&88?#,NN,YUNX\-0P^'Y]1ET>)+(>U44 %%%% !1110
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MTD\TLC]-110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M457N+NUM K75S;VRN2J&XFCA#L!DJID90Q Y(&2!STJM_;&D_P#04T[_ ,#;
M;_X[64J]&$G&=:E"2M>,JD(R5[-73:>J:MZKN!HT5%#-#<1B6WFBGB;(62&1
M)8V*DJP#H64X8$'!X((/(J6M$U)*46G%I------7336C36J:T: ***:'0MM#
M*6'50PW#\,YI@.HH!!&001ZCD44 %%%% !1110 4444 %%%% !1110 4444
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M5QXBO(#,\-QK4V@Z98/J,D,ES=S1?:FD6*>[O)XU6:[N7E /4**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>sganda.jpg
<TEXT>
begin 644 sganda.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M;_V:M97X./!\1XKSP1JOA?0O@YX;\8^(M&T!_'&JZ1XA^+OAY9VMO"6FV_\
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M)+JX\RXD"@/(P H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y@^-/[6G
MPR^!'QG_ &5_@5XSL/%]WXR_:^^('CCX;_"ZZ\/Z5IE]H&G:]\/_ (;:U\4M
M;N/&=]>ZWIEYI.ER^'M"NK73I]*T[7KJXU>:VMIK*UM&GOX/IX$, PZ$ CZ$
M9K\0?^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(H \GO/C1X1
MLKNZLIH-;,UG<W%I*4L8"AEMIG@D*%KU2R%XVVL54LN#@9Q5?_A>/@W_ )]]
M=_\  "V_^3J^8?$'_(?UW_L,ZI_Z77%9%?SQB/$SB:G7K4XRR_EIUJD(WPC;
MY8S<5=^VU=EJ[?\ !#ZU_P"%X^#?^??7?_ "V_\ DZC_ (7CX-_Y]]=_\ +;
M_P"3J^2J\F^.NJ^,M%^$WC._^'GB'PIX6\<BVT6R\*ZWXUU;0=!\/P:MJWBK
M0-(6R.L^*[34/"VF:_KEI?7>@>";SQ/IVI^'(?'6J>&6U[2]3TG[987$TO$O
MBFK5I4E/+8NK4A34I822A%SE&"E)JJVHIN\FDVEK9VLP_0T_'/P6OWH=<7ZV
M-L/YW]'_  O+P9Q^XUSGI_H-MS]/]/Y_"OYM_@IXQ_:*^._P=^!7@;P/\2?C
MY??$O0O$GB*T^+>D>,OC+\%O@/\ %[R;_P""?@KQKX!LKWXJ>!O!/Q6M_BEX
M$)\7P>+VUWP;\/-5\:V/]N^'M,^*MOX<L]$GOIVZI^U!\4O'NCZ[XW\ :K^T
M'X8^%'P%_9G^$/QB\3:QIOCGX"-XLN+;6-6^+>G?$GQY\0+SQ[H.L:%^TC/X
M:O/A!J?A:R\$>%=2^'7@GQFEGXF\3P>,(/%?B_X=6-C[;XOXP56=/ZUDC]G-
MQJ3="48PYZ\L/AG-.K[1?6IQYL.E!JK3DITI35KNWFOZ_K7M\F?TD_\ "\_!
M>=ODZWN_N_8K;/'7C[?F@_'/P6IP8=;!/0&RM@?R-_7X_P"DZ1XAU7]L+4+?
MPU\</CS=^#/ ?@*T^*7Q)\!:YX]L-2^&-UK7QKF\3Z-\(/AUH7@N?P99ZEX=
MT#0=!\)^,/B5>13Z_+K%M/#\/])DG>WN]=$R?M*Z'XB\0^._@9X9\!_'7X\?
M#;Q;\5_%QT&UM/AG\1-%T;P/IWP\^&FEWWQ-^+?CR_\ "][X/U^/Q#X@E\,6
M^G^ M(DFU6+39M;\:^%[BY@-KI%S'>^>O$+BAUJ5%XC*U[3#K$3D\!5_<0]G
M*N_:Q]IS+EP\'B&X<_[F46KRO +?\'39:?YV_P"'/V#_ .%X^#?^??7?_ "V
M_P#DZC_A>/@W_GWUW_P MO\ Y.KY+9@S,P18PS,PC4LRQAF)$:LV794!"JS$
MLP +$DFDK@_XB?Q1WR__ ,(WY?\ 3[U_I:H^M?\ A>/@W_GWUW_P MO_ ).K
MH/#/Q-\.^*]4&DZ9%JB71MYKH-=VL4,/EP&,.-Z7,QW_ +U=HV8//(QS\55Z
MW\%?^1V3_L$:G_Z'9UZ^0^(?$68YUEF!Q+P/L,7C:%"M[/"N$_9U)QC+EDZL
MN5V;L[.WRU:Z^2_5+]3Z]HHHK]V$%%%% !1110 4444 %%%% !1110 4444
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M1WVH6B^)_ GPY\0?%#3/$/Q+F\7:8/$4+:EXHTF^UG]B1T_$_P S^OJ.QXH
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M% !2-]U_]Q__ $ TM(WW7_W'_P#0#2EL_1_D..Z]5^9^@VB_\@;2?^P98?\
MI+%6G69HO_(&TG_L&6'_ *2Q5IU_96%_W;#_ /7BC_Z;B(****W **** "BB
MB@ JK?6D=]9W=E*$:*[MKBVD5XUE1H[B%X7#Q/\ )(I60AD;Y7&5;@FK5% '
MY>:=^PQ)X9\3Z7<>&O@5^QPDFB:SIFKZ)\2Y--^+.F:YI%WI5Y;WVFZ@GPOM
M;W4=-NK[3[FWBN(DA^+FFVDLT"[%M(I/*A_332H+ZUTS3[?5+Y-3U."RMHM1
MU*.S33X[^^2%%N[V.PCFN$LH[F<231VBW%P+9'$/VB?9YKWZ* /Q _X*3_\
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M  0I_P"SK?VH/_6.?B#7[>1_ZN/_ '%_]!%?B'_P4G_Y22?\$*?^SK?VH/\
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MZA_;.\&-#<ZG?W$3'X;_ !^!:*:[FDC;CX0L/F1E/!(YZGK6=_P_#_X)1_\
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M/P_^"4?_ $>9X+_\-Q\?_P#YT%(W_!<3_@E'M;_C,SP6<JP&/AO\?^I4@?\
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MGP^$MI(;ACK-_I=OIQ6&:&9A<D12QRE''L%!&01Z\4 ?E9\,/%_[0/AWXE?
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MQWXHT1X;)?"OAG2M"LM,@'ABZU[^U=>NO6_VAOV1_A%^T?/X6UWQ=H]KI7Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>spinraza.jpg
<TEXT>
begin 644 spinraza.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KY%_;._::N?V5_AAX9\<V>G?#JZNO%?Q<^&/PIAU+XN?$J3X1_#/P
MRWQ%UYM'_P"$F\9>.XO"WC&72-*TH1GRXTT.<ZAJ%Q96'VBT%P;A/KJO%_C-
M\%])^,T?PSBU?5KW2T^&GQC^'OQBL5L[:TNEU/5/AY?7E_8:1>+=@B*QO9;L
M_:+B ?:H3%&\&'Y !XC\.?VVOA3K!^'GA7Q[XX^&[_$;QPWA.V>_^".K>//C
M%\ [/5/B;=7TGPDT1/V@8_ASX9\$6FN?$W1X+*Y\'Z+XG?PUJOB+4+^SL?#]
MIJL6K>'+O7)/&?[=?P9T']D7X@_MG^$;3Q_\3OA'X&\,77BFT;PC\.O'":[X
MUTZWBTQUO/!NCZMX=LM2UW1"^J1Q7/BFPL;GPUIYL=;DN]32+0=6>TA\3_L9
MZ5K_ ,5=7\9VGQ-\6Z%\./&GQ*^#'QG^(_P=T_1O"[Z)XM^*G[/\?@N'X;:[
M:^);C37\2>&M%)^&GPUG\7^&=+:2V\1S^ =!-G?Z!:7_ (MM?$_:2_LK>$KS
M]CY?V.M2U_7KCP>?@5#\"Y?%5O'IUGXE.F0>$H_"T7B.& 6\^D1:U$8HM52W
MDM+C2VO$$,]K/:-)$X!Q'@O]NOX2>(?B[XX^$'B2/7O NMZ%\2O!WPZ\*7GB
M+PIX^L+#7+WQM^SS\./V@-$M?&FHZGX,TS0_A#XRU+3?&FN:)H_P\\?ZUIGB
MG5[CP;?R6MH-0NAH]M[%\'/VEO@_\>IM0M_AGXBU/4Y[+0_#_BVVCUWP9XW\
M$-XA\#>+)-1B\*_$+P8OC?P[X>/C?X=>)Y-)U)/#OCSPF-8\*ZPUI)]CU217
M@:7PZ?\ 8DTWQ'9:Q)\1/B+JWB[7_%_Q[^%O[0/CW4[3PWI?AFQ\2^)?AW\$
M? _P1U+1K;2-/O[M]"T'Q?HW@L:K>+9ZG/J.CWNK74&EWGE6UI*J?L<?L'_#
M7]CD:Q_PAB^$;R:?PEX1^'6C:EH?P7^$/PQUZ/P+X&-X="@\8>(?AYX6T;6_
MB!XLNS=1/XA\2:Y?6^FZC<Z=9ZAIOA30]3N-:O=8 /$]3_;N^._P^\4?';_A
M;WP4^"NA_#KX!?&#]GGX1^*/$W@SXY?$/Q3XDU"X_:/\4_!K3O"OB'3?"VI?
ML^>'+9K3P]X=^+UO?Z[I2:[<:K?>(-%;P]H$.H1ZI:ZG']06?[<G[,]VWAB%
MO'NH:;=^*+3XJWXT_7O ?Q#\.:EX4T_X&:QH^A_&/4/B7I^O>%=.O/A3I_PS
MOO$&A/XRO_B3#X6LM&T[6]&U:>X.F:MIMW=P>)_V1?#/BC6?C)J]QXNURWD^
M,?QO_9B^-VIPQ6.G/%I&J_LR:E\(-2T'1=/>3YKG3O$LGPATR/6+BX)NK)=7
MOS88:"VKE9OV#OAOJ^J_&2X\3^(O$6NZ!\</"_[57@OQCX?\G3M/3_A'/VLK
M[X53^-K33M3@CEN[>;1[3X6VEEHMTR2;QK%U<WD4DEI:*0#K[3]N/]G2^\./
MXBMO$7C5IW\0>&O#&F>"Y?@W\9+7XJ>(]5\::#KWBOP=_P (G\([OP%!\3/%
M6F^*?"GA7Q5XIT36]!\*W^BW?AWPIXLU=M0AL_"WB&33%^.G[4L?@C]E'7OV
MF_@;X4L_C^1I?A/4/ ?@VS\27'@L^.[KQ5XU\/\ @VWT.'5KSPYK5_H.O1W>
MM3VW]CZIX<&I0>(;$^&]7M-)O3=26/R4O_!)/X+_ /"#V6AW7_"K+CQ9H'C_
M ,->//#FKP_LI_LZZ5X%N9O"G@/QM\-;*S^(GPIT7P?IV@_$E]6\+?$3Q?=Z
MWJVN:O9WMCXMU%/$7P__ .$ CADTFY^W/#W[-?A#PI\"?A_\!/#EY%HGA[X>
MZY\,?$.G7F@^$_!?A6";5/AO\4O#?Q:#Q>%/!F@^&O!.BP^(/$?A^3^T+'0-
M!TVSM8=3NI;6V-P/-E /G[Q#_P %$OAOI'QD^$_A*TT_3KCX)^//V9O&W[2W
MB_X]ZCXE?3-*^'N@:1X8T#Q[X)TFY\,IH5]/JK^+/ %UXB\6:O>MK&F3^&+/
M3?#MO#I>O2^+(6T[TJZ_;T_9LLH[&&[U[XA0>)-1\2>*?"%O\.W^!?QQ'Q93
MQ-X.\ Z;\5-;T2[^$O\ PKO_ (6-97Z?#76-.\>Z='=^&H4UOPG<C6M'DO;2
M.=HO!U_X):?" >'M2\)?\)]\14\-7^K_ +3%W:VL<^B_;O#.D_'ZV\)Z=X5\
M->$=0N=/NDT?1/V?=)\"^#])^$5C<66J6MM9^'[&W\0VVK0O?0W?K/@7]BU=
M$^*FB?'3QQ\6O$OQ$^+$/B'Q?X@\4^(;KPQX9\+Z9X@.O?"?0_@[H.CV7AS0
MXQ:^&](\)^&M%DU.VC@N-1O]7\2:_K^H:CJ'V"?2]+TD \LU_P#X*B?"*U^(
M&H>#?"WA/QOXHT32OB3^RMX,/Q$B\,>,XO WBWP_^U=X.OO&/@GQ3\*M7T_P
M=J\?Q-O8K1-(L[3PCX;,^N>(;O6(QI"-':7++]":;^W!^SEK$O@2VTCQ7XFU
M>]\?V3:C:6&D?"OXL:IJ'A*RB\>:I\++JZ^*MA8>"+B]^#T%A\3="U[P!J<G
MQ1M_"8TOQ7X?\0Z5J7V1_#^M26'AG@O_ ()P^&? NL_".XT?XI^)Y?#WPQTG
M]E W>@7OA[09I?$WB[]D?P;J?P[\$^*&UE)HKC18?$G@W57L/%>@06M_9MJ-
MAINK:)=:5(-3M]47QM_P3F\/^+8O"]I%\5M=T6VT'Q[\7?'"ZQ9^ /AS-\1O
M#-Y\7/VAO%7[0^K7_P '?BRVCQ?$;X/>*8-9\3GP?=:[H'B#5-)UKPCIEE]M
M\)1Z_P";K3 'UK\8_P!H_P"$GP&DT2W^(^NZQ9WVOZ=XDUVQTKPSX)\<?$#6
M8O"W@M-+D\:^-=4T;P!X<\3:IHO@7P;'K>C?\)5XTU>TLO#>A2ZQI-M?ZE%>
M:G86]QQ=I^VG^S9>^.=3\ 0?$3&J:-X@UGPGJ>OW'A7QG:_#FR\4Z%\*M.^.
M5YX=G^*UQX>C^&B:U/\ ![4HOB7I>GGQ7]HUGP9;:CKNE)=V>FWCQ>?_ +6W
M["GPU_:N\1^ _&?B4^&K?Q5X(\,^.O -O<^,OA+\,_C5HD_@CXDW_A75/$T-
MCX4^*F@Z]HFB^+[#4_!NAZAX4\96,#OI,JZA8ZYHWBK0=1N-'JAK'[ /PMUW
M0M5\(:CK.K?\(9KGQTUWXR:AX9T[3M)T>P_LWQ#^RQJ/[)][\/K$Z1%91Z1X
M?C\#:E-J.GWFEP65QINI1V]IIUM:Z;;PV\8!7\._\%%O@9X@\6^.--6/QC:>
M%?#W@[]G[7?!^J3_  X^+,7CSXH>(OC_ *K\=(/#OA;P+\&KSX>6?Q&\2;O#
MWP5N/&.BZSX<T?7+'Q#X8U/4]<5=.T7PKJFIL_XR?\%$/@A\.?A_'XO\&7.I
M?%#5[[P]X#\5:?H.C^&_B!9Z?I^A^/OBY:_!O2)?B!XIA\#:KI/PGU&Z\7V_
MBW1=,T/XD#PUK.I^)? OBOPQ'8PZIH>K+8>5^*_^"8VA?$BS;4/BU\7;SXO>
M.='7X()X.UCXE_"/X4^*?!FF0_ /3/CKX9\(V_BGX77.CIX4\;Q>(?"7[07C
MNQ\<-?/I=W>:]/:^*/"%UX'N+'2+#2M:\_X)I>$(/#2>"?!7Q2UWX?\ @SQ'
MX*^&/A'XK^&/"'PX^$OAW0_'DWP@^)FN_%?P5K>CZ/X:\*>'M$^'$\GB3Q9X
MET[Q39>#]*CLO$GAR]M()!9>)+*?Q5J !^FZMN!.,89U_P"^'9<_CMS3J:J[
M01G/S,W_ 'TQ8C\"<4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *8_P!T?[\?M_RT7^?0^HXI]% '\M/CGXG?%;2?V2/B]^S/
M%\2OB5%JUSX>UK]O;0?B(/&WBV+Q+8_!&X\=W^LZW\-K3XBG68O$%D^G_M=6
M-OX8MO#\.O 0_!3Q'%X9AL8?!EHUFGU;\2O^"D_QI\+_ !-^/N@^![OP#XKT
M7P]X _;CG\'6FN:+X5T"\\"^/_V4;*[N?#5GXJ\-:%\7/&GQ2DT7Q/J&F:UI
M6MZE\0_"?PS/B>S@L/%OP^T33M$N;"TUO]UWT?2I(F@?3;!X7MFLVB:RM6B:
MT:7SFMFC:(HUNTO[UH2IB,GSE"W-0GP_H33WUR=&THW&J-OU*X;3K)I]0?[&
M-/WWTK0&2[86 %D&N6E(L_\ 11^X_=T ?C!^T/\ M)?&W18?VK/A'XI^/'PE
M\.>(OAQ\)/B-X4TOP%9>#->\)_%KXP?VW^Q[XL^-,OQQ^%VIZ=XXU34?!FB>
M$_%C7OA+09#H^O\ AS3K7X3^/9O$_CB/Q=J.F'PU]@?L>?%/XPZ]XJ^(/PB^
M+VN^$O%EWX%^$W[,7Q*T'Q)X8\/:OX;ECLOC1X6\<PZEX2U6+5O$GB:?7G\.
MZU\,KN[L?%DLVEW^M67B+[-J>CPW6F?;+[[DN=&TB\NOMUWIFGW-Z;"YTO[7
M<65M-<_V;>LCWFG^?+$\OV&Z>*-[FSW_ &:X>-&FB=D4BU%9VD$LDT-M;Q32
MQ6\$DL<$4<DD-J)1;0O(B*[Q6XFF$$;,4A$L@B5 [Y /Q"^&7CSPK8_M;SCX
M8?M S7'PW\?_  "_:)U76OB/HO[0GB;XR^,M&\0:)<> M<?XG_M3?"+XR:3:
M?#_]G(_"'4G\4^&OAD;'1[K3WGNY?A]XPTSPQH%I#X:E^E_V _C_ /!H_ W5
M]#NOVG?"OQ.N]$_:J_:"^&&G^*_%_P :?#'COQAK][XL_:E^,.C?!S2M6UR/
M6)FN]:\>:3ID4'@#2+2WL;+5K"TBTWP/I$&A:?8Z?:?HHWAOP\_]M;M#TAO^
M$DB,/B'=IEBW]NPFV:S\K6MUN?[6C^R.UKLU#[2OV=F@QY3,AY>#X2_#*U%J
M++P#X0T];+6M"\10)IGAW2=+C&M^&#=-X=U*6/3;2TCNKK0I+RXFTA[I9QIU
MQ)]ILUAG1)% /S+_ ."BOC+X-67BJV\"R_M WW@[]J'Q?\+DA^"7AF[_ &D_
M^%(^!_@#%<>(=;TX_M<>,+.T\3>%H;RQT?7KRRTT6WB>/QS>?$A?!2_##X>^
M"Y++5OBG=R^:Z5XWU#_A>'A75[+XH>+-0_; NO\ @H!XR^&?C/X57'CWQ%!9
MR_L@6FI^-8]*FE^"_P#;TWA?3/A-!^SI;^"_C?X<^(</A5$G^)=]IT\7BQ]9
M\4WT&H_LCXA^'O@/Q;<PWGBGP7X3\275O"EO!<Z_X:T36;B&"-I62&*?4["Z
MECB1IIF6-'5%,LA"@R.6Z!-(TN/4#JJ:=8IJ;6*:8=06TMUOCIL<K3QZ>;P1
MBY-C',S3)9F7[,DK-*L0D):@#\-= ^+6EZE\)_\ @H]X'\!?MJZ'\3_&/A/X
MW^ /&TOC/Q)^T7X2T77;CX6Q_"']DS6/C#I6@>+? +2Z9\"/!OB%]1\=?#70
MO%?@SPYH/@_X3>)?$PUI[K3=:L]8U\_17["7Q)U&6S_:SUG2+;6--_9R\$^*
M/"][\(-&G^(EW^T1=>%;BU^#^EZ]\6_"FE^-O#GB3XA6GB@:3XF6SO+GPA\.
MO''CWP]X=\3ZMKGA70=<_MU-7\/:)^CNB_#GP!X;N9KWP_X(\(:%>7%I/I\]
MWHWAC0M*N9K&YE6>YLY;C3]/MII+2XG19I[9W:":51))&S@$=+IVF:=I%C;:
M9I5C9Z;IUG$L%I8:?:P65E:PIG;%;6EK'%;V\2DDK'#&B DD*"2: /P1^%__
M  43_:2^)VM67@WPWXB^%>H/XT\;?L:2^&?B)<^&?!NIVFF>%/VE/$GQU\/>
M-](N?!GPN^.?Q+L-+UGPE9_"G2=8\,Z!XJ\?Q^--,O-:;3/'4%Q;26]V.6_:
M-_;0^/GB+X#?&#P;K?Q7^&?PK\1>$?A!\7-/L]5L?#&O^'_%O[2'COP%^UG\
M;_V:M97X./!\1XKSP1JOA?0O@YX;\8^(M&T!_'&JZ1XA^+OAY9VMO"6FV_\
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M)+JX\RXD"@/(P H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>66C@'[<?Y_+K14<1<QH945)"H,B(YD1'(RZI(4B,BJQ(60QH9  Y1=VT24
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M<._^$&/\O^IKY?CZW/\ B)7$/_/G*_\ PFQ'E_U&>3^_R/U+_P"&I_@WG/\
M;6K=<_\ (LZYC/)R!]DP"<G) R<G-)_PU-\&_P#H-:L> .?#6NG(&<!B;7+
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M)V*_WG$?]?ZW_IR04445PF 4444 %%%% !1110 5]+_LF_\ )7(O^Q6\0?\
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M<V9'\/!']G\CVSS7XQ?\%)_^4DG_  0I_P"SK?VH/_6.?B#7[=I_JH_]V/\
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MM-O&<TI\TG)QERINM*FE;6G0IU)P;52,*D)?9[*59D)!*,RDC=@E6*Y =4<
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M6NW=_>R6VBZ-#H?AW1?JW^Q)_P#H/:[_ .!5E_\ *ZOSQ_X; ^*'_0+\&?\
M@KU;_P"7U'_#8'Q0_P"@7X,_\%>K?_+ZC_B/' /_ #^S;_PVR_\ EP?\1%X;
M_GQO_A*__EA^AW]B3_\ 0>UW_P "K+_Y74?V)/\ ]![7?_ JR_\ E=7YX_\
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MK5]3U#1+?X6:/XL^)GAK7O!GBZZ?5+N]_;T# Q]?Y]/IZ>V* /Q!_P""D_\
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M%\"O^>GCC_PD3_\ +6OQWHH_U0RGOC/_  ?#_P"4^O\ 2U/[#P7>O_X,C_\
M(?U=^5OV(_X;B^!7_/3QQ_X2)_\ EK1_PW%\"O\ GIXX_P#"1/\ \M:_'>BC
M_5#*>^,_\'P_^4^O]+4_L/!=Z_\ X,C_ /(?U=^5OV(_X;B^!7_/3QQ_X2)_
M^6M'_#<7P*_YZ>./_"1/_P M:_'>BC_5#*>^,_\ !\/_ )3Z_P!+4_L/!=Z_
M_@R/_P A_5WY6_8C_AN+X%?\]/''_A(G_P"6M1S?MR? I8)W,GC@A()W(_X1
M$\JD3L0/^)L#G .!D?6OQ[J&Y_X];S_KSN__ $FEI/A#*;/7&;/_ )?P[?\
M7GU_I:CR+!-6O7_\&1_^0_J_I;^]_P !Q/K'@CP=JUGX@UU+34_"OAS4+5&A
MT6)EMKW1;&Y@5HWTB1XV$4J!D:1V5LAG8@L>YL[2:U\SS=1OK_?MV_;!8CRM
MN[/E_8[*S^_N&_S/,^ZNW;\V[A/@W_R2/X7?]DZ\#_\ J+:37I-?W5A$HX3"
MQ6T</02]%2BD?T)05J-%+I2IK[H(****Z#4**** "BBB@ HHHH 3 SG STSC
MG'IFEHHH _$#_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OVZ7_51_2+^:5^(O\
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M$DD16+*DDB*Q!4LJ.RJQ4\J6 #%3RI.T\@TRE)R2< 9).  JC/95  51T"@
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M\TK\1?\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]N5(\J/KTB['U3VH _@\^//\
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M4K>*]\.W5UI\@L'L;@P75U UR]K=7-O+\F#_ ((KZ", ?\%-_P#@L]@8P/\
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MH_LW+O\ H P/_A)A_P#Y7Y?GW8OJN%_Z!L/_ .":?_R/DON/YS/^(9;]B_\
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MS\S^V?[+T3S]G]F1;OM:BNQ))))))*R2T22V271(Z-M@HHHI@%%%% !1110
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MGZ%X;L-3\0:OXU\0_P#"1'5=&TW3[.7SM/TO4)IC#%#)/%\SWW[?&@1_L]?
M3XWVOPR\2V.J?M%>+6\">#O _C3Q9X"\$VOA7Q3%8^.=3N=/^)WQ+U'6[OX>
M>$A%!\/]9TNT-AJWB2Y\1>*[O2/#/A&T\0WFH).GVOXXM_&MUX4UR#X=:GX7
MT;QO)8L/#6I^--#U?Q)X5L]466)X9M<T'0?$/A75]3L JR++:V'B'2;ARR%;
MQ55D?\PO#G_!/SXQ2?!'X6?"CXG_ !2_9_\ B<GP3\8>)O$/A+POXE_9Y\5:
MU\"_'NG>++;Q%/<P_&;X2>(_C;JS>*_$WA'7_$$FM?#3Q+IOB;3+3PA=P27$
MOAW5[^[2]L0#]$?@?\6=*^.7PM\)_%+1M'U;0=/\56VH21Z7K+Z;<7-O-I.M
M:GH%Z]KJ6B7VIZ'K^B75]I-S>>'/%.@:C?\ A_Q9X>N-+\2Z#>W6DZK9S/ZO
M7@G[,_P03]G;X.^'?A1%X@C\00:#J7B[4K5M/T>3PUX7T"T\5^,-=\66O@CX
M?>$I=9\1R>"_AAX#M]:C\'?#3P4?$&MKX2\$:+H>@1ZG=Q6"/7O= !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%5KR5X;2YF0@/%;SR(2,@-'$[J2,C(W*,C(R.*'HF^P;%F
MBOY*9?\ @L%^VDDLJ#6_AAA9957_ (MI"?E61E7)_P"$@&3@#)[U]O\ _!/+
M_@H9^TE^T?\ M):;\,OB=J?@BZ\*77@?QIKLL.A>"X]#U$ZCH::0U@RWZZO>
M%8%^V3^=#Y!\W*?,NWGX3 ^(>0YCC<+@</3S!5L77IX>DZF'I1IJ=62C%SDL
M3)J-WJU%M)/1Z7^>P_$V78FO1P]..)YZ]2%.#E2@H\TVDG)JJVE=ZM)Z=&?O
MO1117W9]"%%>0^/_ (NZ;X ^('P-^']YI-_?WOQQ\:^+/!6DW]K/;1VNB7?A
M3X4^.OBM<WNI13?OKBWNM.\#7>E01VF94O;ZVFD_T>.:O&--_;H_9VBDDT_Q
MWX^\/_#7Q$?'GQ,\&6GAWQ9JL45]<6/PZ^/GCO\ 9W'C.XFM(9;/2/".O^._
M =]:6NMZS/8Z;I4^H:9INM7UI?7EJMR ?8M%?&&F_MT?!,?&ZW_9]\3ZK_PC
MGC^^T#X]^-K2]21]9\!V7@;]G[QVO@?Q;JWBGX@6EI!X8\(:NL@N]5O_  _K
M=[$_AJVTK4K/7]1M-1.D6^K]Q!^V)^S3<>#;;QZGQ>\*KX:O/&ND?#RTN)VU
M.TU&[\8Z_IQUW1=#M?#UWIL'B2XNM5\+)-XSTUXM':TOO UO<^.+:YD\(V\^
MMQ 'TO17Q1=_MN^ K+]B_P .?MIW/A_5$\$^*O#/@'7])T-]=\*6,D;?$SQ=
MH/@GPL=8\8:WJVC^"=!\.IK'B72KWQ#XUUC6+3PWX<\-"_\ $5_<M96+I+G:
M+^W7X)L/&'P+^%_Q;\#^,OAA\2_V@O$?Q!\.?#NQMCI?Q)\!^((_AUX7T7Q?
MJ?BS1_B=X!N-2\/W/@C5=*UZT@T;6]6MO#]]'JMGK%EK^B:%%I<UXX!]T45\
M.^.?^"BW[)_@3PCIWC:X^(=QXDT/4OBG\*/A+"_@WPOXH\07JZU\:-;N=#\
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MO?!/X>_!GX'?#WP%XF/B"YT_5-%^'U[%XI\,ZA:^*;BVTO\ 3ZB@#\]O"'[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>tecfidera.jpg
<TEXT>
begin 644 tecfidera.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M@U\.?BU--KG@+QQX7\*^*?!5]I@^(":(=)U:RFFNX;"'68IT@U**VA^3H/\
M@E/\"HO$/QCU!)='L-/^)[?%_4M(U30/A!\'-&^+/@WQ3\:O'C?%#Q)XA_X7
MBG@ZZ\?^*O\ A&/',DNI^ ])UVY73[33)W\->.1\0M"M].LK#Z]^ GP*U3X0
MZC\6/%7BCXD:M\4/'/QH\8>'/&_C;Q%J'AW0?"ED-9\-_#3P9\+K.UT#0/#R
MFTTO1QH7@?29TM)[K4KT:A-?2W&J79F41 'T912!@>G?L00?Q! (."#@C..>
ME+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SG^V#+)#^R?\
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MR[_F@?COI,O[,7[=W@?X=?M?2_%;X@VW[7WAW2?#WQ&U#XXZ/?W5GX9\9O\
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M#EQIEI]CTQK5;DFZEGD3S0;R'RXMN7&\@@*:_G)K[I_X)V?\G'0?]B!XP_\
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MA_\ R?7X.>3#_P \8?\ OU'_ /$T>3#_ ,\8?^_4?_Q-'^J-/_H.G_X3Q_\
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M^A:>R.CH2KHRD,K*2K*0RD@@UVE>5? KCX)_"    ?"[X>X & /^*/T;@ <
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M_P!=\I_Y%66?]B_!?^HU(_RFS7_D9YA_V&XK_P!/3"BBBO0. **** "BBB@
MHHHH *_83_@AK=6UG^W?937=Q#;0CX*_%0&6>1(HP?M'@Y\;W*KG8CMC.2%8
M@8!K\>Z_8O\ X(6_\GZ6/_9%/BI_Z5^#*^!\4_\ DW/&O_9.YE_ZCR/NO#+_
M ).#P?\ ]E!EG_J53/[,O^$E\/?]!O2O_ ^V_P#CE'_"2^'O^@WI7_@?;?\
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MKU]2L[*^DA1[NTM=1DL].DO[>VG,D,-Y)I]B]U&BS-:6Y<Q( ?B=_P %)_\
ME))_P0I_[.M_:@_]8Y^(-?MTO^JC^D7\TK\0?^"EC2+_ ,%(?^"%1AC61_\
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MVD?LD_;K".R"ZQ\:O**7J7?F9TSX;[\A;>#R]F%QG=NW'&-IS_,G7^D?T?\
M_DTW"_\ CSW_ -:+-C_/3QU_Y.CQ+Z9-_P"L_E*_3\@I1U'0\C@\ _4^E)17
M[*?D1^L%Y8W=W_P3DT:^CM])^'EAX2OXO$-GJD5A\(/&7@WXC>(].M/"5Q#?
M:7XFM_L'Q2^'7Q\U.\O9+>[TB4^*=6BO?#FO:'JD6@_#Z]T\6'%:QXJ_:)\6
M_$7]FKX,>#[A?C!\6M/^'UO\6'NO'D&A>)HK3XC_ !L\ 2^+&U]Y]=B31M.T
M[X)_"^^\-W>AR:FE[I&@^*['Q!XLN]'U;59X+2OS9\^8VRV1FE-FEY)J*6GF
M/]F749;6*QEU!;?=Y*WTMC##8R7@07,EG##:/*;>*.-8NF,<$$$$<$$'(((Y
M!!Y!'(//6OBJ'"$:7UQU*^ Q$JV.SO'X55\I52GAZ^;X=89?6)/&K%XVG&$\
M2\93EBZ7UQUJ4:<L)'!X=1^PK\5RJ_5(TZ..H1I8+)L#BI4<T<*F(HY57^L/
MV$5A'A<'4E*&'6$J1PM5X3V524UBIXK$.7[7:!'K%AJ_C\>(?#7QU\0_$KPY
M\*/@OX&U;XA_"#X9^&_"G[4OQ2U0_$GQUX@\1?%GP!X:^*7ABU2?X.V6C0V7
MP@\1>--7\/1^/?&2:%\.;SQ$-#L]2U&R3YS3P7=^'OVV/&OB'3_"%KJOA+7_
M (C_ !C\#_#WQ#\.?#'A+7M'\+?%&]^%TWB31KSPKX'U[6K3PWXD\??"&;Q+
MHWB#6? %O?&"]\8V6I:=X*EOM7B\/V$GYNMEV5G)=UW%7=B[IN!5]CL2R[U)
M5PI 925;()!9Y46T)Y<80!0$"($ 0AD 3&T!& 9   I *X(%983@RIA9YA*.
M9TG',<NKY?6@LN<815;#82@JL(4\="G"G2J8656E@Z5.EA*4,37PU&E2H^S4
M-<3Q=3Q,,!&66U4\NS"CCZ,UF"<I>QQ&)K.G.<\%.I*=6&(C2JXNI4JXJI/#
MT<35JU*WM'/[0_;,LM-T_5_@M9ZAJVKZ_P#%F'X0_P#%Y]>\1^%K#P1XJUGQ
M!)X]\72>";_QAX2L[F[O=#\2M\.GT"&6W\4S+X[NM A\.:CXSMK+5KW[%;_&
M5( !G  RS,V !N=CN9V/5G=B2S'+,22Q)I:^IRG /+,!0P4J[Q,J/M6ZWLH4
M(MUJ]2NX4J%+]WA\/2=1TL-AZ?[O#X>%*A#W*<3YG-,:LQQU?&1HK#QK>R2I
M>UG7DE1H4Z"G5KU+5*]>JJ?M<1B*G[ROB)U*T_>FPJM>_P#'E??]>5Y_Z32U
M9JM>_P#'E>_]>5W_ .D\M>E'=>J_,\^6S]'^1_I&? K_ )(I\(/^R7?#W_U#
M]&KU6O$/@A=ZVGP8^$2PZ/!-&/A;\.]LG]K1Q[L^#=$+ HUDQ4JQ*GYB#MW
MX(KU^QGU";S?MUA'9;=GE;+U+OS,[M^=MO!Y>W"XSNW;CTV\_P"0F9_\C''_
M /89B?+_ )?3[G^KN7?\B_ _]@>&_P#3,#0HHHKA.P**** "BBB@ HHHH 3
MSG STSCG'IFEHHH _$#_ (*3_P#*23_@A3_V=;^U!_ZQS\0:_;I?]5'](OYI
M7XB_\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MTO^JC^D7\TIQW7JOS _SD?VC?\
MDX?X_P#_ &7/XQ?^K)\3UXU7LO[1O_)P_P ?_P#LN?QB_P#5D^)Z\:K_ %WR
MG_D599_V+\%_ZC4C_*;-?^1GF'_8;BO_ $],****] X HHHH **** "BBB@
MK]B_^"%O_)^EC_V13XJ?^E?@ROQTK]B_^"%O_)^EC_V13XJ?^E?@RO@?%/\
MY-SQK_V3N9?^H\C[KPR_Y.#P?_V4&6?^I5,_M-HHHK_+4_TN/YH_^#B__D$?
MLB?]ACXV_P#IL^&E?S!U_3Y_P<7_ /((_9$_[#'QM_\ 39\-*_F#K_2/Z/\
M_P FFX7_ ,>>_P#K19L?YZ>.O_)T>)?3)O\ UGLI"BBBOV4_(@HHHH ****
M"BBB@ JM>_\ 'E??]>5Y_P"DTM6:K7O_ !Y7W_7E>?\ I-+3CNO5?F*6S]'^
M1_I&? K_ )(I\(/^R7?#W_U#]&KU6O*O@5_R13X0?]DN^'O_ *A^C5ZK7^0F
M9_\ (RQ__89B?_3TS_5W+O\ D7X'_L#PO_IB 4445PG8%%%% !1110 4444
M%%%% 'X@?\%)_P#E))_P0I_[.M_:@_\ 6.?B#7[=+_JH_I%_-*_$7_@I/_RD
MD_X(4_\ 9UO[4'_K'/Q!K]N5(\J/KTB['U3VIQW7JOS _P Y+]HW_DX?X_\
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M22222LK'E/(LCDW*6393*3;;D\MP;;;:;;;HW;;2;;U;WW9_-I_Q"Z_L'_\
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MEUJG_P Q-?TE_P"?SZT4?ZQ\0_\ 0^SK_P .N/\ +_I_Y(/[ R+_ *$F4?\
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M81C&\G:,5%62L?S:?\0NO[!__1P?_!1'_P 2ZU3_ .8FC_B%U_8/_P"C@_\
M@HC_ .)=:I_\Q-?TET5M_K'Q#_T/LZ_\.N/\O^G_ )(Q_L#(O^A)E'_AMP7E
M_P!./)'\VG_$+K^P?_T<'_P41_\ $NM4_P#F)I&_X-=OV$ K$?M!_P#!1'(!
M(_XRZU3L/^Q)K^DRBC_6/B'_ *'V=?\ AUQ_E_T_\D']@9%_T),H_P##;@O+
M_IQY(_DC_9__ .#<W]C?XG>(?VE=+\1_'_\ ;[2V^$_[2'BCX6>%3IG[5NKV
M<K>%M*^'/PH\569U5V\*7(O=4&J>,M9$MX%MR]K]CA,7[CS'^D?^(77]@_\
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MOA[X"\3'Q!<Z?JFB_#Z]B\4^&=0M?%-Q;:7^GU% 'Y[>$/V ?#'@;P/#\.]
M\:W9\-67QE_9[^(UG)J.B)-K\WA7X!_ +X-? *P\(:MK5AJFG27VKZ]H?PE_
MM5_%EM!IZ:-<Z\;73]"\G2X7GW?V9_V0_%_P-\:^'O%GBWXLZ-X_@\"_LV^
M?V6O ^GZ-\-V\#2P_#[X8^)-0UCPOK_BF\?QKXJCUKQQ?Z?>PZ=XGNM(L_#/
MA>YN;&*_T#PQX?CN;JRD^[** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>tysabri.jpg
<TEXT>
begin 644 tysabri.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M;_V:M97X./!\1XKSP1JOA?0O@YX;\8^(M&T!_'&JZ1XA^+OAY9VMO"6FV_\
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M)+JX\RXD"@/(P H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHH) !). .23T ]30 44@92-P((]<\<=<^F.^>G>@LHX
M) /N0.X'\R!]2* %HI-RYQD9],C/&,\=>,C\Q2T %%%% !1110 4444 %%%%
M !1110 44FY<[<C/I[XSCZXYQUQSTHR.>1@=3V'XT +12;AZCKCWR.O'7@<G
MT'/2ER",@C&,Y[8]<^E !11UZ44 %%%% !1110 4444 %%%% !1110 4444
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M/_Q5(?VJ?V<E!9OC3\.@J@LQ/B6Q "J"22=W0 $FC_5SB#_H19Q_X;,;Y?\
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M#_\ 8G^&/_3'85V5<;\.O^2?^!_^Q/\ #'_ICL*[*O\ .G'_ ._8S_L)K_\
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M5ZX.O]$\N_Y%^!_[ \+_ .F('\$X[_?<9_V%8C_T],****[#E"BBB@ HHHH
M**** "ONG_@G9_R<?!_V('C#_P!'Z#7PM7W3_P $[/\ DX^#_L0/&'_H_0:^
M2X\_Y(SB?_L38[_TS(^IX(_Y*_AS_L;X+_T]$_>^BBBOX,/[7/R=_P""H_\
MQX_!+_K^\?\ _I'X5K\B:_7;_@J/_P >/P2_Z_O'_P#Z1^%:_(FO[6\(?^3>
MY#_BS7_U<Y@?R!XI_P#)=YYZ99_ZJ, %%%%?I1^?!1110 4444 %%%% !44_
M^HG_ .N$W_HIZEJ*?_43_P#7";_T4]..Z]5^8I;/T?Y']5?PZ_Y)_P"!_P#L
M3_#'_ICL*[*N-^'7_)/_  /_ -B?X8_],=A795_G3C_]^QG_ &$U_P#TY(_O
MC!?[GA/^P:A_Z:@%%%%<ATA1110 4444 %9.OKNT/6%^SM=YTK41]E2Q74WN
M<V4X^SIISS6R7[39\I;)KB!;LL+=IHA(9%UJ1ONM]#[=O6@#\*_"GP ?PI\4
M? *'X ^%]NG>)_ASJH\1:-_P3@\!^&K*Q^TR^'=<::W\5M^TM=7_ (:O/#QN
MS9ZEK%OH6J3>%]9TR^DMK+5GTM([K]U!_4]L=S_G/?K7XU3Z;X*M?VPOC!/X
MH\+? "R\0ZC\?O %]I%_\3_V3OC'\>/B9K%LO@OX96&EZWX5^/UK?Z)X-\$6
M?VG3Y--\)^%+*QUG3?A'J.D2ZUJ>KWBZZ=(TC]E1^'4]!CN?U]3W/- 'X@_\
M%)_^4DG_  0I_P"SK?VH/_6.?B#7[=IQ%'_NQ_KM%?B)_P %*"!_P4C_ ."%
M.3C_ (RM_:?'/J?V.OB" /Q/ ]Z_;=9$,48#H21"  PR3E..M..Z]5^8'\:/
MQF_:V^$&D_&+XN:5>2^+1=Z7\4_B/IMV(?##RP_:M/\ &FN6=QY4O]H+YD7G
M0OY<FU=Z;6VKG \V_P"&QO@O_P ]O&/_ (2C_P#RQKX+_:,Y_:'^/Y'3_A>?
MQB_]63XGKQJO]5<KX8RV669=)O$WE@<))VJQM=X>FW;]WM_GN?YCYEQ/F<,Q
MQ\4L+:.-Q*5Z,[V5:6C_ 'N^C^_R/U9_X;&^"_\ SV\8_P#A*/\ _+&C_AL;
MX+_\]O&/_A*/_P#+&ORFHKO_ -5LL_FQ7_@V'_RK^KORMQ?ZTYIVPO\ X)GY
M?]/?)_?Y'ZL_\-C?!?\ Y[>,?_"4?_Y8T?\ #8WP7_Y[>,?_  E'_P#EC7Y3
M44?ZK99_-BO_  ;#_P"5?U=^5C_6G-.V%_\ !,_+_I[Y/[_(_5G_ (;&^"__
M #V\8_\ A*/_ /+&C_AL;X+_ //;QC_X2C__ "QK\IJ*/]5LL_FQ7_@V'_RK
M^KORL?ZTYIVPO_@F?E_T]\G]_D?JS_PV-\%_^>WC'_PE'_\ EC1_PV-\%_\
MGMXQ_P#"4?\ ^6-?E-11_JMEG\V*_P#!L/\ Y5_5WY6/]:<T[87_ ,$S\O\
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M?)))+T22"OV+_P""%O\ R?I8_P#9%/BI_P"E?@ROQTK]B_\ @A;_ ,GZ6/\
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M_!1'_P 2ZU3_ .8FOZ2Z*/\ 6/B'_H?9U_X=<?Y?]/\ R0?V!D7_ $),H_\
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M@_\ @HCD D?\9=:IV'_8DU_2911_K'Q#_P!#[.O_  ZX_P O^G_D@_L#(O\
MH291_P"&W!>7_3CR1_)'^S__ ,&YO[&_Q.\0_M*Z7XC^/_[?:6WPG_:0\4?"
MSPJ=,_:MU>SE;PMI7PY^%'BJS.JNWA2Y%[J@U3QEK(EO MN7M?L<)B_<>8_T
MC_Q"Z_L'_P#1P?\ P41_\2ZU3_YB:_H[L-(TK2Y-1ETS3-/T^75]0DU;59+&
MRMK234]4FM[6TEU+4'MXHVO;^6ULK.VDO+DRW+V]I;0M*8K>)4T*/]8^(?\
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M8(]>]T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/"-2L_K&(I8:')"<Z<7^\K0YKS5HW:NU9_H-17X$C_@H9^TF2 =2\$8R,_\
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MPL_B4^$(Y_LVO'6)?$2Z"_BXZ9%X4&C'Q?)*/!<<GCKS4T%K;_A T;QR)_\
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M%4>M>.+_ $^]AT[Q/=:19^&?"]S<V,5_H'ACP_'<W5E)]V44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
? %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6787901456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Apr. 19, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,893,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6788548896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">602.0<span></span>
</td>
<td class="nump">446.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">563.7<span></span>
</td>
<td class="nump">496.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">567.7<span></span>
</td>
<td class="nump">501.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on assets and liabilities held for sale</a></td>
<td class="nump">115.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">68.2<span></span>
</td>
<td class="nump">103.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">58.1<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">1,987.1<span></span>
</td>
<td class="nump">1,596.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,502.7<span></span>
</td>
<td class="nump">1,534.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">357.3<span></span>
</td>
<td class="num">(41.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">1,860.0<span></span>
</td>
<td class="nump">1,493.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">422.5<span></span>
</td>
<td class="nump">322.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">28.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,408.8<span></span>
</td>
<td class="nump">1,171.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,408.8<span></span>
</td>
<td class="nump">$ 1,172.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 5.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 7.15<span></span>
</td>
<td class="nump">$ 5.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">196.6<span></span>
</td>
<td class="nump">211.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">197.0<span></span>
</td>
<td class="nump">211.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,680.0<span></span>
</td>
<td class="nump">$ 2,523.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">517.4<span></span>
</td>
<td class="nump">443.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 292.4<span></span>
</td>
<td class="nump">$ 164.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6788642896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,408.8<span></span>
</td>
<td class="nump">$ 1,172.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">16.9<span></span>
</td>
<td class="num">(29.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gain (losses) on net investment hedge</a></td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(17.8)<span></span>
</td>
<td class="nump">44.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">1,429.4<span></span>
</td>
<td class="nump">1,185.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 1,429.4<span></span>
</td>
<td class="nump">$ 1,184.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6787835792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,243.2<span></span>
</td>
<td class="nump">$ 1,224.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,665.8<span></span>
</td>
<td class="nump">2,313.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">2,088.9<span></span>
</td>
<td class="nump">1,958.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">527.1<span></span>
</td>
<td class="nump">526.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">770.2<span></span>
</td>
<td class="nump">929.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">682.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">965.4<span></span>
</td>
<td class="nump">687.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,942.6<span></span>
</td>
<td class="nump">7,640.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">1,372.7<span></span>
</td>
<td class="nump">1,375.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,013.8<span></span>
</td>
<td class="nump">3,601.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">447.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,056.2<span></span>
</td>
<td class="nump">3,120.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,639.7<span></span>
</td>
<td class="nump">5,706.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax asset</a></td>
<td class="nump">2,074.4<span></span>
</td>
<td class="nump">2,153.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,898.3<span></span>
</td>
<td class="nump">1,690.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">26,445.5<span></span>
</td>
<td class="nump">25,288.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">238.5<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">378.0<span></span>
</td>
<td class="nump">370.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities', window );">Liabilities held for sale</a></td>
<td class="nump">97.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,435.0<span></span>
</td>
<td class="nump">2,861.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,148.7<span></span>
</td>
<td class="nump">3,295.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">5,943.2<span></span>
</td>
<td class="nump">5,936.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">1,741.7<span></span>
</td>
<td class="nump">1,636.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">436.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,353.8<span></span>
</td>
<td class="nump">1,389.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,623.5<span></span>
</td>
<td class="nump">12,257.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(219.8)<span></span>
</td>
<td class="num">(240.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">17,026.7<span></span>
</td>
<td class="nump">16,257.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">13,829.9<span></span>
</td>
<td class="nump">13,039.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">13,822.0<span></span>
</td>
<td class="nump">13,031.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 26,445.5<span></span>
</td>
<td class="nump">$ 25,288.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77912953&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31958-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6949230992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6791867280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,408.8<span></span>
</td>
<td class="nump">$ 1,171.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and impairments</a></td>
<td class="nump">121.1<span></span>
</td>
<td class="nump">168.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">45.7<span></span>
</td>
<td class="nump">43.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="num">(11.5)<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax', window );">Loss on assets and liabilities held for sale</a></td>
<td class="nump">115.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">228.0<span></span>
</td>
<td class="nump">53.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized (gain) loss on strategic investments</a></td>
<td class="num">(375.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">50.7<span></span>
</td>
<td class="nump">31.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(136.6)<span></span>
</td>
<td class="num">(134.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(129.0)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">138.4<span></span>
</td>
<td class="nump">121.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">170.3<span></span>
</td>
<td class="nump">257.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(171.1)<span></span>
</td>
<td class="num">(20.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">1,459.5<span></span>
</td>
<td class="nump">1,457.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">1,489.2<span></span>
</td>
<td class="nump">4,068.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(825.0)<span></span>
</td>
<td class="num">(1,919.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration paid related to Fumapharm AG acquisition</a></td>
<td class="num">(300.0)<span></span>
</td>
<td class="num">(600.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(127.1)<span></span>
</td>
<td class="num">(194.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by investing activities</a></td>
<td class="nump">238.8<span></span>
</td>
<td class="nump">1,346.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(655.8)<span></span>
</td>
<td class="num">(250.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(32.2)<span></span>
</td>
<td class="num">(21.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(679.3)<span></span>
</td>
<td class="num">(268.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">1,019.0<span></span>
</td>
<td class="nump">2,535.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">1,224.6<span></span>
</td>
<td class="nump">1,573.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 2,243.2<span></span>
</td>
<td class="nump">$ 4,108.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84241550&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=107668666&amp;loc=SL79513924-113897<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6799396320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>2018 Share Repurchase Program</div></th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>2016 Share Repurchase Program</div></th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>Accounting Standards Update 2016-01 </div>
<div>Accumulated Other Comprehensive Income</div>
</th>
<th class="th">
<div>Accounting Standards Update 2016-16 </div>
<div>Retained earnings</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 12,598.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 97.8<span></span>
</td>
<td class="num">$ (318.4)<span></span>
</td>
<td class="nump">$ 15,810.4<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(235.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">12,612.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,172.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,172.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,171.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">13.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (122.9)<span></span>
</td>
<td class="num">$ (127.1)<span></span>
</td>
<td class="num">$ (250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(37.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(37.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">46.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Adoption of new accounting guidance</a></td>
<td class="nump">479.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 478.4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2018</a></td>
<td class="nump">14,037.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(303.9)<span></span>
</td>
<td class="nump">17,334.6<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2018</a></td>
<td class="nump">14,053.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending balance at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(234.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">13,031.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(240.4)<span></span>
</td>
<td class="nump">16,257.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(221.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">13,039.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,408.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,408.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (655.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (655.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (65.6)<span></span>
</td>
<td class="num">$ (590.2)<span></span>
</td>
<td class="num">$ (655.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(48.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">49.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">13,822.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (219.8)<span></span>
</td>
<td class="nump">$ 17,026.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">13,829.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="num">$ (7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(219.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of treasury stock (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784776432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also commercialize biosimilars of advanced biologics.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including Parkinson's disease, ALS, progressive supranuclear palsy, AD, stroke, epilepsy, cognitive impairment associated with schizophrenia and pain.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the European Union (E.U.).</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2018 Form&#160;10-K. Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Assets and Liabilities Held For Sale</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held-for-sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvement for Lessors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and ASU No. 2019-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Codification Improvements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$463.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a corresponding operating lease liability of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$526.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the adoption of the new leasing standards, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will become effective for us on January 1, 2020, and requires adoption using a modified retrospective approach, with certain exceptions. Based on the composition of our investment portfolio, current market conditions and historical credit loss activity, the adoption of this standard is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FASB issued ASU No. 2018-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative and Hedging</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6949188464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Acquisition of Nightstar Therapeutics plc</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into an agreement to acquire Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. NST's lead asset is NSR-REP1 for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder, which leads to blindness and has no approved treatments. NST&#8217;s second clinical program is NSR-RPGR for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no approved treatments.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the proposed acquisition, we would pay NST shareholders </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.50</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which represents an expected total transaction value of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$800.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on a fully diluted basis, after expected transaction expenses and anticipated cash acquired at closing. We plan to fund the proposed acquisition of NST through available cash and to account for it as an acquisition of a business. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is intended that the proposed acquisition will be implemented by means of a U.K. Court-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006. The proposed acquisition remains subject to customary closing conditions, including the approval by NST shareholders and the issuance of an order by the U.K. Court. We expect to complete the proposed acquisition by mid-year 2019.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784769088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures Divestitures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Divestitures</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Divestitures</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$890.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, subject to certain working capital adjustments and other contractual terms. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the proposed transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees. We may adjust this estimate based upon changes in business conditions, which may result in the recognition of additional losses. We are also obligated to indemnify FUJIFILM for liabilities that may exist relating to certain business activities incurred prior to the closing of the proposed transaction.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we have not included these contingent payments in our estimate of the fair value of the operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the proposed transaction, we also expect to enter into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM would use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determined that the operations to be disposed of in the proposed transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2019 the assets and liabilities related to our Hiller&#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale. The following table presents information related to the carrying value of the major classes of assets and liabilities that were reclassified as held for sale in our condensed consolidated balance sheets:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">27.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">629.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">69.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance on disposal group on assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(115.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets held for sale</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">682.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities held for sale</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">97.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019 we recorded a loss of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$174.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income. This estimated loss includes a pre-tax loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$115.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflecting our current estimated fair value of the assets and liabilities held for sale, adjusting for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and our estimate of the fair value of an adverse commitment of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the proposed transaction. Our total estimated loss is based on current exchange rates and business conditions, and any changes to these factors through the closing date of the transaction will result in adjustments to the carrying values of the related assets and liabilities as well as a corresponding adjustment to the loss amount recognized on the sale.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of assets and liabilities expected to be sold to FUJIFILM is a Level 3 measurement and is based on the expected consideration from the sale, including the valuation of the adverse commitment, as discussed above.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proposed transaction remains subject to customary closing conditions, including filings and clearances under the Danish Competition Act. We expect to complete the proposed transaction in the second half of 2019. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&#248;d facility to FUJIFILM at carrying value.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6949279984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">717.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">281.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">998.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">728.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">258.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">986.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">327.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">173.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">500.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">178.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">550.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">245.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">460.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">462.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,290.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">693.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,983.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,350.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">675.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,025.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">223.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">295.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">518.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">188.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">175.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">363.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">124.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">124.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">174.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">174.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,513.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,166.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,680.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,538.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">985.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,523.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">888.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,051.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">141.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">680.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">826.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(25.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(24.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(60.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(233.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(294.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(92.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(378.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(474.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">932.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,083.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">175.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">176.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">907.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">874.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,083.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,051.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">390.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">349.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">126.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">517.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">443.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">264.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">140.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">292.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the three months ended March 31, 2019 and 2018, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$206.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these condensed consolidated financial statements. For additional information on our collaboration arrangement with AbbVie Inc. (AbbVie), please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K. For additional information on our contract manufacturing agreements with Bioverativ, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784801824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">199.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">606.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">108.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">133.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">770.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">770.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">929.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">770.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the three months ended March 31, 2019, we sold hemophilia related inventory to Bioverativ with a cost basis totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$173.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> pursuant to the terms of the manufacture and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$890.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, subject to certain working capital adjustments and other contractual terms. As a result, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of work in process inventory was reclassified to assets held for sale in our condensed consolidated balance sheets as of March 31, 2019. Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred. In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&#248;d facility to FUJIFILM at carrying value.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6949311584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(542.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(542.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,744.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">261.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,734.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">480.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">480.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">476.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">476.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,638.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,389.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,249.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,638.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,330.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,308.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,731.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,675.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,056.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,727.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,607.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,120.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization and impairment of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$103.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. The decrease in amortization and impairment of acquired intangible asset was primarily due to a net overall decrease in our expected rate of amortization for acquired intangible assets. This was primarily due to lower amortization subsequent to the impairment in the fourth quarter of 2018 of the U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and higher expected lifetime revenues of TYSABRI. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and 2018, we had no impairment charges.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$256.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. Acquired and in-licensed rights and patents also includes our rest of world license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. The net book value of the TYSABRI asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,980.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and the net book value of the TECFIDERA asset as of March 31, 2019, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$63.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our TECFIDERA license rights, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the third quarter of 2018. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">200.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">290.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">230.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">190.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,706.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reclassification of goodwill to assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(69.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,639.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The reclassification of goodwill to assets held for sale relates to an allocation based upon the relative fair value of the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the three months ended March 31, 2019, goodwill was reviewed for impairment due to the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, and based upon this review, no impairments were recognized. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other includes changes related to foreign currency exchange rate fluctuations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784664160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2019 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,881.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,881.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,835.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,835.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">921.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">921.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">281.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">281.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">904.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">884.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">104.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">104.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,958.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,938.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">445.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">705.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">705.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,459.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,459.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">969.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">969.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">615.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">563.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,102.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,050.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">434.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairments of our assets measured and carried at fair value during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our agreement with Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,500.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,486.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,489.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,480.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,022.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">995.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">995.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,795.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,738.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,745.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,737.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,838.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,722.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,802.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,722.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,155.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,943.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,037.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd., Stromedix Inc. and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">409.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$265.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the expected timing of the achievement of certain remaining development milestones, a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to an increase in the interest rate used to revalue our contingent consideration liabilities during the period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6643357440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">446.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">192.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,074.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">279.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">168.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">194.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,881.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">705.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2019 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">981.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">981.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">852.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">854.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">683.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">683.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">237.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">237.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">280.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">280.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,035.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,038.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">489.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">904.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,608.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,607.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">854.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">851.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">706.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">705.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">264.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">263.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,694.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,689.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">496.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">615.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated<br clear="none"/>Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,665.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,665.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,314.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,313.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,234.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,237.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,235.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,232.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">135.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">134.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,035.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,038.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,694.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,689.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,489.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,068.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,049.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was reflected as a component of other current assets in our condensed consolidated balance sheet, with the remaining balance included in investments and other assets. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is included in investments and other assets in our condensed consolidated balance sheet. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in equity securities include approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of Ionis' common stock, acquired in June 2018 at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$625.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is remeasured each reporting period and carried at fair value. This investment is classified as a Level 2 marketable security due to certain holding period restrictions. The remainder of our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1. The effect of the holding period restrictions on our Ionis stock valuation are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis' common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in our strategic investment portfolio primarily reflects an increase in the fair value in our investment in Ionis' common stock as well as an increase in the value of a non-marketable equity security.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our June 2018 investment in Ionis' common stock, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -URI http://asc.fasb.org/topic&amp;trid=2122426<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6949282256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,722.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,701.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">170.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">99.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">79.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">72.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,144.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,239.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$44.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$44.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. The carrying value of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of March 31 2019 and December&#160;31, 2018, includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">seven months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of March 31, 2019 and December&#160;31, 2018, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency forward contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$895.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$735.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recognized as a component of other income (expense), net for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">101.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6949311584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,841.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,797.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, depreciation expense totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$52.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$65.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.7 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding related to the construction of this facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. As a result, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$629.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of property, plant and equipment, which is primarily comprised of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$312.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for buildings and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$286.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for machinery and equipment, was reclassified to assets held for sale in our condensed consolidated balance sheets as of March 31, 2019. Additionally, we ceased recording depreciation on these assets as depreciation is not recorded during the period in which a long-lived asset or disposal group is classified as held for sale, even if the asset or disposal group continues to generate revenue during the period. For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6696685248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease real estate, including laboratory and office space, and certain equipment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our leases have remaining lease terms ranging from less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> year to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one year</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> year to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years. Our subleases do not include an option to renew as they are coterminous with our operating leases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All of our leases qualify as operating leases. The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">447.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">72.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">436.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of lease costs in our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sublease income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net lease cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The minimum lease payments, net of income from subleases, for the next five years and thereafter is expected to be as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">69.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">81.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">76.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">69.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">66.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">577.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Present value of operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">87.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">80.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">601.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(26.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(25.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(58.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(182.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">156.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">418.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term in years</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.88</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets obtained in exchange for lease obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. As a result, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating lease assets and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating lease liabilities were reclassified to assets held for sale in our condensed consolidated balance sheets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784776432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Equity (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2019 Share Repurchase Program). Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. We did not repurchase any shares of our common stock under our 2019 Share Repurchase Program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2018 Share Repurchase Program). Our 2018 Share Repurchase Program does not have an expiration date. All share repurchases under our 2018 Share Repurchase Program will be retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$655.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From April 1, 2019 through April 24, 2019, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$491.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our 2018 Share Repurchase Program. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our 2018 Share Repurchase Program as of April 24, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(31.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(243.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(240.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(16.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(30.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(261.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(219.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(104.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(318.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(104.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(316.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(24.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(29.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(133.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(130.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(303.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784661376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,408.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,172.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">196.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">197.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784778864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">27.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784729200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark assets held for sale</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Global Intangible Low-Taxed Income (GILTI)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Changes in Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the three months ended March&#160;31, 2019, compared to the same period in 2018, the increase in our effective tax rate was primarily due to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense related to the proposed divestiture of our subsidiary that owns our Hiller&#248;d, Denmark manufacturing operations.&#160;Although we are recognizing a loss on the proposed divestiture of such subsidiary, the proposed divestiture requires us to write off certain deferred tax assets upon the classification of our Hiller&#248;d, Denmark manufacturing operations as held for sale and results in a taxable gain in certain jurisdictions.&#160;The effect of this increase to our 2019 effective tax rate was partially offset by a higher effective tax rate in 2018 resulting from the sale of inventory, the tax effect of which had been included within prepaid taxes at December 31, 2017, at a higher effective tax rate. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">International Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to the Danish Tax Authority (SKAT) for assessments received for 2009, 2011 and 2013 regarding withholding taxes on certain payments made by our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. We continue to dispute the assessments for all of these periods and believe that the tax positions taken related to these payments are valid. Any amount refunded by SKAT associated with this withholding tax receivable will be paid to our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. This withholding tax receivable from SKAT will be included within the assets that will be transferred to FUJIFILM as part of the proposed transaction. Under the share purchase agreement, FUJIFILM is required to remit any future proceeds refunded by SKAT to us. We have assessed the collectability of the receivable from FUJIFILM and regard it as a contingent gain, which does not meet the probable threshold for recognition under ASC 450, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and therefore we have recorded a pre-tax charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to write the asset down to zero as a component of the loss on assets and liabilities held for sale in the first quarter of 2019. For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Federal and State Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. As a result, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our deferred tax liability was reclassified to liabilities held for sale in our condensed consolidated balance sheets as of March 31, 2019. For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784784368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(47.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(50.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">376.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">357.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(41.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, gain (loss) on investments, net, as reflected in the table above, substantially relate to marketable equity securities held at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The increase in gain (loss) on investments, net, compared to the prior year period, was primarily due to an increase in the fair value in our investment in Ionis' common stock as well as an increase in the value of a non-marketable equity security.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements. For additional information on our investment in Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">907.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">874.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">216.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">261.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">195.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">224.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">160.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">320.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">444.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">99.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">125.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">708.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">609.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,435.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,861.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,353.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,389.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and included accrued income taxes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$796.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$791.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784810112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our BAN2401 and Elenbecestat Collaboration, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration were immaterial. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expense incurred and, beginning January 1, 2019, is reimbursing us for&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expense incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, following the results of a futility analysis conducted by an independent data monitoring committee, we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia. As a result of this decision, in the first quarter of 2019, we accrued approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the termination of various clinical trials and research and development contracts net of the expected </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales and marketing expense incurred were shared in proportion to the same region-based profit split that would have been utilized to co-promote aducanumab had it been commercialized. For additional information on the Aducanumab Collaboration Agreement, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">162.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">89.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense our condensed consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as potential royalties on net commercial sales. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our condensed consolidated statements of income and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$115 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to inventory, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$615 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to developed technology and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$170 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to in-process research and development. A deferred tax liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$225 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years, respectively, one quarter in arrears. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflecting our share of losses for the fourth quarter of 2018 totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and amortization of basis differences of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">729.9 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$642.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of BENEPALI, FLIXABI and IMRALDI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the European Commission granted a marketing authorization in the E.U. for IMRALDI. In April 2018 we and Samsung Bioepis entered into an agreement with AbbVie for the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales in our condensed consolidated statements of income. We began to recognize revenues on sales of IMRALDI to third parties in the E.U. in the fourth quarter of 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect Samsung Bioepis' </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in revenues in relation to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis and our other significant collaboration arrangements, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6949316576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD, including aducanumab. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, following the results of a futility analysis conducted by an independent data monitoring committee, we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimbursed Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$112.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our investments in Neurimmune and other variable interest entities, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6949311584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH&#160;(Fresenius Kabi)&#160;commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen commercializes in Europe, infringes the French counterpart of European Patent No. 3 148 510&#160;(the &#8216;510 Patent), which was issued in June 2018 and expires in May 2035. In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of the Danish Utility Models. In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the Dusseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. A hearing has been scheduled for May 2019 in the proceeding in Denmark.  No hearing has been scheduled in the other proceedings. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom counterpart of the &#8216;510 Patent. Fresenius Kabi has filed a counterclaim asserting infringement of the United Kingdom counterpart of the &#8216;510 Patent and seeking damages and an injunction to restrain infringement if the patent is found valid and infringed. A trial has been set for July 2019. In December 2018 Biogen B.V. and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the &#8216;510 Patent. A trial has been set for October 2019. An estimate of the possible loss or range of loss in the above matters cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Gedeon Richter PLC asserted to Biogen and Samsung Bioepis UK Limited that IMRALDI infringes European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035. We dispute the assertion. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss was denied in part. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we and certain other drug manufacturers and pharmacy benefit managers were served with a qui tam action filed by John Borzilleri on behalf of the U.S. and certain states in the U.S. District Court for the District of Rhode Island. The case was filed under seal in January 2014 and unsealed in April 2018 after the U.S. declined to intervene. The case alleges agreements with pharmacy benefit managers in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys' fees and costs. We, the other defendants and the U.S. have moved to dismiss the case and the motions are pending. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. In March 2018 the court dismissed the complaint with prejudice. The plaintiff's appeal is pending. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, 2018 and 2019 we initiated patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patent infringement proceedings pursuant to the Hatch-Waxman Act are pending against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Banner Life Sciences LLC, Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shipla Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware and against Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial date has not been set in the Delaware actions against Banner Life Sciences LLC or Zydus Pharmaceuticals (USA) Inc. A December 2019 trial date has been set for the other Delaware actions, and a trial date has been set for February 2020 in the West Virginia action against Mylan Pharmaceuticals Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan Pharmaceuticals Inc. filed a petition with the U.S. Patent Trial and Appeal Board seeking </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. On February 6, 2019, the U.S. Patent Trial and Appeal Board instituted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of the '514 Patent.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the European Patent Office (EPO) revoked our European patent number 2 137 537 (the '537 Patent), which includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for March 2020.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and the appeal is pending. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Boards of Appeal and the Enlarged Board of Appeal, if applicable, to make a final determination.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish &#8216;263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU &#8216;127 Patent) (&#8220;Administration of agents to treat inflammation&#8221;).  The Polish &#8216;263 Patent concerns administration of natalizumab (TYSABRI) to treat MS. The Polish &#8216;263 Patent expires in February 2023. A hearing has been scheduled for May 2019. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of The Hague (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which also concerns administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. The Dutch and German counterparts were ruled invalid and we have appealed. No date for a hearing on the merits has been set in the Italian action.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. In October 2018 EMD Serono and Pfizer filed an appeal from the judgment in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we learned that the Prosecution Office of Milan was investigating our interactions with certain healthcare providers in Italy.&#160;In January 2019 the Prosecution Office dismissed the proceeding. We consider the matter closed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties.&#160;We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending.&#160;We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6781107408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also commercialize biosimilars of advanced biologics.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including Parkinson's disease, ALS, progressive supranuclear palsy, AD, stroke, epilepsy, cognitive impairment associated with schizophrenia and pain.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the European Union (E.U.).</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2018 Form&#160;10-K. Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock', window );">Assets and liabilities held for sale</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Assets and Liabilities Held For Sale</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held-for-sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvement for Lessors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and ASU No. 2019-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Codification Improvements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$463.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a corresponding operating lease liability of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$526.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the adoption of the new leasing standards, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will become effective for us on January 1, 2020, and requires adoption using a modified retrospective approach, with certain exceptions. Based on the composition of our investment portfolio, current market conditions and historical credit loss activity, the adoption of this standard is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FASB issued ASU No. 2018-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative and Hedging</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities Held For Sale [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6639461904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures Divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock', window );">Assets and liabilities held for sale</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table presents information related to the carrying value of the major classes of assets and liabilities that were reclassified as held for sale in our condensed consolidated balance sheets:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">27.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">629.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">69.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance on disposal group on assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(115.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets held for sale</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">682.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities held for sale</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">97.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6788265424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">717.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">281.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">998.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">728.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">258.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">986.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">327.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">173.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">500.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">178.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">550.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">245.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">460.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">462.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,290.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">693.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,983.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,350.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">675.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,025.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">223.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">295.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">518.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">188.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">175.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">363.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">124.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">124.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">174.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">174.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,513.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,166.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,680.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,538.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">985.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,523.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">888.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,051.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">141.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">680.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">826.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(25.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(24.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(60.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(233.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(294.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(92.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(378.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(474.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">932.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,083.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">175.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">176.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">907.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">874.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,083.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,051.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">390.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">349.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">126.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">517.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">443.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">264.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">140.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">292.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6638093200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">199.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">606.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">108.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">133.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">770.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">770.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">929.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">770.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6949290384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(542.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(542.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,744.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">261.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,734.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">480.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">480.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">476.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">476.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,638.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,389.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,249.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,638.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,330.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,308.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,731.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,675.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,056.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,727.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,607.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,120.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">200.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">290.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">230.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">190.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,706.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reclassification of goodwill to assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(69.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,639.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6948754816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2019 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,881.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,881.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,835.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,835.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">921.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">921.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">281.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">281.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">904.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">884.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">104.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">104.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,958.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,938.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">445.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">705.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">705.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,459.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,459.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">969.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">969.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">615.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">563.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,102.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,050.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">434.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,500.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,486.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,489.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,480.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,022.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">995.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">995.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,795.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,738.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,745.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,737.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,838.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,722.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,802.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,722.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,155.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,943.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,037.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">409.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6791842608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">446.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">192.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,074.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">279.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">168.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">194.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,881.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">705.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2019 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">981.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">981.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">852.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">854.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">683.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">683.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">237.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">237.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">280.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">280.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,035.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,038.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">489.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">904.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,608.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,607.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">854.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">851.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">706.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">705.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">264.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">263.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,694.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,689.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">496.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">615.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated<br clear="none"/>Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,665.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,665.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,314.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,313.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,234.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,237.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,235.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,232.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">135.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">134.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,035.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,038.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,694.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,689.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,489.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,068.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6788528272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,722.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,701.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">170.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">99.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">79.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">72.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,144.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,239.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">101.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6795930688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LesseeLeaseTableTableTextBlock', window );">Schedule of operating leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">447.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">72.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">436.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Operating lease cost</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of lease costs in our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sublease income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net lease cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating lease liability maturity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The minimum lease payments, net of income from subleases, for the next five years and thereafter is expected to be as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">69.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">81.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">76.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">69.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">66.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">577.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Present value of operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Minimum lease payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">87.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">80.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">601.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(26.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(25.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(58.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(182.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">156.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">418.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world.</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock', window );">Operating lease weighted average remaining term and discount rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term in years</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.88</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock', window );">Operating lease supplemental cash flow disclosure</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets obtained in exchange for lease obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LesseeLeaseTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Lease Table [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LesseeLeaseTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease supplemental cash flow disclosure [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease weighted average remaining term and discount rate [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6625543056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(31.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(243.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(240.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(16.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(30.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(261.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(219.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(104.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(318.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(104.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(316.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(24.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(29.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(133.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(130.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(303.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784724992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,408.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,172.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">196.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">197.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6697365696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">27.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6949205792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark assets held for sale</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Global Intangible Low-Taxed Income (GILTI)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784776432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(47.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(50.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">376.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">357.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(41.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">907.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">874.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">216.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">261.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">195.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">224.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">160.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">320.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">444.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">99.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">125.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">708.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">609.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,435.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,861.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6720303312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">68.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of Activity Related to Aducanumab Collaboration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">162.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">89.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense our condensed consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6795247920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 447.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 508.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6949279984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Business Acquisition (Details Textual) - Nightstar<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share | $ / shares</a></td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value | $</a></td>
<td class="nump">$ 800.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6795018784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures Divestitures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long Lived Assets and Liabilities Held-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on assets and liabilities held for sale</a></td>
<td class="num">$ (115.5)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long Lived Assets and Liabilities Held-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">629.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisposalGroupOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="nump">69.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets</a></td>
<td class="nump">68.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on assets and liabilities held for sale</a></td>
<td class="num">(115.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets held for sale</a></td>
<td class="nump">682.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">49.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisposalGroupOperatingleaseliabilities', window );">Operating lease liabilities</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">46.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Liabilities held for sale</a></td>
<td class="nump">97.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember', window );">Long-term operating lease liabilities | Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long Lived Assets and Liabilities Held-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisposalGroupOperatingleaseliabilities', window );">Operating lease liabilities</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DisposalGroupOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DisposalGroupOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DisposalGroupOperatingleaseliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DisposalGroupOperatingleaseliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6802380864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures Divestitures (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on assets and liabilities held for sale</a></td>
<td class="nump">$ 115.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Expected costs to sell disposal group</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration expected to be received for sale of Denmark Manufacturing Operations</a></td>
<td class="nump">890.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax', window );">Loss on assets and liabilities held for sale, net of tax</a></td>
<td class="nump">174.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on assets and liabilities held for sale</a></td>
<td class="nump">115.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Future minimum batch production for Denmark Manufacturing Operations</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="nump">$ 59.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6797903168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues by Product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">998.8<span></span>
</td>
<td class="nump">986.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">717.7<span></span>
</td>
<td class="nump">728.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">281.1<span></span>
</td>
<td class="nump">258.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">500.9<span></span>
</td>
<td class="nump">550.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">327.3<span></span>
</td>
<td class="nump">371.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">173.6<span></span>
</td>
<td class="nump">178.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">460.4<span></span>
</td>
<td class="nump">462.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">245.0<span></span>
</td>
<td class="nump">249.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">215.4<span></span>
</td>
<td class="nump">212.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">22.9<span></span>
</td>
<td class="nump">24.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">22.9<span></span>
</td>
<td class="nump">24.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,983.0<span></span>
</td>
<td class="nump">2,025.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,290.0<span></span>
</td>
<td class="nump">1,350.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">693.0<span></span>
</td>
<td class="nump">675.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">518.5<span></span>
</td>
<td class="nump">363.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">223.3<span></span>
</td>
<td class="nump">188.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">295.2<span></span>
</td>
<td class="nump">175.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">124.0<span></span>
</td>
<td class="nump">120.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">124.0<span></span>
</td>
<td class="nump">120.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">35.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">35.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">174.4<span></span>
</td>
<td class="nump">127.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">174.4<span></span>
</td>
<td class="nump">127.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,680.0<span></span>
</td>
<td class="nump">2,523.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,513.3<span></span>
</td>
<td class="nump">1,538.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1,166.7<span></span>
</td>
<td class="nump">$ 985.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6797260976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,051.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">826.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(24.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(294.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(474.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,083.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">127.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">141.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(60.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(92.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">116.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">888.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">680.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(25.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(233.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(378.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">932.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">34.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 35.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6696804512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,083.4<span></span>
</td>
<td class="nump">$ 1,051.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">175.8<span></span>
</td>
<td class="nump">176.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 907.6<span></span>
</td>
<td class="nump">$ 874.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6800721408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">390.8<span></span>
</td>
<td class="nump">349.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">126.6<span></span>
</td>
<td class="nump">93.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 517.4<span></span>
</td>
<td class="nump">$ 443.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6797944016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">$ (3,489.8)<span></span>
</td>
<td class="num">$ (3,131.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(3.9)<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(264.1)<span></span>
</td>
<td class="num">(140.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(292.4)<span></span>
</td>
<td class="num">(164.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">$ (24.8)<span></span>
</td>
<td class="num">$ (17.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6788010192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">31.30%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">14.20%<span></span>
</td>
<td class="nump">15.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 292.4<span></span>
</td>
<td class="nump">$ 164.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other | Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 206.8<span></span>
</td>
<td class="nump">$ 47.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6778957008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 199.7<span></span>
</td>
<td class="nump">$ 196.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">462.3<span></span>
</td>
<td class="nump">606.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">108.2<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">770.2<span></span>
</td>
<td class="nump">936.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">770.2<span></span>
</td>
<td class="nump">929.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6794993280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory Inventory (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventorysoldtoBioverativcost', window );">Inventory sold to Bioverativ, cost</a></td>
<td class="nump">$ 173.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventorysoldtoBioverativcost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory sold to Bioverativ, cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventorysoldtoBioverativcost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779102000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory Proposed Divestiture of Denmark Manufacturing Operations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration expected to be received for sale of Denmark Manufacturing Operations</a></td>
<td class="nump">$ 890.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory expected to be sold to FUJIFILM</a></td>
<td class="nump">27.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember', window );">Work-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory expected to be sold to FUJIFILM</a></td>
<td class="nump">$ 27.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6798432464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">$ 7,731.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,727.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,675.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,607.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,056.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,120.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">68.2<span></span>
</td>
<td class="nump">$ 103.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets and Goodwill (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2019 (remaining nine months)</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">290.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">190.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (542.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(542.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">261.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (2,744.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,734.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 256.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,638.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,638.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,249.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (1,389.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,330.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 1,980.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 63.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 480.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6796283360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 5,706.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">5,639.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill held for sale</a></td>
<td class="num">$ (69.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6798141856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 3,038.5<span></span>
</td>
<td class="nump">$ 3,689.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,881.9<span></span>
</td>
<td class="nump">705.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">904.0<span></span>
</td>
<td class="nump">615.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">104.4<span></span>
</td>
<td class="nump">66.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">29.4<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,958.2<span></span>
</td>
<td class="nump">5,102.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">421.3<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="nump">$ 498.0<span></span>
</td>
<td class="nump">$ 523.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">445.4<span></span>
</td>
<td class="nump">434.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,835.7<span></span>
</td>
<td class="nump">2,459.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">921.3<span></span>
</td>
<td class="nump">969.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">281.5<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,881.9<span></span>
</td>
<td class="nump">705.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">884.5<span></span>
</td>
<td class="nump">563.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">104.4<span></span>
</td>
<td class="nump">66.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">29.4<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,938.7<span></span>
</td>
<td class="nump">5,050.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,835.7<span></span>
</td>
<td class="nump">2,459.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">921.3<span></span>
</td>
<td class="nump">969.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">281.5<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">421.3<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">421.3<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6781498128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 5,943.2<span></span>
</td>
<td class="nump">$ 5,936.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">6,155.8<span></span>
</td>
<td class="nump">6,037.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,500.7<span></span>
</td>
<td class="nump">1,489.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,486.6<span></span>
</td>
<td class="nump">1,480.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,022.0<span></span>
</td>
<td class="nump">1,000.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">995.8<span></span>
</td>
<td class="nump">995.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,795.1<span></span>
</td>
<td class="nump">1,745.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,738.2<span></span>
</td>
<td class="nump">1,737.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,838.0<span></span>
</td>
<td class="nump">1,802.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,722.6<span></span>
</td>
<td class="nump">$ 1,722.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6667708976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="num">$ (5.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(20.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">409.8<span></span>
</td>
<td class="nump">523.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 421.3<span></span>
</td>
<td class="nump">$ 498.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6775885488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs', window );">Fair value measurements, changes in valuation inputs</a></td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 274.0<span></span>
</td>
<td class="nump">$ 265.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the changes to the valuation model inputs that led to changes in fair value of the servicing assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=68078379&amp;loc=d3e122625-111746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6788011104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,881.9<span></span>
</td>
<td class="nump">$ 705.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">446.0<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">192.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">1,074.4<span></span>
</td>
<td class="nump">279.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 168.8<span></span>
</td>
<td class="nump">$ 194.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6794918624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 3,035.1<span></span>
</td>
<td class="nump">$ 3,694.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">3,038.5<span></span>
</td>
<td class="nump">3,689.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">3,038.5<span></span>
</td>
<td class="nump">3,689.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">981.0<span></span>
</td>
<td class="nump">1,608.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">981.4<span></span>
</td>
<td class="nump">1,607.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">852.0<span></span>
</td>
<td class="nump">854.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">854.3<span></span>
</td>
<td class="nump">851.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">683.6<span></span>
</td>
<td class="nump">706.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">683.7<span></span>
</td>
<td class="nump">705.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">237.5<span></span>
</td>
<td class="nump">264.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">237.6<span></span>
</td>
<td class="nump">263.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">280.3<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">280.8<span></span>
</td>
<td class="nump">260.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Marketable equity securities, amortized cost</a></td>
<td class="nump">489.3<span></span>
</td>
<td class="nump">496.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable equity securities, gross unrealized gains</a></td>
<td class="nump">421.7<span></span>
</td>
<td class="nump">127.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable equity securities, gross unrealized losses</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">$ 904.0<span></span>
</td>
<td class="nump">$ 615.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6781609280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 1,665.3<span></span>
</td>
<td class="nump">$ 2,314.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">1,665.8<span></span>
</td>
<td class="nump">2,313.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">1,234.8<span></span>
</td>
<td class="nump">1,235.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">1,237.8<span></span>
</td>
<td class="nump">1,232.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">135.0<span></span>
</td>
<td class="nump">143.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">134.9<span></span>
</td>
<td class="nump">143.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">3,035.1<span></span>
</td>
<td class="nump">3,694.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 3,038.5<span></span>
</td>
<td class="nump">$ 3,689.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6949218800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 1,489.2<span></span>
</td>
<td class="nump">$ 4,068.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="num">$ (9.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6696685248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6782142160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 05, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 1,049.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Purchaseofcommonstock', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 90.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstocksharespurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, shares purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstocksharespurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Purchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Purchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6796894944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="nump">$ 44.3<span></span>
</td>
<td class="num">$ (27.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gain (losses) on net investment hedge</a></td>
<td class="nump">14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="num">$ (4.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 895.0<span></span>
</td>
<td class="nump">735.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">101.4<span></span>
</td>
<td class="nump">65.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">8.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">2,144.0<span></span>
</td>
<td class="nump">2,239.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,239.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Remaining duration of Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedges in AOCI</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as net investment hedge, excluded component</a></td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gain (losses) on net investment hedge</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Gain (loss) on reclassification of cash flow hedges, effective portion</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Gain (loss) on reclassification of cash flow hedges, effective portion</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,722.2<span></span>
</td>
<td class="nump">1,701.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,701.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">170.9<span></span>
</td>
<td class="nump">215.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">99.2<span></span>
</td>
<td class="nump">131.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">79.5<span></span>
</td>
<td class="nump">98.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 72.2<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020 | Interest rate swap | Other long-term liabilities | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109247956&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109247956&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109977999&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6797248288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,841.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,797.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">52.9<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Contractual commitments for the construction of the facility</a></td>
<td class="nump">92.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment held for sale</a></td>
<td class="nump">312.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment held for sale</a></td>
<td class="nump">$ 286.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6798987824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 447.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">436.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">508.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Net lease cost</a></td>
<td class="nump">15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">ASC 842 - Minimum lease payments 2019 (remaining nine months)</a></td>
<td class="nump">69.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">ASC 842 - Minimum lease payments, 2020</a></td>
<td class="nump">81.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">ASC 842 - Minimum lease payments, 2021</a></td>
<td class="nump">76.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">ASC 842 - Minimum lease payments, 2022</a></td>
<td class="nump">69.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">ASC 842 - Minimum lease payments, 2023</a></td>
<td class="nump">68.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">ASC 842 - Minimum lease payments, 2024</a></td>
<td class="nump">66.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">ASC 842 - Minimum lease payments, thereafter</a></td>
<td class="nump">146.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">ASC 842 - Minimum lease payments</a></td>
<td class="nump">577.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">$ 68.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">ASC 840 - Minimum lease payments, 2019 (remaining 9 months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">ASC 840 - Minimum lease payments, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">ASC 840 - Minimum lease payments, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">ASC 840 - Minimum lease payments, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">ASC 940 - Minimum lease payments, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">ASC 840 - Minimum lease payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">ASC 840 - Minimum lease payments total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear', window );">ASC 840 - Sublease income, 2019 (remaining 9 months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears', window );">ASC 840 - Sublease income, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears', window );">ASC 840 - Sublease income, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears', window );">ASC 840 - Sublease income, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears', window );">ASC 840 - Sublease income, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter', window );">ASC 840 - Sublease income, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions', window );">ASC 840 - Sublease income total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInOneYear', window );">ASC 840 - Net minimum lease payments 2019 (remaining 9 months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInTwoYear', window );">ASC 840 - Net minimum lease payments, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInThreeYear', window );">ASC 840 - Net minimum lease payments, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFourYear', window );">ASC 840 - Net minimum lease payments, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFiveYear', window );">ASC 840 - Net minimum lease payments, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsThereafter', window );">ASC 840 - Net minimum lease payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePayments', window );">ASC 840 - Net minimum lease payments total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 418.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in years</a></td>
<td class="text">7 years 10 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">3.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="nump">$ 19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease assets obtained in exchange for lease obligations</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Net lease cost</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Sublease income</a></td>
<td class="num">(7.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Net lease cost</a></td>
<td class="nump">23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Sublease income</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">447.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">72.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember', window );">Long-term operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 436.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFiveYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in five year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFiveYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFourYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in four year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFourYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInThreeYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in three year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInThreeYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in two year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized for the period under subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=77891322&amp;loc=d3e41620-112719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779040336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases Leases (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisposalGroupOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisposalGroupOperatingleaseliabilities', window );">Operating lease liabilities</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DisposalGroupOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DisposalGroupOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DisposalGroupOperatingleaseliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DisposalGroupOperatingleaseliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6782115840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Share Repurchases (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 24, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 655.8<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2019ShareRepurchaseProgramMember', window );">2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember', window );">2018 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 655.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember', window );">2016 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2018 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 491.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6782179744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">$ (240,400,000)<span></span>
</td>
<td class="num">$ (318,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(240,400,000)<span></span>
</td>
<td class="num">(318,400,000)<span></span>
</td>
<td class="num">$ (316,900,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">37,300,000<span></span>
</td>
<td class="num">(24,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="num">(16,700,000)<span></span>
</td>
<td class="nump">37,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">20,600,000<span></span>
</td>
<td class="nump">13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(219,800,000)<span></span>
</td>
<td class="num">(303,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">20,600,000<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">7,100,000<span></span>
</td>
<td class="num">(8,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="num">(2,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">34,700,000<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">34,700,000<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">31,200,000<span></span>
</td>
<td class="num">(60,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="num">(14,300,000)<span></span>
</td>
<td class="nump">31,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">16,900,000<span></span>
</td>
<td class="num">(29,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">51,600,000<span></span>
</td>
<td class="num">(133,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">16,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(31,300,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(31,300,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(30,700,000)<span></span>
</td>
<td class="num">(37,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(243,300,000)<span></span>
</td>
<td class="num">(175,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(243,300,000)<span></span>
</td>
<td class="num">(175,500,000)<span></span>
</td>
<td class="num">(175,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="num">(17,800,000)<span></span>
</td>
<td class="nump">44,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(17,800,000)<span></span>
</td>
<td class="nump">44,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (261,100,000)<span></span>
</td>
<td class="num">$ (130,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL34724394-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6775885248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">$ 357.3<span></span>
</td>
<td class="num">$ (41.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">422.5<span></span>
</td>
<td class="nump">322.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3,489.8<span></span>
</td>
<td class="nump">3,131.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,408.8<span></span>
</td>
<td class="nump">1,172.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">16.7<span></span>
</td>
<td class="num">(37.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">32.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6796963040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,408.8<span></span>
</td>
<td class="nump">$ 1,172.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">196.6<span></span>
</td>
<td class="nump">211.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">197.0<span></span>
</td>
<td class="nump">211.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6776064624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 49.0<span></span>
</td>
<td class="nump">$ 46.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">49.5<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">46.2<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(7.4)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">21.7<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">27.8<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 38.8<span></span>
</td>
<td class="nump">$ 39.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6782137200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 49.0<span></span>
</td>
<td class="nump">$ 46.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">49.5<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">46.2<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">34.7<span></span>
</td>
<td class="nump">36.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6781074688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets', window );">Denmark assets held for sale</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">Effective Tax Rate Reconciliation, GILTI tax</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">22.70%<span></span>
</td>
<td class="nump">21.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6781547936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income tax payment, including penalties and interest</a></td>
<td class="nump">$ 60.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="nump">59.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred tax liability held for sale</a></td>
<td class="nump">$ 46.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783246352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 31.2<span></span>
</td>
<td class="nump">$ 26.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(47.9)<span></span>
</td>
<td class="num">(50.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="nump">376.4<span></span>
</td>
<td class="num">(14.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">357.3<span></span>
</td>
<td class="num">$ (41.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,083.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,051.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses</a></td>
<td class="nump">216.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">160.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">147.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Construction in progress</a></td>
<td class="nump">99.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">708.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">2,435.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,861.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 907.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 874.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784811632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 1,353.8<span></span>
</td>
<td class="nump">$ 1,389.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">$ 796.1<span></span>
</td>
<td class="nump">$ 791.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783227312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">68.0<span></span>
</td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">34.0<span></span>
</td>
<td class="nump">26.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember', window );">Skyhawk Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment to Skyhawk</a></td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="nump">74.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="nump">35.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">162.5<span></span>
</td>
<td class="nump">63.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">89.4<span></span>
</td>
<td class="nump">63.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6795092624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="num">$ (28.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">58.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,131.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity maximum</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="nump">$ 28.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="nump">14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of basis differences</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="nump">$ 642.1<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 729.9<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">$ 58.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 24.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventory | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember', window );">Deferred tax liability | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6947539472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">$ 112.2<span></span>
</td>
<td class="nump">$ 28.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInVariableInterestEntitiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6795440576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation Litigation (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_BR', window );">Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSought', window );">Brazil tax assessment, including interest and penalties</a></td>
<td class="text">70.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSought">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the form and magnitude of the award the plaintiff seeks in the legal matter, which may include an unspecified amount of money.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSought</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>117
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MKC_\KL+.&[NS_]CX(BA;^'47\@M02P,$%     @ T(683IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    " #0A9A.7BEC-60"  !U"   &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'U6VXZ;,!#]%<0'+-B&!%8$*4E5M5(K15NU?7:($] "IK83
MMG]?V["4XJ$O^';.G!G;XR'KN7B5)6/*>VOJ5N[\4JGN.0AD4;*&RB?>L5:O
M7+EHJ-)#<0MD)QB]6%)3!S@,-T%#J];/,SMW$GG&[ZJN6G82GKPW#16_#ZSF
M_<Y'_OO$2W4KE9D(\JRC-_:-J>_=2>A1,%FY5 UK9<5;3[#KSM^CYR.*#<$B
M?E2LE[.^9T(Y<_YJ!I\O.S\T'K&:%<J8H+IYL".K:V-)^_%K-.I/FH8X[[];
M_VB#U\&<J61'7O^L+JK<^8GO7=B5WFOUPOM/; PH]KTQ^B_LP6H--YYHC8+7
MTGZ]XBX5;T8KVI6&O@UMU=JV'U8B,M)@ AX)>"+@Z+\$,A+(1$"6$ R>V5 _
M4$7S3/#>$\-I==1<"O1,]&869M+NG5W3T4H]^\C#+'@8,R/B,"#P#($F1*!M
M3P(8$CA@AX[_%3BZ" (+$# "8NED1H]@>@32(TN/9O1XL0$N8@,+Q*! [-"W
M"P$7D< "&U!@X]#3A8"+0"&LL 45MBX?+20 "(8E$E B<?ED(0% 5DXZ!252
ME[\\:@"R(H%".)U"U\)FF5  9KNBLI*TR+60+%4 3+JB F;N'F'' G8>!P"S
M\CP@.'T1<2W@I0J 67DC$)SER$UB'"U57,SJZ<.ICMQ,QHLK=APQL<6TX[F0
M)"4D75Z"8/:(-TS<;+V37L'OK2VVL]FIINZQ+0)_X4-!_DK%K6JE=^9*EQ+[
MX%\Y5TQ[%#YI7TK]#S -:G95IKO5?3$4PF&@>#<6^6#ZT\C_ %!+ P04
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M;0/;MZ_MA&RP)WM#;///S#<39^S%C?$W<:94>N]UU8BE?Y:RG8>AV)]I343
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MY6+*_O?JK:J#?' 2^GAJZF[\NWAZ[?KF,+42K!S*;^?/_7'\?#]_4V13F!Q
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M<]U^5<WW<OO^U?:B+C;ZW;+)[@6WT_\!4$L#!!0    ( -"%F$X <E&EM0$
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M!;4/Q\]XMM.8388W_?R#V/*-BW]02P,$%     @ T(683CQ/^$JT 0  T@,
M !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q]4V%OVR 0_2N('U 2.VNC
MR+;4M)HZ:9.B3EL_$_MLHP+G HZ[?S_ KNMVUKX =]Q[]^XXL@'-LVT!''E5
M4MN<MLYU!\9LV8+B]@H[T/ZF1J.X\Z9IF.T,\"J"E&3)9G/-%!>:%EGTG4R1
M8>^DT' RQ/9*<?/G"!*'G&[IF^-1-*T+#E9D'6_@)[A?W<EXB\TLE5"@K4!-
M#-0YO=T>CKL0'P-^"QCLXDQ")6?$YV!\JW*Z"8) 0ND" _?;!>Y RD#D9;Q,
MG'1.&8#+\QO[UUB[K^7,+=RA?!*5:W.ZIZ2"FO?2/>+P %,]7RB9BO\.%Y ^
M/"CQ.4J4-JZD[*U#-;%X*8J_CKO0<1_&FS2=8.N 9 (D,V ?\[ Q451^SQTO
M,H,#,6/O.QZ>>'M(?&_*X(RMB'=>O/7>2['=7V?L$HBFF.,8DRQCY@CFV><4
MR5J*8_(//%F'IZL*TPA//RB\62?8K1+L(L'NOR6NQ>P_)6&+GBHP39PF2TKL
M=9SDA7<>V-LDOLE[^#CM/[AIA+;DC,Z_;.Q_C>C 2]E<^1%J_0>;#0FU"\<;
M?S;CF(V&PV[Z06S^QL5?4$L#!!0    ( -"%F$Y$2NWFM@$  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;&U386_<( S]*X@?4!+NVEU/2:1>
MIVF3-NG4:=MG+G$25(@S()?NWP](FF5MO@ V?L_/QF0CFF?; CCRHE5G<]HZ
MUQ\9LV4+6M@;[*'S-S4:+9PW3<-L;T!4$:05XTERQ[20'2VRZ#N;(L/!*=G!
MV1 [:"W,GQ,H''.:TE?'DVQ:%QRLR'K1P'=P/_JS\19;6"JIH;,2.V*@SNE#
M>CSM0WP,^"EAM*LS"95<$)^#\:7*:1($@8+2!0;AMRL\@E*!R,OX/7/2)64
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M.QZ>>+M/L#=E<,96Q#L4[]![+K;?=AD[!Z(IYC#&),N8.8(A^YPB64MQ2+[
MDW7X;E7A+L)W'Q2FZP3I*D$:"=(/!)>?2ER+N?J4A"UZJL V<9H<*4VOXR0O
MO// WB;Q3?Z'C]/^D]M&:$=.QN/+QO[7QGA *9L+'*$6/]AL2*A].%[CV8YC
M-AK>=-,/8O,W+OX!4$L#!!0    ( -"%F$ZX5NJAM@$  - #   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;'U3[8Z<(!1]%<(#+*-C.[,3-=G9IFF3
M-IELT_8WHU<E"UP+.&[?OH"N-5W3/\"]G'/N!Y=\1/-L.P!'7I34MJ"=<_V)
M,5MUH+B]PQZTOVG0*.Z\:5IF>P.\CB0E6;K;O6>*"TW+//HNILQQ<%)HN!AB
M!Z6X^7T&B6-!$_KJ>!)MYX*#E7G/6_@&[GM_,=YBBTHM%&@K4!,#34$?DM,Y
M"_@(^"%@M*LS"95<$9^#\;DNZ"XD!!(J%Q2XWV[P"%(&(9_&KUF3+B$#<7U^
M5?\8:_>U7+F%1Y0_1>VZ@AXIJ:'A@W1/.'Z"N9YWE,S%?X$;2 \/F?@8%4H;
M5U(-UJ&:57PJBK],N]!Q'Z>;?3K3M@GI3$@7PC'&85.@F/D'[GB9&QR)F7K?
M\_#$R2GUO:F",[8BWOGDK??>RD.6LUO0F2'G"9*N(,F"8%Y\B9!N13BG;^CI
M-GV_F> ^TO?KZ/>';8%L4R"+ MG_*GP+2>Z/_\1@JXXJ,&V<)4LJ''2<XY5W
M&=>'^(3L+WR:]:_<M$);<D7GWS5VOT%TX%/9W?D!ZOSW6@P)C0O'@S^;:<@F
MPV$__Q^V?.+R#U!+ P04    " #0A9A.2EA@%[4!  #2 P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q,RYX;6Q]4]MNW" 0_17$!P0ONVF3E6TIFZIJI59:
MI6K[S-IC&X6+"WB=_GT'[+A68_4%F.&<,Q>&?+3NV7< @;QH97Q!NQ#Z(V.^
MZD +?V-[,'C36*=%0-.US/<.1)U(6C&>9>^8%M+0,D^^LRMS.P0E#9P=\8/6
MPOT^@;)C07?TU?$DVRY$!ROS7K3P#<+W_NS08HM*+348+ZTA#IJ"/NR.IT/$
M)\ /":-?G4FLY&+M<S0^UP7-8D*@H I10>!VA4=0*@IA&K]F3;J$C,3U^57]
M8ZH=:[D(#X]6_91UZ IZ1TD-C1A4>++C)YCKN:5D+OX+7$$A/&:",2JK?%I)
M-?A@]:R"J6CQ,NW2I'V<;F[W,VV;P&<"7PAW*0Z; J7,/X@@RMS9D;BI][V(
M3[P[<NQ-%9VI%>D.D_?HO9:[^_N<7:/0C#E-&+[&+ B&ZDL(OA7BQ-_0^39]
MOYGA/M'W:WJ6;0L<-@4.2>#PWQ+?8GCV;Y%LU5,-KDW3Y$EE!Y,F>>5=!O:!
MIS?Y"Y^F_:MPK32>7&S ETW];ZP-@*ED-SA"'7ZPQ5#0A'A\CV<WC=ED!-O/
M/X@MW[C\ U!+ P04    " #0A9A.>@C$<[0!  #2 P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q]4V%OW" ,_2N('U!R)-VJ4Q*IUVK:I$TZ==KZ
MF4N<!!7B#,BE^_<#DF;9%NT+8./W_&Q,/J%YL1V (Z]:];:@G7/#D3%;=:"%
MO<$!>G_3H-'">=.TS X&1!U!6C&>).^8%K*G91Y]9U/F.#HE>S@;8D>MA?EY
M H5300_TS?$DV\X%!ROS0;3P%=RWX6R\Q5:66FKHK<2>&&@*>G\XGK(0'P.^
M2YCLYDQ")1?$EV!\J@N:!$&@H'*!0?CM"@^@5"#R,GXLG'1-&8#;\QO[AUB[
MK^4B+#R@>I:UZPIZ1TD-C1B5>\+I(RSUW%*R%/\9KJ!\>%#B<U2H;%Q)-5J'
M>F'Q4K1XG7?9QWV:;])L@>T#^ +@*^ NYF%SHJC\43A1Y@8G8N;>#R(\\>'(
M?6^JX(RMB'=>O/7>:\D3GK-K(%IB3G,,W\0<U@CFV=<4?"_%B?\#Y_OP=%=A
M&N'I'PK3?8)LER"+!-E_2]R+R?Y*PC8]U6#:.$V65#CV<9(WWG5@[WE\D]_A
M\[1_$::5O247=/YE8_\;1 =>2G+C1ZCS'VPU%#0N'-_[LYG';#8<#LL/8NLW
M+G\!4$L#!!0    ( -"%F$[K<,*IM0$  -(#   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;'U3VV[<(!#]%<0'!)O=3:*5;2F;*&JE5EJE:OO,VN.+
M HP+>)W^?0$[KMM:?0%FF'/FS#!D(YI7VP(X\J:DMCEMG>N/C-FR!27L#?:@
M_4V-1@GG3=,PVQL0500IR7B2W#(E.DV++/K.ILAP<++3<#;$#DH)\_,$$L><
MIO3=\=(UK0L.5F2]:. +N*_]V7B++2Q5IT#;#C4Q4.?T(3V>]B$^!GSK8+2K
M,PF57!!?@_&QRFD2!(&$T@4&X;<K/(*4@<C+^#%STB5E *[/[^S/L79?RT58
M>$3YO:M<F]-[2BJHQ2#="XX?8*[G0,E<_">X@O3A08G/4:*T<27E8!VJF<5+
M4>)MVCL=]W&Z.:0S;!O 9P!? /<Q#YL21>5/PHDB,S@2,_6^%^&)TR/WO2F#
M,[8BWGGQUGNO!4\.&;L&HCGF-,7P54RZ1##/OJ3@6RE._!\XWX;O-A7N(GSW
MA\+;;8+])L$^$NS_6^)6S-U?2=BJIPI,$Z?)DA(''2=YY5T&]H''-_D=/DW[
M9V&:3EMR0>=?-O:_1G3@I20W?H1:_\$60T+MPO'.G\TT9I/AL)]_$%N^<?$+
M4$L#!!0    ( -"%F$Z;,#V M@$  -(#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;'U386_<( S]*X@?4!+NUMU.2:1>IVF3-NG4:=UG+G$25 @9
MD$OW[V=(FF5KU"^ C=_SLS'9:.R3:P$\>=:J<SEMO>^/C+FR!2W<C>FAPYO:
M6"T\FK9AKK<@J@C2BO$DN65:R(X66?2=;9&9P2O9P=D2-V@M[.\3*#/F-*4O
MC@?9M#XX6)'UHH'OX'_T9XL66U@JJ:%STG3$0IW3N_1XVH?X&/ H872K,PF5
M7(QY"L:7*J=)$ 0*2A\8!&Y7N >E A'*^#5STB5E *[/+^R?8NU8RT4XN#?J
MIZQ\F],#)1748E#^P8R?8:[G'25S\5_A"@K#@Q+,41KEXDK*P7FC9Q:4HL7S
MM,LN[N-T<WN88=L /@/X CC$/&Q*%)5_%%X4F34CL5/O>Q&>.#UR[$T9G+$5
M\0[%._1>"YX<,G8-1'/,:8KAJYATB6#(OJ3@6RE._!6<;\-WFPIW$;[[1^&'
M;8+])L$^$NS?+'$C)DW^2\)6/=5@FSA-CI1FZ.(DK[S+P-[Q^"9_PZ=I_R9L
M(SM'+L;CR\;^U\9X0"G)#8Y0BQ]L,134/AS?X]E.8S89WO3S#V++-R[^ %!+
M P04    " #0A9A.3DBAQ[4!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6QU4V%OW" ,_2N('U N7-95IR12K].T29MTZK3U,Y<X"2J$#,BE
M^_<S))>F7?8%L/%[?C8F&XU]=BV )R]:=2ZGK??]@3%7MJ"%NS$]='A3&ZN%
M1],VS/461!5!6C&^V]TR+61'BRSZ3K;(S."5[.!DB1NT%O;/$909<YK0J^-1
M-JT/#E9DO6C@!_B?_<FBQ1:62FKHG#0=L5#G]#XY'-,0'P-^21C=ZDQ")6=C
MGH/QM<KI+@@"!:4/# *W"SR 4H$(9?R>.>F2,@#7YRO[YU@[UG(6#AZ,>I*5
M;W-Z1TD%M1B4?S3C%YCK^4#)7/PWN(#"\* $<Y1&N;B2<G#>Z)D%I6CQ,NVR
MB_LXW=Q>8=L /@/X KB+ #8EBLH_"2^*S)J1V*GWO0A/G!PX]J8,SMB*>(?B
M'7HO!4^2C%T"T1QSG&+X*N8U@B'[DH)OI3CR?^!\&[[?5+B/\/T;A?\A2#<)
MTDB0OB'8ORMQ*R9]EX2M>JK!-G&:'"G-T,5)7GF7@;WG\4U>PZ=I_RYL(SM'
MSL;CR\;^U\9X0"F[&QRA%C_88BBH?3A^Q+.=QFPRO.GG'\26;US\!5!+ P04
M    " #0A9A.9OPZZK8!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6QM4]MNW" 0_17$!X0UNTE6*]M2-E652JVT2M3VF;7'-@H7!_ Z_?L
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M\R\;^]]H[<!+V5SY$>K\!YL- 8T+QUM_-M.838;3??I!9/[&Y1M02P,$%
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M[']MC >4DESA"+7XP19#0>W#\3.>[31FD^%-/_\@MGSCXA]02P,$%     @
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M TSU?*)D*OX;7$%B>%"".0HC75Q)T3MOU,2"4I1X&_=6QWT8;_;)!%L'\ G
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MP19#0>W#\1.>[31FD^%-/_\@MGSCXB]02P,$%     @ T(683C0>2V6P 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL?5-A;YPP#/TK47Y
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M;3NMV>1XT\\OB"W/N/@#4$L#!!0    ( -"%F$ZQBK4AL0$  -(#   9
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M    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;'54;6^;,!#^*X@?4(,3"(T
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MI7'3V,[5>"O'P,AN>G#(_.IE?P%02P,$%     @ T(683J \Q?'Y 0  RP4
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M.QSW(3\F_)(PNI5-0B=G8UZ#\[W*:1($@8+2!P:!QP7N0:E A#+>9DZZE S
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M-YJ=$(R$8"($Z8>$<"2$KP3_0P(>"7A!0$,J9F]V1)(BYZQW^%#=CNB?R'_
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M,1^ZY3"1K!LO C3=1L5_4$L#!!0    ( -"%F$[T6/=7SP$  #H$   9
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M[@6%>VZ4LN"L)!OGI7.#/ <<&NNW[]U>Q^<< ZN&:5+)_'=1_@%02P,$%
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M^R"!(8D-=LSQ6X$M@,AAA1@,(C;V\9L@4I@@ 0D20Y",">+)(EA(9B"M@7Q
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M[7UD3%+E8Q2H$W96#=TPJ.E1ZL]<?7/;U=B!9%W?L85#V[CZ U!+ P04
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MPS 8W3R;X]AT0PF32^P.& :CJ5(8&XN4,."$ -=AH#G@"PH<T^YAP D!KN-
M<\ 7Q+ECN->$"2=$N,X#S0E?\"@V9H4A)P2YSL!@%$RD$FYX:!%&G #B9/@
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MM-:,25"*GJO2->K^6@H*M=335,WY]!=/A63#?$'AY98L_@)02P,$%     @
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M78[-6M;S1;W1HFIFI[ =X.;_ %!+ P04    " #0A9A.\6,6"74"  "M"
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M/_H#5RLTNYR;%CK1L,[A<-FY'X*G*M-Z(WAI8!"+N:,K.3+VJA=?SCO7UT!
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M%UR7%#J'C1+?T0%A*)C)3@;2R8#L4-@!1G 9H^4*X9E.@!=HU(/B<;B(..T
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MBT)\(2%#"S,U.6NQTP)DJ1[]ADX-8<XHP)F8A U%B!*<D ;(N(A]-8K"K%&
M-3$)')HR/1$WH()+O%&,J:50!>>>H%G1^"0U9>X1A!6-3V4UCT@,AZ/S[.X/
MAC^RZOUTKA=O9=.417^ ?2C+QK1=MCLR6!Q-MK]=Y.;0=!_C]G,U'.P/%TUY
ML7]:A+=_3C;_ U!+ P04    " #0A9A.3+!\:5T"  "\!P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V,RYX;6Q]E=N.FS 0AE\%\0"<# 96!*FAJEJIE:*M
MVEX[B1/0 J:V$[9O7]NP*&M/>Q.?_IGYQB8SU<SXBV@IE=[KT(]BY[=23D]A
M*$XM'8@(V$1'=7)A?"!2+?DU%!.GY&R,ACY,H@B' ^E&OZ[,WH'7%;O)OAOI
M@7OB-@R$_]G3GLT[/_;?-IZ[:ROU1EA7$[G2[U3^F Y<K<+-R[D;Z"@Z-GJ<
M7G;^A_BIB2-M8!0_.SJ+A[FG4SDR]J(77\X[/])$M*<GJ5T0-=QI0_M>>U(<
MOU>G_A93&S[.W[Q_,LFK9(Y$T(;UO[JS;'=^X7MG>B&W7CZS^3-=$\I\;\W^
M*[W37LDUB8IQ8KTPO][I)B0;5B\*92"OR]B-9IR7$YRM9K!!LAHDFT&<_M<
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M3*I/RCS\BC$)RF,8J.MJU"B< @*5U-N-VG,[$&P@63_..C0-W.(?4$L#!!0
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MCR\;^]\8XP%32>YPA#K\8(LAH?'A>(]G.XW99'C3SS^(+=^X_ -02P,$%
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MA7?30AUF8S%X@$$]PE/J?0@,A=C@"7T48 L@DD?(;@J)4]A$ .89&'[PD&<
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MQ)BDRJ4_4RXOZANAGY3T)/4P46-N+TH[D:SI/@*\_DMD]1=02P,$%     @
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M,4:5P)@M22=IQTE@(G-$9!<=G')6,#A*@?).N^7>V!=&,D=(=N'!$3XE+,Z
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MM2P;TSJ,O[3G86^RW64C-Z]-]S5IOU?#&QC#1E.>[-LET>45E_5_4$L#!!0
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M\CF8U(D#CWRX;'U S,1W01.5CQ[_,@BL[!7"@(IH>'O@44X&AS&_"[D5 E\
M* "$Q!,4\!6 PD^D ZY;%#V2CNCN.6P3 H'PA!CX$D#0+3!UR.#219^H7007
M+X*J=Y02J#31,"7W0;=BX )&4 6G, 6&ZP[[CZ<$PW6'T0,I:4'WBN8NQ KQ
M>EU 1?G1-$S"V;%S+?7_;6^U:\I66'<1@_6U:M9L:_5!8SN]GX0?BUHX6R95
MCV(ZB0-CDBJ%_DQI.ZGFLIN4]"#U,%%C;CLL.Y&L:;M'KVMAE_\!4$L#!!0
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M."-0 8)FJ"0@E02@$HZH)%-58F?\H1E0- 3-_#TI2"0%B(R4WZ33=!-GQ+8
M03%,)0.I9!,JP4Q5(@^N?._QJD$SS0,]4#<=:)BKCP95802!4=D,';#1K)$_
MU<2?\0 W$O2!3H+@5H(>Z24=Z"[;Q$G'F@"H=%#I]W3@AH*@CC+SH2&X$:#X
M Z+ !8R@"IZ(DDS:9Y!.10%0V:2=N(/[KR;LI$<%;NWII1'JIAF<]N/(VE?W
MY^A\H\84?:^^NS$SS@_,3F7#K1T5\G;6=^B14D$D2<^1JI_E6-5O*G(4:IG(
M-3.SA=D(VG9SD]L/;ZM_4$L#!!0    ( -"%F$X5<2WY( ,  ($-   9
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MMC\4]#>"-\.!)QQ/7<M_4$L#!!0    ( -"%F$[[-:XI? (  $,)   9
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M WO)[7J=F.A".JI\BH0:W#UE"!(P40:0&!6>L(D0F: CV10(-SL:($"A#12
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M(Y='W=Q&YK[JSOA=0ZM+__WB#Q]1Z[]02P,$%     @ T(683O1-7V3. 0
M8@0  !D   !X;"]W;W)K<VAE971S+W-H965T.# N>&UL?531CIP@%/T5PP>(
MBCOK3-2D.TW3)FTRV:;M,Z/7T2R(!6;<_GT!&6,=TQ?A7L\YG"-@/@KYIEH
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M-=3T.>U:A]PD;<GMNL&^POK_VIJHV]'730S)RG_M'"G,=L# !$-&A-]Z'T,
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M9ZD5V9;63%,G;5+4:MMO8E_'J'RX0.+N[0N86$D:[8_A7LXYG(.A'+5YM3V
M0^]2*%OAWKEA0XAM>I#,+O0 RJ]TVDCF?&D.Q X&6!M)4A"Z7*Z)9%SANHR]
MG:E+?72"*]@99(]2,O/O$80>*YSA<^.9'WH7&J0N!W: %W"_AYWQ%9E56BY!
M6:X5,M!5^&NVV>8!'P%_.(SV8HY"DKW6KZ'XT59X&0R!@,8%!>:'$VQ!B"#D
M;;PE33QO&8B7\[/Z]YC=9]DS"ULM_O+6]14N,&JA8T?AGO7X!"G/%XQ2^)]P
M N'AP8G?H]'"QB]JCM9IF52\%<G>IY&K.(Y)_TR[3Z")0&="MOHO(4^$_(9
M)F<QZC?F6%T:/2(S_:R!A3N1;7)_F$UHQK.+:SZM]=U37:S6)3D%H81YG##T
M D.O$=O/B'4Q0X@W,+N@=UW0R,^O7#S<%\CO"N118'4E4-S$F##KB%$1DV5T
M<1OE,XH6BULOY.)XPW7_Q<R!*XOVVOD_%<^ST]J!%UPN_!WJ_0N;"P&="],'
M/S?3/9L*IX?TA,C\CNL/4$L#!!0    ( -"%F$YNN(8:P@$  !,$   9
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MOV7AG_\M__/;9%ZL@CCW_'CA7<1YF&^\RYA'")/8._&RI9\&V;_]D/_YWW[
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M@=?Z%/O%(H3OC^&2?KI[Z[6.CN6R>F'L78=1!!<F:WM']I_;;NII^<O[) ?
MI,%3$!=5$G">9'Q-@Z]K7'7V8^T3L.3,CP)82/!U'A6X;\]?)6D>_L97&H<(
M ;'"E. )S_OS?Q1A"CL/8X#48SB+ L_/LB"OK.$VR.#0YTL:9 $+C9(UCE)^
M[BZ [<>/;>\QB .\W?B\OUB%,1&+/'RJ(-]5D@&\8YF87HA"?Q9&81X"B)=!
MM/" +M'FJMCQ2OL[3Z+(GR4IC[1.DX<P]UH1+(W/N@:)IF;P$WAA#G<>CG _
M,-&>6X_ ((YQZP^P9N_)CXH 1E@%?E:D@=K#',@_S(Y_P:]9N AXD34GE*?%
M/"]PK=Y\B:2KLDU&M'D9H<J/">H_I,G* U['$U:>^I@O@7:&<DUDK..V%P>5
M_<J LP .,E"OY/Y7M0)>#< 3+C-<HHA0X@%^?8)=!0&-B1_ *PU#6X-5B,2+
MQOT W_!"F[]1&.+G>1K.BMQ'!,L3+TYB/+8TH<N V!< 9N39?O-5AGL3)G#^
M2) JO-1Z"\Z)R5*%/+SQLW#N 6+&L)K,/'C(1&_#J$ :^6VC? ["QR4,<^(_
M 58!;Q4Z6F1TCSS@#_,B\A'A*[NX29,%X'<M?MT*Z624!9DD/#E_V^]ZB*'^
M.BARV#_<T<?47]6C\8LX!++I-%C"<T#6MO.+K;Q!C]HX:+,TQI=P[KS$"%$!
MX*<81-0H_ WV@90G8^P-,B)!63 'RD$4UW_RPX@.4Y'=;7B[==2YGRV]ARAY
M!C*^> RV7H#W\+;S<DRXC3>58$,C'#0[4@,DYS/@14C/DUD4/A(MV[8.%B[G
M&P^%VRP2WK+XM>!UU!] /2H@F0>"^('GNO>_MKT;9%@PX+1T:6[\M&;P\YIS
M/>2^U;[_BD2K;OP]K](;/_+C>0#26H!L_P77YFTP;Q:IE(K [+XJ,2%B(M,A
M#$7. ^P7[W6-W/8E8!B9*U(5!>:H,R+_GP<PTDRN3&7%1? 2"G4)ER#.:_23
M*8M,6T4D(1 ..!K$@JW/ /D%DI]OVMXZ\D5O1+B1?%.[VX\L.0 N12#2-$E>
MEV71K':L]TFR> 8\J.+ 0Y"B$(;\G]ZO Q[?7)8M$X+'-C@T2(@"'4LVK6 5
MW'"@GVM_@QC0B"0-WU_M+?3.YVD1&.G-;&O[N5HKKX@12=Z\< ?&:I"JKIS$
MCR= ,K3$J,]]R[R,G)%^=<NCO)<M#Z 2&%H'K07G>?5AM.O\F*W]>?#OWZU1
M:$^?@N_^[%4$)Z&LBV!.Y)7%E642@1">?2\":_6B*'AEK(^N?27<'W4[W6[/
MB$YU6T!>7/M>=]3\XG0!I!-H)$ (])_%"8E2ZQ @5H,\Q0I%K$!=!5=V0-Y0
ME:YRX*V6\%<YFY1TEHU:N9^3CE%_A!:[<N#YO_[G:;\W^:D!JA\:N%/]'/5C
M5%#(4CN^G6NUF(4O R#E?H1<[,C[H<&JYTA\[\(8Q@S1-))DX0[K6S-V[8E,
M+Y-TD4N^ SGN18SZ7$F!F:-2HGUBGH=/];1TJB6N#*43X*R  2%PB=BH/"BU
MP%_SEXS_-@"L!ZBS.+C%4%(]/#S2DYF/,,/+ ]"KU<C/]]3<-7TU>G$58RQ!
M5^P&D=A-R*X2/(+\8(3EZA$L@<FRP<J"3JW%A?AO]3BJ(L[^?&D?%F3I\?7K
M:A!L#MQ8G0)MX0^(8$]P4 MOMJE%HUVHS4>P _5NT%H4+.05,MK16E=^KG0P
MN'.K?23/FR(%"&0'O-&$E<0XX'29-<#->E>L_#6@^LJ;OF=+&A.GK4M8;Y,2
M#X!]'1QWP?Z!Z>@.V-NKS1V^57G4WS#YL8 29EE!# "MK?@22VD-%,'STQ31
MDX;9!_V4':1N*PVFGY1DK!:(*/3;,9M1]M1N+AX>@CDQH> KWR0/B8F^5<D!
M8S6J5&U0P!_#&"4' OJ2;%5A4O%F;1DA0%*R]=T=; S?%D.@^>P;[/DD2^Q@
MSMLX\C:YK-FDL%WPVE-FJN)YG>D!E6IVI7BWP5INC7?#*NI!#V_;]M87]Y=J
MMPZS4WS=^O9V$,.KXT.@U/SP#B@UOW@0E)J'V0=*S6]OAY((#XB$=^B2\U-@
M?I_6>$71>#,^Z?9>AO\[!^Z-=^[KC29.,Q'N07VQ;4N3G6^T%?W8]>:+70?;
MC'#-)F"99-O+UE&2L\G6&1K4N#U>:3?H/7 8H>W:,J]Z,":RUAR!4(ME_BK;
MLJ27CYO: S<M_-+B^\[P!;"=5'Y/UEI]T'/S/"@,_2YCOG"]_C/<%!KA18MJ
M?OW<EGXLN<F6D-8B5U4U/MDL3!T'SR#ZZ,O]6  _AU55Y!=R[]L7=ZN?W7W<
MOK5;7]M)(7:_T40A*F\V\.QVK:A7:_3;#I-*>,9^,*F\=E>L0-W8X%G=A8]Q
M^!#.\9)9!/D&A+ :T]N?:Q[98N^PYLFL>2S<6#?,L_\*@2* V!; ]DD"!* "
MF&,RB0+J?L<&J_9W)'U^-^?8'/CSN^< _RVR[^AZ?I<4Z7<>28 EKPP;%$"1
MF-NB:5;,0/L*_116T-%A0]['IR!]"@']98 0SL)[C!(X(&\6)J21^7-R&) K
MGU8#6LB<= >X/8LPFR<P"(5A2 P":1(4DA"%_)7WG*31XAGT+=ARG#Q1:(9X
M(Q DJ-:L@V0=H?WVB5X(\R7HE2!\%QG<SP)0-'FD1>#(],$BX+ /&@O6$9"B
MY6?><Q"A7=U0!,OKX2]^A?V0E;;C?2R0DP&1?N1(*!\Q'7$_*F"E("#D(2XI
MFT=!FF0 F];UW;%90+A:%3&N"Q30:?3;,@A70?I]IM;BM:9OCP402()"O^VM
M %;$.."9)$5#9%OF(Q0!E3J$0XO-(&TSW:K(T%V=UK^; =@!.OHA'V[U>KGQ
M6G?74UZ%O]HD]"&  0&# 3/6UJ97=\<=[W/@D9<]RI+7/V8TFP#( Q6 YH"=
M(FB*/-"GO6GSK_,$[I,Z9+7Q-?IOR>2S7N9+/UK1&QVX 7#$+**V 1%H,\%J
M'24;)G!F5<%\28<7\L53.X0;GM-A1:2PBTT0$30EP,"4B':(2[7G@+SDV=]H
MC9_NOL;.?)DFQ>.2AA# ;!18"!/)A%$''SX:/!9DE$&*)MSPMP!O:1:N0CAR
M!N'B"2GK C^G&R-HSM8:Y(<<V&#0_/[B_-WEVXO;*2#Q+Q\_7/RM[=U<7;R_
MO7S[][9W__>[Z9O;2UK6N^GUS=]OIP0+)$X:/#CO]5W;N[NY_' [_<^&)P /
M>9A/UU.8[KK^J0QP*R5QXQ\%_   ASZ@I]G]TH?#FP<IRMG>3-$Q'/A!6[93
MC/O(F(8 >UFCU0&.^/;R_M/?IA_J)P91^.3G9/$(%Q!N7[19K9?)"F[L'$XL
MQAM#G\PW>/!14'P)5J'OM<ZOKHYMRV,2,^X!2JC9?O[[^<55 TSJ)Z4!8>2V
M]W[ZGW__I>%=>("WC<R;[[Q9]<?SVXM?/MW5O[E.0^)5Y $&Z.%UN+[S6C<W
MBKPAY5QGB(+X^:WZF#=I+DC9L8Q7R9: &:OM6#?;1,7G\QYN0HR7L<W<JZ4_
M $W"]YZ7\/[F)'E&I6H5K&:P #'-W"9S^/<]7*AUQWL'&_6-;AI:P<5)?.A"
MUNQ*Q!AK#YV5%-=L!>T]\3UE5>@VX*B-;!FN,Z]M]FUQ7X.:F?%TR 5<J/L_
MC>,"G@"%(4ES7#7L:>7UNB=_U<>XP5C8 &.S4:YC:"C9SFOQ#_T64_.L6/-X
M,,,B+1XUH=N4PP:]X 'FR0V1PAGGVL]9%HH <V#,N4L]@68W127J@ /Z0M]<
M^XF$EEK$9('D,R62G#_##,'<7P3(W)D$1 PX7&/CC"+:&^2$E=)-('(%KR&'
M)[9 X(%37[",E^9PJ\*$"9O%!SJ #L_TK)XSS&P^::/@"DW,^JSK2696X+(S
M^K*R\J^YIR2<)"Y)2_@RH2V(:PGRJH0B>E-4D_&*PJV>11OX#!U+WL)?8?S;
MW*=USC8\'S,EE^?[ZW5$K!(WF8&8!%?\ >/YOJ*E'=X@_2J)X 0RU/GE+JXP
MR!,TQ2@*XD<E&*"X& 5?-??;*>J "-)VJ!(@+US3 H04P/LU+! EK;=M]$(E
M7^"%8!U&P1H_-4*"%93K9UF"3C?8,\N3\V7X&P@,('V'3&51C& &:8D&?$VL
MTY#-:*XK)$0;RPE\O%M\7APZ,*AASH;O@K22(SA)))M3("^ =!4L0#N(Q3>3
M!O!L(!<0(#LK0,Z(Z>"7@1_ERSG.F&TRH"6 E/=R8>_@=A4 7!#F 3(9D*Q.
MV[O*%T!52U\!;<7U_9J RN=AO$\!XQ&,K >O2'YH&(6_/"8ABX4+-AN@[/WF
MXL/%S?3J$H57+\A]P.%YL,YM<*2B!"$N7'QX<WL!W.[=U>7?IF_X+2#@4?@5
M^-2LZ:W;B^O+<Y D6$*^O+Z=7KWE=_T%'-*JV/+NSY^N+U'@D6MY4: C"=[\
M%./!MBXZGSK'W\13*K!$H-<QELE!C(65Q4+YQ$G>8#_$;G;3.N!AV#R&\9)$
M>8.D+LYYBY<,,!3^Q7:R\F.?]]Q6?&_O)2D1%#-93,QCUF9?(7OD2$H"L&/&
M CIVV4TU3X%5DI,++Q *,W@W?(YM7]LKAO=Q6;7SXSMD\PA7XN@A2HWJ?DH6
M("&QEOH/\\]1*<Q4S@$06;S%Z]SP(\ B[0W"$(;.70<DN>G-,=[4P,$C6P;(
MEP#P?Q1^"@MBTEV2 _[#RY9)$0%U$11"XWL2_UK$<QJ,%HN;M=!CQPD@MN&2
M<8NDVY,*0\:(LGCB"A=,-&L,(T0+@5'/TW!F0(+A-OWN3]X'9>=P_&8F)L4*
M!*%7>C_53T\++\CTOF@C ]6(T-:@9  RS%%P.@GBQANC[%>44@?L,O<5%@4<
M&D?@D2L*(BXP6)1%?)1?4OAL(;$@%O!KX3TK8/0$7@48.^B/ E248"H&+EQR
M/8"+:.3A?;#,0O?2I$H8*1\X&_)B2N%C,?&:A!1E5P,J@L>#DRN A1$JH,!\
M>&_"STTT@II1S?%0P&I)#H4/Z-+%&U$,T,8$2T?RY]XJ$C%X2(R[!)RV9\B"
M1R8??V"S4L="6+QJ'P^D=,!\(O)]-Y BH.[+A%T<^(BC]=BF.[FP\JA2@Y_@
M.W+I* .NAV(;22;/2U2GQ1!"#FU1_CA,'9:1;IC3.9NHO@]KP1,G>\I71'^R
MM$<DOBR!=?:ZW3\I[,'HJ60%X@%)!QA,E2[L2*H#8\*-@:06X)D3/"93 !ZR
M5"Q._#DRA,>@O$+<$D(Y129KP)<J-Q[,3"*ZAH?(SF)50!0IK1JH!&LOESB8
MLI@*?9'SPU!_?\YWEP *X@H@A;"0N8UI9-%:!!BO&I*)'PZ$+MOV(R534,S+
MWK A# 5[X) (ES 766,-4JD_7[),JF;A4U>3D+(U@PONM7K'/%WRS$;G!1 I
MM*Q8\"1^Z)K.M9"L0,]9E B(5I]'-*D2.*P_RY)TYG%J!;S5]H3TD%E'PO,"
M7+^D6G!$3ML>G38T)V:IS1410LA9'*&'+[=E0Q0V"]Q I8ST"=GEL[\A4#+7
M(_)"]LRO(JO,'4DN=>0W*QK<,CT09>38X0)($IX0[CH[Y)B;KC^.I6-K8*MZ
MF>["D(P7)/\[>+GR-T+[$2<+VYU 8EF*&KG[44RZYPK-F$+'#$"2E&;"VX&W
MK>-]8A)V 4M:D9QT3UL,F,L:P>TP*DN,$R.;2*?ROP!"J G:WJ_%XM&(/0#H
M8K7FS1(6X(Y]#E'B*X[B0X!V<XY%1%A+SH 3Y\<AO6V=4>LD.VIS&HYDF'PI
MU[(^A!!D++1Q V ?$_::H4@.&!%@;"WR4L*^I@VN (.2A9BX"=%FY$6WWT%>
M"[(2' \Q0=+RPX \>3$Q8L0MY)4ZD<&%V3->PB@,GAA-T5 -NA)EI.2NN/*\
M#('0H.1+W_!>\ ;!*>'FK+7/DH*/ +3<E"12BB5N.@$[G5/+LW1F^$+MJ72\
MZ3PO2*?@!>+9+\(']*:1(,>*E@83/&].R$Z=^!E3)Y![WOEP_SZM$Y=8$XQ\
M3CF(2$RD]=/M"3/@HK"$1S1@PF$%.9N!0'!&V<E'# 9Z-8_@%2!8]*Z;JD%T
M?4X:Y<**+Q8]G"Y2$&V4(*ML3;5YST*;2XO:SG<=F9GP*T03#!%:22O>;^\$
M)<"&+5M%#S$N,"+>@VP>'9P.>A A,ZG-$;L%-F1 (7* I@DX2/B(@IF-^4].
M'%9@9T.3!D%FI=^,'L/R+/[%^(R?X4)/8*$GM%!]?'@?5@@8D!S),!<!C>"T
M026#6^.S@8_W2D1]#[BAYA7QN1$QX)1\MN<Q%R&!W<!DWX'K8><%*"HP621)
M1V"!^UC1OK8>(-%!V2\-;JD+BDOY&=MOE"E "7#EDV9L;5@^Z8.X2V58U5GN
MB_) 6A4+OF*,=-U<! L7#MNG5Z@*I"- X#R32UE=C"T@ZG@?@F<G8B %H0J4
M>^%N[PA-0\Y$P)_M<N#*VGT!T0Q#B(W)URC:M;%L;Q*,M&F]F]Z].2;)F-4Z
M^1XVG],+LV1!QG1A #Y&TGB^)B(H&?,. ^*FI$<!@@+/CPF:-.PSVI*1(189
MV:1!PWLF@K9(Z$046Z%9"-Q6P X*@'&.FBMO+]-;('&5N,J&?_<QT!TO9*0D
MN60K5:L5+/B0E8+>\:[8FPNB^;M@EA8HB5' (L$8H*?6M2UBL#6]^W3L?4@Z
M$I38;ZMA6_>@[,Z]TR&(Q^@#PU/6AR C8W2XBM$AN6WM<QZQ,KP#]>?4.>2%
M)+ ]^K&8KIT@<UAS2+Z/S(T 1W$8:*">&)@A,/80J#V@+LOB)\G#"6CL(/*!
M3LXGI44P-&K@:0>!SJCAJ^^\:;.C<OJ>T$18G&N=8:::(OX0Y8XJ@1\2V^\8
M5<K.8*4[._H0+.,?Z+Q4']BF.@MDOHJ$0:>M ISM4"2#?I"+<O.K7 (DOQ&@
M.3X.FV>'?2V^X1R&@K,PT\8[KVP@>,EI_3GI %90/P)&,[5(C!?W"B\-S367
MAYA$HA;FJQ(XM K 486>#'>Z4\RI4,MV+KA1;CFO##_[D880+#\]Z?;JL/Q'
M[XH*0\'G7$ (@[-((+T @6V!3BBBDO=F;%B;?A\NB3-)KXM&]05I>6RUMEUQ
M]IMZ,>41&I9YCW5.$ F<$4LO]V'Z#X .R?/)W3Q9!_;#M(TK.%C4A]AS8;U[
MU@B?YNTPNT?:R$>)E\H<(6&]?8@M5,GXS% >P9-$\J*P6!/28^ML_^+'1.+$
MB%B>L7X K\A8 B;RP/P@#?(TT883"U.4(:(M;*0TH[@Z8R0CF9UC 2HQF?C8
M=(]&+ [KILOL2!%I.3"[P]*ZXBK$>@*$C&P*6,4793 R"UUKS P49J*1BV1!
MNMOP-BN?)$;@<7/T*BT4DPJC(BM38*7KHU $PY+I-W',"C&%*S)'YW&(=D7B
M5B7)F,BG$B\$4Y1]MFY4138Q6I#%$V7086GGH?JPB<)Q(%6%"5OS<M('B8PI
M:AN1%B;W7.6AH0D\KO@2-CR)7'9'7%9K9^],K-?/">$/7J^OC.!)R@(</GF
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M;M,.*=XG)F&=IBK9=\DSHC,7P>!*5%@KP-J@Q?.!6M7#1"*@% *6Z:)%-#B
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M'& ]I@.F+^C<#\"3,PS$Q$HI ,Q36@9;SBWKD5V0Y5H33R Q3MO4.XQOL"2
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MISF,?5;S'*V.J$+ : "(D;JT)6GYJ[5 =EAA:A.7LE6<5!H)K('K8' 0DQ_
MJ(KEL\U>H,85_K>)YK ;PB.6?(H% S@6SV$UGPV?T#= =Z, ]AC&Z",+OOK<
M7AO.^ D>P,!X !M=,799YJJ%PD,8::,C03: O7!8D'J3&!>M-U.%G!U>9H7[
M"=,H8>YG%&T>@F?4;(.U:L;,US].*),G2.T$?6=XIE@^V2M4]A/'X(D1&)!E
M@$D8DCB"4?(1_HTAKC22M3UKH*QV)"FF2.])_^Q(F=Y %TN?E%3".]85TXF
M&-A6#T.Z)<"(W-]APZ4H'I ;25<.R:3(U@(&?#I""0F3 E6.F:':=JE+.A<J
M%0CXGA$K)#I-.1(K'TL%9!2$)G*FE;:B:VGH$F"Y_R6(*ZLALJL;AV0:/ (
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MBG3 59A32-Q#0=Q9=_RK8%^.O7Y,P1^^&\%"DIV)4%JULO'3,FC,MD@&0TJ
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M\0JD@SUP'5>L\^)'FRRD:JC(?_D,2(%;!&LD*TC)_9S$!>39.!R7(LJ#@%W
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M\=R)K3 5+YKQS3R7V!,9@6CKU']/(X@43@-88N%HA^/(&2J@J"YIWT]&H_H
M L&JKO(\7$^E+AG;>$#,L]UW\NVQY0U3AH8#U8$/(*K\!8---@U^XQG,[&\
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M#3T1#3W!AJKA@RGU"!TC-%4T&P)_%@:HJ2. 4?Y:!D4R[GR3?B,(1QPWCIV
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MXW&H5+EL8FP[T8FS/4E3P#@/ZP@BJZ?\/B%CX@X/G+B,R=46D8 +GN>2&96
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M@(BPIPQF[=@>.;39\B,X<D)7'Q\F)UE 3C*GMBY*95]*>XY13XWD9#CI4T0
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M/ MZ[;_=3#NBN8:6<2\GB2>?.$M6XI "9^UBN9A9&.X:]*NXQQ4(%K\]@NW
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MG+#W%6+5<-Y-196 #Z-=:+Z-\#F00!PM[J98%4]"A81BO:*Z89$<AB_SF8-
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MVU7S5B* W?@SCDG)JH[:Z;[8PM]02P,$%     @ T8683A2.9.(-!@  1S<
M  \   !X;"]W;W)K8F]O:RYX;6S%FUMOVS@01O\*X:<NL%W'NKI%4R!MVFZ
M;AO$05\7M$S'1"722U))TU_?D1PYPT8>[,O$3[9E78XIB>?C4'YS9]WWI;7?
MQ8^F-OYTL@EA^WHZ]=5&-=+_9;?*P#=KZQH9X*.[F?JM4W+E-TJ%IIXF)R?%
MM)':3-Z^&?9UZ:;X@PVJ"MH:6-@M^*;5G7_\OOLH)*QPJZ[E\G1R,A&R#?:C
MKH-RYS*H3\ZV6VUN3B>SB5AKY\.B.W:_9J.-;O1/M>H_^8V]^]LZ_=.:(.M%
MY6Q=]UMU7_0;P1'\?LDWY8*NHA6#7%Y)8#V=%">PPUOM]5+7.MR?3OKWM9K
MKYBBG]&WP_"Z:\37[O\THUVO=:7.;=4VRH1=.SI5=T<W?J.W?B*,;-3I9%A%
M2+,2'TP &G%A=KN"=;O? H>^6.U^5X 6>X05[K6&+]S%:M:!\T&^MV:EC%<K
M >^\K?4*.%9BT>' I@@R(2"3(T+^FR#(E(!,CP+Y3M;25$H@R(R S(X(&;5D
M3D#FQSS=*8(L",CBF) 9@BP)R)(7<M$VC73WPJ[%0M\8#9M)Z)#.JLJVT"$A
MR#D!.>>%/*O^:^&8_7)$](H@>L5+= Y.\]!?MTYY@3_@/ON$ZK1/> &OU*TR
M+< -;S 8:1-FG5P8X G6W6,@RAPS9G5<0*(P-]U!Q9GW8/S>QI^L7=WINL:4
ME#IFS.[X*+43WV3=*O&/DAXNM6Z#Z*Q2TI@Q6^.C-J '+6O(+SZX]@D<)8L9
MLRW.E=.WLHNAA^@H2\R8-0$I>@MQ]?Y/<5G+(0M"?[?MD^$EQJ0\,6,6Q6>X
MZJ [V;U@*,H+,V8Q=.T$F?GAY<47&(_X/S <I8@9LR,^2&=@<.,%G%ZQV$BG
M<%:FY) PRZ&'>;F473:YE/>_WPX)Y8>$W0^5;92XEC^BRRPA!Q?,BO@:-G *
MHQ3WV.$M L:D')&PCR_J6BZMVW5U73^R [_:K8PQ*5<DS*[H$H /_44GM &I
M.2T[^X*(59R@$LH:";,U/D/>O/E]')Y0IDB834%F]6AHEE"F2)A-<3 ;BQ?7
M<*(Q)N6.A-D=3Q+R#B\62$())&$6R#XJCY&EE$!29H'0F1E7,E+*)2FS2PZ$
MYJ$Y,2:EEY19+Z/A>?2<D\4K9KN,I^A13,HN*;-=HIPZ2D=))666RD-2A2Z[
M;=JZ3Q)#N&BV44!,*=.DS*9Y&EU'6Y*R3,I=N.HS[+LHPXY"4HY)F1V#P^PH
M'*67E%DO9*J-XD1&N29C=@V9:F-,RC49LVOH<(9+TAGEFHS9-;B4*MZU7AOE
MO=@OQ9B4;#)NV1S.D.<J2(Q)SI4PRX;$C*]-RCH9LW6>1MWEO;AT=M56 4@Q
M)F6=C-DZ"-,K!XTI8#?0K+Z?B\!Q+:/,DS&;A\2,3SKEGNS9QS=K9QMQ9H)^
M^?X\PJ0LE#%;:$\W].K#8*R[SS4>+>:4A?+GGD\9 +VX5C]P"2BG+)0_U^S*
M'@_'C9PR3\X^SS*@/86$-L28E'ER9O,\PG6%>=O%2]2QXZ%M3IDG9R^B$2/P
M>)J>G*=G-@^-B5-13IDG9S;/P4+!TTZ(,D_.;!X2,S[IE'ER9O/0F-%)I\R3
M,YN'QL3/9Q24>0IF\QRH#HUT[P5EGH*[UD9BXGZSH"Q4'*?6ML.,;J&"LE#!
M/=U/8D8/.%$6*HXQ[;_'C&XARD(%LX7&,?=+,2;YO!BSA0Y56!_N(8Q)6:A@
MMA#YP$)\"U$6*I@M-%2 QSI*2CL%LW9^*U#C440K:XQ94MHIF;7S4*G>%7^O
MU+9UU0818TQ*.R6S=LB">G0QEI1V2F;M/&!>J:J6WO?%P6X=8=O050PQ)J6=
MDED[8W7_D?NGI)Q3,CMGO/ _1DDIIV16#DDI9AB34D[)K)QX@F*L$<EGDYE-
M,THWVE-2HBF914//H^"L5E+>*8\ZW8.SVISRSORHTSVX->>4=^;L_XJA,*/6
MI+PS?X:BV\%GK2(]SBGOS)F]\_BLE4!OQ_JC.:6>>:^>:;^R?_MFI=;:J-47
M.(2'Y96LJTLGNI=N3[,DR[OG0]=M7;^'95_-9RN[Y?T^AO^PO?T%4$L#!!0
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M+5]O 7H+7V\!>LL*S]KH89NOMP"]A:^W +V%K[< O86OMP"]A:^W +V%K[<
MO86OMP"]A:^W WH[OMX.Z.WX>CN@MUMAKP1MEO#U=D!OQ]?; ;T=7V\']'9\
MO1W0V_'U=D!OQ]?; ;T=7V\/]/9\O3W0V_/U]D!OS]?; [W]"GO=:+.;K[<'
M>GN^WA[H[?EZ>Z"WY^OM@=Z>K[<'>GN^W@'H'?AZ!Z!WX.L=@-Z!KW< >@>^
MW@'H'59X5XE>5O+U#D#OP-<[ +T#7^\ ] Y\O0/0._#U5J"W\O56H+?R]5:@
MM_+U5J"W\O56H+?R]5:@MZYPU@0=-N'KK4!OY>NM0&_EZZU ;^7K'8'>D:]W
M!'I'OMX1Z!WY>D>@=^3K'8'>D:]W!'I'OMX1Z!U7."N(#@OR]8Y [\C7.P*]
M(U_O!/1.?+T3T#OQ]4Y [\37.P&]$U_O!/1.?+W33._2U$,^?!^'<WLJ]R[Y
M9_BG-3.XR_A^R??/N$W]=/V9TN.T2C:WS[O_GVY3_T28>45Y_@U02P,$%
M  @ T8683J8.7*LP @  NC   !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=O?
M;ILP% ;P5XFXG8+C_VQJ>M/N=JNTO8 ')P$%,++=+GW[&=I.6I5)K9I(WTT(
M''/.![%^=[GZ^3A17!V'?HS;HDUI^L)8K%L:7"S]1&.N['P87,JG8<\F5Q_<
MGIC8; RK_9AH3.LT]RBNKVYIY^[[M+IYNCZWWA9NFOJN=JGS(WL8FU=-U\\-
MRT#]LB:VW10_Y07%ZNLQ=XGYVK;(U5BP-TQX?>-\GN_[_D A= V]*YK?[;J:
M&E_?#_F6,DZ!7!-;HC3T96Q=H.9'"MVX?\Y[YT+ZYH;<F!U[]L^"\G(YTF-/
MIP,LE7-.3GE;T*E12^'IDW]HX,MNJ'V@]11R-:3NQ./E2'>Y&MF\\)R/2//6
M::AYT_#<^G(_[&\?#LOW4R_\;S&RY?"QMWZ^' (DAP3)H4!R:) <!B2'!<E1
M@>3X#)*#;U""H(C*44CE**9R%%0YBJH<A56.XBI'@96CR"I09!4HL@H4606*
MK )%5H$BJT"15:#(*E!D%2BR2A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DE
MBJP*15:%(JM"D56AR*I09%4HLBH4616*K I%5H4BJT:15:/(JE%DU2BR:A19
M-8JL&D56C2*K1I%5H\AJ4&0U*+(:%%D-BJP&15:#(JM!D=6@R&I09#4HLEH4
M62V*K!9%5HLBJT61U:+(:E%DM2BR6A19+8JL%8JL%8JL%8JL%8JLU05E78[E
MX+KQ?TE^>7]XF<^6ORQ<_P%02P$"% ,4    " #0A9A.'R// \     3 @
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M2P$"% ,4    " #0A9A.;2B_D;4"  "0"0  &               @ $"$
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ T(683LY_(Y'F
M!   AQ@  !@              ( ![1(  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( -"%F$XR^*#$R0$  &<$   8              "
M 0D8  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #0A9A.
M->M46Y,$  "T%0  &               @ $(&@  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ T(683F[]_)[<!@  ["8  !@
M     ( !T1X  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M -"%F$X <E&EM0$  -(#   8              "  >,E  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " #0A9A./$_X2K0!  #2 P  &
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M970Q,RYX;6Q02P$"% ,4    " #0A9A.>@C$<[0!  #2 P  &0
M    @ %L,0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M -"%F$[K<,*IM0$  -(#   9              "  5<S  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ T(683ILP/8"V 0  T@,  !D
M             ( !0S4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " #0A9A.3DBAQ[4!  #2 P  &0              @ $P-P  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( -"%F$YF_#KJM@$
M -(#   9              "  1PY  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ T(683MXLY'VU 0  T@,  !D              ( !
M"3L  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #0A9A.
MN$2,MK,!  #2 P  &0              @ 'U/   >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( -"%F$Z+BM@PM0$  -(#   9
M      "  =\^  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ T(683A,[Q->T 0  T@,  !D              ( !RT   'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #0A9A.-!Y+9; !  #2 P
M&0              @ &V0@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( -"%F$ZQBK4AL0$  -(#   9              "  9U$  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ T(683OCVNURU
M 0  T@,  !D              ( !A48  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " #0A9A.0T##E+,!  #2 P  &0
M@ %Q2   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -"%
MF$XV.#_X]P$  ,L%   9              "  5M*  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ T(683M_IZJ2X 0  T@,  !D
M         ( !B4P  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " #0A9A.^!)0]/ !  !E!0  &0              @ %X3@  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( -"%F$[]\#SKN0$  -(#
M   9              "  9]0  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ T(683F 7J__0 0  G 0  !D              ( !CU(
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #0A9A.\I"W
M2M,!  "<!   &0              @ &65   >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( -"%F$[/D[M^W0$   $%   9
M  "  :!6  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MT(683HGOQMO= 0   04  !D              ( !M%@  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " #0A9A.H#S%\?D!  #+!0  &0
M            @ '(6@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( -"%F$Z[@QJ Q0$  #<$   9              "  ?A<  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ T(683J.-H?FU 0
MT@,  !D              ( !]%X  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " #0A9A.\)GG5,$!   W!   &0              @ '@
M8   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -"%F$Z^
M,7SFLP$  -(#   9              "  =AB  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ T(683D)O+:3$ 0  -00  !D
M     ( !PF0  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -"%F$Z0SO(14@(  $X'   9              "
M 1YP  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ T(68
M3DUEWGX(!P  J2X  !D              ( !IW(  'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " #0A9A.AO\"8%<#  #E#@  &0
M        @ 'F>0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( -"%F$X)V_GYZ0$  #$%   9              "  71]  !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ T(683M-F0?M1 @  )0<
M !D              ( !E'\  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " #0A9A.<-)71:0"  #,"0  &0              @ $<@@
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( -"%F$[Q8Q8)
M=0(  *T(   9              "  ?>$  !X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ T(683O,T^VXJ @  CP8  !D
M ( !HX<  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #0
MA9A.QUS5U<<!   7!   &0              @ $$B@  >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( -"%F$ZN'?W1V $  .4$   9
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M970U."YX;6Q02P$"% ,4    " #0A9A.)^NW)#T"  "%!@  &0
M    @ '%G@  >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M -"%F$XIB=E:90(  ,0(   9              "  3FA  !X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ T(683J?OHSY4 @  '0@  !D
M             ( !U:,  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " #0A9A.^1N(#JD$  !%&0  &0              @ %@I@  >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( -"%F$Y,L'QI70(
M +P'   9              "  4"K  !X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ T(683@9YXE41 @  ? 4  !D              ( !
MU*T  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #0A9A.
M##T/'[<!  #2 P  &0              @ $<L   >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( -"%F$[L+[0<.P(  'T'   9
M      "  0JR  !X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ T(683I\3S>8"!@  +2,  !D              ( !?+0  'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #0A9A.EI2_YH@"  "5"
M&0              @ &UN@  >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+
M 0(4 Q0    ( -"%F$Y_:E.<W00  "<9   9              "  72]  !X
M;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ T(683M'NAND.
M @  H@8  !D              ( !B,(  'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6Q02P$"% ,4    " #0A9A.DD4+D>("  "K"P  &0
M@ '-Q   >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( -"%
MF$Z&P'!=M 4  .XB   9              "  >;'  !X;"]W;W)K<VAE971S
M+W-H965T-S(N>&UL4$L! A0#%     @ T(683ITF9_TA P  &0T  !D
M         ( !T<T  'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4
M    " #0A9A.+W%+D\4"  #."@  &0              @ $IT0  >&PO=V]R
M:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( -"%F$Z5M&J"K@(  ,@)
M   9              "  274  !X;"]W;W)K<VAE971S+W-H965T-S4N>&UL
M4$L! A0#%     @ T(683A5Q+?D@ P  @0T  !D              ( !"M<
M 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " #0A9A.^S6N
M*7P"  !#"0  &0              @ %AV@  >&PO=V]R:W-H965T<R]S:&5E
M=#<W+GAM;%!+ 0(4 Q0    ( -"%F$X3;\!\_P$  &(%   9
M  "  13=  !X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @
MT(683D)FO^!8 P  4 T  !D              ( !2M\  'AL+W=O<FMS:&5E
M=',O<VAE970W.2YX;6Q02P$"% ,4    " #0A9A.]$U?9,X!  !B!   &0
M            @ '9X@  >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4
M Q0    ( -"%F$[41A'<$P,  )0,   9              "  =[D  !X;"]W
M;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ T(683FPB08'W P
MEA(  !D              ( !*.@  'AL+W=O<FMS:&5E=',O<VAE970X,BYX
M;6Q02P$"% ,4    " #0A9A.VDZAYK$!  #3 P  &0              @ %6
M[   >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( -"%F$YN
MN(8:P@$  !,$   9              "  3[N  !X;"]W;W)K<VAE971S+W-H
M965T.#0N>&UL4$L! A0#%     @ T(683DT$$2R5K   N]<" !0
M     ( !-_   'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ T868
M3B_I"CMW @  O@T   T              ( !_IP! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " #1A9A.%(YDX@T&  !'-P  #P              @ &@GP$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ T8683IOUMHB7 @  (3(  !H
M             ( !VJ4! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ T8683J8.7*LP @  NC   !,              ( !J:@! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     %T 70!]&0  "JL!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>424</ContextCount>
  <ElementCount>377</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>137</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Divestitures Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDivestitures</Role>
      <ShortName>Divestitures Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Revenues Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenues</Role>
      <ShortName>Revenues Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Leases Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesLeases</Role>
      <ShortName>Leases Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2129100 - Disclosure - Equity Equity (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.biogenidec.com/role/EquityEquityNotes</Role>
      <ShortName>Equity Equity (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2130100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2132100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2133100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2135100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2136100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Divestitures Divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDivestituresTables</Role>
      <ShortName>Divestitures Divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DivestituresDivestitures</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Revenues Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesTables</Role>
      <ShortName>Revenues Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesRevenues</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2323301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Leases Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesLeasesTables</Role>
      <ShortName>Leases Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/LeasesLeases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2329301 - Disclosure - Equity Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Equity Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2330301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2331301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2332301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2333301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2334301 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Acquisitions Business Acquisition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsBusinessAcquisitionDetailsTextual</Role>
      <ShortName>Acquisitions Business Acquisition (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Divestitures Divestitures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDivestituresDetails</Role>
      <ShortName>Divestitures Divestitures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DivestituresDivestituresTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Divestitures Divestitures (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDivestituresDetailsTextual</Role>
      <ShortName>Divestitures Divestitures (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DivestituresDivestituresTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Revenues Revenues by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails</Role>
      <ShortName>Revenues Revenues by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2418404 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2418405 - Disclosure - Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2418406 - Disclosure - Revenues Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Revenues Revenues (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual</Role>
      <ShortName>Revenues Revenues (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesRevenuesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Inventory Inventory (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryInventoryDetailsTextual</Role>
      <ShortName>Inventory Inventory (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Inventory Proposed Divestiture of Denmark Manufacturing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryProposedDivestitureOfDenmarkManufacturingOperationsDetails</Role>
      <ShortName>Inventory Proposed Divestiture of Denmark Manufacturing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2421404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2421405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2422405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2422406 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2423402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2424401 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/LeasesLeasesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Leases Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesLeasesDetailsTextual</Role>
      <ShortName>Leases Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/LeasesLeasesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2429402 - Disclosure - Equity Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityShareRepurchasesDetails</Role>
      <ShortName>Equity Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2429403 - Disclosure - Equity Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Equity Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2429404 - Disclosure - Equity Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Equity Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2430402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2431402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2431403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2432402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2432403 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2433402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2433403 - Disclosure - Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2434402 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2434403 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2435401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2436401 - Disclosure - Litigation Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationLitigationDetails</Role>
      <ShortName>Litigation Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>biib-20190331.xml</File>
    <File>biib-20190331.xsd</File>
    <File>biib-20190331_cal.xml</File>
    <File>biib-20190331_def.xml</File>
    <File>biib-20190331_lab.xml</File>
    <File>biib-20190331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>122
<FILENAME>0000875045-19-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-19-000017-xbrl.zip
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MB>?FWA8EGCJF=$'^^;E=G-8_+^R6^/3+^/5@-,XG<69+Y0O203;,WPW'Z2@
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MSZ(U#ZUGT>J%-MQT-3I@LU%H]R2NAAF>&839(=3'4S)OAMW9H<%EO0"&-.V
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MC.3WTY<^^5%?.J-LU,M Z^<IH+G.;%-W%BN=IA>>.2I\P$3\I2" 4()*[DQ
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MK<1Q^#P1,!-:&+Y8M?;;#&B[T7^^R],]QL^F0%YC;PA)*+=,(SDE/S**4UE
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M.@'M1@A77$M@6((XS-%B%C@K2BYE6A3F7S;^?69XE+U%D#U8R<0'RQ175BF
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M>:QN800BQ/L /.QQL9:ZU(_1J&T&L_^@UY$Z82!S"@F26,F#I)8B,CW6;'3
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MO?D.CM?,F4R3^=7@CQ]XO((X)FQ&A3R>W4X8H>7GX5Z%T(R6/EH-"[8#(2?
M@R?.2 %8#,4+N$J.VC1^.:8W#,ZNBM]:8P:G)?'8@-&D7,;R>58FBBG.O-->
ME B^Y'42?+7.H4068^.(P"1PZL!AA_F)$(*A@>NDD''^BB):XNN<<V[G,:-&
M<8]Y2!QAEFMBM 4G@'CA F"QX O)%:_H8_)RX^GV(C.JN9#3PLWQC$,0QFC
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M(BB@_1H1X6TG_ST=3TGP&XQZXXU9B>:6DP0;'K@ )YA8AJG5B0R,8%<L!%M
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M)\89V>\K7Q^M__S2G>D^'=QW\M_?=@:3&Z#D)(K 4[M-BA8QGRCD@^5 ?I
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M4<BR@/6GV_OTVXSWF#-?&QO0&AMC'8WE,QT2)IYQ!:_9>6 %A(OII+#N^ZJ
ME\Y\WP@5!?=>@\)G4:H1"L9**Y CH/R3>(7 RR)4JR,[V&S**F9-XXVNWQD]
M*P!?%H:LKCO6N )\L<)'H#@H'V_@E$:+P(CB)B9":LIW.41XA<MVMNI^B*!
M$BRQ9HP[+;5,B!6,JS"]Y*>DAO'&/>PK7+ZS%1 DB@G#;##>>\Y"T":8>.].
MH)2+0 KQKLM<MN/2V 'T!EO#*1.>8^.M2$CB9-Q/0$26Y"0W2T0JMO4OR32)
MA&H)A,$(Q4)>!L!33*:3R,AX_*&A0G*RA3N;<0HJRAJ*>=228^R5E(9A)8*+
M!ZR20C8$85QO'S*\HA4\7X%; OXI"Y(0R@ +6HL)YHXH3P5.-"\$+RYUX8Y]
M'0!.G%6:Q$MY+4/*XF 0TY2!S7*A".(:)B>_??J<3\GRW0QZ3XE#%V2BB$M
MN\$2<H#AE$AM):9*@_,4;RXJYGVU"U<3$R5U\,%Q!@N6\'A76\  %TE"$T5T
M(@H57N*]L:WDU<A"@=,D!=4 \HWC,IXX!/0>"#?Q- XF!71_J0MWY&M5&--
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M0RP,\*!S6[=G2'@P#!.9)%9Q(IC527 ZH: 2O0BH](3IO@OV@KD!_W7W6;H
MYD]I3 CE8 HU,D3+N"E.,%=>L.+9<BIWK$-0-L9#SW#= EKK0^)UPL"D\<3%
M:GB!!&1 .XF$N0(LA!GN>'I^TPSM9)0-4@#/W7]/LA$T' X^W77R]$.>=<O/
MO3XJII*N3XKI779[-QZ-.WE1Y9#E_9MXX0Q&P1B66&(I-@),F-<HB94VG@/
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M4_!K\W-IRK<R($5"]:)(DRG\])#)@O!1B!2K!NO:@OZ/0_#4XY3'\$+>.E
MQ8L$CHY0\8S+E@(Y(:RR>:?\84^>QU&Z9R^DJRPD!J-MX9<NS+RFM03><NM$
M;=\2VT:A'Z?F97BA:K2H.H)4I;H2M(Y&LQ>B_(>QJP8:*I_>47C;?::?Q\(;
MG7-S[7>Y4G/SV?E_O.7+VTN0__3KZ,_QYXO/5V*Z20LSZ(2V9DG2R>2C 4$Y
MI04HY #N+W][(]6O0W)HR;D/LNE?#I$=I(RH!4428  @1O!5*1 I6Q31>R;[
M(*K?=[//KS]<V;ZA0,T\R!6Y_?RLL5@5JX(BK4K%V%3H#/M8DQ**(JF_O7&#
M/-_EY0Z_X_E)#PIX06GZE\LU3F]FTZ_C.?V&' &3SVR\GM!'OTSGH[--V&&K
M[O3MAQZ^"Z>G_9+PT=D-\#<)ZNJG_'TVO?@ROY[Q'*1S?N-0<C?Y/)K]\>MH
M<O&!6+Q@2/.;SVT"/:V^0@95E.<VW@*&91LHX2UT#7S3129=L[/H #EN5 >W
M;E_.* [^_<M1!$0+&'H0"UX_SRM0="[&&%>!.\^:OE3?M*/M(\ E#=RPO9[K
M]H%W$YKI,U%# K*DKFH1I*+X2=I0"UT%F82*0;?S'Z;!CC](BGNJ(]W>1/="
M-%%TB:HX&Z,CUPP& [@$IOJB,)=VMNBR[WE/5=R1X)Y:&&ZM?R'JP.24*95,
MD]<5O4DV8PI!<?-7P!8QS-CF/>502>ZI%L:8^C8^.Y,O1!-%%.VQ<"G1D^1)
M_)XNA$HBJ^2S;31A&P3]?82WI_ YLIN<3V?+@>^SE;[E<(E2ZZ(T6@H_I>81
M[FQ"PB#ICK0+# ZP2C?2NV?QO[GX_6Q\\MOYY4V[_F<W0OO'=/;'>/)E-CWI
M-@+-U)2U[Z'AG"DA<A.ST5:$(K"016]:LAY71GUNO6CM?B%G% (*C-9E6RC-
MC\Y5%<E"E%(J*MV@J/^MQ?7?3WR'*."RE+'S8)$R"#)[=$93N  %*)774"J_
MZZ:!^R@/B1)N4WH(LVO#@W7SBQ03&66<"369H*6DL$AI""$(18R;QO8?P.;A
MCG<SJVOA5A*(I+CK7/,^8,BR)&85G:TZQ7:VW#5EJP?GF+)>^NWY=X;"8YO
M $!?/J^:\WQ^AJ4ZD[RQ6FA5*5'5D"Q]P46D\XA.MX9%-6"KQY#FPVIGY3^+
MWYO5'/%B?'8ZWKA2+EE?2A;6)ZM<+"DPZJYW=-RS*@D:!ZFE.L!"/T,Y_CHZ
M^32>=!2 W/K<QHVIQ1HR%=J'HJ#FBM@+M21$2B7;D7L\)$797:BOIN>#W^FF
M//:/V?B\R]-ONX\)2X^^IJ $7\I ITI53,:::JWSN<5"7<7S#C3>#Y^;O#T7
M)]$%:44622L14F8^$Z#)I@RLCFB6XCU%?I^?)Y V $95A10E4QJ4JQ>Y:(M2
M5ZME,[UR3XHHHQF_9\ROUKS$T7Q\LLWM4;=Y40%L=!1M: /$#/%E;<DIHHZ!
M3M:J-33P5[@%,C5(RAZTMC?@-JT@0"F'E1RP D7$&E>0%T76$%0M<16M[J_2
M'4!K'I]=G'=;@9O?D:SE$EYB; 7'43KO67>* E<-5E'(L$:R9C6UE\3L1>\F
MZ19;L_ )98*,)M(?BY%!T.'&D.0:Z:XY"4/T7M;DK_H,>'SF]61X[>C.SH!W
M:)D@A8[H@5)ORKMYK3J=%T231.,(FX:17:@['E>;UN\X^K\8*/HT'H26=/(5
M@-&9(:>,:081?UH>+C^,J_$55NO[T9_\+]/"5-VQF=MH2M_N["E&.&+(9D_'
MS988R8IJGO9VNL8[[6$WH&U*VF6>MJ'M6!RU6KK-4:[:U((07 90$%$6F4*F
M&"RC!*N'.5+N?CCBUH0);_U8O+:<UXXK_&?L7B^X8G3GP]LH[R[FGBB@2$M.
M%O(;ALP;)%*G2SHZBD;R,):CDIMXW8GJ>Q?">GU;6<AXR!Z*%A*/U?,*$<%X
MJ#I0$+I"!,VM?% 9+ *//I)Z_6&H\+>-\I/ 3)F;YX5@*9/G]=)K&V( 2$"G
M?XCSW;@>(/->.%VOX>IX=T:@-$H8AD_(N@;FD_+1ZGS 00T+HQ^<U\O.O3N?
MR&/ZASPY.QZ=[6J<+>^^K<)'16X&DT='F:5528'@>'>(\9\84G-'+6\B^_[%
ML,&B.ZFJS%$;%2%D&QB"+ZI@HZS1X- Y9S&8C4[J?L703Y"?\DZ?W\^NVN1N
M TCM@<MU6RJ&YT$\.3NMZ;930.Z]5H8\@'<VW@UL;]T*L:-0=F3BP66TP7*
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M?[.RR6?#,:I2\[*=2J&&Y_0;)65<*4B?M!<%FRF%9D?0<>A^"$EL."2>:ZJ
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M>Z)_A>RM-FABI. ^!R44)5?5,_WTOX*UY"UDOX;\55-S&Y\$*-P&C*'0\85
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MJL_6@Z0(JX5:^\DZOQS7'Y6I11?189KR7CGNZJ_D2$!Z39>X.$PY<S-_5,W
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MR7BZ9W0.A17H:BA-$#+48+4W50]M4X(O,E&8[@UO[2H58\Q6JF+H2QH&5,#
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MJIAP0Q8E 3:3>&3BNYSYNI3MW7*"YJ!X$L*9B$&A2.IKDGA F"A2*E%1P\T
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M11W]&;COY'RWVH)3;B1CR6-PJJ7@X+)IC"+X/M.:)7$C4TWX^UCG9Z6X2L%
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M^+X?C:</NUDOSW%AIP&0$&TL<P2F6@61)G&"S4:EI GA]W#@RT9S;U[8RCP
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MG\<>O)MB(^;8I+1HZ;E>TCSRX(&/TTCR:V&(CU,Q9)PH7X0RYI*36.H(#'&
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M2\Y6XZQGJHKVBUF9O(_9-T 2F+:,Y"N+$?S9,XO>@!NSBX K1OVT[%>_COO
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M+5</]5X[-+UKB*D'@^);.NH!O,'Z6556PEU!.L"OMH,R<2BE4$$",%WP6*G
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M!S3%S\L/':$V'=P7,KSF[L$FX<3I@;F:7?.7-^X;\[D:I[WYY^VYXUO>G]S
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M>W!-P5XV&,RN^<L;]XWY# +?FW_>GL6^Y?W)S3O?OU N=X6B5 !!%/_37.N
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M><W>8O W.QQWM1XQXA3N?YXGXAT8\;$]M"&J@^.>O/AY()NT(H@1(1"WI"M
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M5:W9X5127H;%;"HIIY)R*BFGDG(J*:^6.:>2<BHIUV@+6964O[RP?4PSH/^
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M?:IQM>K)E.J;_AKW?^03,Q<VXMN>1$[(78$3XV>]FZEYV2O1FNKXQ][&I::
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MOD:O((,W*&CML8!UU(+G*,Z&*NRV2KZ LHK%VWN-KT($KXM\MJ![9+O<-6V
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MHFA;ZU;5EG@LG]5=\5-KR\^O>FY_$5>E(H%2H2(*T G("T!NUPT", &8 $P
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M3N;Y[_^[V>FUAGR-$LI/GM0=#SW'2KJRP>;?SOU%)L_?/6*VHEQB$L8_)]9
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M8T.&&J!?M65!#=#4 %W&2B9J@,Y7X-0 G;] J0&:BHTT*3:B!FAJ@*8&:&J
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M#'?&OGI2AWRT)]QTQ8H_@4VXD<&C)2=N^B;.O44@T=A]_:[^H1XP[Q4F#QG
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M\\M!?X(^UR;VPE-PA@]Q%UR7.,FG4XZ'P)PA8];95\L$MI*W?39<F:'BN\C
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M^1S-0=02LUZ#L@^T#]$)";-@XD@A?1CX <N#\(5T[F"4C?WAP]X"OB VXFO
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MM<(CZUKP/65I)TQL\1Z6;9TK(]N>@TQ(;@6!=3D&P+T5&@?,9^!N2P=(O:7
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M![EA(CI_";X\>'R9UVZ%>9L[$55F%NOJW>(Y9*#&1,X[D-20/TF:BRPX6=P
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M)/6;*KL15Q%7$5<15Q%7%9Y4;\T2JFR2T,*P-)-]]%W=-S6'C3S'7LQ>WI^
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MG7**P$D%[B!6W>$.E[[C<+C=PK&?#!=/F)G#34VD/WLVPYQH%W.S='7="VS
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MI8#X5V"8*UYB:)'Q2]ROTVG76[E1K"K 5,[DSC"%<4-R9VX- S$/!=\+.Z2
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MM-]88Y !+;=SXHH!G!LO?K4<#N_P)Y^PGS3#<MG9!]MUN?N.V1:[Y[H/.V2
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M\JNI)MP@W"#<.!+<R+&0I"ZX00&A-4>B-+M&9Y. T#;G#FS>I_! &4J'\Q*
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MTCCO='7][$P[;VO=EMX;]+318'0<C8:'S%\B(QN+\$$(5[:7_-Z\:2XP;"*
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M"HP4V";,<O-@!P&;P)TFJ:^WJZ_!@)Q1TEZDO=[@@+7(_2+MM2&S_"^'\8A
ML$>Q39= 4E]KU%=OD.-9XZ2^2'T=G?H:]//K]E0702'MM9I7SKG++9N[S,+T
M2Y\46 X*C#8#28&1 GN+ LM1@NHB*&]48'IM-=BM%W)G@WJ/W"!Y*?>M-?\)
MJC/"VHFW)+^5OW"V3+E%KZT 57;'NS -O=UN:H>G>VFXF$R9\N8U%0.L9>&\
M@V9%;4S:.@)C#(5&:]#4]P>%9>&[4E67OUB>_9;RZ=45V;*B^XOGIA6[JJ![
MI,IVMR[ UGK#SJ!WWM:[G4[G8J@/>D9+&_7UX5GO;- W]+T68'</57^/%?+
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MXJ+G(FXT$@V=!"$>@ ^F"&\S^8N:"Z(=K!).+C/VL1>I)3 !UF0X$.<KUJV
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M-K;(PCBVM(MS,&/!./\D:T/JE<H$YM;_1@ JJS,Q%OL3W5.]M7<!6"1)7;F
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M(B'#O P9_?I>,. 0NR/8_]:4K4=#-H>K/-H**2?*'AF*=IO/S[.FW5\R<T@
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MY8GGLQONB ;#SBS>A-WRG\3$Q,1E9>)S'DS9)2PQ^YNP[D10!-^63\T17]>
MKY\S,[+NE7LO@G"&_; D1Q,3$Q.7F(F_NY/(M0":;T(>1@$B[S<O"'T1VKZ0
M7'PF7#&Q0_;-@2>364&<6Q+./9==!\U'=@L/"QP>@L/&AM:?D4+?@-B3V/.
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M_?M??OV S[$_XO_^_O\#4$L#!!0    ( -&%F$YQ]94R$A<  )85 0 1
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M$)WBP&AD0#FJP9!LE"IXZM79'Y?T19(AT#J5^= ^K'+[?$ WC9@D,VB3#*C
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M$Y\9$Q2HR 94RA22B>A]:R:B9"[:<,(=GH>'\W['CII4]ZMHI/.<R.R 6NE
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MW\QJJ6BKW.XUT;B?[_%B\3*5"/)Q>29PB9)]O??QP3 =5'LC::3&9U+>4>3
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MUL8HZETJ3_*9R"$RJB%XDM='&BY'$U2K7;F3'JUV/U-M.(F$F6R!9>Y .!*
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M[]2T5!P[@3BZKH:KH'"MIN41\ 26Q/)0 9& OA,3(5&J[*,,6SQV^(_3ZIT
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M(K3@%'G%.7?(T+!^F=I<,0S9]AYPM-V6?GDQ-(*C.#C](9O,TL4BO\ZSJ0\
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M!'(<4FHDY-9A&Y9=NGL/M"=N?';L*)SK*.A>V*Y9U$(]]&+<'.TN &^5<\
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MPFTD)P.^P^FHY7)>5PDW1F&L@_T&D#94D2>(2.C:I^6>'\\9$Y,BXSB".2C
MUFX&"@T3RK2D$@>W 2-#)$#8[69<!UC[FBKT5;.F5]0NY3.M9\KSYIPF'23(
M>"&#KR\1%II3Y946M?3$=;CHB[UJSD1!;P3SBYI,5G>K6;K,INJN*)?Y?Y\J
MU7-^9XDCT@D,&7":0X^ XF#W1@6\VM<6Y:^:4]&1'%,\IV,<)_&,*<>-#J)#
M*HAG4FZWNCD6JD-U'O&J.10!NZ%8\Y385]<O!3G"E^,-$RN@X* *FP(=G <G
M.%,[:8D=LJ;H&")]O:+UR(V(]7-.599Y88$-6%JF'LC;!G5DOGLV\89S2"SG
MC"-+D846U=E9F#'3:-\OCER/V^[UJ)M7B'G6(G':>%#=T^8]YZ*Z%)?79R 1
M%WS(@.G1<C =M'.P]DL7)-)Q%WKY:]PH@JO#P(9@3@R4GFE3%=W<4L BU3[[
M>["R,BTI>)G[1,Z#>[#30Z.YD@%J@;BD"!,>@"(0&H=K?+P;^X'7L9&HI[L9
MVBGE;_*^Q&E424Y_<<[VM!,;_3X1@1G!A"#.M)?X_V_ORYH;Q[%TW^^/N8-]
M>;D16#LR(K=QNKINSPM"*=.VIF71(\E9E?WK!Y1)>4F+I+@)<G5$=U;:29 X
MWSD SH9S+/=:[G$SG$QY/H_<3Z0UQX[N)W(<AJ>U]R:IG_HC+O1\_7.:KTS3
MLK/\V.NOGKYS9SF?-N;SKP\'A1GPF'@B#-%,8FE,F0XGN%#XA$57]Y,U#^MU
M_%MS?\XWG@_*,<$YC<N>(1@)BHI[>5M!, )\]Z3]P7MS=F?-+Y9&?R"F-)U;
MIJ@6%ZX?-MNH2ZP/F;9O/QBTQEI0J1W5G ->W!)R>])YCPH#HS>U[,7(?$!0
MQLP^+H[H+]<OIEA[X?3@\\$;RXU40OEHC!M HCF^IXE#Y](T[OHR*!\/FO?!
M]J3,HB2X/9!QHA?YCYTJ_*/>$'G]7* :QAEJ(X5GU@K/J1?5T<9%C^L#HUS[
M& #G?#@T>B3UEL?))H\G>/XTC7F^>2LAJGE0\ I2"*.EC:(^@AB%R*AJYA[V
MJ.DR8BIW;SUK<%PF,0C+Z7Y=Y_>%.F<7/[+-=A$-VBC:]4;NJ7M/C.] :F<[
M33:+@(W$SBL-E""28D<, 100+IT%G+%6I?C/E1?-9MXD,PB6,P"UA!!*#0A4
M$!89BP4/C+.L1\'5P0W'!.5R\MA7%YXE'1[^^O!]N9C_MBU;,NWW[X:@;MVP
MH#D&"#*J$874&P@<P"4\7N!)[TAW: R<D/CDHX$^54SKT)0OXRP:PU?-@X.,
M%@QBP&'A@9( &69)1;4'D*9IB0_+T)92TANUOXK,)&7&IRXJ ]F,O^?K?RY6
M]X\-'>J-_#<>#<!0PQD2WFKNB](^!JIJEA# [DGJH]F'0T*?#XK.=(GG?XW$
M-*XU,(XJ9:F3%!$HHJ%>*K/&VN[;S<@=%5+7AI)DWU\O5T@R*)F-G&-Q4^(:
M.^%@A0^" J2M@:4F1 ,E#75CRK^%]S5.2:J"?U&9/9=$-ZRIA4BJHGHE5 Y!
MYTE%!Q"R>^&(Y!+=6G/LZ$2WXS \R;Y5#Y.)M.SJD#9<R.WZRJ*"IG34<FL4
MQ$!J"V6ITUM([;.F[<E(V3DXD"=B1X("NS= X3#2^O2^X 0Q4"@%J6>1)THC
M;RILK,-)5EYZ5Z+:F1=3!HPGRA?>; N.1O;\?;9>%)_\L-IFD7];%U$K/#&G
MG\$4><8?L]FFZ4L37%VM5EB;P/BO#P<DK )<*N-85#X@4 9P"B0""$L"=2OU
M?63*&N_BOG@P* F<9U@QI05"Q&AG*XJ88VK*1)?::' ?9KR^@]L'@:1CJ\_/
MC8\%JPJ6U/LD#PT)5@MJ&))1(T;64RPU=T^PV"FMBN.NMW;D;CX*+E,I7F]-
MM]&)<7A0*$QO!V!<1M$R\A9 B$Q))><1Q;2=;/V9UT(:>B'U7N4B2?]52N(P
MD%.I5+57-\M"KYH]MNZK;V-Z<$1@(DY148^485 XA.*GJCE'2Z%55MZTIOT0
M#,C' &>R<DCS>50ZKCY&?;X,Z#:V*STT)!AK!,/"&^4<PBC^A["*0LET]Y-^
M-'-Y0/8/C$[G!?TQ7]U$J^PN?R&)RQ;\/69X<,8  QR4D'C(*:% ^XH:@WUW
M+]YH18:'7NKC('6B'(:62G[-J."%(D7)(L2U\5@)#^6>3FM<]WND(V<+#*3G
M#P?-B46@4:NK'1>P5IP5P12!HLA3P95&):U"Q660ML(_"!?;248OO-ZWC"2I
M_*<G&J<1B8LL*K;K^:U:797MUXNINS_OBQ;=C<ICB]'!.8V,])@ZC*"RF#)G
M*[J!\ G=?1R8C_G86$TE(]^RY;(H!9NMHFZTW$6>[B([BJJSV\6/K"2AV=0X
MZCTA HLE4]AQZS@3F N-*RRLA-VWE:G"=0/)S9BH325!7[:WV?ISOMIKUX]0
MM=UFV@P/@!",*&- $8 $4E;L_?["X1[NBA$;I8PA+R. -9F85%/>A04O%C>W
MVR_7OVT>BSK5R4?=N,"U\I)1Z(OB(4P*I61E#TK(?((5OP:,:@T)S6G$H/*]
M5%5A6LO!ZX%!.0Z8D]!1471MX90B4%$KD9@R _[4@M 3FQ-+0MS=YEV%X6EL
MH$07]0^TQ(X Z: "<@^E$3S!UEKCRT-G>$XL$L<+0M#&2JRD8I)*9J.%!_<N
M7"E%CW-AM'Y8X[/_2%!.PW3S=OV6PP\';"E55/NHVD @J6)8D8HJ0'L4-QBM
MB=5HK.Z QVFXO'FE'G][^+[SR5]$XWGU4)?+=-1[ N/0:Z5)Q#.>>3YJQJ"2
M^*@6F^Y-849K5C6:; P+U51B\S&+NFQV8$/[.ONY2W.\R IH(U^^7/O%9CY;
M_B.;U9F<W5\:K'?6:2RH42#:W,87:ZU$R0#:_5P9K<O0@ (U&6Y)29=]R#YG
M?VXO_\B6/[)/^6I[6Q=WZ_K*@+T&U ),H4/6 Q\W[\I<4TCY[H7_Y'N1K/ZH
MI297Q=*X_",?0)S*-P4C!!"<6DD\9U1*I;'?KS/<ISPL>$=BU VM)*4G?KA.
M73KZ75%]%(!#)"1B40T@F I2.9D5-;B'1^T<7&ICXY6B#/G\H;>V].Q5P0K,
M'6(N[LC.@&AM2E^YFS2/('67H'/PQ8T,5Y("M/@QU!Y4O"HN*:U=U!(M]\1+
MQX4W>T00]CT.L7-PWHT,5VH"I*ZWV7I *7KQOF"4(H):JI"7% L.G*E.>"V4
MZU&TZ1P<@5-@EIH\#2!"@6-CK)"4N:+=$M-:J^J2@"82][@(=0X^Q9%@2D)0
M?EM=%;>7'U;;[,K]6=0O4W?%3UVEYM#[@B9($4T$+VY>2U,<Y9475EL$>RA!
MY^!ZG *S$WFN_4-19_Q39,S=P]VSU7!L!+OI10%CX$UA0C!EH"#:X/WJ,H2I
M'D<7/P,)&A6LQ$3GP^KRC[PX?NL<BT>_*S!/N;3, X<5 <!CO[_&%''2/2SY
M<W!6CXU7>C)4N".&DZ+]VP*ASECE7-0(%:72.\@KW[VAP/8H W0.KNGQ$4M.
MD@JWQ&""M']98 1H[YF$7@&%(9.&B_T>K5V/2X?GX)L>';#TQ"@:D\.)4?6R
M$%<5-LY:+Y'W1C#MU7YQ.=9C.T+GX* >';#$Q.CR-EMGL\(_T5^*GMX5N%72
M$XN9(;P !0B ]SNTZ7&O"9V#CWILO!*3H?Z2$XB3S%D!"3+*($H%Y96/U1AH
M>J07GX-+>AR4II*2%]-]2GM:;6?+S;?9,ML1]7TV_^?E>K;:S.:[XGF_+[:W
MB]675=:02]3_Y:&XU$,!LAH:K!$M.JQ57+'&HAYZT3GXJ"<'\ S$KH4[8("W
M!RXAM%A;KXO;8P1(+*KD&6NIQMT%[QS<W-,C> Z2U\:),,C[@V,(:*<M!-H8
MX[00NK)NK*2JA_2=@X?\%!B>@?RU<3T,\?K C5'QR #<*,*(0(*#ZC:V%<!U
MC\^@<_"NGP#"<Q"^%@Z+(5X?CPUM..=442X$I(P@\K1LB>F>ZXO.P3-_ @B3
M%KY6+HZ>;PY*>PL =@PP8)4@18BCPLM+U^.T/0<G_K3H)2UM0\M8@!XC+S54
MF')+O' >5CJPDZY'BA4^![?^%)@UR].!"H.?LVTYL]TT*E=-L9=^J/%MM!X;
M()4.:((0$I0AIQV$U;IPU*CNF9HX95_\6/B,P^?26.W$YW)L (A0IAVSUA+F
M0#QR?95>X9Q"W>]1XI3=Y6/A,Q*?*[.P&Z>KT<%CCHL"$=9 J+F0%E&]IP6)
M[IH"3MG5/1Y"XW"[,L,Z,;L:'+056GJF@=0(8J<$PY4)Y[CLT44=I^QZ'@V@
MD5A=&CW=6%T.#KA(R@40<F&+NG,*>+*GQ'C2/>*)4W;VC@;0T*RN-0+;#0PP
M2JI@0&E"%.3:6<'H7JOT/>KZXI0]JJ. ,S1[CV1J0-X:A>*K,>:, 1E_JJHQ
M>*5\C]6:LGMR0$A.DX+P>U848<NNU(_XVYOLL19"]8^7V?JNKO/=L:\*!&*)
M&>1*D>+FA<:,5%JGMT)V;WJ'S\&-.#)<20B0+2]*7$34OF;K^3$7#)I?%8#Q
MU%"A((.:4@J)E7B_I#CMX;HY!Z?@R'"=1H!J#ISZ <%*PXJ*8$3PHCHV9D_Z
MCY<2=-]-R#GX\08!92J6ORKU^>7[-J*577U8N3_GM[/53>;S]?&U]'J\-410
M')"0 VV TX!'#:O*,?6 L.Y%V$C*CL#ID7N2L-&ZI3[F^#W^^?+CH_0'??RS
M[!)Z&3_Q,%L>^.S4>^G5CIM/?71;[ZFO!P:AHRQYX16U4#B%BB:\%& "C8S_
M):TLLW$H_C:_S:X>EMF7ZS=):&PMVF)X,#*:2 @(9!QTBEDLH"RI-\+"[A[%
M@1N.#L7$UT7>A\=HEG)+TO$[6Q_7^VBD"03+&*1%;41'H1:*2JQTR3*+C9E2
MK(]KHS2H/-;W24D#^ZGTLJ/H^#R[RQJ[\W1\8X" (%YDIVJAF4'4$0HJ?!1@
MB3=S34V(\E,RY=_"^QJGTPCM<4VG_BHR.Y#;W&:KN]GZGY]FJX?KV7S[L(YS
M>YI/?2/,-F.#YHXS#"!2"!*%%%/"5W0 0WM<8A_+/AV=8_FX&';<MS;K[;,]
M*_[T>K^*OPH7A5%]0 M\\>]!:<BTU$HBSJ S1%AC*Z7=&#9EI]O3*VE]H!F=
MG0<7^:LG I&.<&0QEH87*9F>.5C-&VM+TM1M.F+_FG.],#@?'B9UQ$_+NNE8
M5H99:YGVXIF@A+$&&$TPP)*YXF!1U=P%,]W=O(.?HIU1SX>A?52^S?YLYMOS
M9P*WPE$G@62$ T>0M[[2"1Q1/:K1#9Z^.0C?>M ^E;7U5H6\(DS]Y=I$[6X=
M=; :PZIY</"&(L:40QQ[JR'D<;?:2ZOJ<;MR-'UW)._KX%B=4D(NLE7VQVQ9
MS/](\7@V,@ @XS*("TE1):(.C[##);U>NQZ'[VC)W!/*1G>@NAN_SRV]E[-Y
MI/2@Y=LT,$B(A8<0<0TX=QIKZBL+P1MF>J0$G@FK1\%I8$[O[@PMRXCP(CN2
MW:]'1X@H1%99IRVW,&)%G-K3@DUWDW>TG.[I>-X3K(G#[SLK?^0@?!QUL_/R
M3/29I[^5,?^3!?L?/;:7LS_-SI\6YSS_^;%%K+]V7)"(20Z4=@A#C(R2'CXJ
M$UI'+0.U4KRFH[<IOG]P3) *(.*!=P92@P$P%MF2SJ+Z=_=TL8&#^@-QZ\TP
M9W]<SB"0'XE4#]O;?+W8_FP5>'\](&"OD+(X[N)"8@6@%5B6D! !G[JZI!8H
M'X#)A\2F#T!3&2"_3K8QXG=H2' 8.EZH5M08JXWWG(IJG7&H39H^VZ'8UB@%
MO5!ZC_*0E/\W-3'HP_Y-U,IN\A__L4MN7_\LN,^K'PK&\V>,+W\=],4;+'[Z
MQ\ AY<[1" &V<9)0(UX!0)WLTZE@+(.C/_1Y3Q0F\R+EF\VSX\O.[F8WV>9;
M_G!S6^MAK!D6H&,2 T.AQUQQBQS$L*24:=).Q3T1OP=5 @<$:0+#\LOV-EO'
MZ6[RY>)JMLVN_&(U6\T7L^4^:>71(AO5$&P]BU-;A[]>#ZA9+F_<)8"82E)T
M%V4$40^%0;H,$P(G$6EUPHU,66-R]XL' Z!""V"Y 8R3>%+@G?ME1Y&U$"23
MQMV'&:]3M_L@D+1M]SP_[6/!JH(E]=;=H2&!<@:8)<IYH""/)R!6J((E_C%E
MOMYQ.38=N9N/@LM4&L%;TVU4Y \/"HP8@[4CABIB.4>$,UA1*9E(W+3KS[P6
MTM +J?<J%TF:>"F)PVG$X%%!>VRK]O$I4'(PV:35N, @,=YR36$$T7#@#0+5
M 2QDGY:^8YD,0S#N]1WC 2%*R6!H_6##_<Z)+8P)HFM?UWG41[8_OT99*JX!
MN/]Y6-P7,SCX#XE-Y]16V,&)M;'*F@<'*P2V"GNJ$&/$8F)(&?<WG#J=Q,7<
M@V2TOYQ;_XI D76.6"J5M A&RXA7FJ^A&* I%?A:RVY(AAZ\I#LH5DG;@ <I
MU3\OX^P;S,$6HP,2,IYCSC$ !(JG)<5:5&!Q2:8,$G>\?3&4-.1C@S>5?G@8
MD#B-1GNAQ>@@,((""4 )CZO8:$P]K^B&BJFT#<I!.=M6:GJC]]>1GB3-SM2%
MYD0>B8?%LKCRV&A[OGPP1(  PU!(9C@3 @%"=46-$B#!NYZ#\NBU!Z(/.%.Q
M^M-L?AMUN/7/Y\0W\KUF5 "["NL81J 8Q1YCHRJX&->^1X^5<Q2"X9#JG/OL
M9_-=Q:N&:,/!9P/55BG&@9600R*$YA!5\V2R3__H,U4FAX)J,)8>/,!KG@Y1
MVKQU0B$,J=960$!8-5?CJ4U3W1L ^SHN]L(F;7XFI8"EP<:!V/<M7^;;VX?U
MZML?B^V_LG7<9:[J2V<<'A$L=A(;$:?M+%$:6<SVIX+W<-(B+/7GYR#(YV.@
M,I7VI.;SA[N'9>'LMMG].ILOR@L6]\MLA_[J2MWEZ^WB7[O?-SJ?WU"UAOI$
M8-YH*K6U&##$E8-6[!UTRJ$I74)]];+^7L<3H3J57#ZGJ4:VGC\6D$5(:F 1
M Q8X3)BC>TH8LMU+#$ROM_>7CQ[(3,7C(M*V73_L&IM]*"3T9IUM-G];YYLZ
MYW'-J&"5A((HBI'2EF%-&*\<'1Q9W:/9U!E*P'! 39M D-_=+;8-9\JK)R,]
M#B@N+65$.6>(5::R?[C&J+O)/MK%U1$9WP^<R7;XY[=LZVN4==$ZAGA]()1)
M'I<*C&O"2U6H<-4R$9@QWUFL1FM\-.:),CVB$Z2J7&0_LCCWS6[15#^<.G<A
M@CJ[B=OUXVWG+]?EO#ZVR%QH&AH,-DXK@85C!NY*_)%'+ZZ5UB%TPNSR U-O
MRE6H&Q8 EP0BC+5Q7DO.B72VI%8Q:KMW0QHX/V$XMOVZ:H=")^F,A,+3_>5:
MK==%!:CBJPTY"&\^'SRS1CBD">%"Q+V*<[@'1#N>;-;!,%S.AX=H,C_&TRPW
M\<#YG*]F3[]YWD"Y,3)TY)L"0L)S:'"1\P^!!QA 5^&!I$5I.J$'XO%KI\0D
MV/U;II)RA)^'*)W*Q;&,XI 76O&/[!E)C1)3/S!(I(R!!EFNN>3"1V4:E]1J
M@G1W>W<T5^AH_/S%ZS$@<!W%I%4ISF@C73W,MU_6W[+UC\6\KB;U6X\&B:%
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M\)M7/Q3LYL_87?XZ_/;M#=X^_6,P'A:EW;G$@!DIF>"H<KDS+R=-PFAQ/@^
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M,-_+X3R_62W^%4G(UHL\/K?9;CZVB.X,_*6 !?<  (:H@4 0#Z5^M/X-%<"
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M:.$0*>DH_O@>@?E__^=_ 5!+ P04    " #1A9A.QP!M$B > 0"O]0X %0
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M0?75]>"<_AJQH:3 U]6RVM[OUJOK[^7V?Q9KT6P6367- IX&-!$&.0LQ@2Q
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MI5HVT.4.O7H,L<])]8,"S<_HG+AU%B>5]8\)A,A@E=8C)P<67HM:_**Y(%<
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MI-#+AKLT)&%Y-2[O"-AH=]2>8^G,FH(5<J>QIF#'E<I!X^O?IP['[K ?^W%
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MAK;M.M^6WXH&PJ;!$".810'R0QH!CB'#*88MAA2GOEYGM&O;>;=LX%YX=WO
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MAO#T\N#5S>!]V="9%JQ61V9XYC.8140483[)6, #UE[921$--5^GU?[\(!.
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MH*4\\V->9!_J[+':, ,P@2@A7@1=2"P2!,%@UK.(AA)-<6/FT\QKQ84<(VA
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MUR7A]%"9+\$"RM%V0F?&J9W@@%(OXMW6$0J9W';'? +H>X'XT1M])@U/CT]
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M-)HU+.6?LR(O#VP*5S<"T (%!P923K!U$BTFS@MQ+"?$'"0XH;P!/4[ @=Z
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M?77#Y:=?_V>/8CWU']E0WE4\/F7%MF_RE2W_N2NVS3<X-7]>(78'LJK*52^
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M:L%%<N)V7>^,U,!Y"IXRI9?V]JVY9Q[R:=&^T[, RTQJB?$BBM(DC$&"(8.
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M:<&HU'NHL2*A<O8(45.Y#H=6$8P:*2H5,-;(T2Q_D25)L@CFT+RS%3!:',Q
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MCA-]I>FWJU#(/!;Y 40Q)A[$-.TWTY%HS3).:R0'N8;:C"GLUZ!15W$L,&A
M<ZY9U?^"'"7=4>1SKLJC:L:;VJ/%B_S96CM.OD)5-_3^7*_+L !S*42)'].8
M_Y+% '<WD(@,R_>9XM5M!D:TOI.]!^EDXOZE=J(5 T[5$S<#),L>O$W+KNKY
MVR&MO7X=%@I<91DG0=K%,SESE,]#U(Q:].*$SC1;TO66Y68U#-Z74_%58^Q&
M"13?QD<X"7P:=".E'DJ5:IMTGF^[PK*LG951*=,B44ZZ;/.G)E6"NIG*U2M$
M72JT'$'K/.1HE 6GI96CV5"O6JJ&^W'>%YO\79T_5@LO24B* T@92",W\,,T
MZ$O*L4N9TD;2N)$FJUNJG#\%*J>!I5VSI$6F;.XT%8^J6=/!+6'[Z\/DZ+1<
MO?0*4U+E2V,8GH<J&;+E; '3>(;4E>I++I::HMH\JW?;HG[V%IX7>C".O"AE
MG@N@RW_;%TUAG/A(=?$W8BCKJ[XO3<%->>>L=NWEFY7XS5U7D=/W:10_^"O;
MKH;J)L6CO'%TJTJ999YUE>S&&8 Y/;)K:=A+BJ0D; 2S<U.P,::<%;#1_+RE
M7T7SC<S!B#QGYY,V6Z-'<:/+PB4!#@'TL1>BF # HK#_/AO[+O-D<JRQ8UC.
MKM#]_3:_%S4ZFPZ7DS7 Y"1I-(.7U6A*\O2%J ?EH,O,2?0_;@T6&A1TOQ;J
M$QRHSQN4O"(\IDB\KN88LZ(T^VHI]&;X8[/-LW7Q'_FJ;P.65Y\V715G?['A
M0?[V,:_37"0/W[(?"YC"./09BN.8^CA,7(QICR?R2;C8---X=5F-[..0FG))
M.^4.(4O//('YOPG03KEQ[L1BYGNSF#&8:$W@K<NZ-Q,W:5ZGU,-V!&[GEQ;Y
MK\)=?6WZ<*/JT<J4&W#CW#8F.-R&V?A*H=G$;'RFUXBBU3XQE39Y[>SVGKQO
M/+GF]OSJ;$6S,/ZSNG3JA]SIOC(HWIR,PT<=307UZF!;YWB'>=EWPWAEK[GZ
M%Y[V+T6068D1LR6W<M?"*9OJOF7Y^+3-'_)-);[1*C;\]WF/-/]1BSW7^B&K
M6^1' _&_+9"(*DN^7&[,N^7_YNXN7PJ4_S*R^\:8-^.5H#[=VS:#KAW3V%E.
M/8\-MDOFDV*=555Q5^0KQLE#^XGQ";][MZG+=\U4H/WK_+G<"F7@N!<>3;TX
MQ#1"+N-KJA2EN#\L(U%*E<J$K@;2\C+I]P/]XW%L.UC27DLO].Y$37@\&[3#
M>6H-,=B=V:K#5;>(9NQKW57=P2$=]^0^D?G5.;3,$4+E'-CF<.-XU.&QHS7O
MQAD,=#H+FSSG^IT,3'A*:I?K2B_'W';(KD6#2E?JZ?QB*NB5]QL1I-]M6F#O
M-OD)-+19M4DM_;%<[U:M70/^35Y5W_)*=.P2-M TCKV80,\+XP3',4"PKY C
ME*1*O;#GA7S"\+@=;!,9NEA'%)T4YITA39)>;C2JX.9$J:$H.=_WP$KH/'@U
M^@AY8'(?(YULL^IV4YW>[#;6'AGN=);/,*0:=>N(.'N=U^OG"+Y7XD8Q(E_3
M@[)AFOYS5]3/'_+ZH5SM&\]]^FO#0\E#\?0YYYJQJ;/[?,&S G$OL.<#''BI
M%_"U\C ^<T.I(S7SHUH.CRU0IT5ZT';QQAG .GNTTPJ9-(D71,B\(^8A(!;L
M*FV_PKKY];=\^_CIKN\ALO"#,, A]3TWBL7-#R =]K!(&,@=?8\>Q/*TW!>0
M].4Z8A_GE<ZHJM_:Z[.JFE-:)%3_/%R $DSBMYHW6<[,CLF12J(T^9R'7(TW
MXVQJ,HH763%ZN>DNO>4.(@ Q=1- H9_$'@[9T)F-,C]4NA30(@S+@O;'ZP=V
M9;\,'T2MW:$6BS#T";]3$S>;7I*3OYDXR,"QN,%#<2M:JL_T!;6=P'WST.,I
M#"TGGQIJFH[*9;$?\5]W'-S=,T^YVF_W\G[)BOL=073'=:^! T*  8OXR"'C
M_^?Z29_O4H3#6$71K8&8[-,7YY\#:%$B\9J<C]]?M><K.5V?A9O45%V$SYL#
MP7;^]<A/?VL=,VQA#M!OG$R GU[1=3F^H.?6W38/-;=O9CGQ=% H73T(&KLJ
M7Q4;KD![ 6KTA_^DO*NS'[T*#2)4;)8\*/%_E;?_NX" 4!_#)**>C]P810GN
MKQ.G<1A1Z2O()D4UP1%:U6;L^?F<75_DK^!&B1K7V7I0=_>C<H0=^Y//4_>)
MGY9W#K?G-5<ZO4W.+[U5O\[6O0IEL;-ULUZ9[%7<+5=F:I+I<V6G5_'F#,I0
MKV-W>>UYI+;@DUAW'IQS?BSKB_U<JD6$/, 2[",,780  V'4WU=%_0@BN>]>
MKH7.^M<PXK3B_B1UN.MJX;OJ]U^ZRPB/*O=-?Y,\N=OEEI2S]+=6BB&_:7A8
M?^/(=*$Y[VHK2U##/KFP,KV6]^>Q8+V:]>4\YJ#N2?C0-N/3W?Z'B&MKO7"]
M%$( $Q2Q "#*,("X'SI$:IN21@:<;@,R$WAN#K[QTCT2'T.OZO'X1,QJ5TJB
MEM1]2YX;Y_>M^+2U^8-KG9N?9TWJ#-T Z?,04+,FG3U;-\:7(:GK.^0_+V(/
M8A^[0<S\D ",^.C]\,SS4]>@W,D/.IWD]7=M/%N3/06JC4B?'9:UY>_]GN"7
M$CC\X:QD<$"E+X7J3O@IY%##+#5)U.5-ZH#CZ^[Q,=L^EW=(5$WS0;ZT:^6Z
MY#FEFV2;58H^^L#U<+GF_ZALZP6_9;?K_%O^HTXY4?]8Q!3X08192A"F<11Z
M(4 -KI3YD,A5(4V'QK*0=C:([8C>"N?+?@.B,Z#YTH.N\\UMOLRK.JN=(Y,4
M-K^G\:#$F<;LG*>FSV_XK;&A\5KOP2,SG#\;0QQAB=.8(MFH<T(?*AQ<S,Z7
M>@<6+YTB]OL<(ZZ6[AQZYL3"!,7G3BHF==\,3BBFM;>\UD0Q$M?1:K?,-KO'
M[/82))3$-/;B5'0"BQE,8T! #RG!6.JNP4F 7#>:[VVP$+\->6I4Z)[>24:C
M]CG_V K7AEQF)%)/[[HI@_0;GK47G:5H50_,9KTUZYALV%2Y<&R#7]F-QZ_+
MAWRU6_-5?7\I9_F4B_'% 4_36*0]J3X!DWAN"#V7!'% $A>G+/*Z Q^.,(U"
MM0[BED"HZ(-6;_%/KY[I-R5&:GN2MKP@MT,Y _H5(VL'6 CP<(/P@+GK8N'\
M0OLB"X6(:F4#4X_@"]N9ECTVC\U-VT:6D\X"75E&R^5VEZ\.[D@^ 4"IRY@7
MI#ZDHJMA0@,/] !H$J>Z4CQZ8.ORVR%T.N&MFGV1ILY*5WW'DZVJN).RK*^R
M/=5'U[//1E7?(E%*28UY8F[J:<ZPLXIIF#OI4_.B6J[+:K?-Q8?PCT(%FLRY
MRZQQ6=75UX=LFZ>BR/9S]MQ4*QUJ=YBDGA\EGD= C/V()EU#^2C 'G(5[\&Q
MC,:ZGC;@?KL5Z)P>GN+9NFV'2!ZYS\@3BB?Q _*V6\<>^[#!T*"_<5YS%I?D
M:XGQ2,HO'=U/Y,QYR/9DUIX>]$_*LG0:7//!F_9+=U]K/LQ#N>;\5VV+)G1;
MM:U/"(\G,(GBQ"51F":8P+!-P0F%,/)EKPHT,YC%?*S')Z3A$.%_=;IN9G_V
M**?.Q&28NY2$&65^'A/9L$VGJ9<%QJ3[1RR7HK4A7Q=S%)M5MEU5?SRM.![^
M=D1>U%W ZA.7A)$7AU$4!S$*0.@'W=@)\XA2^Q\S(UH^CMN#= :43@O3$3A_
M\R+%W@]F>)83O^DI5A,_"7:O='.S%',7Q,\L\_,0/\,VG79AL,"8K/A]YF].
MOMWFJT9VNZ'BT(,H!)1%,(Q=S_58T@^54L*@BM9I#6!9V@9,3B5 J<F8'F-R
MJF6=+#61VO/4X+F2(+U&R@7]&<7A/.1FG FEP7=*34SX0NNQW!R.PRC#$,<!
M33T6D0@0-R'].%S0F(J2J#_=LHRT@'0T1(,H.0&QRY&:>G3T7%,Z7M!Q03?T
MJ9N':(S 7YIZB1077JM5T5Z(^CDK5N\V.'LJZFS=2Q1T \]S"8C2U'43[ 4I
M[L>$# =*"ZY1(]E>: W@G">.[K=BXRQ;?(KKJW%T2JZK)F-2<3VU)_%S1V('
M[5K+J$M$75H^&2%X'I)DR);3Y9)!AA3VB(9KJL2!/#Z\ [0MI^B7:3#UJ(^8
M!U/@$^;%7CA(I>>E1'&?R-"H]O>*]M?3-05,1U"["B;E[2)3E$MO&5V!;469
M$Y?_H;K>%K>[NBE7J$LN>%NQBWZU[2(YUBYO&1EF?B;Z9]ZNEUM'5IB3U<4O
M>9V)JXQIMA6W7%3=8('K^AY?7P(64T0 32(WZ0=SN0JKB*#F$)85KT?EY!TL
M-7'3Y4U.R2:@3$VV!K9Z1%<2J]>)N:!,(YF<APR--:(T^G:I"<PWT4APMWT^
M7(T"FJ8^2U,/AB1.0!AA$'8C8>R'2K=)ZSS?LK3TD'0VEK3HDA,5VTRI*<I
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M9#"6:=3(4TXN2KUIF^Y?N[O#IS.?;)@B<Q[*--J*-YL]Z+ R<3.VE&*/Q6G
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M?^W ^CKJ*4FGA'B:=LR\M-.X=6>DTPZ+YLN"%BX,0I>/'5 7!\2G(/+Z?=G
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M 6<PP1))0:VQ!%(%UF 2[K@[W\0M,^&,%Y/TZGH+GC/]\.1?2Q-LSQ0^MJE
M&.=$2XF)X!@8)%0DW1H5(X2XC,G< BN*7H%^G,O][!E/NJN^9;,:F\2S&L%[
M+9FD2B-LXU*%%6.V&A\V#EX&D;H7_XZ=HAG<YZ13^>,T36UQEV3YD<3ZKFZ
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MBEC&?&2\9YO 5J$P;'0IYP<\OF@5[?X2F'Q)\\76Y>=YD>"A,<)+IKC0#AG
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M5".QME&^VJ%K2QV9::>C>X:#CJ?^\R//-[96#9!)A1ABA%NMM?#*H^INDW)
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M80&<9X)3L9F=%#99)(<;9WE.<K8KD+XI&O6,I\KR<L7? EL-AM9L*6B+C(-
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M^A#*F[8 *FF)M%(!AH7<:+0&*W1I ;NMDWRHHNIQ]9U/%Z/R_<+\QL2-XN;
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MMHQC:N*V&E2X5[N"?W[#M46(^SNP6V5&_9#,TX]?D_N#/-I>(<1Q>8\4Q09
M"J0BN)QYR]'%.6F;G!4/4#OOA#ZM(-L7;[9I  >4JEU5@HS+-:>( ,?*=PR8
M-IQ4(X1:-=G(!OAVX@ 5JI8D<T[N'52E=E<*BF$F(&3$8BD8U#Y:P=4H%>(7
MYI!L+NP:[#D)V5[/ 5<A8?/5*\;USOZV5 E,8.F,8P1@8^+R;B2N8L&D,:!7
MQ>D\W#E6U-L.^YHCVQ=WU&@T741YK!_AS&I$J.RJ$H#'@@ENO-1.,66AV612
M4<J("].9.N!.2\CV'7^P"B:='\.A0U7+A], 4T(RRO3J+0-5:8DJVL9-N#1
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M!&QY;Z&R92VUC5XH&.!9?3=\ZPCL_BVG3^GT[NJZ.E.H9>1\7R4@3+&A#D'
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M;]^5RU7]HYZMYR?=3SK['<%P 0"+"PX!A*B2AE3IHB*.&H*)O01V0ZE#V\3
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MKN$?@^7Q:'^O:N5^+)+C8Q1Y>N)>W\P6_UG,CE8MR.\]<.N,Y!)KR[C0$%L
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M48THI-Y X "N9NH%?E[X_EJ9.%K^E+V)ZM*D_!Q'<3*3RNG&049[$S'@L/!
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MMB)*W3AH*[3T3 .I$<1."89K4]EQ:;/.G&FFANH-W)YH4AF7[6A2-0XX!0(
M"+FP*>&U I[L9V(\R7G]Q].,P>@-W*YI<M10;]8PP,ARP8#2A"C(M;."T;T&
M[K-J8N#S;^JOG1ZM@>V:&F<2(B!OC4*Q:XPY8T#&G^K,4UXIG[5+G'_M?>TT
M.!/.R[@!_;M(^7V+6_4C_NW7XCZO3_V/GXO5'7R%1&V["@1BB1GD2I$4H:8Q
M([6&[JV0.4G \+2OIWN&>A3DLU5 V<>(VH=B=5.<$8AUNJL C*>&"@49U)12
M2*S$^^7(:=:UWK0OFWN&^C+D.W)('F\0K#0L)8PE@J?R1Y@]Z'M>2I"SBY%I
MWP]W NA0='F6^?[]'YM9*M3^9NG^OODV6WXM?+DZ/\5S1J\A@N* A!QH YP&
M/&J4M5^[!X3EY/<ETPXB& [U!W;^W__[!>!Q(G_N_NG5?ZGZ>8'A'_/R:[&<
MWQ8W_^NFO+M'_]X_^/X_GPZ@^'M3+&^+V_]KB #_V:.JZT=(__3#8 G GB?/
M980<!E!K%H\'3* QD"/<Z'*SKQF]#'E??XZ0ZOC[_CPZPV,-@Z>2(, =8!@@
M2BA#%M4S]I)G14&.;^&V%7>#_ .M,;W NK1%W&46NQ%O9XNK6Z5>,T4H5T1*
M@;3@*.ZZ]_A*8VBS>A7]S.C3S;?B=KLHWG]Y2H[;W>:^WI5-.C+/)LV#D1A#
M! 0R#CK%+!90UK,7%N8\P(Q_Q386_?.24]TC.Y2V]RPI^^,JS+NR?K?S),79
M(ID[BW*]C:+5/^,/W\OU;/';JMQ^3WG=%]O;..>=2;2,L]\6MQ40Y7)]7LWB
MG@80+&.0ICSRCD(M%)58Z0I]BXV9&*^[)>3Q4K;CD-A0Z^6L>;R;W14G*R^W
M[#% 0!!/<1I::&80=82"&A\%V+1KYUZ<=.4EA-CZH<06R[O9ZL_?9\OMEWC0
M;5=Q; _C.5CKM'';H+GC41^%2"%(%%),"5_/ Q@Z,46_=VF7_>+?<K-<KS:/
M-LKXT_--,OY5^)BN%0Z<^4_^/2@-F99:2<09=(8(:VPU9F<,RPI+'1]G>CF2
M<P#MG00'MY5G7P0B'>'(8BP-3Z[9GCE8CQMKF_,,/Z+-HZ6LGDNZ%69]RKIZ
M SXJ[2??!"6,-<!H@@&6S*4]4-5C%\SDW.>.4=[G2JSL!K=>93[[^[3,'W\3
MN!6..@DD(QPX@KSU]='GB,I*1SJBS;X3F6?@=IDGQ>H(VS]7-'Y:?-XP" V4
M\<(K:J%P"DF*ZPN8^"?)<L@:#TL&L=([17HH7KUV]9W\.MY_,5&Q/GF/>ZIQ
M\(8BQI1#''NK(>3Q]-WOH"HK-']$)T_7%&CP/I&%\R79];%8%G_-%FG\9U+K
M4<L @(Q;<]S<%54BFEX(N^JI1WKMLC38$9UN%^!5>Y#;WY4\-NZ?CN9^I@<O
M2DXU#!)BX2%$7 /.G<::^GHO]X:9B1UO'=.D%XP[9LDN\'-1N5#,BS.I\KQU
MA(A"9)5UVG(+(U;$J?U<L,FY(1EAWJ[A^)()] 7>U'>ZX/5YO # 4MT7(YEF
M@!L$M*KLGPBTTHWR<C1<D/>GQ[TRDL"Z_X\C+BP-6@6@HLJM*(:0*N:XQYY5
MMS3:42',M/3%ML(K^P)T.,5P=E]D^B1I3K0(DJ;BJAXIS %7BC*O4#T_+&T.
M84:H"&82IELP+VE%[+TF?Y^E!YK-SS.(='9O@0MG'"4(4TV%M1X @VM<I,)9
MX203)EG?0 ]%P(=KHR=Y1^[SC=3.Y2\<>]>-*=E)_\$1"XU@+!7 1-12(H2K
ML5/&9CEM3Y:DEX"^M0GT5)W^JPJ/F=V'QZSJV*R(_=UL>5M7S8HM&JIF'74?
MD ?6<2(9 0X:(Y$C^U-$ YMC1(TPCVP7.MQED.^(A^OM]^^+G8_0;'$S6W_[
MLBC_NMT[!;6AWCD]!NLQQ@X;20 @E@B-=77SJ;V'696^1YC[M7NV]0CV4&;[
M?#/_NFMY.7.]7*_-SA,ICN[FYYOEES*NU1V=_BBWFX<11KTGD:2)8=^RR\"@
M%=(QRI' P"'!I;L_C+1.*GTC9;4O1?[K;%$/=WG[,+MYT]B7!NT#U\G0M9HI
M+R6'#@C@Z_E#! =U;HD[^!]EWUM"[T1YH=AW+X;!MXJ'_U9%S[38.PX<CY]G
M?]\\R./(4C_R=4#:>JM(/,^1,<IK!XFIX(/.XD9!Y'T&,,1A/R+=J4B8@VV"
M5  1#[PSD!H<[3V+;#7/5%(XQ[0>T85?)Y)^-2H@']-A U_B>-5V\ZU,QG^C
M0)7G#0+V"BF+-5!"8@7B)H9E-3LB(,RJ=#L>QG0HY4.\R8'U<J0Y&=YQJ$EP
M&#J>WBBI,58;[SD5U0PIAWIB;PNY8C[)FE:HGL>;=3R[OY8__O>]O?LST8;7
M/R3&\$>,J?XZZ(^O<./A'P.'E$<])T* ;1PDU(C7 % G\PIE7P,+SA5;F8G@
MX#O%HXWR;0,'R:/M@D1,<A M:80A1D9)#UD]5\105N+X$;.E^\.F W0'>V]Z
M:E#9V=WL:['^5&Z_?CO#8'_2+$#') :&0H^YXA8YB&$U4Z9)%H_&O.OD2?VY
MW=D=P .9F^\WWXI5'/*Z7,QO9YOBUL^7LV@GSQ;[N,I[Z_-B%U?O5U]GR_G_
M[&;W,-!$L.7MAT<S?__EY=";W&)UTG_@CI H4LZD8(0B Y&LKCFA$]'ZOIPQ
M_! 'NQ__HPN8A]C8)M=;9_<5B'=.>4.9,9IXJC26E7-'7 :*3>ZJ:V VE</*
M9VR;4ON+L5]I;T+>"< E\1P8C@GV&E:>C,#$B36*L^K);:$>[,D\-4\^#( *
M+8#E!C!.HI&%=_Z>NQE9"YOMMM>CJPS,@N?^!SG0#Z40/\[]\#:).Z%S_.[N
M4)- .0/,$N4\4)!'(Q+7+F; IF?$:9&KK7C+7M"\)%].7ML=;A08,09K1PQ5
MQ'*."&>PGJ5D4W,*SA=V _:T0G:P8->=AK)=K78I.?=! P>#GQNU"PP2XRW7
M%$80#0<^;LS57*/:YW,JF%P)B\X5^O, UP[A'<QU\T5JUR9ZT,-=!<14$B!X
M*K%)/10&:5O/2B(R,??RCHZK;!R'NS..F!;KS?U]E?O[>[%<%^^*30/CX533
MX+"B&#MCG#<2Q;5FZF2DP&G.<PJPG<V<Z['-V^K1'8MC. +^B(-.$-P/O)[&
M4>*]WB0H*"0A4&&;'/.,5QS6V[KC.*M"UR@O@[H3^0LN=8+PT)M8A4"#/:OZ
M,GA(!0!,>:RE\Q)R5P=X0L P&V:+DO>,619?TUW4M3(F!]BAB/*QF"WF_Y.2
MT=?\_BVJ@^OTK/)JX'2C=@%)JXV"DC#N>!0GXMK7<[6H6<3I]<1&]4:A+D$>
MBE"^7!7SK\M[D^#FYZ-:RVGL:>BZ^%(F)_*_C]#KC%Z"QY(*[AD"C"$3%Y5W
MO,9!:> SR'9VC--5GW']@3[H)<&[<EG6T0Q/,#IU2W"P8:!02:B=!,QQ%BUD
M3JBL9RL=SJ'8"*.7>B-8IR@/Q:DV=#H\1T^XXA1:*3&'T@K/I:CF"#6D.7<'
M(ZQUV1N3N@)X*!*IFYO5-HKEX8:LNC-K<*MPLFV@SBKEXY:,+6(0,TM-_7@-
MF<C*=W"VNC7]:X6NY3$4!_]CMMC>H[18E'^EB^ 4J?,QPK6*ZF5U-WR$AXW:
M!\VB4D"-<HX*#3T6S-1:*>38#9I6=@@N=LB&LG^\6X?WFG(1*5'>YSLO[O?:
MJ!S&N3\4%WH>Q72L36!&2ZVYQ98RK22%SLK]N*W(<;D>X25Z]RSI&N&!3\*/
MY<_9XA$.I\^_YRT"C]J"3I[JU"IC!$72\/W\$!HT <MU[S3=(#P4@]S=]T7Y
MLR@^%HO=[> +/(YPZ63;@!71R>G/4N0Q1A0"L,=0T*Q]:8094_KC5-=(#^:G
MLEW/ET5R*K_[(RJ/E8IY[U^^2<KF_+:J^K'/6W2:=NT[#8)(QHVA"2&'&==6
M5EHJ1-9GU><X^^KANG>YP80P%%73F#>K[>Z&[L/L9WJ>K[%:WD8+^>8D+QOV
M$)"F! CF/90PY342&.IZ_E [..BMQ15OBOW@/>CMZD%P3MVN'FP8+/>2*<"]
MT<@2PZ1PH)ZMIR+G=I7_6EM<IT /2JOS^?2:1N&98EQY)1UR6D&F/-PO&^YR
MZI^)7VF;Z@;?L86N-/[PXD63KR/(A3(>SR4BE:("(\6,TU6J(*^CLG3!;#3/
M^=M(%SK<*#U,(4Z-!'&:0!"-2!U'ZHWA>')>5 /SX\3NTUH0 U]I[0.<&Q+N
M6+,@D(6(>B8=<YYZ;(0 ]4P113D>-".\'KTLX3H4Q-C.O M7++B.@\QI;83"
MTI.D&1-K$*F?C+ERS0K"]!2I\%";[*CK1(NLTN=T&"0$5$!@<=QC)3#:,U@_
M,G&M64X^U0D?@(UY=3#_=(]"&BS89C^9E_9*"]J>ZB0X!U+668VB;6N,DRZ>
M"#4*3O*<6-()AUCD4[5CP0QTD'Y8I:6U^?EA,=O=P;G_WLZ_)V@._L/%SM*#
M(VIP3IYL&Z)93[FE6&B+G9::"55YIQNE,6QTPSOPO,]+I').-P%0[)&4,*J-
M A,3_U? &@V FIFVUQ,6VB$[RL% '^T&<>D,*?WN$]0K2J!DWB%#( /4&%,)
MB5!^R4N?AZ/HX"Q.YCQIV$6@R#I'+)5*6@0M!;P.@C44 S2QA!4=LN*@^M I
MX$/IM@<'K7]^C@,YD0ZE0>N A 3>.,< $(@J0K$6];RY)!/)A-T?'9J>1ZTA
MOSC5TKA/YE%IT#H(C*!  E#"J4)&8^IY/6^HL@(_1TBU3IG0E&6MT1[.^2F"
M-E]^/9E5Y>F'(0($&(9",L.9$ @0JNO9* %R'EZOB3MMY/O"22D#V*%H\OLL
M(K0L5C\?3_XD9XZT"@ [:A2&$2@6S0",C:KA8ES[B3UW]$F@[E!N'2O@9S<[
M[[FWQ]/"'?PV4&V58AQ8"3DD0F@.43W.]! S+3;TIO5T!7!G1#BHIQSY.D2.
M>NN$0AA2K:V @+!ZK,;3B:3HZD!6QZ3>"LO6<O]4+LK-M^UJ^>FO^>9_BE6D
M\^W!X^%$BV"QD]B(.&QGB=+(8K;?M+R'$[&U.Y%:V0>B%[=PWC;(TG:Z<;!"
M8*NPCZ<I8\2F&\8J',IPZG1.7NP1YB2YG"G=%O$!O76V=]M=4(HMHMANYO=K
MK?B^**IW,W57KC;5F]K)AZ#7/7LZ^16!>:.IU-9BP!!7+A7GJQ%4+BO$;41[
M7Q^4>NGB<PF)#,7IQW,ZPLO'GP5D$9(:6,2 !0X3YNA^)@QEE08?H9+=([<R
M4+U$I-";Q.ZO47#KWU;E^MBA>J15L$I"013%2&G+L":,UW=C'%F=<ULXPM.T
M1_9T!_*@\1JFO+N;;TZ<@\^^C/-Q0'%I*2/*.4.L,K6NP37.<FH=86QMCZ3)
M W:P4VF^_EZN9XM(YNWW-\N;Q3;=;*:G_UW8Y;:XK:J.M].RNN@^$,HDC\L,
MQO7DI4JF4;W$!&9L8IF]^CP%AY?&0"X@'XL?11S_>K?HZA\Z+Q"]ZWU5]7ZJ
M/O2K'P=+DT'OD(! .;6+D;B_)[!2QF/D@E5G(@UF7^/!]K5R1:Q0/.6/<:Q9
M2*F;(,)8&^>UY)Q(9ZO9*D9M3DSRB&RC+L3]<J5VA>I0)TEZ%WG_1:U6L^77
MG>?J"=>*5[\/GEDC'-*$<"'B5L,YW,]-.SXQ:[H;,9?= SO81<_#*-?WX?6S
MA[]YE-ST= V1,WL*" G/H<&I-@($'F  78T'DG9B[J.9G'A^4],KUL,9W/O$
M7#^*1U,Z2;7C#8-$RAAHD.6:2RY\5)-P-5M-\A)KCY!9O7'AA0W>(>@M*;9>
M;1[1*_[TG%KQKY+^?KN]V;Q??2I6/^8WASP,#WT:)(8">8,1A)AB!Z*B+>J9
M4*YS=*81WOEU>@)VA.D [$A+I1K@^N"+^]'O@XTKAR*F#' J<IPHJ>J%I%'4
M+J>QS>2+]"4WLL$<ZH2Z3_;W\^2!].2[  UG'L6!2VF4%W'#Q?NMD!DW:''A
M08B1(\_GU1PRD&SMBK$S'6_*U?=TNA6U#7G<&>-8F\!0\D. W&L-,,?,46&J
M<1NN=<[6,*(CI%L&=(WJ@"X9"8$' '9S.+EE'&L6L4.$1L080L!@3S#5J)ZI
MIUFE%$;T<-3/#M(AL'WJ(;_/_JM<F>UZ4]Y%@(_HJ"\_#$RE1R\N->1*6&6!
M(/71:[##.1KJB.C1FX::C6B?O'@WNRO>?WDRQ*/ZZ<'O@Q8@+A@N#-,4(2,%
MK1R9XYRBE38A-21'H&7W4+;60]0??_S'O#BN=SS^)CA 4Q8?8&U*LP,$5NYA
M.X-\(C<='<FF[ ;%]@Z_L[OU=OE5S\OU_&Z^F*U4W-2.7W@U:A><8@P2K 17
M2"(!&<*J&K^%3@^:S>.J6- QL@.Z#+QV(+YMX )\JFDPV#BM!!:.&4@=H8#H
M>L8N CLM[Y->GG\ZQGBPNX[*V#IVS5%]$K3F1$/(M*74(&.=JK)0Q!EH#X9Y
M5AZP_FEW(GU1O+(5H@,[==3E='RYVOFJ;.^?&AY*[E2.'L]&V3Z?1R--^:'T
MS_+V_VQGB_F7G_/E5W53C>^P=TCSQH$1*X"A#A"4*K#9:"-6>X#2!J%&<55#
MS?A1NI@#+B-G]Q&@-5XY+*@TPD=.0U[E6(_SY\0-FM.N7]6B:T*4PT ^U.EP
MO,Y6@T0>S3H(B@'I"!,(T:AN28VM(]7LHVK')_2HTA,KSJJ/UA+V<9#N9$*/
M)LU#G*G#$'G,H,#1=' >@WKFT-*<,.H1$:XO.IS%ME:(MS:WJ]_Z)9J*L_6W
MO=YRW-8^VB@(IHQ$4?5'G%@K, >LWOQ-U/\FYK+4K3#+GE!NS8]4UB@=Z7'K
M5;?_M;TO'7^"'L?:!$YEW)*! =YHH*D%Q.ZA (CEQ."/Z!JF?W9T"/)0!]6G
MV2)929OM:OG4,#KY#'BB94@/G0 )1X3FFA&!@:]W8FLAS%' 1_C4TPNI^H&Z
MSS>@IJKAL1N_5OT$("GEB&(J*1<13 * K#' GC:*CAC_'M:_^CT$^N/0PKLJ
MB>V!, (;A)T#3B#%B#3UW!4:-H/-]V(U+V\_;6:KS<7YUX(=K4IDGX=_>ZWK
MOF+(AU7Y8[Y.7LF?R\IAH[ILK,>U*XD:$?E<[O;M-\NJY7\6L\/J61>=!T:M
M%X1@1X%A!FMM)*Z1D-I/1(\;AH,7$TO[-_@'E;/Q,#_$[6*5!GDP@UM>K\$8
M07RTR!5%D"#H%""NGCO'.B<-17,M<(#WE@%).:A$6K/QP^SG;HBUVOK]^V)>
MW*JO40]>;TZ-NL&.V57_P7*@/-,N:N24Q*5I#:S>WY4SU R3M6!:#+V0;"[#
MU?W2ZH6I^]X#5%IZK+W'#@"F$2.UKX^*?V&'J13^#T^S)3,MXP>@.&,H&*#:
M.<TL1K*^TG#(NARS^^S2X??&CUM>,R_[1'^DOA?/KL4GX'MAA)?"&P>DTI0D
MD]37=RY, WC)BH-U;;"3M5*>?)@"6+2!6%M/HZT-H()5:>@X(^S=1'(K]"'B
MYU>Y.;@.=714V\NG;T6Q>7L\R_>I)L%:(@C%4DH @;3>0E^YLRM.?%9 T(B8
MDRO>YV4"ND'SDGPYZ>-PN%$ #E*'D !:>\1E-$NIJF?)A,73XDR^L!NPIQ6R
M@Z5RJ7;7C\5-,?^15L[IG"T'F@3OC5 .2Z(LERYNSMCL9^CPL+5L+\.=<T7]
M,I=N%\@.Q9W[7(GW=P:/JI.>)-#1=L$:Z96Q<<*&((U2R'9]92L\M1,)@^Z1
M15W".Y@O1'UX'WN=/OQQ@ @+ X!(N[3G5FBMZ]LJP8282#13QZI.-H[3ND]1
M4!)B?30HC$4<N/C_9#]WZG.BF$9X?.4(O]6%R7GP#GYA\C2.:?#:LM4 ?)13
M[<KV[_GF6QVPV*#";,,>@J&.8B6L1%'%)<) 5)O/VDDBNHM.Z1J#)K6HFW81
M, (>0\D]]]@2#8"L@S2U@]9-I/91;]QX/2*M:]@OM GHG]4#Q*4+3A^((&RP
M&9QH&:"R4GFA(?$0(.Z$JFK@68TH;);B=] Y9R4TAA8(C+W7"%-+4L3WGG48
M$3B1C >=R_Z<[,;G0=RG'VQN)D>&A%0"$(.HCW.@46E!]4RB6C218+)NA7HJ
MD^-YF [ C@XR.>*4(X(KI GDV@(M&2+UG+RS$]E4\D7:*)/C>6"V]C;Y7-Q\
MB6?_:G8\8N?99P%P:/[_]JYMN6TDR;[OQ\S6_?(R$77M581M*2Q[=V=>$#0)
M28RA" 5)N4?[]5M%$=3%(@FB !"$.Z9CNML-@%4G3V5E969E4D20M, +(1PC
MF&_G*F%*)ET_19TBH:(Q(&N+^6(>4 J8%O/]<G[_7,:8((P![#S2&C!ON=FD
M#&AB*4V)?O3(C=2"H!.1K+^@GY:C'XOI9C8'5O4'SV8($\DXDB*P3WDJ&5;;
M<0HO4R3>HZM2;2SM=#1K2]VKSU?_^*KVB_O-0QD(1UIM,;*"*$R1XA*8<F2:
MN)2N:CTJ4=2"G%-@K"W@?UY\T5__\>V A-\^E5&A8+!!3-AC"-6$05EFK(:Q
MR23_;8\:3K4@XB0<:\OX\_7;-,\#MZAW/)X18Z2SVA@OO?=.0TKA=K0VJ:K4
MT5F09R7U9@"M+?[KJXLO7]4_#RSQMT]E)"!&@8$8>LH%HHQB5H[-4)D2YN.#
M%G82CK5EK-T7=Z4^7>R7\=NG,J2%PQ*',2FJ6)BE '0SMC!*GY+6+ 8MXR0<
MZ]MBGR[^5^D#(G[S4$8L\9!('P\"$#ND9-GU15-J14J>D!RTA%-@K'^8_OQ5
M?;('!/SFH8PJX+D7GAG%63 AK'"@')DV:9%T,&@)I^!87TUO2]D>L,%^>3##
M2"+,"/:*,( 0,P)L1V@\3U'6<-BNL50LZROL[Y^5=5\_']#8;Y[*N)?Q+J"0
MFL1Z*5ZS8#ELQL95M6L5N^0\;,]8$I!=)5@=\I]]^%SFL)*,$RRU)T)H&8Z*
M97B((FR2(F6#=9XU 66; ;)M7M@?>7&[&#W<3<>CV9X8ZL[GLW#$4(H!&RBN
M!6%*$%12G2',?Z>6>'4"J4T!VRI9\MOW(]P;3=WY?,84!.&TXDBP>2 G$ I3
M+B-&]%!Z3C<DUZ)Y1(]CR3(?_^VV^/F?Z^L*BZ=(%%[^2^0)?\63S1]GWZ\_
M(,7+?\R,A['1$I<8,",E$QR5L0/FY5#R+AJ269$(7U>&Q9=B_OWPA9!73V5"
M*(HAH<(++I"BBI;=C<,\J!I0(:7F:)".8U=\:+,+B1+6 <,5=EIYP"F%V[PV
M)B%.*;3;(VNT%7NC)8R[8M4Q74@PUEH1P#FR2'-E$2$E-)QR.;#2W<T)=%</
MDN/P/%%&]R:1.^:A/XYF;X<TR$L>6!.))= 4Z["5!*&Z4JP2<Z8KN=C/)[_;
M,>X!59 K1B R%A-7=MS"DB6UMNSAFFZ< \?D>1\'=9_SO(&1"CJKH110.QCF
M52HN28+QE!)+[B%IFA'JH3SOXS ]CSQO8!%S'EEJ* VS(T))4LZ)\Z2VW#WB
M2;I(*^5Y'P=FQ^[O1KMQ:XB8-X:$OZ"B#GC/2NU+L/4#:J3;@+2/Z<9]'+!M
MZIB4;MS(*0@1% YB*K5Q%*'M+#SQ*5<*>N3F:&WW24:T35XTUXV;*RH!$-0B
M0PC%PD9/SO.<J UG^>$HD12!5NK&?1R4M:/K@>FKQ?3'8Y##Y?Q 5^Z/GLTX
M0,XHJH@AB &LI52T'&?0F0,Q2QN25=$LFDU(_=N?166I;Y_-.$$"4Q)X[3@0
M-DS;F>V,-4\IU=>C[:!=J==%,R5OZF>^"'C_/)@V]>:Y3 F.G2".N:C?I-$8
M;,?GO$KQ5_3(4]V"M!.1'$*4(\P->:2\H1(19(#AG&]G3$%*;F6/N-.*X=@2
MQGV,<AC";<SR=E0@K@F%:'MJIQREY>L=7[&^G89(S8MS5XSC.#1K[R=NOIJN
MGOYG.LFO\L4X0G^;;Z<3W;UK/?IJQ]O9.>;X+V4 2TX(AI*&%17T,35B<R5$
M,NI_DP-I?<YT _N)PF=QZ"K,S4P0^'87-N"'_'$U'5\M8N;"_?+499*Z"ZL1
M)P17P@LI*'4:(6++E@*0\VJWB,\GK&:T @@Z";3 3#H S;;0.E0R+;F_?RJA
M<0X<$U8[#NH^A]68%4X2A34 !'.'XE6S<B9.JM\CO^)(H1XLGW04IN<15D/"
M$($L4\HHQ22QL,Q75 @#.I!BX>DBK116.P[,V@9J:0_$^8V"/3 .]L#JQ1YX
MV-@#^[TA1WTD,\(ZR(DR5$#"'?:J=!,HY"E*2>KK)TU2I%MT!'-?@VH>$F>9
MM((*[:TDT;@N9Q&O4OX69YCZ>T\RHF<25!-6:(,093;ZAPDAL"R7CC%C ZGS
MG2K0:D&UHZ"LO^\4X[O\CT7Q^/!'/@]SSL=W!_:872]D#GF%PV$;(H A,0"&
M'RM'+ T;2-WGAJ16M #I$'SP7#DL/*$:ACV3A .AQV5W((R,2DD).S<?_+'[
M3$L8UU8MUW<!@\L;$[LYWQ=Q+.$?;J:KG:[5G2^$=2"L1D1"8JEW876ALN"*
MPDSK@;E+FA-@T0*ZM?FPSC1;O+.=C?W0=MY%D6.^D0'O*=4\J$QEI95">E+V
MX\':F=_#9DUD38N ]S*X1P'C3&@).:1* (;9YIZP(@YUO/T4J]'LO"B3B.>)
M8C#K[?9WB+%HSJ%@ABHJ+31<,K2]R*RY=9448O<QEBK-:2J]GV&D,65 * 4<
MM2[04927?S4@.*52;0_-B,99<434I2[FM8T+-1_-GI;3Y>6-NH\W]\/?YQ-S
M-YK?YA?SCYO>'R17,Q_.F.,*86$9H)#AL"-R4%:$U$JZE(21'IHA;;'N),*H
M?_9YO+\?+9XN;SX>U,5\/'L,N\O%/&"T+&;3R6B53UXWK*S(SJ9_)PLG .&]
M!T 0&8Z;C!'S"A^=XL3IX?F[5;*>6#:-A:)V6/O5"%KK8QDRW$G#D&$F'"D8
M$8B4M="#*<E2,O5[5%*^$Q9V(8!F7 +5"+7GE8PB9(1Q5DE +>-(<52.VGB#
M!E*FOA/:- =S1X>ZM7M+CY;YY&KT%(O_G+2WX'A6+!^?W6WW#_E\N9[2UWP6
M5;PIEJOE>K@_7@^W6NO!A ]G1%,<#_..,$XU18+)9X>R89A:?L+VI)4G]D;
M%0^&*5_.)*0R7HN5$%K"#6).@A(S U6GGN>?^>)'T;X7L1.*_7J6[%!,)U-)
MIT[G[:MFHE1+)8-E"XB5&')IL'L6'PW[BSBA8^IZ?)=/'F=A6N[^858\Y?DF
M@^A%N*_G&]MTC[?^D'%Q.Y_^7YAOOI@6SR <RAINY?<RC8$2$BG+-6 2(RFU
M+O&%0 W,\=45&8O^B:ZKF$HXO 8;\Z71_68F.W+**KR5A4,M,49#)Z FR@N$
M@2SGJ8-2'Q9%3\R5HBVYG)A_.]/6*KV78<"%B!<=%7'4*8/*;%!#N;!H8&JR
M$:E78U(M?+N+#R_S\%MW:CZQX< [*Q[BT-V_X^K;76;BB+<SXIT"B%,J.66*
M8RL4*.<=3N"=ZK8N#A$-L>"7H'+32'?%L.M\%KYY&[/[%J-9&+^:W$_G\:YB
MO&^?;Z9PN)CS4=_).$.>8@:CY\XI9)54J,0B&#B=-@DX7]:UB7EG1=C6^!TN
MNO;JL4P#R #Q5%O-G,=A]+BT)43T_'49"#I?]B1 VA4YFC% /U5(_FWXES(L
M>#RE,40-# :+AU*K$D]@P, "Z_TZ,IQ6EIUMW >F%;,/9J/E<GHS??Z#B[F?
MSD?S\70TVZJ2*OZS9G\H"S)TB#%(G?"<2D0%(R6:QIM.#S)=*.^3L?&]L7!*
M,7:U*#;3R2<?SW9C$>TA>[4/9)80;H@0G-J @%7<;>J$A-D383N]QMP%B4]%
MGJ(#Z?2+FU_RU>7-M]&_DSE:?BBS!CCL)$$Z=A-5+%B'MD1#8)ERE_IX4Z3U
MO/&S8FI-&9V7^6U&#],@]?BGSYF1K9OAO_QB!E7LG*L8%QHCZCA 6&XU0F!9
M)R?&;6&TVTB,;^U;Y?U8"OV0:=I5P5T+^'6BY')=Q*%TNNS,BJWWN0P;"#75
M C*FD;=F>W_)4!DK] \K[?#$U.U04KW2Y6$KTOD\OYFNGC/WCK&<F_F!S'EL
MF8/48^0=D()9S4KT&/,IEG7U/,FWFGK(3#^I]$Z=Z_1N*?Z5[)2)8'H*%WBB
M#??>:X#(\W5K0R3BI%(9M[^2G7:[-*$U-"P0#1$0L1 ]]9IL\=5P(.7/NB9C
M)\E.QXFN,Z?"GZ/%Y%OXR0/I36^>RY#6"DOAJ-9&(*D!T+*<"T=B(,VM>L*'
M]YZ!!$F<.+:P6,3;C.M%JI]^V577$WN9W7QR-1O-8SFB@YE/;?Q<YI2D2$C-
MD8]W?)FW5I7(*N\'TD0GD5758@1="J+V.?WS:/&O?'6]*L;_^CZ?K@Z4H_SX
MZ8P3;!V"&D' O%:&"[,YNQ'%-.M4,9[0K]^1P(NF!5*;/-^F]_E_Y\M@E'S-
M8YGV<?3<5J12E7<S%_8*K!5B$D -"0'4\G(>(*WZ8"\3GOI#K!;$4YMF9K2\
MN\Y7J]G:GK@I%O?/%ZH##@=(=OC-+-C'W&@:9F!];'ZD$(';.7">$ECOX?7X
M_A"L<=%TEGI7F8('WL@ 8B <T" RGBH(O><ORP?SI.(UY^.<[I9ZS8JDMD9[
M_?-;I;I9#=/Y^H_V*[;*'\BT<5YK#05STFGCI:#E@2L 1%*:Y?7P!GTO2-:J
MA%KB7%3'*91[>3_S&@5=#9'S4%F@H-.\=$!I(TE*S(W]Q;BZC*LMH-J$V[J-
MXF"N'A?CNX! G.A^GAUX+2/$(,R(9,1:8(,%"A$J1T^U2^F9PO\Z$^PC6+.2
MZ54(MY?9\%)+X!$(-HA0V@*IJ  EGLBB%+?*;Y,-7]???%I9IE>IVYN&H9;+
M8CR-P:187LA.;P(1@H3*%G5[ J;-_T@6M VA/)SU).6,&B:<?D$F39_#MKAZ
M,G9\6(WN!&+H5_9O>F:Z@!YZ:BT/VU_8M3SFO'28:BG\8(H"G9(X];+2CY-,
MOWC9?%:Z)B; P;4UW,0+T9R(TF[34.+!.,3/CJ<U)71>1G ?<M)C13",N9/*
M(,,TTUR4^L ( %+,A?[EI/=H&?1#GN>>C\Z%-L:&8[*Q5@O)%%"E?]E(;U+T
M=X]<_CV@;8=2.ED^[HF[7/0U&U<339U#@$MD*$76>>DWV=0&L&I-E<\D&[="
MN=36?C.3,&AM*RA5QC(D/:9FB[.2L-/N@&=02+4R+=O.RZTIP,ZR*+?S?3VM
M.'1?+'YU=+_R@[^>^L?@K '03]%G7;D1S4G&D\FPPV&+<-B* %>: D5?V )!
MI]>/?XO%U5_A=F5?;.VU:= 9\=Y4F/!X'(WTZ?SVJIA-Q],36AN_#J6");'[
MI0QJCYRCU$@-8@<$R."FI[Q#'JA*I89:4H#[\*^DL2I](".* \XL)@9@YF,5
M*^A*!"2 *7'Z/J9Z-T"%]\JC#9Q[M=JK/77J&NA-JP;C3&QYZ:43GBFJ(&6;
M;AA6$R K]:II23645U</WL-[\V!FG:9* >ZMUQY;9<HBAF%&3*"!-/)N4K3O
MEWH*GIUEIBZ*Y4,^CD4LU:1X>+9-ON1_OL)C4<S#/XXW)LS^RV]U/A< !@@I
M; 0#3BB!D>5;9+1% [NJ69<6[[-1VT>ZL\#8=LA_/$XG,1?M8'KTKE<RBCD2
M\3*6=I*'\ZASFU(E<;%"(X?%I79)\#ZHU0SFW;,JK+CY9+28++\_Q.YZ*!9@
M14=0;,_[&8!.:1-L,TZ==U)$JVTS=Z,5'=C]WG0*[.14<R!WYG3:5@FND.?W
MZ\.9UMQ@!2'P'EG,G H@EK.2R*6HJCZFZC6S[27CV!4[+A_R6!M\?OLI'RWS
MK]/;N]7ES?=U\"K?=\;8^U[&F, B4!ZR&,NRWEI0KC/#PMH8EKI)$7;1'JRG
MH="GZ>C'=#9=/54FS_:-+&AE@*R4##M+*;5$J_((8Y1EE3IKG:&J:9HV=0'M
MBC!?'N-V&6,X#\5B%?7L=7[[I@OF!YS9_5+FE0]3#,L"<^A!L!<15]M]-TQ_
M6+1IP070&+:U<U@NY@&X?+FZF%\__EA.)]/1XB,%LO/9#%#GG,!,,DDTE?&6
M(]ZJ1D%2LD]ZV0&B018T!>H9NG<'%_HQF#@F0$P<"@J?(.;UQB%OO8.FEG]W
MQY+5C\NP;RV7ES]CS#[_<SV6IX,ML0^\EOG 608)HU0"&89,-2HM;@\![=0S
M<NJ%7%6816OX=F42Z-%RNKR\>0?&TV%.'?>!3'"'$#2<4.XEX1X1P<K9&]&M
MA7EF[&H5Z:YX9HKY,@QTLA9>=7;M>RVS' ;#FD'GP[&,.20%MEL@I4N)0)V=
MZ5&34PWBVQ63PJ'\\L8M5]/[<(K;=W!Y^V"F.$26*Z&M"Z<\9A"CNIR-U";%
M-7)TFO29LB4)T=I'E+4+9CF:3\KC=9C*?^6S2<RF&LWRBN;/<5_) (/A?P1Z
M;0& &GF'Y%:+*I.2*]?#$B=-VT*M@MV9MV1WG.Q8(^G83V7 6JP4=D9IQP5@
M0&[*:01$*) I)3-[6.^D!575,N(5CMR;_Q#_+^:7_OT__A]02P$"% ,4
M" #1A9A.(C)J8$Y$ @!&NBH $0              @ $     8FEI8BTR,#$Y
M,#,S,2YX;6Q02P$"% ,4    " #1A9A.<?65,A(7  "6%0$ $0
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M) 0 8FEI8BTR,#$Y,#,S,5]P<F4N>&UL4$L%!@     &  8 B@$  #+=!
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
